Saatja: Ester Timmas </O=JM/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=EE800FEFCADB45FABBC2E9F4F28E8235-ESTER TIMMAS>
Saaja: Ülle Näksi
Teema: FW: sildfinantseerimise taotlus
Teadmiseks.
Ester
From: Olga Galaburda <
[email protected]>
Sent: Monday, April 1, 2019 3:44 PM
To: Lia Hussar <
[email protected]>
Cc:
[email protected]; Ester Timmas <
[email protected]>
Subject: sildfinantseerimise taotlus
Tere
Terviseamet taotleb sildfinantseerimise avamist. Taotluse vorm koos lepingutega on manuses. Modex projekti leping on liiga suur e-postiga saatmiseks, kas ma tohin lepingu edastada Delta kaudu?
Lugupidamisega
Olga Galaburda
Terviseamet
Tel: 7943 513
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Director
GRANT AGREEMENT
NUMBER — 761297 — JATC
This Agreement (‘the Agreement’) is between the following parties:
on the one part,
the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under
the powers delegated by the European Commission ('the Commission'),
represented for the purposes of signature of this Agreement by Veronique WASBAUER, Director,
or his duly authorised representative,
and
on the other part,
1. ‘the coordinator’:
HELLENIC CANCER SOCIETY (HCS) GR4, 3331, established in A. TSOCHA 18-20, ATHINA
11521, Greece, EL090045296 represented for the purposes of signing the Agreement by PLSIGN,
Constantine VARDAVAS
and the following other beneficiaries, if they sign their ‘Accession Form’ (see Annex 3 and Article 40):
2. OSTERREICHISCHE AGENTUR FUR GESUNDHEIT UND
ERNAHRUNGSSICHERHEIT GMBH (AGES), FN223056Z, established in
SPARGELFELDSTRASSE 191, WIEN 1220, Austria, ATU54088605
3. SERVICE PUBLIC FEDERAL SANTE PUBLIQUE, SECURITE DE LA CHAINE
ALIMENTAIRE ET ENVIRONNEMENT (FPS BHTC), N/A, established in SQUARE VICTOR
HORTA 40 BUR 1D 1G, BRUSSELS 1060, Belgium, N/A
4. NATSIONALEN CENTAR PO OBSHTESTVENO ZDRAVE I ANALIZI (NCPHA),
176094665, established in ACAD IVAN GESHOV BLVD 15, SOFIA 1431, Bulgaria, BG176094665
5. Ministry of Health of the Republic of Cyprus (MoH CY), established in 1 Prodromou Street &
17 Chilonos Street 1 & 17, Nicosia 1448, Cyprus
6. SIKKERHEDSSTYRELSEN (SIK), 27403123, established in NORREGADE 63, ESBJERG
6700, Denmark, DK27403123
7. TERVISEAMET (TA), 70008799, established in PALDISKI MNT 81, TALLINN 10617, Estonia,
EE101339803
1
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
8. AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L
ENVIRONNEMENT ET DU TRAVAIL (ANSES), 130012024, established in 14 RUE PIERRE
ET MARIE CURIE, MAISONS ALFORT 94700, France, FR54130012024
9. BUNDESINSTITUT FUER RISIKOBEWERTUNG (BfR), N/A, established in MAX DOHRN
STRASSE 8-10, BERLIN 10589, Germany
10. ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH) GR8,
PD772000, established in CHARILAOU THERMI ROAD 6 KM, THERMI THESSALONIKI 57001,
Greece, EL099785242
11. SEMMELWEIS EGYETEM (SU (SE)) HU13, FI62576, established in ULLOI UTCA 26,
BUDAPEST 1085, Hungary, HU15329808
12. EMBAETTI LANDLAEKNIS (DoH I), 7101695009, established in BARONSSTIG 47,
REYKJAVIK 101, Iceland
13. HEALTH SERVICE EXECUTIVE HSE (HSE), established in LIMETREE AVENUE 2ND
FLO OAK HOUSE, NAAS, Ireland, IE66093541
14. ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI (IRFMN) IT3,
CF03254210150, established in VIA GIUSEPPE LA MASA 19, MILANO 20156, Italy,
IT03254210150
15. ISTITUTO SUPERIORE DI SANITA (ISS), 80211730587, established in Viale Regina Elena
299, ROMA 00161, Italy, IT03657731000
16. MINISTERO DELLA SALUTE (MoH IT), N/A, established in Via Giorgio Ribotta 5, ROMA
00144, Italy, N/A
17. VESELIBAS INSPEKCIJA (HI), 432, established in KLIJANU STREET 7, RIGA 1012, Latvia,
LV90002448818
18. NARKOTIKU TABAKO IR ALKOHOLIO KONTROLES DEPARTAMENTAS (NTAKD)
LT3, 302610311, established in SV STEPONO GATVE 27, VILNIUS 01312, Lithuania
19. NACIONALINE VISUOMENES SVEIKATOS PRIEZIUROS LABORATORIJA
(NVSPL), 195551983, established in ZOLYNO G. 36, VILNIUS 10210, Lithuania, LT
20. Ministry for Health - Government of Malta (DEH), not applicable, established in Palazzo
Castellania, Merchants Street 15, Valletta VLT 200, Malta, MT12979127
21. RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), 30276683,
established in Antonie Van Leeuwenhoeklaan 9, BILTHOVEN 3721 MA, Netherlands,
NL821772302B01
22. FOLKEHELSEINSTITUTTET (NIPH), 983744516, established in LOVISENBERGGATA 8,
OSLO 0456, Norway, NO983744516MVA
23. STATENS LEGEMIDDELVERK (NOMA) NO6, 974761122, established in SVEN
OFTEDALS VEI 8, OSLO 0950, Norway
24. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (MS ), Decreto-Lei n.º 212/2006,
de 27 de Outubro , established in Av. João Crisóstomo, 9, LISBOA 1049-062 , Portugal
2
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
25. INSTITUT ZA JAVNO ZDRAVLJE SRBIJE 'MILAN JOVANOVIC - BATUT' (BATUT-
IANPH), 5218003/6012569869, established in DR SUBOTICA STREET 5, BEOGRAD 11000,
Serbia, RS102000930
26. NACIONALNI LABORATORIJ ZA ZDRAVJE, OKOLJE IN HRANO (NLZOH) SI2,
6489087000, established in PRVOMAJSKA ULICA 1, MARIBOR 2000, Slovenia, SI19651295
27. INSTITUT CATALA D'ONCOLOGIA (ICO), established in AV GRAN VIA DE
L'HOSPITALET 199-203, L'HOSPITALET DEL LLOBREGAT 08908, Spain, ESQ5856383D
28. CONSEJERIA DE SALUD DE LA JUNTA DE ANDALUCIA (CSJA), not applicable,
established in EDIF. ARENA 1. AVDA DE LA INNOVACION S//N, Sevilla 41020, Spain,
ESS4111001F
29. FOLKHALSOMYNDIGHETEN (FoHM), 2021006545, established in NOBELS VAG 18,
SOLNA 171 82, Sweden, SE202100654501
30. Department of Health (UK-DH), -, established in Quarry House, Quarry Hill, Leeds LS2 7UE,
United Kingdom, 888815064
31. ELLINIKI PNEYMONOLOGIKI ETAIREIA (HTS) GR4, Not applicable, established in
MAIANDROU 23, ATHINA 115 28, Greece, EL090340027
Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator.
The parties referred to above have agreed to enter into the Agreement under the terms and conditions
below.
By signing the Agreement or the Accession Form, the beneficiaries accept the grant and agree to
implement the action under their own responsibility and in accordance with the Agreement, with all
the obligations and conditions it sets out.
The Agreement is composed of:
Terms and Conditions
Annex 1 Description of the action
Annex 2 Estimated budget for the action
Annex 3 Accession Forms
Annex 4 Model for the financial statements
Annex 5 Model for the certificate on the financial statements (CFS)
3
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
TERMS AND CONDITIONS
TABLE OF CONTENTS
CHAPTER 1 GENERAL.................................................................................................................................................9
ARTICLE 1 — SUBJECT OF THE AGREEMENT.........................................................................................9
CHAPTER 2 ACTION.................................................................................................................................................... 9
ARTICLE 2 — ACTION TO BE IMPLEMENTED......................................................................................... 9
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION......................................................9
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS.........................................................9
4.1 Estimated budget..................................................................................................................................... 9
4.2 Budget transfers.......................................................................................................................................9
CHAPTER 3 GRANT......................................................................................................................................................9
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND FORMS OF
COSTS........................................................................................................................................................... 9
5.1 Maximum grant amount.......................................................................................................................... 9
5.2 Form of grant, reimbursement rates and forms of costs.......................................................................10
5.3 Final grant amount — Calculation........................................................................................................10
5.4 Revised final grant amount — Calculation.......................................................................................... 11
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS................................................................................ 12
6.1 General conditions for costs to be eligible........................................................................................... 12
6.2 Specific conditions for costs to be eligible...........................................................................................12
6.3 Conditions for costs of affiliated entities to be eligible........................................................................15
6.4 Ineligible costs.......................................................................................................................................16
6.5 Consequences of declaration of ineligible costs................................................................................... 16
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES......................................................................... 16
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION................. 16
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION.........................16
7.1 General obligation to properly implement the action........................................................................... 17
7.2 Consequences of non-compliance......................................................................................................... 17
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE
ACTION...................................................................................................................................................... 17
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES............................................................ 17
9.1 Rules for purchasing goods, works or services.................................................................................... 17
9.2 Consequences of non-compliance......................................................................................................... 18
4
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS............................18
10.1 Rules for subcontracting action tasks................................................................................................. 18
10.2 Consequences of non-compliance....................................................................................................... 18
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES....................... 19
11.1 Rules for calling upon affiliated entities to implement part of the action.......................................... 19
11.2 Consequences of non-compliance....................................................................................................... 19
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION............... 19
ARTICLE 12 — GENERAL OBLIGATION TO INFORM............................................................................19
12.1 General obligation to provide information upon request....................................................................20
12.2 Obligation to keep information up to date and to inform about events and circumstances likely to
affect the Agreement..............................................................................................................................20
12.3 Consequences of non-compliance....................................................................................................... 20
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION........................................ 20
13.1 Obligation to keep records and other supporting documentation....................................................... 20
13.2 Consequences of non-compliance....................................................................................................... 21
ARTICLE 14 — SUBMISSION OF DELIVERABLES................................................................................. 21
14.1 Obligation to submit deliverables....................................................................................................... 22
14.2 Consequences of non-compliance....................................................................................................... 22
ARTICLE 15 — REPORTING — PAYMENT REQUESTS.......................................................................... 22
15.1 Obligation to submit reports............................................................................................................... 22
15.2 Reporting periods................................................................................................................................ 22
15.3 Periodic reports — Requests for interim payments............................................................................22
15.4 Final report — Request for payment of the balance.......................................................................... 24
15.5 Currency for financial statements and conversion into euro.............................................................. 24
15.6 Language of reports.............................................................................................................................24
15.7 Consequences of non-compliance — Suspension of the payment deadline — Termination.............. 25
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS.......................................................... 25
16.1 Payments to be made.......................................................................................................................... 25
16.2 Pre-financing payment — Amount..................................................................................................... 25
16.3 Interim payments — Amount — Calculation.....................................................................................25
16.4 Payment of the balance — Amount — Calculation........................................................................... 26
16.5 Notification of amounts due................................................................................................................27
16.6 Currency for payments........................................................................................................................ 27
16.7 Payments to the coordinator — Distribution to the beneficiaries.......................................................27
16.8 Bank account for payments.................................................................................................................27
5
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
16.9 Costs of payment transfers..................................................................................................................27
16.10 Date of payment................................................................................................................................ 27
16.11 Consequences of non-compliance..................................................................................................... 28
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF
FINDINGS................................................................................................................................................... 28
17.1 Checks, reviews and audits by the Agency and the Commission...................................................... 28
17.2 Investigations by the European Anti-Fraud Office (OLAF)...............................................................30
17.3 Checks and audits by the European Court of Auditors (ECA)...........................................................30
17.5 Consequences of findings in checks, reviews, audits and investigations —Extension of
findings...................................................................................................................................................31
17.6 Consequences of non-compliance....................................................................................................... 32
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION........................................................32
18.1 Right to evaluate the impact of the action..........................................................................................32
18.2 Consequences of non-compliance....................................................................................................... 33
SECTION 3 OTHER RIGHTS AND OBLIGATIONS........................................................................................33
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS (INCLUDING
INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS)...............................................................33
19.1 Pre-existing rights and access rights to pre-existing rights................................................................ 33
19.2 Ownership of results and rights of use............................................................................................... 33
19.3 Consequences of non-compliance....................................................................................................... 33
ARTICLE 20 — CONFLICT OF INTERESTS...............................................................................................33
20.1 Obligation to avoid a conflict of interests.......................................................................................... 33
20.2 Consequences of non-compliance....................................................................................................... 34
ARTICLE 21 — CONFIDENTIALITY...........................................................................................................34
21.1 General obligation to maintain confidentiality................................................................................... 34
21.2 Consequences of non-compliance....................................................................................................... 34
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING....................................34
22.1 Communication activities by the beneficiaries................................................................................... 34
22.2 Communication activities by the Agency........................................................................................... 35
22.3 Consequences of non-compliance....................................................................................................... 36
ARTICLE 23 — PROCESSING OF PERSONAL DATA.............................................................................. 36
23.1 Processing of personal data by the Agency and the Commission...................................................... 36
23.2 Processing of personal data by the beneficiaries................................................................................ 37
23.3 Consequences of non-compliance....................................................................................................... 37
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY................... 37
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES........................................ 37
6
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES............................37
25.1 Roles and responsibilities towards the Agency.................................................................................. 37
25.2 Internal division of roles and responsibilities..................................................................................... 37
25.3 Internal arrangements between beneficiaries — Consortium agreement............................................38
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — PENALTIES
— DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE................................................. 39
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY —
PENALTIES...........................................................................................................................................................39
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS.............................................................................. 39
26.1 Conditions............................................................................................................................................ 39
26.2 Ineligible costs to be rejected — Calculation — Procedure...............................................................39
26.3 Effects.................................................................................................................................................. 39
ARTICLE 27 — REDUCTION OF THE GRANT......................................................................................... 40
27.1 Conditions............................................................................................................................................ 40
27.2 Amount to be reduced — Calculation — Procedure..........................................................................40
27.3 Effects.................................................................................................................................................. 40
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS............................................................................... 40
28.1 Amount to be recovered — Calculation — Procedure.......................................................................41
ARTICLE 29 — ADMINISTRATIVE AND FINANCIAL PENALTIES.......................................................43
29.1 Conditions............................................................................................................................................ 43
29.2 Duration — Amount of penalty — Calculation................................................................................. 43
29.3 Procedure............................................................................................................................................. 43
SECTION 2 LIABILITY FOR DAMAGES..........................................................................................................44
ARTICLE 30 — LIABILITY FOR DAMAGES............................................................................................. 44
30.1 Liability of the Agency....................................................................................................................... 44
30.2 Liability of the beneficiaries............................................................................................................... 44
SECTION 3 SUSPENSION AND TERMINATION.............................................................................................45
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE....................................................................... 45
31.1 Conditions............................................................................................................................................ 45
31.2 Procedure............................................................................................................................................. 46
ARTICLE 32 — SUSPENSION OF PAYMENTS..........................................................................................46
32.1 Conditions............................................................................................................................................ 46
32.2 Procedure............................................................................................................................................. 46
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION................................................... 47
33.1 Suspension of the action implementation, by the beneficiaries..........................................................47
7
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
33.2 Suspension of the action implementation, by the Agency..................................................................47
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR
MORE BENEFICIARIES........................................................................................................................... 48
34.1 Termination of the Agreement, by the beneficiaries...........................................................................48
34.2 Termination of the participation of one or more beneficiaries, by the beneficiaries...........................49
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency................................................................................................................................................... 50
SECTION 4 FORCE MAJEURE........................................................................................................................... 53
ARTICLE 35 — FORCE MAJEURE.............................................................................................................. 53
CHAPTER 7 FINAL PROVISIONS............................................................................................................................54
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES...............................................................54
36.1 Form and means of communication....................................................................................................54
36.2 Date of communication....................................................................................................................... 54
36.3 Addresses for communication............................................................................................................. 54
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT.................................................................... 55
37.1 Precedence of the Terms and Conditions over the Annexes...............................................................55
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES........................................... 55
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT......................................................................... 55
39.1 Conditions............................................................................................................................................ 55
39.2 Procedure............................................................................................................................................. 55
ARTICLE 40 — ACCESSION TO THE AGREEMENT............................................................................... 56
40.1 Accession of the beneficiaries mentioned in the Preamble................................................................ 56
40.2 Addition of new beneficiaries............................................................................................................. 56
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES.............................................. 57
41.1 Applicable law.....................................................................................................................................57
41.2 Dispute settlement............................................................................................................................... 57
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT................................................................ 57
8
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAPTER 1 GENERAL
ARTICLE 1 — SUBJECT OF THE AGREEMENT
This Agreement sets out the rights and obligations and the terms and conditions applicable to the grant
awarded to the beneficiaries for implementing the action set out in Chapter 2.
CHAPTER 2 ACTION
ARTICLE 2 — ACTION TO BE IMPLEMENTED
The grant is awarded for the action entitled ‘Joint Action on Tobacco Control — JATC’ (‘action’),
as described in Annex 1.
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION
The duration of the action will be 36 months as of 16/10/2017 (‘starting date of the action’).
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS
4.1 Estimated budget
The ‘estimated budget’ for the action is set out in Annex 2.
It contains the estimated eligible costs and the forms of costs, broken down by beneficiary (and
affiliated entity) and budget category (see Articles 5, 6).
4.2 Budget transfers
The estimated budget breakdown indicated in Annex 2 may be adjusted by transfers of amounts
between beneficiaries or between budget categories (or both). This does not require an amendment
according to Article 39, if the action is implemented as described in Annex 1.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1,
unless such additional subcontracts are approved by an amendment or in accordance with Article 10.
CHAPTER 3 GRANT
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND
FORMS OF COSTS
5.1 Maximum grant amount
The ‘maximum grant amount’ is EUR 1,999,018.07 (one million nine hundred and ninety nine
thousand eighteen EURO and seven eurocents).
9
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
5.2 Form of grant, reimbursement rates and forms of costs
The grant reimburses 80% of the action's eligible costs (see Article 6) (‘reimbursement of eligible
costs grant’) (see Annex 2).
The estimated eligible costs of the action are EUR 2,498,773.08 (two million four hundred and ninety
eight thousand seven hundred and seventy three EURO and eight eurocents).
Eligible costs (see Article 6) must be declared under the following forms ('forms of costs' or 'costs
forms'):
(a) for direct personnel costs: as actually incurred costs (actual costs);
(b) for direct costs of subcontracting: as actually incurred costs (actual costs);
(c) for other direct costs: as actually incurred costs (actual costs);
(d) for indirect costs: on the basis of a flat-rate applied as set out in Article 6.2.D (‘flat-rate costs’);
5.3 Final grant amount — Calculation
The ‘final grant amount’ depends on the actual extent to which the action is implemented in
accordance with the Agreement’s terms and conditions.
This amount is calculated by the Agency — when the payment of the balance is made — in the
following steps:
Step 1 – Application of the reimbursement rate to the eligible costs
Step 2 – Limit to the maximum grant amount
Step 3 – Reduction due to the no-profit rule
Step 4 – Reduction due to improper implementation or breach of other obligations
5.3.1 Step 1 — Application of the reimbursement rate to the eligible costs
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate
costs; see Article 6) declared by the beneficiaries and affiliated entities (see Article 15) and approved
by the Agency (see Article 16).
5.3.2 Step 2 — Limit to the maximum grant amount
If the amount obtained following Step 1 is higher than the maximum grant amount set out in Article
5.1, it will be limited to the latter.
5.3.3 Step 3 — Reduction due to the no-profit rule
The grant must not produce a profit.
‘Profit’ means the surplus of the amount obtained following Steps 1 and 2 plus the action’s total
receipts, over the action’s total eligible costs.
10
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The ‘action’s total eligible costs’ are the consolidated total eligible costs approved by the Agency.
The ‘action’s total receipts’ are the consolidated total receipts generated during its duration (see
Article 3).
The following are considered receipts:
(a) income generated by the action;
(b) financial contributions given by third parties to the beneficiary or to an affiliated entity
specifically to be used for costs that are eligible under the action.
The following are however not considered receipts:
(a) financial contributions by third parties, if they may be used to cover costs other than the eligible
costs (see Article 6);
(b) financial contributions by third parties with no obligation to repay any amount unused at the
end of the period set out in Article 3.
If there is a profit, it will be deducted in proportion to the final rate of reimbursement of the eligible
actual costs approved by the Agency (as compared to the amount calculated following Steps 1 and 2).
5.3.4 Step 4 — Reduction due to improper implementation or breach of other obligations —
Reduced grant amount — Calculation
If the grant is reduced (see Article 27), the Agency will calculate the reduced grant amount by
deducting the amount of the reduction (calculated in proportion to the improper implementation of
the action or to the seriousness of the breach of obligations in accordance with Article 27.2) from the
maximum grant amount set out in Article 5.1.
The final grant amount will be the lower of the following two:
- the amount obtained following Steps 1 to 3 or
- the reduced grant amount following Step 4.
5.4 Revised final grant amount — Calculation
If — after the payment of the balance (in particular, after checks, reviews, audits or investigations;
see Article 17) — the Agency rejects costs (see Article 26) or reduces the grant (see Article 27), it
will calculate the ‘revised final grant amount’ for the action.
This amount is calculated by the Agency on the basis of the findings, as follows:
- in case of rejection of costs: by applying the reimbursement rate to the revised eligible costs
approved by the Agency for the action, limiting it to the maximum grant amount and making
a reduction if there is a profit (see Article 5.3);
- in case of reduction of the grant: by deducting the amount of the reduction (calculated in
proportion to the improper implementation of the action or to the seriousness of the breach
of obligations in accordance with Article 27.2) from the maximum grant amount set out in
Article 5.1.
11
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
In case of rejection of costs and reduction of the grant, the revised final grant amount for the action
will be the lower of the two amounts above.
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS
6.1 General conditions for costs to be eligible
‘Eligible costs’ are costs that meet the following criteria:
(a) for actual costs:
(i) they must be actually incurred by the beneficiary;
(ii) they must be incurred in the period set out in Article 3, with the exception of costs relating
to the submission of the periodic report for the last reporting period and the final report
(see Article 15);
(iii) they must be indicated in the estimated budget set out in Annex 2;
(iv) they must be incurred in connection with the action as described in Annex 1 and necessary
for its implementation;
(v) they must be identifiable and verifiable, in particular recorded in the beneficiary’s
accounts in accordance with the accounting standards applicable in the country where the
beneficiary is established and with the beneficiary’s usual cost accounting practices;
(vi) they must comply with the applicable national law on taxes, labour and social security, and
(vii) they must be reasonable, justified and must comply with the principle of sound financial
management, in particular regarding economy and efficiency;
(b) for flat-rate costs:
(i) they must be calculated by applying the flat-rate set out in Annex 2, and
(ii) the costs (actual costs) to which the flat-rate is applied must comply with the conditions
for eligibility set out in this Article.
6.2 Specific conditions for costs to be eligible
Costs are eligible if they comply with the general conditions (see above) and the specific conditions
set out below, for each of the following budget categories:
A. direct personnel costs;
B. direct costs of subcontracting;
C. other direct costs;
D. indirect costs;
12
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
‘Direct costs’ are costs that are directly linked to the action implementation and can therefore be
attributed to it directly. They must not include any indirect costs (see Point D below).
‘Indirect costs’ are costs that are not directly linked to the action implementation and therefore cannot
be attributed directly to it.
A. Direct personnel costs
Types of eligible personnel costs
A.1 Personnel costs are eligible if they are related to personnel working for the beneficiary under
an employment contract (or equivalent appointing act) and assigned to the action (‘costs for
employees (or equivalent)’). They must be limited to salaries (including during parental leave),
social security contributions, taxes and other costs included in the remuneration, if they arise
from national law or the employment contract (or equivalent appointing act).
They may also include additional remuneration for personnel assigned to the action (including
payments on the basis of supplementary contracts regardless of their nature), if:
(a) it is part of the beneficiary’s usual remuneration practices and is paid in a consistent manner
whenever the same kind of work or expertise is required;
(b) the criteria used to calculate the supplementary payments are objective and generally
applied by the beneficiary, regardless of the source of funding used.
A.2 The costs for natural persons working under a direct contract with the beneficiary other
than an employment contract or seconded by a third party against payment are eligible personnel
costs, if:
(a) the person works under the beneficiary’s instructions and, unless otherwise agreed with
the beneficiary, on the beneficiary’s premises;
(b) the result of the work carried out belongs to the beneficiary, and
(c) the costs are not significantly different from those for personnel performing similar tasks
under an employment contract with the beneficiary.
Calculation
Personnel costs must be calculated by the beneficiaries as follows:
{hourly rate
multiplied by
the number of actual hours worked on the action}.
The number of actual hours declared for a person must be identifiable and verifiable (see Article 13).
The total number of hours declared in EU or Euratom grants, for a person for a year, cannot be higher
than the annual productive hours used for the calculations of the hourly rate. Therefore, the maximum
number of hours that can be declared for the grant are:
13
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
{the number of annual productive hours for the year (see below)
minus
total number of hours declared by the beneficiary, for that person for that year, for other EU or Euratom grants}.
The ‘hourly rate’ is the amount calculated as follows:
{actual annual personnel costs for the person
divided by
number of annual productive hours}.
The beneficiaries must use the annual personnel costs and the number of annual productive hours for
each financial year covered by the reporting period. If a financial year is not closed at the end of the
reporting period, the beneficiaries must use the hourly rate of the last closed financial year available.
For the ‘number of annual productive hours’, the beneficiaries may choose one of the following:
(i) ‘fixed number of hours’: 1 720 hours for persons working full time (or corresponding pro-rata
for persons not working full time);
(ii) ‘individual annual productive hours’: the total number of hours worked by the person in the year
for the beneficiary, calculated as follows:
{annual workable hours of the person (according to the employment contract, applicable collective labour
agreement or national law)
plus
overtime worked
minus
absences (such as sick leave and special leave)}.
‘Annual workable hours’ means the period during which the personnel must be working, at the
employer’s disposal and carrying out his/her activity or duties under the employment contract,
applicable collective labour agreement or national working time legislation.
If the contract (or applicable collective labour agreement or national working time legislation)
does not allow to determine the annual workable hours, this option cannot be used;
(iii) ‘standard annual productive hours’: the ‘standard number of annual hours’ generally applied
by the beneficiary for its personnel in accordance with its usual cost accounting practices. This
number must be at least 90% of the ‘standard annual workable hours’.
If there is no applicable reference for the standard annual workable hours, this option cannot
be used.
For all options, the actual time spent on parental leave by a person assigned to the action may be
deducted from the number of annual productive hours;
14
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
B. Direct costs of subcontracting (including related duties, taxes and charges, such as non-deductible
value added tax (VAT) paid by beneficiaries that are not public bodies acting as public authority) are
eligible if the conditions in Article 10.1.1 are met.
C. Other direct costs
C.1 Travel costs and related subsistence allowances (including related duties, taxes and charges,
such as non-deductible value added tax (VAT) paid by beneficiaries that are not public bodies
acting as public authority) are eligible if they are in line with the beneficiary’s usual practices
on travel.
C.2 The depreciation costs of equipment, infrastructure or other assets (new or second-hand)
as recorded in the beneficiary’s accounts are eligible, if they were purchased in accordance
with Article 9.1.1 and written off in accordance with international accounting standards and the
beneficiary’s usual accounting practices.
The costs of renting or leasing equipment, infrastructure or other assets (including related duties,
taxes and charges, such as non-deductible value added tax (VAT) paid by beneficiaries that are not
public bodies acting as public authority) are also eligible, if they do not exceed the depreciation
costs of similar equipment, infrastructure or assets and do not include any financing fees.
The only portion of the costs that will be taken into account is that which corresponds to the
duration of the action and rate of actual use for the purposes of the action.
C.3 Costs of other goods and services (including related duties, taxes and charges, such as non-
deductible value added tax (VAT) paid by beneficiaries that are not public bodies acting as public
authority) are eligible, if they are purchased specifically for the action and in accordance with
Article 9.1.1.
Such goods and services include, for instance, consumables and supplies, dissemination,
protection of results, certificates on the financial statements (if they are required by the
Agreement), translations and publications.
D. Indirect costs
Indirect costs are eligible if they are declared on the basis of the flat-rate of 7% of the eligible direct
costs (see Article 5.2 and Points A to C above).
Beneficiaries receiving an operating grant1 financed by the EU or Euratom budget cannot declare
indirect costs for the period covered by the operating grant.
6.3 Conditions for costs of affiliated entities to be eligible
Costs incurred by affiliated entities are eligible if they fulfil — mutatis mutandis — the general and
specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 11.1.1.
1 For the definition, see Article 121(1)(b) of Regulation (EU, Euratom) No 966/2012 of the European Parliament and
of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing
Council Regulation (EC, Euratom) No 1605/2002 (OJ L 218, 26.10.2012, p.1) (‘Financial Regulation No 966/2012’):
‘operating grant’ means direct financial contribution, by way of donation, from the budget in order to finance the
functioning of a body which pursues an aim of general EU interest or has an objective forming part of and supporting
an EU policy.
15
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
6.4 Ineligible costs
‘Ineligible costs’ are:
(a) costs that do not comply with the conditions set out above (Article 6.1 to 6.3), in particular:
(i) costs related to return on capital;
(ii) debt and debt service charges;
(iii) provisions for future losses or debts;
(iv) interest owed;
(v) doubtful debts;
(vi) currency exchange losses;
(vii) bank costs charged by the beneficiary’s bank for transfers from the Agency;
(viii)excessive or reckless expenditure;
(ix) deductible VAT;
(x) costs incurred during suspension of the implementation of the action (see Article 33);
(xi) in-kind contributions provided by third parties;
(b) costs declared under another EU or Euratom grant (including grants awarded by a Member
State and financed by the EU or Euratom budget and grants awarded by bodies other than the
Agency for the purpose of implementing the EU or Euratom budget); in particular, indirect
costs if the beneficiary is already receiving an operating grant financed by the EU or Euratom
budget in the same period.
6.5 Consequences of declaration of ineligible costs
Declared costs that are ineligible will be rejected (see Article 26).
This may also lead to any of the other measures described in Chapter 6.
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE
ACTION
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION
16
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
7.1 General obligation to properly implement the action
The beneficiaries must implement the action as described in Annex 1 and in compliance with the
provisions of the Agreement and all legal obligations under applicable EU, international and national
law.
7.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES
INVOLVED IN THE ACTION
The beneficiaries must have the appropriate resources to implement the action.
If it is necessary to implement the action, the beneficiaries may:
- purchase goods, works and services (see Article 9);
- call upon subcontractors to implement action tasks described in Annex 1 (see Article 10);
- call upon affiliated entities to implement action tasks described in Annex 1 (see Article 11).
In these cases, the beneficiaries retain sole responsibility towards the Agency and the other
beneficiaries for implementing the action.
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES
9.1 Rules for purchasing goods, works or services
9.1.1 If necessary to implement the action, the beneficiaries may purchase goods, works or services.
The beneficiaries must make such purchases ensuring the best value for money or, if appropriate, the
lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their contractors.
9.1.2 Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC2 or
‘contracting entities’ within the meaning of Directive 2004/17/EC3 must comply with the applicable
national law on public procurement.
2 Directive 2004/18/EC of the European Parliament and of the Council of 31 March 2004 on the coordination of
procedures for the award of public work contracts, public supply contracts and public service contracts (OJ L 134,
30.04.2004, p. 114).
17
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
9.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 9.1.1, the costs related to the contract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
If a beneficiary breaches any of its obligations under Article 9.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS
10.1 Rules for subcontracting action tasks
10.1.1 If necessary to implement the action, the beneficiaries may award subcontracts covering the
implementation of certain action tasks described in Annex 1.
Subcontracting may cover only a limited part of the action.
The beneficiaries must award the subcontracts ensuring the best value for money or, if appropriate,
the lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The tasks to be implemented and the estimated cost for each subcontract must be set out in Annex
1 and the total estimated costs of subcontracting per beneficiary must be set out in Annex 2. The
Agency may however approve subcontracts not set out in Annex 1 and 2 without amendment (see
Article 39), if:
- they are specifically justified in the periodic technical report and
- they do not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their subcontractors.
10.1.2 The beneficiaries must ensure that their obligations under Articles 20, 21, 22 and 30 also apply
to the subcontractors.
Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC or
‘contracting entities’ within the meaning of Directive 2004/17/EC must comply with the applicable
national law on public procurement.
10.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 10.1.1, the costs related to the subcontract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
3 Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement
procedures of entities operating in the water, energy, transport and postal services sectors (OJ L 134, 30.04.2004, p. 1).
18
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
If a beneficiary breaches any of its obligations under Article 10.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES
11.1 Rules for calling upon affiliated entities to implement part of the action
11.1.1 The following affiliated entities4 may implement the action tasks attributed to them in Annex 1:
- FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL),
affiliated or linked to ICO
- AGENCIA DE GESTION AGRARIA Y PESQUERA DE ANDALUCIA (AGAPA), affiliated or
linked to CSJA
- FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD (FPS), affiliated or linked to CSJA
The affiliated entities may declare as eligible the costs they incur for implementing the action tasks
in accordance with Article 6.3.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors (ECA)
and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and 18 also
towards their affiliated entities.
11.1.2 The beneficiaries must ensure that their obligations under Articles 13, 15, 20, 21 and 22 also
apply to their affiliated entities.
11.2 Consequences of non-compliance
If any obligation under Article 11.1.1 is breached, the costs of the affiliated entity will be ineligible
(see Article 6) and will be rejected (see Article 26).
If any obligation under Article 11.1.2 is breached, the grant may be reduced (see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT
ADMINISTRATIONFR
ARTICLE 12 — GENERAL OBLIGATION TO INFORM
4 For the definition, see Article 122 of the Financial Regulation (EU, Euratom) No 966/2012: entities affiliated to the
beneficiary are:
(a) entities that form a ‘sole beneficiary’ (i.e. where an entity is formed of several entities that satisfy the criteria for
being awarded a grant, including where the entity is specifically established for the purpose of implementing
an action to be financed by a grant);
(b) entities that satisfy the eligibility criteria and that do not fall within one of the situations referred to in Article
131(4) and that have a link with the beneficiary, in particular a legal or capital link, which is neither limited to
the action nor established for the sole purpose of its implementation.
19
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
12.1 General obligation to provide information upon request
The beneficiaries must provide — during implementation of the action or afterwards and in accordance
with Article 25.2 — any information requested in order to verify eligibility of the costs, proper
implementation of the action and compliance with any other obligation under the Agreement.
12.2 Obligation to keep information up to date and to inform about events and circumstances
likely to affect the Agreement
Each beneficiary must keep information stored in the 'Beneficiary Register' (via the electronic
exchange system; see Article 36) up to date, in particular, its name, address, legal representatives,
legal form and organisation type.
Each beneficiary must immediately inform the coordinator — which must immediately inform the
Agency and the other beneficiaries — of any of the following:
(a) events which are likely to affect significantly or delay the implementation of the action or the
EU’s financial interests, in particular:
(i) changes in its legal, financial, technical, organisational or ownership situation or those
of its affiliated entities and
(ii) changes in the name, address, legal form, organisation type of its affiliated entities;
(b) circumstances affecting:
(i) the decision to award the grant or
(ii) compliance with requirements under the Agreement.
12.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION
13.1 Obligation to keep records and other supporting documentation
The beneficiaries must — for a period of five years after the payment of the balance — keep records
and other supporting documentation, in order to prove the proper implementation of the action and
the costs they declare as eligible.
They must make them available upon request (see Article 12) or in the context of checks, reviews,
audits or investigations (see Article 17).
If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under
the Agreement (including the extension of findings; see Articles 17), the beneficiaries must keep the
records and other supporting documentation until the end of these procedures.
20
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The beneficiaries must keep the original documents. Digital and digitalised documents are considered
originals if they are authorised by the applicable national law. The Agency may accept non-original
documents if it considers that they offer a comparable level of assurance.
13.1.1 Records and other supporting documentation on the scientific and technical
implementation
The beneficiaries must keep records and other supporting documentation on the technical
implementation of the action, in line with the accepted standards in the respective field.
13.1.2 Records and other documentation to support the costs declared
The beneficiaries must keep the records and documentation supporting the costs declared, in particular
the following:
(a) for actual costs: adequate records and other supporting documentation to prove the costs
declared, such as contracts, subcontracts, invoices and accounting records. In addition, the
beneficiaries’ usual cost accounting practices and internal control procedures must enable direct
reconciliation between the amounts declared, the amounts recorded in their accounts and the
amounts stated in the supporting documentation;
(b) for flat-rate costs: adequate records and other supporting documentation to prove the eligibility
of the costs to which the flat-rate is applied. The beneficiaries do not need to identify the costs
covered or provide supporting documentation (such as accounting statements) to prove the
amount declared at a flat-rate.
In addition, for personnel costs (declared as actual costs), the beneficiaries must keep time records
for the number of hours declared. The time records must be in writing and approved by the persons
working on the action and their supervisors, at least monthly. In the absence of reliable time records
of the hours worked on the action, the Agency may accept alternative evidence supporting the number
of hours declared, if it considers that it offers an adequate level of assurance.
As an exception, for persons working exclusively on the action, there is no need to keep time records,
if the beneficiary signs a declaration confirming that the persons concerned have worked exclusively
on the action.
For costs declared by affiliated entities (see Article 11), it is the beneficiary that must keep the
originals of the financial statements and the certificates on the financial statements of the affiliated
entities.
13.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, costs insufficiently substantiated
will be ineligible (see Article 6) and will be rejected (see Article 26), and the grant may be reduced
(see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 14 — SUBMISSION OF DELIVERABLES
21
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
14.1 Obligation to submit deliverables
The coordinator must submit the ‘deliverables’ identified in Annex 1 (if any), in accordance with the
timing and conditions set out in it.
14.2 Consequences of non-compliance
If the coordinator breaches any of its obligations under this Article, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 15 — REPORTING — PAYMENT REQUESTS
15.1 Obligation to submit reports
The coordinator must submit to the Agency (see Article 36) the technical and financial reports set out
in this Article. These reports include the requests for payment and must be drawn up using the forms
and templates provided in the electronic exchange system (see Article 36).
15.2 Reporting periods
The action is divided into the following ‘reporting periods’:
- RP1: from month 1 to month 18
- RP2: from month 19 to month 36
15.3 Periodic reports — Requests for interim payments
The coordinator must submit a periodic report within 60 days following the end of each reporting
period.
The periodic report must include the following:
(a) a ‘periodic technical report’ containing:
(i) an explanation of the work carried out by the beneficiaries;
(ii) an overview of the progress towards the objectives of the action, including milestones
and deliverables identified in Annex 1.
This report must include explanations justifying the differences between work expected
to be carried out in accordance with Annex 1 and that actually carried out;
(iii) a summary for publication by the Agency;
(iv) the answers to the ‘questionnaire’, covering issues related to the action implementation
and its impact, if required in Annex 1;
(b) a ‘periodic financial report’ containing:
(i) an ‘individual financial statement’ (see Annex 4) from each beneficiary and from each
affiliated entity, for the reporting period concerned.
22
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The individual financial statement must detail the eligible costs (actual costs and flat-rate
costs; see Article 6) for each budget category (see Annex 2).
The beneficiaries and affiliated entities must declare all eligible costs, even if — for actual
costs and flat-rate costs — they exceed the amounts indicated in the estimated budget (see
Annex 2). Amounts which are not declared in the individual financial statement will not
be taken into account by the Agency.
If an individual financial statement is not submitted for a reporting period, it may be
included in the periodic financial report for the next reporting period.
The individual financial statements of the last reporting period must also detail the
receipts of the action (see Article 5.3.3).
Each beneficiary and each affiliated entity must certify that:
- the information provided is full, reliable and true;
- the costs declared are eligible (see Article 6);
- the costs can be substantiated by adequate records and supporting documentation
(see Article 13) that will be produced upon request (see Article 12) or in the context
of checks, reviews, audits and investigations (see Article 17), and
- for the last reporting period: that all the receipts have been declared (see
Article 5.3.3);
(ii) an explanation of the use of resources and the information on subcontracting (see
Article 10) from each beneficiary and from each affiliated entity, for the reporting period
concerned;
(iii) not applicable;
(iv) a ‘periodic summary financial statement’ (see Annex 4), created automatically by
the electronic exchange system, consolidating the individual financial statements for the
reporting period concerned and including — except for the last reporting period — the
request for interim payment.
(v) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each affiliated entity, if:
- the (cumulative) amount of payments it requests as reimbursement of actual costs
(and for which no certificate has yet been submitted) is EUR 325 000 or more and
- the maximum grant amount indicated, for that beneficiary or affiliated entity, in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000
or more.
23
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
15.4 Final report — Request for payment of the balance
In addition to the periodic report for the last reporting period, the coordinator must submit the final
report within 60 days following the end of the last reporting period.
The final report must include the following:
(a) a ‘final technical report’ with a summary for publication containing:
(i) an overview of the results and their dissemination;
(ii) the conclusions on the action and
(iii) the impact of the action;
(b) a ‘final financial report’ containing:
(i) a ‘final summary financial statement’ (see Annex 4), created automatically by the
electronic exchange system, consolidating the individual financial statements for all
reporting periods and including the request for payment of the balance and
(ii) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each affiliated entity, if:
- the cumulative amount of payments it requests as reimbursement of actual costs
(and for which no certificate has been submitted) is EUR 325 000 or more and
- the maximum grant amount indicated, for that beneficiary or affiliated entity, in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000
or more.
15.5 Currency for financial statements and conversion into euro
Financial statements must be drafted in euro.
Beneficiaries and affiliated entities with accounting established in a currency other than the euro
must convert the costs recorded in their accounts into euro at the average of the daily exchange
rates published in the C series of the Official Journal of the European Union, calculated over the
corresponding reporting period.
If no daily euro exchange rate is published in the Official Journal of the European Union for the
currency in question, they must be converted at the average of the monthly accounting rates published
on the Commission’s website, calculated over the corresponding reporting period.
Beneficiaries and affiliated entities with accounting established in euro must convert costs incurred
in another currency into euro according to their usual accounting practices.
15.6 Language of reports
All reports (technical and financial reports, including financial statements) must be submitted in the
language of the Agreement.
24
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
15.7 Consequences of non-compliance — Suspension of the payment deadline — Termination
If the reports submitted do not comply with this Article, the Agency may suspend the payment deadline
(see Article 31) and apply any of the other measures described in Chapter 6.
If the coordinator breaches its obligation to submit the reports and if it fails to comply with this
obligation within 30 days following a written reminder sent by the Agency, the Agreement may be
terminated (see Article 34).
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS
16.1 Payments to be made
The following payments will be made to the coordinator:
- one pre-financing payment;
- one or more interim payments, on the basis of the request(s) for interim payment (see
Article 15), and
- one payment of the balance, on the basis of the request for payment of the balance (see
Article 15).
16.2 Pre-financing payment — Amount
The aim of the pre-financing is to provide the beneficiaries with a float.
It remains the property of the EU until the payment of the balance.
The amount of the pre-financing payment will be EUR 799,607.23 (seven hundred and ninety nine
thousand six hundred and seven EURO and twenty three eurocents).
The Agency will — except if Article 32 applies — make the pre-financing payment to the coordinator
within 30 days, either from the entry into force of the Agreement (see Article 42) or from 10 days
before the starting date of the action (see Article 3), whichever is the latest.
16.3 Interim payments — Amount — Calculation
Interim payments reimburse the eligible costs incurred for the implementation of the action during
the corresponding reporting periods.
The Agency will pay to the coordinator the amount due as interim payment within 60 days from
receiving the periodic report (see Article 15.3), except if Articles 31 or 32 apply.
Payment is subject to the approval of the periodic report. Its approval does not imply recognition of
the compliance, authenticity, completeness or correctness of its content.
The amount due as interim payment is calculated by the Agency in the following steps:
Step 1 – Application of the reimbursement rate
25
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Step 2 – Limit to 90% of the maximum grant amount
16.3.1 Step 1 — Application of the reimbursement rate
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate costs;
see Article 6) declared by the beneficiaries and the affiliated entities (see Article 15) and approved
by the Agency (see above) for the concerned reporting period.
16.3.2 Step 2 — Limit to 90% of the maximum grant amount
The total amount of pre-financing and interim payments must not exceed 90% of the maximum grant
amount set out in Article 5.1. The maximum amount for the interim payment will be calculated as
follows:
{90% of the maximum grant amount (see Article 5.1)
minus
{pre-financing and previous interim payments}}.
16.4 Payment of the balance — Amount — Calculation
The payment of the balance reimburses the remaining part of the eligible costs incurred by the
beneficiaries for the implementation of the action.
If the total amount of earlier payments is greater than the final grant amount (see Article 5.3), the
payment of the balance takes the form of a recovery (see Article 28).
If the total amount of earlier payments is lower than the final grant amount, the Agency will pay the
balance within 60 days from receiving the final report (see Article 15.4), except if Articles 31 or 32
apply.
Payment is subject to the approval of the final report. Its approval does not imply recognition of the
compliance, authenticity, completeness or correctness of its content.
The amount due as the balance is calculated by the Agency by deducting the total amount of pre-
financing and interim payments (if any) already made, from the final grant amount determined in
accordance with Article 5.3:
{final grant amount (see Article 5.3)
minus
{pre-financing and interim payments (if any) made}}.
If the balance is positive, it will be paid to the coordinator.
The amount to be paid may however be offset — without the beneficiary’s consent — against any
other amount owed by a beneficiary to the Agency, the Commission or another executive agency
(under the EU or Euratom budget), up to the maximum EU contribution indicated, for that beneficiary,
in the estimated budget (see Annex 2).
If the balance is negative, it will be recovered.
26
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
16.5 Notification of amounts due
When making payments, the Agency will formally notify to the coordinator the amount due,
specifying whether it concerns an interim payment or the payment of the balance.
For the payment of the balance, the notification will also specify the final grant amount.
In the case of reduction of the grant or recovery of undue amounts, the notification will be preceded
by the contradictory procedure set out in Articles 27 and 28.
16.6 Currency for payments
The Agency will make all payments in euro.
16.7 Payments to the coordinator — Distribution to the beneficiaries
Payments will be made to the coordinator.
Payments to the coordinator will discharge the Agency from its payment obligation.
The coordinator must distribute the payments between the beneficiaries without unjustified delay.
Pre-financing may however be distributed only:
(a) if 90% of the beneficiaries have acceded to the Agreement (see Article 40) and
(b) to beneficiaries that have acceded to the Agreement (see Article 40).
16.8 Bank account for payments
All payments will be made to the following bank account:
Name of bank: PIRAEUS BANK SA
Address of branch: 4 AMERIKIS STREET ATHENS, Greece
Full name of the account holder: ELLINIKI ANTIKARNIKI ETAIREIA
Full account number (including bank codes):
IBAN code: GR6301715580006558141582600
16.9 Costs of payment transfers
The cost of the payment transfers is borne as follows:
- the Agency bears the cost of transfers charged by its bank;
- the beneficiary bears the cost of transfers charged by its bank;
- the party causing a repetition of a transfer bears all costs of the repeated transfer.
16.10 Date of payment
Payments by the Agency are considered to have been carried out on the date when they are debited
to its account.
27
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
16.11 Consequences of non-compliance
16.11.1 If the Agency does not pay within the payment deadlines (see above), the beneficiaries are
entitled to late-payment interest at the rate applied by the European Central Bank (ECB) for its main
refinancing operations in euros (‘reference rate’), plus three and a half points. The reference rate is
the rate in force on the first day of the month in which the payment deadline expires, as published in
the C series of the Official Journal of the European Union.
If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only
upon request submitted within two months of receiving the late payment.
Late-payment interest is not due if all beneficiaries are EU Member States (including regional and
local government authorities or other public bodies acting on behalf of a Member State for the purpose
of this Agreement).
Suspension of the payment deadline or payments (see Articles 31 and 32) will not be considered as
late payment.
Late-payment interest covers the period running from the day following the due date for payment (see
above), up to and including the date of payment.
Late-payment interest is not considered for the purposes of calculating the final grant amount.
16.11.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced
(see Article 27) and the Agreement or the participation of the coordinator may be terminated (see
Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION
OF FINDINGS
17.1 Checks, reviews and audits by the Agency and the Commission
17.1.1 Right to carry out checks
The Agency or the Commission will — during the implementation of the action or afterwards — check
the proper implementation of the action and compliance with the obligations under the Agreement,
including assessing deliverables and reports.
For this purpose, the Agency or the Commission may be assisted by external persons or bodies.
The Agency or the Commission may also request additional information in accordance with Article 12.
The Agency or the Commission may request beneficiaries to provide such information to it directly.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
17.1.2 Right to carry out reviews
28
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out reviews on the proper implementation of the action (including assessment of deliverables
and reports) and compliance with the obligations under the Agreement.
Reviews may be started up to five years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the review is carried out on a third party (see Articles 9, 10, 11), the beneficiary concerned must
inform the third party.
The Agency or the Commission may carry out reviews directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information and data in addition to deliverables and reports already submitted (including information
on the use of resources). The Agency or the Commission may request beneficiaries to provide such
information to it directly.
The coordinator or beneficiary concerned may be requested to participate in meetings, including with
external experts.
For on-the-spot reviews, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the review findings, a ‘review report’ will be drawn up.
The Agency or the Commission will formally notify the review report to the coordinator or beneficiary
concerned, which has 30 days to formally notify observations (‘contradictory review procedure’).
Reviews (including review reports) are in the language of the Agreement.
17.1.3 Right to carry out audits
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out audits on the proper implementation of the action and compliance with the obligations under
the Agreement.
Audits may be started up to five years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the audit is carried out on a third party (see Articles 9, 10, 11), the beneficiary concerned must
inform the third party.
The Agency or the Commission may carry out audits directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
29
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information (including complete accounts, individual salary statements or other personal data) to
verify compliance with the Agreement. The Agency or the Commission may request beneficiaries to
provide such information to it directly.
For on-the-spot audits, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the audit findings, a ‘draft audit report’ will be drawn up.
The Agency or the Commission will formally notify the draft audit report to the coordinator or
beneficiary concerned, which has 30 days to formally notify observations (‘contradictory audit
procedure’). This period may be extended by the Agency or the Commission in justified cases.
The ‘final audit report’ will take into account observations by the coordinator or beneficiary
concerned. The report will be formally notified to it.
Audits (including audit reports) are in the language of the Agreement.
The Agency or the Commission may also access the beneficiaries’ statutory records for the periodical
assessment of flat-rate amounts.
17.2 Investigations by the European Anti-Fraud Office (OLAF)
Under Regulations No 883/20135 and No 2185/966 (and in accordance with their provisions and
procedures), the European Anti-Fraud Office (OLAF) may — at any moment during implementation
of the action or afterwards — carry out investigations, including on-the-spot checks and inspections,
to establish whether there has been fraud, corruption or any other illegal activity affecting the financial
interests of the EU.
17.3 Checks and audits by the European Court of Auditors (ECA)
Under Article 287 of the Treaty on the Functioning of the European Union (TFEU) and Article 161 of
the Financial Regulation No 966/20127, the European Court of Auditors (ECA) may — at any moment
during implementation of the action or afterwards — carry out audits.
5 Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013
concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC)
No 1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ
L 232, 18.09.2013, p. 1).
6 Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections
carried out by the Commission in order to protect the European Communities' financial interests against fraud and other
irregularities (OJ L 292, 15.11.1996, p. 2).
7 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the
financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No
1605/2002 (‘Financial Regulation No 966/2012’) (OJ L 298, 26.10.2012, p. 1).
30
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The ECA has the right of access for the purpose of checks and audits.
17.4 Checks, reviews, audits and investigations for international organisations
Not applicable
17.5 Consequences of findings in checks, reviews, audits and investigations —Extension of
findings
17.5.1 Findings in this grant
Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead
to the rejection of ineligible costs (see Article 26), reduction of the grant (see Article 27), recovery of
undue amounts (see Article 28) or to any of the other measures described in Chapter 6.
Rejection of costs or reduction of the grant after the payment of the balance will lead to a revised final
grant amount (see Article 5.4).
Findings in checks, reviews, audits or investigations may lead to a request for amendment for the
modification of Annex 1 (see Article 39).
Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or
breach of obligations may also lead to consequences in other EU or Euratom grants awarded under
similar conditions (‘extension of findings from this grant to other grants’).
Moreover, findings arising from an OLAF investigation may lead to criminal prosecution under
national law.
17.5.2 Findings in other grants
The Agency or the Commission may extend findings from other grants to this grant (‘extension of
findings from other grants to this grant’), if:
(a) the beneficiary concerned is found, in other EU or Euratom grants awarded under similar
conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of
obligations that have a material impact on this grant and
(b) those findings are formally notified to the beneficiary concerned — together with the list of
grants affected by the findings — no later than five years after the payment of the balance
of this grant.
The extension of findings may lead to the rejection of costs (see Article 26), reduction of the grant
(see Article 27), recovery of undue amounts (see Article 28), suspension of payments (see Article 32),
suspension of the action implementation (see Article 33) or termination (see Article 34).
17.5.3 Procedure
The Agency or the Commission will formally notify the beneficiary concerned the systemic or
recurrent errors and its intention to extend these audit findings, together with the list of grants affected.
17.5.3.1 If the findings concern eligibility of costs: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings;
31
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(b) the request to submit revised financial statements for all grants affected;
(c) the correction rate for extrapolation established by the Agency or the Commission on
the basis of the systemic or recurrent errors, to calculate the amounts to be rejected, if the
beneficiary concerned:
(i) considers that the submission of revised financial statements is not possible or
practicable or
(ii) does not submit revised financial statements.
The beneficiary concerned has 90 days from receiving notification to submit observations, revised
financial statements or to propose a duly substantiated alternative correction method. This period
may be extended by the Agency or the Commission in justified cases.
The Agency or the Commission may then start a rejection procedure in accordance with the procedure
set out in Article 26, either on the basis of the revised financial statements or the rate announced.
17.5.3.2 If the findings concern improper implementation or a breach of another obligation: the
formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings and
(b) the flat-rate the Agency or the Commission intends to apply according to the principle of
proportionality.
The beneficiary concerned has 90 days from receiving notification to submit observations or to
propose a duly substantiated alternative flat-rate.
The Agency or the Commission may then start a reduction procedure in accordance with the procedure
set out in Article 27, either on the basis of the alternative flat-rate or the flat-rate announced.
17.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, any insufficiently substantiated costs
will be ineligible (see Article 6) and will be rejected (see Article 26).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION
18.1 Right to evaluate the impact of the action
The Agency or the Commission may carry out interim and final evaluations of the impact of the action
measured against the objective of the EU programme.
Evaluations may be started during implementation of the action and up to five years after the
payment of the balance. The evaluation is considered to start on the date of the formal notification
to the coordinator or beneficiaries.
The Agency or the Commission may make these evaluations directly (using its own staff) or indirectly
(using external bodies or persons it has authorised to do so).
32
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the
action, including information in electronic format.
18.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the Agency may apply the measures
described in Chapter 6.
SECTION 3 OTHER RIGHTS AND OBLIGATIONS
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS
(INCLUDING INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS)
19.1 Pre-existing rights and access rights to pre-existing rights
Where industrial and intellectual property rights (including rights of third parties) exist prior to the
Agreement, the beneficiaries must establish a list of these pre-existing industrial and intellectual
property rights, specifying the owner and any persons that have a right of use.
The coordinator must — before starting the action — submit this list to the Agency.
The beneficiaries must give each other (and their affiliated entities) access to any pre-existing
industrial and intellectual property rights needed for the implementation of the action and compliance
with the obligations under the Agreement.
19.2 Ownership of results and rights of use
The results of the action (including the reports and other documents relating to it) are owned by the
beneficiaries.
The beneficiaries must give the Agency and the Commission the right to use the results for their
communication activities under Article 22.
19.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 20 — CONFLICT OF INTERESTS
20.1 Obligation to avoid a conflict of interests
The beneficiaries must take all measures to prevent any situation where the impartial and objective
implementation of the action is compromised for reasons involving economic interest, political or
national affinity, family or emotional ties or any other shared interest (‘conflict of interests’).
They must formally notify to the Agency without delay any situation constituting or likely to lead to
a conflict of interests and immediately take all the necessary steps to rectify this situation.
33
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The Agency may verify that the measures taken are appropriate and may require additional measures
to be taken by a specified deadline.
20.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27) and the Agreement or participation of the beneficiary may be terminated (see Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 21 — CONFIDENTIALITY
21.1 General obligation to maintain confidentiality
During implementation of the action and for five years after the payment of the balance, the parties
must keep confidential any data, documents or other material (in any form) that is identified as
confidential at the time it is disclosed (‘confidential information’).
They may use confidential information to implement the Agreement.
The confidentiality obligations no longer apply if:
(a) the disclosing party agrees to release the other party;
(b) the information becomes generally and publicly available, without breaching any
confidentiality obligation;
(c) the disclosure of the confidential information is required by EU or national law.
21.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING
22.1 Communication activities by the beneficiaries
22.1.1 General obligation to promote the action and its results
The beneficiaries must promote the action and its results.
22.1.2 Information on EU funding — Obligation and right to use of the EU emblem
Unless the Agency requests or agrees otherwise, any communication activity related to the action
(including at conferences, seminars, in information material, such as brochures, leaflets, posters,
presentations, etc., in electronic form, via social media, etc.) and any infrastructure, equipment or
major results funded by the grant must:
34
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(a) display the EU emblem and
(b) include the following text:
“This [insert appropriate description, e.g. report, publication, conference, infrastructure, equipment, insert
type of result, etc.] is part of the project / joint action ‘761297 / JATC’ which has received funding from the
European Union’s Health Programme (2014-2020).”
When displayed in association with another logo, the EU emblem must have appropriate prominence.
For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem
without first obtaining approval from the Agency.
This does not, however, give them the right to exclusive use.
Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by
registration or by any other means.
22.1.3 Disclaimer excluding Agency/Commission responsibility
Any communication activity related to the action must indicate the following disclaimer:
“The content of this [insert appropriate description, e.g. report, publication, conference, etc.] represents the
views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the
European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other
body of the European Union. The European Commission and the Agency do not accept any responsibility for
use that may be made of the information it contains.”
22.2 Communication activities by the Agency
22.2.1 Right to use the beneficiaries’ materials, documents or information
The Agency may use information relating to the action, documents notably summaries for publication
and public deliverables as well as any other material, such as pictures or audio-visual material that it
receives from any beneficiary (including in electronic form).
This does not change the confidentiality obligations in Article 21, which still apply.
The right to use the beneficiary’s materials, documents and information includes:
(a) use for its own purposes (in particular, making them available to persons working for the
Agency or any other EU institution, body, office or agency or body or institutions in EU
Member States; and copying or reproducing them in whole or in part, in unlimited numbers);
(b) distribution to the public (in particular, publication as hard copies and in electronic or digital
format, publication on the internet, as a downloadable or non-downloadable file, broadcasting
by any channel, public display or presentation, communicating through press information
services, or inclusion in widely accessible databases or indexes);
(c) editing or redrafting for communication and publicising activities (including shortening,
summarising, inserting other elements (such as meta-data, legends, other graphic, visual, audio
or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a
compilation);
35
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(d) translation;
(e) giving access in response to individual requests under Regulation No 1049/20018, without
the right to reproduce or exploit;
(f) storage in paper, electronic or other form;
(g) archiving, in line with applicable document-management rules, and
(h) the right to authorise third parties to act on its behalf or sub-license the modes of use set out
in Points (b),(c),(d) and (f) to third parties if needed for the communication and publicising
activities of the Agency.
If the right of use is subject to rights of a third party (including personnel of the beneficiary), the
beneficiary must ensure that it complies with its obligations under this Agreement (in particular, by
obtaining the necessary approval from the third parties concerned).
Where applicable (and if provided by the beneficiary), the Agency will insert the following
information:
“© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) under conditions.”
22.3 Consequences of non-compliance
If the beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 23 — PROCESSING OF PERSONAL DATA
23.1 Processing of personal data by the Agency and the Commission
Any personal data under the Agreement will be processed by the Agency or the Commission under
Regulation No 23/20019 and according to the ‘notifications of the processing operations’ to the Data
Protection Officer (DPO) of the Agency or the Commission (publicly accessible in the DPO register).
Such data will be processed by the ‘data controller’ of the Agency or the Commission, for the
purposes of implementing, managing and monitoring the Agreement or protecting the financial
interests of the EU or Euratom (including checks, reviews, audits and investigations; see Article 17).
The persons whose personal data are processed have the right to access and correct their own personal
data. For this purpose, they must send any queries about the processing of their personal data to the data
controller, via the contact point indicated in the privacy statement(s) on the Agency and Commission
websites.
8 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access
to European Parliament, Council and Commission documents, OJ L 145, 31.5.2001, p. 43.
9 Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection
of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free
movement of such data (OJ L 8, 12.01.2001, p. 1).
36
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
They also have the right to have recourse at any time to the European Data Protection Supervisor
(EDPS).
23.2 Processing of personal data by the beneficiaries
The beneficiaries must process personal data under the Agreement in compliance with applicable EU
and national law on data protection (including authorisations or notification requirements).
The beneficiaries may grant their personnel access only to data that is strictly necessary for
implementing, managing and monitoring the Agreement.
The beneficiaries must inform the personnel whose personal data are collected and processed by the
Agency or the Commission. For this purpose, they must provide them with the privacy statement(s)
(see above), before transmitting their data to the Agency or the Commission.
23.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 23.2, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY
The beneficiaries may not assign any of their claims for payment against the Agency to any third
party, except if approved by the Agency on the basis of a reasoned, written request by the coordinator
(on behalf of the beneficiary concerned).
If the Agency has not accepted the assignment or the terms of it are not observed, the assignment
will have no effect on it.
In no circumstances will an assignment release the beneficiaries from their obligations towards the
Agency.
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
25.1 Roles and responsibilities towards the Agency
The beneficiaries have full responsibility for implementing the action and complying with the
Agreement.
The beneficiaries are jointly and severally liable for the technical implementation of the action as
described in Annex 1. If a beneficiary fails to implement its part of the action, the other beneficiaries
become responsible for implementing this part (without being entitled to any additional EU funding
for doing so), unless the Agency expressly relieves them of this obligation.
The financial responsibility of each beneficiary is governed by Articles 28, 29 and 30.
25.2 Internal division of roles and responsibilities
The internal roles and responsibilities of the beneficiaries are divided as follows:
37
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(a) Each beneficiary must:
(i) keep information stored in the 'Beneficiary Register' (via the electronic exchange
system) up to date (see Article 12);
(ii) inform the coordinator immediately of any events or circumstances likely to affect
significantly or delay the implementation of the action (see Article 12);
(iii) submit to the coordinator in good time:
- individual financial statements for itself and its affiliated entities and, if
required, certificates on the financial statements (see Article 15);
- the data needed to draw up the technical reports (see Article 15);
- any other documents or information required by the Agency or the Commission
under the Agreement, unless the Agreement requires the beneficiary to submit
this information directly to the Agency or the Commission.
(b) The coordinator must:
(i) monitor that the action is implemented properly (see Article 7);
(ii) act as the intermediary for all communications between the beneficiaries and the
Agency (in particular, providing the Agency with the information described in
Article 12), unless the Agreement specifies otherwise;
(iii) provide a pre-financing guarantee if requested by the Agency (see Article 16.2);
(iv) request and review any documents or information required by the Agency and verify
their completeness and correctness before passing them on to the Agency;
(v) submit the deliverables and reports to the Agency (see Articles 14 and 15);
(vi) ensure that all payments are made to the other beneficiaries without unjustified delay
(see Article 16).
The coordinator may not delegate the above-mentioned tasks to any other beneficiary or subcontract
them to any third party.
25.3 Internal arrangements between beneficiaries — Consortium agreement
The beneficiaries must have internal arrangements regarding their operation and co-ordination to
ensure that the action is implemented properly. These internal arrangements must be set out in a written
‘consortium agreement’ between the beneficiaries, which may cover:
- internal organisation of the consortium;
- management of access to the electronic exchange system;
38
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
- distribution of EU funding;
- additional rules on rights and obligations related to background and results (including whether
access rights remain or not, if a beneficiary is in breach of its obligations) (see Section 3 of
Chapter 4);
- settlement of internal disputes;
- liability, indemnification and confidentiality arrangements between the beneficiaries.
The consortium agreement must not contain any provision contrary to the Agreement.
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— PENALTIES — DAMAGES — SUSPENSION — TERMINATION — FORCE
MAJEURE
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— PENALTIES
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS
26.1 Conditions
26.1.1 The Agency will — at the time of an interim payment, at the payment of the balance or
afterwards — reject any costs which are ineligible (see Article 6), in particular following checks,
reviews, audits or investigations (see Article 17).
26.1.2 The rejection may also be based on the extension of findings from other grants to this grant,
under the conditions set out in Article 17.5.2.
26.2 Ineligible costs to be rejected — Calculation — Procedure
Ineligible costs will be rejected in full.
If the Agency rejects costs without reduction of the grant (see Article 27) or recovery of undue
amounts (see Article 28), it will formally notify the coordinator or beneficiary concerned the rejection
of costs, the amounts and the reasons why (if applicable, together with the notification of amounts
due; see Article 16.5). The coordinator or beneficiary concerned may — within 30 days of receiving
notification — formally notify the Agency of its disagreement and the reasons why.
If the Agency rejects costs with reduction of the grant or recovery of undue amounts , it will
formally notify the rejection in the ‘pre-information letter’ on reduction or recovery set out in
Articles 27 and 28.
26.3 Effects
If the Agency rejects costs at the time of an interim payment or the payment of the balance, it will
deduct them from the total eligible costs declared, for the action, in the periodic or final summary
financial statement (see Articles 15.3 and 15.4). It will then calculate the interim payment or payment
of the balance as set out in Articles 16.3 or 16.4.
39
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
If the Agency — after an interim payment but before the payment of the balance — rejects costs
declared in a periodic summary financial statement, it will deduct them from the total eligible costs
declared, for the action, in the next periodic summary financial statement or in the final summary
financial statement. It will then calculate the interim payment or payment of the balance as set out
in Articles 16.3 or 16.4.
If the Agency rejects costs after the payment of the balance, it will deduct the amount rejected from
the total eligible costs declared, by the beneficiary, in the final summary financial statement. It will
then calculate the revised final grant amount as set out in Article 5.4.
ARTICLE 27 — REDUCTION OF THE GRANT
27.1 Conditions
27.1.1 The Agency may — at the payment of the balance or afterward — reduce the maximum
grant amount (see Article 5.1), if the action has not been implemented properly as described in Annex
1 to the Specific Agreement concerned or another obligation under the Agreement has been breached.
27.1.2 The Agency may also reduce the maximum grant amount on the basis of the extension of
findings from other grants to this grant, under the conditions set out in Article 17.5.2.
27.2 Amount to be reduced — Calculation — Procedure
The amount of the reduction will be proportionate to the improper implementation of the action or
to the seriousness of the breach.
Before reduction of the grant, the Agency will formally notify a ‘pre-information letter’ to the
coordinator or beneficiary concerned:
- informing it of its intention to reduce the grant, the amount it intends to reduce and the reasons
why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive any observations or decides to pursue reduction despite the observations
it has received, it will formally notify confirmation of the reduction (if applicable, together with the
notification of amounts due; see Article 16).
27.3 Effects
If the Agency reduces the grant at the time of the payment of the balance, it will calculate the
reduced grant amount for the action and then determine the amount due as payment of the balance
(see Article 5.3.4 and Article 16.4).
If the Agency reduces the grant after the payment of the balance, it will calculate the revised final
grant amount (see Article 5.4). If the revised final grant amount is lower than the final grant amount,
the Agency will recover the difference (see Article 28).
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS
40
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
28.1 Amount to be recovered — Calculation — Procedure
The Agency will — at the payment of the balance or afterwards — claim back amount that was
paid but is not due under the Agreement.
The coordinator is fully liable for repaying debts of the consortium (under the Agreement) even if it
has not been the final recipient of those amounts.
In addition, the beneficiaries (including the coordinator) are jointly and severally liable for repaying
any unpaid debts under the Agreement (due by the consortium or any beneficiary, including late-
payment interest) — up to the maximum EU contribution indicated, for each beneficiary, in the
estimated budget (as last amended; see Annex 2).
Undue amounts paid by the Agency for costs declared by an affiliated entity will be considered as
amounts unduly paid to the beneficiary.
28.1.1 Recovery at payment of the balance
If the payment of the balance takes the form of a recovery (see Article 16.4), the Agency will formally
notify a ‘pre-information letter’ to the coordinator:
- informing it of its intention to recover, the amount due as the balance and the reasons why and
- inviting the coordinator to submit observations within 30 days of receiving notification.
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator a
debit note with the terms and the date for payment (together with the notification of amounts due;
see Article 16.5).
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s consent — against any amounts owed to the
coordinator by the Agency, Commission or another executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) not applicable;
(c) by holding the other beneficiaries jointly and severally liable — up to the maximum EU
contribution indicated, for each beneficiary, in the estimated budget (as last amended; see
Annex 2);
(d) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
41
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
28.1.2 Recovery of amounts after payment of the balance
If — after the payment of the balance — the Agency revised the final grant amount for the action (see
Article 5.4), due to a rejection of costs or reduction of the grant, and the revised final grant amount is
lower than the final grant amount (see Article 5.3), the Agency will:
- if the rejection or reduction does not concern a specific beneficiary (or its affiliated entities):
claim back the difference from the coordinator (even if it has not been the final recipient of
the amount in question)
or
- otherwise: claim back the difference from the beneficiary concerned.
The Agency will formally notify a pre-information letter to the coordinator or beneficiary concerned:
- informing it of its intention to recover, the amount to be repaid and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator or
beneficiary concerned a debit note. This note will also specify the terms and the date for payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s or beneficiary’s consent — against any amounts
owed to the coordinator or beneficiary by the Agency, Commission or another executive agency
(from the EU or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) by holding the other beneficiaries jointly and severally liable, up to the maximum EU
contribution indicated, for each beneficiary, in the estimated budget (as last amended; see
Annex 2);
(c) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
42
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the date
for payment in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
ARTICLE 29 — ADMINISTRATIVE AND FINANCIAL PENALTIES
29.1 Conditions
Under Articles 109 and 131(4) of the Financial Regulation No 966/2012, the Agency may impose
administrative and financial penalties if a beneficiary:
(a) has committed substantial errors, irregularities or fraud or is in serious breach of its obligations
under the Agreement or
(b) has made false declarations about information required under the Agreement or for the
submission of the proposal (or has not supplied such information).
Each beneficiary is responsible for paying the financial penalties imposed on it.
Under Article 109(3) of the Financial Regulation No 966/2012, the Agency or the Commission may —
under certain conditions and limits — publish decisions imposing administrative or financial penalties.
29.2 Duration — Amount of penalty — Calculation
Administrative penalties exclude the beneficiary from all contracts and grants financed from the EU
or Euratom budget for a maximum of five years from the date the infringement is established by the
Agency.
If the beneficiary commits another infringement within five years of the date the first infringement is
established, the Agency may extend the exclusion period up to 10 years.
Financial penalties will be between 2% and 10% of the maximum EU contribution indicated, for the
beneficiary concerned, in the estimated budget (see Annex 2).
If the beneficiary commits another infringement within five years of the date the first infringement is
established, the Agency may increase the rate of financial penalties to between 4% and 20%.
29.3 Procedure
Before applying a penalty, the Agency will formally notify the beneficiary concerned:
- informing it of its intention to impose a penalty, its duration or amount and the reasons why and
- inviting it to submit observations within 30 days.
43
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
If the Agency does not receive any observations or decides to impose the penalty despite of
observations it has received, it will formally notify confirmation of the penalty to the beneficiary
concerned and — in case of financial penalties — deduct the penalty from the payment of the balance
or formally notify a debit note, specifying the amount to be recovered, the terms and the date for
payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission may
recover the amount:
(a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Agency, Commission or another executive agency (from the EU
or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date in the debit note;
(b) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
SECTION 2 LIABILITY FOR DAMAGES
ARTICLE 30 — LIABILITY FOR DAMAGES
30.1 Liability of the Agency
The Agency cannot be held liable for any damage caused to the beneficiaries or to third parties as a
consequence of implementing the Agreement, including for gross negligence.
The Agency cannot be held liable for any damage caused by any beneficiaries or third parties involved
in the action, as a consequence of implementing the Agreement.
30.2 Liability of the beneficiaries
30.2.1 Conditions
Except in case of force majeure (see Article 35), the beneficiaries must compensate the Agency for
any damage it sustains as a result of the implementation of the actione or because the action was not
implemented in full compliance with the Agreement.
44
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Each beneficiary is responsible for paying the damages claimed from it.
30.2.2 Amount of damages - Calculation
The amount the Agency can claim from a beneficiary will correspond to the damage caused by that
beneficiary.
30.2.3 Procedure
Before claiming damages, the Agency will formally notify the beneficiary concerned:
- informing it of its intention to claim damages, the amount and the reasons why and
- inviting it to submit observations within 30 days.
If the Agency does not receive any observations or decides to claim damages despite the observations
it has received, it will formally notify confirmation of the claim for damages and a debit note,
specifying the amount to be recovered, the terms and the date for payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission may
recover the amount:
(a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Agency, Commission or another executive agency (from the EU
or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date in the debit note;
(b) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 79(2) of the Financial Regulation No 966/2012 and Article 299 of the Treaty on the
Functioning of the EU (TFEU).
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
SECTION 3 SUSPENSION AND TERMINATION
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE
31.1 Conditions
The Agency may — at any moment — suspend the payment deadline (see Article 16.2 to 16.4) if a
request for payment (see Article 15) cannot be approved because:
45
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(a) it does not comply with the provisions of the Agreement (see Article 15);
(b) the technical reports or financial reports have not been submitted or are not complete or
additional information is needed, or
(c) there is doubt about the eligibility of the costs declared in the financial statements and additional
checks, reviews, audits or investigations are necessary.
31.2 Procedure
The Agency will formally notify the coordinator of the suspension and the reasons why.
The suspension will take effect the day notification is sent by the Agency (see Article 36).
If the conditions for suspending the payment deadline are no longer met, the suspension will be lifted
— and the remaining period will resume.
If the suspension exceeds two months, the coordinator may request the Agency if the suspension will
continue.
If the payment deadline has been suspended due to the non-compliance of the technical or financial
reports (see Article 15) and the revised report or statement is not submitted or was submitted but is
also rejected, the Agency may also terminate the Agreement or the participation of the beneficiary
(see Article 34.3.1).
ARTICLE 32 — SUSPENSION OF PAYMENTS
32.1 Conditions
The Agency may — at any moment — suspend, in whole or in part, the pre-financing payment and
interim payments for one or more beneficiaries or the payment of the balance for all beneficiaries,
if a beneficiary:
(a) has committed or is suspected of having committed substantial errors, irregularities, fraud or
serious breach of obligations in the award procedure or under this Agreement or
(b) has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
32.2 Procedure
Before suspending payments, the Agency will formally notify the coordinator:
- informing it of its intention to suspend payments and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the suspension procedure is not continued.
46
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The suspension will take effect the day the confirmation notification is sent by the Agency.
If the conditions for resuming payments are met, the suspension will be lifted. The Agency will
formally notify the coordinator.
During the suspension, the periodic report(s) (see Article 15.3) must not contain any individual
financial statements from the beneficiary concerned and its affiliated entities. When the Agency
resumes payments, the coordinator may include them in the next periodic report.
The beneficiaries may suspend implementation of the action (see Article 33.1) or terminate the
Agreement or the participation of the beneficiary concerned (see Article 34.1 and 34.2).
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION
33.1 Suspension of the action implementation, by the beneficiaries
33.1.1 Conditions
The beneficiaries may suspend implementation of the action or any part of it, if exceptional
circumstances — in particular force majeure (see Article 35) — make implementation impossible or
excessively difficult.
33.1.2 Procedure
The coordinator must immediately formally notify to the Agency the suspension (see Article 36),
stating:
- the reasons why and
- the expected date of resumption.
The suspension will take effect the day this notification is received by the Agency.
Once circumstances allow for implementation to resume, the coordinator must immediately formally
notify the Agency and request an amendment of the Agreement, to set the date on which the action
will be resumed, extend the duration of the action and make other changes necessary to adapt the action
to the new situation (see Article 39) — unless the Agreement or the participation of a beneficiary has
been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This
date may be before the date on which the amendment enters into force.
Costs incurred during suspension of the action implementation are not eligible (see Article 6).
33.2 Suspension of the action implementation, by the Agency
33.2.1 Conditions
The Agency may suspend implementation of the action or any part of it:
47
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(a) if a beneficiary has committed or is suspected of having committed substantial errors,
irregularities, fraud or serious breach of obligations in the award procedure or under this
Agreement or
(b) if a beneficiary has committed — in other EU or Euratom grants awarded to it under similar
conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations
that have a material impact on this grant (extension of findings from other grants to this
grant; see Article 17.5.2).
33.2.2 Procedure
Before suspending implementation of the action, the Agency will formally notify the coordinator:
- informing it of its intention to suspend the implementation and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the procedure is not continued.
The suspension will take effect five days after confirmation notification is received by the coordinator
(or on a later date specified in the notification).
It will be lifted if the conditions for resuming implementation of the action are met.
The coordinator will be formally notified of the lifting and the Agreement will be amended, to set the
date on which the action will be resumed, extend the duration of the action and make other changes
necessary to adapt the action to the new situation (see Article 39) — unless the Agreement has already
been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This date
may be before the date on which the amendment enters into force.
Costs incurred during suspension are not eligible (see Article 6).
The beneficiaries may not claim damages due to suspension by the Agency (see Article 30).
Suspension of the action implementation does not affect the Agency’s right to terminate the Agreement
or participation of a beneficiary (see Article 34), reduce the grant or recover amounts unduly paid
(see Articles 27 and 28).
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION
OF ONE OR MORE BENEFICIARIES
34.1 Termination of the Agreement, by the beneficiaries
34.1.1 Conditions and procedure
The beneficiaries may terminate the Agreement.
The coordinator must formally notify termination to the Agency (see Article 36), stating:
48
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
- the reasons why and
- the date the termination will take effect. This date must be after the notification.
If no reasons are given or if the Agency the Agreement will be considered to have been ‘terminated
improperly’.
The termination will take effect on the day specified in the notification.
34.1.2 Effects
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a periodic report (for the open reporting period until termination; see Article 15.3) and
(ii) the final report (see Article 15.4).
If the Agency does not receive the reports within the deadline (see above), only costs which are
included in an approved periodic report will be taken into account.
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see Article 16.4)
on the basis of the reports submitted. Only costs incurred until termination are eligible (see Article 6).
Costs relating to contracts due for execution only after termination are not eligible.
Improper termination may lead to a reduction of the grant (see Article 27).
After termination, the beneficiaries’ obligations (in particular, Articles 15, 17, 18, Section 3 of Chapter
4, 21, 22 and 24) continue to apply.
34.2 Termination of the Specific Agreement, by the Agency
34.2.1 Conditions and procedure
The participation of one or more beneficiaries may be terminated by the coordinator, on request of
the beneficiary concerned or on behalf of the other beneficiaries.
The coordinator must formally notify termination to the Agency (see Article 36) and inform the
beneficiary concerned.
If the coordinator’s participation is terminated without its agreement, the formal notification must be
done by another beneficiary (acting on behalf of the other beneficiaries).
The notification must include:
- the reasons why;
- the opinion of the beneficiary concerned (or proof that this opinion has been requested in
writing);
- the date the termination takes effect. This date must be after the notification, and
- a request for amendment (see Article 39), with a proposal for reallocation of the tasks and the
estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the
49
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
addition of one or more new beneficiaries (see Article 40). If termination takes effect after the
period set out in Article 3, no request for amendment must be included, unless the beneficiary
concerned is the coordinator. In this case, the request for amendment must propose a new
coordinator.
If this information is not given or if the Agency considers that the reasons do not justify termination,
the participation will be considered to have been terminated improperly.
The termination will take effect on the day specified in the notification.
34.2.2 Effects
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to the date
when termination takes effect.
This information must be included by the coordinator in the periodic report for the next reporting
period (see Article 15.3).
If the request for amendment is rejected by the Agency (because it calls into question the decision
awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be
terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to introduce the
necessary changes (see Article 39).
Improper termination may lead to a reduction of the grant (see Article 27) or termination of the
Agreement (see Article 34).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18, Section
3 of Chapter 4, 21, 22 and 24) continue to apply.
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency
34.3.1 Conditions
The Agency may terminate the Agreement or the participation of one or more beneficiaries, if:
(a) one or more beneficiaries do not accede to the Agreement (see Article 40);
(b) a change to their legal, financial, technical, organisational or ownership situation (or those of
its affiliated entities) is likely to substantially affect or delay the implementation of the action
or calls into question the decision to award the grant;
(c) following termination of participation for one or more beneficiaries (see above), the necessary
changes to the Agreement would call into question the decision awarding the grant or breach
the principle of equal treatment of applicants (see Article 39);
50
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(d) implementation of the action is prevented by force majeure (see Article 35) or suspended by
the coordinator (see Article 33.1) and either:
(i) resumption is impossible, or
(ii) the necessary changes to the Agreement would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants;
(e) a beneficiary is declared bankrupt, being wound up, having its affairs administered by the
courts, has entered into an arrangement with creditors, has suspended business activities, or
is subject to any other similar proceedings or procedures under national law;
(f) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has been found guilty of professional misconduct, proven by any means;
(g) a beneficiary does not comply with the applicable national law on taxes and social security;
(h) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed fraud, corruption, or is involved in a criminal organisation, money
laundering or any other illegal activity affecting the EU’s financial interests;
(i) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has — in the award procedure or under the Agreement — committed:
(i) substantial errors, irregularities, fraud or
(ii) serious breach of obligations, including improper implementation of the action,
submission of false information, failure to provide required information, breach of
ethical principles;
(j) a beneficiary has committed — in other EU or Euratom grants awarded to it under similar
conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations
that have a material impact on this grant (‘extension of findings from other grants to this
grant’).
34.3.2 Procedure
Before terminating the Agreement or participation of one or more beneficiaries, the Agency will
formally notify the coordinator:
- informing it of its intention to terminate and the reasons why and
- inviting it, within 30 days of receiving notification, to submit observations and — in case of
Point (i.ii) above — to inform the Agency of the measures to ensure compliance with the
obligations under the Agreement.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify to the coordinator confirmation of the termination and the date
it will take effect. Otherwise, it will formally notify that the procedure is not continued.
The termination will take effect:
51
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
- for terminations under Points (b), (c), (e), (g) and (i.ii) above: on the day specified in the
notification of the confirmation (see above);
- for terminations under Points (a), (d), (f), (h), (i.i) and (j) above: on the day after the notification
of the confirmation is received by the coordinator.
34.3.3 Effects
(a) for termination of the Agreement:
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a periodic report (for the last open reporting period until termination; see Article 15.3)
and
(ii) a final report (see Article 15.4).
If the Agreement is terminated for breach of the obligation to submit the reports (see
Articles 15.7 and 34.3.1), the coordinator may not submit any reports after termination.
If the Agency does not receive the reports within the deadline (see above), only costs which
are included in an approved periodic report will be taken into account.
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see
Article 16.4) on the basis of the reports submitted. Only costs incurred until termination takes
effect are eligible (see Article 6). Costs relating to contracts due for execution only after
termination are not eligible.
This does not affect the Agency's right to reduce the grant (see Article 27) or to impose
administrative and financial penalties (Article 29).
The beneficiaries may not claim damages due to termination by the Agency (see Article 30).
After termination, the beneficiaries’ obligations (in particular Articles 15, 17, 18, Section 3 of
Chapter 4, 21, 22 and 24) continue to apply.
(b) for termination of the participation of one or more beneficiaries:
The coordinator must — within 60 days from when termination takes effect — submit a request
for amendment (see Article 39), with a proposal for reallocation of the tasks and estimated
budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the addition of
one or more new beneficiaries (see Article 40). If termination is notified after the period set out
in Article 3, no request for amendment must be submitted unless the beneficiary concerned is
the coordinator. In this case the request for amendment must propose a new coordinator.
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
52
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(ii) a financial statement covering the period from the end of the last reporting period to
the date when termination takes effect.
This information must be included by the coordinator in the periodic report for the next
reporting period (see Article 15.3).
If the request for amendment is rejected by the Agency (because it calls into question the
decision awarding the grant or breaches the principle of equal treatment of applicants), the
Agreement may be terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to
introduce the necessary changes (see Article 39).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18,
Section 3 of Chapter 4, 21, 22 and 24) continue to apply.
SECTION 4 FORCE MAJEURE
ARTICLE 35 — FORCE MAJEURE
‘Force majeure’ means any situation or event that:
- prevents either party from fulfilling their obligations under the Agreement,
- was unforeseeable, exceptional situation and beyond the parties’ control,
- was not due to error or negligence on their part (or on the part of third parties involved in the
action), and
- proves to be inevitable in spite of exercising all due diligence.
The following cannot be invoked as force majeure:
- any default of a service, defect in equipment or material or delays in making them available,
unless they stem directly from a relevant case of force majeure,
- labour disputes or strikes, or
- financial difficulties.
Any situation constituting force majeure must be formally notified to the other party without delay,
stating the nature, likely duration and foreseeable effects.
The parties must immediately take all the necessary steps to limit any damage due to force majeure
and do their best to resume implementation of the action as soon as possible.
The party prevented by force majeure from fulfilling its obligations under the Agreement cannot be
considered in breach of them.
53
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAPTER 7 FINAL PROVISIONS
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES
36.1 Form and means of communication
Communication under the Agreement (information, requests, submissions, 'formal notifications', etc.)
must:
- be made in writing and
- bear the number of the Agreement.
Until the payment of the balance: all communication must be made through the electronic exchange
system and using the forms and templates provided there.
After the payment of the balance: formal notifications must be made by registered post with proof
of delivery (‘formal notification on paper’).
Communications in the electronic exchange system must be made by persons authorised according
to the ‘Terms and Conditions of Use of the electronic exchange system’. For naming the authorised
persons, the partner must have designated— before the signature of the Framework Partnership
Agreement — a ‘Legal Entity Appointed Representative (LEAR)’. The role and tasks of the LEAR are
stipulated in his/her appointment letter (see Terms and Conditions of Use of the electronic exchange
system).
If the electronic exchange system is temporarily unavailable, instructions will be given on the Agency
and Commission websites.
36.2 Date of communication
Communications are considered to have been made when they are sent by the sending party (i.e. on
the date and time they are sent through the electronic exchange system).
Formal notifications through the electronic exchange system are considered to have been made when
they are received by the receiving party (i.e. on the date and time of acceptance by the receiving party,
as indicated by the time stamp). A formal notification that has not been accepted within 10 days after
sending is considered to have been accepted.
Formal notifications on paper sent by registered post with proof of delivery (only after the payment
of the balance) are considered to have been made on either:
- the delivery date registered by the postal service or
- the deadline for collection at the post office.
If the electronic exchange system is temporarily unavailable, the sending party cannot be considered
in breach of its obligation to send a communication within a specified deadline.
36.3 Addresses for communication
The electronic exchange system must be accessed via the following URL:
54
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
https://ec.europa.eu/research/participants/portal/desktop/en/projects/
The Agency will formally notify the coordinator and beneficiaries in advance any changes to this URL.
Formal notifications on paper (only after the payment of the balance) addressed to the Agency must
be sent to the following address:
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA)
Health Unit Health Unit
Drosbach Building
L-2920 Luxembourg
Formal notifications on paper (only after the payment of the balance) addressed to the beneficiaries
must be sent to their legal address as specified in the 'Beneficiary Register'.
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT
37.1 Precedence of the Terms and Conditions over the Annexes
The provisions in the Terms and Conditions of the Agreement take precedence over its Annexes.
Annex 2 takes precedence over Annex 1.
37.2 Privileges and immunities
Not applicable
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES
In accordance with Regulation No 1182/7110, periods expressed in days, months or years are calculated
from the moment the triggering event occurs.
The day during which that event occurs is not considered as falling within the period.
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT
39.1 Conditions
The Agreement may be amended, unless the amendment entails changes to the Agreement which
would call into question the decision awarding the grant or breach the principle of equal treatment
of applicants.
Amendments may be requested by any of the parties.
39.2 Procedure
The party requesting an amendment must submit a request for amendment signed in the electronic
exchange system (see Article 36).
10 Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods,
dates and time-limits (OJ L 124, 8/6/1971, p. 1).
55
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see
Annex 3).
If a change of coordinator is requested without its agreement, the submission must be done by another
beneficiary (acting on behalf of the other beneficiaries).
The request for amendment must include:
- the reasons why;
- the appropriate supporting documents, and
- for a change of coordinator without its agreement: the opinion of the coordinator (or proof that
this opinion has been requested in writing).
The Agency may request additional information.
If the party receiving the request agrees, it must sign the amendment in the electronic exchange system
within 45 days of receiving notification (or any additional information the Agency has requested). If
it does not agree, it must formally notify its disagreement within the same deadline. The deadline may
be extended, if necessary for the assessment of the request. If no notification is received within the
deadline, the request is considered to have been rejected.
An amendment enters into force on the day of the signature of the receiving party.
An amendment takes effect on the date agreed by the parties or, in the absence of such an agreement,
on the date on which the amendment enters into force.
ARTICLE 40 — ACCESSION TO THE AGREEMENT
40.1 Accession of the beneficiaries mentioned in the Preamble
The other beneficiaries must accede to the Agreement by signing the Accession Form (see Annex 3) in
the electronic exchange system (see Article 36) within 30 days after its entry into force (see Article 42).
They will assume the rights and obligations under the Agreement with effect from the date of its entry
into force (see Article 42).
If a beneficiary does not accede to the Agreement within the above deadline, the coordinator must
— within 30 days — request an amendment to make any changes necessary to ensure proper
implementation of the action. This does not affect the Agency's right to terminate the Agreement (see
Article 34).
40.2 Addition of new beneficiaries
In justified cases, the beneficiaries may request the addition of a new beneficiary.
For this purpose, the coordinator must submit a request for amendment in accordance with Article 39.
It must include an Accession Form (see Annex 3) signed by the new beneficiary in the electronic
exchange system (see Article 36).
56
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
New beneficiaries must assume the rights and obligations under the Agreement with effect from the
date of their accession specified in the Accession Form (see Annex 3).
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES
41.1 Applicable law
The Agreement is governed by the applicable EU law, supplemented if necessary by the law of
Belgium.
41.2 Dispute settlement
If a dispute concerning the interpretation, application or validity of the Agreement cannot be settled
amicably, the General Court — or, on appeal, the Court of Justice of the European Union — has sole
jurisdiction. Such actions must be brought under Article 272 of the Treaty on the Functioning of the
EU (TFEU).
As an exception, if such a dispute is between the Agency and ‘EMBAETTI LANDLAEKNIS’,
‘FOLKEHELSEINSTITUTTET’, ‘STATENS LEGEMIDDELVERK’, ‘INSTITUT ZA JAVNO
ZDRAVLJE SRBIJE 'MILAN JOVANOVIC - BATUT'’, the competent Belgian courts have sole
jurisdiction.
If a dispute concerns administrative or financial penalties, offsetting or an enforceable decision under
Article 79(2) of the Financial Regulation No 966/2012 and Article 299 TFEU (see Articles 28, 29 and
30), the beneficiaries must bring action before the General Court — or, on appeal, the Court of Justice
of the European Union — under Article 263 TFEU. Actions against enforceable decisions must be
brought against the Commission (not against the Agency).
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT
The Agreement will enter into force on the day of signature by the Agency or the coordinator,
depending on which is later.
SIGNATURES
For the coordinator For the Agency
[--TGSMark#signature-933772441_75_210--] [--TGSMark#signature-service_75_210--]
Constantine VARDAVAS with ECAS id nvardcon signed in
the Participant Portal on 18/12/2017 at 12:41:32
(transaction id SigId-163100-
SwFiZyzPrVcvLYa8yuPzzgx6f6zPbXcsd6VtWjwZP0XlfXP
ZkypYCgMH3k5JHACtkfdfr49jwj779SlocvHyeaW-
PHslUMVSXYCIMrSeUedOzH-
3Mr036iuFUxaHVIFQiYL2HyTgszLw0FPXHVDPCC67eW)
. Timestamp by third party at
Mon Dec 18 12:41:50 CET 2017
57
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Health Unit
ANNEX 1 (part A)
Project
NUMBER — 761297 — JATC
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Table of Contents
1.1. The project summary................................................................................................................................. 3
1.2. The list of beneficiaries..............................................................................................................................4
1.3. Workplan Tables - Detailed implementation..............................................................................................6
1.3.1. WT1 List of work packages........................................................................................................... 6
1.3.2. WT2 List of deliverables................................................................................................................ 7
1.3.3. WT3 Work package descriptions................................................................................................. 10
Work package 1......................................................................................................................... 10
Work package 2......................................................................................................................... 13
Work package 3......................................................................................................................... 16
Work package 4......................................................................................................................... 19
Work package 5......................................................................................................................... 22
Work package 6......................................................................................................................... 27
Work package 7......................................................................................................................... 31
Work package 8......................................................................................................................... 35
Work package 9......................................................................................................................... 39
1.3.4. WT4 List of milestones................................................................................................................ 43
1.3.5. WT5 Critical Implementation risks and mitigation actions........................................................... 47
1.3.6. WT6 Summary of project effort in person-months.......................................................................48
1.3.7. WT7 Tentative schedule of project reviews.................................................................................50
1.4. Ethics Requirements................................................................................................................................ 51
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.1. The project summary
Project Number 1 761297 Project Acronym 2 JATC
One form per project
General information
Project title 3
Joint Action on Tobacco Control
Starting date 4 16/10/2017
Duration in months 5 36
Call (part) identifier 6 HP-JA-2016
HP-JA-03-2016
Topic
Tobacco control
Fixed EC Keywords
Free keywords tobacco products directive, EU public health policy, tobacco control
Abstract 7
Smoking and other forms of tobacco consumption are considered the single most important cause of preventable
morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-related deaths and illness
in the EU consist of the Tobacco Products Directive (TPD), and the WHO Framework Convention on Tobacco Control
(FCTC). The TPD lays down rules governing the manufacture, presentation and sale of tobacco and related products.
The TPD stipulates that Member States shall require manufacturers and importers of tobacco products to submit to
their competent authorities information, via a common entry gate (EU-CEG) – an IT tool designed to ensure uniform
application of the reporting and notification obligations, harmonise the submission of data, facilitate comparison and
reduce administrative burden.
The general objective of the Joint Action on Tobacco Control will be to provide support for the implementation of
the TPD throughout the 28 EU MS through the mining of EU-CEG data, supporting of laboratory collaborations and
effort to evaluate priority additives. The specific aims of the project are:
• To ensure appropriate coordination and evaluation
• To support the dissemination of information to the public, regulators and researchers.
• To enhance the ease of access to the data collected through the EU CEG
• To monitor and provide support to the tasks of tobacco and e-cigarette product regulation
• Assist EU MS networking and collaborations between laboratories for tobacco evaluation.
• Support EU MS in the process of monitoring and updating priority additives
• To integrate the JATC results into national policies
With the above in mind, this proposal comes at a perfect timing to aid the regulatory activities that would be needed
across the EU MS with regards to the implementation of the TPD across 28 EU MS spanning a population of 508
Million people.
Page 3 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.2. List of Beneficiaries
Project Number 1 761297 Project Acronym 2 JATC
List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
1 HELLENIC CANCER SOCIETY HCS Greece 1 36
OSTERREICHISCHE AGENTUR
2 FUR GESUNDHEIT UND AGES Austria 1 36
ERNAHRUNGSSICHERHEIT GMBH
SERVICE PUBLIC FEDERAL SANTE
3 PUBLIQUE, SECURITE DE LA CHAINE FPS BHTC Belgium 1 36
ALIMENTAIRE ET ENVIRONNEMENT
NATSIONALEN CENTAR PO
4 NCPHA Bulgaria 1 36
OBSHTESTVENO ZDRAVE I ANALIZI
5 Ministry of Health of the Republic of Cyprus MoH CY Cyprus 1 36
6 SIKKERHEDSSTYRELSEN SIK Denmark 1 36
7 TERVISEAMET TA Estonia 1 36
AGENCE NATIONALE DE LA SECURITE
8 SANITAIRE DE L ALIMENTATION DE L ANSES France 1 36
ENVIRONNEMENT ET DU TRAVAIL
BUNDESINSTITUT FUER
9 BfR Germany 1 36
RISIKOBEWERTUNG
ETHNIKO KENTRO EREVNAS KAI
10 CERTH Greece 1 36
TECHNOLOGIKIS ANAPTYXIS
11 SEMMELWEIS EGYETEM SU (SE) Hungary 1 36
12 EMBAETTI LANDLAEKNIS DoH I Iceland 1 36
13 HEALTH SERVICE EXECUTIVE HSE HSE Ireland 1 36
ISTITUTO DI RICERCHE
14 IRFMN Italy 1 36
FARMACOLOGICHE MARIO NEGRI
15 ISTITUTO SUPERIORE DI SANITA ISS Italy 1 36
16 MINISTERO DELLA SALUTE MoH IT Italy 1 36
17 VESELIBAS INSPEKCIJA HI Latvia 1 36
NARKOTIKU TABAKO IR ALKOHOLIO
18 NTAKD Lithuania 1 36
KONTROLES DEPARTAMENTAS
NACIONALINE VISUOMENES
19 SVEIKATOS PRIEZIUROS NVSPL Lithuania 1 36
LABORATORIJA
20 Ministry for Health - Government of Malta DEH Malta 1 36
RIJKSINSTITUUT VOOR
21 RIVM Netherlands 1 36
VOLKSGEZONDHEID EN MILIEU
22 FOLKEHELSEINSTITUTTET NIPH Norway 1 36
23 STATENS LEGEMIDDELVERK NOMA Norway 1 36
Page 4 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
MINISTERIO DA SAUDE - REPUBLICA
24 MS Portugal 1 36
PORTUGUESA
INSTITUT ZA JAVNO ZDRAVLJE SRBIJE
25 BATUT-IANPH Serbia 1 36
'MILAN JOVANOVIC - BATUT'
NACIONALNI LABORATORIJ ZA
26 NLZOH Slovenia 1 36
ZDRAVJE, OKOLJE IN HRANO
27 INSTITUT CATALA D'ONCOLOGIA ICO Spain 1 36
CONSEJERIA DE SALUD DE LA JUNTA
28 CSJA Spain 1 36
DE ANDALUCIA
29 FOLKHALSOMYNDIGHETEN FoHM Sweden 1 36
30 Department of Health UK-DH United Kingdom 1 36
31 ELLINIKI PNEYMONOLOGIKI ETAIREIA HTS Greece 1 36
Page 5 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3. Workplan Tables - Detailed implementation
1.3.1. WT1 List of work packages
Person- Start End
WP Number 9 WP Title Lead beneficiary 10
months 11 month 12 month 13
WP1 Coordination of the action 1 - HCS 49.00 1 36
WP2 Dissemination 25 - BATUT-IANPH 39.30 1 36
WP3 Evaluation of the action 2 - AGES 15.30 1 36
Integration into national policies
WP4 5 - MoH CY 48.65 1 36
and sustainability
Common Entry Gate (CEG) data
WP5 6 - SIK 56.25 1 36
extraction and handling
WP6 Tobacco product evaluation 27 - ICO 87.00 1 36
WP7 E-cigarette product evaluation 1 - HCS 86.70 1 36
Laboratory verification,
WP8 14 - IRFMN 80.40 1 36
collaboration and analyses
Additives subject to enhanced
WP9 21 - RIVM 53.60 1 36
reporting obligations
Total 516.20
Page 6 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3.2. WT2 list of deliverables
Due
Deliverable WP Lead Dissemination
Deliverable Title Type 15 Date (in
Number 14 number 9 beneficiary level 16
months) 17
First periodical
D1.1 technical and financial WP1 1 - HCS Report Public 18
report
D1.2 Final report WP1 1 - HCS Report Public 36
Final dissemination 25 - BATUT-
D2.1 WP2 Report Public 36
report IANPH
25 - BATUT-
D2.2 Leaflet WP2 Report Public 3
IANPH
Layman version of the 25 - BATUT-
D2.3 WP2 Report Public 36
final report IANPH
25 - BATUT-
D2.4 Web-site WP2 Report Public 4
IANPH
D3.1 Evaluation Plan WP3 2 - AGES Report Public 5
Interim evaluation
D3.2 WP3 2 - AGES Report Public 18
report
D3.3 Final evaluation report WP3 2 - AGES Report Public 35
Report on TPD
mapping and
D4.1 sustainability activities WP4 5 - MoH CY Report Public 18
including in house
capacity
Sustainability plan,
including scenarios
D4.2 WP4 5 - MoH CY Report Public 36
for long-term
sustainability
Report on the
principles to
D5.1 distinguish what WP5 1 - HCS Report Public 6
data is public non
confidential
Defined legal aspects
of accessing other
D5.2 WP5 6 - SIK Report Public 9
MS data in the JATC
project
Technical solution for
securely accessing and
D5.3 WP5 6 - SIK Report Public 15
processing public non
confidential data
Technical solution
D5.4 for public non WP5 6 - SIK Report Public 18
confidential data
Proposal of permanent
D5.5 mechanism for sharing WP5 6 - SIK Report Public 30
of EU-CEG data
Page 7 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Due
Deliverable WP Lead Dissemination
Deliverable Title Type 15 Date (in
Number 14 number 9 beneficiary level 16
months) 17
Report for M1-18
on the potential
D5.6 improvements/ WP5 6 - SIK Report Public 12
alterations identified
through Task 3.1
Report for M18-34
on the potential
D5.7 WP5 6 - SIK Report Public 34
improvements/
alterations identified
Report of the WP6
needs assessment
D6.1 WP6 27 - ICO Report Public 6
evaluation from EU
MS regulators
First report on tobacco
D6.2 WP6 27 - ICO Report Public 18
product data analysis
Second report on
D6.3 tobacco product WP6 27 - ICO Report Public 34
analysis
Report of the WP7
needs assessment
D7.1 WP7 1 - HCS Report Public 6
evaluation from EU
MS regulators
Checklist for e-
D7.2 cigarette product WP7 1 - HCS Report Public 18
compliance to the TPD
First report on e-
D7.3 cigarette product data WP7 1 - HCS Report Public 18
analyses
Report on a proposed
system for the
D7.4 WP7 1 - HCS Report Public 24
reporting of adverse
events
Second report on
D7.5 e-cigarette product WP7 1 - HCS Report Public 35
analyses
Report on the status
D8.1 quo of laboratories WP8 14 - IRFMN Report Public 12
that EU MS use
Report on the
D8.2 requirements for WP8 14 - IRFMN Report Public 22
laboratories
Report on the results
of inter-laboratory
D8.3 WP8 14 - IRFMN Report Public 23
variability of EU MS
emission data
Report on the
D8.4 WP8 14 - IRFMN Report Public 34
replication
Page 8 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Due
Deliverable WP Lead Dissemination
Deliverable Title Type 15 Date (in
Number 14 number 9 beneficiary level 16
months) 17
of laboratory
measurements
An assessment/
evaluation framework
D9.1 and guidelines for WP9 21 - RIVM Report Public 8
‘good experimental
practicing’
To report on type of
information from the
D9.2 EU-CEG system on WP9 21 - RIVM Report Public 12
enhanced reporting of
priority additives
Report on the
peer review of the
D9.3 enhanced reporting WP9 21 - RIVM Report Public 24
information on priority
additives
Evaluation reports and
toxicological data on
D9.4 additives which may WP9 21 - RIVM Report Public 30
be subject to enhanced
reporting
Page 9 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3.3. WT3 Work package descriptions
Work package number 9 WP1 Lead beneficiary 10 1 - HCS
Work package title Coordination of the action
Start month 1 End month 36
Objectives
The general objective is to coordinate the overall management of the project, and to coordinate and support the activities
of individual work packages. The specific objectives are:
1- To ensure the overall management of the project
2- To coordinate the financial management
3- To provide scientific support to the work in individual WPs,
4- To communicate with and report to CHAFEA.
5- To address emerging issues related to the TPD during the course of the project
6- To manage confidentiality, ethics and absence of conflict of interest
Description of work and role of partners
WP1 - Coordination of the action [Months: 1-36]
HCS, HTS
*************************************
Objective 1: To support overall management of the project. (Lead: HCS; Participants: all consortium parties; M1-36)
Task 1.1: Develop and implement a Consortium Agreement. The Consortium agreement will describe the consortium
management: a steering Committee, comprised by the representatives of the WP leaders will be created. More general
issues will be discussed with all associated partners as part of the consortium assembly. Voting procedures, terms and
guidelines will be clearly presented in the Consortium Agreement.
Task 1.2: Monitor and guide the progress of individual WPs. This tasks will monitor the progress of the activities
throughout the project and for all parties involved. It will ensure a smooth implementation of the activities outlines in
the grant agreement.
Task 1.3: Stimulate the integrated progress of the work, by fostering collaboration between individual WPs, linking up
with third parties and networks, and stimulating the use of additional data sources or innovative methodologies.
Task 1.4: Organize, chair and take minutes of meetings of the Steering Committee meetings and Consortium Meetings.
The WP1 leader will host a kick-off meeting preferably in Athens (M3, with participants representing all partners) for
launching the project, as well as the 2nd and 3rd meeting consortium meetings at an annual basis. The purpose of this
meeting will be to share the workplan, brainstorm and ensure common understanding of the approach, methodologies
and activities to be performed under the joint action.
*************************************
Objective 2: To coordinate financial management. (Lead: HCS; Participants: all consortium parties; M1-36)
Task 2.1: Communicate rules for financial administration and management, and ensure their implementation by all
partners.
Task 2.2: Prepare interim and final financial reports for CHAFEA and acquire all information and documents needed for
this task including but not limited to the collection of internal reports from members of the consortium and WP leaders.
Task 2.3: To adapt if necessary financial planning and aspects of the project activities based on the progress of the
project, the completion of milestones and deliverables and partner engagement.
*************************************
Objective 3: To support communication activities. (Lead: HCS; Participants: all consortium parties; M1-36)
Task 3.1: Together with the leader of WP2, prepare a structure for external communication.
Task 3.2: Develop and operate a structure for internal communication, aimed specifically to monitor progress of each
WP and to stimulate collaboration between WPs.
*************************************
Objective 4: To provide scientific support to individual WPs. (Lead: HCS; Participants: all consortium parties; M1-36).
Task 4.1: Provide timely scientific advice on the plans, progress and outcomes of the each WP.
Page 10 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Task 4.2: Undertake any other action that may benefit the work in WPs, such as organising special workshops on
common research interests.
*************************************
Objective 5: To communicate and report to the EC. (Lead: HCS; Participants: all consortium parties; M1-36)
Task 5.1: Invite representatives of the EC to attend the project meetings and dissemination events.
Task 5.2: Prepare an interim report and one final report to the EC.
*************************************
Objective 6: To address emerging issues related to the implementation of the TPD for which the JATC could contribute
scientifically (Lead: HCS; Participants: all consortium parties; Months 1-36)
Task 6.1: To maintain a connection of experts that can provide feedback on issues that may arise during TPD
implementation with regards to tobacco product reporting.
*************************************
Objective 7: To manage issues of ethics, confidentiality and absence of a conflict of interest (Lead HTS; Participants:
all consortium parties; Months: 1-6)
Task 7.1: To manage issues of ethics and to ensure that all participating partners adhere to confidentiality and have an
absence of conflict of interest.
Participation per Partner
Partner number and short name WP1 effort
1 - HCS 44.00
31 - HTS 5.00
Total 49.00
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
First periodical
D1.1 technical and 1 - HCS Report Public 18
financial report
D1.2 Final report 1 - HCS Report Public 36
Description of deliverables
General Description
The first periodical technical and financial report is a mandatory deliverable (MD). This report describes the activities
carried out, milestones and results achieved in the first half of the project. The Final report is delivered at the end
of the project (M36), this report describes the project implementation and the results achieved. The deliverables are
annexed.
Detailed Description
D1.1 : First periodical technical and financial report [18]
This report describes the activities carried out, milestones and results achieved in the first half of the project.
Deliverables can be attached as annexes.
D1.2 : Final report [36]
This report describes the project implementation and the results achieved. The deliverables are annexed.
Page 11 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Minutes of the 1st Minutes of the 1st
Consortium kick off Consortium kick off
MS1 1 - HCS 4
Meeting approved by Meeting approved by the
the consortium consortium
Minutes of the 2nd
Consortium Meeting as
Minutes of the 2nd
MS2 1 - HCS 16 approved by the partners.
Consortium Meeting
This is the annual meeting
of Year 2.
Minutes of the 3rd
Consortium Meeting
Minutes of the 3rd
MS3 1 - HCS 26 as approved by the
Consortium Meeting
consortium This is the Y3
meeting. (M26)
Page 12 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP2 Lead beneficiary 10 25 - BATUT-IANPH
Work package title Dissemination
Start month 1 End month 36
Objectives
The general objective is to maximise the impact of the project by supporting the consultation with stakeholders and the
dissemination of the project’s results. The specific objectives are:
1- To disseminate, as widely as possible, the process, updates and recommendations of the joint action by producing
manuscripts, policy reports, conference abstracts and digital leaflets/documentation that will be disseminated through
multiple avenues of communication.
2- To set up a network of interested policy makers, professionals and other stakeholders at EU level, and to maintain
communication and dissemination with this network of the overall progress of the joint action and organize a final
project conference to conclude the projects activities and to provide a framework for the dissemination of the project’s
conclusions and activities and support sustainability.
Description of work and role of partners
WP2 - Dissemination [Months: 1-36]
BATUT-IANPH, HCS, MoH CY, SU (SE)
*************************************
Objective 1: To disseminate, as widely as possible, the policy recommendations of the project to the target audiences
identified in section 3 of the current JATC proposal (Lead: BATUT, Participants: HCS, MOHCY, SE, LSMU, external
contractor; M1-36).
Task 1.1: To create a dissemination plan for the development and reporting of dissemination activities (M6). This
dissemination plan will include detailed information of whom will be contacted and include all the methods needed to
perform the dissemination activities of the JATC.
Task 1.2: Project website/social media development and maintenance. The website is conceived as ‘dynamic’ in the
sense that continual updates will be made as the project work advances. The project website must include sufficient
information for the general public, researchers and regulators to be informed of the impact and progress of the project.
Website development will be provided to an external subcontractor. As the website and social media accounts (i.e.
twitter) will be the public face of the project the information provided will be in layman format with the ability to
identify further detailed material deeper within the website. Within the above, small “snippets” of key information will
be used and may be released to the public and stakeholders so as to increase engagement.
Task 1.3: Produce digital leaflets, scientific manuscripts, policy reports and conference abstracts that would disseminate
the findings and recommendations of the project. This activity is integrated throughout the entire proposal and in all
research WPs. This will aim to disseminate information for the public, stakeholders and policy makers in all official
languages, in a digital format, in order to promote health literacy in this field. The project leaflet will be designed and
also printed for use at external dissemination events. Dissemination will take place both through traditional but also
social and electronic media so as to ensure a broader outreach and the reaching of appropriate target audiences identified
in Section 3 of this proposal. Three newsletters will be released throughout the duration of the project, one in each year
so as to maintain interest among the stakeholders
*************************************
Objective 2. To set up a network of interested policy makers, professionals and other stakeholders at an EU level, and
to maintain communication and dissemination with this network (Lead: BATUT, Participants: all WP partners; M2-36).
Task 2.1: Network development and upkeep. In order to ensure that the project findings reach the relevant end users,
it is critical to perform a stakeholder analysis and identify and build partnerships with regulators, professionals and
other stakeholders involved in tobacco control, public health policy and practice. This network will be provided with
the information produced through the JATC and will be able to maximize its outreach. The members of these target
groups have been previously described above. This task will have direct feedback from and will provide feedback to
WP4, to ensure issues of sustainability and national implementation through the use of this network.
*************************************
Objective 3: To organize a final project conference (Lead: HCS, Participants: all WP partners; M31-36).
Page 13 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Task 3.1 We will organize the final project conference where the final findings of the project will be presented as
will the overview of all related outcomes and reports, so as to facilitate potential sustainability of the JATC. The final
project conference will take place in Brussels, with the involvement of all involved parties, tobacco control stakeholders
and policymakers. We aim that this conference be followed by 200 participants and will request that this takes place
within the European parliament building if feasible. The digital material of the conference will be disseminated to
larger audiences through the networks of participating stakeholders and will also include a dissemination report that will
clearly show the results (with qualitative and quantitative indicators). The visibility of EU co-financing will be ensured.
The participation of all partners of the consortium has been assured through the earmarking of travel funds within each
partners budget. The facilitation of the activity (organization, invitations, coffee breaks, etc.) may also be subcontracted.
Participation per Partner
Partner number and short name WP2 effort
1 - HCS 11.30
5 - MoH CY 1.00
11 - SU (SE) 3.00
25 - BATUT-IANPH 24.00
Total 39.30
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Final dissemination 25 - BATUT-
D2.1 Report Public 36
report IANPH
25 - BATUT-
D2.2 Leaflet Report Public 3
IANPH
Layman version of 25 - BATUT-
D2.3 Report Public 36
the final report IANPH
25 - BATUT-
D2.4 Web-site Report Public 4
IANPH
Description of deliverables
General Description
The website, leaflet and layman version of the final report are all Mandatory Deliverables (MD).
Detailed Description
D2.1 : Final dissemination report [36]
At the end of the project a dissemination report that will indicate the extent of dissemination activities will be
developed. The dissemination report will include all public results with qualitative and quantitative indicators and
ensuring the visibility of EU co-financing.
D2.2 : Leaflet [3]
A leaflet to promote the project will be produced in the beginning. The leaflet will include information about the
project, its objectives and expected outcomes, the partnership etc. and it will be used in all partners’ contacts with
stakeholders.
D2.3 : Layman version of the final report [36]
This is a short (e.g. 10 pages) version of the final report, written for the interested public as a target group.
Page 14 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
D2.4 : Web-site [4]
A website that explains in detail the layman aspects of the project and can be a vehicle for further dissemination.
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
MS4 Project Logo 25 - BATUT-IANPH 3 Project Logo
List of tobacco M2.2 List of tobacco
MS5 control stakeholders 25 - BATUT-IANPH 6 control stakeholders and
and regulators regulators (M6)
Draft programme
Draft programme for
MS6 for Final Project 1 - HCS 33
Final Project Conference
Conference
Page 15 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP3 Lead beneficiary 10 2 - AGES
Work package title Evaluation of the action
Start month 1 End month 36
Objectives
1- To create and implement an evaluation plan, that will describe the criteria, methods, activities and timeline for project
evaluation, as well as the procedures and tools for project‘s quality assurance
2- To create and implement a financial evaluation plan that will revise and monitor the financial components of all WPs
Description of work and role of partners
WP3 - Evaluation of the action [Months: 1-36]
AGES, HCS
*************************************
Objective 1: To create and implement an evaluation plan, that will describe the criteria, methods, activities and timeline
for project evaluation, as well as the procedures and tools for project‘s quality assurance. (Lead: AGES, Participants:
all WP partners; M1-4).
Task 1.1. To define process, output and outcome indicators. Process, output and outcome indicator are defined in close
cooperation with WP leaders and delivered to steering group. The proposal, including the tasks and deliverables of each
WP, is used as a starting point for the definition of indicators by evaluators. Written and personal conversation will
assist WP leaders to define additional indicators where needed and determine the final version. A Logical Evaluation
Framework (LogFrame) is developed, by systematically merging specific objectives of technical and horizontal WPs
with activities, process, output and outcome indicators, as well as methods, and delivered to Coordinator (M3). The
LogFrame provides an overview and is used throughout the project period.
Task 1.2. To finalise instruments for WP3 data collection. Most process and output indicators are monitored by
the Coordinator and measured through routine monitoring systems implemented in the project, including meeting
minutes, reports and assessments. Most of the outcome indicators, to monitor the overall expected outcome in the areas
‘enhancement of knowledge and literacy’, ‘collaboration between member states’ and ‘access to data’, are measured
with three new instruments for data collection. Firstly, a topic guide for semi-structured interviews is developed to gain
a comprehensive perspective on the starting environment. Content related to ‘access to data’ are communicated to leader
of WP 5 as input for the development of EU-CEG questionnaire. Secondly, a topic guide for focus groups is developed
to evaluate the outcomes at the end of the project period. Thirdly, a quality questionnaire, with the aim to monitor and
evaluate the projects procedures and quality throughout the project period, is finalised and delivered to steering group.
The content of the topic guides and the questionnaire are finalised and delivered to the steering group.
Task 1.3. To prepare and obtain approval of the evaluation plan from the steering committee. Evaluation plan is
finalised, including communication and reporting plan, methods, techniques and instruments for data collection. (M4).
The evaluation plan, as the guiding document for the whole period of the JATC, includes a stakeholder assessment, the
evaluation questions, evaluation design and timeframe, a description of the data collection process, the LogFrame, a
communication and reporting plan and a section on the analysis and interpretation of the data.
*************************************
Objective 2: To implement the evaluation plan throughout the duration of the project (Lead: AGES, Participants: all
WP partners; M4-36).
Task 2.1. To implement the evaluation plan. Overview evaluation activities is obtained, tasks/duties of the evaluation
are distributed in the evaluation team and to WP leader for decentralised activities. Specific duties are communicated
to other WP leaders and the project team in a general session.
Task 2.2. To collect and analyse qualitative and quantitative WP3 evaluation data.
Qualitative primary data is collected for outcome measurement and quality assurance. The quality questionnaire ,
including the domains ‘information quality‘, ‘organisation of meetings’, ‘communication and team work’, is distributed
digitally with a survey tool to all participants of the Joint Action on a regular basis. Data is collected with an online
tool and analysed with statistical methods. Semi-structured interviews on the starting environment are held with
representatives of the each WP via webconferences and on general meetings at the beginning of the project. Interviewer’s
notes and records are collected, analysed and findings interpreted. Focus groups, addressing the aggregated topics from
the interviews, are held with representatives of each WP on general meetings at the end of the project. Where possible,
Page 16 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
the same interview partners for interviews and focus group are chosen. Interviewer’s notes and records are collected,
analysed and findings interpreted with regard to the interviews. Where applicable results will be communicated to WP
leader 5, with the aim to feed into the initial development and final interpretation of EU-CEG questionnaire findings.
Quantitative secondary data on process and output indicators is collected from regular monitoring system, coordinator
and WP leaders and analysed within the LogFrame matrix.
Task 2.3. To create progress reports on the evaluation process. Results of the Quality questionnaire are communicated
to steering group and to JACT team in general meeting. Results of the evaluation of the indicators are incorporated, the
evaluation plan adapted and delivered. (M12, M24)
Task 2.4. To develop the final evaluation report. Findings from output measurement (LogFrame matrix), from outcome
measurement (interviews, focus groups) and from quality assurance (quality questionnaire) will be interpreted. Results
partly build upon each other, which will be accordingly referred to in the interpretation. Final evaluation report is
delivered. (M36)
Participation per Partner
Partner number and short name WP3 effort
1 - HCS 1.00
2 - AGES 14.30
Total 15.30
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
D3.1 Evaluation Plan 2 - AGES Report Public 5
Interim evaluation
D3.2 2 - AGES Report Public 18
report
Final evaluation
D3.3 2 - AGES Report Public 35
report
Description of deliverables
General Description
The evaluation plan is created at the start of the project, an interim evaluation report is created by M18, while the
final report is uploaded at the end of the project (M35)
Detailed Description
D3.1 : Evaluation Plan [5]
Evaluation plan is finalised, including communication and reporting plan, methods, techniques and instruments for
data collection, and delivered to Coordinator and CHAFEA.
D3.2 : Interim evaluation report [18]
The evaluation report of M1-18 activities.
D3.3 : Final evaluation report [35]
The evaluation report of activities from M18-35
Page 17 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Quality questionnaire M3.1. Quality
MS7 finalised and 2 - AGES 3 questionnaire finalised
communicated and communicated (M3)
Communication M3.2. Communication
and reporting and reporting
MS8 2 - AGES 3
plan finalised and plan finalised and
communicated communicated (M3)
Topic guides M3.3. Topic guides
MS9 finalised and outline 2 - AGES 3 finalised and outline
communicated communicated (M3)
Evaluation M3.4. Evaluation
indicators finalised indicators finalised and
MS10 2 - AGES 4
and overview overview communicated
communicated (M4)
Interviews held M3.5. Interviews held and
MS11 and summary 2 - AGES 6 summary communicated
communicated (M6)
Interim focus groups M3.6. Interim Focus
MS12 held and summary 2 - AGES 17 groups held and summary
communicated communicated (M17)
Final Focus groups M3.7 Final Focus groups
MS36 held and summary 2 - AGES 33 held and summary
communicated communicated (M33)
Page 18 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP4 Lead beneficiary 10 5 - MoH CY
Work package title Integration into national policies and sustainability
Start month 1 End month 36
Objectives
1- To map the capacity building and knowledge needs for the effective and efficient application of the TPD across the
28 EU MS and EEA where applicable.
2- To develop a series of guides and an e-learning platform for a sustainable long term educational intervention and
organise internal and external meetings to enhance training and collaboration between regulators
Description of work and role of partners
WP4 - Integration into national policies and sustainability [Months: 1-36]
MoH CY, HCS, NCPHA, TA, ANSES, BfR, SU (SE), HSE, IRFMN, NTAKD, CSJA
*************************************
Objective 1: To map the capacity building and knowledge needs for the effective and efficient application of the TPD
across the 28 EU MS and EEA where applicable. (Lead MOH-CY, Participants, all WP partners; Months 1-12, 24-36)
Task 1.1: This objective is to help the EU MS understand their gaps so that these can be identified at the beginning of
the project. Its aim is to the capacity building and knowledge needs. The proactive data collection process would collect
information outside those already collected in EU-CEG. This task will be performed at the beginning (M1-M12) and
the last year of the project (M24-36).
Task 1.2: To map tobacco control funding across the EU MS, including submission fees to the EU-CEG or fees for
implementation of TPD Art7(13) and TPD Art20(2) through a survey to EU MS regulators and competent authorities
(M1-M9, M24-M30).
Task 1.3: To identify and map in-house and cross border regulatory, scientific and technical capacity resources available
to regulators that are needed to ensure the up-take of the outcomes of the Joint Action and the maintenance of the
mechanisms set up as part of the JATC (M1-M9, M24-M30).
The above tasks, 1.1, 1.2, and 1.3 will be performed through a survey that will contain both closed and open ended
questions that will allow for a qualitative and quantitative analysis of the data. The content of the survey will be
developed through discussions among WP4 members during both phases.
*************************************
Objective 2: To develop a series of “how to” guides and an online repository for a sustainable long term educational
intervention and to organise internal and external meetings/training seminars including stakeholder NGOs, researchers
and regulators. (Lead HCS; Participants: all WP partners; Months 1-36)
Task 2.1: To develop a series of “how-to” guides for regulators including but not limited to aspects related to EU-CEG
data handling, data extraction, product evaluation, product compliance. They may be provided directly through the EU-
CEG or through an independent platform. Directly related to sustainability, up to 5 “how-to” guides will be created and
uploaded, each one may contain one or more areas of interest to regulators.
Task 2.2: To develop and continuously update an online repository of the designed “how-to” guides so to aid future
regulator training, enhance homogeneity and support sustainability in training. The platform will be continuously fed
with reports created from vertical WPs of the JATC and also with dissemination material released through WP2, too
make sure that the 28 EU MS commit themselves to the maintenance of the keeping the how-to guides and information
up to date after JATC period ends.
Task 2.3: To organise external joint meetings between tobacco control stakeholder NGOs, researchers and regulators so
as to engage them in future activities and enhance TPD implementation and monitoring. Meetings may be in person or
via distance webinar communication. Researchers and NGO’s would also be trained on the existence and potential use
of the publicly available data released from WP5 so as to enhance the likelihood that more people would be working
on the wealth of data after the JATC has been completed.
Task 2.4: To organise internal joint action training seminars for regulators so as to enhance TPD implementation and
monitoring. Meetings may be in person or via distance webinar communication. The rationale here is that by improving
the regulators knowledge they would be able to use the EU-CEG better. These training seminars then directly would
increase the possibility that the same tasks are performed after the JATC has concluded. They may coincide with the
Y2 and Y3 meeting.
Page 19 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Participation per Partner
Partner number and short name WP4 effort
1 - HCS 8.00
4 - NCPHA 10.00
5 - MoH CY 5.50
7 - TA 3.20
8 - ANSES 1.00
9 - BfR 0.10
11 - SU (SE) 12.00
13 - HSE 0.10
14 - IRFMN 3.75
18 - NTAKD 4.00
28 - CSJA 0.50
FPS 0.50
Total 48.65
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Report on TPD
mapping and
D4.1 sustainability 5 - MoH CY Report Public 18
activities including
in house capacity
Sustainability
plan, including
D4.2 5 - MoH CY Report Public 36
scenarios for long-
term sustainability
Description of deliverables
General Description
The deliverables include reports which aim to identify the mapping and sustainability in the EU MS (M18), and
provide a long term sustainability plan (M36)
Detailed Description
D4.1 : Report on TPD mapping and sustainability activities including in house capacity [18]
An outline of the capacity and sustainability possibilities across EU MS, half way through the project.
D4.2 : Sustainability plan, including scenarios for long-term sustainability [36]
The overall WP4 sustainability plan for the continuation of activities post the JATC.
Page 20 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Questionnaire M4.1 Questionnaire
MS13 for mapping and 5 - MoH CY 3 for mapping and
sustainability sustainability (M3)
Action plan for M4.2 Action plan for
MS14 sustainability 5 - MoH CY 6 sustainability activities
activities (M6)
First “how-to” M4.3 First “how-to”
MS15 guide developed and 5 - MoH CY 12 guide developed and
uploaded uploaded (M12)
“How-to” guide M4.4 “How-to” guide
MS16 repository fully 5 - MoH CY 16 repository fully functional
functional (M16)
Update of the
M4.5 Update of the status
status quo of the
MS37 5 - MoH CY 26 quo of the repository for
repository for long
long term planning (M26)
term planning
Page 21 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP5 Lead beneficiary 10 6 - SIK
Work package title Common Entry Gate (CEG) data extraction and handling
Start month 1 End month 36
Objectives
The aim of this WP is to provide the framework for the efficient usage of the data submitted through the EU-CEG,
including in light of the application of TPD Art 5, p 4 and TPD Art 5, p7 “Member States shall store the information
electronically and shall ensure that the Commission and other Member States have access to that information for the
purposes of applying this Directive.”
1- To identify the public data available within the information submitted via the EU-CEG and to make this information
available to the general public.
2- To define and complete the technical and legal aspects necessary for data transfer and handling and subsequently
request and pool the data from the CEG from each EU MS.
3- Evaluate the utility of the CEG with a quantitative/qualitative survey and a focus group evaluation of EU regulators
and propose improvements to the CEG so as to enhance its future utility.
Description of work and role of partners
WP5 - Common Entry Gate (CEG) data extraction and handling [Months: 1-36]
SIK, HCS, AGES, FPS BHTC, NCPHA, TA, ANSES, MoH IT, NTAKD, NOMA, MS , NLZOH, CSJA, FoHM, UK-
DH
*************************************
Objective 1: To identify the variables that should be considered public within the information submitted via the EU
common entry gate (EU-CEG) and to facilitate making this information available to the general public ( Participants:
all WP partners; Months 1-36)
Task 1.1: To identify the variables that should be considered public and not confidential within the common formats for
the notification of tobacco products and e-cigarettes published through implementing acts 2015/2186 and 2015/2183
and within the context of TPD Art5(4). (M1-6) [D5.1] (Lead, HCS)
Task 1.2 To outline the requirements (legal/technical etc.) for making the information identified through Task 1.1,
available to the general public through collaboration with the competent authorities. (M6-30) [D5.2](Lead, SIK)
The information classification model will be suggested by information security specialist. The model will use existing
models from, a)EU-CEG information classification model, b)EU information classification model and if adoptions
to existing models are needed use ISO/IEC 27002:2014 chapter 8.2 as theoretical background to draft an EU-CEG
information classification model that with focus on the aspect confidentiality. In task 1.1 the model will be used to
classify data in EU-CEG that is “non-confidential public”. The participants will evaluate the classification model and the
instructions to MS on how to apply the model. The classification will be approved by EU-CEG system owner [SANTE]
before send out to all MS with data in EU-CEG. The aim is that the classification of “TPD non-confidential public”
data by the WP will be accepted by EU-CEG MS as proposed.
A report to clarify the legal situation between EU-regulation, MS national legislation and existing contracts between
owner and MS as information owners regarding EU-CEG will be produced by external legal specialist. The legal
report will focus on the aspects of MS publishing public non-confidential and share non-confidential and confidential
data and how to deal with classification of data by manufacturer and importers when this is not in line with TPD.
The results from the report will additionally be the basis of legal requirements for publishing and to share non-
confidential public data. To identify technical requirements on security measures for publishing data from EU-CEG to
general public existing security requirements for EU-CEG will be used as basis. Additional technical and administrative
requirements will be drawn from ISO/IEC 27002 chapter 9 (Access Control), chapter 10 (Cryptography), chapter 12
(Operation Security), chapter 13 (Communication Security) and chapter 14 (System Acquisition, development and
maintenance).The requirements will be documented by information security specialist in a format agreed on with system
owner [SANTE]. Quality check of the requirements, both legal and technical will be done by all WP5 partners.
*************************************
Objective 2: To define and complete the technical and legal aspects necessary for data transfer and handling and
subsequently request the data from the EU-CEG for the purpose of the JATC and with regards to sales/market data
Page 22 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
from each EU MS (Lead SIK, Participants: HCS, BHTC, NCPA, SIK, TA, ANSES, MOHIT, NTAKD, NOMA, MS,
NLZOH, CSJA, FOHM, UK-DOH, 1-36 Months)
Task 2.1: To define the technical and legal requirements for the transfer and handling of data that has been submitted
via the CEG for use within the Joint Action and for use after the Joint Action, within the context of TPD Art5(6-7) and
TPD Art20(7). (Lead SIK, Months 1-36) [D.5.3; D5.4]
A report on the legal situation of accessing/transfer information up to the level of business confidential regulated in
EU-regulation, MS national legislation and existing contracts between EU-CEG system owner and MS in the role of
information owners will be produced by external legal specialist.
The classification model in task 1.1 will be extended to classify also confidential data and most likely also non
public, non-confidential, data from the TPD perspective and MS national regulations. A proposal of extension of
the classification model will be done by information security specialist. The classification model will together with
instructions on how to apply the model be sent out to involved partners for proof of concept (PoC). The classification
model will be approved by EU-CEG System owner [SANTE] before send out to all MS with data in EU-CEG. The
result of the classification is together with the legal report and existing documentation regarding requirements of EU-
CEG the basis of legal and technical requirements in the continuing development of EU-CEG.
Also in the extended version of the classification model additional administrative and technical requirements, if needed,
will be drawn from ISO/IEC 27002 chapter 9 (Access Control), chapter 10 (Cryptography), chapter 12 (Operation
Security), chapter 13 (Communication Security) and chapter 14 (System Acquisition, development and maintenance).
The requirements will be documented by information security specialist in a format agreed with system owner [SANTE].
Quality check of the requirements will be done by all WP5 partners. If needed as a result of the legal report templates
for information access/transfer between MS and the JATC-project and between MS and MS for long time information
share will be suggested to System Owner [SANTE]
Task 2.2: To collect the list of variables that are requested by WP6-9 and to request and obtain access to the data
belonging to each participating EU MS as submitted via the EU- CEG. (Lead SIK, Months 6-30)
Documented need of data access in WP6-9 are controlled against MS classification. If needed information sharing
agreements for data sharing are sent out to MS information owner, EU-CEG system owner, JATC-project and the WP6-9
leaders. The information sharing agreement template should have been approved by system owner and MS as part of
task 2.1. The material to grant information sharing will be forwarded to HCS for implementing task 2.3
Task 2.3: To create individual datasets that will include only the variables needed for each specific objective within
WP6, WP7, WP8 and WP9 and forward these datasets to the relevant task leaders. (Lead SIK, Months 6-30)
This data, as downloaded through the secure methodology identified above through task 2.1, will be handled to create
datasets that will be relevant for each WP. This data will be provided in a statistical analysis format, such as SPSS,
SATA or SAS that can be handled by the WP6-7-8-9 researchers. These would provide clean data in a format that would
be ready for deeper analysis.
*************************************
Objective 3: To enhance utility and propose improvements to the EU-CEG, including on the basis of feedback from
EU MS regulators. (Lead SIK; Participants, AGES, MOH-IT, NTAKD, FOHM, NOMA, CSJA, DGS, HCS, NLZOH;
Months 3-36)
Task 3.1: To perform an active data collection process from EU MS regulators on aspects that may enhance the utility of
the reporting formats and the EU-CEG including but not limited to: the easiness of use of the CEG, the ability to access
data, to perform product evaluation and reach informed decisions based on the data. The overall aim is to support the
use of data by MS regulators including through suggesting potential improvements/alterations based on the feedback
so as to improve utility of the CEG (Lead: SIK; M3-36) [D5.5, D5.6]
Within this task, we will create two survey’s including closed and open type questions that will be circulated to EU MS
regulators so as to collect information at a practical level on what are the EU MS regulators questions, concerns and
difficulties that they may face with the EU-CEG. The first survey will commence on M3 (questionnaire development),
while at M6 the questionnaires will be circulated to partners, we aim by M12 to have this report finalised and proposed
to the EC. This task will be repeated annually.
Participation per Partner
Partner number and short name WP5 effort
1 - HCS 12.00
2 - AGES 3.60
Page 23 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Partner number and short name WP5 effort
3 - FPS BHTC 0.50
4 - NCPHA 6.00
6 - SIK 17.75
7 - TA 1.50
8 - ANSES 0.40
16 - MoH IT 3.00
18 - NTAKD 2.00
23 - NOMA 0.50
24 - MS 3.00
26 - NLZOH 3.00
28 - CSJA 0.50
FPS 0.50
29 - FoHM 1.50
30 - UK-DH 0.50
Total 56.25
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Report on the
principles to
D5.1 distinguish what 1 - HCS Report Public 6
data is public non
confidential
Defined legal
aspects of
D5.2 accessing other MS 6 - SIK Report Public 9
data in the JATC
project
Technical solution
for securely
accessing and
D5.3 6 - SIK Report Public 15
processing public
non confidential
data
Technical solution
D5.4 for public non 6 - SIK Report Public 18
confidential data
Proposal of
D5.5 permanent 6 - SIK Report Public 30
mechanism for
Page 24 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
sharing of EU-
CEG data
Report for M1-18
on the potential
improvements/
D5.6 6 - SIK Report Public 12
alterations
identified through
Task 3.1
Report for M18-34
on the potential
D5.7 improvements/ 6 - SIK Report Public 34
alterations
identified
Description of deliverables
General Description
The deliverables are related to the process of the release of the information from the EU-CEG system to JATC
researchers.
Detailed description
D5.1 : Report on the principles to distinguish what data is public non confidential [6]
A report that would outline the parameters which could be used to define the confidentiality of submitted data through
EU-CEG.
D5.2 : Defined legal aspects of accessing other MS data in the JATC project [9]
As the EU-CEG data belongs to each respective EU MS, specific legal requirements should be met to allow for
sharing of data. If needed a template for data exchange agreement will be provided.
D5.3 : Technical solution for securely accessing and processing public non confidential data [15]
As the EU-CEG data are stored centrally and contain also potentially confidential data, this report will indicate the IT
solutions for the transfer of data for analyses.
D5.4 : Technical solution for public non confidential data [18]
This report will provide the technical solution for securely accessing and processing public non confidential data
including best practices on making data available to the general public at national level
D5.5 : Proposal of permanent mechanism for sharing of EU-CEG data [30]
As data sharing should continue after the end of the JATC, this report would include the proposal of how this activity
can be sustained.
D5.6 : Report for M1-18 on the potential improvements/alterations identified through Task 3.1 [12]
This report would propose alterations/improvements to the EU-CEG reporting format and submission process.
D5.7 : Report for M18-34 on the potential improvements/alterations identified [34]
Report for M18-36 on the potential improvements/alterations identified
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Identification of a M5.1 Identification of
MS17 6 - SIK 8
model/framework, a model/framework,
Page 25 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
with focus on identifying
with focus on
public non-confidential
identifying public
data, for classifying data
non-confidential data
in EU-CEG (M8)
Request to EU MS to M5.2 Request to EU MS
MS18 submit their data to 6 - SIK 9 to submit their data to
JATC JATC (M9)
M5.3 EU MS datasets
EU MS datasets ready ready for provision to
MS19 1 - HCS 12
for provision the relevant vertical WPs
(M12)
M5.4 Second round of
Second round of EU EU MS datasets ready for
MS20 1 - HCS 24
MS datasets ready provision to the relevant
vertical WPs (M24)
Reporting to WP1 on M5.5 Reporting to WP1
MS21 the tasks performed 6 - SIK 34 on the tasks performed
under WP5 under WP5 (M34)
Page 26 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP6 Lead beneficiary 10 27 - ICO
Work package title Tobacco product evaluation
Start month 1 End month 36
Objectives
The aim of this vertical WP is to handle aspects pertinent to tobacco product data handling on data collected by EU MS
in light of the obligations of the TPD. Specific objectives include:
1- To perform a needs assessment of EU MS regulators with regards to tobacco product evaluation through EU-CEG
2- To assess tobacco product description, tobacco product presentation and sales/market data and investigate into cross
EU MS comparability.
3- To monitor tobacco ingredient and additive data in light of supporting actions under TPD
4- To evaluate the toxicological/addictive data submitted for tobacco product ingredients, including also information
on priority additives
Description of work and role of partners
WP6 - Tobacco product evaluation [Months: 1-36]
ICO, HCS, AGES, FPS BHTC, SIK, ANSES, BfR, CERTH, HSE, IRFMN, ISS, MoH IT, NTAKD, RIVM, NIPH,
MS , NLZOH, CSJA, FoHM, UK-DH, HTS
*************************************
Objective 1: To perform a needs assessment evaluation of EU regulators with regards to aspects of priority within EU-
CEG (Lead ICO; Participants: HCS, BHTC, SIK, ANSES, BfR, CERTH, HTS, HSE, IRFMN, IS, MOHIT, NTAKD,
RIVM, NIPH, MS, NLZOH, ICO, CSJA, FOHM< UK-DOH; Months 1-6)
Task 1.1: To perform a qualitative needs assessment of EU regulators so as to flag issues of importance to EU MS. (M6)
Within this process a questionnaire will be sent to all EU MS regulators in which their opinions and experience will
be requested with regards to their potential areas of priority that they wish to handle first. This process will commence
immediately with the start of their JATC so as to set the base, expectations and issues that EU MS regulators may have.
It is likely that this survey will be performed in close collaboration with Task 1.1 of WP7 (handling e-cigarettes).
*************************************
Objective 2: To assess tobacco product information as submitted data via the EU-CEG (Lead ICO, Participants: HCS,
BHTC, SIK, ANSES, BfR, CERTH, HTS, HSE, IRFMN, IS, MOHIT, NTAKD, RIVM, NIPH, MS, NLZOH, ICO,
CSJA, FOHM< UK-DOH; Months 6-36) [D6.2 and D6.3]
At the start of Objective 2 we will create an analysis plan. A list of priority analyses/investigations will be formulated
so that when the data for WP7 becomes available that analyses can be quickly performed.
Task 2.1: To assess tobacco product description data with regards to product submissions, descriptors and product
specific data so as to investigate into cross EU MS comparability and map unique and/or emerging product
characteristics.
Task 2.2: To evaluate tobacco product presentation and sales/market data so as to investigate into cross EU MS
comparability and map unique and/or emerging product characteristics.
Both the above tasks can commence at a theoretical level from M6, however the actual data analysis needs the existence
of original data from WP5. In light of the above, a list of priority analyses/investigations will be created so that when
the data becomes available that analyses can be quickly performed. These priority analyses will be also based on the
information collected through the survey in Task 1.1 of W6.
*************************************
Objective 3: To monitor tobacco product ingredient and additive data (Lead ICO; Participants: HCS, BHTC, SIK,
ANSES, BfR, CERTH, HTS, HSE, IRFMN, IS, MOHIT, NTAKD, RIVM, NIPH, MS, NLZOH, ICO, CSJA, FOHM,
UK-DOH; Months 6-36) [D6.2 and D6.3]
Task 3.1: To perform an assessment of the tobacco ingredients and additives in relation to their function, weight and
registration within REACH and CLP classification and evaluate trends and product associations. This statistical and
qualitative analysis can take place only after the provision of the original data in WP5.
Task 3.2: To investigate into the associations between declared tobacco product information (recipe) vs. measured
tobacco product information in relation to tobacco product submitter notifications (product modification, new product
Page 27 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
notification etc.) and in line with TPD Art 5(1). Within this process we will statistically evaluate the differences and
assess if these variables are appropriately used (or misued) by the manufacturers or importers.
Task 3.3: In collaboration with WP8, to qualitatively assess the submitted emission data for tobacco products. The
common reporting format collects information on emissions of tobacco products and within this Task collaborations
between WP6 and WP8 will be facilitated so as to combine the data analysis of WP6 with the laboratory verification
processes of WP8.
Task 3.4: To identify and further evaluate products that have characterising flavours or containing the additives with
characteristics described in TPD Art7(6-7). This tasks may also support activities outlined in Commission Implementing
Decision (EU) 2016/786 of 18 May 2016 laying down the procedure for the establishment and operation of an
independent advisory panel assisting Member States and the Commission in determining whether tobacco products
have a characterising flavour.
*************************************
Objective 4: To evaluate the toxicological/addictive data submitted for tobacco products, including also information on
priority additives (4.1 Lead ICO/4.2 lead RIVM; Participants: All WP partners; Months 6-36) [D6.2 and D6.3]
Task 4.1: Evaluate the toxicological information on additives in line with TPD Art5, p3. This analysis will be performed
at both a qualitative and quantitative level. For this purpose a group of experts from the WP, in cooperation with potential
external experts, will be able to evaluate qualitatively and quantitatively the toxicological information available in
primarily pdf format.
Task 4.2: To obtain the data on priority additives as reported per brand and product type, and to perform a qualitative
and quantitative analysis of the types of basic submitted information. Evidence may feed into WP9 with regards to the
additives that may be flagged to potentially be added to the list subject to enhanced reporting obligations or which may
come under TPD Art7(9-11).
Participation per Partner
Partner number and short name WP6 effort
1 - HCS 12.00
2 - AGES 2.00
3 - FPS BHTC 1.00
6 - SIK 1.00
8 - ANSES 2.80
9 - BfR 2.00
10 - CERTH 1.00
13 - HSE 0.40
14 - IRFMN 10.00
15 - ISS 2.00
16 - MoH IT 2.50
18 - NTAKD 4.00
21 - RIVM 4.00
22 - NIPH 0.30
24 - MS 3.00
26 - NLZOH 7.00
27 - ICO 20.00
28 - CSJA 0.00
AGAPA 3.00
Page 28 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Partner number and short name WP6 effort
29 - FoHM 4.00
30 - UK-DH 1.00
31 - HTS 4.00
Total 87.00
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Report of the WP6
needs assessment
D6.1 27 - ICO Report Public 6
evaluation from
EU MS regulators
First report on
D6.2 tobacco product 27 - ICO Report Public 18
data analysis
Second report on
D6.3 tobacco product 27 - ICO Report Public 34
analysis
Description of deliverables
General Description
The first deliverable of WP6 is the needs assessment evaluation (M6), followed by reports on tobacco product
analyses.
Detailed Description
D6.1 : Report of the WP6 needs assessment evaluation from EU MS regulators [6]
This report will outline the results of task 1.1 where EU MS regulators would provide feedback of what they need/
expect from the tobacco product data handling in EU/CEG.
D6.2 : First report on tobacco product data analysis [18]
The results of the first data analysis.
D6.3 : Second report on tobacco product analysis [34]
The results of the second data analysis.
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
M6.1. Needs assessment
Needs assessment
questionnaire for WP6
MS22 questionnaire for 27 - ICO 3
finalised and sent to
WP6 finalised
regulators (M3)
Analysis Plan/ M6.2. Analysis Plan/
Initiation of first wave Initiation of first wave
MS23 27 - ICO 12
of tobacco product of tobacco product data
data analyses analyses (M12)
Page 29 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Initiation of second M6.3. Initiation of second
MS24 wave tobacco product 27 - ICO 28 wave tobacco product
data analyses data analyses (M28)
List of additional M6.4. List of additional
additives that additives that could be
MS25 could be subject to 21 - RIVM 30 subject to enhanced
enhanced reporting reporting obligations
obligations (M30)
Page 30 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP7 Lead beneficiary 10 1 - HCS
Work package title E-cigarette product evaluation
Start month 1 End month 36
Objectives
The overall objective of this WP is to support the activities of EU MS in ensuring that electronic cigarettes and refill
containers are placed on the market in compliance with the TPD. Specific objectives include:
1- To perform a needs assessment of EU MS regulators with regards to e-cigarette product evaluation through EU-CEG
2- To assess e-cigarette data submitted via the EU-CEG
3- To monitor reported e-cigarette liquid ingredient and emission data in line with TPD Art20(2)
4- To create a checklist for e-cigarette product compliance to the TPD and developa reporting format for adverse effects
on human health
Description of work and role of partners
WP7 - E-cigarette product evaluation [Months: 1-36]
HCS, AGES, FPS BHTC, ANSES, BfR, CERTH, DoH I, HSE, IRFMN, ISS, MoH IT, HI, NTAKD, RIVM, NIPH,
NOMA, MS , ICO, CSJA, FoHM, UK-DH, HTS
*************************************
Objective 1: To perform a needs assessment of EU MS regulators with regards to aspects of priority for e-cigarette
products within EU-CEG (Lead: HCS, Participants: BHTC, ANSES, CERTH, BfR, DOHI, HSE, IRFMN, ISS, MOH-
IT, HI, NTAKD, RIVM, NOMA, MS, ICO, CSJA, UKDOH,, Months 1-6)
Task 1.1: To perform a qualitative needs assessment of EU regulators so as to flag issues of importance with regards to
e-cigarette products. This activity would aid the identification of potential areas of prioritisation and that could address
the needs of EU MS regulators. Within this process a questionnaire will be sent to all EU MS regulators in which their
opinions and experience will be requested. This process will commence immediately with the start of their JATC so as
to set the base, expectations and issues that EU MS regulators may have. It is likely that this survey will be performed
in close collaboration with Task 1.1 of WP6 (handling tobacco products). [D7.1]
*************************************
Objective 2: To assess e-cigarette product data as submitted data via the EU-CEG. At the start of Objective 2 we will
create an analysis plan. A list of priority analyses/investigations will be formulated so that when the data for WP7
becomes available that analyses can be quickly performed. This data comes from EU-CEG and as available through the
mechanisms outlined in Art20(7) of the TPD. These priority analyses will be also based on the information collected
through the survey in Task 1.1 of W7. (Lead HCS, Participants: BfR, DOHI, HSE, IRFMN, HI, ISS, MOH-IT, DGS,
ICO, FOHM, UKDOH, Months 6-36) [D7.3 and D7.5]
Task 2.1: To assess e-cigarette submission description data and technical design data as included within Section 3 and
6 of Annex 1 of the Commission Implementing Decision 2015/2183. Within this task the relevant data as provided by
WP5 will be analysed with statistical software at a quantitative level so as to investigate into cross EU MS comparability
and map unique and/or emerging product characteristics. This process will be repeated for each time original data is
provided by WP5.
Task 2.2: To monitor product presentation (as included within Section 3 of Annex 1 of the Commission Implementing
Decision 2015/2183) and sales/market data (as specified in TPD Article 20(7) as collected by the competent authorities
so as to investigate into cross EU MS comparability and map unique and/or emerging product characteristics.
Task 2.3: Evaluate the toxicological information on ingredients as submitted through EU-CEG and in line with TPD
Art20(2) and Sections 3,4 and 6 of Annex 1 of the Commission Implementing Decision 2015/2183 with regards to the
product's ingredients and emissions, including when heated, and referring in particular to their effects on the health of
consumers when inhaled and taking into account, inter alia, any addictive effect.
*************************************
Objective 3: To monitor reported e-cigarette liquid ingredient and emission data in line with TPD Art20(2). (Lead
IRFMN, Participants, HCS, ANSES, BfR, CERTH, HTS, DOHI, ISS, HSE, HI, NTAKD, RIVM, ICO, FOHM, UK-
DOH; Months 6-36) [D7.3 and D7.5]
Page 31 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Task 3.1: To perform a statistical analysis of the data provided by EU-CEG on e-liquid ingredients and additives in
relation to their function, weight and registration within REACH and CLP classification and evaluate trends and product
associations.
Task 3.2: To assess the emission data and their equivalent emission protocols as submitted through EU-CEG (according
to Section 3 of Annex 1 of the Commission Implementing Decision 2015/2183) and to collect and scientifically review
emission protocols for e-cigarettes that are under development by different international bodies. This will be performed
in cooperation with WP8. The methodologies of these emission protocols will be compared and a report will be prepared
comparing all e-cigarette emissions from EU-CEG and international protocols. A snow ball analysis technique will be
used to identify the relevant international; protocols from the partners in the JATC.
Task 3.3: To evaluate issues of product production and safety and flag aspects that may need further evaluation by EU
MS regulators. This task will be based on the evaluation of the information outlined in Section 6 of Annex 1 of the
Commission Implementing Decision 2015/2183 and as provided by WP5 through EU-CEG.
*************************************
Objective 4: To create a checklist to monitor e-cigarette product compliance to the TPD and support EU MS in the
development of a system for the collection of information about suspected adverse effects on human health in line with
Art20(9) (Lead HCS, Participants: AGES, DOHI, ISS, HSE, , HI, NOMA, ICO, UKDOH, Months 1-24) [D7.2 and
D7.4]]
Task 4.1: Create a checklist that would aid monitoring of e-cigarette product compliance to the TPD under the auspices
of TPD Art20(1) and including but not limited to Art20(3-4) and implementing act 2016/586. (M1-18)
Task 4.2: Support the EU MS in the development of a system for the reporting of information on suspected adverse
effects on human health in line with TPD Art.20(9), and its cross referencing with national data (M1-24). This will be
performed through a) the creation of a short reporting template on adverse effects, b) the communication of this template
to EU-MS, c) the collection of information from manufactures and importers and the reporting of this information to
regulators, d) analysis of the data collected from the EU-MS and e) cross referencing with a collection of information
from national poison centres through an electronic survey.
Participation per Partner
Partner number and short name WP7 effort
1 - HCS 21.00
2 - AGES 2.20
3 - FPS BHTC 1.00
8 - ANSES 6.30
9 - BfR 1.50
10 - CERTH 1.00
12 - DoH I 2.00
13 - HSE 0.50
14 - IRFMN 10.00
15 - ISS 2.00
16 - MoH IT 2.50
17 - HI 4.50
18 - NTAKD 4.00
21 - RIVM 4.00
22 - NIPH 0.20
23 - NOMA 0.50
24 - MS 3.00
Page 32 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Partner number and short name WP7 effort
27 - ICO 6.00
28 - CSJA 0.00
AGAPA 2.00
29 - FoHM 6.00
30 - UK-DH 2.50
31 - HTS 4.00
Total 86.70
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Report of the WP7
needs assessment
D7.1 1 - HCS Report Public 6
evaluation from
EU MS regulators
Checklist for e-
cigarette product
D7.2 1 - HCS Report Public 18
compliance to the
TPD
First report on e-
D7.3 cigarette product 1 - HCS Report Public 18
data analyses
Report on a
proposed system
D7.4 1 - HCS Report Public 24
for the reporting of
adverse events
Second report on
D7.5 e-cigarette product 1 - HCS Report Public 35
analyses
Description of deliverables
General Description
The first deliverable of this WP is a needs assessment from EU MS regulators (M6), followed by a checklist for
product compliance (M18), a report on the proposed reporting system for adverse events (M24), as also two waves of
data analysis reports (M18 and M35 respectively)
Detailed Description
D7.1 : Report of the WP7 needs assessment evaluation from EU MS regulators [6]
This report will outline the results of task 1.1 where EU MS regulators would provide feedback of what they need/
expect from the e-cigarette product data handling in EU/CEG.
D7.2 : Checklist for e-cigarette product compliance to the TPD [18]
This checklist would be developed to help regulators monitor in the long term e-cigarette compliance easier.
D7.3 : First report on e-cigarette product data analyses [18]
First report on e-cigarette product data analyses
D7.4 : Report on a proposed system for the reporting of adverse events [24]
Page 33 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
A reporting system for adverse events must be developed as noted in the TPD, this report would outline the
requirements for such a system.
D7.5 : Second report on e-cigarette product analyses [35]
The results of the second data analysis. Including information on the e-cigarette emissions and international protocols
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Needs assessment M7.1. Needs assessment
questionnaire for questionnaire for WP7
MS26 1 - HCS 3
WP7 finalised and finalised and sent to
sent to regulators regulators (M3)
Analysis Plan/ M7.2. Analysis Plan/
Initiation of first wave Initiation of first wave of
MS27 1 - HCS 12
of e-cigarette product e-cigarette product data
data analyses analyses (M12)
M7.3. Initiation of second
Initiation of second
wave of e-cigarette
MS28 wave of e-cigarette 1 - HCS 28
product data analyses
product data analyses
(M28)
M7.4. Internal report on
Internal report on the
the e-cigarette emissions
e-cigarette emissions
MS29 14 - IRFMN 30 and international
and international
protocols completed
protocols completed
(M30)
Page 34 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP8 Lead beneficiary 10 14 - IRFMN
Work package title Laboratory verification, collaboration and analyses
Start month 1 End month 36
Objectives
1- To develop requirements of independent laboratories for ingredient evaluation
2- To review laboratory analysis activities routinely performed by MS and to assess comparability across laboratories.
3- To develop collaborations and communication with other international activities on tobacco laboratory assessment
Description of work and role of partners
WP8 - Laboratory verification, collaboration and analyses [Months: 1-36]
IRFMN, HCS, AGES, BfR, CERTH, NVSPL, RIVM, NLZOH, CSJA, HTS
*************************************
Objective 1: To develop requirements of independent laboratories for ingredient evaluation (Lead IRFMN, Months
1-24) [D8.1 and D8.2]
Task 1.1: To map the current status quo of laboratories that currently perform analyses for EU MS so as to evaluate
laboratory capacity, requirements, protocols and independency. Within this task, various MS competent authorities will
be enquired, through specific surveys, to collect updated information about the laboratory presence, activities, and
distribution across various countries. (M 1-12)
IRFMN will prepare a draft of the specific survey form, necessary to map EU laboratories and their activities, which
will be submitted to all MS CAs. Each WP8 partner will review the draft. By consensus, a final form will be prepared.
IRFMN will submit to all MS CAs the final version of the questionnaire. WP8 partners will assure, also through direct
contact, that the forms are filled by various CAs within the scheduled timetable for all the 28 MS. A report will be
prepared by IRFMN in collaboration with all WP8 partners.
Task 1.2: To collect and review laboratory based protocols for ingredient, contents and emission evaluation within
all EU MS authorities (M1-20). Through the collaboration with MS competent authorities, we will collect protocols
for emission evaluation of both tobacco products and electronic cigarettes. The available protocols will be critically
reviewed by WP partners in WP8 (Tobacco) and WP7 (e-cigarettes) respectively.
IRFMN will prepare a draft of the survey form on the protocols used for ingredient, contents and emission evaluation
which will be submitted to various European laboratories, both identified in Task 1.1 and proposed by international
experts (Task 3.1). Each WP8 partner will review the draft. By consensus, a final questionnaire will be prepared. IRFMN
will submit to all European laboratories the final version of the form possibly supported by a cover letter from each
corresponding CA. In case of non-response of European laboratories, we propose to notify it to the corresponding
national CA, in order to jointly decide how to improve response rate. IRFMN, CERTH, CSJA and RIVM, with the
contribution of all WP8 partners, will conduct the review of the laboratory based protocols. The review will form the
base of the discussion on laboratory capacity requirements at the internal Meeting 1 (Task 1.3).
Task 1.3: To develop laboratory capacity requirements for ingredient, content and emission evaluation. (M 8-24) The
criteria used for approval and the methods of monitoring applied will be defined by consensus during a dedicated
meeting (WP8 internal Meeting 1, M14) among WP8 participants and will include but are not limited to ISO fulfillment,
instrumental capacity, lab independence.
The WP8 internal Meeting 1 will be organized in Milan by IRFMN. During the meeting, after having defined the internal
rules to reach consensus agreement, WP8 partners will define a list of chemicals categories, instruments and methods to
be considered for the laboratory capacity requirement documents, also taking into account the review developed in Task
1.2. For each chemicals category considered, WP8 partners will provide during the meeting a proposal on the capacity
requirements for independent laboratories. IRFMN, CERTH and CSJA will then prepare a draft of the requirements, to
be revised by all other WP8 partners. WP8 partners will then identify possible lacks of internationally agreed approaches
on laboratory testing for tobacco products and electronic cigarette data. The proposed laboratory testing approaches and
requirements will be described in the report [D8.2].
*************************************
Objective 2: To review laboratory analysis activities performed by MS and to assess comparability across laboratories.
(Lead IRFMN, Months 1-36) [D8.3 and D8.4]
Page 35 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Task 2.1: We will review laboratory activities routinely performed by MS competent authorities, critically evaluating
the quality of these activities and the independence of the corresponding laboratories. (M1-24) Available analytical data
will be collected and processed using pooled- or meta-analytical approaches with the purpose of making comparisons
between the same products measured through different laboratories. These data will be presented and discussed within
the second internal meeting (WP8 Meeting 2; M 24)
According to the activities conducted by each European laboratory (as from Task 1.1), IRFMN will prepare laboratory
specific request forms which will be submitted to various EU laboratories in order to collect analytical data in the form
of electronic databases. A template will be prepared to be submitted along with this request. Available analytical data
will be collected and evaluated in terms of both quantity and quality by IRFMN, HTS and CSJA. Moreover, these data
will be further analyzed by IRFMN possibly using pooled- or meta-analytical approaches. These data will be presented
and discussed with all WP8 partners within the second internal meeting.
Task 2.2: To perform replicate laboratory measurements to compare ingredient data for tobacco products across verified
laboratories. (M25-36)
During the second internal meeting, the WP8 partners will select the replicate laboratory measurements to be conducted
to compare ingredient data for tobacco products and electronic cigarettes across verified laboratories. These new
laboratory analyses will be distributed among IRFMN, CERTH, RIVM, CSJA and AGES. Following a joint discussion
among various WP8 partners, results will be summarized in a report on the replication of laboratory measurements
[D8.4].
*************************************
Objective 3: To develop collaborations and communication with other international activities on tobacco laboratory
assessment (Lead CSJA, Months 10-36)
Task 3.1: To develop collaborations and communication with other large international initiatives so as to enhance
collaboration on the area of tobacco product emission evaluation. (M10-36)
Selected international experts, including representatives of GoToLAB and TobLabNet, will be invited to the first internal
meeting (WP8 Meeting 1; M 10) to contribute to the discussion on the area of tobacco product emission evaluation,
with a specific focus on TPD Article 3. Selected international experts, including representatives of GoToLAB and
TobLabNet, will be contacted by the Task leader
Participation per Partner
Partner number and short name WP8 effort
1 - HCS 1.80
2 - AGES 2.60
9 - BfR 3.00
10 - CERTH 12.00
14 - IRFMN 27.00
19 - NVSPL 5.00
21 - RIVM 4.00
26 - NLZOH 4.00
28 - CSJA 0.00
AGAPA 10.00
31 - HTS 11.00
Total 80.40
Page 36 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Report on the
status quo of
D8.1 14 - IRFMN Report Public 12
laboratories that
EU MS use
Report on the
D8.2 requirements for 14 - IRFMN Report Public 22
laboratories
Report on the
results of inter-
D8.3 laboratory 14 - IRFMN Report Public 23
variability of EU
MS emission data
Report on the
replication
D8.4 14 - IRFMN Report Public 34
of laboratory
measurements
Description of deliverables
General Desacription
The first deliverable is a report on the status quo of laboratories that EU MS use, followed by a report on the
requirements for laboratories, a report on the results of inter-laboratory variability of EU MS emission data, and
finally the report on the replication of laboratory measurements (M34)
Detailed Description
D8.1 : Report on the status quo of laboratories that EU MS use [12]
An overview of the status quo of tobacco product laboratories in Europe.
D8.2 : Report on the requirements for laboratories [22]
A report on the technical requirements and standards that TPD accredited laboratories should use.
D8.3 : Report on the results of inter-laboratory variability of EU MS emission data [23]
Evaluation of the comparison between European laboratories.
D8.4 : Report on the replication of laboratory measurements [34]
Report on the results of the replication tasks.
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Finalisation of data M8.1 Finalisation of data
MS30 collection survey 14 - IRFMN 4 collection survey from
from WP8 WP8 (M4)
Finalisation of
M8.2 Finalisation of data
data collection on
collection on the status
MS31 the status quo of 14 - IRFMN 9
quo of laboratories across
laboratories across the
the EU (M9)
EU
Page 37 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
M8.3 Minutes of the first
Minutes of the first
MS32 14 - IRFMN 15 WP8 internal meeting
WP8 internal meeting
(M15)
Commencement
M8.4 Commencement of
of the replicate
MS33 14 - IRFMN 24 the replicate laboratory
laboratory
measurements (M24)
measurements
M8.5 Minutes of the
Minutes of the second
MS34 14 - IRFMN 25 second WP8 internal
WP8 internal meeting
meeting (M25)
Page 38 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Work package number 9 WP9 Lead beneficiary 10 21 - RIVM
Work package title Additives subject to enhanced reporting obligations
Start month 1 End month 36
Objectives
The overall aim of this WP is to aid EU MS in the evaluation of data submitted with regards to enhanced reporting
obligations under TPD Art. 6 which shall apply to certain additives contained in cigarettes and roll-your-own tobacco
that are included in a priority list outlined in the Commission Implementing Decision 2016/787.
Specific objectives include:
1. To compose an assessment/evaluation framework and guidelines for ‘good experimental practising’.
2. To facilitate peer review of the submitted information by a panel of suitable experts.
3. To assess the comprehensiveness of the reporting template for the types of studies.
4. To select additional additives that could be subject to enhanced reporting obligations.
Description of work and role of partners
WP9 - Additives subject to enhanced reporting obligations [Months: 1-36]
RIVM, HCS, SIK, ANSES, BfR, IRFMN, ISS, NIPH, CSJA, FoHM
*************************************
Objective 1: To compose an assessment/evaluation framework and guidelines for ‘good experimental practising’ (GEP).
(Lead RIVM, Participants, HCS, SIK, ANSES, BfR, ANSES, IRFMN, RIVM, FOHM, Months 1-8)
Task 1.1: Compose of an assessment/evaluation framework and guidelines for ‘good experimental practising’. To
provide guidelines on how the enhanced reporting documents on priority additives will be judged an assessment and
evaluation framework will be composed. This framework will be of importance for both the JA consortium, the panel
of peer reviewers, and the tobacco industry. Aspects that will be included in this framework are the parameters and
boundaries defining which information is regarded as good/sufficient, and in which situation more information is needed.
Information of the recently published SCHEER opinion II on Additives used in Tobacco Products will be used as a
basis for this framework.
To anticipate on the study design and parameters used for enhanced reporting by industry themselves, we will prepare a
‘good experimental practicing’ (GEP) guideline. In this guideline experimental study characteristics will be described
and recommended which will also be used to judge the studies on priority additives by the peer reviewers in the
assessment and/evaluation framework. For the different type of studies these guidelines will elaborate for example on
the preferred study design, experimental exposure (and control) conditions, exposure duration and intensity, sample size
etc. Scientific information and best practices in experimental designs in each field of research (toxicity, addictiveness
and characterising flavours), will be used as basis for the composition of the GEP guidelines.
RIVM and BfR will be concerned with the writing of these documents, partners in this task will add and review in the
process both by regular teleconference calls and by electronic document editing.
*************************************
Objective 2: To facilitate peer review of the enhanced reporting information submitted, by a panel of suitable experts
(Lead RIVM, Participants, HCS, SIK, ANSES, BfR, ISS, RIVM, CSJA, FOHM. Months 9-30).
Task 2.1: To obtain, (translate) and evaluate the type of information on enhanced reporting of priority additives that
is submitted. (Months 9-18).
CSJA will evaluate the submitted documents describing experimental results per priority additive, by examining
duplicates between products, manufacturers and countries. An inventory of the available documents on each priority
additive will be reported on by CSJA in collaboration with RIVM. Any lack of reports on specific topics will be recorded
and consequences and actions will be discussed. In addition, results of the analysis on basic information on these priority
additives will be obtained by RIVM from WP6 and incorporated in the evaluation. In the case of an excessive amount
of enhanced reporting documents submitted, a selection of the most relevant documents will be made for each priority
additive by CSJA and RIVM. If (selected) reports are only available in the local language, these must be translated
into English.
Task 2.2: To create, organise and coordinate an appropriate panel of scientists that would comprise the peer review panel
outlined in TPD Art 6, p4.Participants: HCS, SIK, BfR, ISS, RIVM (Month 10-20)
Page 39 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The first step taken by RIVM (in consultation with consortium partners in this task) is to identify the specific field
of expertise that is needed and present in the consortium to perform the peer review on priority additives with regard
to toxicity, addictiveness and characterising flavours. Also, an inventory will be made of MS obliged to perform the
review of enhanced reporting on priority additives themselves. A second step discussed with consortium all partners
involved in this task, is to define a method of the peer review procedure, e.g. how to divide the topics (on additive or
field of expertise, how many peer reviewers per topic etc.). An appropriate panel with the defined expertise will be
organised by RIVM. We possibly will have to make an appeal to all consortium partners to bring up these experts from
inside their organisation or when necessary even from outside their organisation. For the field of attractiveness we will
probably also consult the ‘Independent Advisory panel on Characterising Flavours in Tobacco products’ installed by
the EU. Reports on priority additives will be assigned to reviewer(s) in close consultation with participants involved in
the review process during a physical ‘training’ meeting (see task 2.3).
Task 2.3: To facilitate the peer review process of the evaluation of the submitted information on priority
additives outlined in TPD Art6, p4 and request if necessary supplementary information regarding the additives
concerned.Participants: RIVM, HCS, BfR, ISS, FOHM, (Month 12-22)
RIVM will organise a meeting in which experts performing the peer review, will be trained by BfR (assisted by FOHM,
RIVM and HCS) on the review procedure, and in using the developed assessment and evaluation framework. Facilitating
and continuation of the review process itself will be guided by FOHM. Moreover, FOHM will stay in close contact with
reviewers to identify emerging problems and answering questions. Regular TC meetings with all partners in this task
will be held to discuss the review process and emerging problems.
Task 2.4: To peer review reports of priority additives on toxicity, addictiveness and attractiveness. Participants: HCS,
ANSES, BfR, FOHM, NIPH, eventually subcontractors selected from potential international experts, Month 12-24)
This activity is the core activity of this WP and will have 23PM devoted to the peer review of the documents. Reviewers
will read and judge systematically the reports on priority additives using the assessment and evaluation framework,
Regular teleconference calls with reviewers or the group of reviewers will help to overcome general and more specific
problems. RIVM will contact MS who indicated to perform also a review of enhanced reporting reports on priority
additives themselves to discuss and share experiences. During the review process (after approx. 6 months), a second
physical meeting will be organised by RIVM to discuss the first results and problems encountered. The reviewers will
write a report based on their findings for each priority additive.
Task 2.5: To create a final report and provide a summary of the submitted information on priority additives and report
this towards the general public. (Participants: RIVM, HCS, SIK, BfR, FOHM, Month 24).
An internal report will be written by BfR and FOHM about the findings, conclusions and recommendations of the peer
review team for each additive separately. Other consortium partners in this task will review on the report. In addition,
the yearly analyses and recommendations of WP6 evaluation on basic data on priority additives as submitted in EU-
CEG will be discussed among all consortium partners in this task. To report a summary of these finding to the general
public of each member state partner, a general guideline will be composed ensuring consistent and univocal reporting
of the information in all member states By SIK and HCS.
*************************************
Objective 3: To evaluate the comprehensiveness of the assessment/evaluation template for the types of studies. (Lead
NIPH, Participants, RIVM, HCS, ANSES, BfR, FOHM, CSJA, Months 23-30)
Task 3.1: To perform an evaluation of the comprehensiveness and utility of the provided assessment/evaluation
framework for the priority additives through focus group discussions with the panel of experts. (Participants: HCS,
ANSES, BfR, RIVM, NIPH, CSJA, FOHM, Month 23).
An assessment of the comprehensiveness and utility of the provided assessment/evaluation framework for the priority
additives will be performed, organised and led by NIPH. Experience of the composers of the assessment framework,
the reviewers and the facilitators of the peer review process will be identified in a collaboration between all consortium
partners participating in this task..
Task 3.2: To prepare a report on the utility of the assessment/evaluation framework including if necessary suggestions
that would enhance its improvement. (Participants: HCS, ANSES, BfR, RIVM, NIPH, CSJA, FOHM, Month 34). The
results of this assessment and necessary suggestions that would enhance its improvement will be reported by NIPH. All
consortium partners in this task will contribute to this report.
Objective 4: To provide feedback on additional additives that could be subject to enhanced reporting obligations in
collaboration with WP6 and WP7. (Lead BfR, Participants, RIVM, HCS, FOHM, Months 27-30)
Task 4.1: To provide feedback on additives and in cooperation with WP6 and WP7 prepare a report on additives that
could potentially be added to the list of additives subject to enhanced reporting obligations, including its supporting
evidence. The assessment and evaluation framework developed, will be used in this assessment.
Page 40 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
BfR will organize a collaborative meeting with WP6, WP7, HCS, BfR and FOHM to discuss the results of the enhanced
reporting of the 15 priority additives and the results on candidate compounds identified in WP6 and WP7. A report with
recommendations will be prepared by consortium partners involved in this task.
Participation per Partner
Partner number and short name WP9 effort
1 - HCS 7.90
6 - SIK 1.25
8 - ANSES 4.90
9 - BfR 12.40
14 - IRFMN 0.25
15 - ISS 1.00
21 - RIVM 11.90
22 - NIPH 5.00
28 - CSJA 0.00
AGAPA 3.00
29 - FoHM 6.00
Total 53.60
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
An assessment/
evaluation
framework and
D9.1 21 - RIVM Report Public 8
guidelines for
‘good experimental
practicing’
To report on type
of information
from the EU-
D9.2 CEG system 21 - RIVM Report Public 12
on enhanced
reporting of
priority additives
Report on the
peer review of the
D9.3 enhanced reporting 21 - RIVM Report Public 24
information on
priority additives
Evaluation reports
and toxicological
D9.4 21 - RIVM Report Public 30
data on additives
which may be
Page 41 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
subject to enhanced
reporting
Description of deliverables
General Description
The first deliverable in WP9 is the evaluation framework and guidelines for ‘good experimental practicing’ which can
be used for enhanced reporting of priority additives. This is followed by a report on the type of information from the
EU-CEG system on enhanced reporting of priority additives; a report on the peer review of the enhanced reporting
information on priority additives is provided as also evaluation reports and toxicological data on additives which may
be subject to enhanced reporting from WP6 and WP7
Detailed Description
D9.1 : An assessment/evaluation framework and guidelines for ‘good experimental practicing’ [8]
Guidelines on how the enhanced reporting documents on priority additives will be judged an assessment and
evaluation framework will be composed
D9.2 : To report on type of information from the EU-CEG system on enhanced reporting of priority additives [12]
Report of the information available on priority additives as submitted to EU MS
D9.3 : Report on the peer review of the enhanced reporting information on priority additives [24]
Report on the peer review outcomes
D9.4 : Evaluation reports and toxicological data on additives which may be subject to enhanced reporting [30]
Final WP9 report
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Obtainment of M9.1 Obtainment of
MS35 Enhanced Data on 21 - RIVM 9 Enhanced Data on priority
priority additives additives (M9)
Page 42 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3.4. WT4 List of milestones
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Minutes of the
Minutes of the 1st
1st Consortium
Consortium kick off
MS1 kick off Meeting WP1 1 - HCS 4
Meeting approved by the
approved by the
consortium
consortium
Minutes of the 2nd
Minutes of the Consortium Meeting as
MS2 2nd Consortium WP1 1 - HCS 16 approved by the partners.
Meeting This is the annual meeting
of Year 2.
Minutes of the 3rd
Minutes of the Consortium Meeting as
MS3 3rd Consortium WP1 1 - HCS 26 approved by the consortium
Meeting This is the Y3 meeting.
(M26)
25 - BATUT-
MS4 Project Logo WP2 3 Project Logo
IANPH
List of tobacco
M2.2 List of tobacco
control 25 - BATUT-
MS5 WP2 6 control stakeholders and
stakeholders and IANPH
regulators (M6)
regulators
Draft programme
Draft programme for Final
MS6 for Final Project WP2 1 - HCS 33
Project Conference
Conference
Quality
M3.1. Quality questionnaire
questionnaire
MS7 WP3 2 - AGES 3 finalised and communicated
finalised and
(M3)
communicated
Communication
M3.2. Communication and
and reporting
MS8 WP3 2 - AGES 3 reporting plan finalised and
plan finalised and
communicated (M3)
communicated
Topic guides
M3.3. Topic guides
finalised
MS9 WP3 2 - AGES 3 finalised and outline
and outline
communicated (M3)
communicated
Evaluation
M3.4. Evaluation indicators
indicators finalised
MS10 WP3 2 - AGES 4 finalised and overview
and overview
communicated (M4)
communicated
Interviews held M3.5. Interviews held and
MS11 and summary WP3 2 - AGES 6 summary communicated
communicated (M6)
Interim focus
M3.6. Interim Focus
groups held
MS12 WP3 2 - AGES 17 groups held and summary
and summary
communicated (M17)
communicated
Page 43 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Questionnaire M4.1 Questionnaire for
MS13 for mapping and WP4 5 - MoH CY 3 mapping and sustainability
sustainability (M3)
Action plan for M4.2 Action plan for
MS14 sustainability WP4 5 - MoH CY 6 sustainability activities
activities (M6)
First “how-to” M4.3 First “how-to” guide
MS15 guide developed WP4 5 - MoH CY 12 developed and uploaded
and uploaded (M12)
“How-to” guide M4.4 “How-to” guide
MS16 repository fully WP4 5 - MoH CY 16 repository fully functional
functional (M16)
Identification of a M5.1 Identification of a
model/framework, model/framework, with
with focus on focus on identifying public
MS17 WP5 6 - SIK 8
identifying public non-confidential data, for
non-confidential classifying data in EU-CEG
data (M8)
Request to EU MS M5.2 Request to EU MS to
MS18 to submit their data WP5 6 - SIK 9 submit their data to JATC
to JATC (M9)
M5.3 EU MS datasets ready
EU MS datasets
MS19 WP5 1 - HCS 12 for provision to the relevant
ready for provision
vertical WPs (M12)
M5.4 Second round of
Second round of
EU MS datasets ready for
MS20 EU MS datasets WP5 1 - HCS 24
provision to the relevant
ready
vertical WPs (M24)
Reporting to
M5.5 Reporting to WP1 on
WP1 on the tasks
MS21 WP5 6 - SIK 34 the tasks performed under
performed under
WP5 (M34)
WP5
M6.1. Needs assessment
Needs assessment
questionnaire for WP6
MS22 questionnaire for WP6 27 - ICO 3
finalised and sent to
WP6 finalised
regulators (M3)
Analysis Plan/
M6.2. Analysis Plan/
Initiation of first
Initiation of first wave
MS23 wave of tobacco WP6 27 - ICO 12
of tobacco product data
product data
analyses (M12)
analyses
Initiation of second
M6.3. Initiation of second
wave tobacco
MS24 WP6 27 - ICO 28 wave tobacco product data
product data
analyses (M28)
analyses
List of additional
M6.4. List of additional
MS25 additives that WP6 21 - RIVM 30
additives that could be
could be subject to
Page 44 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
enhanced reporting subject to enhanced
obligations reporting obligations (M30)
Needs assessment M7.1. Needs assessment
questionnaire for questionnaire for WP7
MS26 WP7 1 - HCS 3
WP7 finalised and finalised and sent to
sent to regulators regulators (M3)
Analysis Plan/
M7.2. Analysis Plan/
Initiation of first
Initiation of first wave of
MS27 wave of e-cigarette WP7 1 - HCS 12
e-cigarette product data
product data
analyses (M12)
analyses
Initiation of second
M7.3. Initiation of second
wave of e-cigarette
MS28 WP7 1 - HCS 28 wave of e-cigarette product
product data
data analyses (M28)
analyses
Internal report
on the e-cigarette M7.4. Internal report on
emissions and the e-cigarette emissions
MS29 WP7 14 - IRFMN 30
international and international protocols
protocols completed (M30)
completed
Finalisation of data M8.1 Finalisation of data
MS30 collection survey WP8 14 - IRFMN 4 collection survey from WP8
from WP8 (M4)
Finalisation of
M8.2 Finalisation of data
data collection on
collection on the status quo
MS31 the status quo of WP8 14 - IRFMN 9
of laboratories across the
laboratories across
EU (M9)
the EU
Minutes of the M8.3 Minutes of the first
MS32 first WP8 internal WP8 14 - IRFMN 15 WP8 internal meeting
meeting (M15)
Commencement
M8.4 Commencement of
of the replicate
MS33 WP8 14 - IRFMN 24 the replicate laboratory
laboratory
measurements (M24)
measurements
Minutes of the M8.5 Minutes of the second
MS34 second WP8 WP8 14 - IRFMN 25 WP8 internal meeting
internal meeting (M25)
Obtainment of M9.1 Obtainment of
MS35 Enhanced Data on WP9 21 - RIVM 9 Enhanced Data on priority
priority additives additives (M9)
Final Focus groups M3.7 Final Focus groups
MS36 held and summary WP3 2 - AGES 33 held and summary
communicated communicated (M33)
M4.5 Update of the status
Update of the
MS37 WP4 5 - MoH CY 26 quo of the repository for
status quo of the
long term planning (M26)
Page 45 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
repository for long
term planning
Page 46 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3.5. WT5 Critical Implementation risks and mitigation actions
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
In the case that a partner organization does
not fulfill its obligations to the project, the
coordinator will ask this organization to withdraw
Partners not carrying out
1 WP1 from the partnership and seek for replacement.
their assignment.
Alternatively, the coordinator or another
existing partner will undertake the tasks of the
withdrawing partner.
Repeated communications with partners to
WP1, WP2, WP3, WP4,
Delay in deliverable increase output Identification of barriers to
2 WP5, WP6, WP7, WP8,
production effective delivery of results Allocation of
WP9
additional person-time to that aspect of the project
Each partner contributes with at least two
WP1, WP2, WP3, WP4,
Change in partner or key personnel to allow for a back up to exist
3 WP5, WP6, WP7, WP8,
personnel Discussions with other partners in that EU MS
WP9
that would be able to cover satisfactory the gap
WP1, WP2, WP3, WP4, Repeated communication between partners
Mis-communication between
4 WP5, WP6, WP7, WP8, Involvement of the Steering Committee In depth
partners
WP9 discussions to diffuse the situations
Communictions with CHAFEA/DG SANTE to
WP1, WP2, WP3, WP4, re-prioritise as necessary based on the current
Insufficient budget to cover
5 WP5, WP6, WP7, WP8, requirements. Reorganisation of the tasks and
the requested tasks
WP9 activities to partners with a lower person month
cost.
Change in the focus area Communications with CHAFEA/DG SANTE to
6 of EU tobacco product WP6, WP7, WP8, WP9 reprioritise the activties as necessary based on the
regulatory interest current requirements.
Work closely with EU MS so as to obtain access
to confidential data sets even for a limited number
Confidential data from EU-
WP5, WP6, WP7, WP8, of EU MS Request de-identified confidential
7 CEG not provided by EU-
WP9 data that would be aggregated and not be linked
MS
to a specific company Use only public non
confidential data.
Page 47 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3.6. WT6 Summary of project effort in person-months
Total Person/Months per
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9
Participant
1 - HCS 44 11.30 1 8 12 12 21 1.80 7.90 119
2 - AGES 0 0 14.30 0 3.60 2 2.20 2.60 0 24.70
3 - FPS BHTC 0 0 0 0 0.50 1 1 0 0 2.50
4 - NCPHA 0 0 0 10 6 0 0 0 0 16
5 - MoH CY 0 1 0 5.50 0 0 0 0 0 6.50
6 - SIK 0 0 0 0 17.75 1 0 0 1.25 20
7 - TA 0 0 0 3.20 1.50 0 0 0 0 4.70
8 - ANSES 0 0 0 1 0.40 2.80 6.30 0 4.90 15.40
9 - BfR 0 0 0 0.10 0 2 1.50 3 12.40 19
10 - CERTH 0 0 0 0 0 1 1 12 0 14
11 - SU (SE) 0 3 0 12 0 0 0 0 0 15
12 - DoH I 0 0 0 0 0 0 2 0 0 2
13 - HSE 0 0 0 0.10 0 0.40 0.50 0 0 1
14 - IRFMN 0 0 0 3.75 0 10 10 27 0.25 51
15 - ISS 0 0 0 0 0 2 2 0 1 5
16 - MoH IT 0 0 0 0 3 2.50 2.50 0 0 8
17 - HI 0 0 0 0 0 0 4.50 0 0 4.50
18 - NTAKD 0 0 0 4 2 4 4 0 0 14
19 - NVSPL 0 0 0 0 0 0 0 5 0 5
20 - DEH 0 0 0 0 0 0 0 0 0 0
21 - RIVM 0 0 0 0 0 4 4 4 11.90 23.90
22 - NIPH 0 0 0 0 0 0.30 0.20 0 5 5.50
23 - NOMA 0 0 0 0 0.50 0 0.50 0 0 1
Page 48 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Total Person/Months per
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9
Participant
24 - MS 0 0 0 0 3 3 3 0 0 9
25 - BATUT-IANPH 0 24 0 0 0 0 0 0 0 24
26 - NLZOH 0 0 0 0 3 7 0 4 0 14
27 - ICO 0 0 0 0 0 20 6 0 0 26
· IDIBELL 0 0 0 0 0 0 0 0 0 0
28 - CSJA 0 0 0 0.50 0.50 0 0 0 0 1
· AGAPA 0 0 0 0 0 3 2 10 3 18
· FPS 0 0 0 0.50 0.50 0 0 0 0 1
29 - FoHM 0 0 0 0 1.50 4 6 0 6 17.50
30 - UK-DH 0 0 0 0 0.50 1 2.50 0 0 4
31 - HTS 5 0 0 0 0 4 4 11 0 24
Total Person/Months 49 39.30 15.30 48.65 56.25 87 86.70 80.40 53.60 516.20
Page 49 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.3.7. WT7 Tentative schedule of project reviews
No project reviews indicated
Page 50 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1.4. Ethics Requirements
No ethics requirements indicated
Page 51 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1. Project number
The project number has been assigned by the Commission as the unique identifier for your project. It cannot be
changed. The project number should appear on each page of the grant agreement preparation documents (part A
and part B) to prevent errors during its handling.
2. Project acronym
Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym should
appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its
handling.
3. Project title
Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are
possible if agreed during the preparation of the grant agreement.
4. Starting date
Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement,
the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into
force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a
written justification.
5. Duration
Insert the duration of the project in full months.
6. Call (part) identifier
The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated
in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the
Commission in the letter inviting to prepare the grant agreement.
7. Abstract
8. Project Entry Month
The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start
dates being relative to this start date.
9. Work Package number
Work package number: WP1, WP2, WP3, ..., WPn
10. Lead beneficiary
This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this
work package
11. Person-months per work package
The total number of person-months allocated to each work package.
12. Start month
Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other
start dates being relative to this start date.
13. End month
Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.
14. Deliverable number
Deliverable numbers: D1 - Dn
15. Type
Please indicate the type of the deliverable using one of the following codes:
R Document, report
DEM Demonstrator, pilot, prototype
DEC Websites, patent fillings, videos, etc.
OTHER
ETHICS Ethics requirement
ORDP Open Research Data Pilot
16. Dissemination level
Page 52 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Please indicate the dissemination level using one of the following codes:
PU Public
CO Confidential, only for members of the consortium (including the Commission Services)
EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC)
EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC)
EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)
17. Delivery date for Deliverable
Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates
being relative to this start date.
18. Milestone number
Milestone number:MS1, MS2, ..., MSn
19. Review number
Review number: RV1, RV2, ..., RVn
20. Installation Number
Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be
used independently from the rest.
21. Installation country
Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is
an international organization, an ERIC or a similar legal entity.
22. Type of access
VA if virtual access,
TA-uc if trans-national access with access costs declared on the basis of unit cost,
TA-ac if trans-national access with access costs declared as actual costs, and
TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of
unit cost.
23. Access costs
Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access
fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the
basis of unit cost will result from the unit cost by the quantity of access to be provided.
Page 53 of 53
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Table of changes
Section Change performed
2.2 • Increased the number of stakeholder interactions from 5 to 6 for specific objective 2
• Increased the level of detail presented for specific objective 3, with the addition of 6 more
output indicators
• Specification of the outcome indicators for specific objective 4
• Increased level of detail for specific objective 5
• Increased the level of detail presented for specific objective 6, with the addition of 4 more
output indicators
• Clarification of the output and outcome indicators of specific objective 7
3 Additional target groups have been included within the list of stakeholders
4.2 Further clarification on the added value in the EU in the field of public health.
4.3 Updating on the number of countries and partners in the JATC
Updated the map to reflect the current number of partners
5 • Addition of EU funding text in the dissemination WP description
• Updating of the Evaluation WP with further detail
• Improving the focus of WP4 on regulators knowledge improvement
• Extensive detail on the methods was presented in WP5
• Additional detail was presented for WP6, 7, 8 and 9 with more technical procedures
outlined.
6 Addition of more expected outcomes for the project taking into account the detail provided
Old 7-8 Sections 7-8 (WPs and Milestones) was deleted from the text here as already in Annex Ia
There was a change in the WP5 leader from FOHM to SIK due to a change in important personnel
available within FOHM.
7 Partners were moved to collaborating partners and one new partner (Malta) was included.
8.3 Budget lines were corrected. There was a transition of costs from partners who are now
collaborating stakeholders so as to facilitate their travel expenses (since they no longer have an
individual budget)
11 Collaborating stakeholders have been updated. These now include also partners who were unable
to perform the registration/validation process and who have opted for joining as collaborating
stakeholders.
Joint Action on Tobacco Control (JATC) Page 1 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Table of Abbreviations
JATC Joint Action on Tobacco Control
EU European union
TPD Tobacco Products Directive
FCTC Framework Convention on Tobacco Control
MS Member States
GEP good experimental practising
SCHEER Scientific Committee on Health, Environmental and Emerging Risks
EU-CEG European Union – Common Entry Gate
COI Conflict of interest
WHO World Health Organisation
WP Work Package
ENSP European Network on Smoking and Tobacco Prevention
CMR carcinogenic, mutagenic or reprotoxic
CHAFEA Consumers Health and Food Executive Agency
DG SANTE Directorate General of Health (SANTE)
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
CLP classification, labelling and packaging
GEP Good Experimental Practice
IT Information Technology
Joint Action on Tobacco Control (JATC) Page 2 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Contents
1. PROBLEM ANALYSIS INCLUDING EVIDENCE BASE.................................................................. 4
2. AIMS AND OBJECTIVES OF THE PROJECT ................................................................................... 5
2.1. General objective of the project ............................................................................................................... 5
2.2. Specific objective(s) of the project .......................................................................................................... 6
3. TARGET GROUPS ................................................................................................................................ 10
4. POLITICAL RELEVANCE .................................................................................................................. 11
4.1. Contribution to meeting the objectives and priorities defined in the annual work programme ............. 11
4.2. Added value at EU level in the field of public health ............................................................................ 12
4.3. Pertinence of geographical coverage ..................................................................................................... 14
4.4. Consideration of the social, cultural and political context ..................................................................... 14
5. METHODS AND MEANS ..................................................................................................................... 16
6. EXPECTED OUTCOMES .................................................................................................................... 19
7. PROJECT MANAGEMENT STRUCTURE ....................................................................................... 20
7.1. Quality of the partnership / Capacity of the staff ................................................................................... 22
7.2. External and internal risk analysis and contingency planning ............................................................... 35
7.3. Financial management ........................................................................................................................... 36
8. BUDGET ................................................................................................................................................. 37
8.1. Content description and justification ..................................................................................................... 37
8.2. Summary of staff effort.......................................................................................................................... 39
8.3. Detailed budget ...................................................................................................................................... 40
9. PREVIOUS AND CURRENT GRANTS RELEVANT TO THE PROGRAMME (LIMITED TO THE
LAST 3 YEARS) ............................................................................................................................... 74
10. CURRENT APPLICATIONS RELEVANT TO THE PROGRAMME .......................................... 74
11. EXCEPTIONAL UTILITY ................................................................................................................. 75
12. COLLABORATING STAKEHOLDERS........................................................................................... 76
Joint Action on Tobacco Control (JATC) Page 3 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1. PROBLEM ANALYSIS INCLUDING EVIDENCE BASE
Smoking and other forms of tobacco consumption are considered the single most important cause of preventable
morbidity and premature mortality worldwide, with tobacco the major single cause for premature deaths in the
European Union (EU). Despite considerable progress made in recent years, the number of smokers in the EU is
still high – 26% of the overall population and 25% of young Europeans aged 15-24 smoke, according to the
most recent Eurobarometer 1 . Compared to the rest of the world, the World Health Organization’s (WHO)
European Region has one of the highest proportions of deaths attributable to tobacco, with an estimated 16% of
all deaths among adults over thirty years of age due to tobacco use, compared to the global average of 12%.
Efforts to reduce the devastation of tobacco-related deaths and illness in the EU consist of its newly adopted
binding legislation, the Tobacco Products Directive (TPD), and the ongoing implementation of the WHO
Framework Convention on Tobacco Control (FCTC). The TPD (2014/40/EU) 2 entered into force on 19 May
2014 and became applicable in the EU Member States (EU MS) on 20 May 2016. The TPD lays down rules
governing the manufacture, presentation and sale of tobacco and related products. These include
cigarettes, roll your own tobacco, pipe tobacco, cigars, cigarillos, smokeless tobacco, electronic cigarettes, novel
tobacco and herbal products for smoking with the final aim to facilitate the smooth functioning of the internal
market for tobacco and related products, taking as a base a high level of protection of human health, especially
for young people, and to meet the obligations of the Union under the WHO FCTC.
One key aspect of the TPD is the development of an EU common reporting format for submission of data
on ingredients contained in tobacco and related products and disclosure of the collected data to the public.
This above aspect was extensively covered through the EUREST project, on which this Joint Action is
extensively based3. Indeed, the current TPD stipulates that MS require manufacturers and importers of tobacco
products to report on the ingredients used in such products, the ground for their inclusion and relevant
toxicological information. Moreover, the TPD seeks to further harmonise the approach on ingredients regulation
in the context of the internal market and to rationalise the reporting system for manufacturers and importers.
Knowledge on tobacco and e-cigarette ingredients additives and technical design is important so as to be
able to formulate and monitor European tobacco control policies and product evolution 4 . It is well
acknowledged that sensory characteristics that maintain tobacco product appeal and ease of use are important
in influencing smoking behaviour independent of the direct effects of nicotine. Research5 we had performed on
the Eurobarometer has indicated that several elements of cigarette design and manufacture were significantly
associated with increased product appeal and reduced harm perception among several population groups across
the EU. These elements fell into three main groups: (1) Modifications involving cigarette stick characteristics
(e.g., length or diameter) or tobacco ingredient formulation (e.g., tobacco blend)—which are generally the most
important determinants of the chemosensory properties of tobacco smoke including taste, irritation, strength
and impact. (2) Additive enhancements such as the use of characterizing flavors to increase smoking
appeal/attractiveness, particularly among naïve smokers and (3) Marketing features, including tobacco pricing,
as well as a plethora of tobacco packaging elements such as color schemes and brand descriptors that could
subtly convey false messages of reduced risk or heightened perception of reward from tobacco use. Within the
context of the JATC such data will be available and would be able to support the decision making process of
tobacco product regulation by EU MS regulators and the EC for the protection of consumer and public health.
1
Special Eurobarometer 429. Attitudes of Europeans Towards Tobacco And Electronic Cigarettes.
2
Directive 2014/40/EU of the European Parliament and of the Council
3
https://ec.europa.eu/health/sites/health/files/tobacco/docs/reportingformat_dataingredients_en.pdf
4
https://ec.europa.eu/health/sites/health/files/tobacco/docs/evidence_ingredients_tobaccoproducts_en.pdf
5
Agaku, Omaduvie, Fillipidis, Vardavas. Tob Control 2014;0:1–8. doi:10.1136/tobaccocontrol-2014-051922
Joint Action on Tobacco Control (JATC) Page 4 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Hence, we are at a unique time in the history of European tobacco regulatory science as over the next 3
years the TPD will come into full swing and the wealth of information that will be available to regulators will
be unprecedented. This knowledge and vast datasets will be complex, technical in many aspects and need a
unique consortium of regulators and scientists to take the lead. This is what we will aim to address within this
Joint Action.
2. AIMS AND OBJECTIVES OF THE PROJECT
2.1. General objective of the project
The general objective of the project will be to provide support for the implementation of the TPD
throughout the 28 EU MS. The TPD is a complex legislative document with the aim to preserve a high level
of European public health and support the functioning of the internal market of tobacco products in the EU.
Through the provisions of the TPD both tobacco products, including novel tobacco products and e-cigarettes
are regulated. This JA is a collaborative action between the European Commission and the EU MS to implement
an action-oriented initiative based on evidence-based tobacco control policies and implementation at the
national, regional or European level with the overarching aim to improve the protection of EU Public Health.
In certain areas, the European Parliament and the Council have empowered the European Commission to adopt
further legislative acts to aid the implementation process of Directive 2014/40/EU 6. This legislation takes the
form of delegated or implementing acts which outline in more detail the rules and measures regarding tobacco
and related products. Moreover, under the TPD (2014/40/EU), manufacturers and importers of tobacco
products, e-cigarettes and refill containers have to submit key information to the authorities in the Member
States in which they plan to market the products. This submission of information is performed through the EU
Common Entry Gate (EU-CEG) 7. EU-CEG was designed to reduce administrative burden for companies and
regulators, and make it easier to compare data on products within and across EU MS. The tool was developed
by the European Commission, working closely with Member States, stakeholders and in close cooperation with
the EUREST Consortium with regards to the data variables that are to be requested by EU MS.
The reporting and notification obligations follow from Articles 5(5) and 20(13) the Tobacco Products Directive
(2014/40/EU). The specific rules on common electronic formats have been established by Commission
Implementing Decision (EU) 2015/2186 for tobacco products and Commission Implementing Decision (EU)
2015/2183 for electronic cigarettes and refill containers (within which the EUREST project, performed by the
JATC coordinators, played a key role as it developed the “data dictionary” on which the EU-CEG was
structured) 8,9.
The specific aims of the project are addressed in detail over the next pages and will be addressed within
the context of the following specific objectives:
Objective 1: To ensure appropriate coordination and evaluation
Objective 2: To support the dissemination of information to the public, regulators and researchers.
Objective 3: To enhance the ease of access to the data collected through the EU CEG
Objective 4: To monitor and provide support to the tasks of tobacco and e-cigarette product regulation
Objective 5: Assist EU MS networking and collaborations between laboratories for tobacco evaluation.
Objective 6: Support EU MS in the process of monitoring and updating priority additives
Objective 7: To integrate the JATC results into national policies and enhance EU networking between MS.
6
Directive 2014/40/EU of the European Parliament and of the Council
7
https://ec.europa.eu/health/euceg/introduction_en
8
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32015D2183
9
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32015D2183
Joint Action on Tobacco Control (JATC) Page 5 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
2.2. Specific objective(s) of the project
The specific objectives of this proposal are directly relevant to the text of the call for proposals in the Work
Programme of 2016 so as to ensure direct relevance to the call and to the objectives that the European
Commission aims to accomplish through the JATC. The objectives have been formulated to be "SMART":
Specific, Measurable, Acceptable for the target group, Realistic, and Time-bound as identifiable
through the WP text.
Specific Objective 1
Number
Specific Objective Effective coordination of the project
Process Indicator(s) Target
Consortium agreement developed 1
Absence of Conflict of Interest (COI) and confidentiality forms written 1
Project’s meetings 3
Steering Committee meetings 3
Evaluation group questionnaires and meetings 1 (3)
Output Indicator(s) Target
Signed consortium agreement by all parties 1
COI forms signed by all partners 34
Project meeting minutes 3
Periodically cost statement and activity reporting 2
Interim and final reporting 2
Evaluation feedback response 75%
Outcome/Impact Indicator(s) Target
Effective coordination as identified through internal evaluation n/a
Specific Objective 2
Number
Specific Objective To support the dissemination of information to the regulators and general
public.
Process Indicator(s) Target
Project’s website launched 1
Project’s conference 1
Project’s leaflet developed 1
Dissemination plan developed 1
Presentations and stakeholder interactions at events and conferences 6
Joint Action on Tobacco Control (JATC) Page 6 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Output Indicator(s) Target
Visits to project website 1000
Participation in the JATC final conference 100
Project leaflets handed out 500
Project result reports disseminated 3
International and National Tobacco control Stakeholders engaged 20
Outcome/Impact Indicator(s) Target
Increased visibility and awareness among EU MS policymakers 28 (100%)
Specific Objective 3
Number
Specific Objective To enhance the ease of access to the data collected through the EU CEG
Process Indicator(s) Target
Difference between EU-CEG “public non confidential” data, “non-public non 1
confidential” data and “confidential” data.
Technical/legal framework for the sharing of data reported data in EU-CEG 1
Proposal of mechanisms for sharing EU-CEG data between EU-CEG MS and 1
the JATC-project
Proposal of mechanism for sharing EU-CEG data between EU-CEG MS 1
permanently
Output Indicator(s) Target
Requirement specification on technical and administrative security measures to 1
protect EU-CEG-data depending on level of need of protection from WP5 and
EU MS classification of EU-CEG data.
Information sharing agreement template for sharing data within the JATC- 1
project produced and implemented.
Information sharing agreement template for sharing data permanently between 1
EU MS in place. (This is done only if there is a need for – this is not already
agreed on in more general EU MS agreements or in earlier EU-CEG MS
agreements.)
Technical solution for making EU-CEG MS publish public non-confidential 1
data
Technical solution for sharing EU-CEG data with WP6-9 1
Technical solution for permanent sharing of EU-CEG data between EU MS. The 1
Technical solutions will be suggested and decided by system owner (SANTE).
The Requirement specification will be basis for the work.
Proportion of EU MS that provide public data 28 (100%)
Proportion of EU MS that provide some form of confidential data 20 (70%)
Joint Action on Tobacco Control (JATC) Page 7 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Proportion of EU MS that upload public data 28 (100%)
Outcome/Impact Indicator(s) Target
Greater sharing of data by EU MS to other EU MS 14 (50%)
Specific Objective 4
Number
Specific Objective Monitor and provide support to the tasks of tobacco and e-cigarette product
regulation
Process Indicator(s) Target
Data from EU MS regulators regarding requirements for EU-CEG 28
Analysis plans for tobacco and e-cigarette products 2
Checklist for e-cigarette product compliance created 1
Proposed system for adverse event reporting outlined 1
Output Indicator(s) Target
First wave of product analyses for domains in EU-CEG 4/5 domains
Second wave of product analyses for domains in EU-CEG 5/5 domains
Outcome/Impact Indicator(s) Target
awareness of EU-CEG capabilities by EU MS regulators 20/28
awareness on ingredient function, role and toxicity 20/28n
awareness on product design and evolution 20/28n
Checklist for e-cigarettes applied in EU MS 3
Specific Objective 5
Number
Specific Objective Assist EU MS networking and collaborations between laboratories for
tobacco evaluation
Process Indicator(s) Target
Collection of information from EU MS on tobacco laboratories. Within WP8, 20 EU MS
we will collect information about EU tobacco laboratories and their
activities.
Collection of data from EU MS laboratories. Within WP8, for each EU 5 laboratories
laboratory, we will request to obtain analytical data for predefined products,
which will be critically evaluated and re-analysed at a European scale.
Networking meeting with EU and international laboratories. Task 3.1 of 1
WP8 has been specifically designed to develop collaborations and
Joint Action on Tobacco Control (JATC) Page 8 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
communication with large international initiatives, including GoToLab and
TobLabNet, to further improve networking between labs.
Output Indicator(s) Target
Networking meeting minutes, including minutes from the two internal 1
meetings of WP8
Capacity for EU MS laboratories identified, within WP8, laboratory capacity 1
requirements will be provided in D8.2
Report on emission protocols concluded, laboratory capacity requirements 1
will be provided in D8.3
Networking with other laboratories in the EU and internationally 10
Outcome/Impact Indicator(s) Target
Enhanced collaboration between EU MS with regards to emissions and n/a
ingredient analysis. Once WP8 objectives are accomplished, laboratory
methods will be harmonized throughout the EU MS, improving
collaborations among independent laboratories.
Specific Objective 6
Number
Specific Objective Support EU MS in the process of monitoring and updating priority
additives
Process Indicator(s) Target
Identification of good experimental practicing guidelines 1
Obtainment of priority additive data and supporting information 1
Recruitment of peer reviewers, experts in the field 10
Peer review process commenced 1
Output Indicator(s) Target
Inventory on reports on priority additives obtained and categorised 15 additives
Peer review meeting minutes 2
Assessment/Evaluation Framework 1
Good experimental practice guidelines 1
Trained experts in document review 12
Report with reviewers judgement on each priority additive 15
Outcome/Impact Indicator(s) Target
Update on the number of additives subject to enhanced reporting n/a
requirements
Specific Objective 7
Number
Joint Action on Tobacco Control (JATC) Page 9 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Specific Objective To integrate the JATC results into national policies
Process Indicator(s) Target
Mapping survey of activities and capacity from EU MS 1
Creation of “how to” guides 3
Creation of “how to” guide platform 1
Sustainability plan detailed 1
Output Indicator(s) Target
Mapping activities and capacity from EU MS regulators 28/28 (100%)
Downloads/sharing of e-learning material by EU MS regulators 28/28
Uptake of e-learning material by EU MS regulators 20 (70%)
Outcome/Impact Indicator(s) Target
awareness of EU MS regulators on domains covered in the “how to” guides. n/a
3. TARGET GROUPS
The proposed project seeks to reach a variety of primary target groups:
EU Regulators and national policymakers are the primary target group of the JATC, due to their
direct relevance with the topics covered by the JATC: These are the main beneficiaries that would
benefit most from the JATC as the actions and tasks that will be performed address aspects of the TPD
that have to be addressed by EU regulators within the context of TPD implementation at a national
level. In order to ensure wider use of any research evidence and its translation into public health policy
and subsequent public health gain, it is important to engage EU regulators in all aspects of the project
development and dissemination, and as early as possible. It is important to note that the participating
partners in the current JATC project, are by majority either EU MS regulators or relevant competent
authorities across the EU MS and hence their engagement would be both feasible, beneficial and
measurable. We envisage that all 28 EU MS competent authorities and those from the participating
EEA countries would directly benefit from the JATC.
International and National Tobacco control stakeholders are a secondary group that would benefit
from these outcomes. Tobacco control stakeholders will benefit from the amount of information that
would be released with regards to tobacco and e-cigarette product development, legislation and product
safety. This target group will be reached through interactions at both the dissemination level (WP2) and
the “networking and sustainability level” (WP4). We aim to reach out to 50 tobacco control
stakeholders that are active within the European Union. This will include also patient organisations,
international institutions (WHO, IARC), EU institutions (such as DG ECFIN, TAXUD etc.).
Stakeholder networks with broad outreach across the European region and that have close
collaborations with national stakeholders active in tobacco control, such as the European Network on
Smoking and Tobacco Prevention (ENSP) will also be sought so as to increase stakeholder involvement.
Researchers would also benefit greatly both from the use of knowledge that will be produced as
outcomes of the JATC project but also due to data that may be released (taking all aspects of clearance
into account). The engagement of additional researchers would increase the potential utility of the
Joint Action on Tobacco Control (JATC) Page 10 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
findings for the production of scientific evidence. Researchers will also be targeted under WP2 and
WP4 so as to enhance their awareness of such data and enhance the usage of the wealth of data collected
through the EU-CEG.
General public. Tobacco use is the largest preventable cause of death and disability within Europe and
hence the general European public will benefit from the implementation of this Joint Action as it will
support both the successful implementation of the TPD across the EU but also address issues that would
ensure a high level of public health through the appropriate regulation of tobacco products. Moreover,
the TPD mandates that information on tobacco product ingredients and additives should be provided to
the general public after ensuring the protection of trade secrets. The general public would be able to
obtain further information on tobacco product descriptors and ingredients and increase their health
literacy in this area. This indirectly would influence the 508 million people (smokers and non-smokers)
covered by the legislative articles of the TPD.
4. POLITICAL RELEVANCE
4.1. Contribution to meeting the objectives and priorities defined in the annual work programme
The EU Health Strategy provided a policy framework for all the areas covered by the Health Programme - Work
Programme for 2016 10. This work programme sets out the priorities and actions to be undertaken, including the
allocation of resources, to implement the third Programme of the Union’s action in the field of health (2014-
2020). According to the EU Health Strategy “Health is central in people's lives and needs to be supported by
effective policies and actions in Member States, at EC level and at global level”. Tobacco use within the
European Union remains the most detrimental threat to European public Health, a fact which is stressed within
the Work programme for 2016 and within the EC white paper on health in the EU11.
Specifically for tobacco control, the work programme notes that “Reporting, assessing and regulating tobacco
ingredients are important aspects of an effective and comprehensive tobacco control policy which contributes
to the broad objective of promoting good health, reducing tobacco related disease and deliver real benefits to
citizens. Based on this introductory text the following priorities and objectives to be pursued:
In general and as taken from the text of the call, the JA “…will focus on the reporting of ingredients and the
notification of e-cigarettes, including laboratory capacity, analysis and assessment” – issues which we address
with WP6 WP7 and WP8 respectively.
It is also important to note that according to the Framework call text “The new reporting obligations represent
a challenge both in terms of quantity and the type of the data as some of the collected data are completely new,
and neither collected previously in the EU nor in other jurisdictions”. To address this “gatekeeping activity”
we identified the need to create an important “gatekeeping” work package (WP5) that will handle the technical,
practical and legal issues of handling such data that is needed to accomplish the main objectives of the proposal.
Specific objectives to be funded include the following:
Domain 1: “The activities should also include an assessment of data on ingredients in tobacco products
submitted for the first time under the new reporting format in 2016”
10
Health Programme - Work Programme for 2016. http://ec.europa.eu/health/programme/docs/wp2016_annex_en.pdf
11
WHITE PAPER. Together for Health: A Strategic Approach for the EU 2008-2013
Joint Action on Tobacco Control (JATC) Page 11 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
o Indeed in the JATC, two WP will have the base on the evaluation of the data submitted on
ingredients within tobacco products. WP5 will handle the collection of such data, while WP6
will handle the analysis of such data related to tobacco products.
Domain 2: “Support the building up of appropriate laboratory capacity to verify the submitted data and
support the enforcement.”
o Addressed through WP8, within the JATC we aim to identify, organise and network the
laboratory capacities across EU MS and work to develop homogenised approaches in product
evaluation across the EU MS. It is imperative to develop the requirement of appropriate
laboratory capacity needed to verify the submitted data and support TPD enforcement.
Domain 3: “Evaluation of e-cigarettes regulators will receive notifications of all e-cigarettes currently
available in the EU, and will begin to receive prior notification of e-cigarettes still to be launched”
o To address this objective, WP7 will focus exclusively on the reporting of data submitted to EU
MS on e-cigarettes and covers all areas of the reporting and pre-notification as also aid the
enhancement of comparability of the submitted data on e-cigarettes.
Domain 4: “The action should process….results of comprehensive studies on priority additives which
will have to be conducted and submitted by the tobacco industry. The system to be put in place should
facilitate the peer-review...”
o Indeed in the JATC we will have one entire WP dedicated to the analysis and peer review of
the data submitted on priority additives as outlined in the Commission Implementing Decision
(EU) 2016/787 of 18 May 2016 laying down a priority list of additives contained in cigarettes
and roll-your-own tobacco subject to enhanced reporting obligations.
Domain 5: “to support the above work with dissemination and networking”
o An important part of the call of the annual work plan, dissemination and networking. These
crucial aspects facilitate the greater awareness of the general public and regulators of the results
of the JATC but also support the sustainability activities needed to ensure that the JATC results
and activities can be sustained after the end of the JATC.
4.2. Added value at EU level in the field of public health
The TPD stipulates that EU MS shall require manufacturers and importers of tobacco products to submit
information, the exact requirements of which are set out in the TPD and in two Implementing Decisions:
2015/2186 of 25 November 2015 that establish a common format for the submission and making available of
information on tobacco products 12 and Commission Implementing Decision 2015/2183 of 24 November 2015
establishing a common format for the notification of electronic cigarettes and refill containers 13. These decisions
clarify that the information should be submitted to EU MS via a common entry gate (EU-CEG) – an IT tool
designed to ensure uniform application of the reporting and notification obligations, harmonise the submission
of data, facilitate comparison and reduce administrative burden for regulators and industry stakeholders alike.
This JATC hence has significant added value as it addresses the issue of tobacco product monitoring at
an EU wide level –an activity that would be impossible to be done by one, or a few, EU MS by themselves.
12
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AJOL_2015_312_R_0003
13
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32015D2183
Joint Action on Tobacco Control (JATC) Page 12 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
This is an unprecedented opportunity as coordinating the work at European level is greater than the sum of the
impacts of national activities.
While the EU-CEG it-system is owned by commission (The European Commission is System owner), each EU
MS own their data in the EU-CEG (Each MS is information owner of their data), while the TPD states that EU
MS should share data with other EU MS and with the Commission, however data sharing has not been done yet
regarding any data so we have no predefined way to access MS data.
Overall the actions to be performed brings significant added value to the existing public health knowledge
as the vast majority, if not almost all of the data submitted, has never been evaluated on a comprehensive scale.
Furthermore, the detail of information on tobacco product design and evolution will be a significant departure
from the status quo as to date the reporting of data has substantially increased from the <20 variables (according
to the 2006 practical guide on the reporting of tobacco products) to the now >100 variables covering all aspects
of tobacco and e-cigarette product design, ingredients and toxicity amongst others. This project will be able to
enhance the mechanisms of tobacco control and regulation in the short and long term and across the EU
population.
This increase in knowledge is highly likely to provide the scientific evidence needed to further regulate tobacco
products across the EU MS and lead to a JA that would provide substantial added value in the field of public
health, and be able to contribute to the protection of European Public Health, especially within the light of the
devastating toll of tobacco use and addiction on the European population.
EU added value will be achieved in the following areas as outlined in the following table
Path to EU added value How this is addressed in the JATC
Implementing EU The entire scope of the JATS is practically “how to ensure that the TPD is
legislation implemented appropriately over the next few years. As a unique public policy
support project the JATC will directly aid EU MS in their implementation of the
activities of the TPD. Non EU MS participants will also benefit.
Achieving economies of Substantial value for money at a European level will be obtained through this JATC
scale as the activities performed within this project would support EU MS regulatory
activities for which substantial scientific and technical expertise would be needed.
This expertise would be provided through the JATC.
Promoting best practice With access to large European Wide datasets, the JATC will be able to facilitate an
unprecedented opportunity to use “big data” for tobacco control research and to
support evidence based decision making.
Bench making for decision The JATC will play a key role in the formulation of the “next steps” of TPD
making implementation across the 28 EU MS, the results of which would be used to fuel
public health policy decision making with regards to tobacco products and e-
cigarettes.
Tackling cross-border Tobacco is the largest threat to European Public Health, responsible for more than
threats 700,000 deaths in the EU annually. The JATC will tackle exactly this public health
epidemic of gigantic proportions.
Networking The JATC as a true collaborative and European wide project has been developed
to enhance networking between countries. A direct result of this networking is
increased collaborations between MS. As we have more than 30partners from most
EU countries we are confident that the networking needs will be met and surpassed.
Joint Action on Tobacco Control (JATC) Page 13 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
4.3. Pertinence of geographical coverage
The JATC involves the majority of EU MS which are representative of the south, central and east part of the
European Union, while this proposal also includes non EU MS countries, such as Norway, Iceland, Moldova
and Serbia. Hence taking this broad geographical scope into account, within the context of this proposal when
the term “EU regulators” is referred to, these cover regulators both from EU MS as also from EEA countries.
Indeed within this JA, we have >30 participating partners across many European countries.
The geographical coverage of the JATC is clearly demonstrated. Only 3 EU MS do not participate as either
a partner or collaborating stakeholder in this JA (LU, FI, SI), indicating the broad outreach of this proposal.
Furthermore, collaborating partners were added from other countries so as to encourage engagement in these
areas too.
4.4. Consideration of the social, cultural and political context
Tobacco consumption is the single largest avoidable health risk in the European Union. It is the most significant
cause of premature death in the EU, responsible for nearly 700,000 deaths every year. Around 50% of smokers
die prematurely (on average 14 years earlier) and cause a significant drain to the economic wellbeing and excess
stress to the healthcare system. Tobacco-related morbidity is expected to have a significant impact on the
provision of health care and pose an additional burden to economies within the Eurozone, many of which are
already under significant economic constraints. Hence tobacco use and addiction is not only a health risk but its
impact on society as a whole is staggering.
Within the context of battling this maelstrom of epidemic proportions the EU MS, together with the European
Commission, are active partners in the WHO Framework Convention on Tobacco Control (FCTC), a legally
binding international treaty that aims to reduce the damaging health and economic impacts of tobacco
consumption. Legislative action at the EU level has also been noted as necessary in order to implement the
WHO FCTC of May 2003, the provisions of which are binding on the Union and its Member States. The FCTC
provisions on the regulation of the contents of tobacco products, the regulation of tobacco product disclosures,
the packaging and labelling of tobacco products, and electronic nicotine delivery devices (e-cigarettes) are
particularly relevant to the JATC.
Tobacco product design and constituents provides a major industry tool for innovations that undermine
public health programs and support tobacco use and dependence. The past century has seen the
development and adoption of many new cigarette technologies and design features including new tobacco
blends, filters, ventilation, altered paper porosity, and additives including flavors, humectants, and analgesics.
In some cases, industry created these innovations to respond to perceived health, social, and regulatory concerns.
In others, they reflected practical industry concerns, including cost and availability of materials and growing
understanding of the complex chemistry of tobacco and nicotine delivery. Unregulated tobacco product design
and innovation over the last half century have resulted in products that are more attractive, less harsh, milder
tasting, and more satisfying, while at the same time facilitating the inhalation of nicotine and other substances
deep into the lung.
Cigarettes are now meticulously engineered using complex systems in which design features interrelate
with behavioral and neurobiological responses to regulate nicotine dosing. These designs ease inhalation
of smoke and reduce perceived effort while lowering perceptions of health risks. In short, manufacturers have
evolved their products to make the process of nicotine dosing and reward enjoyable, easy, and highly effective,
yet no safer. The research views all cigarettes are more or less equally toxic and that any changes in toxicant
levels within the parameters of maintaining product appeal will do little to reduce it. While all cigarettes have
Joint Action on Tobacco Control (JATC) Page 14 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
relatively equal levels of nicotine in the unburned rod, differences in nicotine delivery, free nicotine, aerosol
transfer, absorption, additives and flavorings that impact central nervous sensory perception (olfactory) are
critical to abuse liability. For example, product evaluation for regulation must take into account systems such
as i.e. the use of menthol in the context of tar/nicotine ratios, free nicotine, nicotine analogues and other
chemosensory components and additives. For conventional style cigarettes, a number of parameters including
filter ventilation, resistance, tobacco weight and blend, additives and flavors may all contribute, individually or
in combination, to the way in which a cigarette is smoked and its yields of toxic constituents, its addictiveness
and attractiveness. In light of the above, the EU Commission issued a Commission Implementing Decision (EU)
2015/2186 of 25 November 2015 establishing a format for the submission and making available of information
on tobacco products that would facilitate the process of monitoring tobacco product evolution.
Additives can make cigarettes more attractive by disguising some of the undesirable effects of inhaling
burnt tobacco. Additive enhancements such as the use of characterising flavours to increase smoking
appeal/attractiveness, particularly among naïve smokers. These additives are intentionally added to tobacco
products by the tobacco industry in order to render toxic tobacco products palatable and acceptable to
consumers. For example, they mask the bitter taste and harsh smell of the smoke that is inhaled; make the
inhaled smoke milder, reducing the irritation of the airways (which essentially silences any warning that the
smoke is dangerous); turn the ash and smoke white; improve the appearance of cigarettes etc. Both empirical
tobacco industry internal research and flavor industry science has found taste to be a complex of effects on
tactile, (trigeminal), odor (olfactory) and flavor (gustatory) nerves on perceptions affecting use. “Flavors”
appear to activate neural transmission of signals to the brain that may affect the abuse potential of products and
population impact. For instance based on our teams; recent secondary analysis of the 2012 Eurobarometer data,
and after adjustment, female current smokers had higher OR than males of choosing a cigarette brand based on
a specific sweet, menthol, fruity or spicy flavour (AOR=1.33; 95% CI 1.14 to 1.56) 14 . These flavours are
additives. This issue has been outlined in the Commission Implementing Regulation (EU) 2016/779 of 18 May
2016 laying down uniform rules as regards the procedures for determining whether a tobacco product has a
characterising flavour and area which we will touch upon in the JATC.
Moreover, studies have also shown that burning tobacco additives can result in the formation of harmful
compounds. With respect to toxicity, additives can in particular have carcinogenic, mutagenic or reprotoxic
properties (jointly referred as CMR) in burnt or unburnt form. The industry is also aware of the fact that
cigarettes contain a host of cytotoxic and carcinogenic substances that are generated, for the most part, in the
cigarette smoke during the combustion process (pyrolysis). A key example is acetaldehyde, a known carcinogen
produced from the burning of sugars added as sweeteners. These key priority additives have been outlined in
Commission Implementing Decision (EU) 2016/787 of 18 May 2016 laying down a priority list of additives
contained in cigarettes and roll-your-own tobacco subject to enhanced reporting obligations, an area which also
will be covered under the JATC. Furthermore, new products of combustion are formed as a consequence of the
burning of various ingredients and these substances may be toxic or pharmacologically active. Article 9 of the
FCTC 15 recommends parties to propose guidelines for testing and measuring the contents and emissions of
tobacco products and Article 10 recommends to implement effective legislative, executive, administrative
measures requiring tobacco companies to disclose contents and emissions of tobacco products
Moreover a second key area addressed by the TPD are e-cigarettes. E-cigarettes are a relatively new product
on the EU market. They have been gaining increasing popularity as nicotine delivery tools in recent years.
Electronic cigarettes (e-cigarettes) are battery operated electronic nicotine delivery systems (ENDS) designed
to provide nicotine and mimic the sensory perception of smoking without combustion. For example, the
14
Agaku, Omaduvie, Fillipidis, Vardavas. Tob Control 2014;0:1–8. doi:10.1136/tobaccocontrol-2014-051922
15
WHO. World Health Organization Framework Convention on Tobacco Control (WHO FCTC).
Joint Action on Tobacco Control (JATC) Page 15 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
presence of ‘vapour’ (propylene glycol or vegetable glycerine), and the hand-to-mouth motions of smoking
associated with e-cigarettes have been designed to simulate smoking. E-cigarettes vary widely in design and
content. E-cigarettes can be disposable or rechargeable with single use cartridges, or refillable by means of a
refill container. As e-cigarettes represent an emerging market and are newly regulated under the TPD it is
imperative to set the base for product regulation in regards to their manufacture and health risk/benefit and also
monitor the implementation of the technical standards for these products too, for the protection of European
public health for the protection of public health as outlined in Commission Implementing Decision (EU)
2016/586 of 14 April 2016 on technical standards for the refill mechanism of electronic cigarettes.
With the above in mind, this proposal comes at a perfect timing to aid the regulatory activities that would be
needed across the EU MS with regards to the implementation of the TPD across 28 EU MS spanning a
population of 508 Million people.
Privacy and ethical considerations: As with all EU activities, data protection and privacy is an issue of utmost
importance. The EU Directive 95/46/EC on the protection of individuals with regard to the processing of
personal data and on the free movement of such data will be respected. No commercial use will be made of the
contact details gathered during the implementation of the JATC. Background materials from any research,
possible focus groups, meetings and working groups, will only be made public if the relevant permission has
been given. Should processing of personal data arise as a result of this project, informed consent declarations
will be signed by all participants, along with confidentiality agreements by all researchers, in order to ensure all
sensitive information will be handled with care and according to the legislative background as regards personal
data protection. Overall, all applicable EU, national and local legislation will be adhered to. Within the JATC,
a specific task in the Coordination WP has been dedicated specifically to issues of COI, confidentiality and
ethics.
5. METHODS AND MEANS
The JATC is a 36-month project that consists of an integrated sequence of nine (9) work packages (4 horizontal
and 5 core WPs). Further descriptions of all Work Packages, including their objectives, tasks, milestones, and
deliverables are presented in detail throughout the technical part of the proposal. However, in short, the proposed
methods and means used in the project for each WP, are as follows:
Coordination (WP1): The project coordination (WP1) will establish a clear and effective coordination and
communication system between partners, participating networks, important stakeholders, and the EU. Among
other specific objectives, it will ensure and establish high standards and quality criteria needed for the designated
milestones and deliverables of each WP of the Project. For the coordination and management of the project,
Consortium Meetings will take place and the steering committee and the management team will be established.
Consortium and Steering Committee meetings to ensure smooth work progress and sound financial resource
management will take place while close communication with CHAFEA and DG SANTE will be sought.
Dissemination (WP2): The project considers the dissemination activities as a continuing progress and a shared
responsibility, strategically planned to perfuse throughout the whole project’s duration. This work package aims
to disseminate the project’s results to policymakers, scientists and the public, with a main focus on its relevance
to public health in the EU. A dissemination strategy will be developed at the beginning of the project to ensure
the dissemination of the project’s results to the competent authorities and experts. The dissemination process
aims at stimulating the interest and attention of the scientific community as well as that of the policy makers
both at national and European level. The dissemination activities will take place in the following order: (a)
dissemination & exploitation planning including stakeholder and event mapping & analysis; (b) project website
and logo development, c) production of leaflets and reports that would disseminate the JATC findings and
policy implications, d) the creation and set up of a network of interested policy makers and e) to conclude with
Joint Action on Tobacco Control (JATC) Page 16 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
the organisation of a final project conference that will take place in Brussels, with the involvement of all
involved parties, tobacco control stakeholders and policymakers.
As the research and results involve information from multiple EU MS, reports for dissemination will be
produced in both English and the national language of the participating EU MSs to the extent possible. It is
important to state that EU funding will be acknowledged throughout the dissemination materials as appropriate
and according to the grant agreement.
Evaluation (WP3): An evaluation strategy will be developed to ensure the project’s efficient implementation.
The plan will specify the procedures and standards for the implementation, monitoring and evaluation of the
project, according to specific performance & quality indicators. Evaluation can be defined as the systematic
appraisal of the success of a project. It is a joined learning process for all involved, generating useful information
and knowledge to improve the project and the outcomes and outputs. The overall aim of this evaluation is to
measure if the project objectives have been achieved, measure if the outcomes of the JATC meet the needs of
the project targets group and assess the process used to ensure that the project activities are implemented as
intended. Throughout the project, but in particular towards the projects end, the evaluation results will be a
useful guide to make decisions about further steps after the end of the project. More particularly findings from
the evaluation shall contribute to further improve the implementation of TPD in all EU MS. In this WP activities
include the performance of interviews and focus groups within the project so as to ensure its quality and timely
delivery. Detailed processes of WP3 are described in the relevant WP section in this proposal.
Integration in National Policies and Sustainability (WP4): This WP covers actions undertaken to enhance
integration into national policies and ensure sustainability through the identification, and shared use of
regulatory and technical capacities in Member States, at the national level and across borders including also the
WP4 interview, focus group and survey activities that could identify both the capacity available as also the
funding needs of ingredient data handling and mining. The JATC will set up a plan that demonstrates the
potential of the results for integration in policies (at national levels), support national plan development, and
aim to ensure the sustainability of the JA activities. For this purpose within the JATC and in WP4 emphasis will
be placed on capacity development and training for the regulators at the EU MS level and also ensuring long
term training to interested parties in the form of “how to” guides available within an electronic data repository.
These “how to” guides will respond to questions and on to steps that EU MS regulators will need to take in their
daily regulatory duties. Furthermore, it is important to note that within WP4, preliminary mapping activities
will be performed so as to identify both gaps but also strengths and capacity within and across EU MS that
could be used both during and after the JATC. WP4 will obtain direct feedback from WP5, WP6 and WP7.
Common Entry Gate data handling and analysis (WP5): The TPD (2014/40/EU) requires manufacturers
and importers of tobacco products, electronic cigarettes and refill containers to submit key information –
including on ingredients, emissions and toxicological data – to the competent authorities of the EU MS in which
they place/intend to place these products on the market.
Within WP5 we will provide the framework for the accessibility of the data submitted through the EU-CEG,
including in light of the application of TPD Art 5, p 4 and TPD Art 5, p7 according to which “Member States
shall store the information electronically and shall ensure that the Commission and other Member States have
access to that information for the purposes of applying this Directive.”. The framework will be developed in
the light of ISO/IEC 27001 Information technology – Security techniques – Requirements and 27002
Information technology – Security techniques – Code of practice.
Hence, within the JATC we will need to access MS data to analyse the data, find improvements and suggest
them to the Commission at the end of the project, the JATC project would need to access as much of MS data
as early in the project as possible.
Joint Action on Tobacco Control (JATC) Page 17 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
It is important to note that in relation to the EU-CEG, the EU Commission would need to approve of all changes
made to the IT-system as the system owner is responsible that the data is stored safely. In light of the above,
resources from the European commission regarding changes in the IT-system would need to be secured.
The JATC-project have communicated the need of support from the EU-CEG system owner and the
maintenance/development resources working with EU-CEG at the EU Commission regarding working out
technical solution and implementing the identified needs to make EU-CEG data accessible to the project and
later on to all MS so that EU-CEG becomes an efficient tool in the work of implementing TPD. The needs of
new functionality and improved usability of the EU-CEG would need to be approved by the system owner, as
it is the system owner responsibility that the data in EU-CEG is handled and stored in a secure way
However, it is ultimately left to Member States, as information owner, to decide whether or not the technical
solution and the information sharing agreements will be enough, and to ensure that national rules are fulfilled
regarding sharing confidential data treatment of, trade secrets.
WP5, will provide support to EU MS in their decisions regarding sharing data by a) identify the public variables,
b) identify the legal and technical requirements to facilitate for MS to decide to what extent their national rules
allows data sharing and c) facilitate for MS to decide to what extent their data in EU-CEG can be made available
to WP6, WP7, WP8, WP9. The results of the work in WP5 and by the system owner of EU-CEG will be a
precondition for a continuing structured and safe handling of EU-CEG data.
Tobacco Product Evaluation (WP6): The aim of this vertical WP is to handle aspects pertinent to tobacco
product data handling on data collected by EU MS in light of the obligations of the TPD and within the context
of Commission Implementing Decision (EU) 2015/2186 of 25 November 2015 establishing a format for the
submission and making available of information on tobacco products. Through this WP we will perform an
evaluation of the data submitted via the EU-CEG with regards to all related domains to tobacco products. The
precise scope and format of data to be provided via the EU-CEG is defined in the Annexes to Commission
Implementing Decision (EU) 2015/2186 for tobacco products. In WP6 we will evaluate each of the domains
submitted and be able to respond to “burning questions” that may be brought forward by EU MS regulators and
policy makers by analysing the evidence as submitted through EU-CEG. Any such question will be handled by
the WP. Moreover WP6 also feeds into WP4 (sustainability), WP8 (Emissions) and WP9 (priority additives).
E-cigarette product Evaluation (WP7): Directive 2014/40/EU stipulates that manufacturers and importers of
electronic cigarettes and refill containers are to submit to the competent authorities of the EU MS a notification
of any such products which they intend to place on the market or which are already placed on the market on 20
May 2016. This data, as submitted through EU-CEG using the notification format for submission of information
on electronic cigarettes and refill containers should allow for the JATC to process, compare, analyse and draw
conclusions from the information received. The central analysis of such data will be able to support regulatory
activities as specific questions will be able to be addressed to WP7m, and specific responses based on the EU
data will be provided. The format of data to be provided via the EU-CEG is defined in the Annexes to
Commission Implementing Decision (EU) 2015/2183 for electronic cigarettes and refill containers. Within WP7
the evaluation of such submitted data will take place. Moreover, within WP7 the JATC will further provide
support for the monitoring of implementation of the Commission Implementing Decision (EU) 2016/586 which
lays down the technical standards for the refill mechanism of electronic cigarettes and include appropriate
instructions for refilling, including diagrams, as part of the instructions for use required by Article 20(4)(a)(i)
of Directive 2014/40/EU. Through WP7, a working group comprised of members from each partner in the WP
will be created to respond to specific requests brought forward by EU MS. These questions will be received by
the WP leader and circulated to relevant partners for their response.
Laboratory verification, collaboration and analyses (WP8): Throughout the European Union, it is today
extremely important that independent and certified laboratories analyze ingredients and emissions of various
Joint Action on Tobacco Control (JATC) Page 18 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
tobacco products and e-cigarette liquids, in order to verify the compliance of the tobacco and e-cigarette industry
with current regulations and to understand the emissions and constituents of all products in the EU market..
There is an urgent need to define the guidelines for the requirements of such independent laboratories. Only
filling this knowledge gap, the TPD will represent an important and effective milestone in the control of tobacco
ingredients and emissions. Within WP8 we will be supporting collaborations across laboratories, identification
of suggested methodologies and test analyses for reporting homogenisation and the building up of appropriate
laboratory capacity to verify the submitted data and support the enforcement. As with the previous WPs (6 and
7), questions regarding the area under WP8 will be forwarded to the WP lead who will share the question with
the partners and provide a scientifically based response.
Additives subject to enhanced reporting obligations (WP9): Article 6 of the TPD requires the European
Commission to develop and update a priority list of at least 15 additives contained in cigarettes and roll-your-
own tobacco by May 2016. These first 15 priority additives were noted under Commission Implementing
Decision (EU) 2016/787 and was established on the basis of available data suggesting that an additive may
contribute to toxic, addictive or carcinogenic, mutagenic or reprotoxic properties (‘CMR properties’) of
cigarettes and roll-your own tobacco, result in a characterising flavour, or facilitate inhalation or nicotine uptake.
In fulfilling their obligations manufacturers and importers of cigarettes and roll-your-own tobacco will submit
comprehensive studies on the 15 additives listed by 1 July 2018. Before that time an assessment and evaluation
framework will be composed together with guidelines for good experimental practicing. This will indicate and
guide manufactures on which aspects the enhanced reporting documents will be judged. While the evaluation
of the complete submissions on the primarily identified priority additives could only start from 1 July 2018,
data provided through WP5, 6 and 7 in relation to the 15 priority additives could also be assessed around that
time. Once the enhanced reporting information has been received, WP9 will facilitate the peer review process
by a panel of suitable experts. These experts will be trained to judge systematically the reports on priority
additives using the assessment and evaluation framework. Due to the current lack of expertise in the field of
toxicity, addictiveness and characterising flavours assessment, the training and gathered expertise in this JA is
of vital importance for the consortium and MS in the continuation of this task in the future. A recommendation
on the use of the 15 priority additives in tobacco products will be provided for the Commission Implementing
Decision. Furthermore, in corporation with WP6 and WP7 recommendations will be made on additives that
could potentially be added to the list of priority additives.
6. EXPECTED OUTCOMES
Policymakers and EU MS regulators are the main target group followed by researchers and the general public.
The increased regulatory vigilance on tobacco product evolution and development will protect European Public
Health through the increased awareness of product related data including but not limited to ingredients,
additives, design parameters, toxicological data and emissions. This increased domain specific literacy would
aid regulatory activities as also set standards for product placement in the EU market.
The expected outcomes of this project are related to the main target groups include but are not limited to the
following:
Increased EU MS implementation of the TPD through the provision of support and technical/scientific
capacity to EU regulators.
Increases EU MS regulator training through the provision of capacity building (toolkits, e-learning).
Common approach on handling tobacco product evidence based decisions across EU MS, within the
context of their national legislative approach.
Joint Action on Tobacco Control (JATC) Page 19 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Increased data sharing and collaborations between EU MS on tobacco product regulatory science.
Responses to questions on “burning topics” as brought forward by EU MS regulators.
Increased literacy on tobacco product design, constituents and toxicity by regulators and the public.
Close monitoring of e-cigarette compliance to the TPD across the EU MS.
Increased knowledge of e-cigarette design parameters, ingredients and emissions.
Enhanced collaborations between EU MS laboratories for tobacco product ingredient and emission
measurements.
Increased scientific scrutiny and decisions on potential priority additives within tobacco products.
For the general public and researchers greater access to data on tobacco products and e-cigarettes which
would be able to fuel population awareness and enhance research and policy actions. The provision of
such public data will be an unprecedented opportunity for tobacco control research.
7. PROJECT MANAGEMENT STRUCTURE
There are four horizontal supporting work packages, one core data handling WP and 4 vertical core, WP in the
JATC. The coordination of JATC will be done by participant no 1 (HCS). The JATC organisational structure
during the period funded by the EC is presented in Figure 2 below, which has been successfully applied
within the context of other EU and international projects:
Joint Action on Tobacco Control (JATC) Page 20 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Footnote for Figure 2: WP5: EU-CEG Data handling
WP1: Coordination WP6: Tobacco product reporting
WP2: Dissemination WP7: E-cigarette product reporting
WP3: Evaluation WP8: Laboratory verification, collaboration and analyses
WP4: Sustainability WP9: Additives subject to enhanced reporting obligations
The organizational structure, introduces the following bodies which are the following and described in detail
below.
Project Coordinator, (Prof Panagiotis Behrakis)
Project Associate Coordinators (Dr Constantine Vardavas and Dr Anna Tzorzti)
Project Manager/Secretariat
Steering Committee
Consortium meetingConsortium Meeting
Work Package Leaders
External Advisory Group
The project coordinator and project associate coordinators: The JATC has one work package for
coordination, led by the Hellenic Cancer Society (HCS). Prof Panagiotis Behrakis is the coordinator of the JATC
and he will be assisted by two associate coordinators, Dr Constantine Vardavas and Dr Ana Tzortzi. They will
be assisted by a part time project manager and a part time project secretariat. This team will provide the day-to-
day management of the project. Internal project management is coordinated through a project steering
committee and the Consortium meetingconsortium meeting.
The Coordinator’s tasks are:
To act as the intermediary between the consortium and the Commission
To receive all payments made by the Commission, transfer the Community contribution to the project
and allocate it between parties and activities
To keep accounts and to inform the Commission of the distribution of the funds on an annual basis
To ensure the highest standards of scientific research are adhered to and performed.
To ensure that the other parties duly sign the contract with the Commission in good time.
Technical and scientific project management and monitoring
Financial and administrative project management and monitoring
Management of knowledge (working closely with WP Dissemination)
Management of the ethical issues
Communication within the project (working closely with WP Dissemination)
The Project Secretariat/Manager supports the coordination team and Steering Committee within the project.
The Project Manager supports the Coordinator for the day-to-day management. As a consequence the Project
Secretariat/Manager facilitates primarily financial and administrative project management and monitoring and
communication between the coordination team and partners. This professional staff will be appointed in the
secretariat and will assist the Steering committee and the Coordinating team in particular.
The Steering Committee involves the coordinator and associate coordinators representing the main partner,
and the WP leaders. A representative from DG SANTE and a representative from CHAFEA will also participate,
however without voting rights. Collectively, they serve as the project management team, by actively leading
and contributing to WP implementation. The Steering Committee oversees the work and progress of individual
Joint Action on Tobacco Control (JATC) Page 21 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
WPs, notably monitoring the milestones and deliverables through periodic conference calls and meetings. It
also ensures that high standards of technical and administrative excellence are maintained, in order to facilitate
successful delivery of the JA outputs. The Committee is also responsible for resolving any potential conflict.
The Steering Committee provides support, guidance and oversight of progress. It will meet regularly by
teleconference, in person within the context of the annual meeting and at other moments that may be deemed
necessary so as to ensure smooth running of the processes.
The Consortium meeting meets on an annual basis to make strategic decisions, including on the working and
management plan for the JATC. It will involve a representative from each partner in the project. The Consortium
meeting can also be viewed as the main policy-setting body, which involves wider participation and
dissemination between WPs and across groups, particularly to partners who are not WP leaders. The Coordinator
will be ultimately responsible for the content of these meetings and will be greatly assisted by the Steering
Committee regarding both scientific content as well as practical details.
Work package Leaders, will be responsible for the effective management of their respective WPs, in the
context of monitoring and coordinating the allocated work per WP partners, so as to ensure the effective
production of the scheduled deliverables and outcomes that collectively the WP partners will have jointly
produced and for which they are jointly responsible. The WP leaders will be monitored by the overall project
leader (P1) and will report any divergence from the schedule so as to decide on remedial actions, in conjunction
with the Steering Committee.
An External Advisory Group will be appointed by the Steering Committee to both study and report on a
specific strategic matter regarding the scope of the project activities, and to focus on public health relevance,
innovation and dissemination of the project outcomes. The External Advosory Group will be comprised of
between 3-8 members, who will be independent experts or significant stakeholders in this field that would be
able to provide added value to the project.. The members of the EAG will be suggested by the coordinator and
other partners, discussed with the European Commission and will be ratified at the kick off meeting of the
JATC.
7.1. Quality of the partnership / Capacity of the staff
A successful JATC has to deliver in the following ways:
Accurate planning of each work package (WP) as requested in the tender specifications
Smooth execution of planned activities and tasks in each WP
High quality outputs, deliverables and reporting
Effective and efficient use of resources
To address these issues we propose the following consortium partners/staff capacity that will be able to meet
and exceed the expectations.
Partner 1: Hellenic Cancer Society (HCS), Greece
The Hellenic Cancer Society is a non-profit Organization, founded in 1958. The mission of the George D.
Behrakis Research Lab of the Hellenic Cancer Society is to contribute and support tobacco prevention through
scientific research, education and communication in national and international level.
Panagiotis Behrakis. Dr Behrakis, MD, PhD, Professor, Institute of Public Health of the American College of
Greece,George D.Behrakis Research Lab of the Hellenic Cancer Society, Biomedical Research Foundation of
the Academy of Athens Greece
He is an MD (Athens University) with two PhDs ( Mc Gill and Athens Universities) and three medical
specialties (Internal Medicine, Pulmonary Medicine and Critical Care Medicine). He is former Associate
Joint Action on Tobacco Control (JATC) Page 22 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Professor of Respiratory Physiology at Athens University and former Adjunct Professor at Harvard University.
He is currently the Director of the George D.Behrakis Research Lab of the Hellenic Cancer Society and of the
Institute of Public Health of the American College of Greece. Currently he is the PI of the EU funded projects,
HEART, EUREST, PRECISE, DIRECT, TOB-G and is actively involved in a number of other projects
(EPACTT, TACK-SHS). He is Chair of the ENSP Scientific Committee, Immediate former ENSP President
and the Editor-in-Chief of the ENSP journal “Tobacco Prevention & Cessation”. He is also member of the Board
of Regents of the American College of Chest Physicians.the JATC his role is to provide leadership of the whole
project; ensure integration of all the different project elements and acts as the final arbiter and decision-maker
on all issues and overall project strategy; responsible for the final economic handling, while acting as a focal
point for external contacts on behalf of the project. Prof Behrakis will be the Coordinator of the JATC.
Constantine Vardavas. Dr Constantine Vardavas, is a medical epidemiologist with a specific postgraduate
training at an MPH, PhD and postdoc level on tobacco product regulation and science. Dr Vardavas has been
the PI or co-I on a number of tobacco regulatory grants at an international level, and is experienced in organizing
and implementing large public health initiatives and commission funded projects. He is an internationally
recognized expert on the role of ingredients and additives, electronic reporting of tobacco products, and issues
of substantial equivalence of tobacco products and adverse health outcomes. Within the JATC, Dr Vardavas
will be responsible for the scientific management of tasks, responsible for the scientific quality of final
deliverables, such as studies and reports and ensuring that they include the state of the art knowledge on the
topic; ensure that questions on issues to be clarified, background information are collected and provided to
experts and researchers. Dr Vardavas will liaison for Prof Behrakis when he is unavailable, as the Associate
Coordinator.
Anna Tzortzi, Scientific Director of George D. Behrakis RESEARCH LAB, Hellenic Cancer Society. Anna
Tzortzi, MD, FCCP is Scientific Director of “George D. Behrakis RESEARCH LAB” at the Hellenic Cancer
Society and Associate Director of the “Institute of Public Health” of the American College of Greece. Dr.
Tzortzi is an experienced Respiratory Physician, Clinician, Lung Function Specialist and Researcher with
special interest on the impact of active and passive smoking on Lung Function. In the Tack-SHS project, she is
responsible for a study aimed to assess clinical impact of passive exposure to e-cigarettes emissions on the
respiratory system.
Dimitris Kagkos, as project manager will aid in project administration (minutes, reports) including timesheets,
inter partner communications, reporting requirements, day to day communication
Penelope Stambouli, project secretary. A supportive part time role in the day to day activities of the steering
committee and coordination team.
TBD, researcher – will be identified for the needs of WP6 and WP7 analyses. Prior experience on tobacco
related research is required as is excellent knowledge of the TPD and its implementing acts.
TBD, data analyst – will be identified for the needs of the project for WP5 dataset handling, WP6 and WP7
analyses. Prior experience on tobacco related research is required as is excellent knowledge of the TPD and its
implementing acts.
Partner 2: Austrian Agency for Health and Food Safety (AGES), Austria
The Austrian Agency for Health and Food Safety (AGES) is a company of the Republic of Austria. AGES
supports the management of the federal ministries and the two federal agencies subordinated to it in questions
relating to public health, animal health, food safety, medical and drug safety, food security and consumer
protection along the food chain by providing professional and independent scientific expertise
Friedrich Sövegjarto: Head of Area Food Safety of AGES; Financial and Scientific responsibility for Official
Food Safety Institutes in Austria; PhD and Master in Food Chemistry, University of Vienna; Experience in
Analytical Chemistry; Experience in Food and Tobacco Legislation; Project and Workpackage Leader in
Twinning projects.
Iris Schroll studied at the University of Vienna and the Vienna Univeristy of Economics and Business, and
holds a Masters Degree in International Development and a PhD in Management. 2012 she entered the Austrian
Joint Action on Tobacco Control (JATC) Page 23 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Agency for Health and Food Safety and works in the Unit for Business Development. She is responsible for the
design, implementation and management of projects as well as business analysis.
Monika Schagerl studied at the University of Applied Sciences in Krems, Austria and holds a Master’s Degree
in Health Care Management. 2005 she entered the Austrian Agency for Health and Food Safety and was working
as process manager in the Unit for Organisation & IT. In 2009 she became head of the department “Data
Management”. With her team of nine persons she is responsible for the Content management of AGES
laboratory software (LISA) from data maintenance to connecting lab equipment as well as for collection,
collation, analysis and summarization of data and allocation to internal customers as well as national and
international authorities. For this purpose the department of Data Management is operating and developing the
AGES’ Data Warehouse.
Harald Binder, guides IT operations and is responsible for development and support of AGES applications,
taking into account the needs of the different divisions. The definition and control of standard for the design
and use of software falls under his responsibility together with the management, coordination and
implementation of projects in national and international context. Furthermore, he is responsible for tendering,
analysis and design of IT solutions.
Werner Brueller has a qualification as EUROPEAN Registered Toxicologist. He is official assessor in the field
of safety of all kinds of substances, efficacy (with pharmaceuticals), versed in technical theory and practice, but
also in statutory matters. Working profile: Risk assessment in life sciences, Toxicology, non-clinical studies,
MRLs. Scientific Expert, giving assistance in the field of risk assessment within the Austrian Agency for Health
and Food Safety AGES. Risk assessment of GMO food and feed products; external scientific expert of EFSA,
national expert of EMA. Involved in tasks: risk assessment strategies, guidance to experts and reviewing.
Katharina Vejdovszky studied at the University of Vienna. In the course of her PhD thesis she worked on
toxicological evaluations of combinatory effects in chemical mixtures. During this time she attended the Vienna
Toxicology Course for postgraduates and will receive a master´s degree in toxicology shortly. Now working in
the Department Risk Assessment of the Austrian Agency for Health and Food Safety AGES her tasks as expert
in toxicology comprise risk assessment of all kinds of substances.
Thomas Kuhn, Head of Institute for Food Safety Vienna, Financial and Scientific responsibility for Austria’s
largest Institute for Food Safety; Master in Food Science, University of Natural Resources and Life Sciences,
Experience in Food and Tobacco Legislation; Member of the International Codex Alimentarius Commission;
Experience in organisation and Implementation of Trainings in cooperation with EU and UN Organisations.
Martin Gutternigg, senior expert in the AGES department for food ingredients and food additives.
Partner 3: Federal Public Service Health, (BHTC) Belgium
The FPS Public Health, Food Chain Safety and Environment, more commonly known as the FPS Health, is a
Federal Public Service of Belgium. It was created by Royal Order on May 23, 2001, as part of the plans of the
Verhofstadt I Government to modernise the federal administration. It is responsible for guaranteeing the public
health, the safety of the food chain and a safe environment.
Mathieu Capouet is a senior tobacco expert for the Belgian Ministry of Health. He prepare and implement
Belgian laws and policies on tobacco control. He has follow the preparation and the transposition and the
implementation of the TPD. He represents Belgium in EU institutions, and WHO
Partner 4: National Center of Public Health and Analyses (NCPHA), Bulgaria
The National Center of Public Health and Analyses (NCPHA) is a structure within the national healthcare
system and carries out activities for protecting public health, promoting health and preventing diseases,
providing information for healthcare management. The NCPHA examines the population's health status and
the relationship with environmental factors and living conditions; conducts epidemiological surveys and
evaluates risk factors for chronic non-communicable diseases; participates in the development, coordination
Joint Action on Tobacco Control (JATC) Page 24 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
and performance of national programmes and action plans as well as in international research programmes
oriented to strengthening public health, among many other activities.
Prof. Plamen Dimitrov, MD, PhD – project coordinator for Bulgaria. Deputy Director of NCPHA, Head of
Directorate "Health Promotion and Disease Prevention. Focus on prevention and control of non
communicable diseases, health promotion and disease prevention, health policy, health management, etc.;
National coordinator of the National Program for prevention and control of non communicable diseases and the
coordinator of the first CHRODIS JA; National coordinator of the CINDI Program; WHO focal point for Non
communicable diseases; Member of EU Expert group on social determinants of health.
Assoc. Prof. Antoaneta Manolova, MD, PhD. Head of Department "Child and Adolescent health", National
Center for Public Health and Analysis (NCPHA).Member of the National Program Board of National Program
for Prevention of Chronic Non-communicable Diseases 2014-2020 – Smoking prevention and control
coordinator; Experience in health policy development, implementation and evaluation of health promotion and
disease prevention programs, project planning, capacity building, sustainability and the application of
theoretical and empirical evidence; Focus on child and adolescent health, medical, behavioral, social and
environmental risk assessment; development of strategies and programs for risk control and prevention.
Anna Dimitrova, MSc Chief expert in "Behavioral Risk Factors and NCDs Prevention", NCPHA. Experience
in national sociological and epidemiological surveys, analyses and reports; Works on the implementation of
National Program for Prevention of Chronic Non-communicable Diseases 2014-2020.
Elena Teolova, MSc Chief expert in "Behavioral Risk Factors and NCDs Prevention", NCPHA. Focus on
practical and communication aspects of health promotion, prevention and education with a view to help change
medical paradigm in national health promotion with holistic one; Participates in the National Program for
Prevention of Chronic Non-communicable Diseases 2014-2020; Experience in national and international
epidemiological surveys, analyses and reports;
Partner 5: Cyprus, Ministry of Health (MoH CY)
The Cyprus Ministry of Health has as a main responsibility the organization and provision of quality healthcare
services and medical treatment to the citizens of Cyprus. The Mission of the Ministry of Health is the continuous
improvement of the health of the population of Cyprus, through the prevention of disease, and the provision to
every citizen of high level health care, respecting the rights of every patient to high quality medical care
delivered with dignity.
Dr Vasiliki Christodoulou is a counselling psychologist. She is trained in smoking cessation programs and co-
ordinates the Cypriot smoking cessation clinics. Cyprus will participate with a minimal role in the JATC, with
an emphasis on WP2 and WP4.
Partner 6: Danish Safety Technology Authority (SIK)
The Danish Safety Technology Authority is the relative competent authority for the regulation of tobacco
products and e-cigarettes in Denmark including the handling of EU-CEG data at a national level.
Ruth Severinsen, Engineer, Special Consultant, Danish Safety Technology Authority (DSTA). Great experience
in working with product legislation, related to EU legislation and EU product standards both on strategic level
and on single case level under the coop of DG-Growth.
Rikke Brynaa Lintrup, an Engineer will also contribute to the activities
Partner 7: Estonian Health Board (TA)
The mission of the Estonian Health Board is to work for people's health and good living environment
in Estonia. The Agency's areas of activity are health, surveillance of communicable diseases and
epidemic control, environmental health, chemical safety and the safety of medical devices
Kristina Aidla: MSc: I have been working in as a chief specialist in Estonian Health Board in Environmental
Health department in Risk Assessment Bureau for 5 years. Our focus is on assessing human health risks that
come from the environment. I have been the coordinator of a large project „Study of the Health Impact of Oil
Shale Sector” in Estonia.
Joint Action on Tobacco Control (JATC) Page 25 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Annemari Linno. M.Sc degree on chemistry: Have been working in the fields of patents (Attorney’s assistant,
patent translator/editor), Cancer research (researcher), and at the current time as a chief specialist in Estonian
Healt Board in the field of tobacco products, biocides, detergents, volatile organic compounds and as an expert
for custom inquiries.
Partner 8: French agency for food, environmental and occupational health & safety (ANSES)
The French agency for Food, Environmental and Occupational Health Safety (ANSES) is a public
administrative institution reporting to the Ministers for Health, Agriculture, the Environment, Labour and
Consumer Affairs. ANSES implements independent, multi-disciplinary scientific expertise. Its principal mission
is to contribute to the protection of human health with respect to the environment, the workplace and food.
Benoît Labarbe, PhD (food science), has worked during the past 16 years on food technology, ingredient
formulation, plant metabolites, analytical chemistry, data mining and databases management issues, in private
sector then at ANSES since 2009. Formerly Head of different units, he has recently been appointed as senior
project manager on tobacco and related products with the objective to set up this new activity within the agency.
Jean-Nicolas Ormsby, MD, Public Health specialist, Public Health Medical General Inspector, has been
working for more than 30 years on epidemiology, environmental health and broader public health issues with
different assignments in the public administration at French, European and international level before joining
ANSES in 2007. He is currently Deputy Director of the Risk Assessment Department, in charge of
environmental health and senior expert in this area.
A senior toxicologist, PhD/PharmD, to be designated among permanent staff, with significant experience in risk
assessment related to chemicals in consumer products, and in project coordination.
A regulatory toxicologist, MSc/PharmD, to be designated among the permanent staff, with experience in the
REACh-CLP regulations framework.
A junior project officer, MSc/PharmD, to be recruited for this project, with skills in toxicology and in data
statistical analysis.
Partner 9: Federal Instiute for Risk Assessment (Bundesinstitut für Risikobewertung) (BfR)
"Identify risks - Protect health" - this is the guiding principle for the work of the German Federal Institute for
Risk Assessment (BfR) in the field of consumer health protection. The Institute was set up in November 2002 to
strengthen consumer health protection. It is the scientific agency of the Federal Republic of Germany which is
responsible for preparing expert reports and opinions on food and feed safety as well as on the safety of
substances and products.
Frank Henkler. Senior Scientific Officer at the German Federal Insitute for Risk Assessment (BfR). Responsible
for toxicological risk assessment of ingredients, additives, flavours of tobacco products, as well as compliance
of tobacco products with the German Tobacco Directive (menthol, sugars, starches, waxes, flavours, colours,
flexibilizer, adhesives, humectants); Risk assessment for authorisations according to §37a or §47a of the
German Provisional Tobacco Ac; Risk assessment of nicotine containing products: toxicity and addictiveness
of nicotine, potential of additives to increase addictiveness; Member of the Working committee „Tobacco and
Tobacco products” of German Institute for Standardisation (DIN).
E Pieper. Responsible for toxicological risk assessment of ingredients, additives, flavours of tobacco and related
products (menthol, sugars, starches, waxes, flavours, colours, flexibilizer, adhesives, humectants).Risk
assessment for authorisations according to §37a or §47a of the German Provisional Tobacco Act. Risk
assessment of nicotine containing products: toxicity and addictiveness of nicotine, potential of additives to
increase addictiveness
Jürgen Hahn, responsible for surveillance of tobacco products. Expert on emissions.
Partner 10: Aerosol and Particle Technology Laboratory (APTL) of the Chemical Process and Energy Resources
Institute at the Centre for Research & Technology Hellas (CERTH).
Joint Action on Tobacco Control (JATC) Page 26 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
The Aerosol and Particle Technology Laboratory (APTL) was established in 1996 within CPERI/CERTH with
the rationale that the solution of many environmental, health, energy, materials and process industry related
issues relies on understanding and exploiting the science of fine particles and their suspensions in various
media.
Akrivi Asimakopoulou, Chemical Engineer PhD, Affiliated researcher in APTL/CERTH with background in the
development of management and characterization systems of aerosols, expert on the development of systems
for the study of the effects of nanoparticle exposure to the environment and human health (member of the finalist
research group of the 2nd “Greece Innovates!” competition (2013) with the “System for preliminary in-vitro
health impact assessment of size-selected nanoparticles”).
Penelope Baltzopoulou, Chemical Engineer MSc on Environmental Physics, Research engineer in
APTL/CERTH, with expertise in particulate emissions measurements, aerosol characterization, as well as
assessment of the health effects of nanoparticle exposure (member of the finalist research group of the 2nd
“Greece Innovates!” competition (2013) with the “System for preliminary in-vitro health impact assessment of
size-selected nanoparticles”). She is awarded with the Trojan Horse Prize by the Swiss Foundations “Doctors
for the Environment” for the best contribution on the investigation health effects of automotive emissions,
during the 21st ETH-Conference on Combustion Generated Nanoparticles at Zurich (2017).
Eleni Papaioannou, Chemical Engineer, Chief Operating Officer in APTL/CERTH with long background in
the catalytic emission control technologies, expert on the assessment of their biological effects on cell lines
(representative of the finalist research group of the 2nd “Greece Innovates!” competition (2013) with the
“System for preliminary in-vitro health impact assessment of size-selected nanoparticles”).
Partner 11: Semmelweis University, Hungary
The oldest medical school in Hungary, Semmelweis University, has 250 years of experience in training doctors
and medical professionals for their careers. Today, the university has a unique status in Hungary, providing
the country with a high proportion of the country's medically-trained personnel. Instead of being based on a
single campus, Semmelweis has hospitals and facilities all over Budapest, the capital of Hungary.
Ms Melinda Pénzes has got an M.D. and has a postgraduate specialty in preventive medicine and public health.
She is a Ph.D. candidate at the doctoral School of Semmelweis University in Budapest. She works at the Institute
of Public Health, Semmelweis University since 2007. She has been working in the field of tobacco research
almost 10 years. She is involved in capacity building projects for tobacco research since 2007, funded by the
NIH Fogarty International Centre.
Mr András Terebessy, M.D, Ph.D. He works at the Institute of Public Health, Semmelweis University since
2001 (current position: senior lecturer). He has been working in the field of lifestyle research (tobacco, alcohol
etc) for 8 years. He has got a postgraduate specialty in preventive medicine and public health. He is involved in
various research and health promotion projects since 2010.
Mr László Bencze has got a JD and postgraduate degree in EU law. He started his career with environmental
law. For more than 15 years now has been working in the field of health law and policy. He served at the
Permanent Representation of Hungary to the EU in Brussels as health attaché from 2011 to 2014. From 2015
on he is policy expert and project coordinator at Semmelweis University in Budapest.
Partner 12: Directorate of Health (DOHI)
The Directorate of Health is a government agency headed by the Director of Health. Its principal role is to
promote high-quality and safe health care for the people of Iceland, health promotion, and effective disease
prevention measures.
Vidar Jensson. Worked for Tobacco Control Task Force of Iceland since 1997. Later as project manager in
tobacco control and tobacco prevention for Public Health Institute of Iceland when established in 2003. Now
working for Directorate of Health former the Public Health Institute of Iceland. Has study of computing and is
graduated from Iðnskólinn í Reykjavík.
Joint Action on Tobacco Control (JATC) Page 27 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Sveinbjörn Kristjánsson. Worked in public health since 1999 primarily in tobacco and alcohol field. Behavioural
scientist at Directorate of Health former the Public Health Institute of Iceland since 2006. Worked at Stockholm
Centre for Public Health 1999 – 2005. Doctoral degree from Karolinska Institutet in Stockholm, Sweden
Dora Gudrun Gudmundsdottir. cand.psych., PhD
Partner 13: Health Service Executive (HSE), Ireland
The Health Service Executive (HSE) provides all of Ireland's public health services in hospitals and
communities across the country. The vision of HSE is “a healthier Ireland with a high quality health service
valued by all”. . HSE is responsible for tobacco regulation in Ireland.
Maurice Mulcahy PhD, MSc, CMIOSH, MEHOA, CFCIEH. Dr Mulcahy, is the Chief Environmental Health
Officer for the Health Service Executive West Region, Ireland. He has vast experience as a regulator in the
Environmental Health field, including tobacco control. He holds an MSc in Occupational Safety from the
Robens Institute, University of Surrey and was awarded a PhD by NUI Galway in 2010 for his research
investigating the Environmental Health perspectives of tobacco control, with a particular focus on the Irish
smoking ban. He is as an adjunct lecturer with the Centre for Health from Environment (CHfE), Ryan Institute,
NUI Galway and a Visiting Professor at K U Leuven, Belgium. He was a recipient of the UK Chartered Institute
of Environmental Health (CIEH), Presidents Award in 2004, for his outstanding contribution to and excellence
in the field of Environmental Health. In 2007 he was awarded the inaugural Tom Power Medal by the Office of
Tobacco Control, for his commitment, leadership and vision in defeating the tobacco epidemic in Ireland. In
December 2014 he was awarded an Excellence Award by the Environmental Health Association of Ireland.
Caitriona Stack: Mrs. Stack is a Senior Environmental Health Officer with over 17 years’ experience in the
enforcement of public health legislation and has been involved in policy development and its implementation
in a number of areas. She is a member of the Environmental Health Service National Tobacco Control
Operational Unit. She is a former Chair Person of the Environmental Health Association of Ireland which
involved leading an officer board and coordinating all work activities within the organisation on behalf of its
members. This position also involved lobbying/liaising with Government Ministers and their officials in relation
to public health issues. She has coordinated two All Island Environmental Health Conferences and numerous
other national training events on matters of public health. She represents the Environmental Health Association
of Ireland on the European and International Federation of Environmental Health Committees.
Partner 14: Istituto di Ricerche Farmacologiche “Mario Negri” (IRCCS -IRFMN), Italy
IRFMN is a not-for-profit biomedical research organization, with a staff of around 750 workers. IRCCS was
established in Milan in 1961, under the terms of the will of Mario Negri (1891-1960), a Milanese jeweller and
philanthopist. The Institute’s main aim is to defend human health and life.
IRFMN is a not-for-profit biomedical research organization, with a staff of around 750 workers. The Institute’s
main aim is to defend human health and life.
Enrico Davoli has a Doctoral Degree in Animal Sciences (University of Milan, 1983). Currently he is head of
the Laboratory of Mass Spectrometry, Department of Environmental Health Sciences. His main research areas
include the development of methodology, instrumentation and software for environmental research. Author of
more than 60 peer reviewed scientific publications. For the JA he is co-PI for IRFMN and leader of WP8.
Silvano Gallus has a Degree of Doctor in Computer Science (University of Milan, 1999). He is currently head
of the Unit of Epidemiology for Clinical Research, Department of Epidemiology. In his 19 years of experience
in the field of epidemiology and public health, Dr Gallus gained wide knowledge and expertise in Tobacco
Control. Author of more than 230 publications in peer-reviewed journals. For the JA he is co-PI for IRFMN.
Alessandra Lugo has a degree in Biostatistics (University of Milan-Bicocca, 2012) and a PhD in Biomedical
Statistics (University of Milan, 2015). Since 2011 she is researcher at the Department of Epidemiology of Mario
Negri where she works mainly in the field of tobacco control. She is author of 25 papers in peer-reviewed
journals.
Joint Action on Tobacco Control (JATC) Page 28 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Tbd one PhD student working in the Laboratory of Mass Spectrometry will also be involved in the project.
Partner 15: National Institute of Health (Istituto Superiore di Sanita) (ISS)
National Institute of Health (Istituto Superiore di Sanita - ISS) is the leading technical and scientific public
body of the Italian National Health Service. The institute conducts scientific research in a wide variety of fields,
from cutting-edge molecular and genetic research to population-based studies of risk factors for disease and
disability.
TBD, Lead Researcher: Supervisor of national guidelines on tobacco smoking, alcohol and doping,
epidemiological studies, preparation of informative material for school students and teachers, for health
personnel, family doctors, policy makers concerning Tobacco, Alcohol ,Drugs of Abuse and Doping Agent.
Supervisor of analytical laboratory on drugs and doping agents in non conventional matrices related to clinical
and forensic pharmacotoxicology.
TBD, Junior Researcher: Literature reviews on tobacco smoking including tobacco ingredients or additives and
electronic cigarette through a research process that includes searching the literature, gathering, reading and
summarizing results of a number of relevant studies retrieved. In particular, specific publications concerning
toxic emission other than nicotine and carbon monoxide should be searched for and reviewed, together with
eventual clinical outcome in specific studied populations.
Partner 16: MOH-IT.
The Ministry of Health is a governmental agency of Italy, headquartered in Rome. The MOH-IT is responsible
for tobacco product regulation in Italy.
Lorenzo Spizzichino. A statistician working in the prevention department of Italian Ministry of Health. Involved
in tobacco control policies since 2005 and participated in transposition of the Directive 40/2014/EU. A
participant to the tobacco experts group meetings for the implementation of the TPD. The contact person for
Italy for EU-CEG
Partner 17: Health Inspectorate, Ministry of Health (HI), Latvia
Health Inspectorate of Latvia is a state administrative institution supervised by the Ministry of Health of the
Republic of Latvia. The main purpose of the HI is to reduce the risk for society and consumer health by realizing
state surveillance. HI of Latvia will be participating with 4.5person months
Maija Rumpetere, Head of the Product Safety and Market Surveillance Division. Health Inspectorate of Latvia
Partner 18: Drug, tobacco and alcohol control department (NTAKD)
Drug, Tobacco and Alcohol Control Department was established on the 1st April 2011. Regulations of the
Department were approved on 23 February 2011 by the decision No. 244 of the Government of the Republic of
Lithuania. The EMCDDA’s mission statement sets out the agency’s four main tasks: collecting and analysing
existing data; improving data-comparison methods; disseminating data and information; and cooperating with
EU institutions, international partners and with non-EU countries.
Grazina Belian, Drug, tobacco and alcohol control department deputy director. Responsible for alcohol, tobacco
and drugs control policy development, implementation and enforcement arrangements, according to her
competence, her work to coordinate other state and municipal authorities in the field of alcohol and tobacco
control, advise operators of alcohol and tobacco, tobacco related products control issues, submit proposals to
the Government of the Lithuania, Lithuanian Parliament members, Committees and the Commission's on
alcohol and tobacco control policies and priorities of this performance improvement, ensure cooperation with
non-governmental organizations working in this field. Master in Economy and Law. From 2012 freelance
Joint Action on Tobacco Control (JATC) Page 29 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Parliamentary Health Committee adviser. In 2016 has been awarded by European Network for Smoking and
Tobacco Prevention (ENSP) as excellent in tobacco control.
Violeta Verseckiene, Drug, tobacco and alcohol control department, Head of Licensing division. Responsible
for the activity of Licensing division in alcohol products, tobacco products manufacturing and wholesale trade,
tobacco farming licenses issuing, permits to buy and use non-denatured or denatured ethyl alcoholl, activities
related to drug (precursors) licensing, registration certificates, import and export authorization for these
materials issuing. Responsible for submitting to the European Commission reports on tobacco products and
novel tobacco products, e-cigarettes and e-cigarettes refill containers intended for sale in the Republic of
Lithuania throught EU-CEG.
Jolita Ignataviciene, chief specialist in Licensing division. From 2014 - gathering and submitting to the
European Commission reports on tobacco products intended for sale in the Republic of Lithuania, analysing
and summarizing information on tobacco product ingredients and their toxicological effects, preparation of
tobacco product ingredients data for publication on the website www.ntakd.lt
Jurgita Miliauskaite -Merkiene, Head of Tobacco and Alcohol Control Division.Responsible for alcohol,
tobacco and related products law implementation and enforcement arrangements, according to her competence,
her division coordinates other state and municipal authorities in the field of alcohol and tobacco control, advise
operators of alcohol, tobacco and related products control issues, submit proposals to the Government of the
Lithuania, Lithuanian Parliament members, Committees and the Commission's on alcohol, tobacco and related
control policies and priorities of this performance improvement.
Partner 19: National Public Health Surveillance Laboratory (NVSPL)
A National reference laboratory (NRL) in food contact materials area and the only laboratory in Lithuania
responsible for tobacco products analysis. NPHSL is a member of: European Network of National reference
laboratories in food contact materials area; European Network of Governmental Laboratories for Tobacco
and Tobacco Products (GoToLab); World Health Organization Tobacco Laboratory Network (WHO
TobLabNet );
Tomas Murauskas, National Public Health Sureillance Laboratory (NPHSL). Specialist of chemistry in
sub-Department of Environmental research
Regina Milienė, Chemist. Experience in organization of works of chemical laboratory, ensuring quality control
procedures, knowledge and experience in testing of tobacco smoking, water, air and wastewater in laboratory.
Accreditation according LST ISO 17025 of 4 methods of Tobacco products testing
Gintautas Švilpa. Extensive experience in GC-MS, LC-UV, and capillary electrophoresis. Fast learner to new
technologies and analysis methods; capable of planing and executing experiments, evaluating data. Extensive
experience in creating and optimising mixed GC/LC/MS methods for intricate sample matrixes. Good statistical
analysis knowledge.
Partner 20: DEH
The Ministry of Health from Malta is responsible to ensure the effective and efficient operation and delivery of
healthcare services with an emphasis on clinical and corporate governance, service delivery and quality review
with in an established framework of controlled decentralisation and autonomy involving user participation. The
ministry of Health from Malta will participate mainly in the meetings of the JATC.
Partner 21: National Institute for Public Health and the Environment (RIVM), The Netherlands
RIVM protects and promotes human health and environmental quality. It acts as the Dutch government’s main
centre of expertise in these areas. The National Institute for Public Health and the Environment (RIVM) performes
research on the composition of tobacco products. This includes research on tobacco additives. Yearly tobacco
Joint Action on Tobacco Control (JATC) Page 30 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
manufacturers send their tobacco ingredient lists to the RIVM. RIVM coordinated the European project PITOC
(Public Information Tobacco Control).
Reinskje Talhout, PhD in chemistry. Senior researcher, team leader tobacco group, head of WHO collaborating
centre for Tobacco Product Regulation and Control, Contributor to various collaborative European projects in
the field of tobacco control (HETOC, PITOC, ATASC, EMTOC)
Lotte van Nierop PhD in neurobiology and cognitive neuroscience. Researcher with expertise in addictiveness
of tobacco, tobacco additives and tobacco-related products. In addition, monitoring, analysing and reporting of
database on tobacco ingredients (EMTOC).
Wouter Visser, PhD in biochemistry and analytical chemistry. Researcher with expertise in assessment of
chemical composition and emissions of tobacco and e-cigarettes.
TBD, researcher – will be identified for the needs of WP6, WP7, WP8 and WP9 analyses. Prior experience on
tobacco related research is required as is excellent knowledge of the TPD and its implementing acts.
Partner 22: Norwegian Institute of Public Health
The Norwegian Institute of Public Health (NIPH) acts as a national competence institution placed directly
under the Ministry of Health and Care Services, with employees in Oslo and Bergen.
Per E. Schwarze is Department Director at the Norwegian Institute of Public Health. He has been working in
Toxicology and risk assessment for more than 25 years and he is a EUROTOX registered toxicologist. Since
about 2004 Per Schwarze has also worked with epidemiologic studies, which completes his expertise in risk
assessment. He has contributed to the development of indoor air guidelines on passive smoking in Norway, and
has been co-author on two reports, smokeless tobacco (snus) and e-cigarettes in Norway. He is also national
expert in the WHO led Task Force on Health on Long Range Transboundary Air Pollution. In conjunction with
his work as an expert nationally and internationally he conducts high level research in the field of indoor and
outdoor air pollution and noise. His Web of Science H-factor is 40.
Partner 23: Norwegian Medicines Agency (NOMA)
The Norwegian Medicines Agency (NoMA) is the national, regulatory authority for new and existing medicines
and the supply chain. The agency is responsible for supervising the production, trials and marketing of
medicines
NOMA will participate at a minimal level in two aspects of the JATC, on the handling of data and on e-
cigarettes. In both cases activities will only be supportive.
Partner 24: MS, Portugal.
The Directorate-General of Health (DGS) is a public body of the Ministry of Health that positions itself as a
reference for all those who think and operate in the healthcare field. DGS is responsible as the competent
authority also for tobacco regulation in Portugal.
Emília Nunes – Medical doctor, Senior Public Health Specialist, Director of the National Programme for
smoking Prevention ant Tobacco control, at the General-Directorate of Health. Portuguese representative in the
Expert Group on tobacco policy, coordinated by European Commission. Member of the Tobacco Products
Directive Committee. SLA administrator of EU-CEG – tobacco products and electronic cigarretes. Focal point
of WHO for FCTC implementation.
Partner 25: Institute of Public Health of Serbia (BATUT-IANPH), Serbia
The Institute of Public Health of Serbia was established in 1919 as the Ministerial Commission for
Epidemiology organized by the Ministry of Health to perform communicable disease surveillance. Institute of
Public Health of Serbia "Dr Milan Jovanović Batut" represents an expert institution for Public Health, which
Joint Action on Tobacco Control (JATC) Page 31 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
provides advice, support and guidance for the Serbian government and conducts independent researches on
issues related to public health in Serbia.
Biljana Kilibarda is specialist in social medicine, with more than 15 years’ experience in health promotion. She
is also a Head of the Office for Smoking Prevention at the Institute of Public Health of Serbia. She participated
in numerous activities such as research, monitoring, coordination, smoking prevention and campaigns, including
cooperation with national and international institutions/organizations. She is also member of the Expert
Commission on Tobacco Control, the advisory body for the Ministry of Health.
Milena Vasic, DMD, MSc, PhD, Associate Professor, specialist in social medicine/public health, master in
Health Services Management is a Head of Department for International Cooperation and Project Management
at the Institute of Public Health of Serbia. She has more than 20 years of experience in the public health. She
has been working on projects preparation, implementation, (including dissemination, visibility and
exploitation), monitoring and evaluation
Partner 26: National Laboratory of Health, Environment and Food, (MZLOH), Slovenia
The National Laboratory of Health, Environment and Food is the central and the largest laboratory for public
health, dealing with hygienic and health related ecological activities, environment protection problems,
microbiological diagnostics and chemical analyses of samples of different kind and research activities. In
cooperation with other institutions in Slovenia and abroad, the NLZOH cooperates in national and international
research, applicative and advisory projects.
Lucija Smojver; Expert. Bachelor of Science (EQF level 7) of chemical engineering; Postgraduate study
(Faculty of Medicine): in progress. Work experience: 2010-present (National Laboratory of Health,
Environment and Food): ▪Analysis and assessment of the results of analyzes of items of common use, such as:
food contact materials, toys, child care articles, drinking water contact materials, tobacco products; Assessment
of the risks for health according to exceeded value of certain parameters on items of common use; Activities
according to the new tobacco legislation; Research work. She will work on WP6.
Alenka Labović Senior Expert. Education: Bachelor of Science (EQF level 7) of chemical engineering. Work
experience: 1988-present (National Laboratory of Health, Environment and Food):▪Analysis and assessment of
the results of analyses of items of common use, such as: food contact materials, toys, child care articles, drinking
water contact materials, tobacco products; Quality Assurance; Expert in the Group on Toy Safety, (European
Commission). He will work on WP6 activities
Dejan Hanžekovič, Expert. Education: Master of Informatic and technologies of Communication (EQF level 7);
Work experience: 2001-present (National Laboratory of Health, Environment and Food): Developer (Oracle
tools: designer, forms, reports, bipublisher, jdeveloper, APEX, SQL, PL/SQL); Development and maintenance
of laboratory information system; Development of new IT solutions (java, VBA, android); Applications
maintenance; Application servers maintenance; DBA (Oracle database installation, maintenance, backup);
Virtualization (VMware, pano zero client); Document management system. He will work on WP5.
Brigita Kozolc, WP8. Bachelor of Science (EQF level 7) of chemistry. Work experience: 2006-present (National
Laboratory of Health, Environment and Food): Analyst in laboratory for organic chemistry: tobacco, food,
commodities of general use, drinking water; Quality Assurance; Research work. She will work on WP8.
Partner 27: Catalan Institute of Oncology (ICO) – included affiliated partner IDIBELL
The Catalan Institute of Oncology (ICO, in Catalan) is a public institute founded in 1995 by the Ministry of
Health of Catalonia. Tobacco control is one of the priority themes of the Catalan Health Plan and various
master plans (oncology and respiratory disease) and therefore our aim is that this projects developed at UCT
have impact on the prevention and tobacco control in both, our immediate environment (ICO), as nationally
and internationally.
Dr. Fernández (MD, PhD) is the Director of the Tobacco Control Unit of the Catalan Institute of Oncology, a
WHO Collaborating Centre for Tobacco Control. Professor of Epidemiology and Public Health at the School
of Medicine of the University of Barcelona. He has an extensive professional experience in the area of tobacco
Joint Action on Tobacco Control (JATC) Page 32 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
control, including evaluation of tobacco control policies, secondhand smoke assessment, and new forms of
tobacco use. He is the author of more than 200 articles in peer review journals.
Dr. Baena (BSc, PhD) is Postdoctoral Researcher at the Tobacco Control Unit of the Catalan Institute of
Oncology, a WHO Collaborating Centre for Tobacco Control. He is Assistant Professor (Master Degree in
Clinical Psychology) at the Open University of Catalonia. He has experience in the areas of tobacco cessation,
with special focus on use of ICT, evaluation of tobacco control policies, and expertise with database preparation
and statistical analysis.
Partner 28: Consejería de Salud Junta de Andalucía (CSJA) – including affiliated partners AGAPA and FPS
The Ministry of Health is the public administration responsible for the design and development of health policies
in Andalusia and directs the agencies responsible for the management and provision of health services.
Josefa Ruiz, MD. General Secretary of Health and Consumer Affairs of the Regional Ministry of Health of the
Government of Andalusia. Master of Public Health and Health Administration, Master in Health Centres
Management Author of numerous publications on Public Health, co-author of the book "The minimal
intervention on smoking in primary care centers”. She has participated in research projects in the field of public
health, especially in the field of health promotion.
Carmen Lama, MD. Currently she is Deputy Director of Health Promotion, Participation and Health Plans. She
has participated as coordinator of the Andalusian team taking part in the Joint Action CHRODIS. Senior Advisor
of the General Secretariat of Health and Consumer Affairs of the Regional Ministry of Health of the Government
of Andalusia. She has participated in numerous research projects and publications in different health areas:
tobacco control, nutrition, infectious diseases.
Ana Carriazo, MD PhD specialist in Preventive Medicine and Public Health. Currently Senior Advisor for
external action in the Regional Ministry of Health of the Government of Andalusia. She has been involved in
several European projects and coordinates European networks on health issues.
Francisco Ruiz, PhD on Social Psychology (Hyogo Joint University, Japan), Expert in Health Promotion
(Andalusian School Of Public Health-Granada University), BA in Psychology (Seville University). He co-
authored the Comprehensive Tobacco Action Plan for Andalusia and has been the technical advisor of this
Action Plan since 2005.
Miguel Merino, University Degree in Chemistry (Granada University, Biochemistry Specialty), PGCert in
Neurobiology (Seville University). Since 2000, as Technical Head in Laboratorio Agroalimentario de Sevilla
(Agrarian and Fisheries regional Ministry in Andalusia), working in analysis of tobacco, and related issues, the
most of them developed in joint plans with Health regional Ministry of Andalusia. Since 2013 until now, Lab
Manager. Himself Auditor of Spanish Accreditation Body (ENAC), the Lab got in 2010 the accreditation for
Tobacco smoke analysis. Since 2000, member of Spanish Technical Committee for tobacco (AENOR CTN118);
since 2005, joining all the plenary Meetings of TobLabNet, and some of the specific working groups in order
to coordinate the validation of Ammonia WHO method.
Rocío Vaquero, University Degree in Economics. Since 2008, as project manager in the Project Office of the
Andalusian Public Health System (Fundación Progreso y Salud), she has been involved in a wide number of
European projects and Joint Actions on health issues.
TBD Technician for supporting CSJA in WP 4 and 5 tasks development.
Partner 29: The Public Health Agency of Sweden (FOHM)
The Public Health Agency of Sweden has a national responsibility for public health issues and works to ensure
good public health. The agency also works to ensure that the population is protected against communicable
diseases and other health threats including tobacco.
Veronica Åberg Del Din: PhD in organic chemistry, synthesis and biological evaluation. Public authority project
manager and process manager, work within the area of research and technology development. She will work on
WP6.
Joint Action on Tobacco Control (JATC) Page 33 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Åsa Bertilsson: PhD Medical Cell Biology, MSc in toxicology. Experience of risk assessment, exposure
assessment, toxicological evaluation, data requirements, development of processes and legislations of biocides
and plant protection products at national and EU level (> 10 years). Experience of participation in EU expert
groups of health risk assessment. Also experience in environmental risk assessment and evaluation of residues
in food of prescription drugs. She will work on WP7
Johanna EL Andaloussi-Lilja: PhD Neurochemistry and Molecular Neurobiology. Experiences of international
work regrading laws, guidelines and processes used in the approval of pesticides at national and EU level.
Reviewed and assessed the health effects of biocidal products. She will work on WP9
Partner 30: Department of Health, UK
The Department of Health (DH) is the Ministerial Department of the United Kingdom Government responsible
for government policy on health and adult social care matters in England.
Dave Jones – Tobacco Control Manager. Project Manager for the Competent Authority for EU TPD tobacco,
herbal and novel tobacco products. Nominated contact for the UK in all actions related to the tobacco products
directive. Background in stop smoking service delivery, management, training and commissioning.
Claymore Richardson – Senior Policy Manager, European Union. Policy lead on negotiation and
implementation of EU regulations, UK support for EU priorities and how UK input and leadership on initiatives
within the EU regulatory network. Policy lead for the e-cigarettes elements of the Tobacco Products Directive.
Beryl Keeley – E-Cigarette Notification Scheme Lead. Policy lead for implementation of the e-cigarette
notification scheme by MHRA as UK competent authority under the Tobacco Products Directive. Background
in medical biochemistry and expertise in medicines regulation.
Ovnair Sepai PhD – Group Leader, Toxicology Department (PHE), Principal toxicologist, Scientific
secretariat to DH Expert committees on toxicity, and mutagenicity of chemicals in food consumer products
and the environment. Member of Defra Hazardous Substances Advisory Committee and PHE-DH Lead on
Human Biomonitoring.
Partner 31: Hellenic Thoracic Society
The aim is of the Hellenic Thoracic Society is to promote knowledge on issues related to respiratory function
and diseases. It also aims to inform the public on issues related to the prevention and treatment of Specialty
Diseases
Christina Gratziou, M.D., Ph.D. is a Professor of Pulmonary Medicine in Athens Medical School (National and
Kapodistrian University of Athens), with clinical duties at Evgenideio Hospital, Head of the Asthma, COPD
and Smoking Cessation Unit. She was Chair of Advocacy Council of European Respiratory Society and ERS
Secretary for EU Affairs and was Chair of Tobacco Control Committee of ERS.
Paraskevi Katsaounou M.D., Ph.D is an Assistant Professor of Pulmonary Medicine in Athens Medical School
(National and Kapodistrian University of Athens), with clinical duties at Evaggelismos Hospital, Head of the
Asthma and Smoking Cessation outpatient clinic. She is Chair of European Respiratory Society Group 6.3
Tobacco smoking control and health education, Chair of Smoking Cessation & Public Health Group of the
Hellenic Thoracic Society, Trainer in smoking cessation and member of Tobacco Control Committee of ERS.
Efthimios Zervas, Chemical Engineer, Ph.D, is an Associate Professor of Environmental Technology in School
of Science and Technology (Hellenic Open University). He is Director of the MSc Program
“Environmental Design of Infrastructure Works” and member of Hellenic Thoracic Society and ERS. He
is currently working on e-cigarette ingredients with an HTS grant.
Data Analyst, TBD: The Data Analyst will collect, retrieve and analyse both qualitative and quantitative data
for evaluation and reporting.
Technicians (TBD) To provide assistance to Tasks 1-2 of WP8 & Technician for WP8.
Joint Action on Tobacco Control (JATC) Page 34 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
7.2. External and internal risk analysis and contingency planning
Our consortium has put in place a streamlined management team and an experienced and well qualified pool of
scientific expertise. To manage this system efficiently, attention needs to be paid to internal communication and
monitoring of activities. We will maintain clear channels of communication with the experts, making full use
of online collaboration tools such as calendars, shared document repositories and telephone/video conferencing
facilities (Dropbox Pro, Skype Pro, Go to Meeting, etc.) and maintain frequent communication to ensure that
all members of the extended team are aware of the proposed workflow for each task and the timeframe for
delivery and to avoid letting any potential risks develop.
Risks have been identified and for each risk contingency plans have been outlined and are presented as in the
table below.
Identified Risk Likelihood Impact Contingency planning
Partners not carrying out Low Medium In the case that a partner organization does not
their assignment. fulfill its obligations to the project, the coordinator
will ask this organization to withdraw from the
partnership and seek for replacement.
Alternatively, the coordinator or another existing
partner will undertake the tasks of the withdrawing
partner.
Delay in deliverable Low Medium Repeated communications with partners to increase
production output
Identification of barriers to effective delivery of
results
Allocation of additional person-time to that aspect
of the project
Change in partner or key Low Medium Each partner contributes with at least two personnel
personnel to allow for a back up to exist
Discussions with other partners in that EU MS that
would be able to cover satisfactory the gap
Mis-communication Medium Medium Repeated communication between partners
between partners Involvement of the Steering Committee
In depth discussions to diffuse the situations
Insufficient budget to medium medium Communictions with CHAFEA/DG SANTE to re-
cover the requested tasks prioritise as necessary based on the current
requirements.
Reorganisation of the tasks and activities to
partners with a lower person month cost.
Change in the focus area low low Communications with CHAFEA/DG SANTE to
of EU tobacco product reprioritise the activties as necessary based on the
regulatory interest current requirements.
Joint Action on Tobacco Control (JATC) Page 35 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Confidential data from Medium Medium Work closely with EU MS so as to obtain access to
EU-CEG not provided confidential data sets even for a limited number of
by EU-MS EU MS
Request de-identified confidential data that would
be aggregated and not be linked to a specific
company
Use only public non confidential data.
7.3. Financial management
Administrative and financial management groups all the activities to be carried out by the Coordinator and
includes the preparation of statements; the periodic reporting that summarizes the participants’ financial
activity; the preparation and review of financial documents; establishing and maintaining financial records and
the coordination and consolidation of annual cost claims. The main aim of financial management is to minimize
risks of financial difficulties for the project and reassure smooth and efficient operation.
The first step that has to be considered in the whole process of financial management is budgeting, so as for the
resources to be allocated effectively and efficiently among project’s activities. The budget will cover all
activities, will state the time period and will include all categories of expenditure.
In parallel with budgeting, a substantial process is the planning and the construction of a well- organized
timetable, which will include the conditions under which all payments will be made, an estimated date of
payment and further information about the payment method and process.
All project costs will be included in the relative reporting templates (excel format) that will be provided to all
partners. The financial officer will provide all partners with the appropriate explanations on the use of reporting
template and a list referring to the required supporting documents.
Every 6 months the consortium will compile a detailed report including among others:
the progress (including milestones) achieved within this timeframe
deviations from the plan and causes of such deviations
corrective actions
detailed planning for the next 2-month period
details about project expenditures during this period
All project costs will be included in the relative reporting templates (excel format) that will be provided to all
partners. The project manager will provide all partners with the appropriate explanations on the use of reporting
template and a list referring to the required supporting documents. Moreover, the above mentioned explanations
and notes will be accompanied by reference documents, such as financial and administrative handbooks that
will ensure the smooth running of the project.
The staff costs will be controlled by each partner and the Coordinator. The monitoring of this significant
category of expenditure will include the filling of a staff cost documentation file; a relative timesheet indicating
the time of personnel spent on each activity; and supporting documentation if necessary (contracts, payslips
etc).
Apart from costs on personnel, another crucial expenditure category is travelling and subsistence. In this case,
the preparation of a list of travel and subsistence invoices and receipts is necessary to support the percentage of
the budget that these costs cover.
Joint Action on Tobacco Control (JATC) Page 36 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
8. BUDGET
8.1. Content description and justification
The project budget is related directly to the activities described in Work Packages and depends on specific
identified costs related to the described activities. The budget is designed to provide an appropriate level of
resources for the successful achievement of its objectives. The total budget of this JATC is 2.5 Million, for
which we will be requesting 80% of European Commission contribution.
The breakdown of PM per WP is depicted in Figure 4 while Figure 5 provides the approximate budget per WP.
List of subcontracting costs
Partner Justification Amount
HCS Subcontracting to an external group for dissemination 40,000
activities with direct relevance to European tobacco control
so as to support WP2 dissemination activities.
AGES External contractor for the external evaluation of the JATC 15,000
activities. The external contractor will review and input on
the evaluation plan and assist in evaluation implementation
RIVM External scientific experts review work for WP9 documents 35,000
SIK External contractor for IT requirements. This external 16,500
subcontractor may be needed to contribute to the activities of
WP5 for the identification of the IT requirements for EU
CEG data sharing.
Note: Subcontracting will be performed as per national regulations for each partner.
Figure 3. Overall budget breakdown
Salary
85%
Other Direct
6%
Subcontracting
2%
indirect
7%
Joint Action on Tobacco Control (JATC) Page 37 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Figure 4. PM by WP
WP9 WP1
WP2
WP1
WP8 WP3
WP2
WP3
WP4
WP4 WP5
WP6
WP7
WP8
WP7
WP5 WP9
WP6
Figure 5. Budget per WP
WP1
WP9 9%
16% WP2
6%
WP3
WP1
6%
WP2
WP8 WP3
12% WP4 WP4
6% WP5
WP6
WP7
WP8
WP5 WP9
13%
WP7
16%
WP6
16%
Joint Action on Tobacco Control (JATC) Page 38 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
8.2. Summary of staff effort
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 Total P/M
HCS 44 11.3 1 8 12 12 21 1.8 7.9 119
AGES 14.3 3.6 2 2.2 2.6 24.7
BHTC 0.5 1 1 2.5
NCPHA 10 6 16
MoH CY 1 5.5 6.5
SIK 17.75 1 1.25 20
TA 3.2 1.5 4.7
ANSES 1 0.4 2.8 6.3 4.9 15.4
BfR 0.1 2 1.5 3 12.4 19
CERTH 1 1 12 14
SE 3 12 15
DOHI 2 2
HSE 0.1 0.4 0.5 1
IRFMN 3.75 10 10 27 0.25 51
ISS 2 2 1 5
MOH-IT 3 2.5 2.5 8
HI 4.5 4.5
NTAKD 4 2 4 4 14
NPHSL 5 5
RIVM 4 4 4 11.9 23.9
NIPH 0.3 0.2 5 5.5
NOMA 0.5 0.5 1
MS 3 3 3 9
BATUT 24 24
NLZOH 3 7 4 14
ICO 20 6 26
IDIBELL 0
CSJA 0.5 0.5 1
FPS 0.5 0.5 1
AGAPA 3 2 10 3 18
FOHM 1.5 4 6 6 17.5
UKDH 0.5 1 2.5 4
HTS 5 4 4 11 24
TOTAL 49 39.3 15.3 48.65 56.25 87 86.7 80.4 53.6 516.2
Joint Action on Tobacco Control (JATC) Page 39 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
8.3. Detailed budget
Applicant Number/
1 - HCS
(A) Direct personnel costs
Estimated
Staff function Monthly Cost Person- Sum Cost (€)
month
Coordinator 5000 15 75000
Assosc. Coordinator 5000 15 75000
Assosc. Coordinator 5000 15 75000
Project Manager 2500 18 45000
Project secretary 2000 18 36000
Researcher 1 2000 20 40000
Researcher 2 2000 18 36000
Total PM Total Costs (€) for (A)
119 382,000
Justification
WP1-9 activities across all WPs
(B) Direct costs of sub-
Costs (€) Task(s)/Justification
contracting
Subcontracting to external groups for dissemination activities so as
Dissemination expert group 40,000
to support WP2.
Total Costs (€) of (B) 40,000
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
Travel to the consortium meetings for approximately
33 person/trips for:
• Coordinating team staff
28,000 • Collaborating experts that have will have their
travel expenses covered to participate in meetings.
• The per person rate for travel and accommodation
is calculated at €833.3 per meeting.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and
Costs (€) Justification
services
Kick off, interim and final meeting expenses (room,
9000
audiovisual, catering etc) 3000 per meeting
2100 Consumables for needs
Total Costs (€) of (C) 39,100
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 32,277
Total estimated eligible
493,377
costs
Joint Action on Tobacco Control (JATC) Page 40 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 2 - AGES
Short Name
(If affiliated entity: Affiliated to which
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Supervisor 8.060,00 6.6 53196
Evaluator 7.410,00 6.6 48906
Assistant 4.000,00 1.1 4400
Data Manager 7.410,00 2 14820
Data Manager 7.410,00 2 14820
Analyst 7.410,00 1.2 8892
Analyst 7.410,00 1.2 8892
Toxicologist 7.410,00 2 14820
Toxicologist 7.410,00 2 14820
Total person Total Costs (€) for (A)
month
24.7 183566
Justification
Participation in multiple WPs includingWP3 lead.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
15.000,00 External contractor for the external evaluation of
the JATC activities. The external contractor will
review and input on the evaluation plan and assist
in evaluation implementation
Total Costs (€) of (B) 15.000,00
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5000 Two persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 5000
(D) Indirect Costs Total Costs
(€)
(Max. 7% on A, B and C) 14249.62
Total estimated eligible costs 217,815.62
Joint Action on Tobacco Control (JATC) Page 41 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 3 - BHTC
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert for WP5,6,7 6436 2.5 16090
Total person Total Costs (€) for (A)
month
2.5 16090
Justification
Expert in tobacco control for participation in WP 5,6,7
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One person at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1301.3
Total estimated eligible costs 19,891.30
Joint Action on Tobacco Control (JATC) Page 42 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 4 - NCPHA
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Experts senior 1000 5 5000
Experts junior 500 11 5500
Total person Total Costs (€) for (A)
month
16 10500
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 910
Total estimated eligible costs 13,910
Joint Action on Tobacco Control (JATC) Page 43 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 5 -MOH-CY
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 4000 6.5 26000
Total person Total Costs (€) for (A)
month
6.5 26000
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1995
Total estimated eligible costs 30495
Joint Action on Tobacco Control (JATC) Page 44 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 6 -SIK
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 7500 20 150000
Total person Total Costs (€) for (A)
month
20 150000
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 16500 IT consultancy for supporting WP5 tasks
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5000 Two people at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 5000
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 12,005
Total estimated eligible costs 183,505
Joint Action on Tobacco Control (JATC) Page 45 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 7 -TA
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Researcher 1950 3.2 6240
Senior Researcher 1950 1.5 2925
Total person Total Costs (€) for (A)
month
4.7 9165
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
€2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 816.55
Total estimated eligible costs 12481.55
Joint Action on Tobacco Control (JATC) Page 46 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 8 ANSES
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior project manager 8,400 € 1.1 9240
Senior expert 14,500 € 0.5 7250
Senior toxicologist 7,500 € 0.9 6750
Regulatory toxicologist 5,000 € 0.9 4500
Junior project officer 4,300 € 12.0 51600
Total person Total Costs (€) for (A)
month
15.4 79340
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
0
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5000 Two persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 4300
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 5903.80
Total estimated eligible costs 90243.80
Joint Action on Tobacco Control (JATC) Page 47 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 9 BfR
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 5500 19 104,500
Total person Total Costs (€) for (A)
month
19 104,500
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 7490
Total estimated eligible costs 114,490
Joint Action on Tobacco Control (JATC) Page 48 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 10 CERTH
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 2600 14 36400
Total person Total Costs (€) for (A)
month
14 36400
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2723
Total estimated eligible costs 41,623
Joint Action on Tobacco Control (JATC) Page 49 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 11 - SE
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Researchers 2250 15 33750
Total person Total Costs (€) for (A)
month
15 33750
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2537
Total estimated eligible costs 38787,50
Joint Action on Tobacco Control (JATC) Page 50 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 12 DOHI
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 6,377 2 12,754
Total person Total Costs (€) for (A)
month
2 12,754
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,067.78
Total estimated eligible costs 16,321.78
Joint Action on Tobacco Control (JATC) Page 51 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 13 HSE
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 6,855 1 6,855
Total person Total Costs (€) for (A)
month
1 6,855
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5,000 Travel to kick-off, Y2 and Y3 meeting at €833.3
per meeting per person for two participants
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 5,000
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 829.85
Total estimated eligible costs 12,684.85
Joint Action on Tobacco Control (JATC) Page 52 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 14 IRFMN
Short Name
(If affiliated entity: Affiliated to -
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Laboratory Head (WP8 leader) 5,250.00 € 15 78,750.00
Unit Head (WP8 co-leader) 3,950.00 € 12 47,400.00
Computer Technician 3,040.00 € 4 12,160.00
Senior researcher (statistician) 2,200.00 € 8 17,600.00
Phd Student (to be recruited) 1,188.00 € 12 14,256.00
Total person Total Costs (€) for (A)
month
51 170,166
Justification
Coordination of WP8, plus relevant roles in tobacco product evaluation
(WP6) and E-cigarettes product evaluation (WP7).
Participation in management (WP1), dissemination (WP2), integration
into national policies (WP4) and additives (WP9).
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each - -
subcontract foreseen)
Total Costs (€) of (B) -
Justification
-
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5,000.00 Travel to kick-off, Y2 and Y3 meeting at €833.3 per
meeting per person.
15,000.00 Costs for 2 internal WP8 meetings (organization and
reimbursement of participants’ travel and
accommodation costs only- 10 participants each)
(C.2) Equipment Costs (€) Justification
5,000.00 Costs for 2 PCs devoted to database and statistical
analysis (2,000 €), plus costs for dedicated statistical
analysis software (3,000 €)
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 25,000.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 13,661.62 Institutional overheads
Total estimated eligible costs 208,827.62
Joint Action on Tobacco Control (JATC) Page 53 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 15 ISS
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 1 4705 3 14,115
Expert 2 4103 2 8,206
Total person Total Costs (€) for (A)
month
5 22,321
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1737.47
Total estimated eligible costs 26,558.47
Joint Action on Tobacco Control (JATC) Page 54 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 16 MOHIT
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 3000 8 24,000
Total person Total Costs (€) for (A)
month
8 24,000
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,855
Total estimated eligible costs 28,355
Joint Action on Tobacco Control (JATC) Page 55 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 17 HI
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 2000 4.5 9,000
Total person Total Costs (€) for (A)
month
4.5 9,000
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 805
Total estimated eligible costs 12,305
Joint Action on Tobacco Control (JATC) Page 56 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 18 NTAKD
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Deputy director 2,368.00 € 4 9,472.00 €
licensing expert 1 1,506.00 € 4 6,024.00 €
licensing expert 2 1,044.00 € 3 3,132.00 €
tobacco expert 1,641.00 € 3 4,923.00 €
Total person Total Costs (€) for (A)
month
14 23,551
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,823.57
Total estimated eligible costs 27,874.57
Joint Action on Tobacco Control (JATC) Page 57 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 19 NVSPL
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Experts 2000 5 10000
Total person Total Costs (€) for (A)
month
5 10000
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 875
Total estimated eligible costs 13,375
Joint Action on Tobacco Control (JATC) Page 58 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 20 DEH
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
0 0 0
Total person Total Costs (€) for (A)
month
0
Justification
They participate only with travel to the meetings.
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 175
Total estimated eligible costs 2,675
Joint Action on Tobacco Control (JATC) Page 59 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 21 RIVM
Short Name
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Scientific Researchers €7525,81 4 30103.24
Scientific Researchers €7525,81 4 30103.24
Scientific Researchers €7525,81 4 30103.24
Scientific Researchers €7525,81 12 90309.72
Total person Total Costs (€) for (A)
month
24 180,619.44
Justification: these are average monthly costs depending on the
person who is performing the work
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
External Scientific Researchers 35,000 Review work in WP9
Total Costs (€) of (B) 35,000
Justification: several external scientific research experts will perform
review work for WP9
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3 JA consortium meetings 5,000,00 Two persons at the kick-off, Y2 and Y3 meeting
at €833.3 per meeting per person.
External Scientific Researchers €10.000,00 External experts travel cost attending WP9
meeting 1 and 2
(C.2) Equipment Costs (€) Justification
N/A
(C.3) Other goods and services Costs (€) Justification
Chemicals etc. €3,000,- Laboratory material for ring studies
WP 9 meetings €10.000,00 Location and organisation of WP9 meetings and
travel costs for two persons to these meetings
Total Costs (€) of (C) €28,000
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 17,053.40
Total estimated eligible costs 260,672.80
Joint Action on Tobacco Control (JATC) Page 60 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 22 NIPH
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 9444 5.5 51,942
Total person Total Costs (€) for (A)
month
5.5 51942
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 3810.94
Total estimated eligible costs 58,252.94
Joint Action on Tobacco Control (JATC) Page 61 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 23 NOMA
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 7000 1 7000
Total person Total Costs (€) for (A)
month
1 7000
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 665
Total estimated eligible costs 10,165
Joint Action on Tobacco Control (JATC) Page 62 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 24 MS
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 5223 9 47007
Total person Total Costs (€) for (A)
month
9 47,007
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each 0
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 3,465.49
Total estimated eligible costs 52,972.49
Joint Action on Tobacco Control (JATC) Page 63 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 25 BATUT-IANPH
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 1 1400 16 22400
Expert 2 1400 8 11200
Total person Total Costs (€) for (A)
month
24 33600
Justification
WP2 dissemination leader
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B) 0
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2527
Total estimated eligible costs 38,627
Joint Action on Tobacco Control (JATC) Page 64 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 26 NLZOH
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert WP6 2,406.00 € 5 12,030.00 €
Expert WP6 4,249.00 € 2 8,498.00 €
Expert WP5 2,585.00 € 3 7,755.00 €
Expert WP6 2,665.00 € 4 10,660.00 €
Total person Total Costs (€) for (A)
month
14 38,943
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2,901.01
Total estimated eligible costs 44,344.01
Joint Action on Tobacco Control (JATC) Page 65 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 27 ICO
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior expert 6,806.25 € 6 40,837.50 €
Junior expert 4,412.25 € 20 88,245.00 €
Total person Total Costs (€) for
month (A)
26 129,082.50 €
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5000 Travel to at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 5000
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 9385.78
Total estimated eligible costs 143,468.28
Joint Action on Tobacco Control (JATC) Page 66 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ IDIBELL
Short Name
(If affiliated entity: Affiliated to ICO
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Total person Total Costs (€) for (A)
month
Justification
The Fundació Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)
is a third party of ICO assisting in administrative/financial tasks as
foreseen by Article 12 of the Annotated Model Grant Agreement,
including issues related to employment and payment of personnel,
purchase of consumables, etc. This relationship is governed by a prior
agreement between ICO and IDIBELL signed on 02/10/2007.
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 0
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C)
Total estimated eligible costs
Joint Action on Tobacco Control (JATC) Page 67 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 28 CSJA
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 3700 1 3700
Total person Total Costs (€) for (A)
month
1 3700
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C)
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 259
Total estimated eligible costs 3959.00
Joint Action on Tobacco Control (JATC) Page 68 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ FPS
Short Name
Affiliated to which Applicant CSJA
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert 3700 1 3700
Total person month Total Costs (€) for (A)
1 3700
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5000 Two persons at kick-off, Y2 and Y3 meeting
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 5000
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 609
Total estimated eligible costs 9309
Joint Action on Tobacco Control (JATC) Page 69 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ AGAPA
Short Name
Affiliated to which Applicant CSJA
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Experts 3700 18 66,600
Total person month Total Costs (€) for (A)
18 66,600
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
0
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
4000 Travel to kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person
(C.2) Equipment Costs (€) Justification
0
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 0
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 4,942
Total estimated eligible costs 75542
Joint Action on Tobacco Control (JATC) Page 70 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 29 FOHM
Short Name
(If affiliated entity: Affiliated to which
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Analyst, WP5 5000€ 1.5 7,500
Analyst, WP7 and 9 5000€ 6 30,000
Analyst, WP7 and 9 5000€ 6 30,000
Analyst, WP6 5000€ 4 20,000
Total person Total Costs (€) for
month (A)
17.5 87,500€
Justification
(B) Direct costs of sub-contracting Costs Task(s)/Justification
(€)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2500 Travel to kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person
(C.2) Equipment Costs (€) Justification
0
(C.3) Other goods and services Costs (€) Justification
0
Total Costs (€) of (C) 2500
(D) Indirect Costs Total Costs
(€)
(Max. 7% on A, B and C) 6300
Total estimated eligible costs 77040
Joint Action on Tobacco Control (JATC) Page 71 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 30 UK-DOH
Short Name
(If affiliated entity: Affiliated to
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert1 5,500 € 2.5 13,750.0
Expert2 9,000 € 0.5 4,500.0
Expert3 14,000 € 0.5 7,000.0
Expert4 7,000 € 0.5 3,500.0
Total person Total Costs (€) for (A)
month
4 28,750
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each
subcontract foreseen)
Total Costs (€) of (B)
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2,500 One persons at kick-off, Y2 and Y3 meeting €833.3
per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 2,500
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2187.50
Total estimated eligible costs 33,437.50
Joint Action on Tobacco Control (JATC) Page 72 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
Applicant Number/ 31 HTS
Short Name
(If affiliated entity: Affiliated to -
which Applicant number/Short
name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior tobacco expert 3000 7 21000
Tobacco expert 2300 5 11500
Aerosol expert WP8 2500 5 12500
Technician for WP6 and WP7 1800 3 5400
Laboratory Technician WP8 1600 4 6400
Total person Total Costs (€) for (A)
month
24 56,800
Justification
(B) Direct costs of sub- Costs (€) Task(s)/Justification
contracting
(please repeat line for each - -
subcontract foreseen)
Total Costs (€) of (B) -
Justification
-
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5,000 Two persons at kick-off, Y2 and Y3 meeting at
€833.3 per meeting per person.
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
Total Costs (€) of (C) 5,000
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 4,326 Institutional overheads
Total estimated eligible costs 66,126
Joint Action on Tobacco Control (JATC) Page 73 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
9. PREVIOUS AND CURRENT GRANTS RELEVANT TO THE PROGRAMME (LIMITED TO THE LAST 3
YEARS)
EUREST-PLUS: Hοrizon2020 — H2020-HCO-2015. Proposal No: 681109 - EUREST-PLUS – RIA.
“European Regulatory Science on tobacco, policies to reduce lung disease”
TOB-G: Tobacco Cessation Guidelines For High Risk Groups. TOB-G project aims to develop and
implement an innovative and cost effective approach to prevent chronic diseases related to tobacco dependence.
High risk populations are considered those who suffer from cardiovascular diseases, COPD, type 2 diabetes,
adolescents & pregnant women. TOB-G will enhance the overall European capacity in the treatment of tobacco
dependence, thus, in the prevention of chronic diseases, through offering smoking cessation tools, appropriately
assessed and fitted to the specific needs of high risk groups.
TACK-SHS: Hοrizon2020 — H2020-HCO-2015. Proposal No: 681040 – TACK SHS – RIA. «Tackling
secondhand tobacco smoke and e-cigarette emissions: exposure assessment, novel interventions, impact on lung
diseases and economic burden in diverse European populations».
DIRECT: Study concerning assessment of available evidence on toxicity, addictiveness and
attractiveness of ingredients contained in tobacco and related products on the basis of information submitted by
the industry in the context of reporting obligations introduced by Directive 2001/37/EC
PRECISE: EAHC/2013/Health/23 "Multiple Framework Contracts with reopening of competition to
support tobacco policies - Composition of tobacco and related products and its impact on human health"
concerning the provision of a study on the identification of potential risks to public health associated with the
use of refillable electronic cigarettes and development of technical specifications for refill mechanisms.
EUREST: N° EAHC/2013/Health/12 for the implementation of Framework Contract N°
EAHC/2013/Health/23 "Multiple Framework Contracts with reopening of competition to support tobacco
policies - Composition of tobacco and related products and its impact on human health " concerning the
development of a EU common reporting format for submission of data on ingredients contained in tobacco and
related products and disclosure of the collected data to the public.
10. CURRENT APPLICATIONS RELEVANT TO THE PROGRAMME
None under application
Joint Action on Tobacco Control (JATC) Page 74 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
11. EXCEPTIONAL UTILITY
It is well known that tobacco use is the largest threat to European Public Health as it is one of the leading causes
of premature death and disability in Europe. In this framework, JATC will enhance the overall European
capacity in tobacco product regulatory science and as identifiable through its 9 WPs, it is clear that the project
demonstrates excellence in furthering public health in Europe and it has a very significant EU added value.
According to CHAFEA criteria, to receive up to 80% of co-funding, the proposals must comply with the
following:
Criteria How JATC meets these criteria
At least 30% of the budget of the proposed action is More than 30% of the budget is in MS whose
allocated to Member States whose gross national GNI is less than 90%.
income (GNI) per inhabitant is less than 90 % of the
Union average.
Bodies from at least 14 participating countries >25countries participate in this joint action,
participate in the action, out of which at least four and hence the criteria of “at least 14 partners”
are countries whose GNI per inhabitant is less than is exceeded.
90% of the Union
We have >4countries with a GMI<90% of the
average
EU average and hence the criteria has been
exceeded.
Joint Action on Tobacco Control (JATC) Page 75 / 76
Tuesday, 5 December 2017
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
12. COLLABORATING STAKEHOLDERS
Institution Contact person Country
(First name and last name)
WHO* - FCTC secretariat TBD Switzerland
European Respiratory Society (ERS) TBD Switzerland
CHEST Panagiotis Behrakis USA
Institute of Public Health-ACG Panagiotis Behrakis Greece
Aer Pur Romania Florin Mihaltan Romania
National Supervisory Authority for Reetta Honkanen Finland
Welfare and Health (Valvira)
Bureau for Chemical Substances Justyna Wasikowska Poland
Norwegian Directorate of Health Rita Lindbak Norway
National Center for Public Health Ion Salaru Moldova
Universitat Internacional de Catalunya Jose M Martínez-Sánchez Spain
(UIC-Barcelona)
Individual Expert - Hungary Tibor Demjen Hungary
Lithuanian University of Health Asta Raskiliene Lithuania
Sciences
Athens Medical Center Christos Liapis Greece
*: In the process of contacting and getting approval.
Joint Action on Tobacco Control (JATC) Page 76 / 76
Tuesday, 5 December 2017
Grant Agreement number: 761297 — JATC — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 1 of 4) Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
1. HCS 382000.00 40000.00 39100.00 32277.00 493377.00 394701.60 0.00 0.00 0.00
2. AGES 183566.00 15000.00 5000.00 14249.62 217815.62 174252.50 0.00 0.00 0.00
3. FPS BHTC 16090.00 0.00 2500.00 1301.30 19891.30 15913.04 0.00 0.00 0.00
4. NCPHA 10500.00 0.00 2500.00 910.00 13910.00 11128.00 0.00 0.00 0.00
5. MoH CY 26000.00 0.00 2500.00 1995.00 30495.00 24396.00 0.00 0.00 0.00
6. SIK 150000.00 16500.00 5000.00 12005.00 183505.00 146804.00 0.00 0.00 0.00
7. TA 9165.00 0.00 2500.00 816.55 12481.55 9985.24 0.00 0.00 0.00
8. ANSES 79340.00 0.00 5000.00 5903.80 90243.80 72195.04 0.00 0.00 0.00
9. BfR 104500.00 0.00 2500.00 7490.00 114490.00 91592.00 0.00 0.00 0.00
10. CERTH 36400.00 0.00 2500.00 2723.00 41623.00 33298.40 0.00 0.00 0.00
11. SU (SE) 33750.00 0.00 2500.00 2537.50 38787.50 31030.00 0.00 0.00 0.00
12. DoH I 12754.00 0.00 2500.00 1067.78 16321.78 13057.42 0.00 0.00 0.00
13. HSE 6855.00 0.00 5000.00 829.85 12684.85 10147.88 0.00 0.00 0.00
14. IRFMN 170166.00 0.00 25000.00 13661.62 208827.62 167062.10 0.00 0.00 0.00
15. ISS 22321.00 0.00 2500.00 1737.47 26558.47 21246.78 0.00 0.00 0.00
1
Grant Agreement number: 761297 — JATC — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 2 of 4) Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
16. MoH IT 24000.00 0.00 2500.00 1855.00 28355.00 22684.00 0.00 0.00 0.00
17. HI 9000.00 0.00 2500.00 805.00 12305.00 9844.00 0.00 0.00 0.00
18. NTAKD 23551.00 0.00 2500.00 1823.57 27874.57 22299.66 0.00 0.00 0.00
19. NVSPL 10000.00 0.00 2500.00 875.00 13375.00 10700.00 0.00 0.00 0.00
20. DEH 0.00 0.00 2500.00 175.00 2675.00 2140.00 0.00 0.00 0.00
21. RIVM 180619.44 35000.00 28000.00 17053.36 260672.80 208538.24 0.00 0.00 0.00
22. NIPH 51942.00 0.00 2500.00 3810.94 58252.94 46602.35 0.00 0.00 0.00
23. NOMA 7000.00 0.00 2500.00 665.00 10165.00 8132.00 0.00 0.00 0.00
24. MS 47007.00 0.00 2500.00 3465.49 52972.49 42377.99 0.00 0.00 0.00
25. BATUT- 33600.00 0.00 2500.00 2527.00 38627.00 30901.60 0.00 0.00 0.00
IANPH
26. NLZOH 38943.00 0.00 2500.00 2901.01 44344.01 35475.21 0.00 0.00 0.00
27. ICO 129082.50 0.00 5000.00 9385.78 143468.28 114774.62 0.00 0.00 0.00
- IDIBELL 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total beneficiary 129082.50 0.00 5000.00 9385.78 143468.28 114774.62 0.00 0.00 0.00
2
Grant Agreement number: 761297 — JATC — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 3 of 4) Associated with document Ref. Ares(2017)6172119 - 15/12/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
28. CSJA 3700.00 0.00 0.00 259.00 3959.00 3167.20 0.00 0.00 0.00
- AGAPA 66600.00 0.00 4000.00 4942.00 75542.00 60433.20 0.00 0.00 0.00
- FPS 3700.00 0.00 5000.00 609.00 9309.00 7447.20 0.00 0.00 0.00
Total beneficiary 74000.00 0.00 9000.00 5810.00 88810.00 71047.60 0.00 0.00 0.00
29. FoHM 87500.00 0.00 2500.00 6300.00 96300.00 77040.00 0.00 0.00 0.00
30. UK-DH 28750.00 0.00 2500.00 2187.50 33437.50 26750.00 0.00 0.00 0.00
31. HTS 56800.00 0.00 5000.00 4326.00 66126.00 52900.80 0.00 0.00 0.00
7
Total consortium 2045201.94 106500.00 183600.00 163471.14 2498773.08 80 1999018.47 1999018.07 0.00 0.00 0.00
3
Grant Agreement number: 761297 — JATC — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 4 of 4) Associated with document Ref. Ares(2017)6172119 - 15/12/2017
(1) See Article 6 for the eligibility conditions
(2) The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme). A beneficiary that receives an operating grant during the action's duration
cannot claim any indirect costs for the year(s)/reporting period(s) covered by the operating grant
(3) This is the theoretical amount of the EU contribution that the system calculates automatically (by multiplying all the budgeted costs by the reimbursement rate). This theoretical amount is capped by the 'maximum grant
amount' (that the Agency decided to grant for the action) (see Article 5.1)
(4) The 'maximum grant amount' is the maximum grant amount decided by the Agency. It normally corresponds to the requested grant, but may be lower
(5) See Article 5 for the cost forms
(6) flat rate : 7% of eligible direct costs
(7) The reimbursement rate is applied at consortium level only (i.e. to the total costs). The reimbursement rate is normally 60% (or 80% in cases of exceptional utility)
4
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
OSTERREICHISCHE AGENTUR FUR GESUNDHEIT UND ERNAHRUNGSSICHERHEIT
GMBH (AGES), FN223056Z, established in SPARGELFELDSTRASSE 191, WIEN 1220, Austria,
ATU54088605 ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘2’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998254743_75_210--]
1
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SERVICE PUBLIC FEDERAL SANTE PUBLIQUE, SECURITE DE LA CHAINE
ALIMENTAIRE ET ENVIRONNEMENT (FPS BHTC), N/A, established in SQUARE VICTOR
HORTA 40 BUR 1D 1G, BRUSSELS 1060, Belgium, N/A ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘3’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998853815_75_210--]
2
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NATSIONALEN CENTAR PO OBSHTESTVENO ZDRAVE I ANALIZI (NCPHA),
176094665, established in ACAD IVAN GESHOV BLVD 15, SOFIA 1431, Bulgaria, BG176094665
('the beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘4’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-986300754_75_210--]
3
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Ministry of Health of the Republic of Cyprus (MoH CY), established in 1 Prodromou Street &
17 Chilonos Street 1 & 17, Nicosia 1448, Cyprus ('the beneficiary'), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘5’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-994267946_75_210--]
4
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SIKKERHEDSSTYRELSEN (SIK), 27403123, established in NORREGADE 63, ESBJERG 6700,
Denmark, DK27403123 ('the beneficiary'), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary (‘6’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-949828657_75_210--]
5
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
TERVISEAMET (TA), 70008799, established in PALDISKI MNT 81, TALLINN 10617, Estonia,
EE101339803 ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘7’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-933659727_75_210--]
6
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L
ENVIRONNEMENT ET DU TRAVAIL (ANSES), 130012024, established in 14 RUE PIERRE
ET MARIE CURIE, MAISONS ALFORT 94700, France, FR54130012024 ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘8’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-983552356_75_210--]
7
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
BUNDESINSTITUT FUER RISIKOBEWERTUNG (BfR), N/A, established in MAX DOHRN
STRASSE 8-10, BERLIN 10589, Germany ('the beneficiary'), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘9’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998771171_75_210--]
8
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH) GR8,
PD772000, established in CHARILAOU THERMI ROAD 6 KM, THERMI THESSALONIKI 57001,
Greece, EL099785242 ('the beneficiary'), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary (‘10’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998802502_75_210--]
9
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SEMMELWEIS EGYETEM (SU (SE)) HU13, FI62576, established in ULLOI UTCA 26,
BUDAPEST 1085, Hungary, HU15329808 ('the beneficiary'), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘11’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999860675_75_210--]
10
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
EMBAETTI LANDLAEKNIS (DoH I), 7101695009, established in BARONSSTIG 47,
REYKJAVIK 101, Iceland ('the beneficiary'), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary (‘12’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-955430213_75_210--]
11
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HEALTH SERVICE EXECUTIVE HSE (HSE), established in LIMETREE AVENUE 2ND FLO
OAK HOUSE, NAAS, Ireland, IE66093541 ('the beneficiary'), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘13’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-993521919_75_210--]
12
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI (IRFMN) IT3,
CF03254210150, established in VIA GIUSEPPE LA MASA 19, MILANO 20156, Italy,
IT03254210150 ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘14’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999661146_75_210--]
13
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ISTITUTO SUPERIORE DI SANITA (ISS), 80211730587, established in Viale Regina Elena 299,
ROMA 00161, Italy, IT03657731000 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘15’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999978821_75_210--]
14
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERO DELLA SALUTE (MoH IT), N/A, established in Via Giorgio Ribotta 5, ROMA
00144, Italy, N/A ('the beneficiary'), represented for the purpose of signing this Accession Form by
the undersigned,
hereby agrees
to become beneficiary (‘16’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999531942_75_210--]
15
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
VESELIBAS INSPEKCIJA (HI), 432, established in KLIJANU STREET 7, RIGA 1012, Latvia,
LV90002448818 ('the beneficiary'), represented for the purpose of signing this Accession Form by
the undersigned,
hereby agrees
to become beneficiary (‘17’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-917264690_75_210--]
16
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NARKOTIKU TABAKO IR ALKOHOLIO KONTROLES DEPARTAMENTAS (NTAKD)
LT3, 302610311, established in SV STEPONO GATVE 27, VILNIUS 01312, Lithuania ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘18’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-925909427_75_210--]
17
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NACIONALINE VISUOMENES SVEIKATOS PRIEZIUROS LABORATORIJA (NVSPL),
195551983, established in ZOLYNO G. 36, VILNIUS 10210, Lithuania, LT ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘19’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-933651094_75_210--]
18
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Ministry for Health - Government of Malta (DEH), not applicable, established in Palazzo
Castellania, Merchants Street 15, Valletta VLT 200, Malta, MT12979127 ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘20’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-974144423_75_210--]
19
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), 30276683,
established in Antonie Van Leeuwenhoeklaan 9, BILTHOVEN 3721 MA, Netherlands,
NL821772302B01 ('the beneficiary'), represented for the purpose of signing this Accession Form by
the undersigned,
hereby agrees
to become beneficiary (‘21’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999991431_75_210--]
20
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FOLKEHELSEINSTITUTTET (NIPH), 983744516, established in LOVISENBERGGATA 8,
OSLO 0456, Norway, NO983744516MVA ('the beneficiary'), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘22’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999478883_75_210--]
21
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATENS LEGEMIDDELVERK (NOMA) NO6, 974761122, established in SVEN OFTEDALS
VEI 8, OSLO 0950, Norway ('the beneficiary'), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary (‘23’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-923895416_75_210--]
22
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (MS ), Decreto-Lei n.º 212/2006,
de 27 de Outubro , established in Av. João Crisóstomo, 9, LISBOA 1049-062 , Portugal ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘24’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-986364095_75_210--]
23
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUT ZA JAVNO ZDRAVLJE SRBIJE 'MILAN JOVANOVIC - BATUT' (BATUT-
IANPH), 5218003/6012569869, established in DR SUBOTICA STREET 5, BEOGRAD 11000,
Serbia, RS102000930 ('the beneficiary'), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary (‘25’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-941063349_75_210--]
24
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NACIONALNI LABORATORIJ ZA ZDRAVJE, OKOLJE IN HRANO (NLZOH) SI2,
6489087000, established in PRVOMAJSKA ULICA 1, MARIBOR 2000, Slovenia, SI19651295 ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘26’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-949131227_75_210--]
25
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUT CATALA D'ONCOLOGIA (ICO), established in AV GRAN VIA DE L'HOSPITALET
199-203, L'HOSPITALET DEL LLOBREGAT 08908, Spain, ESQ5856383D ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘27’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998420031_75_210--]
26
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
CONSEJERIA DE SALUD DE LA JUNTA DE ANDALUCIA (CSJA), not applicable, established
in EDIF. ARENA 1. AVDA DE LA INNOVACION S//N, Sevilla 41020, Spain, ESS4111001F ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘28’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-950939307_75_210--]
27
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FOLKHALSOMYNDIGHETEN (FoHM), 2021006545, established in NOBELS VAG 18, SOLNA
171 82, Sweden, SE202100654501 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘29’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-949789954_75_210--]
28
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Department of Health (UK-DH), -, established in Quarry House, Quarry Hill, Leeds LS2 7UE,
United Kingdom, 888815064 ('the beneficiary'), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary (‘30’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-986454887_75_210--]
29
Grant Agreement number: 761297 — JATC — HP-JA-2016
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ELLINIKI PNEYMONOLOGIKI ETAIREIA (HTS) GR4, Not applicable, established in
MAIANDROU 23, ATHINA 115 28, Greece, EL090340027 ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘31’)
in Grant Agreement No 761297 (‘the Agreement’)
between HELLENIC CANCER SOCIETY and the Consumers, Health, Agriculture and Food
Executive Agency (CHAFEA) ('the Agency'), under the powers delegated by the European Commission
('the Commission'),
for the action entitled ‘Joint Action on Tobacco Control (JATC)’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-917258870_75_210--]
30
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
i print format A4
MODEL ANNEX 4 CHAFEA MGA — MULTI
landscape
FINANCIAL STATEMENT FOR [BENEFICIARY [name]/AFFILIATED ENTITY [name]] FOR REPORTING PERIOD [reporting period]
1 Receipts
Eligible costs (per budget category) EU contribution
Financial
A. Direct personnel B. Direct costs of C. Other direct D. Indirect Income generated contributions given Requested EU
2 Total costs Total receipts 3
costs subcontracting costs costs by the action by third parties to contribution
the beneficiaries
A.1 Employees C.1 Travel
A.2 Natural persons
C.2 Equipment
under direct contract
and seconded persons
C.3 Other goods and
services
5
4 Actual Actual Actual Flat-rate
Cost form
7%
d= e=
a b c f g h=f+g i
0,07 * (a + b + c) a+b+c+d
[short name
beneficiary/affiliated
entity]
The beneficiary/affiliated entity hereby confirms that:
The information provided is complete, reliable and true.
The costs declared are eligible (see Article 6).
The costs can be substantiated by adequate records and supporting documentation that will be produced upon request or in the context of checks, reviews, audits and investigations (see Articles 12, 13
and 17).
For the last reporting period: that all the receipts have been declared (see Article 5.3.3).
i Please declare all eligible costs, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Only amounts that were declared in your individual financial statements can be
taken into account lateron, in order to replace other costs that are found to be ineligible.
1
See Article 6 for the eligibility conditions
2
The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme); see Article 6.2.D. If you have received an operating
grant during this reporting period, you cannot claim any indirect costs
3
You may request up to 100% of the total cost declared. The reimbursement rate mentioned in Article 5.2 applies only at consortium level (and will only be checked by the Agency at the payment of
the balance)
4
See Article 5 for the cost forms
5
Flat rate : 7% of eligible direct costs
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
i print format A4
ANNEX 4 CHAFEA MGA — MULTI: Details
landscape
A. Direct personnel costs
A.1 Employees
Name/Function No of hours worked for the project Hourly rate Total costs
(a) (b) (c) = (a) * (b)
Total for A.1 Employees
A.2 Natural persons under direct contract and seconded persons
Name/Function No of hours worked for the project Hourly rate Total costs
(a) (b) (c) = (a) * (b)
Total for A.2 Natural persons under direct contract and
seconded persons
Total for A. Direct personnel costs
B. Direct costs of subcontracting
Invoice Number Subcontractor and Description of task Price
Total for B. Direct costs of subcontracting
C. Other direct costs
C.1 Travel
Description (Name of person travelling, meeting as referenced in the technical report, place of the meeting) Travel cost No of days Daily rate Total costs
(a) (b) (c) (d) = (a) + ((b) * (c))
Total for C.1 Travel
C.2 Equipment
Number of month of
Depreciation method (36 % of use for the purpose
Invoice Number Description of the equipment Purchase price Date of purchase depreciation allocated to Total costs
or 60 month) of the project
the project
(a) (b) (c) (d) (e) (f) = ((d)/(c) * (e)) * (a)
Total for C.2 Equipment
C.3 Other goods and services
Invoice Number Description of service or good Purchase price
Total for C.3 Other goods and services
Total for C. Other direct costs
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
ANNEX 5
MODEL OF THE CERTIFICATE ON THE FINANCIAL STATEMENTS
For options [in italics in square brackets]: choose the applicable option. Options not chosen should
be deleted.
For fields in [grey in square brackets]: enter the appropriate data
TABLE OF CONTENTS
1. TERMS OF REFERENCE FOR INDEPENDENT CERTIFICATE ON FINANCIAL STATEMENTS
AND REPORT ON FINDINGS ON COSTS DECLARED UNDER A GRANT AGREEMENT
FINANCED UNDER THE HEALTH AND CONSUMER PROGRAMMES 2014-2020
2.MODEL OF CERTIFICATE ON FINANCIAL STATEMENTS TO BE PROVIDED BY
INDEPENDENT AUDITOR
3. TEMPLATE OF THE REPORT ON FINDINGS ON COSTS DECLARED UNDER A GRANT
AGREEMENT FINANCED UNDER HEALTH AND CONSUMER PROGRAMMES 2014-2020
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Terms of Reference for an Independent Certificate on Financial Statements and Report
on Findings on costs declared under a Grant Agreement financed under the Health and
Consumer Programmes 2014-2020
This document sets out the ‘Terms of Reference (ToR)’ under which
[insert name of the beneficiary] (‘the Beneficiary’)]
agrees to engage
[insert legal name of the auditor] (‘the Auditor’)
to issue an Independent Certificate on the Financial Statements’ (‘CFS’) referred to in Articles
15.3 and 15.4 of the Agreement based on the compulsory reporting template stipulated by the
Agency, and
to produce an independent Report of findings (‘the Report’) concerning the Financial
Statement(s)1 drawn up by the [Beneficiary] [Affiliated Entity] for the [Health] / [Consumer]
Programme 2014-2020 grant agreement [insert number of the grant agreement, title of the
action, acronym and duration from/to] (‘the Agreement’),
The Agreement has been concluded under the [Health] / [Consumer] Programme 2014-2020
between the Beneficiary and Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) (‘the Agency’), under the powers delegated by the European Commission (‘the
Commission’).
The Agency is mentioned as a signatory of the Agreement with the Beneficiary only. The
Agency is not a party to this engagement.
1.1 Subject of the engagement
The coordinator must submit to the Agency the final report within 60 days following the end
of the each reporting period which should include, amongst other documents, a CFS for each
beneficiary (and linked affiliated entity), for which the total contribution in the form of
reimbursement of actual costs as referred to in Article 5.2 of the Agreement is at least EUR
750.000, and which requests a reimbursement in that form of EUR 325 000 or more, as
reimbursement of actual costs calculated on the basis of its usual cost accounting practices.
The CFS must cover the reporting period of the beneficiary (or linked Affiliated Entity)
concerned by the payment.
The Beneficiary must submit to the coordinator the CFS for itself and for its linked Affiliated
Entity, if the CFS must be included in the interim and final reports according to Articles 15.3
and 15.4 of the Agreement.
The CFS is composed of the following documents:
1
By which costs under the Agreement are declared (see template ‘Model Financial Statements’ in
Annex 4 to the Grant Agreement).
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
- The Terms of Reference (‘the ToR’) to be signed by the [Beneficiary] [Affiliated
Entity] and the Auditor;
- the Auditor’s Certificate on Financial Statements and Independent Report of Findings
(‘the Report’) to be issued on the Auditor’s letterhead, dated, stamped and signed by
the Auditor (or the competent public officer) which includes the agreed-upon checks
(laid down in the Annex I to the Report) to be performed by the Auditor, and the
standard findings (‘the Findings’) to be confirmed by the Auditor.
If the CFS must be included in the interim and final report according to Articles 15.3 and 15.4
of the Agreement, the request for interim payment or payment of the balance to the
Agreement cannot be made without the CFS. However, the payment for reimbursement of
costs covered by the CFS does not preclude the Agency, the European Anti-Fraud Office and
the European Court of Auditors from carrying out checks, reviews, audits and investigations
in accordance with Article 17 of the Agreement.
1.2 Responsibilities
The [Beneficiary] [Linked Affiliated Entity]:
must draw up the Financial Statement(s) for the action financed by the Agreement in
compliance with the obligations under the Agreement. The Financial Statement(s)
must be drawn up according to the [Beneficiary’s] [Linked Affiliated Entity’s]
accounting and book-keeping system and the underlying accounts and records;
must send the Financial Statement(s) to the Auditor;
is responsible and liable for the accuracy of the Financial Statement(s);
is responsible for the completeness and accuracy of the information provided to enable
the Auditor to carry out the checks.;
accepts that the Auditor cannot carry out the checks unless he/she is given full access
to the [Beneficiary’s] [Linked Affiliated Entity’s] staff and accounting as well as any
other relevant records and documentation.
The Auditor:
[Option 1 by default: is qualified to carry out statutory audits of accounting
documents in accordance with Directive 2006/43/EC of the European Parliament and
of the Council of 17 May 2006 on statutory audits of annual accounts and consolidated
accounts, amending Council Directives 78/660/EEC and 83/349/EEC and repealing
Council Directive 84/253/EEC or similar national regulations].
[Option 2 if the Beneficiary or Linked Affiliated Officer has an independent Public
Officer: is a competent and independent Public Officer for which the relevant national
authorities have established the legal capacity to audit the Beneficiary].
The Auditor:
must be independent from the Beneficiary [and the Linked Affiliated Entity], in
particular, it must not have been involved in preparing the [Beneficiary’s] [Linked
Affiliated Entity’s] Financial Statement(s);
must plan work so that the checks may be carried out and the Findings may be
assessed;
must adhere to the checks laid down in Annex I to the Report and the compulsory
report format;
must carry out the engagement in accordance with this ToR;
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
must document matters which are important to support the Report;
must base its Report on the evidence gathered;
must submit the Report to the [Beneficiary] [Linked Affiliated Entity].
The Agency sets out the list of checks to be carried out by the Auditor which is defined in
detail in the Annex I to the Report. The Auditor has to examine the Financial Statements and
verify the supporting documentation in order to provide a reasonable assurance on their
correctness.
1.3 Applicable Standards
The Auditor must comply with these Terms of Reference and with2:
- the International Standard on Related Services (‘ISRS’) 4400 Engagements to
perform Agreed-upon Procedures regarding Financial Information as issued by
the International Auditing and Assurance Standards Board (IAASB);
- the Code of Ethics for Professional Accountants issued by the International Ethics
Standards Board for Accountants (IESBA). Although ISRS 4400 states that
independence is not a requirement for engagements to carry out agreed-upon
checks, the Agency requires that the Auditor also complies with the Code’s
independence requirements.
The Auditor’s Report must state that there is no conflict of interests in establishing this Report
between the Auditor and the Beneficiary [and the Linked Affiliated Entity], and must specify -
if the service is invoiced - the total fee paid to the Auditor for providing the Report.
1.4 Reporting
The Report must be written in the language of the Agreement.
Under Article 17 of the Agreement, the Agency, the European Anti-Fraud Office and the
Court of Auditors have the right to audit any work that is carried out under the action and for
which costs are declared from the European Union budget. This includes work related to this
engagement. The Auditor must provide access to all working papers (e.g. recalculation of
hourly rates, verification of the time declared for the action) related to this assignment if the
Agency, the European Anti-Fraud Office or the European Court of Auditors requests them.
1.5 Timing
The CFS must be provided together with the request for the interim and balance payment, if
required according to Articles 15.3 and 15.4 of the Agreement.
1.6 Other terms
2
Supreme Audit Institutions applying INTOSAI-standards may carry out the Procedures according
to the corresponding International Standards of Supreme Audit Institutions and code of ethics
issued by INTOSAI instead of the International Standard on Related Services (‘ISRS’) 4400 and
the Code of Ethics for Professional Accountants issued by the IAASB and the IESBA.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
[The [Beneficiary] [Linked Affiliated Entity] and the Auditor can use this section to agree
other specific terms, such as the Auditor’s fees, liability, applicable law, etc. Those specific
terms must not contradict the terms specified above.]
[legal name of the Auditor [legal name of the [Beneficiary][Linked Affiliated
Entity]]
[name & function of authorised representative] [name & function of authorised
representative]
[dd Month yyyy] [dd Month yyyy]
Signature of the Auditor Signature of the [Beneficiary][Linked Affiliated
Entity]
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Independent certificate on the financial statements declared under grant agreements
signed under the Health and Consumer Programmes 2014-2020
(To be submitted by each beneficiary if the maximum grant amount in the form of reimbursement of ‘actual
costs’ is at least EUR 750 000 and if it requests a reimbursement of actual costs of at least EUR 325 000 (see
Articles 15.3 and 15.4)
To be drawn up and signed by an approved auditor or, in case of public bodies, by a competent and independent
public officer (and printed on their letterhead).)
To
[ name of contact person(s)], [Position]
[ [Beneficiary’s] [Linked Affiliated Entity’s] name ]
[ Address]
[ dd Month yyyy]
Dear [Name of contact person(s)],
As agreed under the terms of reference dated [dd Month yyyy]
with [OPTION 1: [insert name of the beneficiary] (‘the Beneficiary’)] [OPTION 2: [insert
name of the linked Affiliated Entity (‘the Linked Affiliated Entity), Affiliated Entity linked to
the Beneficiary [insert name of the beneficiary] (‘the Beneficiary’)],
we
[name of the auditor ] (‘the Auditor’),
established at
[full address/city/state/province/country],
represented by
[name and function of an authorised representative],
have carried out an audit relating to the provisions of the Terms of Reference, the costs
declared in the Financial Statement(s)3 of the [Beneficiary] [Linked Affiliated Entity], the
documents provided in their support , to which this Certificate is attached, and which is to be
presented to Agency together with the request for payment under the grant agreement [insert
grant agreement reference: number, title of the action and acronym] (‘the Agreement’), for the
following period (s) covered by Agreement [insert period(s) covered by the Financial
Statements].
The audit and subsequent checks were carried out solely to assist Agency in evaluating
whether the[Beneficiary][Linked Affiliated Entity’s] costs in the accompanying Financial
Statement(s) were declared in accordance with the Agreement. The Agency will draw its own
conclusions from the Report and any additional information it may require.
The above mentioned Financial Statement(s) of the [Beneficiary] [Linked Affiliated Entity],
their supporting documentation and accounting records were examined in accordance with
3
By which the Beneficiary declares costs under the Agreement (see template ‘Financial Statement’
in Annex 4 to the Agreement).
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
the upon-agreed checks , as detailed in Annex I to the Report, in order to provide Agency with
the following reasonable assurance:
the amount of the total eligible costs ([insert amount in number] ([insert amount in
words4])) declared in the attached Financial Statement(s) of the [Beneficiary] [Linked
Affiliated Entity] is complying with the following cumulative conditions, as defined in the
Article 6.1 of the Agreement:
they are actual and recorded in the [Beneficiary’s] [Linked Affiliated
Entity’s]accounts at the date of the establishment of this audit certificate;
they have been incurred during the periods covered by the Financial Statement(s)
concerned by this audit certificate;
[they also include the eligible costs incurred in drawing up the final reports
referred to in Article 15 of the Agreement, which may be incurred up to two
calendar months after the end of the action;]
they are determined in accordance with the beneficiary’s accounting standards
applicable in the country where the [Beneficiary] [Linked Affiliated Entity]is
established, and with the beneficiary’s usual cost accounting practices;
they comply with the national law on taxes, labour and social security applicable in
the country where the [Beneficiary] [Linked Affiliated Entity]is established;
they are exclusive of any non-eligible costs identified below which are established
in Article 6.4 of the above mentioned agreement with the Agency:
return on capital;
debt and debt service charges;
provisions for future losses or debts;
interest owed;
doubtful debts;
currency exchange losses;
bank costs charged by the beneficiary’s bank for transfers from the
Agency;
deductible VAT;
costs incurred during suspension of the implementation of the action;
excessive or reckless expenditure;
contributions in kind provided by third-parties;
costs declared under another EU or Euratom grant, in particular,
indirect costs if beneficiary is already receiving an operating grant
financed by EU or Euratom in the same period.
[they are claimed according to the EUR conversion rate as defined in the Article
15.5 of the Agreement;
as declared in the Financial Statement(s) of the [Beneficiary] [Linked Affiliated Entity]
and only for the request of payment of the balance, the total amount of receipts for the
total period covered by this(those) Financial Statement(s) is equal to ([insert amount in
number] ([insert amount in words5]) ;
4
In EUR.
5
In EUR.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
accounting procedures used in the recording of eligible costs and receipts respect the
accounting rules of the State in which the beneficiary is established and permit the direct
reconciliation between the costs and receipts incurred for the implementation of the
project covered by the Agreement and the overall statement of accounts relating to the
beneficiary’s overall business activity6;
based on our audit, we can conclude that the financial management of the grant was
carried out in an acceptable manner and in compliance with the requirements of [grant
agreement reference: title, acronym, number]
our company [organisation – for competent public officers] is qualified to deliver this
audit certificate in full compliance with the Articles 15.3 and 15.4 of the agreement;
[Relevant information establishing this qualification is included with this audit
certificate;]7
The list of Findings, Exceptions and Further remarks, if any, is presented in the Report
annexed to this Certificate.
The Certificate on Financial Statement(s) and Report was prepared solely for the confidential
use of the [Beneficiary] [Linked Affiliated Entity] and the Agency, and only to be submitted
to the Agency in connection with the requirements set out in Articles 15.3 and 15.4 of the
Agreement. The Certificate and Report may not be used by the [Beneficiary] [Linked
Affiliated Entity] or by the Agency for any other purpose, nor may it be distributed to any
other parties. The Agency may only disclose these documents to authorised parties, in
particular to the European Anti-Fraud Office (OLAF) and the European Court of Auditors.
Both Certificate and Report relate only to the Financial Statement(s) submitted to the Agency
by the [Beneficiary] [Linked Affiliated Entity] for the Agreement. Therefore, they do not
extend to any other of the [Beneficiary’s] [Linked Affiliated Entity’s] Financial Statement(s).
There was no conflict of interest8 between the Auditor and the Beneficiary [and Linked
Affiliated Entity] in establishing these documents. As declared in the Financial Statement(s)
the total fee paid to the Auditor for providing the Report was EUR ______ (including
EUR______ of deductible VAT).
.
[legal name of the Auditor]
[name and function of an authorised representative]
6
Article 6.1.
7
If the auditor is not known internationally or for a competent public officer whose competence to provide an audit
certificate has not been attested to by its national authorities.
8
A conflict of interest arises when the Auditor's objectivity to establish the certificate is compromised in fact or in
appearance when the Auditor for instance:
- was involved in the preparation of the Financial Statements;
- stands to benefit directly should the certificate be accepted;
- has a close relationship with any person representing the beneficiary;
- is a director, trustee or partner of the beneficiary; or
- is in any other situation that compromises his or her independence or ability to establish the certificate impartially.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
[dd Month yyyy]
Signature of the Auditor
Report of Findings on costs declared under grant agreement signed under Health and
Consumer Programmes 2014-2020
Not applicable Findings
We examined the Financial Statement(s) stated above and considered the following Findings
not applicable:
Explanation (to be removed from the Report):
If a Finding was not applicable, it must be marked as ‘N.A.’ (‘Not applicable’) in the corresponding row on the
right-hand column of the table and means that the Finding did not have to be corroborated by the Auditor and
the related check(s) did not have to be carried out.
The reasons of the non-application of a certain Finding must be obvious i.e.
i) if no cost was declared under a certain category then the related Finding(s) and check(s) are not
applicable;
ii) if the condition set to apply certain check(s) are not met the related Finding(s) and those check(s)
are not applicable. For instance, for ‘beneficiaries with accounts established in a currency other
than euro’ the check and Finding related to ‘beneficiaries with accounts established in euro’ are not
applicable. Similarly, if no additional remuneration is paid, the related Finding(s) and check(s) for
additional remuneration are not applicable.
List here all Findings considered not applicable for the present engagement and explain
the reasons of the non-applicability.
….
Exceptions
The [Beneficiary] [Linked Affiliated Entity] provided the Auditor all the documentation and
accounting information needed by the Auditor to carry out the requested checks and evaluate
the Findings.
Explanation (to be removed from the Report):
- If the Auditor was not able to successfully complete a procedure requested,. The reason such as the
inability to reconcile key information or the unavailability of data that prevents the Auditor from
carrying out the audit must be indicated below.
- If the Auditor cannot corroborate a standard finding after having carried out the corresponding audit,
it must state, the reasons why the Finding was not fulfilled and its possible impact must be explained
here below.
List here any exceptions and add any information on the cause and possible
consequences of each exception, if known. If the exception is quantifiable, include the
corresponding amount.
….
Example (to be removed from the Report):
1. The Beneficiary was unable to substantiate the Finding number 1 on … because ….
2. Finding number 30 was not fulfilled because the methodology used by the Beneficiary to
calculate daily costs was different from the one accepted by the Agency. The differences were as
follows: …
3. After carrying out the agreed checks to confirm the Finding number 31, the Auditor found a
difference of _____________ EUR. The difference can be explained by …
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Further Remarks
In addition to reporting on the results of the specific procedures carried out, the Auditor
would like to make the following general remarks:
Example (to be removed from the Report):
1. Regarding Finding number 8 the conditions for additional remuneration were considered as
fulfilled because …
2. In order to be able to confirm the Finding number 15 we carried out the following additional
procedures: ….
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
ANNEX I to the Report on Findings: Agreed-upon checks to be performed and standard findings to be confirmed by the Auditor
The Agency reserves the right to i) provide the auditor with additional guidance regarding the checks to be followed or the facts to be ascertained
and the way in which to present them (this may include sample coverage and findings) or to ii) change the checks, by notifying the Beneficiary in
writing. The list of checks to be carried out by the auditor in order to confirm the standard findings is laid down in the table below.
If this certificate relates to a Linked Affiliated Entity, any reference here below to ‘the Beneficiary’ is to be considered as a reference to ‘the Linked Affiliated Entity’.
The ‘result’ column has three different options: ‘C’, ‘E’ and ‘N.A.’:
‘C’ stands for ‘confirmed’ and means that the auditor can confirm the ‘standard finding’ and, therefore, there is no exception to be
reported.
‘E’ stands for ‘exception’ and means that the Auditor carried out the checks but cannot confirm the ‘standard finding’, or that the Auditor
was not able to carry out a specific check (e.g. because it was impossible to reconcile key information or data were unavailable),
‘N.A.’ stands for ‘not applicable’ and means that the Finding did not have to be examined by the Auditor and the related check(s) did not
have to be carried out. The reasons of the non-application of a certain Finding must be obvious i.e. i) if no cost was declared under a
certain category then the related Finding(s) and check(s) are not applicable; ii) if the condition set to apply certain checks(s) are not met
then the related Finding(s) and checks(s) are not applicable. For instance, if no additional remuneration is paid, the related Finding(s) and
check(s) for additional remuneration are not applicable.
Result
Ref Checks Standard finding (C / E
/N.A)
ACTUAL PERSONNEL COSTS CALCULATED BY THE BENEFICIARY IN ACCORDANCE WITH ITS USUAL COST
A
ACCOUNTING PRACTICE
The Auditor draws the full list of persons (including employees and natural persons
working under a direct contract ) whose costs were declared in the Financial
Statement(s) in order to carry out the checks indicated in the consecutive points of this
section A.
(The Auditor sampled ______ people out of the total of ______ people.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
A.1 PERSONNEL COSTS 1) The employees were i)
For the persons declared by the beneficiary or Linked Affiliated Entity in the Financial directly hired by the
Statement, and working under an employment contract or equivalent act (general Beneficiary in accordance
procedures for individual actual personnel costs) with its national legislation,
ii) under the Beneficiary’s
To confirm standard findings 1-5 listed in the next column, the Auditor reviewed
sole technical supervision and
following information/documents provided by the Beneficiary:
responsibility and iii)
o a list of the persons declared by Beneficiary or Linked Affiliated Entity indicating remunerated in accordance
the period(s) during which they worked for the action, their position with the Beneficiary’s usual
(classification or category) and type of contract; practices.
o the payslips of the employees;
o reconciliation of the personnel costs declared in the Financial Statement(s) with 2) Personnel costs were recorded
the accounting system (project accounting and general ledger) and payroll system; in the Beneficiary's
o information concerning the employment status and employment conditions of the accounts/payroll system.
declared personnel, in particular their employment contracts or equivalent;
3) Costs were adequately
o the Beneficiary’s usual policy regarding payroll matters (e.g. salary policy,
supported and reconciled with
overtime policy, variable pay);
the accounts and payroll
o applicable national law on taxes, labour and social security and
records.
o any other document that supports the personnel costs declared.
4) Personnel costs did not
contain any ineligible
elements.
5) There were no discrepancies
between the personnel costs
charged to the action and the
costs recalculated by the
Auditor.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
Further procedures if ‘additional remuneration’ is paid 6) The Beneficiary paying
To confirm standard factual findings 6-8 listed in the next column, the Auditor: “additional remuneration”
was a non-profit legal entity.
o reviewed relevant documents provided by the Beneficiary (legal form,
legal/statutory obligations, the Beneficiary’s usual policy on additional
7) The amount of additional
remuneration, criteria used for its calculation…);
remuneration paid
o recalculated the amount of additional remuneration eligible for the action based corresponded to the
on the supporting documents received (full-time or part-time work, exclusive or Beneficiary’s usual
non-exclusive dedication to the action, etc.). remuneration practices and
was consistently paid
whenever the same kind of
IF ANY PART OF THE REMUNERATION PAID TO THE EMPLOYEE IS NOT MANDATORY ACCORDING work or expertise was
TO THE NATIONAL LAW OR THE EMPLOYMENT CONTRACT ("ADDITIONAL REMUNERATION") AND required.
IS ELIGIBLE UNDER THE PROVISIONS OF ARTICLE 6.2.A., THIS CAN BE CHARGED AS ELIGIBLE
COST TO THE ACTION. 8) The criteria used to calculate
the additional remuneration
were objective and generally
applied by the Beneficiary
regardless of the source of
funding used.
For natural persons included in the sample and working with the Beneficiary under a 9) The natural persons reported
direct contract other than an employment contract, such as consultants (no to the Beneficiary (worked under
the Beneficiary’s instructions).
subcontractors).
To confirm standard factual findings 9-13 listed in the next column the Auditor reviewed 10) They worked on the
following information/documents provided by the Beneficiary: Beneficiary’s premises (unless
otherwise agreed with the
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
o the contracts, especially the cost, contract duration, work description, place of Beneficiary).
work, ownership of the results and reporting obligations to the Beneficiary;
o the employment conditions of staff in the same category to compare costs and;
o any other document that supports the costs declared and its registration (e.g. 11) The results of work carried
invoices, accounting records, etc.). out belong to the Beneficiary.
12) Their costs were not
significantly different from those
for staff who performed similar
tasks under an employment
contract with the Beneficiary.
13) The costs were supported by
audit evidence and registered in
the accounts.
A.2 PRODUCTIVE HOURS 14) The Beneficiary applied
method [choose one option and
To confirm standard factual findings 14-19 listed in the next column, the Auditor delete the others]
reviewed relevant documents, especially national legislation, labour agreements and
[A: 1720 hours]
contracts and time records of the persons included in the sample, to verify that:
[B: the ‘total number of
o the annual productive hours applied were calculated in accordance with one of the
hours worked’]
methods described below,
[C: ‘annual productive
o the full-time equivalent (FTEs) ratios for employees not working full-time were
hours’ used correspond to
correctly calculated.
usual accounting practices]
If the Beneficiary applied method B, the auditor verified that the correctness in which the 15) Productive hours were
total number of hours worked was calculated and that the contracts specified the annual calculated annually.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
workable hours. 16) For employees not working
full-time the full-time equivalent
If the Beneficiary applied method C, the auditor verified that the ‘annual productive (FTE) ratio was correctly
hours’ applied when calculating the hourly rate were equivalent to at least 90 % of the applied.
‘standard annual workable hours’. The Auditor can only do this if the calculation of the
standard annual workable hours can be supported by records, such as national legislation, If the Beneficiary applied
labour agreements, and contracts. method B.
17) The calculation of the
BENEFICIARY'S PRODUCTIVE HOURS' FOR PERSONS WORKING FULL TIME SHALL BE ONE OF THE number of ‘annual workable
FOLLOWING METHODS: hours’, overtime and absences
A. 1720 ANNUAL PRODUCTIVE HOURS (PRO-RATA FOR PERSONS NOT WORKING FULL-TIME) was verifiable based on the
documents provided by the
B. THE TOTAL NUMBER OF HOURS WORKED BY THE PERSON FOR THE BENEFICIARY IN THE YEAR Beneficiary.
(THIS METHOD IS ALSO REFERRED TO AS ‘TOTAL NUMBER OF HOURS WORKED’ IN THE NEXT
COLUMN). THE CALCULATION OF THE TOTAL NUMBER OF HOURS WORKED WAS DONE AS If the Beneficiary applied
FOLLOWS: ANNUAL WORKABLE HOURS OF THE PERSON ACCORDING TO THE EMPLOYMENT method C.
CONTRACT, APPLICABLE LABOUR AGREEMENT OR NATIONAL LAW PLUS OVERTIME WORKED 18) The calculation of the
MINUS ABSENCES (SUCH AS SICK LEAVE OR SPECIAL LEAVE). number of ‘standard annual
C. THE STANDARD NUMBER OF ANNUAL HOURS GENERALLY APPLIED BY THE BENEFICIARY FOR workable hours’ was verifiable
ITS PERSONNEL IN ACCORDANCE WITH ITS USUAL COST ACCOUNTING PRACTICES (THIS based on the documents
METHOD IS ALSO REFERRED TO AS ‘TOTAL ANNUAL PRODUCTIVE HOURS’ IN THE NEXT provided by the Beneficiary.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
COLUMN). THIS NUMBER MUST BE AT LEAST 90% OF THE STANDARD ANNUAL WORKABLE
19) The ‘annual productive
HOURS.
hours’ used for calculating the
hourly rate were consistent with
‘ANNUAL WORKABLE HOURS’ MEANS THE PERIOD DURING WHICH THE PERSONNEL MUST BE the usual cost accounting
WORKING, AT THE EMPLOYER’S DISPOSAL AND CARRYING OUT HIS/HER ACTIVITY OR DUTIES
practices of the Beneficiary and
UNDER THE EMPLOYMENT CONTRACT, APPLICABLE COLLECTIVE LABOUR AGREEMENT OR
were equivalent to at least 90 %
NATIONAL WORKING TIME LEGISLATION.
of the ‘annual workable hours’.
A.3 TIME RECORDING SYSTEM 20) All persons recorded their
To verify that the time recording system ensures the fulfilment of all minimum time dedicated to the action on a
requirements and that the hours declared for the action were correct, accurate and daily/ weekly/ monthly basis
properly authorised and supported by documentation, the Auditor made the following using a paper/computer-based
checks for the persons included in the sample that declare time as worked for the action system. (delete the answers that
on the basis of time records: are not applicable)
o description of the time recording system provided by the Beneficiary (registration,
21) Their time-records were
authorisation, processing in the HR-system);
authorised at least monthly by
o its actual implementation; the project manager or other
o time records were signed at least monthly by the employees (on paper or superior.
electronically) and authorised by the project manager or another manager;
22) Hours declared were worked
o the hours declared were worked within the project period; within the project period and
o there were no hours declared as worked for the action if HR-records showed were consistent with the
absence due to holidays or sickness (further cross-checks with travels are carried presences/absences recorded in
out in B.1 below) ; HR-records.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
o the hours charged to the action matched those in the time recording system.
23) There were no discrepancies
between the number of hours
ONLY THE HOURS WORKED ON THE ACTION CAN BE CHARGED. ALL WORKING TIME TO BE
charged to the action and the
CHARGED SHOULD BE RECORDED THROUGHOUT THE DURATION OF THE PROJECT, ADEQUATELY
number of hours recorded.
SUPPORTED BY EVIDENCE OF THEIR REALITY AND RELIABILITY (SEE SPECIFIC PROVISIONS
BELOW FOR PERSONS WORKING EXCLUSIVELY FOR THE ACTION WITHOUT TIME RECORDS).
If the persons are working exclusively for the action and without time records
For the persons selected that worked exclusively for the action without time records, the 24) The exclusive dedication is
Auditor verified evidence available demonstrating that they were in reality exclusively supported by a declaration
dedicated to the action and that the Beneficiary signed a declaration confirming that they signed by the Beneficiary’s and
have worked exclusively for the action. by any other evidence gathered.
B COSTS OF SUBCONTRACTING
B.1 The Auditor obtained the detail/breakdown of subcontracting costs and sampled 25) The use of claimed
______ cost items selected randomly (full coverage is required if there are fewer than subcontracting costs was
10 items, otherwise the sample should have a minimum of 10 item, or 10% of the total, foreseen in Annex 1 to the
whichever number is highest). Agreement and costs were
To confirm standard factual findings 25-29 listed in the next column, the Auditor declared in the Financial
Statements under the
reviewed the following for the items included in the sample:
subcontracting category.
o the use of subcontractors was foreseen in Annex 1of grant agreement;
26) There were documents of
o subcontracting costs were declared in the subcontracting category of the Financial requests to different providers,
Statement; different offers and assessment
of the offers before selection of
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
o supporting documents on the selection and award procedure were followed; the provider in line with internal
procedures and procurement
o the Beneficiary ensured best value for money (key elements to appreciate the
rules. Subcontracts were
respect of this principle are the award of the subcontract to the bid offering best
awarded in accordance with the
price-quality ratio, under conditions of transparency and equal treatment. In case
principle of best value for
an existing framework contract was used the Beneficiary ensured it was
money.
established on the basis of the principle of best value for money under conditions
of transparency and equal treatment). (When different offers were
not collected the Auditor
In particular,
explains the reasons
i. if the Beneficiary acted as a contracting authority within the meaning of Directive provided by the Beneficiary
2004/18/EC or of Directive 2004/17/EC, the Auditor verified that the applicable under the caption
national law on public procurement was followed and that the subcontracting “Exceptions” of the Report.
complied with the Terms and Conditions of the Agreement. The Agency will analyse this
ii. if the Beneficiary did not fall under the above-mentioned category the Auditor information to evaluate
verified that the Beneficiary followed their usual procurement rules and respected whether these costs might be
the Terms and Conditions of the Agreement.. accepted as eligible)
For the items included in the sample the Auditor also verified that: 27) The subcontracts were not
awarded to other Beneficiaries
o the subcontracts were not awarded to other Beneficiaries in the consortium; of the consortium.
o there were signed agreements between the Beneficiary and the subcontractor;
28) All subcontracts were
o there was evidence that the services were provided by subcontractor; supported by signed agreements
between the Beneficiary and the
subcontractor.
29) There was evidence that the
services were provided by the
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
subcontractors.
C OTHER ACTUAL DIRECT COSTS
C.1 COSTS OF TRAVEL AND RELATED SUBSISTENCE ALLOWANCES 30) Costs were incurred,
The Auditor sampled ______ cost items selected randomly (full coverage is required approved and reimbursed in line
if there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, with the Beneficiary's usual
policy for travels.
or 10% of the total, whichever number is the highest).
The Auditor inspected the sample and verified that: 31) There was a link between the
o travel and subsistence costs were consistent with the Beneficiary's usual policy for trip and the action.
travel. In this context, the Beneficiary provided evidence of its normal policy for
32) The supporting documents
travel costs (e.g. use of first class tickets, reimbursement by the Beneficiary on the
were consistent with each other
basis of actual costs, a lump sum or per diem) to enable the Auditor to compare
regarding subject of the trip,
the travel costs charged with this policy;
dates, duration and reconciled
o travel costs are correctly identified and allocated to the action (e.g. trips are with time records and
directly linked to the action) by reviewing relevant supporting documents such as accounting.
minutes of meetings, workshops or conferences, their registration in the correct
project account, their consistency with time records or with the dates/duration of 33) No ineligible costs or
the workshop/conference; excessive or reckless
expenditure was declared.
o no ineligible costs or excessive or reckless expenditure was declared.
C.2 DEPRECIATION COSTS FOR EQUIPMENT, INFRASTRUCTURE OR OTHER 34) Procurement rules,
ASSETS principles and guides were
The Auditor sampled ______ cost items selected randomly (full coverage is required followed.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
if there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, 35) There was a link between the
or 10% of the total, whichever number is the highest). grant agreement and the asset
charged to the action.
For “equipment, infrastructure or other assets” selected in the sample the Auditor verified
that: 36) The asset charged to the
o the assets were acquired in conformity with the Beneficiary's internal guidelines action was traceable to the
and procedures; accounting records and the
underlying documents.
o they were correctly allocated to the action (with supporting documents such as
delivery note invoice or any other proof demonstrating the link to the action) 37) The depreciation method
used to charge the asset to the
o they were entered in the accounting system; action was in line with the
o the extent to which the assets were used for the action (as a percentage) was applicable rules of the
supported by reliable documentation (e.g. usage overview table); Beneficiary's country and the
Beneficiary's usual accounting
The Auditor recalculated the depreciation costs and verified that they were in line with policy.
the applicable rules in the Beneficiary’s country and with the Beneficiary’s usual 38) The amount charged
accounting policy (e.g. depreciation calculated on the acquisition value). corresponded to the actual usage
The Auditor verified that no ineligible costs such as deductible VAT, exchange rate for the action.
losses, excessive or reckless expenditure were declared (see Article 6.4 GA). 39) No ineligible costs or
excessive or reckless
expenditure were declared.
C.3 COSTS OF OTHER GOODS AND SERVICES 43) Contracts for works or
The Auditor sampled ______ cost items selected randomly (full coverage is required services did not cover tasks
if there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, described in Annex 1to the
Grant Agreement.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
or 10% of the total, whichever number is highest). 44) Costs were allocated to the
For the purchase of goods, works or services included in the sample the Auditor verified correct action and the goods
were not placed in the inventory
that:
of durable equipment.
o the contracts did not cover tasks described in Annex 1;
45) The costs were charged in
o they were correctly identified, allocated to the proper action, entered in the line with the Beneficiary’s
accounting system (traceable to underlying documents such as purchase orders, accounting policy and were
invoices and accounting); adequately supported.
o the goods were not placed in the inventory of durable equipment; 46) No ineligible costs or
o the costs charged to the action were accounted in line with the Beneficiary’s usual excessive or reckless
accounting practices; expenditure were declared. For
internal invoices/charges only
o no ineligible costs or excessive or reckless expenditure were declared (see Article the cost element was charged,
6.4 GA). without any mark-ups.
In addition, the Auditor verified that these goods and services were acquired in
conformity with the Beneficiary's internal guidelines and procedures, in particular: 47) Procurement rules,
principles and guides were
o if Beneficiary acted as a contracting authority within the meaning of Directive followed. There were documents
2004/18/EC or of Directive 2004/17/EC, the Auditor verified that the applicable of requests to different
national law on public procurement was followed and that the procurement providers, different offers and
contract complied with the Terms and Conditions of the Agreement. assessment of the offers before
o if the Beneficiary did not fall into the category above, the Auditor verified that the selection of the provider in line
Beneficiary followed their usual procurement rules and respected the Terms and with internal procedures and
Conditions of the Agreement. procurement rules. The
purchases were made in
For the items included in the sample the Auditor also verified that:
accordance with the principle of
o the Beneficiary ensured best value for money (key elements to appreciate the best value for money.
respect of this principle are the award of the contract to the bid offering best
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
price-quality ratio, under conditions of transparency and equal treatment. In case (When different offers were
an existing framework contract was used the Auditor also verified that the not collected the Auditor
Beneficiary ensured it was established on the basis of the principle of best value explains the reasons
for money under conditions of transparency and equal treatment); provided by the Beneficiary
under the caption
SUCH GOODS AND SERVICES INCLUDE, FOR INSTANCE, CONSUMABLES AND SUPPLIES,
“Exceptions” of the Report.
DISSEMINATION (INCLUDING OPEN ACCESS), PROTECTION OF RESULTS, SPECIFIC EVALUATION
The Agency will analyse this
OF THE ACTION IF IT IS REQUIRED BY THE AGREEMENT, CERTIFICATES ON THE FINANCIAL
information to evaluate
STATEMENTS IF THEY ARE REQUIRED BY THE AGREEMENT AND CERTIFICATES ON THE
whether these costs might be
METHODOLOGY, TRANSLATIONS, REPRODUCTION.
accepted as eligible)
D USE OF EXCHANGE RATES
D.1 a) For Beneficiaries with accounts established in a currency other than euros
The Auditor sampled ______ cost items selected randomly and verified that the
exchange rates used for converting other currencies into euros were in accordance
with the following rules established in the Agreement ( full coverage is required if
there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, 48) The exchange rates used to
or 10% of the total, whichever number is highest): convert other currencies into
Euros were in accordance with
COSTS INCURRED IN ANOTHER CURRENCY SHALL BE CONVERTED INTO EURO AT THE AVERAGE the rules established of the Grant
OF THE DAILY EXCHANGE RATES PUBLISHED IN THE C SERIES OF OFFICIAL JOURNAL OF THE Agreement and there was no
EUROPEAN UNION (https://www.ecb.int/stats/exchange/eurofxref/html/index.en.html ), difference in the final figures.
DETERMINED OVER THE CORRESPONDING REPORTING PERIOD.
IF NO DAILY EURO EXCHANGE RATE IS PUBLISHED IN THE OFFICIAL JOURNAL OF THE
EUROPEAN UNION FOR THE CURRENCY IN QUESTION, CONVERSION SHALL BE MADE AT THE
AVERAGE OF THE MONTHLY ACCOUNTING RATES ESTABLISHED BY THE COMMISSION AND
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)6172119 - 15/12/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
PUBLISHED ON ITS WEBSITE
(http://ec.europa.eu/budget/contracts_grants/info_contracts/inforeuro/inforeuro_en.cfm
), DETERMINED OVER THE CORRESPONDING REPORTING PERIOD.
b) For Beneficiaries with accounts established in euros
The Auditor sampled ______ cost items selected randomly and verified that the
exchange rates used for converting other currencies into euros were in accordance
with the following rules established in the Agreement ( full coverage is required if 49) The Beneficiary applied
there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, its usual accounting
or 10% of the total, whichever number is highest): practices.
COSTS INCURRED IN ANOTHER CURRENCY SHALL BE CONVERTED INTO EURO BY APPLYING THE
BENEFICIARY’S USUAL ACCOUNTING PRACTICES.
[legal name of the audit firm]
[name and function of an authorised representative]
[dd Month yyyy]
<Signature of the Auditor
Digitally sealed by the European Commission
Date: 2017.12.15 17:00:21 CET
This document is digitally sealed. The digital sealing mechanism uniquely binds the
document to the modules of the Participant Portal of the European Commission, to the
transaction for which it was generated and ensures its integrity and authenticity.
Any attempt to modify the content will lead to a breach of the electronic seal, which can
be verified at any time by clicking on the digital seal validation symbol.
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Director
GRANT AGREEMENT
NUMBER — 761296 — EU-JAMRAI
This Agreement (‘the Agreement’) is between the following parties:
on the one part,
the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under
the powers delegated by the European Commission ('the Commission'),
represented for the purposes of signature of this Agreement by Veronique WASBAUER, Director,
or his duly authorised representative,
and
on the other part,
1. ‘the coordinator’:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
180036048, established in RUE DE TOLBIAC 101, PARIS 75654, France, FR31180036048
represented for the purposes of signing the Agreement by Regional representative, Armelle BARELLI
and the following other beneficiaries, if they sign their ‘Accession Form’ (see Annex 3 and Article 40):
2. MINISTERE DES AFFAIRES SOCIALES ET DE LA SANTE (MoH-FR), N/A, established
in AVENUE DUQUESNE 14, PARIS CEDEX 75350, France, N/A
3. GESUNDHEIT ÖSTERREICH GMBH (GÖG) GMBH, FN281909Y, established in
STUBENRING 6, WIEN 1010, Austria, ATU62777178
4. SERVICE PUBLIC FEDERAL SANTE PUBLIQUE, SECURITE DE LA CHAINE
ALIMENTAIRE ET ENVIRONNEMENT (FPS HFCSE), N/A, established in SQUARE VICTOR
HORTA 40 BUR 1D 1G, BRUSSELS 1060, Belgium, N/A
5. NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES (NCIPD ),
000662721, established in blvd. Yanko Sakazov 26, SOFIA 1504, Bulgaria
6. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), 080407487, established in
ROCKEFELLEROVA 7, ZAGREB 10000, Croatia, HR75297532041
7. STATNI ZDRAVOTNI USTAV (NIPH), 75010330, established in Srobarova 48, PRAHA 10
10042, Czech Republic
1
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
8. STATENS SERUM INSTITUT (SSI), 46837428, established in ARTILLERIVEJ 5,
KOBENHAVN S 2300, Denmark, DK46837428
9. TERVISEAMET (TA), 70008799, established in PALDISKI MNT 81, TALLINN 10617, Estonia,
EE101339803
10. ROBERT KOCH-INSTITUT (RKI), n/a, established in Nordufer 20, Berlin 13353, Germany
11. KENTRO ELENCHOU & PROLIPSIS NOSIMATON (HCDCP) GR8, 2071, established in
AGRAFON STREET 3-5, MAROUSI 15123, Greece, EL090193594
12. ETHNIKI SCHOLI DIMOSIAS YGEIAS (ESDY-NSPH), 2194, established in 196
ALEXANDRAS AVENUE, ATHINA 11521, Greece, EL099017070
13. DIOIKHSH YGEIONOMIKHS PERIFEREIAS KRHTHS (7HC), ., established in 3RD KM
NATIONAL ROAD HERAKLION MOIRES, HERAKLION 71500, Greece, EL999161778
14. UNIVERSITA DEGLI STUDI DI FOGGIA (UNIFG), CF94045260711, established in VIA
GRAMSCI 89/91, FOGGIA 71122, Italy, IT03016180717
15. ISTITUTO SUPERIORE DI SANITA (ISS), 80211730587, established in Viale Regina Elena
299, ROMA 00161, Italy
16. PAULA STRADINA KLINISKA UNIVERSITATES SLIMNICA (PSKUS) SIA,
40003457109, established in PILSONU IELA 13, RIGA 1002, Latvia, LV40003457109
17. LIETUVOS SVEIKATOS MOKSLU UNIVERSITETO LIGONINE KAUNO KLINIKOS
(LSMULKK) LT3, 135163499, established in EIVENIU 2, KAUNAS 50009, Lithuania,
LT351634917
18. VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS
(VULSK) LT3, 124364561, established in SANTARISKIU G 2, VILNIUS 08661, Lithuania,
LT243645610
19. HIGIENOS INSTITUTAS (HI), 111958286, established in DIDZIOJI STREET 22, VILNIUS
LT-01128, Lithuania
20. NACIONALINIS VISUOMENES SVEIKATOS CENTRAS PRIE SVEIKATOS
APSAUGOS MINISTERIJOS (NVSC), 291349070, established in KALVARIJU 153, VILNIUS
LT-08221, Lithuania
21. MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT (VWS), N/A,
established in PARNASSUSPLEIN 5, DEN HAAG 2500 EJ, Netherlands
22. HELSEDIREKTORATE (HdiR), 983544622, established in UNIVERSITETSGATA 2, OSLO
0164, Norway
23. FOLKEHELSEINSTITUTTET (FHI), 983744516, established in LOVISENBERGGATA 8,
OSLO 0456, Norway, NO983744516MVA
24. VETERINAERINSTITUTTET - NORWEGIAN VETERINARY INSTITUTE (NVI),
970955623, established in ULLEVALSVEIEN 68, OSLO 0454, Norway
25. NARODOWY INSTYTUT LEKOW (NMI), 015244176, established in ULICA CHELMSKA
30/34, WARSZAWA 00 725, Poland, PL5213212384
2
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
26. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (DGS), Decreto-Lei n.º 212/2006,
de 27 de Outubro , established in Av. João Crisóstomo, 9, LISBOA 1049-062 , Portugal
27. UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA
(UMPIH), 263327, established in Emil Isac Street 13, Cluj-Napoca 400023, Romania, RO4288047
28. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) SI2, 6462642000, established in
TRUBARJEVA CESTA 2, LJUBLJANA 1000, Slovenia, SI44724535
29. AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS (AEMPS),
established in c/ Campezo Edificio 8 1, MADRID 28022, Spain, ESQ2827023I
30. DEPARTAMENT DE SALUT - GENERALITAT DE CATALUNYA (GENCAT), established
in Trav. de les Corts (Pavelló Ave Maria) 131-159, BARCELONA 08028, Spain
31. CONSELLERIA DE SALUD (IdISBa) ES8, established in PLAZA DE ESPANA 9, PALMA
DE MALLORCA 07002, Spain, ESS0711001H
32. FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA
REGION DE MURCIA (FFIS) ES3, 92, established in CALLE LUIS FONTES PAGAN 9 EDIF
EMI HOSPITAL REINA SOFIA, MURCIA 30003, Spain, ESG73338857
33. FUNDACION PUBLICA MIGUEL SERVET (FMS) ES3, 406, established in
CALLE IRUNLARREA 3 CENTRO INVESTIGACION BIOMEDICA RECINTO COMPLEJO
HOSPITALARIO DE NAVARRA, PAMPLONA 31008, Spain, ESG31187420
34. SERVICIO ANDALUZ DE SALUD (SAS), not applicable, established in AVENIDA DE LA
CONSTITUCION 18, SEVILLA 41071, Spain, ESQ9150013B
35. INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, ESQ2827015E
36. SERVICIO MADRILENO DE SALUD (SERMAS), 142005, established in PLAZA CARLOS
TRIAS BERTRAN 7, MADRID 28020, Spain, ESQ2801221I
37. FOLKHALSOMYNDIGHETEN (FoHM), 2021006545, established in NOBELS VAG 18,
SOLNA 171 82, Sweden, SE202100654501
38. SOCIALSTYRELSEN (SoS), 2021000555, established in RALAMBSVAGEN 3,
STOCKHOLM 106 30, Sweden, SE202100055501
39. STATENS JORDBRUKSVERK (SBA), 2021004151, established in JONKOPING,
JONKOPING 551 82, Sweden, SE202100415101
40. LIVSMEDELS VERKET (NFA), 202100-1850 , established in Hamnesplanaden 5, UPPSALA
751 26, Sweden
41. STATENS VETERINAERMEDICINSKA ANSTALT (SVA), 2021001868, established in Ulls
Vaeg 2B, UPPSALA 75189, Sweden
42. VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL (SRC), 2021005208,
established in VASTRA JARNVAGSGATAN 3, STOCKHOLM 111 64, Sweden
43. UPPSALA LANS LANDSTING (UAS), 2321000024, established in PO BOX 602, UPPSALA
751 25, Sweden, SE232100002401
3
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
44. AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L
ENVIRONNEMENT ET DU TRAVAIL (ANSES), 130012024, established in 14 RUE PIERRE
ET MARIE CURIE, MAISONS ALFORT 94700, France, FR54130012024
Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator.
The parties referred to above have agreed to enter into the Agreement under the terms and conditions
below.
By signing the Agreement or the Accession Form, the beneficiaries accept the grant and agree to
implement the action under their own responsibility and in accordance with the Agreement, with all
the obligations and conditions it sets out.
The Agreement is composed of:
Terms and Conditions
Annex 1 Description of the action
Annex 2 Estimated budget for the action
Annex 3 Accession Forms
Annex 4 Model for the financial statements
Annex 5 Model for the certificate on the financial statements (CFS)
4
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
TERMS AND CONDITIONS
TABLE OF CONTENTS
CHAPTER 1 GENERAL...............................................................................................................................................10
ARTICLE 1 — SUBJECT OF THE AGREEMENT.......................................................................................10
CHAPTER 2 ACTION.................................................................................................................................................. 10
ARTICLE 2 — ACTION TO BE IMPLEMENTED....................................................................................... 10
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION....................................................10
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS.......................................................10
4.1 Estimated budget................................................................................................................................... 10
4.2 Budget transfers.....................................................................................................................................10
CHAPTER 3 GRANT....................................................................................................................................................10
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND FORMS OF
COSTS......................................................................................................................................................... 10
5.1 Maximum grant amount........................................................................................................................ 10
5.2 Form of grant, reimbursement rates and forms of costs.......................................................................11
5.3 Final grant amount — Calculation........................................................................................................11
5.4 Revised final grant amount — Calculation.......................................................................................... 12
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS................................................................................ 13
6.1 General conditions for costs to be eligible........................................................................................... 13
6.2 Specific conditions for costs to be eligible...........................................................................................13
6.3 Conditions for costs of affiliated entities to be eligible........................................................................16
6.4 Ineligible costs.......................................................................................................................................17
6.5 Consequences of declaration of ineligible costs................................................................................... 17
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES......................................................................... 17
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION................. 17
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION.........................17
7.1 General obligation to properly implement the action........................................................................... 18
7.2 Consequences of non-compliance......................................................................................................... 18
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE
ACTION...................................................................................................................................................... 18
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES............................................................ 18
9.1 Rules for purchasing goods, works or services.................................................................................... 18
9.2 Consequences of non-compliance......................................................................................................... 19
5
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS............................19
10.1 Rules for subcontracting action tasks................................................................................................. 19
10.2 Consequences of non-compliance....................................................................................................... 19
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES....................... 20
11.1 Rules for calling upon affiliated entities to implement part of the action.......................................... 20
11.2 Consequences of non-compliance....................................................................................................... 20
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION............... 21
ARTICLE 12 — GENERAL OBLIGATION TO INFORM............................................................................21
12.1 General obligation to provide information upon request....................................................................21
12.2 Obligation to keep information up to date and to inform about events and circumstances likely to
affect the Agreement..............................................................................................................................21
12.3 Consequences of non-compliance....................................................................................................... 21
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION........................................ 21
13.1 Obligation to keep records and other supporting documentation....................................................... 21
13.2 Consequences of non-compliance....................................................................................................... 23
ARTICLE 14 — SUBMISSION OF DELIVERABLES................................................................................. 23
14.1 Obligation to submit deliverables....................................................................................................... 23
14.2 Consequences of non-compliance....................................................................................................... 23
ARTICLE 15 — REPORTING — PAYMENT REQUESTS.......................................................................... 23
15.1 Obligation to submit reports............................................................................................................... 23
15.2 Reporting periods................................................................................................................................ 23
15.3 Periodic reports — Requests for interim payments............................................................................23
15.4 Final report — Request for payment of the balance.......................................................................... 25
15.5 Currency for financial statements and conversion into euro.............................................................. 25
15.6 Language of reports.............................................................................................................................26
15.7 Consequences of non-compliance — Suspension of the payment deadline — Termination.............. 26
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS.......................................................... 26
16.1 Payments to be made.......................................................................................................................... 26
16.2 Pre-financing payment — Amount..................................................................................................... 26
16.3 Interim payments — Amount — Calculation.....................................................................................26
16.4 Payment of the balance — Amount — Calculation........................................................................... 27
16.5 Notification of amounts due................................................................................................................28
16.6 Currency for payments........................................................................................................................ 28
16.7 Payments to the coordinator — Distribution to the beneficiaries.......................................................28
16.8 Bank account for payments.................................................................................................................28
6
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
16.9 Costs of payment transfers..................................................................................................................28
16.10 Date of payment................................................................................................................................ 29
16.11 Consequences of non-compliance..................................................................................................... 29
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF
FINDINGS................................................................................................................................................... 29
17.1 Checks, reviews and audits by the Agency and the Commission...................................................... 29
17.2 Investigations by the European Anti-Fraud Office (OLAF)...............................................................31
17.3 Checks and audits by the European Court of Auditors (ECA)...........................................................32
17.5 Consequences of findings in checks, reviews, audits and investigations —Extension of
findings...................................................................................................................................................32
17.6 Consequences of non-compliance....................................................................................................... 33
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION........................................................34
18.1 Right to evaluate the impact of the action..........................................................................................34
18.2 Consequences of non-compliance....................................................................................................... 34
SECTION 3 OTHER RIGHTS AND OBLIGATIONS........................................................................................34
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS (INCLUDING
INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS)...............................................................34
19.1 Pre-existing rights and access rights to pre-existing rights................................................................ 34
19.2 Ownership of results and rights of use............................................................................................... 34
19.3 Consequences of non-compliance....................................................................................................... 34
ARTICLE 20 — CONFLICT OF INTERESTS...............................................................................................35
20.1 Obligation to avoid a conflict of interests.......................................................................................... 35
20.2 Consequences of non-compliance....................................................................................................... 35
ARTICLE 21 — CONFIDENTIALITY...........................................................................................................35
21.1 General obligation to maintain confidentiality................................................................................... 35
21.2 Consequences of non-compliance....................................................................................................... 35
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING....................................35
22.1 Communication activities by the beneficiaries................................................................................... 36
22.2 Communication activities by the Agency........................................................................................... 36
22.3 Consequences of non-compliance....................................................................................................... 37
ARTICLE 23 — PROCESSING OF PERSONAL DATA.............................................................................. 37
23.1 Processing of personal data by the Agency and the Commission...................................................... 38
23.2 Processing of personal data by the beneficiaries................................................................................ 38
23.3 Consequences of non-compliance....................................................................................................... 38
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY................... 38
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES........................................ 39
7
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES............................39
25.1 Roles and responsibilities towards the Agency.................................................................................. 39
25.2 Internal division of roles and responsibilities..................................................................................... 39
25.3 Internal arrangements between beneficiaries — Consortium agreement............................................40
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — PENALTIES
— DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE................................................. 40
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY —
PENALTIES...........................................................................................................................................................40
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS.............................................................................. 40
26.1 Conditions............................................................................................................................................ 40
26.2 Ineligible costs to be rejected — Calculation — Procedure...............................................................41
26.3 Effects.................................................................................................................................................. 41
ARTICLE 27 — REDUCTION OF THE GRANT......................................................................................... 41
27.1 Conditions............................................................................................................................................ 41
27.2 Amount to be reduced — Calculation — Procedure..........................................................................41
27.3 Effects.................................................................................................................................................. 42
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS............................................................................... 42
28.1 Amount to be recovered — Calculation — Procedure.......................................................................42
ARTICLE 29 — ADMINISTRATIVE AND FINANCIAL PENALTIES.......................................................44
29.1 Conditions............................................................................................................................................ 44
29.2 Duration — Amount of penalty — Calculation................................................................................. 45
29.3 Procedure............................................................................................................................................. 45
SECTION 2 LIABILITY FOR DAMAGES..........................................................................................................46
ARTICLE 30 — LIABILITY FOR DAMAGES............................................................................................. 46
30.1 Liability of the Agency....................................................................................................................... 46
30.2 Liability of the beneficiaries............................................................................................................... 46
SECTION 3 SUSPENSION AND TERMINATION.............................................................................................47
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE....................................................................... 47
31.1 Conditions............................................................................................................................................ 47
31.2 Procedure............................................................................................................................................. 47
ARTICLE 32 — SUSPENSION OF PAYMENTS..........................................................................................47
32.1 Conditions............................................................................................................................................ 48
32.2 Procedure............................................................................................................................................. 48
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION................................................... 48
33.1 Suspension of the action implementation, by the beneficiaries..........................................................48
8
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
33.2 Suspension of the action implementation, by the Agency..................................................................49
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR
MORE BENEFICIARIES........................................................................................................................... 50
34.1 Termination of the Agreement, by the beneficiaries...........................................................................50
34.2 Termination of the participation of one or more beneficiaries, by the beneficiaries...........................51
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency................................................................................................................................................... 52
SECTION 4 FORCE MAJEURE........................................................................................................................... 54
ARTICLE 35 — FORCE MAJEURE.............................................................................................................. 54
CHAPTER 7 FINAL PROVISIONS............................................................................................................................55
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES...............................................................55
36.1 Form and means of communication....................................................................................................55
36.2 Date of communication....................................................................................................................... 56
36.3 Addresses for communication............................................................................................................. 56
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT.................................................................... 56
37.1 Precedence of the Terms and Conditions over the Annexes...............................................................56
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES........................................... 56
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT......................................................................... 57
39.1 Conditions............................................................................................................................................ 57
39.2 Procedure............................................................................................................................................. 57
ARTICLE 40 — ACCESSION TO THE AGREEMENT............................................................................... 57
40.1 Accession of the beneficiaries mentioned in the Preamble................................................................ 58
40.2 Addition of new beneficiaries............................................................................................................. 58
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES.............................................. 58
41.1 Applicable law.....................................................................................................................................58
41.2 Dispute settlement............................................................................................................................... 58
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT................................................................ 59
9
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAPTER 1 GENERAL
ARTICLE 1 — SUBJECT OF THE AGREEMENT
This Agreement sets out the rights and obligations and the terms and conditions applicable to the grant
awarded to the beneficiaries for implementing the action set out in Chapter 2.
CHAPTER 2 ACTION
ARTICLE 2 — ACTION TO BE IMPLEMENTED
The grant is awarded for the action entitled ‘European Joint Action on antimicrobial resistance and
associated infections — EU-JAMRAI ’ (‘action’), as described in Annex 1.
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION
The duration of the action will be 36 months as of 01/09/2017 (‘starting date of the action’).
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS
4.1 Estimated budget
The ‘estimated budget’ for the action is set out in Annex 2.
It contains the estimated eligible costs and the forms of costs, broken down by beneficiary (and
affiliated entity) and budget category (see Articles 5, 6).
4.2 Budget transfers
The estimated budget breakdown indicated in Annex 2 may be adjusted by transfers of amounts
between beneficiaries or between budget categories (or both). This does not require an amendment
according to Article 39, if the action is implemented as described in Annex 1.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1,
unless such additional subcontracts are approved by an amendment or in accordance with Article 10.
CHAPTER 3 GRANT
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND
FORMS OF COSTS
5.1 Maximum grant amount
The ‘maximum grant amount’ is EUR 4,178,162.75 (four million one hundred and seventy eight
thousand one hundred and sixty two EURO and seventy five eurocents).
10
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
5.2 Form of grant, reimbursement rates and forms of costs
The grant reimburses 60% of the action's eligible costs (see Article 6) (‘reimbursement of eligible
costs grant’) (see Annex 2).
The estimated eligible costs of the action are EUR 6,963,604.61 (six million nine hundred and sixty
three thousand six hundred and four EURO and sixty one eurocents).
Eligible costs (see Article 6) must be declared under the following forms ('forms of costs' or 'costs
forms'):
(a) for direct personnel costs: as actually incurred costs (actual costs);
(b) for direct costs of subcontracting: as actually incurred costs (actual costs);
(c) for other direct costs: as actually incurred costs (actual costs);
(d) for indirect costs: on the basis of a flat-rate applied as set out in Article 6.2.D (‘flat-rate costs’);
5.3 Final grant amount — Calculation
The ‘final grant amount’ depends on the actual extent to which the action is implemented in
accordance with the Agreement’s terms and conditions.
This amount is calculated by the Agency — when the payment of the balance is made — in the
following steps:
Step 1 – Application of the reimbursement rate to the eligible costs
Step 2 – Limit to the maximum grant amount
Step 3 – Reduction due to the no-profit rule
Step 4 – Reduction due to improper implementation or breach of other obligations
5.3.1 Step 1 — Application of the reimbursement rate to the eligible costs
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate
costs; see Article 6) declared by the beneficiaries and affiliated entities (see Article 15) and approved
by the Agency (see Article 16).
5.3.2 Step 2 — Limit to the maximum grant amount
If the amount obtained following Step 1 is higher than the maximum grant amount set out in Article
5.1, it will be limited to the latter.
5.3.3 Step 3 — Reduction due to the no-profit rule
The grant must not produce a profit.
‘Profit’ means the surplus of the amount obtained following Steps 1 and 2 plus the action’s total
receipts, over the action’s total eligible costs.
11
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The ‘action’s total eligible costs’ are the consolidated total eligible costs approved by the Agency.
The ‘action’s total receipts’ are the consolidated total receipts generated during its duration (see
Article 3).
The following are considered receipts:
(a) income generated by the action;
(b) financial contributions given by third parties to the beneficiary or to an affiliated entity
specifically to be used for costs that are eligible under the action.
The following are however not considered receipts:
(a) financial contributions by third parties, if they may be used to cover costs other than the eligible
costs (see Article 6);
(b) financial contributions by third parties with no obligation to repay any amount unused at the
end of the period set out in Article 3.
If there is a profit, it will be deducted in proportion to the final rate of reimbursement of the eligible
actual costs approved by the Agency (as compared to the amount calculated following Steps 1 and 2).
5.3.4 Step 4 — Reduction due to improper implementation or breach of other obligations —
Reduced grant amount — Calculation
If the grant is reduced (see Article 27), the Agency will calculate the reduced grant amount by
deducting the amount of the reduction (calculated in proportion to the improper implementation of
the action or to the seriousness of the breach of obligations in accordance with Article 27.2) from the
maximum grant amount set out in Article 5.1.
The final grant amount will be the lower of the following two:
- the amount obtained following Steps 1 to 3 or
- the reduced grant amount following Step 4.
5.4 Revised final grant amount — Calculation
If — after the payment of the balance (in particular, after checks, reviews, audits or investigations;
see Article 17) — the Agency rejects costs (see Article 26) or reduces the grant (see Article 27), it
will calculate the ‘revised final grant amount’ for the action.
This amount is calculated by the Agency on the basis of the findings, as follows:
- in case of rejection of costs: by applying the reimbursement rate to the revised eligible costs
approved by the Agency for the action, limiting it to the maximum grant amount and making
a reduction if there is a profit (see Article 5.3);
- in case of reduction of the grant: by deducting the amount of the reduction (calculated in
proportion to the improper implementation of the action or to the seriousness of the breach
of obligations in accordance with Article 27.2) from the maximum grant amount set out in
Article 5.1.
12
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
In case of rejection of costs and reduction of the grant, the revised final grant amount for the action
will be the lower of the two amounts above.
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS
6.1 General conditions for costs to be eligible
‘Eligible costs’ are costs that meet the following criteria:
(a) for actual costs:
(i) they must be actually incurred by the beneficiary;
(ii) they must be incurred in the period set out in Article 3, with the exception of costs relating
to the submission of the periodic report for the last reporting period and the final report
(see Article 15);
(iii) they must be indicated in the estimated budget set out in Annex 2;
(iv) they must be incurred in connection with the action as described in Annex 1 and necessary
for its implementation;
(v) they must be identifiable and verifiable, in particular recorded in the beneficiary’s
accounts in accordance with the accounting standards applicable in the country where the
beneficiary is established and with the beneficiary’s usual cost accounting practices;
(vi) they must comply with the applicable national law on taxes, labour and social security, and
(vii) they must be reasonable, justified and must comply with the principle of sound financial
management, in particular regarding economy and efficiency;
(b) for flat-rate costs:
(i) they must be calculated by applying the flat-rate set out in Annex 2, and
(ii) the costs (actual costs) to which the flat-rate is applied must comply with the conditions
for eligibility set out in this Article.
6.2 Specific conditions for costs to be eligible
Costs are eligible if they comply with the general conditions (see above) and the specific conditions
set out below, for each of the following budget categories:
A. direct personnel costs;
B. direct costs of subcontracting;
C. other direct costs;
D. indirect costs;
13
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
‘Direct costs’ are costs that are directly linked to the action implementation and can therefore be
attributed to it directly. They must not include any indirect costs (see Point D below).
‘Indirect costs’ are costs that are not directly linked to the action implementation and therefore cannot
be attributed directly to it.
A. Direct personnel costs
Types of eligible personnel costs
A.1 Personnel costs are eligible if they are related to personnel working for the beneficiary under
an employment contract (or equivalent appointing act) and assigned to the action (‘costs for
employees (or equivalent)’). They must be limited to salaries (including during parental leave),
social security contributions, taxes and other costs included in the remuneration, if they arise
from national law or the employment contract (or equivalent appointing act).
They may also include additional remuneration for personnel assigned to the action (including
payments on the basis of supplementary contracts regardless of their nature), if:
(a) it is part of the beneficiary’s usual remuneration practices and is paid in a consistent manner
whenever the same kind of work or expertise is required;
(b) the criteria used to calculate the supplementary payments are objective and generally
applied by the beneficiary, regardless of the source of funding used.
A.2 The costs for natural persons working under a direct contract with the beneficiary other
than an employment contract or seconded by a third party against payment are eligible personnel
costs, if:
(a) the person works under the beneficiary’s instructions and, unless otherwise agreed with
the beneficiary, on the beneficiary’s premises;
(b) the result of the work carried out belongs to the beneficiary, and
(c) the costs are not significantly different from those for personnel performing similar tasks
under an employment contract with the beneficiary.
Calculation
Personnel costs must be calculated by the beneficiaries as follows:
{hourly rate
multiplied by
the number of actual hours worked on the action}.
The number of actual hours declared for a person must be identifiable and verifiable (see Article 13).
The total number of hours declared in EU or Euratom grants, for a person for a year, cannot be higher
than the annual productive hours used for the calculations of the hourly rate. Therefore, the maximum
number of hours that can be declared for the grant are:
14
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
{the number of annual productive hours for the year (see below)
minus
total number of hours declared by the beneficiary, for that person for that year, for other EU or Euratom grants}.
The ‘hourly rate’ is the amount calculated as follows:
{actual annual personnel costs for the person
divided by
number of annual productive hours}.
The beneficiaries must use the annual personnel costs and the number of annual productive hours for
each financial year covered by the reporting period. If a financial year is not closed at the end of the
reporting period, the beneficiaries must use the hourly rate of the last closed financial year available.
For the ‘number of annual productive hours’, the beneficiaries may choose one of the following:
(i) ‘fixed number of hours’: 1 720 hours for persons working full time (or corresponding pro-rata
for persons not working full time);
(ii) ‘individual annual productive hours’: the total number of hours worked by the person in the year
for the beneficiary, calculated as follows:
{annual workable hours of the person (according to the employment contract, applicable collective labour
agreement or national law)
plus
overtime worked
minus
absences (such as sick leave and special leave)}.
‘Annual workable hours’ means the period during which the personnel must be working, at the
employer’s disposal and carrying out his/her activity or duties under the employment contract,
applicable collective labour agreement or national working time legislation.
If the contract (or applicable collective labour agreement or national working time legislation)
does not allow to determine the annual workable hours, this option cannot be used;
(iii) ‘standard annual productive hours’: the ‘standard number of annual hours’ generally applied
by the beneficiary for its personnel in accordance with its usual cost accounting practices. This
number must be at least 90% of the ‘standard annual workable hours’.
If there is no applicable reference for the standard annual workable hours, this option cannot
be used.
For all options, the actual time spent on parental leave by a person assigned to the action may be
deducted from the number of annual productive hours;
15
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
B. Direct costs of subcontracting (including related duties, taxes and charges, such as non-deductible
value added tax (VAT) paid by beneficiaries that are not public bodies acting as public authority) are
eligible if the conditions in Article 10.1.1 are met.
C. Other direct costs
C.1 Travel costs and related subsistence allowances (including related duties, taxes and charges,
such as non-deductible value added tax (VAT) paid by beneficiaries that are not public bodies
acting as public authority) are eligible if they are in line with the beneficiary’s usual practices
on travel.
C.2 The depreciation costs of equipment, infrastructure or other assets (new or second-hand)
as recorded in the beneficiary’s accounts are eligible, if they were purchased in accordance
with Article 9.1.1 and written off in accordance with international accounting standards and the
beneficiary’s usual accounting practices.
The costs of renting or leasing equipment, infrastructure or other assets (including related duties,
taxes and charges, such as non-deductible value added tax (VAT) paid by beneficiaries that are not
public bodies acting as public authority) are also eligible, if they do not exceed the depreciation
costs of similar equipment, infrastructure or assets and do not include any financing fees.
The only portion of the costs that will be taken into account is that which corresponds to the
duration of the action and rate of actual use for the purposes of the action.
C.3 Costs of other goods and services (including related duties, taxes and charges, such as non-
deductible value added tax (VAT) paid by beneficiaries that are not public bodies acting as public
authority) are eligible, if they are purchased specifically for the action and in accordance with
Article 9.1.1.
Such goods and services include, for instance, consumables and supplies, dissemination,
protection of results, certificates on the financial statements (if they are required by the
Agreement), translations and publications.
D. Indirect costs
Indirect costs are eligible if they are declared on the basis of the flat-rate of 7% of the eligible direct
costs (see Article 5.2 and Points A to C above).
Beneficiaries receiving an operating grant1 financed by the EU or Euratom budget cannot declare
indirect costs for the period covered by the operating grant.
6.3 Conditions for costs of affiliated entities to be eligible
Costs incurred by affiliated entities are eligible if they fulfil — mutatis mutandis — the general and
specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 11.1.1.
1 For the definition, see Article 121(1)(b) of Regulation (EU, Euratom) No 966/2012 of the European Parliament and
of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing
Council Regulation (EC, Euratom) No 1605/2002 (OJ L 218, 26.10.2012, p.1) (‘Financial Regulation No 966/2012’):
‘operating grant’ means direct financial contribution, by way of donation, from the budget in order to finance the
functioning of a body which pursues an aim of general EU interest or has an objective forming part of and supporting
an EU policy.
16
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
6.4 Ineligible costs
‘Ineligible costs’ are:
(a) costs that do not comply with the conditions set out above (Article 6.1 to 6.3), in particular:
(i) costs related to return on capital;
(ii) debt and debt service charges;
(iii) provisions for future losses or debts;
(iv) interest owed;
(v) doubtful debts;
(vi) currency exchange losses;
(vii) bank costs charged by the beneficiary’s bank for transfers from the Agency;
(viii)excessive or reckless expenditure;
(ix) deductible VAT;
(x) costs incurred during suspension of the implementation of the action (see Article 33);
(xi) in-kind contributions provided by third parties;
(b) costs declared under another EU or Euratom grant (including grants awarded by a Member
State and financed by the EU or Euratom budget and grants awarded by bodies other than the
Agency for the purpose of implementing the EU or Euratom budget); in particular, indirect
costs if the beneficiary is already receiving an operating grant financed by the EU or Euratom
budget in the same period.
6.5 Consequences of declaration of ineligible costs
Declared costs that are ineligible will be rejected (see Article 26).
This may also lead to any of the other measures described in Chapter 6.
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE
ACTION
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION
17
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
7.1 General obligation to properly implement the action
The beneficiaries must implement the action as described in Annex 1 and in compliance with the
provisions of the Agreement and all legal obligations under applicable EU, international and national
law.
7.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES
INVOLVED IN THE ACTION
The beneficiaries must have the appropriate resources to implement the action.
If it is necessary to implement the action, the beneficiaries may:
- purchase goods, works and services (see Article 9);
- call upon subcontractors to implement action tasks described in Annex 1 (see Article 10);
- call upon affiliated entities to implement action tasks described in Annex 1 (see Article 11).
In these cases, the beneficiaries retain sole responsibility towards the Agency and the other
beneficiaries for implementing the action.
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES
9.1 Rules for purchasing goods, works or services
9.1.1 If necessary to implement the action, the beneficiaries may purchase goods, works or services.
The beneficiaries must make such purchases ensuring the best value for money or, if appropriate, the
lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their contractors.
9.1.2 Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC2 or
‘contracting entities’ within the meaning of Directive 2004/17/EC3 must comply with the applicable
national law on public procurement.
2 Directive 2004/18/EC of the European Parliament and of the Council of 31 March 2004 on the coordination of
procedures for the award of public work contracts, public supply contracts and public service contracts (OJ L 134,
30.04.2004, p. 114).
18
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
9.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 9.1.1, the costs related to the contract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
If a beneficiary breaches any of its obligations under Article 9.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS
10.1 Rules for subcontracting action tasks
10.1.1 If necessary to implement the action, the beneficiaries may award subcontracts covering the
implementation of certain action tasks described in Annex 1.
Subcontracting may cover only a limited part of the action.
The beneficiaries must award the subcontracts ensuring the best value for money or, if appropriate,
the lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The tasks to be implemented and the estimated cost for each subcontract must be set out in Annex
1 and the total estimated costs of subcontracting per beneficiary must be set out in Annex 2. The
Agency may however approve subcontracts not set out in Annex 1 and 2 without amendment (see
Article 39), if:
- they are specifically justified in the periodic technical report and
- they do not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their subcontractors.
10.1.2 The beneficiaries must ensure that their obligations under Articles 20, 21, 22 and 30 also apply
to the subcontractors.
Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC or
‘contracting entities’ within the meaning of Directive 2004/17/EC must comply with the applicable
national law on public procurement.
10.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 10.1.1, the costs related to the subcontract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
3 Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement
procedures of entities operating in the water, energy, transport and postal services sectors (OJ L 134, 30.04.2004, p. 1).
19
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
If a beneficiary breaches any of its obligations under Article 10.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES
11.1 Rules for calling upon affiliated entities to implement part of the action
11.1.1 The following affiliated entities4 may implement the action tasks attributed to them in Annex 1:
- Centre hospitalier universitaire de Limoges (CHU Limoges), affiliated or linked to INSERM
- UNIVERSITE DE LIMOGES (UL), affiliated or linked to INSERM
- University General Hospital of Heraklion - General Hospital "Venizelei"o (GH Heraklion),
affiliated or linked to 7HC
- Consejería de Salud-Región de Murcia (DGPIFAC), affiliated or linked to FFIS
- SERVICIO MURCIANO DE SALUD (SMS), affiliated or linked to FFIS
- FUNDACION PUBLICA ANDALUZA PARA LAGESTION DE LA INVESTIGACION EN
SALUD DE SEVILLA (FISEVI), affiliated or linked to SAS
- FUNDACIÓN PARA LA INVESTIGACIÓN E INNOVACIÓN BIOMÉDICA DE ATENCIÓN
PRIMARIA (FBRIPC), affiliated or linked to SERMAS
The affiliated entities may declare as eligible the costs they incur for implementing the action tasks
in accordance with Article 6.3.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors (ECA)
and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and 18 also
towards their affiliated entities.
11.1.2 The beneficiaries must ensure that their obligations under Articles 13, 15, 20, 21 and 22 also
apply to their affiliated entities.
11.2 Consequences of non-compliance
If any obligation under Article 11.1.1 is breached, the costs of the affiliated entity will be ineligible
(see Article 6) and will be rejected (see Article 26).
If any obligation under Article 11.1.2 is breached, the grant may be reduced (see Article 27).
4 For the definition, see Article 122 of the Financial Regulation (EU, Euratom) No 966/2012: entities affiliated to the
beneficiary are:
(a) entities that form a ‘sole beneficiary’ (i.e. where an entity is formed of several entities that satisfy the criteria for
being awarded a grant, including where the entity is specifically established for the purpose of implementing
an action to be financed by a grant);
(b) entities that satisfy the eligibility criteria and that do not fall within one of the situations referred to in Article
131(4) and that have a link with the beneficiary, in particular a legal or capital link, which is neither limited to
the action nor established for the sole purpose of its implementation.
20
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Such breaches may also lead to any of the other measures described in Chapter 6.
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT
ADMINISTRATIONFR
ARTICLE 12 — GENERAL OBLIGATION TO INFORM
12.1 General obligation to provide information upon request
The beneficiaries must provide — during implementation of the action or afterwards and in accordance
with Article 25.2 — any information requested in order to verify eligibility of the costs, proper
implementation of the action and compliance with any other obligation under the Agreement.
12.2 Obligation to keep information up to date and to inform about events and circumstances
likely to affect the Agreement
Each beneficiary must keep information stored in the 'Beneficiary Register' (via the electronic
exchange system; see Article 36) up to date, in particular, its name, address, legal representatives,
legal form and organisation type.
Each beneficiary must immediately inform the coordinator — which must immediately inform the
Agency and the other beneficiaries — of any of the following:
(a) events which are likely to affect significantly or delay the implementation of the action or the
EU’s financial interests, in particular:
(i) changes in its legal, financial, technical, organisational or ownership situation or those
of its affiliated entities and
(ii) changes in the name, address, legal form, organisation type of its affiliated entities;
(b) circumstances affecting:
(i) the decision to award the grant or
(ii) compliance with requirements under the Agreement.
12.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION
13.1 Obligation to keep records and other supporting documentation
The beneficiaries must — for a period of three years after the payment of the balance — keep records
and other supporting documentation, in order to prove the proper implementation of the action and
the costs they declare as eligible.
21
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
They must make them available upon request (see Article 12) or in the context of checks, reviews,
audits or investigations (see Article 17).
If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under
the Agreement (including the extension of findings; see Articles 17), the beneficiaries must keep the
records and other supporting documentation until the end of these procedures.
The beneficiaries must keep the original documents. Digital and digitalised documents are considered
originals if they are authorised by the applicable national law. The Agency may accept non-original
documents if it considers that they offer a comparable level of assurance.
13.1.1 Records and other supporting documentation on the scientific and technical
implementation
The beneficiaries must keep records and other supporting documentation on the technical
implementation of the action, in line with the accepted standards in the respective field.
13.1.2 Records and other documentation to support the costs declared
The beneficiaries must keep the records and documentation supporting the costs declared, in particular
the following:
(a) for actual costs: adequate records and other supporting documentation to prove the costs
declared, such as contracts, subcontracts, invoices and accounting records. In addition, the
beneficiaries’ usual cost accounting practices and internal control procedures must enable direct
reconciliation between the amounts declared, the amounts recorded in their accounts and the
amounts stated in the supporting documentation;
(b) for flat-rate costs: adequate records and other supporting documentation to prove the eligibility
of the costs to which the flat-rate is applied. The beneficiaries do not need to identify the costs
covered or provide supporting documentation (such as accounting statements) to prove the
amount declared at a flat-rate.
In addition, for personnel costs (declared as actual costs), the beneficiaries must keep time records
for the number of hours declared. The time records must be in writing and approved by the persons
working on the action and their supervisors, at least monthly. In the absence of reliable time records
of the hours worked on the action, the Agency may accept alternative evidence supporting the number
of hours declared, if it considers that it offers an adequate level of assurance.
As an exception, for persons working exclusively on the action, there is no need to keep time records,
if the beneficiary signs a declaration confirming that the persons concerned have worked exclusively
on the action.
For costs declared by affiliated entities (see Article 11), it is the beneficiary that must keep the
originals of the financial statements and the certificates on the financial statements of the affiliated
entities.
22
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
13.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, costs insufficiently substantiated
will be ineligible (see Article 6) and will be rejected (see Article 26), and the grant may be reduced
(see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 14 — SUBMISSION OF DELIVERABLES
14.1 Obligation to submit deliverables
The coordinator must submit the ‘deliverables’ identified in Annex 1 (if any), in accordance with the
timing and conditions set out in it.
14.2 Consequences of non-compliance
If the coordinator breaches any of its obligations under this Article, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 15 — REPORTING — PAYMENT REQUESTS
15.1 Obligation to submit reports
The coordinator must submit to the Agency (see Article 36) the technical and financial reports set out
in this Article. These reports include the requests for payment and must be drawn up using the forms
and templates provided in the electronic exchange system (see Article 36).
15.2 Reporting periods
The action is divided into the following ‘reporting periods’:
- RP1: from month 1 to month 18
- RP2: from month 19 to month 36
15.3 Periodic reports — Requests for interim payments
The coordinator must submit a periodic report within 60 days following the end of each reporting
period.
The periodic report must include the following:
(a) a ‘periodic technical report’ containing:
(i) an explanation of the work carried out by the beneficiaries;
(ii) an overview of the progress towards the objectives of the action, including milestones
and deliverables identified in Annex 1.
This report must include explanations justifying the differences between work expected
to be carried out in accordance with Annex 1 and that actually carried out;
23
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(iii) a summary for publication by the Agency;
(iv) the answers to the ‘questionnaire’, covering issues related to the action implementation
and its impact, if required in Annex 1;
(b) a ‘periodic financial report’ containing:
(i) an ‘individual financial statement’ (see Annex 4) from each beneficiary and from each
affiliated entity, for the reporting period concerned.
The individual financial statement must detail the eligible costs (actual costs and flat-rate
costs; see Article 6) for each budget category (see Annex 2).
The beneficiaries and affiliated entities must declare all eligible costs, even if — for actual
costs and flat-rate costs — they exceed the amounts indicated in the estimated budget (see
Annex 2). Amounts which are not declared in the individual financial statement will not
be taken into account by the Agency.
If an individual financial statement is not submitted for a reporting period, it may be
included in the periodic financial report for the next reporting period.
The individual financial statements of the last reporting period must also detail the
receipts of the action (see Article 5.3.3).
Each beneficiary and each affiliated entity must certify that:
- the information provided is full, reliable and true;
- the costs declared are eligible (see Article 6);
- the costs can be substantiated by adequate records and supporting documentation
(see Article 13) that will be produced upon request (see Article 12) or in the context
of checks, reviews, audits and investigations (see Article 17), and
- for the last reporting period: that all the receipts have been declared (see
Article 5.3.3);
(ii) an explanation of the use of resources and the information on subcontracting (see
Article 10) from each beneficiary and from each affiliated entity, for the reporting period
concerned;
(iii) not applicable;
(iv) a ‘periodic summary financial statement’ (see Annex 4), created automatically by
the electronic exchange system, consolidating the individual financial statements for the
reporting period concerned and including — except for the last reporting period — the
request for interim payment.
24
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(v) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each affiliated entity, if:
- the (cumulative) amount of payments it requests as reimbursement of actual costs
(and for which no certificate has yet been submitted) is EUR 325 000 or more and
- the maximum grant amount indicated, for that beneficiary or affiliated entity, in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000
or more.
15.4 Final report — Request for payment of the balance
In addition to the periodic report for the last reporting period, the coordinator must submit the final
report within 60 days following the end of the last reporting period.
The final report must include the following:
(a) a ‘final technical report’ with a summary for publication containing:
(i) an overview of the results and their dissemination;
(ii) the conclusions on the action and
(iii) the impact of the action;
(b) a ‘final financial report’ containing:
(i) a ‘final summary financial statement’ (see Annex 4), created automatically by the
electronic exchange system, consolidating the individual financial statements for all
reporting periods and including the request for payment of the balance and
(ii) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each affiliated entity, if:
- the cumulative amount of payments it requests as reimbursement of actual costs
(and for which no certificate has been submitted) is EUR 325 000 or more and
- the maximum grant amount indicated, for that beneficiary or affiliated entity, in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000
or more.
15.5 Currency for financial statements and conversion into euro
Financial statements must be drafted in euro.
Beneficiaries and affiliated entities with accounting established in a currency other than the euro
must convert the costs recorded in their accounts into euro at the average of the daily exchange
rates published in the C series of the Official Journal of the European Union, calculated over the
corresponding reporting period.
25
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
If no daily euro exchange rate is published in the Official Journal of the European Union for the
currency in question, they must be converted at the average of the monthly accounting rates published
on the Commission’s website, calculated over the corresponding reporting period.
Beneficiaries and affiliated entities with accounting established in euro must convert costs incurred
in another currency into euro according to their usual accounting practices.
15.6 Language of reports
All reports (technical and financial reports, including financial statements) must be submitted in the
language of the Agreement.
15.7 Consequences of non-compliance — Suspension of the payment deadline — Termination
If the reports submitted do not comply with this Article, the Agency may suspend the payment deadline
(see Article 31) and apply any of the other measures described in Chapter 6.
If the coordinator breaches its obligation to submit the reports and if it fails to comply with this
obligation within 30 days following a written reminder sent by the Agency, the Agreement may be
terminated (see Article 34).
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS
16.1 Payments to be made
The following payments will be made to the coordinator:
- one pre-financing payment;
- one or more interim payments, on the basis of the request(s) for interim payment (see
Article 15), and
- one payment of the balance, on the basis of the request for payment of the balance (see
Article 15).
16.2 Pre-financing payment — Amount
The aim of the pre-financing is to provide the beneficiaries with a float.
It remains the property of the EU until the payment of the balance.
The amount of the pre-financing payment will be EUR 1,253,448.83 (one million two hundred and
fifty three thousand four hundred and forty eight EURO and eighty three eurocents).
The Agency will — except if Article 32 applies — make the pre-financing payment to the coordinator
within 30 days, either from the entry into force of the Agreement (see Article 42) or from 10 days
before the starting date of the action (see Article 3), whichever is the latest.
16.3 Interim payments — Amount — Calculation
Interim payments reimburse the eligible costs incurred for the implementation of the action during
the corresponding reporting periods.
26
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The Agency will pay to the coordinator the amount due as interim payment within 60 days from
receiving the periodic report (see Article 15.3), except if Articles 31 or 32 apply.
Payment is subject to the approval of the periodic report. Its approval does not imply recognition of
the compliance, authenticity, completeness or correctness of its content.
The amount due as interim payment is calculated by the Agency in the following steps:
Step 1 – Application of the reimbursement rate
Step 2 – Limit to 90% of the maximum grant amount
16.3.1 Step 1 — Application of the reimbursement rate
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate costs;
see Article 6) declared by the beneficiaries and the affiliated entities (see Article 15) and approved
by the Agency (see above) for the concerned reporting period.
16.3.2 Step 2 — Limit to 90% of the maximum grant amount
The total amount of pre-financing and interim payments must not exceed 90% of the maximum grant
amount set out in Article 5.1. The maximum amount for the interim payment will be calculated as
follows:
{90% of the maximum grant amount (see Article 5.1)
minus
{pre-financing and previous interim payments}}.
16.4 Payment of the balance — Amount — Calculation
The payment of the balance reimburses the remaining part of the eligible costs incurred by the
beneficiaries for the implementation of the action.
If the total amount of earlier payments is greater than the final grant amount (see Article 5.3), the
payment of the balance takes the form of a recovery (see Article 28).
If the total amount of earlier payments is lower than the final grant amount, the Agency will pay the
balance within 60 days from receiving the final report (see Article 15.4), except if Articles 31 or 32
apply.
Payment is subject to the approval of the final report. Its approval does not imply recognition of the
compliance, authenticity, completeness or correctness of its content.
The amount due as the balance is calculated by the Agency by deducting the total amount of pre-
financing and interim payments (if any) already made, from the final grant amount determined in
accordance with Article 5.3:
{final grant amount (see Article 5.3)
minus
{pre-financing and interim payments (if any) made}}.
27
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
If the balance is positive, it will be paid to the coordinator.
The amount to be paid may however be offset — without the beneficiary’s consent — against any
other amount owed by a beneficiary to the Agency, the Commission or another executive agency
(under the EU or Euratom budget), up to the maximum EU contribution indicated, for that beneficiary,
in the estimated budget (see Annex 2).
If the balance is negative, it will be recovered.
16.5 Notification of amounts due
When making payments, the Agency will formally notify to the coordinator the amount due,
specifying whether it concerns an interim payment or the payment of the balance.
For the payment of the balance, the notification will also specify the final grant amount.
In the case of reduction of the grant or recovery of undue amounts, the notification will be preceded
by the contradictory procedure set out in Articles 27 and 28.
16.6 Currency for payments
The Agency will make all payments in euro.
16.7 Payments to the coordinator — Distribution to the beneficiaries
Payments will be made to the coordinator.
Payments to the coordinator will discharge the Agency from its payment obligation.
The coordinator must distribute the payments between the beneficiaries without unjustified delay.
Pre-financing may however be distributed only:
(a) if 90% of the beneficiaries have acceded to the Agreement (see Article 40) and
(b) to beneficiaries that have acceded to the Agreement (see Article 40).
16.8 Bank account for payments
All payments will be made to the following bank account:
Name of bank: TRESOR PUBLIC
Address of branch: PL OCCITANE TOULOUSE, France
Full name of the account holder: AGENT COMPTABLE SECONDAIREDE L INSERM
Full account number (including bank codes):
IBAN code: FR7610071310000000100135407
16.9 Costs of payment transfers
The cost of the payment transfers is borne as follows:
- the Agency bears the cost of transfers charged by its bank;
28
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
- the beneficiary bears the cost of transfers charged by its bank;
- the party causing a repetition of a transfer bears all costs of the repeated transfer.
16.10 Date of payment
Payments by the Agency are considered to have been carried out on the date when they are debited
to its account.
16.11 Consequences of non-compliance
16.11.1 If the Agency does not pay within the payment deadlines (see above), the beneficiaries are
entitled to late-payment interest at the rate applied by the European Central Bank (ECB) for its main
refinancing operations in euros (‘reference rate’), plus three and a half points. The reference rate is
the rate in force on the first day of the month in which the payment deadline expires, as published in
the C series of the Official Journal of the European Union.
If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only
upon request submitted within two months of receiving the late payment.
Late-payment interest is not due if all beneficiaries are EU Member States (including regional and
local government authorities or other public bodies acting on behalf of a Member State for the purpose
of this Agreement).
Suspension of the payment deadline or payments (see Articles 31 and 32) will not be considered as
late payment.
Late-payment interest covers the period running from the day following the due date for payment (see
above), up to and including the date of payment.
Late-payment interest is not considered for the purposes of calculating the final grant amount.
16.11.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced
(see Article 27) and the Agreement or the participation of the coordinator may be terminated (see
Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION
OF FINDINGS
17.1 Checks, reviews and audits by the Agency and the Commission
17.1.1 Right to carry out checks
The Agency or the Commission will — during the implementation of the action or afterwards — check
the proper implementation of the action and compliance with the obligations under the Agreement,
including assessing deliverables and reports.
For this purpose, the Agency or the Commission may be assisted by external persons or bodies.
29
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The Agency or the Commission may also request additional information in accordance with Article 12.
The Agency or the Commission may request beneficiaries to provide such information to it directly.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
17.1.2 Right to carry out reviews
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out reviews on the proper implementation of the action (including assessment of deliverables
and reports) and compliance with the obligations under the Agreement.
Reviews may be started up to three years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the review is carried out on a third party (see Articles 9, 10, 11), the beneficiary concerned must
inform the third party.
The Agency or the Commission may carry out reviews directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information and data in addition to deliverables and reports already submitted (including information
on the use of resources). The Agency or the Commission may request beneficiaries to provide such
information to it directly.
The coordinator or beneficiary concerned may be requested to participate in meetings, including with
external experts.
For on-the-spot reviews, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the review findings, a ‘review report’ will be drawn up.
The Agency or the Commission will formally notify the review report to the coordinator or beneficiary
concerned, which has 30 days to formally notify observations (‘contradictory review procedure’).
Reviews (including review reports) are in the language of the Agreement.
17.1.3 Right to carry out audits
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out audits on the proper implementation of the action and compliance with the obligations under
the Agreement.
30
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Audits may be started up to three years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the audit is carried out on a third party (see Articles 9, 10, 11), the beneficiary concerned must
inform the third party.
The Agency or the Commission may carry out audits directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information (including complete accounts, individual salary statements or other personal data) to
verify compliance with the Agreement. The Agency or the Commission may request beneficiaries to
provide such information to it directly.
For on-the-spot audits, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the audit findings, a ‘draft audit report’ will be drawn up.
The Agency or the Commission will formally notify the draft audit report to the coordinator or
beneficiary concerned, which has 30 days to formally notify observations (‘contradictory audit
procedure’). This period may be extended by the Agency or the Commission in justified cases.
The ‘final audit report’ will take into account observations by the coordinator or beneficiary
concerned. The report will be formally notified to it.
Audits (including audit reports) are in the language of the Agreement.
The Agency or the Commission may also access the beneficiaries’ statutory records for the periodical
assessment of flat-rate amounts.
17.2 Investigations by the European Anti-Fraud Office (OLAF)
Under Regulations No 883/20135 and No 2185/966 (and in accordance with their provisions and
procedures), the European Anti-Fraud Office (OLAF) may — at any moment during implementation
of the action or afterwards — carry out investigations, including on-the-spot checks and inspections,
to establish whether there has been fraud, corruption or any other illegal activity affecting the financial
interests of the EU.
5 Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013
concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC)
No 1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ
L 232, 18.09.2013, p. 1).
6 Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections
carried out by the Commission in order to protect the European Communities' financial interests against fraud and other
irregularities (OJ L 292, 15.11.1996, p. 2).
31
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
17.3 Checks and audits by the European Court of Auditors (ECA)
Under Article 287 of the Treaty on the Functioning of the European Union (TFEU) and Article 161 of
the Financial Regulation No 966/20127, the European Court of Auditors (ECA) may — at any moment
during implementation of the action or afterwards — carry out audits.
The ECA has the right of access for the purpose of checks and audits.
17.4 Checks, reviews, audits and investigations for international organisations
Not applicable
17.5 Consequences of findings in checks, reviews, audits and investigations —Extension of
findings
17.5.1 Findings in this grant
Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead
to the rejection of ineligible costs (see Article 26), reduction of the grant (see Article 27), recovery of
undue amounts (see Article 28) or to any of the other measures described in Chapter 6.
Rejection of costs or reduction of the grant after the payment of the balance will lead to a revised final
grant amount (see Article 5.4).
Findings in checks, reviews, audits or investigations may lead to a request for amendment for the
modification of Annex 1 (see Article 39).
Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or
breach of obligations may also lead to consequences in other EU or Euratom grants awarded under
similar conditions (‘extension of findings from this grant to other grants’).
Moreover, findings arising from an OLAF investigation may lead to criminal prosecution under
national law.
17.5.2 Findings in other grants
The Agency or the Commission may extend findings from other grants to this grant (‘extension of
findings from other grants to this grant’), if:
(a) the beneficiary concerned is found, in other EU or Euratom grants awarded under similar
conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of
obligations that have a material impact on this grant and
(b) those findings are formally notified to the beneficiary concerned — together with the list of
grants affected by the findings — no later than three years after the payment of the balance
of this grant.
7 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the
financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No
1605/2002 (‘Financial Regulation No 966/2012’) (OJ L 298, 26.10.2012, p. 1).
32
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The extension of findings may lead to the rejection of costs (see Article 26), reduction of the grant
(see Article 27), recovery of undue amounts (see Article 28), suspension of payments (see Article 32),
suspension of the action implementation (see Article 33) or termination (see Article 34).
17.5.3 Procedure
The Agency or the Commission will formally notify the beneficiary concerned the systemic or
recurrent errors and its intention to extend these audit findings, together with the list of grants affected.
17.5.3.1 If the findings concern eligibility of costs: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings;
(b) the request to submit revised financial statements for all grants affected;
(c) the correction rate for extrapolation established by the Agency or the Commission on
the basis of the systemic or recurrent errors, to calculate the amounts to be rejected, if the
beneficiary concerned:
(i) considers that the submission of revised financial statements is not possible or
practicable or
(ii) does not submit revised financial statements.
The beneficiary concerned has 90 days from receiving notification to submit observations, revised
financial statements or to propose a duly substantiated alternative correction method. This period
may be extended by the Agency or the Commission in justified cases.
The Agency or the Commission may then start a rejection procedure in accordance with the procedure
set out in Article 26, either on the basis of the revised financial statements or the rate announced.
17.5.3.2 If the findings concern improper implementation or a breach of another obligation: the
formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings and
(b) the flat-rate the Agency or the Commission intends to apply according to the principle of
proportionality.
The beneficiary concerned has 90 days from receiving notification to submit observations or to
propose a duly substantiated alternative flat-rate.
The Agency or the Commission may then start a reduction procedure in accordance with the procedure
set out in Article 27, either on the basis of the alternative flat-rate or the flat-rate announced.
17.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, any insufficiently substantiated costs
will be ineligible (see Article 6) and will be rejected (see Article 26).
Such breaches may also lead to any of the other measures described in Chapter 6.
33
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION
18.1 Right to evaluate the impact of the action
The Agency or the Commission may carry out interim and final evaluations of the impact of the action
measured against the objective of the EU programme.
Evaluations may be started during implementation of the action and up to three years after the
payment of the balance. The evaluation is considered to start on the date of the formal notification
to the coordinator or beneficiaries.
The Agency or the Commission may make these evaluations directly (using its own staff) or indirectly
(using external bodies or persons it has authorised to do so).
The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the
action, including information in electronic format.
18.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the Agency may apply the measures
described in Chapter 6.
SECTION 3 OTHER RIGHTS AND OBLIGATIONS
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS
(INCLUDING INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS)
19.1 Pre-existing rights and access rights to pre-existing rights
Where industrial and intellectual property rights (including rights of third parties) exist prior to the
Agreement, the beneficiaries must establish a list of these pre-existing industrial and intellectual
property rights, specifying the owner and any persons that have a right of use.
The coordinator must — before starting the action — submit this list to the Agency.
The beneficiaries must give each other (and their affiliated entities) access to any pre-existing
industrial and intellectual property rights needed for the implementation of the action and compliance
with the obligations under the Agreement.
19.2 Ownership of results and rights of use
The results of the action (including the reports and other documents relating to it) are owned by the
beneficiaries.
The beneficiaries must give the Agency and the Commission the right to use the results for their
communication activities under Article 22.
19.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
34
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 20 — CONFLICT OF INTERESTS
20.1 Obligation to avoid a conflict of interests
The beneficiaries must take all measures to prevent any situation where the impartial and objective
implementation of the action is compromised for reasons involving economic interest, political or
national affinity, family or emotional ties or any other shared interest (‘conflict of interests’).
They must formally notify to the Agency without delay any situation constituting or likely to lead to
a conflict of interests and immediately take all the necessary steps to rectify this situation.
The Agency may verify that the measures taken are appropriate and may require additional measures
to be taken by a specified deadline.
20.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27) and the Agreement or participation of the beneficiary may be terminated (see Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 21 — CONFIDENTIALITY
21.1 General obligation to maintain confidentiality
During implementation of the action and for five years after the payment of the balance, the parties
must keep confidential any data, documents or other material (in any form) that is identified as
confidential at the time it is disclosed (‘confidential information’).
They may use confidential information to implement the Agreement.
The confidentiality obligations no longer apply if:
(a) the disclosing party agrees to release the other party;
(b) the information becomes generally and publicly available, without breaching any
confidentiality obligation;
(c) the disclosure of the confidential information is required by EU or national law.
21.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING
35
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
22.1 Communication activities by the beneficiaries
22.1.1 General obligation to promote the action and its results
The beneficiaries must promote the action and its results.
22.1.2 Information on EU funding — Obligation and right to use of the EU emblem
Unless the Agency requests or agrees otherwise, any communication activity related to the action
(including at conferences, seminars, in information material, such as brochures, leaflets, posters,
presentations, etc., in electronic form, via social media, etc.) and any infrastructure, equipment or
major results funded by the grant must:
(a) display the EU emblem and
(b) include the following text:
“This [insert appropriate description, e.g. report, publication, conference, infrastructure, equipment, insert
type of result, etc.] is part of the project / joint action ‘761296 / EU-JAMRAI ’ which has received funding
from the European Union’s Health Programme (2014-2020).”
When displayed in association with another logo, the EU emblem must have appropriate prominence.
For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem
without first obtaining approval from the Agency.
This does not, however, give them the right to exclusive use.
Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by
registration or by any other means.
22.1.3 Disclaimer excluding Agency/Commission responsibility
Any communication activity related to the action must indicate the following disclaimer:
“The content of this [insert appropriate description, e.g. report, publication, conference, etc.] represents the
views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the
European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other
body of the European Union. The European Commission and the Agency do not accept any responsibility for
use that may be made of the information it contains.”
22.2 Communication activities by the Agency
22.2.1 Right to use the beneficiaries’ materials, documents or information
The Agency may use information relating to the action, documents notably summaries for publication
and public deliverables as well as any other material, such as pictures or audio-visual material that it
receives from any beneficiary (including in electronic form).
This does not change the confidentiality obligations in Article 21, which still apply.
The right to use the beneficiary’s materials, documents and information includes:
36
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(a) use for its own purposes (in particular, making them available to persons working for the
Agency or any other EU institution, body, office or agency or body or institutions in EU
Member States; and copying or reproducing them in whole or in part, in unlimited numbers);
(b) distribution to the public (in particular, publication as hard copies and in electronic or digital
format, publication on the internet, as a downloadable or non-downloadable file, broadcasting
by any channel, public display or presentation, communicating through press information
services, or inclusion in widely accessible databases or indexes);
(c) editing or redrafting for communication and publicising activities (including shortening,
summarising, inserting other elements (such as meta-data, legends, other graphic, visual, audio
or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a
compilation);
(d) translation;
(e) giving access in response to individual requests under Regulation No 1049/20018, without
the right to reproduce or exploit;
(f) storage in paper, electronic or other form;
(g) archiving, in line with applicable document-management rules, and
(h) the right to authorise third parties to act on its behalf or sub-license the modes of use set out
in Points (b),(c),(d) and (f) to third parties if needed for the communication and publicising
activities of the Agency.
If the right of use is subject to rights of a third party (including personnel of the beneficiary), the
beneficiary must ensure that it complies with its obligations under this Agreement (in particular, by
obtaining the necessary approval from the third parties concerned).
Where applicable (and if provided by the beneficiary), the Agency will insert the following
information:
“© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA) under conditions.”
22.3 Consequences of non-compliance
If the beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 23 — PROCESSING OF PERSONAL DATA
8 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access
to European Parliament, Council and Commission documents, OJ L 145, 31.5.2001, p. 43.
37
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
23.1 Processing of personal data by the Agency and the Commission
Any personal data under the Agreement will be processed by the Agency or the Commission under
Regulation No 23/20019 and according to the ‘notifications of the processing operations’ to the Data
Protection Officer (DPO) of the Agency or the Commission (publicly accessible in the DPO register).
Such data will be processed by the ‘data controller’ of the Agency or the Commission, for the
purposes of implementing, managing and monitoring the Agreement or protecting the financial
interests of the EU or Euratom (including checks, reviews, audits and investigations; see Article 17).
The persons whose personal data are processed have the right to access and correct their own personal
data. For this purpose, they must send any queries about the processing of their personal data to the data
controller, via the contact point indicated in the privacy statement(s) on the Agency and Commission
websites.
They also have the right to have recourse at any time to the European Data Protection Supervisor
(EDPS).
23.2 Processing of personal data by the beneficiaries
The beneficiaries must process personal data under the Agreement in compliance with applicable EU
and national law on data protection (including authorisations or notification requirements).
The beneficiaries may grant their personnel access only to data that is strictly necessary for
implementing, managing and monitoring the Agreement.
The beneficiaries must inform the personnel whose personal data are collected and processed by the
Agency or the Commission. For this purpose, they must provide them with the privacy statement(s)
(see above), before transmitting their data to the Agency or the Commission.
23.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 23.2, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY
The beneficiaries may not assign any of their claims for payment against the Agency to any third
party, except if approved by the Agency on the basis of a reasoned, written request by the coordinator
(on behalf of the beneficiary concerned).
If the Agency has not accepted the assignment or the terms of it are not observed, the assignment
will have no effect on it.
In no circumstances will an assignment release the beneficiaries from their obligations towards the
Agency.
9 Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection
of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free
movement of such data (OJ L 8, 12.01.2001, p. 1).
38
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
25.1 Roles and responsibilities towards the Agency
The beneficiaries have full responsibility for implementing the action and complying with the
Agreement.
The beneficiaries are jointly and severally liable for the technical implementation of the action as
described in Annex 1. If a beneficiary fails to implement its part of the action, the other beneficiaries
become responsible for implementing this part (without being entitled to any additional EU funding
for doing so), unless the Agency expressly relieves them of this obligation.
The financial responsibility of each beneficiary is governed by Articles 28, 29 and 30.
25.2 Internal division of roles and responsibilities
The internal roles and responsibilities of the beneficiaries are divided as follows:
(a) Each beneficiary must:
(i) keep information stored in the 'Beneficiary Register' (via the electronic exchange
system) up to date (see Article 12);
(ii) inform the coordinator immediately of any events or circumstances likely to affect
significantly or delay the implementation of the action (see Article 12);
(iii) submit to the coordinator in good time:
- individual financial statements for itself and its affiliated entities and, if
required, certificates on the financial statements (see Article 15);
- the data needed to draw up the technical reports (see Article 15);
- any other documents or information required by the Agency or the Commission
under the Agreement, unless the Agreement requires the beneficiary to submit
this information directly to the Agency or the Commission.
(b) The coordinator must:
(i) monitor that the action is implemented properly (see Article 7);
(ii) act as the intermediary for all communications between the beneficiaries and the
Agency (in particular, providing the Agency with the information described in
Article 12), unless the Agreement specifies otherwise;
(iii) provide a pre-financing guarantee if requested by the Agency (see Article 16.2);
39
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(iv) request and review any documents or information required by the Agency and verify
their completeness and correctness before passing them on to the Agency;
(v) submit the deliverables and reports to the Agency (see Articles 14 and 15);
(vi) ensure that all payments are made to the other beneficiaries without unjustified delay
(see Article 16).
The coordinator may not delegate the above-mentioned tasks to any other beneficiary or subcontract
them to any third party.
25.3 Internal arrangements between beneficiaries — Consortium agreement
The beneficiaries must have internal arrangements regarding their operation and co-ordination to
ensure that the action is implemented properly. These internal arrangements must be set out in a written
‘consortium agreement’ between the beneficiaries, which may cover:
- internal organisation of the consortium;
- management of access to the electronic exchange system;
- distribution of EU funding;
- additional rules on rights and obligations related to background and results (including whether
access rights remain or not, if a beneficiary is in breach of its obligations) (see Section 3 of
Chapter 4);
- settlement of internal disputes;
- liability, indemnification and confidentiality arrangements between the beneficiaries.
The consortium agreement must not contain any provision contrary to the Agreement.
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— PENALTIES — DAMAGES — SUSPENSION — TERMINATION — FORCE
MAJEURE
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— PENALTIES
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS
26.1 Conditions
26.1.1 The Agency will — at the time of an interim payment, at the payment of the balance or
afterwards — reject any costs which are ineligible (see Article 6), in particular following checks,
reviews, audits or investigations (see Article 17).
40
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
26.1.2 The rejection may also be based on the extension of findings from other grants to this grant,
under the conditions set out in Article 17.5.2.
26.2 Ineligible costs to be rejected — Calculation — Procedure
Ineligible costs will be rejected in full.
If the Agency rejects costs without reduction of the grant (see Article 27) or recovery of undue
amounts (see Article 28), it will formally notify the coordinator or beneficiary concerned the rejection
of costs, the amounts and the reasons why (if applicable, together with the notification of amounts
due; see Article 16.5). The coordinator or beneficiary concerned may — within 30 days of receiving
notification — formally notify the Agency of its disagreement and the reasons why.
If the Agency rejects costs with reduction of the grant or recovery of undue amounts , it will
formally notify the rejection in the ‘pre-information letter’ on reduction or recovery set out in
Articles 27 and 28.
26.3 Effects
If the Agency rejects costs at the time of an interim payment or the payment of the balance, it will
deduct them from the total eligible costs declared, for the action, in the periodic or final summary
financial statement (see Articles 15.3 and 15.4). It will then calculate the interim payment or payment
of the balance as set out in Articles 16.3 or 16.4.
If the Agency — after an interim payment but before the payment of the balance — rejects costs
declared in a periodic summary financial statement, it will deduct them from the total eligible costs
declared, for the action, in the next periodic summary financial statement or in the final summary
financial statement. It will then calculate the interim payment or payment of the balance as set out
in Articles 16.3 or 16.4.
If the Agency rejects costs after the payment of the balance, it will deduct the amount rejected from
the total eligible costs declared, by the beneficiary, in the final summary financial statement. It will
then calculate the revised final grant amount as set out in Article 5.4.
ARTICLE 27 — REDUCTION OF THE GRANT
27.1 Conditions
27.1.1 The Agency may — at the payment of the balance or afterward — reduce the maximum
grant amount (see Article 5.1), if the action has not been implemented properly as described in Annex
1 to the Specific Agreement concerned or another obligation under the Agreement has been breached.
27.1.2 The Agency may also reduce the maximum grant amount on the basis of the extension of
findings from other grants to this grant, under the conditions set out in Article 17.5.2.
27.2 Amount to be reduced — Calculation — Procedure
The amount of the reduction will be proportionate to the improper implementation of the action or
to the seriousness of the breach.
Before reduction of the grant, the Agency will formally notify a ‘pre-information letter’ to the
coordinator or beneficiary concerned:
41
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
- informing it of its intention to reduce the grant, the amount it intends to reduce and the reasons
why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive any observations or decides to pursue reduction despite the observations
it has received, it will formally notify confirmation of the reduction (if applicable, together with the
notification of amounts due; see Article 16).
27.3 Effects
If the Agency reduces the grant at the time of the payment of the balance, it will calculate the
reduced grant amount for the action and then determine the amount due as payment of the balance
(see Article 5.3.4 and Article 16.4).
If the Agency reduces the grant after the payment of the balance, it will calculate the revised final
grant amount (see Article 5.4). If the revised final grant amount is lower than the final grant amount,
the Agency will recover the difference (see Article 28).
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS
28.1 Amount to be recovered — Calculation — Procedure
The Agency will — at the payment of the balance or afterwards — claim back amount that was
paid but is not due under the Agreement.
The coordinator is fully liable for repaying debts of the consortium (under the Agreement) even if it
has not been the final recipient of those amounts.
In addition, the beneficiaries (including the coordinator) are jointly and severally liable for repaying
any unpaid debts under the Agreement (due by the consortium or any beneficiary, including late-
payment interest) — up to the maximum EU contribution indicated, for each beneficiary, in the
estimated budget (as last amended; see Annex 2).
Undue amounts paid by the Agency for costs declared by an affiliated entity will be considered as
amounts unduly paid to the beneficiary.
28.1.1 Recovery at payment of the balance
If the payment of the balance takes the form of a recovery (see Article 16.4), the Agency will formally
notify a ‘pre-information letter’ to the coordinator:
- informing it of its intention to recover, the amount due as the balance and the reasons why and
- inviting the coordinator to submit observations within 30 days of receiving notification.
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator a
debit note with the terms and the date for payment (together with the notification of amounts due;
see Article 16.5).
42
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s consent — against any amounts owed to the
coordinator by the Agency, Commission or another executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) not applicable;
(c) by holding the other beneficiaries jointly and severally liable — up to the maximum EU
contribution indicated, for each beneficiary, in the estimated budget (as last amended; see
Annex 2);
(d) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
28.1.2 Recovery of amounts after payment of the balance
If — after the payment of the balance — the Agency revised the final grant amount for the action (see
Article 5.4), due to a rejection of costs or reduction of the grant, and the revised final grant amount is
lower than the final grant amount (see Article 5.3), the Agency will:
- if the rejection or reduction does not concern a specific beneficiary (or its affiliated entities):
claim back the difference from the coordinator (even if it has not been the final recipient of
the amount in question)
or
- otherwise: claim back the difference from the beneficiary concerned.
The Agency will formally notify a pre-information letter to the coordinator or beneficiary concerned:
- informing it of its intention to recover, the amount to be repaid and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
43
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator or
beneficiary concerned a debit note. This note will also specify the terms and the date for payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s or beneficiary’s consent — against any amounts
owed to the coordinator or beneficiary by the Agency, Commission or another executive agency
(from the EU or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) by holding the other beneficiaries jointly and severally liable, up to the maximum EU
contribution indicated, for each beneficiary, in the estimated budget (as last amended; see
Annex 2);
(c) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the date
for payment in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
ARTICLE 29 — ADMINISTRATIVE AND FINANCIAL PENALTIES
29.1 Conditions
Under Articles 109 and 131(4) of the Financial Regulation No 966/2012, the Agency may impose
administrative and financial penalties if a beneficiary:
(a) has committed substantial errors, irregularities or fraud or is in serious breach of its obligations
under the Agreement or
(b) has made false declarations about information required under the Agreement or for the
submission of the proposal (or has not supplied such information).
Each beneficiary is responsible for paying the financial penalties imposed on it.
Under Article 109(3) of the Financial Regulation No 966/2012, the Agency or the Commission may —
under certain conditions and limits — publish decisions imposing administrative or financial penalties.
44
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
29.2 Duration — Amount of penalty — Calculation
Administrative penalties exclude the beneficiary from all contracts and grants financed from the EU
or Euratom budget for a maximum of five years from the date the infringement is established by the
Agency.
If the beneficiary commits another infringement within five years of the date the first infringement is
established, the Agency may extend the exclusion period up to 10 years.
Financial penalties will be between 2% and 10% of the maximum EU contribution indicated, for the
beneficiary concerned, in the estimated budget (see Annex 2).
If the beneficiary commits another infringement within five years of the date the first infringement is
established, the Agency may increase the rate of financial penalties to between 4% and 20%.
29.3 Procedure
Before applying a penalty, the Agency will formally notify the beneficiary concerned:
- informing it of its intention to impose a penalty, its duration or amount and the reasons why and
- inviting it to submit observations within 30 days.
If the Agency does not receive any observations or decides to impose the penalty despite of
observations it has received, it will formally notify confirmation of the penalty to the beneficiary
concerned and — in case of financial penalties — deduct the penalty from the payment of the balance
or formally notify a debit note, specifying the amount to be recovered, the terms and the date for
payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission may
recover the amount:
(a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Agency, Commission or another executive agency (from the EU
or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date in the debit note;
(b) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
45
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
SECTION 2 LIABILITY FOR DAMAGES
ARTICLE 30 — LIABILITY FOR DAMAGES
30.1 Liability of the Agency
The Agency cannot be held liable for any damage caused to the beneficiaries or to third parties as a
consequence of implementing the Agreement, including for gross negligence.
The Agency cannot be held liable for any damage caused by any beneficiaries or third parties involved
in the action, as a consequence of implementing the Agreement.
30.2 Liability of the beneficiaries
30.2.1 Conditions
Except in case of force majeure (see Article 35), the beneficiaries must compensate the Agency for
any damage it sustains as a result of the implementation of the actione or because the action was not
implemented in full compliance with the Agreement.
Each beneficiary is responsible for paying the damages claimed from it.
30.2.2 Amount of damages - Calculation
The amount the Agency can claim from a beneficiary will correspond to the damage caused by that
beneficiary.
30.2.3 Procedure
Before claiming damages, the Agency will formally notify the beneficiary concerned:
- informing it of its intention to claim damages, the amount and the reasons why and
- inviting it to submit observations within 30 days.
If the Agency does not receive any observations or decides to claim damages despite the observations
it has received, it will formally notify confirmation of the claim for damages and a debit note,
specifying the amount to be recovered, the terms and the date for payment.
If payment is not made by the date specified in the debit note, the Agency or the Commission may
recover the amount:
(a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the
beneficiary concerned by the Agency, Commission or another executive agency (from the EU
or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date in the debit note;
46
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(b) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 79(2) of the Financial Regulation No 966/2012 and Article 299 of the Treaty on the
Functioning of the EU (TFEU).
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
SECTION 3 SUSPENSION AND TERMINATION
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE
31.1 Conditions
The Agency may — at any moment — suspend the payment deadline (see Article 16.2 to 16.4) if a
request for payment (see Article 15) cannot be approved because:
(a) it does not comply with the provisions of the Agreement (see Article 15);
(b) the technical reports or financial reports have not been submitted or are not complete or
additional information is needed, or
(c) there is doubt about the eligibility of the costs declared in the financial statements and additional
checks, reviews, audits or investigations are necessary.
31.2 Procedure
The Agency will formally notify the coordinator of the suspension and the reasons why.
The suspension will take effect the day notification is sent by the Agency (see Article 36).
If the conditions for suspending the payment deadline are no longer met, the suspension will be lifted
— and the remaining period will resume.
If the suspension exceeds two months, the coordinator may request the Agency if the suspension will
continue.
If the payment deadline has been suspended due to the non-compliance of the technical or financial
reports (see Article 15) and the revised report or statement is not submitted or was submitted but is
also rejected, the Agency may also terminate the Agreement or the participation of the beneficiary
(see Article 34.3.1).
ARTICLE 32 — SUSPENSION OF PAYMENTS
47
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
32.1 Conditions
The Agency may — at any moment — suspend, in whole or in part, the pre-financing payment and
interim payments for one or more beneficiaries or the payment of the balance for all beneficiaries,
if a beneficiary:
(a) has committed or is suspected of having committed substantial errors, irregularities, fraud or
serious breach of obligations in the award procedure or under this Agreement or
(b) has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
32.2 Procedure
Before suspending payments, the Agency will formally notify the coordinator:
- informing it of its intention to suspend payments and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the suspension procedure is not continued.
The suspension will take effect the day the confirmation notification is sent by the Agency.
If the conditions for resuming payments are met, the suspension will be lifted. The Agency will
formally notify the coordinator.
During the suspension, the periodic report(s) (see Article 15.3) must not contain any individual
financial statements from the beneficiary concerned and its affiliated entities. When the Agency
resumes payments, the coordinator may include them in the next periodic report.
The beneficiaries may suspend implementation of the action (see Article 33.1) or terminate the
Agreement or the participation of the beneficiary concerned (see Article 34.1 and 34.2).
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION
33.1 Suspension of the action implementation, by the beneficiaries
33.1.1 Conditions
The beneficiaries may suspend implementation of the action or any part of it, if exceptional
circumstances — in particular force majeure (see Article 35) — make implementation impossible or
excessively difficult.
33.1.2 Procedure
The coordinator must immediately formally notify to the Agency the suspension (see Article 36),
stating:
48
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
- the reasons why and
- the expected date of resumption.
The suspension will take effect the day this notification is received by the Agency.
Once circumstances allow for implementation to resume, the coordinator must immediately formally
notify the Agency and request an amendment of the Agreement, to set the date on which the action
will be resumed, extend the duration of the action and make other changes necessary to adapt the action
to the new situation (see Article 39) — unless the Agreement or the participation of a beneficiary has
been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This
date may be before the date on which the amendment enters into force.
Costs incurred during suspension of the action implementation are not eligible (see Article 6).
33.2 Suspension of the action implementation, by the Agency
33.2.1 Conditions
The Agency may suspend implementation of the action or any part of it:
(a) if a beneficiary has committed or is suspected of having committed substantial errors,
irregularities, fraud or serious breach of obligations in the award procedure or under this
Agreement or
(b) if a beneficiary has committed — in other EU or Euratom grants awarded to it under similar
conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations
that have a material impact on this grant (extension of findings from other grants to this
grant; see Article 17.5.2).
33.2.2 Procedure
Before suspending implementation of the action, the Agency will formally notify the coordinator:
- informing it of its intention to suspend the implementation and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the procedure is not continued.
The suspension will take effect five days after confirmation notification is received by the coordinator
(or on a later date specified in the notification).
It will be lifted if the conditions for resuming implementation of the action are met.
The coordinator will be formally notified of the lifting and the Agreement will be amended, to set the
date on which the action will be resumed, extend the duration of the action and make other changes
49
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
necessary to adapt the action to the new situation (see Article 39) — unless the Agreement has already
been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This date
may be before the date on which the amendment enters into force.
Costs incurred during suspension are not eligible (see Article 6).
The beneficiaries may not claim damages due to suspension by the Agency (see Article 30).
Suspension of the action implementation does not affect the Agency’s right to terminate the Agreement
or participation of a beneficiary (see Article 34), reduce the grant or recover amounts unduly paid
(see Articles 27 and 28).
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION
OF ONE OR MORE BENEFICIARIES
34.1 Termination of the Agreement, by the beneficiaries
34.1.1 Conditions and procedure
The beneficiaries may terminate the Agreement.
The coordinator must formally notify termination to the Agency (see Article 36), stating:
- the reasons why and
- the date the termination will take effect. This date must be after the notification.
If no reasons are given or if the Agency the Agreement will be considered to have been ‘terminated
improperly’.
The termination will take effect on the day specified in the notification.
34.1.2 Effects
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a periodic report (for the open reporting period until termination; see Article 15.3) and
(ii) the final report (see Article 15.4).
If the Agency does not receive the reports within the deadline (see above), only costs which are
included in an approved periodic report will be taken into account.
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see Article 16.4)
on the basis of the reports submitted. Only costs incurred until termination are eligible (see Article 6).
Costs relating to contracts due for execution only after termination are not eligible.
Improper termination may lead to a reduction of the grant (see Article 27).
After termination, the beneficiaries’ obligations (in particular, Articles 15, 17, 18, Section 3 of Chapter
4, 21, 22 and 24) continue to apply.
50
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
34.2 Termination of the Specific Agreement, by the Agency
34.2.1 Conditions and procedure
The participation of one or more beneficiaries may be terminated by the coordinator, on request of
the beneficiary concerned or on behalf of the other beneficiaries.
The coordinator must formally notify termination to the Agency (see Article 36) and inform the
beneficiary concerned.
If the coordinator’s participation is terminated without its agreement, the formal notification must be
done by another beneficiary (acting on behalf of the other beneficiaries).
The notification must include:
- the reasons why;
- the opinion of the beneficiary concerned (or proof that this opinion has been requested in
writing);
- the date the termination takes effect. This date must be after the notification, and
- a request for amendment (see Article 39), with a proposal for reallocation of the tasks and the
estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the
addition of one or more new beneficiaries (see Article 40). If termination takes effect after the
period set out in Article 3, no request for amendment must be included, unless the beneficiary
concerned is the coordinator. In this case, the request for amendment must propose a new
coordinator.
If this information is not given or if the Agency considers that the reasons do not justify termination,
the participation will be considered to have been terminated improperly.
The termination will take effect on the day specified in the notification.
34.2.2 Effects
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to the date
when termination takes effect.
This information must be included by the coordinator in the periodic report for the next reporting
period (see Article 15.3).
If the request for amendment is rejected by the Agency (because it calls into question the decision
awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be
terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to introduce the
necessary changes (see Article 39).
51
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Improper termination may lead to a reduction of the grant (see Article 27) or termination of the
Agreement (see Article 34).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18, Section
3 of Chapter 4, 21, 22 and 24) continue to apply.
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency
34.3.1 Conditions
The Agency may terminate the Agreement or the participation of one or more beneficiaries, if:
(a) one or more beneficiaries do not accede to the Agreement (see Article 40);
(b) a change to their legal, financial, technical, organisational or ownership situation (or those of
its affiliated entities) is likely to substantially affect or delay the implementation of the action
or calls into question the decision to award the grant;
(c) following termination of participation for one or more beneficiaries (see above), the necessary
changes to the Agreement would call into question the decision awarding the grant or breach
the principle of equal treatment of applicants (see Article 39);
(d) implementation of the action is prevented by force majeure (see Article 35) or suspended by
the coordinator (see Article 33.1) and either:
(i) resumption is impossible, or
(ii) the necessary changes to the Agreement would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants;
(e) a beneficiary is declared bankrupt, being wound up, having its affairs administered by the
courts, has entered into an arrangement with creditors, has suspended business activities, or
is subject to any other similar proceedings or procedures under national law;
(f) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has been found guilty of professional misconduct, proven by any means;
(g) a beneficiary does not comply with the applicable national law on taxes and social security;
(h) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed fraud, corruption, or is involved in a criminal organisation, money
laundering or any other illegal activity affecting the EU’s financial interests;
(i) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has — in the award procedure or under the Agreement — committed:
(i) substantial errors, irregularities, fraud or
(ii) serious breach of obligations, including improper implementation of the action,
submission of false information, failure to provide required information, breach of
ethical principles;
52
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(j) a beneficiary has committed — in other EU or Euratom grants awarded to it under similar
conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations
that have a material impact on this grant (‘extension of findings from other grants to this
grant’).
34.3.2 Procedure
Before terminating the Agreement or participation of one or more beneficiaries, the Agency will
formally notify the coordinator:
- informing it of its intention to terminate and the reasons why and
- inviting it, within 30 days of receiving notification, to submit observations and — in case of
Point (i.ii) above — to inform the Agency of the measures to ensure compliance with the
obligations under the Agreement.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify to the coordinator confirmation of the termination and the date
it will take effect. Otherwise, it will formally notify that the procedure is not continued.
The termination will take effect:
- for terminations under Points (b), (c), (e), (g) and (i.ii) above: on the day specified in the
notification of the confirmation (see above);
- for terminations under Points (a), (d), (f), (h), (i.i) and (j) above: on the day after the notification
of the confirmation is received by the coordinator.
34.3.3 Effects
(a) for termination of the Agreement:
The coordinator must — within 60 days from when termination takes effect — submit:
(i) a periodic report (for the last open reporting period until termination; see Article 15.3)
and
(ii) a final report (see Article 15.4).
If the Agreement is terminated for breach of the obligation to submit the reports (see
Articles 15.7 and 34.3.1), the coordinator may not submit any reports after termination.
If the Agency does not receive the reports within the deadline (see above), only costs which
are included in an approved periodic report will be taken into account.
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see
Article 16.4) on the basis of the reports submitted. Only costs incurred until termination takes
effect are eligible (see Article 6). Costs relating to contracts due for execution only after
termination are not eligible.
53
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
This does not affect the Agency's right to reduce the grant (see Article 27) or to impose
administrative and financial penalties (Article 29).
The beneficiaries may not claim damages due to termination by the Agency (see Article 30).
After termination, the beneficiaries’ obligations (in particular Articles 15, 17, 18, Section 3 of
Chapter 4, 21, 22 and 24) continue to apply.
(b) for termination of the participation of one or more beneficiaries:
The coordinator must — within 60 days from when termination takes effect — submit a request
for amendment (see Article 39), with a proposal for reallocation of the tasks and estimated
budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the addition of
one or more new beneficiaries (see Article 40). If termination is notified after the period set out
in Article 3, no request for amendment must be submitted unless the beneficiary concerned is
the coordinator. In this case the request for amendment must propose a new coordinator.
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to
the date when termination takes effect.
This information must be included by the coordinator in the periodic report for the next
reporting period (see Article 15.3).
If the request for amendment is rejected by the Agency (because it calls into question the
decision awarding the grant or breaches the principle of equal treatment of applicants), the
Agreement may be terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to
introduce the necessary changes (see Article 39).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18,
Section 3 of Chapter 4, 21, 22 and 24) continue to apply.
SECTION 4 FORCE MAJEURE
ARTICLE 35 — FORCE MAJEURE
‘Force majeure’ means any situation or event that:
- prevents either party from fulfilling their obligations under the Agreement,
- was unforeseeable, exceptional situation and beyond the parties’ control,
- was not due to error or negligence on their part (or on the part of third parties involved in the
action), and
54
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
- proves to be inevitable in spite of exercising all due diligence.
The following cannot be invoked as force majeure:
- any default of a service, defect in equipment or material or delays in making them available,
unless they stem directly from a relevant case of force majeure,
- labour disputes or strikes, or
- financial difficulties.
Any situation constituting force majeure must be formally notified to the other party without delay,
stating the nature, likely duration and foreseeable effects.
The parties must immediately take all the necessary steps to limit any damage due to force majeure
and do their best to resume implementation of the action as soon as possible.
The party prevented by force majeure from fulfilling its obligations under the Agreement cannot be
considered in breach of them.
CHAPTER 7 FINAL PROVISIONS
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES
36.1 Form and means of communication
Communication under the Agreement (information, requests, submissions, 'formal notifications', etc.)
must:
- be made in writing and
- bear the number of the Agreement.
Until the payment of the balance: all communication must be made through the electronic exchange
system and using the forms and templates provided there.
After the payment of the balance: formal notifications must be made by registered post with proof
of delivery (‘formal notification on paper’).
Communications in the electronic exchange system must be made by persons authorised according
to the ‘Terms and Conditions of Use of the electronic exchange system’. For naming the authorised
persons, the partner must have designated— before the signature of the Framework Partnership
Agreement — a ‘Legal Entity Appointed Representative (LEAR)’. The role and tasks of the LEAR are
stipulated in his/her appointment letter (see Terms and Conditions of Use of the electronic exchange
system).
If the electronic exchange system is temporarily unavailable, instructions will be given on the Agency
and Commission websites.
55
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
36.2 Date of communication
Communications are considered to have been made when they are sent by the sending party (i.e. on
the date and time they are sent through the electronic exchange system).
Formal notifications through the electronic exchange system are considered to have been made when
they are received by the receiving party (i.e. on the date and time of acceptance by the receiving party,
as indicated by the time stamp). A formal notification that has not been accepted within 10 days after
sending is considered to have been accepted.
Formal notifications on paper sent by registered post with proof of delivery (only after the payment
of the balance) are considered to have been made on either:
- the delivery date registered by the postal service or
- the deadline for collection at the post office.
If the electronic exchange system is temporarily unavailable, the sending party cannot be considered
in breach of its obligation to send a communication within a specified deadline.
36.3 Addresses for communication
The electronic exchange system must be accessed via the following URL:
https://ec.europa.eu/research/participants/portal/desktop/en/projects/
The Agency will formally notify the coordinator and beneficiaries in advance any changes to this URL.
Formal notifications on paper (only after the payment of the balance) addressed to the Agency must
be sent to the following address:
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA)
Health Unit Health Unit
Drosbach Building
L-2920 Luxembourg
Formal notifications on paper (only after the payment of the balance) addressed to the beneficiaries
must be sent to their legal address as specified in the 'Beneficiary Register'.
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT
37.1 Precedence of the Terms and Conditions over the Annexes
The provisions in the Terms and Conditions of the Agreement take precedence over its Annexes.
Annex 2 takes precedence over Annex 1.
37.2 Privileges and immunities
Not applicable
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES
56
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
10
In accordance with Regulation No 1182/71 , periods expressed in days, months or years are calculated
from the moment the triggering event occurs.
The day during which that event occurs is not considered as falling within the period.
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT
39.1 Conditions
The Agreement may be amended, unless the amendment entails changes to the Agreement which
would call into question the decision awarding the grant or breach the principle of equal treatment
of applicants.
Amendments may be requested by any of the parties.
39.2 Procedure
The party requesting an amendment must submit a request for amendment signed in the electronic
exchange system (see Article 36).
The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see
Annex 3).
If a change of coordinator is requested without its agreement, the submission must be done by another
beneficiary (acting on behalf of the other beneficiaries).
The request for amendment must include:
- the reasons why;
- the appropriate supporting documents, and
- for a change of coordinator without its agreement: the opinion of the coordinator (or proof that
this opinion has been requested in writing).
The Agency may request additional information.
If the party receiving the request agrees, it must sign the amendment in the electronic exchange system
within 45 days of receiving notification (or any additional information the Agency has requested). If
it does not agree, it must formally notify its disagreement within the same deadline. The deadline may
be extended, if necessary for the assessment of the request. If no notification is received within the
deadline, the request is considered to have been rejected.
An amendment enters into force on the day of the signature of the receiving party.
An amendment takes effect on the date agreed by the parties or, in the absence of such an agreement,
on the date on which the amendment enters into force.
ARTICLE 40 — ACCESSION TO THE AGREEMENT
10 Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods,
dates and time-limits (OJ L 124, 8/6/1971, p. 1).
57
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
40.1 Accession of the beneficiaries mentioned in the Preamble
The other beneficiaries must accede to the Agreement by signing the Accession Form (see Annex 3) in
the electronic exchange system (see Article 36) within 30 days after its entry into force (see Article 42).
They will assume the rights and obligations under the Agreement with effect from the date of its entry
into force (see Article 42).
If a beneficiary does not accede to the Agreement within the above deadline, the coordinator must
— within 30 days — request an amendment to make any changes necessary to ensure proper
implementation of the action. This does not affect the Agency's right to terminate the Agreement (see
Article 34).
40.2 Addition of new beneficiaries
In justified cases, the beneficiaries may request the addition of a new beneficiary.
For this purpose, the coordinator must submit a request for amendment in accordance with Article 39.
It must include an Accession Form (see Annex 3) signed by the new beneficiary in the electronic
exchange system (see Article 36).
New beneficiaries must assume the rights and obligations under the Agreement with effect from the
date of their accession specified in the Accession Form (see Annex 3).
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES
41.1 Applicable law
The Agreement is governed by the applicable EU law, supplemented if necessary by the law of
Belgium.
41.2 Dispute settlement
If a dispute concerning the interpretation, application or validity of the Agreement cannot be settled
amicably, the General Court — or, on appeal, the Court of Justice of the European Union — has sole
jurisdiction. Such actions must be brought under Article 272 of the Treaty on the Functioning of the
EU (TFEU).
As an exception, if such a dispute is between the Agency and ‘HELSEDIREKTORATE’,
‘FOLKEHELSEINSTITUTTET’, ‘VETERINAERINSTITUTTET - NORWEGIAN VETERINARY
INSTITUTE’, the competent Belgian courts have sole jurisdiction.
If a dispute concerns administrative or financial penalties, offsetting or an enforceable decision under
Article 79(2) of the Financial Regulation No 966/2012 and Article 299 TFEU (see Articles 28, 29 and
30), the beneficiaries must bring action before the General Court — or, on appeal, the Court of Justice
of the European Union — under Article 263 TFEU. Actions against enforceable decisions must be
brought against the Commission (not against the Agency).
58
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT
The Agreement will enter into force on the day of signature by the Agency or the coordinator,
depending on which is later.
SIGNATURES
For the coordinator For the Agency
[--TGSMark#signature-999997833_75_210--] [--TGSMark#signature-service_75_210--]
Armelle BARELLI with ECAS id nbarelar signed in the Signed by Jacques REMACLE with ECAS id remacjs as
Participant Portal on 28/08/2017 at 09:45:44 (transaction an authorised representative on 28-08-2017 18:01:56
id SigId-2706- (transaction id SigId-9702-
KlStvOeh6ZZLdYNvTbf2RaNo2IzMdUAQSk8ZjeS6YZTvq tEBk21LFkzI2MEyB56Rv1xH7KzqKULP3zGzmzQX8azQ
fI498swIbFQTd97zTSkXqosvMpmcKwBQfhJj6c9Q7- uWmw5t6LNzYcKbZXrrVu1wIR6PcPYBzsykV5AQHVu6Z
Jj71zxYb8yrN6HT4pVHCoC- WT-Jj71zxYb8yrN6HT4pVHCoC-
59
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Health Unit
ANNEX 1 (part A)
Project
NUMBER — 761296 — EU-JAMRAI
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Table of Contents
1.1. The project summary................................................................................................................................. 3
1.2. The list of beneficiaries..............................................................................................................................4
1.3. Workplan Tables - Detailed implementation..............................................................................................6
1.3.1. WT1 List of work packages........................................................................................................... 6
1.3.2. WT2 List of deliverables................................................................................................................ 7
1.3.3. WT3 Work package descriptions................................................................................................. 10
Work package 1......................................................................................................................... 10
Work package 2......................................................................................................................... 13
Work package 3......................................................................................................................... 18
Work package 4......................................................................................................................... 24
Work package 5......................................................................................................................... 28
Work package 6......................................................................................................................... 33
Work package 7......................................................................................................................... 40
Work package 8......................................................................................................................... 45
Work package 9......................................................................................................................... 51
1.3.4. WT4 List of milestones................................................................................................................ 55
1.3.5. WT5 Critical Implementation risks and mitigation actions........................................................... 60
1.3.6. WT6 Summary of project effort in person-months.......................................................................63
1.3.7. WT7 Tentative schedule of project reviews.................................................................................66
1.4. Ethics Requirements................................................................................................................................ 67
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.1. The project summary
Project Number 1 761296 Project Acronym 2 EU-JAMRAI
One form per project
General information
Project title 3
European Joint Action on antimicrobial resistance and associated infections
Starting date 4 01/09/2017
Duration in months 5 36
Call (part) identifier 6 HP-JA-2016
HP-JA-04-2016
Topic
Antimicrobial resistance and Health Care Associated Infections
Fixed EC Keywords
Antimicrobial resistance, Health-Care Associated Infections, One Health , Public Health
Free keywords
Policies, Research
Abstract 7
Antimicrobial resistance (AMR) is a serious public health threat that is gaining swift ground. The increase of multi-
resistant bacteria associated to the lack of new antibiotics represents a threat to global health. Some patients are faced
with no therapeutic solutions as some bacteria resist to all antibiotics. Moreover, “old” antibiotics and to some extent
more “recent” ones are gradually removed from the market because they are not economically sustainable, albeit being
still possibly efficient. The issue of antimicrobial resistance is a real challenge that decision-makers are well aware of
and has gained a high priority among public health challenges.
A closely related challenge is the issue of Healthcare Associated Infections that shall not be considered separately.
In fact, infection prevention and control strategies should go hand in hand with i) prudent use of antibiotics ii)
appropriate tools for monitoring and surveillance and iii) accurate diagnostic tests to decide on the right therapy.
The various national, European and international initiatives that have emerged over the last decade have shown a great
commitment to actively tackle these issues.It is essential that all actors in the field of AMR join forces so as to avoid
duplication of efforts and ensure greater coherence. Moreover, it is essential that the strategies adopted extend beyond
the sole human health domain and bring a global One Health response.
The overall objective of the AMR-HCAI JA is to ensure that policies for control of AMR and HCAI are adopted and
implemented across EU MS in a coordinated way, ensuring national specificities are accounted for, in line with the
ECDC and WHO guidelines and recommendations, and in conjunction with other European initiatives.This will be
made possible by bringing together different networks of policy makers, experts and organizations on AMR and HCAI
working in different European and International initiatives and projects relevant for policy decision.
Page 3 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.2. List of Beneficiaries
Project Number 1 761296 Project Acronym 2 EU-JAMRAI
List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
INSTITUT NATIONAL DE LA SANTE ET
1 INSERM France 1 36
DE LA RECHERCHE MEDICALE
MINISTERE DES AFFAIRES SOCIALES
2 MoH-FR France 1 36
ET DE LA SANTE
3 GESUNDHEIT ÖSTERREICH GMBH GÖG Austria 1 36
SERVICE PUBLIC FEDERAL SANTE
4 PUBLIQUE, SECURITE DE LA CHAINE FPS HFCSE Belgium 1 36
ALIMENTAIRE ET ENVIRONNEMENT
NATIONAL CENTER OF INFECTIOUS
5 NCIPD Bulgaria 1 36
AND PARASITIC DISEASES
HRVATSKI ZAVOD ZA JAVNO
6 CIPH Croatia 1 36
ZDRAVSTVO
7 STATNI ZDRAVOTNI USTAV NIPH Czech Republic 1 36
8 STATENS SERUM INSTITUT SSI Denmark 1 36
9 TERVISEAMET TA Estonia 1 36
10 ROBERT KOCH-INSTITUT RKI Germany 1 36
KENTRO ELENCHOU & PROLIPSIS
11 HCDCP Greece 1 36
NOSIMATON
12 ETHNIKI SCHOLI DIMOSIAS YGEIAS ESDY-NSPH Greece 1 36
DIOIKHSH YGEIONOMIKHS
13 7HC Greece 1 36
PERIFEREIAS KRHTHS
14 UNIVERSITA DEGLI STUDI DI FOGGIA UNIFG Italy 1 36
15 ISTITUTO SUPERIORE DI SANITA ISS Italy 1 36
PAULA STRADINA KLINISKA
16 PSKUS Latvia 1 36
UNIVERSITATES SLIMNICA
LIETUVOS SVEIKATOS MOKSLU
17 UNIVERSITETO LIGONINE KAUNO LSMULKK Lithuania 1 36
KLINIKOS
VIESOJI ISTAIGA VILNIAUS
18 UNIVERSITETO LIGONINE SANTAROS VULSK Lithuania 1 36
KLINIKOS
19 HIGIENOS INSTITUTAS HI Lithuania 1 36
NACIONALINIS VISUOMENES
20 SVEIKATOS CENTRAS PRIE SVEIKATOS NVSC Lithuania 1 36
APSAUGOS MINISTERIJOS
MINISTERIE VAN VOLKSGEZONDHEID,
21 VWS Netherlands 1 36
WELZIJN EN SPORT
22 HELSEDIREKTORATE HdiR Norway 1 36
Page 4 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
23 FOLKEHELSEINSTITUTTET FHI Norway 1 36
VETERINAERINSTITUTTET -
24 NVI Norway 1 36
NORWEGIAN VETERINARY INSTITUTE
25 NARODOWY INSTYTUT LEKOW NMI Poland 1 36
MINISTERIO DA SAUDE - REPUBLICA
26 DGS Portugal 1 36
PORTUGUESA
UNIVERSITATEA DE MEDICINA SI
27 FARMACIE IULIU HATIEGANU CLUJ- UMPIH Romania 1 36
NAPOCA
NACIONALNI INSTITUT ZA JAVNO
28 NIJZ Slovenia 1 36
ZDRAVJE
AGENCIA ESPANOLA DE
29 MEDICAMENTOS Y PRODUCTOS AEMPS Spain 1 36
SANITARIOS
DEPARTAMENT DE SALUT -
30 GENCAT Spain 1 36
GENERALITAT DE CATALUNYA
31 CONSELLERIA DE SALUD IdISBa Spain 1 36
FUNDACION PARA LA FORMACION E
32 INVESTIGACION SANITARIAS DE LA FFIS Spain 1 36
REGION DE MURCIA
33 FUNDACION PUBLICA MIGUEL SERVET FMS Spain 1 36
34 SERVICIO ANDALUZ DE SALUD SAS Spain 1 36
35 INSTITUTO DE SALUD CARLOS III ISCIII Spain 1 36
36 SERVICIO MADRILENO DE SALUD SERMAS Spain 1 36
37 FOLKHALSOMYNDIGHETEN FoHM Sweden 1 36
38 SOCIALSTYRELSEN SoS Sweden 1 36
39 STATENS JORDBRUKSVERK SBA Sweden 1 36
40 LIVSMEDELS VERKET NFA Sweden 1 36
STATENS VETERINAERMEDICINSKA
41 SVA Sweden 1 36
ANSTALT
VETENSKAPSRADET - SWEDISH
42 SRC Sweden 1 36
RESEARCH COUNCIL
43 UPPSALA LANS LANDSTING UAS Sweden 1 36
AGENCE NATIONALE DE LA SECURITE
44 SANITAIRE DE L ALIMENTATION DE L ANSES France 1 36
ENVIRONNEMENT ET DU TRAVAIL
Page 5 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3. Workplan Tables - Detailed implementation
1.3.1. WT1 List of work packages
Person- Start End
WP Number 9 WP Title Lead beneficiary 10
months 11 month 12 month 13
WP1 Coordination 1 - INSERM 54.20 1 36
WP2 Dissemination 29 - AEMPS 70.60 1 36
WP3 Evaluation of the project 15 - ISS 22.00 1 36
Integration into national policies
WP4 2 - MoH-FR 16.40 3 36
and sustainability
Implementation of One Health
WP5 national strategies and National 21 - VWS 132.60 1 36
Action Plans for AMR
Policies for prevention of Health-
WP6 Care-Associated Infections and 37 - FoHM 341.40 1 36
their implementation
Appropriate use of antimicrobials
WP7 23 - FHI 334.60 1 36
in human and animals
Awareness raising and
WP8 29 - AEMPS 91.60 1 36
Communication
Prioritizing and implementing
WP9 research and innovation for public 1 - INSERM 84.30 1 36
health needs
Total 1,147.70
Page 6 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3.2. WT2 list of deliverables
Due
Deliverable WP Lead Dissemination
Deliverable Title Type 15 Date (in
Number 14 number 9 beneficiary level 16
months) 17
Confidential,
only for members
of the consortium
D1.1 Interim reports WP1 1 - INSERM Report 18
(including the
Commission
Services)
Confidential,
only for members
of the consortium
D1.2 Final report WP1 1 - INSERM Report 36
(including the
Commission
Services)
D2.1 Dissemination plan WP2 29 - AEMPS Report Public 10
D2.2 Layman report WP2 29 - AEMPS Report Public 33
Final conference on
D2.3 WP2 29 - AEMPS Report Public 36
dissemination
Confidential,
only for members
of the consortium
D3.1 Evaluation plan WP3 15 - ISS Report 4
(including the
Commission
Services)
Confidential,
only for members
Validation of the of the consortium
D3.2 WP3 15 - ISS Report 12
evaluation tools (including the
Commission
Services)
Confidential,
Progress monitoring only for members
and quality assessment of the consortium
D3.3 WP3 15 - ISS Report 12
of JA documentation (including the
and deliverables Y1 Commission
Services)
Confidential,
Progress monitoring only for members
and quality assessment of the consortium
D3.4 WP3 15 - ISS Report 24
of JA documentation (including the
and deliverables Y2 Commission
Services)
Confidential,
Progress monitoring only for members
and quality assessment of the consortium
D3.5 WP3 15 - ISS Report 36
of JA documentation (including the
and deliverables Y3 Commission
Services)
Page 7 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Due
Deliverable WP Lead Dissemination
Deliverable Title Type 15 Date (in
Number 14 number 9 beneficiary level 16
months) 17
Confidential,
only for members
Report on stakeholders
of the consortium
D3.6 evaluation and on JA WP3 15 - ISS Report 36
(including the
impact in Europe
Commission
Services)
Integration plan and
D4.1 WP4 2 - MoH-FR Report Public 30
sustainability Strategy
Report on integration
D4.2 WP4 2 - MoH-FR Report Public 30
plan
Updated report on
D4.3 WP4 2 - MoH-FR Report Public 36
integration plan
Report on
D4.4 WP4 2 - MoH-FR Report Public 36
sustainability plan
Tool for country self-
D5.1 WP5 21 - VWS Report Public 6
assessments
Summary Country-to-
D5.2 WP5 21 - VWS Report Public 36
country assessments
Overview enforcement
and recommendations
D5.3 WP5 21 - VWS Report Public 36
to be presented to the
One Health Network
Assessment of the
cost-benefit for the
D5.4 implementation of WP5 11 - HCDCP Report Public 36
an infection control
program
Revised guidelines for
the implementation
D6.1 of infection control WP6 11 - HCDCP Report Public 13
program in healthcare
settings
An Universal Infection
Control framework
with specific roles,
priorities, resources
D6.2 and interventions for WP6 11 - HCDCP Report Public 36
the implementation of
an infection control
plan in healthcare
settings
Report on experience
from country teams
D6.3 of introducing and WP6 37 - FoHM Report Public 18
working with the
implementation model
Page 8 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Due
Deliverable WP Lead Dissemination
Deliverable Title Type 15 Date (in
Number 14 number 9 beneficiary level 16
months) 17
Updated report on
experience from
country teams of
D6.4 WP6 37 - FoHM Report Public 36
introducing and
working with the
implementation model
Experience from
non-EU country
D6.5 WP6 37 - FoHM Report Public 36
teams of introducing
implementation model
Websites,
Website with
patents
D7.1 evaluated tools and WP7 23 - FHI Public 12
filling,
information
etc.
Report on workshop
of models for
D7.2 WP7 23 - FHI Report Public 13
implementation of
stewarship tools
Indicators used for
monitoring antibiotic
D7.3 WP7 23 - FHI Report Public 36
use and resistance in
humans and animals
Surveillance of
D7.4 antimicrobial use and WP7 34 - SAS Report Public 36
resistance in human
Surveillance of
D7.5 antimicrobial use and WP7 44 - ANSES Report Public 36
resistance in animal
Awareness and
D8.1 WP8 29 - AEMPS Report Public 10
Communication Plan
European Prize: better
journalism report or
D8.2 WP8 29 - AEMPS Report Public 27
better video about
antibiotics
European competition
D8.3 with High Schools WP8 29 - AEMPS Report Public 32
students
Awareness and
D8.4 Communication High WP8 29 - AEMPS Report Public 34
Level Meeting
National priority-
D9.1 WP9 1 - INSERM Report Public 34
setting best practices
Implementation
D9.2 strategy for EU WP9 23 - FHI Report Public 36
collaboration
Dissemination
D9.3 WP9 1 - INSERM Report Public 36
strategies
Page 9 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3.3. WT3 Work package descriptions
Work package number 9 WP1 Lead beneficiary 10 1 - INSERM
Work package title Coordination
Start month 1 End month 36
Objectives
The main objective of this WP is to set up an effective management framework and ensure the smooth management and
coordination of the project towards the planned objectives through effective internal communication.
The specific objectives of this WP are three-fold:
1. At the strategic level, to ensure that the project reaches its objectives;
2. At the managerial level, to put in place the procedures and tools needed to ensure that the project progresses in
conformity with the work plan and produces timely and quality results as well as overseeing conformity of all activities
to EC rules and the Consortium agreement;
3. At the administrative level, to organise project meetings, prepare project reports, manage the project budget and
payments.
Description of work and role of partners
WP1 - Coordination [Months: 1-36]
INSERM, MoH-FR
Task 1.1 : Strategic steering
Leader: INSERM / Contributors: Governance bodies / Start date: M1 End date: M36
Task description: this task involves setting up and managing the relevant steering and management bodies described
fully in section:
• General Assembly: deciding board made up of one representative per associated partner
• Executive Board: operational body made up of WP leaders
• Steering Committee: composed of one representative (competent authority) from each Member State. The members
will be nominated at the start of the project.
• Stakeholders Forum: composed of external experts from international organizations such as WHO, ECDC, OECD,
EFSA, OIE, FAO and other representatives from healthcare professionals’ organizations and of patients (see section 9
for details). The members will be nominated at the start of the project.
This governance structure will ensure the relevance of the JA AMR HCAI activities in line with the work plan and
national and European strategies.
Task 1.2: Contractual and financial management
Leader: INSERM / Contributors: WP Leaders / Start date: M1 End date: M36
Task description: this task will be coordinated by the Joint Action Secretariat (JAS) that will be responsible for the
day-to-day management. It is composed of the project coordinator (Marie-Cécile Ploy, INSERM) assisted by resources
including a project manager based at INSERM. The JAS will be in charge of:
• Preparation of the Consortium Agreement to be signed by all beneficiaries at the start of the project
• Appraisal and monitoring of the project costs in order to oversee and check the overall costs incurred per work package
and per participant
• Management and distribution of EC payments
• Assistance to individual project partners on specific administrative and financial issues
The PMT will meet monthly and will hold every 4 months teleconferences with the Executive Board to share updates
on progress of the WPs.
Task 1.3 : Periodic reporting
Leader: INSERM / Contributors: Executive Board (technical), All partners (financial reporting) / Start date: M1 End
date: M36
Task description: this task will:
• Monitor the progress of the project in terms of deliverables, milestones, etc., using dedicated project management tools;
• Identify and monitor risks and propose appropriate mitigation measures to the General Assembly and the Steering
Committee;
• Prepare periodic and final reporting to ensure timely and efficient submission to the EC
Page 10 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Task 1.4 : Communication: internal and with CHAFEA / DG SANTE
Leader : INSERM; Participants: MoH-FR / Start date: M1 End date: M36
Task description: the following activities will be carried out:
• To use the project website to be set up in WP2. It will act as a platform to share internal project documents;
• Regular web/audio conferences to support WP collaboration and interactions;
• Every 4 months, activity reports updating all project collaborators on the project activities;
The project coordinator will act as the official representative towards the CHAFEA and DG SANTE. The project
coordinator will provide those two interims and a final report, assisted by the JAS (composed of a project manager at
Inserm and an assistant manager at MoH-FR).
Participation per Partner
Partner number and short name WP1 effort
1 - INSERM 46.00
2 - MoH-FR 8.20
Total 54.20
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Confidential, only
for members of
the consortium
D1.1 Interim reports 1 - INSERM Report 18
(including the
Commission
Services)
Confidential, only
for members of
the consortium
D1.2 Final report 1 - INSERM Report 36
(including the
Commission
Services)
Description of deliverables
D1.1 : Interim reports [18]
This report describes the activities carried out, milestones and results achieved in the first half of the project.
Deliverables can be attached as annexes.
D1.2 : Final report [36]
This report describes the project implementation and the results achieved. The deliverables are annexed.
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Organisation of the kick-
MS1 Kick-off meeting 1 - INSERM 1
off meeting completed
Page 11 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
(meeting, agenda &
preparatory documents)
The Steering
The Steering committee
committee and
MS2 1 - INSERM 2 and Advisory Boards
Advisory Boards
Forum are set up
Forum are set up
Organisation of First
annual meeting completed
MS3 First annual meeting 1 - INSERM 10
(meeting, agenda &
preparatory documents)
Organisation of second
Second annual annual meeting completed
MS4 1 - INSERM 22
meeting (meeting, agenda &
preparatory documents)
Page 12 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP2 Lead beneficiary 10 29 - AEMPS
Work package title Dissemination
Start month 1 End month 36
Objectives
The main objective of this WP is to ensure correct dissemination on high quality information on JA deliverables and
progress among targeted groups through organised dissemination activities, which in turn will allow for sustainability
beyond the project end. The specific objectives of this WP are to:
• Develop an internal communication strategy to ensure back and forth communication amongst WPs to build on the
work coming from all the different WPs within the JA.
• Develop external communication strategies to disseminate information on JA both to general public and stakeholders
as well as ensuring the promotion of the project outcomes and results amongst the targeted public and stakeholders.
• To widely and effectively coordinate and disseminate research outcomes and results through various channels,
including online dissemination channels (website; twitter; Facebook; newsletter) so that we can actively engage all
partners and stakeholders throughout the course of the project to ensure applicable and appropriate results to the targeted
public and partners.
Description of work and role of partners
WP2 - Dissemination [Months: 1-36]
AEMPS, INSERM, MoH-FR, GÖG, FPS HFCSE, NCIPD , CIPH, NIPH, SSI, TA, RKI, HCDCP, ESDY-NSPH,
UNIFG, ISS, PSKUS, LSMULKK, VULSK, HI, NVSC, VWS, HdiR, FHI, DGS, UMPIH, NIJZ, FFIS, FMS, SAS,
ISCIII, FoHM, SRC, ANSES
WP Methodology
In order to meet the main objectives, WP2 will pay special attention to both, its internal and external communication
and will line up a qualified team for its development. A wide variety of dissemination methods and tools to inform,
engage and promote the outcomes of the JA will be put in place.
To start with, all WPs will designate a contact person to collaborate with WP2 for all matters related to dissemination
activities (events, articles, reports…). Communication between the WP2 leader and each WP contact person (informing
WP leaders and also the coordinator) will be carried out via email on regular basis, and also via TLC, depending on
the project’s needs.
WP2 facilitates coherent and sustainable external communication of the JA and ensures that its objectives, activities,
results, and deliverables are known. In order to do so, AEMPS will develop a dissemination plan that is planned to cover
relevant stakeholders and identify the appropriate timing of release of interim and final results through appropriate and
effective dissemination activities such as conferences, congresses or publications so that widespread dissemination is
achieved. This plan will be a living document and will be monitored and adapted to reflect progress and changes.
The main dissemination tools (website, leaflet, layman report...) and materials will be produced in English. There will
be the option to send the same material translated into different languages (translated by the country itself), however,
that would depend on the tool or activity (relevance) and the resources of the country to carry out this translation and
work. Each participant will ensure language is appropriate for the audiences addressed. This WP will ensure the quality
of the website and tools as well as engage with other WP leaders and partners so as to ensure the appropriate level of
dissemination for each of the WP outputs, services, tools, events, etc.
Task 2.1: Design of a dissemination plan
Leader: AEMPS / Start date: M1 End date: M10
The main principles in order to elaborate the dissemination plan will be: Defining key messages, establishing target
audiences and selecting the appropriate tools and activities so that we can achieve the following aims of this task:
• To ensure that the results and deliverables are known to all partners and available to all key audiences and target groups
• To bring knowledge, experience and best practice together in order to achieve the objectives, activities, results and
deliverables are known to all identified stakeholders and wider audience on EU and national / regional levels.
• Assist different WPs in their communicational needs. Thus, active and collaborating partners will be able to ask for
support for any sort of dissemination event or activity related to their own aims, as well as any advice to develop any
of their initiatives. This assistance will strengthen the dissemination and make it more effective.
Page 13 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Creation of an official website with the aim of gathering and collecting a group of useful reference tools that could
be progressively updated.
Task 2.2: Communication tool-kit (visual identity)
All the dissemination related material, such as project logo, templates for internal and public documents, leaflet format,
etc., will be defined at the very beginning of the project in order to establish the project image as soon as possible. The
corporate identity and communication tools will be developed for the project in line with what will be developed by
JA to ensure consistency.
Leader: AEMPS / Start date: M1 End date: M12
Task description: a tool-kit will be developed, including
• Logo and claim: they should incorporate the project mission into one single graphic along with a catchy slogan/claim
able to engage with the target audience. Logo will indicate co-foundation as do other materials.
• Web banner design as an extra tool, complementary one, for all the others (logo etc. ).-
• Develop Templates: Word, Power point
• Leaflets and Factsheet: Editing, publication and distribution of promotional leaflet for broad public with focus on the
promotion of JA objectives and planned activities that constitutes Leaflet will contain also logo - JA visual identity and
distribution will be realized according stakeholder analysis within the first period of the dissemination plan. This tool
will be targeted at all stakeholders through online dissemination channel website, e – mail. Two “official” leaflets will be
produced during the JA. One first hand-out disseminated at an early stage of the JA to inform people about the project,
and which would include a general description of the project goals, aimed at informing the target groups about the
project existence and the planned activities. The second leaflet to be issued in the later stages of the JA when the results
are more visible and tangible. Special leaflet can also be created for promotional purposed for a special Conference
where our Joint Action can be represented and promoted.
• Distribution List
• Newsletter sent to different countries and different stakeholders, produced 3-monthly (M 1,4, 7,10,13,16, 19, 22, 25,
28, 31, 34). The exact timing could be adapted according to JA events and meetings, milestones, political occasions or
presidency activity. Dissemination channel used: website, e – mail, social media. Newsletter will be free to view and
download on our website.
• Social media communications strategy will be an essential component of the overall communications strategy of the
JA (Dissemination through twitter and facebook of all events/results related to JA)
• Website is the main tool where all the outcomes will be collected. (see task 2.4)
Task 2.3: Identification of the relevant target audiences and their expectations from the JA
Leader: AEMPS; Start date:M1 End date:M36
Task description: to design a plan that allows for dissemination strategies, it will be necessary to build a consistent
strategy based on a stakeholder analysis that has carefully planned to cover different target groups to allow maximizing
the impact of the efforts. The first step will be the identification of the relevant target audiences by a stakeholder analysis
looking at the different users of the JA relevant information and their needs in regards with this output at EU level
and within MSs. This analysis will include 4 target groups i.e. citizens (that includes patients and the mass media),
healthcare professionals (HCP, managers, veterinarians), industries (agribusiness, livestock farming), and authorities
(governments, regulators, public health and food safety agencies). This work will be conducted with the support of the
stakeholder forum. Regular updates will be conducted since new target audiences might arise regularly
In order to analyze the target audience/stakeholders involvement on AMR and HCAI, it would be possible to use social
networks analysis tool.
Regular updates will be conducted since new target audiences might arise regularly
Task 2.4: Web site Design: Internal and external use
Leader: AEMPS ; Contributors: UMPIH/ Start date:M1 End date:36
Task description: A website as central hub for internal communication as well as main platform to communicate outputs
and disseminate the information to the targeted audiences. This task is one of the most important dissemination tools
for the second JA period (2nd and 3rd year) and will aim to :
• Design a sharing platform (see task 2.4) as for internal communication.
• Design and Implementation of a web platform (use of English for all dissemination activities) as for external
dissemination. We believe the JA would benefit from easy to use software that will enable correct classification, efficient
search and interactive collaboration.
• Used of the web banner designed (see task 2.1) on the webs of beneficiaries and collaborative partners. This banner
will boost the JA visibility and will lead other websites' visitors to get to JA website
Page 14 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The first part of this task will involve the development of an interactive file-sharing platform where all partners can
interact and share relevant information. This platform will have private access for the partners and the capacity of store
the information.
The informative content of the website whose access is opened to all public, will consist partly of the information of the
project (each WP will have a section etc.) and also a section to publish project news, events and all relevant information.
This website activity will be regularly monitored through feedback via public tools (Google analytics) and internal
methods (internal communications working groups, surveys, etc)
The benefit of developing this website in a way that best suits the needs of the project will ensure the key role of WP2 as
the coordinating body of the dissemination activities for the project and make sure that results and relevant information
produced over the lifetime of the project will not be lost and can continue to be a crucial part of JA products and services
well into the future. It will include conferences and materials produced for each WP and websites of interest that can
be shared as a tool for people to access relevant information about the JA and the topic.
Task 2.5: Implement the Dissemination Plan
Leader: AEMPS ; Contributors: UMPIH/ Start date:M1 End date:36
Task description:
The main principles in order to ensure the implementation of the dissemination plan will be:
• Implementation of contents related to the JA: reports, interviews to key spokesperson within the JA and general
information about AMR and HCAI. Video interviews will allow us to edit the clips or promos that will energize the
website. For example, animated infographics videos will also contribute to get some more attention into the project.
• Encourage the participation of all partners in international seminars and conferences to promote the project. WP
leaders/co-leaders will be responsible for writing at least one (informative) editorial related to the JA specific results
and send it to the WP2 leader/co-leader. This editorial will be then disseminated by each partner through their networks/
social media channels and to any known relevant organization and/or person of interest they may consider. On the other
hand, all these editorials will be gathered on the main website of the JA and maybe, as an idea, also the summaries of
those articles could be gathered on a wordpress/blog to help disseminate and engage more public.
• To develop one promotional online campaign (competition or game, at European level) in the 2nd and 3rd years to
attract general public to the website (campaign non-related to promote communication materials). For example in a
previous JA, that WP2 prepared a Facebook competition and games to attract public, offering certain limited number
of T-Shirts designed and signed by one celebrity and with a message related to antibiotic use. Also, another example
would be a photography contest related to the overuse of medicines or something similar to get people thinking about
the topic in their day-to-day life. This might be used at European level.
• To plan press releases informing about newsworthy outcomes and activities. Newsletters.
• Layman report: At the end of the project, beneficiaries should produce a Layman’s report, a comprehensive information
brochure targeted at a non-specialist audience. It serves to inform decision makers and non-technical parties of the
project objectives and results with a full overview of the project outcomes.
• To organise a final Dissemination Conference (3º year). A final Conference will be organized at the end of the
project to disseminate the project results. This Conference will target at researchers, clinicians and general practitioners,
professional associations, mass media, patient organizations, etc., and also participate some representatives of the JA
active partners.
• To be able to verify if the strategy was well chosen and well implemented through an evaluation component (in
collaboration with WP3) into all dissemination activities to monitor the quality and to verify whether they have achieved
their aim.
Participation per Partner
Partner number and short name WP2 effort
1 - INSERM 4.00
2 - MoH-FR 1.70
3 - GÖG 0.10
4 - FPS HFCSE 0.50
5 - NCIPD 0.70
6 - CIPH 0.20
Page 15 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Partner number and short name WP2 effort
7 - NIPH 0.50
8 - SSI 0.50
9 - TA 2.00
10 - RKI 0.10
11 - HCDCP 1.00
12 - ESDY-NSPH 1.00
14 - UNIFG 0.40
15 - ISS 1.00
16 - PSKUS 1.00
17 - LSMULKK 1.00
18 - VULSK 1.00
19 - HI 0.50
20 - NVSC 0.10
21 - VWS 2.00
22 - HdiR 0.10
23 - FHI 1.50
26 - DGS 1.00
27 - UMPIH 2.50
28 - NIJZ 1.50
29 - AEMPS 39.00
32 - FFIS 1.00
33 - FMS 0.50
34 - SAS 1.00
35 - ISCIII 0.80
37 - FoHM 1.00
42 - SRC 0.40
44 - ANSES 1.00
Total 70.60
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
D2.1 Dissemination plan 29 - AEMPS Report Public 10
D2.2 Layman report 29 - AEMPS Report Public 33
Final conference
D2.3 29 - AEMPS Report Public 36
on dissemination
Page 16 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Description of deliverables
A dissemination plan, a layman report and a final conference on dissemination will be delivered in WP2.
D2.1 : Dissemination plan [10]
Dissemination plan report
D2.2 : Layman report [33]
Layman report
D2.3 : Final conference on dissemination [36]
Conference event agenda and minutes
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Communication tool-
MS5 29 - AEMPS 6 Communication tool-kit
kit
Dissemination Plan:
Dissemination Plan:
MS6 intermediate control 29 - AEMPS 7
intermediate control point
point
Layman report:
intermediate control point
MS7 Layman report 29 - AEMPS 30
about document design
and draft
Final Conference
Final Conference on
MS8 29 - AEMPS 30 on dissemination:
dissemination
intermediary control point
Page 17 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP3 Lead beneficiary 10 15 - ISS
Work package title Evaluation of the project
Start month 1 End month 36
Objectives
The main objectives of this WP are:
(i) to assess the achievement of the project objectives;
(ii) to assess whether the outcomes meet the needs of the target groups.
The specific objectives of WP3 are:
1. Develop, share and disseminate an Evaluation Plan (EP);
2. Develop Evaluation Tools (ETs) for data collection according to the EP;
3. Perform interim and final evaluation;
4. Develop quality assessment and report it as a specific paragraph/chapter in JA deliverables and documentation;
5. Report and share the evaluation results to participants and relevant stakeholders;
6. Evaluate the impact of JA in Europe (MS and regional governments).
Description of work and role of partners
WP3 - Evaluation of the project [Months: 1-36]
ISS, INSERM, MoH-FR, HCDCP, UNIFG, VWS, FHI, AEMPS, FFIS, FoHM
WP Methodology
The evaluation process will include two major issues:
i) Progress and results evaluation (Internal evaluation);
ii) Quality evaluation (External evaluation).
The details of the evaluation process will be included in the Evaluation Plan (EP).
Relevant stakeholders will be engaged in the different phases of the evaluation process:
• one or more delegates for every WP and ECDC (due to its experience in infection prevention and control) for Internal
evaluation (progress and results evaluation);
• Institutions at national (e.g. representatives of Ministry of Health, Agriculture, Environment, Research) and regional/
local level, Policy-makers, Industries, Patients Association, Healthcare professionals Association, Scientific Societies
(ECDC, EPHA), International Organizations (WHO Europe, OECD, FAO) for External evaluation (quality evaluation).
In order to reach the main objective (i) (progress and results evaluation), for every single JA objective and milestone
process, output and outcome will be explored through specific indicators, defined and shared with WPs’ leaders and
relevant stakeholders.
These indicators will help evaluating the project progress, outcomes, impact and expected and unexpected development.
Tools
i. Surveys through on-line questionnaires designed to be completed through self-assessment at country level by project
participants and internal stakeholders;
ii. Recording data out of routine documentation of WPs and pre-release deliverables (data from internal WP surveys,
training materials, developed guidelines, operations manual, recommendations, results of pilot projects, questionnaire
exploring: the carrying out and accomplishments of general and technical meetings, characteristics of participants,
outcomes emerged and appreciation degree);
iii. Meetings (on-line or face to face) to agree the Evaluation Plan, agree and share Evaluation Tools and share reports
(interim and final) results with participant representatives of all JA WPs.
In order to reach the main objective (ii) (quality evaluation), the evaluation plan will be based on comments, suggestions
and/or recommendation made by the Steering Committee and the Stakeholders Forum, which will give their contribution
to assess:
• accuracy of Evaluation Plan in all its phases and efficacy and usefulness of Evaluation tools;
• relevance of JA AMR and HAI issues perceived at different level (institutional, academic and operational level);
• reproducibility, truthfulness and completeness of data provided by WPs’ leaders and partners (e.g. through surveys’
questionnaires) through National and Regional health institutions web-sites consultation, requests for integrations/
clarifications, dispatch of additional documentation, etc.;
Page 18 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• comprehensiveness and accessibility of contents of deliverables and documentation released (e.g. clarity and realistic
nature of conclusion and proposal);
• representativeness and relevance of stakeholders engaged and experts involved and of their performance;
• satisfaction degree about JA strategies, actions, tools and outcomes by policy makers, HCWs, Patients Associations
and other stakeholders.
Tools
i. Surveys through on-line questionnaires designed to be completed through self-assessment at country level;
ii. Consultations involving different participants and stakeholders (WP leaders and partners, external stakeholders...)
experts in HAI prevention and AMR;
iii. Meetings (on-line or face to face) to share reports (interim and final) with external stakeholders.
iv. EU MS National and Regional health institutions web-sites consultation for the availability of official data.
Progress and results evaluation and Quality evaluation will be included in interim and final reports, which will be shared
with both internal and external stakeholders.
The team of evaluators will be composed by several professionals from Institutions/University with expertise in “projects
evaluation” and previously engaged in similar experiences, both from Institution participating in the JA or subcontracted.
Task descriptions
Task 3.1: Definition of the evaluation plan (EP)
Leader: ISS ; Contributors: DGPIFAC / Start date: M1 End date: M4
Task description: EP, specifying evaluation activities, will be developed by the WP3 leader based on the set of defined
indicators and reviewed by collaborating with representatives of all relevant JA WPs. The evaluation activities will
include data recording out of routine documentation of WPs and pre-release deliverables, surveys (conducted through
web-based questionnaires) and consultations involving different participants and stakeholders, and monitoring with a
calendar of JA milestones. For each of these activities the evaluation plan will identify specific responsibilities, time
for completion and mode of data collection for evaluation.
Revision of the EP will be carried out during the project, if necessary.
Specific and well-defined actions:
i. assessment of the achievement of every single WP tasks and outputs;
ii. the respect of the defined timeline and deadlines for WPs activities and outputs;
iii. assessment of the correct development of general and technical meetings;
iv. monitoring (support, early reaction, securing data) of the calendar of JA milestones;
v. engagement of every single WPs leader and associated partner who contribute to the development of WP3 by
providing evaluation information on their own activities, attended events (meetings, conferences, etc.) and deliverables.
Task 3.2: Development of evaluation tools.
Leader: ISS (subcontracting) ; Contributors: DGPIFAC / Start date: M1 End date: M36
Task description: Based on the definition of the EP, ETs will be developed to collect all information that is not easily
accessible by data recording out of routine documentation of WPs and pre-release deliverables and require instead
surveys and consultations involving different participants and stakeholders. This task will include the definition and
implementation of web based tools to facilitate data collection and surveys conduction. Prior to use, ETs will be reviewed
by all relevant stakeholders included the participants of the Stakeholders forum, this will maximise evaluation response
rate and avoid issues during data collection activities, thus minimising risks for the task. All ETs will be tested and
piloted before their use and they will be revised during the project, if necessary.
Task 3.3: Conduct interim and final evaluation.
Leader: DGPIFAC; Contributors: UNIFG, ISS / Start date: M5 End date: M36
Task description: based on the EP, interim and final evaluation activities will be carried out to monitor the implementation
process for WPs activities and assessment of achievement of JA specific objectives. Evaluation activities (as described
in the EP, see task 3.1) will provide information on WPs progress and timely attainment of the milestones, deliverables
together with assessment of pilot projects. In case of issues in carrying out the evaluation activities, direct consultations
will be performed with relevant partners and/or stakeholders (e.g. reminders to partners not responding surveys,
communication with WP leaders and partners in case of delays with deliverables/activities, etc.).
Task 3.4: Quality Assessment.
Leader: DGPIFAC; Contributors: UNIFG, ISS / Start date: M1 End date: M36
Task description: WP3 leader, in collaboration with the leaders of others WP, will support the quality assessment of JA
documentation and deliverables and report it as a specific paragraph/chapter in JA deliverables and documentation.
Deliverables and documentation will be assessed for quality aspects (e.g. comprehensibility, completeness, etc.) by the
WP3 leader, who will coordinate the evaluation involving relevant internal and external stakeholders.
Page 19 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Task 3.5: Report of evaluation results to relevant stakeholders
Leader: ISS (subcontracting) ; Contributors: UNIFG / Start date: M18 End date: M36
Task description: based on results from evaluation activities, the WP3 leader will produce an interim and a final report
including all collected information and indicators. Reports will be shared with internal and external stakeholders,
including the Steering Committee and the Stakeholders forum. This will ensure that quality of JA output is always a
top priority to the management bodies.
The final evaluation report will be focused on the positive and negative aspects of the impact of the action and the
reached aims (as a result of task 3.3); it will also evaluate usability and comprehensibility of JA results and deliverables
in the target population (as a result of task 3.4).
Task 3.6 : Evaluation of the JA impact in Europe
Leader: ISS (subcontracting) ; Contributors: UNIFG / Start date: M18 End date: M36
Task description: A final evaluation of the JA impact in Europe will be performed (M36). The first positive results (if
any) will be assessed, as well as possible barriers/room for improvements.
The impact will be evaluated at different levels:
• increase in number of professionals with skills on HAI prevention and AMR;
• availability of guidelines;
• increase in training initiatives for professionals.
According to the actions effectively adopted and the goals achieved by the Joint Action, also the following items will
be assessed:
• decrease in HAI prevalence rate in MS participating to JA;
• decrease in prescriptions/consumption of antibiotics (overall and of one or more classes);
• lower rate of AMR in human and veterinary areas for one or more target microorganism;
To reach the objectives two main actions will be adopted:
• Questionnaires to national, regional and local authorities as well as to professionals and citizens associations on the
main topics of the project; opinions will be collected about the first results of the JA;
• EU MS national and subnational web-site consultation for the availability of official data.
Participation per Partner
Partner number and short name WP3 effort
1 - INSERM 3.50
2 - MoH-FR 0.60
11 - HCDCP 1.00
14 - UNIFG 2.50
15 - ISS 6.00
21 - VWS 1.00
23 - FHI 0.40
29 - AEMPS 1.00
32 - FFIS 5.00
37 - FoHM 1.00
Total 22.00
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Confidential, only
D3.1 Evaluation plan 15 - ISS Report 4
for members of
Page 20 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
the consortium
(including the
Commission
Services)
Confidential, only
for members of
Validation of the the consortium
D3.2 15 - ISS Report 12
evaluation tools (including the
Commission
Services)
Progress Confidential, only
monitoring for members of
and quality the consortium
D3.3 15 - ISS Report 12
assessment of JA (including the
documentation and Commission
deliverables Y1 Services)
Progress Confidential, only
monitoring for members of
and quality the consortium
D3.4 15 - ISS Report 24
assessment of JA (including the
documentation and Commission
deliverables Y2 Services)
Progress Confidential, only
monitoring for members of
and quality the consortium
D3.5 15 - ISS Report 36
assessment of JA (including the
documentation and Commission
deliverables Y3 Services)
Confidential, only
Report on
for members of
stakeholders
the consortium
D3.6 evaluation and 15 - ISS Report 36
(including the
on JA impact in
Commission
Europe
Services)
Description of deliverables
D3.1 : Evaluation plan [4]
Release of the evaluation plan
D3.2 : Validation of the evaluation tools [12]
Report on the evaluation tools. All processes reported on a yearly basis.
D3.3 : Progress monitoring and quality assessment of JA documentation and deliverables Y1 [12]
Reports on actions and initiatives to support teams responsible for the release of deliverables and documents. Interim
and final evaluation reports based on the EP
D3.4 : Progress monitoring and quality assessment of JA documentation and deliverables Y2 [24]
Reports on actions and initiatives to support teams responsible for the release of deliverables and documents. Interim
and final evaluation reports based on the EP
D3.5 : Progress monitoring and quality assessment of JA documentation and deliverables Y3 [36]
Page 21 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Reports on actions and initiatives to support teams responsible for the release of deliverables and documents. Interim
and final evaluation reports based on the EP
D3.6 : Report on stakeholders evaluation and on JA impact in Europe [36]
Report on the evaluation of the actions and documents released by the different WPs by relevant stakeholders. Report
on the impact of actions and documents on MS at national and subnational level
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Agreement on ETs
MS9 15 - ISS 5 Agreement on ETs plan
plan
Availability of the
Availability of the web
web platform with
MS10 15 - ISS 7 platform with tools to
tools to support the
support the monitoring
monitoring
Periodic (every six
months) check of
MS11 Periodic check 1 15 - ISS 6 correspondence between
planned activities and
timetable
Periodic (every six
months) check of
MS12 Periodic check 2 15 - ISS 12 correspondence between
planned activities and
timetable
Periodic (every six
months) check of
MS13 Periodic check 3 15 - ISS 18 correspondence between
planned activities and
timetable
Periodic (every six
months) check of
MS14 Periodic check 5 15 - ISS 30 correspondence between
planned activities and
timetable
Periodic (every six
months) check of
MS15 Periodic check 6 15 - ISS 36 correspondence between
planned activities and
timetable
Identification
Identification of
MS16 of interested 15 - ISS 6
interested stakeholders
stakeholders
Report on quality of
Quality meeting the meetings within
MS17 15 - ISS 2
report 1 two months after their
conclusion
Quality meeting Report on quality of
MS18 15 - ISS 13
report 2 the meetings within
Page 22 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
two months after their
conclusion
Report on quality of
Quality meeting the meetings within
MS19 15 - ISS 25
report 3 two months after their
conclusion
Report on quality of
Quality meeting the meetings within
MS20 15 - ISS 36
report 4 two months after their
conclusion
Interim evaluation of
MS21 15 - ISS 19 Interim evaluation of JA
JA
Final report on JA Final report on JA impact
MS22 15 - ISS 36
impact in Europe in Europe
Page 23 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP4 Lead beneficiary 10 2 - MoH-FR
Work package title Integration into national policies and sustainability
Start month 3 End month 36
Objectives
This overarching task of WP4 is to foster the integration into national policies of the recommendations issued by
the consortium and/or ECDC and encourage healthcare workers and policy makers to expand and maintain their
implementation in their respective countries when and where needed.
Since this JA involves 47 partners from 28 countries, one goal of WP4 is to secure the contribution of all participants to
the JA (i.e associate and collaborative partners), and other bodies and institutions at the national and EU level, beyond
the participating institutions. Specifically, the ECDC, FAO, OIE, WHO Europe and the European Commission will be
involved to contribute to and support the sustainability of actions proposed within WP4.
The general approach taken within this WP is to build upon the work done in the JA WPs, especially guidelines,
recommendations and tools for implementation. Since the scope of these studies will be rather limited within the time-
frame of the JA, the task of planning the scaling-up of the results obtained when needed and obtaining adhesion to
best practices from other institutions, partners, and MS relies on this WP. Support from the ECDC to address a specific
problem through adapting guidelines or recommendation will be sought.
Several actions will need to be carried forward beyond the 3-year JA duration to ensure sustainability of results and
actions initiated during the JA. The first task of WP4 will be to design an integration and sustainability strategy and plan
based on the expected outputs from the JA. The strategy will account for potential differences in identified priorities
based on public health organisation, geographical area and epidemiology, and also define potential indicators for follow-
up of actions undertaken. As action on AMR and HCAI implies multilevel, multi-actor and multi-sectoral approach, the
WP will provide for tailored recommendation to JA partners and groups targeted, associated with clear and measurable
goals.
The specific objectives of this WP will include:
1. Developing an integration and sustainability plan
2. Ensuring integration of preventive strategies for AMR and HCAI into national policies
3. Fostering sustainability of core actions engaged by the JA WPs
Description of work and role of partners
WP4 - Integration into national policies and sustainability [Months: 3-36]
MoH-FR, AEMPS
WP Methodology
In general, the approach taken in WP4 will be through workshops and consultation of stakeholders, policy makers and
competent authorities represented in the Steering Committee, and partners.
Given the specific role of this WP in terms of extension/dissemination of actions and implementation of sustainability
strategies within Europe, it is clearly of importance that a maximum possible of MS, and whenever possible associated
states and non-EU members contribute or be associated with the steps taken within this WP.
Task descriptions
Task 4.1: Integration plan and sustainability strategy
Leader: MoH-FR ; Contributors : NMI, AEMPS / Start date: M3 ; End date: M30
Task description: the integration plan and sustainability strategy will propose, within the remit of the priorities identified
by the WP and validated by Member States, an implementation plan on AMR and HCAI, compliant with EU Action plan
as well as WHO Global action plan. It will identify for each actor, from patient groups to international organisations,
achievable and realistic actions that are “game-changer”. Based on the gap analysis performed within WP5, and a SWOT
analysis of national strategies, the integration plan will propose specific roadmap for national competent authorities to
adapt their national strategy to identified priority areas for intervention. Being focused on achieving reasonable and
concrete objectives, the JA will share the best practice and deliverables it has produce with key players.
The WP will ensure that all core WPs (5,6,7,8,9) take into account the sustainability of their action within their work
and reports. Close cooperation during the JA lifespan will ensure that from the beginning, sustainability and integration
into national policies are carefully considered. WP4 leaders will therefore closely follow-up and contribute to the work
done by other WPs through participation at meetings, iterative process of deliverables, observation and guidance on
other WP’s outputs.
Page 24 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
4.1.1: Identify outputs from the JA which will should be widely disseminated and integrated into national strategies
for control of AMR and HCAI.
This preliminary step aims to analyse the expected outputs from the JA in terms of guidelines, recommendations or
implementation tools which are planned to be available by the end of the 3-year duration of the JA, and would need
to be promoted at the regional/ national/ EU level. This analysis will be based on the compilation of objectives and
deliverables from the JA WPs, and timing of availability of these outputs. After having analysed the MS priorities with
regard to prevention and control of AMR and HCAI through a survey of Stakeholders and competent authorities as well
as integrating information from gap analyses performed within WP5,6 and 7, these outputs will be put in perspective
with MS priorities and existing reference documents (e.g., from ECDC, WHO,…) and analysed for their added value
and potential for integration into national policies and action plans. This will form the basis for a draft version of the
integration & sustainability plan. This draft version will be made available of the JA website (with WP2) for all JA
partners and advisory bodies to comment and provide input on the draft plan.
4.1.2. Produce a sustainability plan
From the analysis performed in 4.1.1., priority areas for improvement will be discussed with the stakeholders forum
and incorporated into a development program for prevention of AMR and HCAI, which will form the final version
of the integration plan and sustainability strategy, produced by M30. This task will be coordinated by MoH-FR with
the contribution of all partners. Representatives of Member States will be consulted regularly during the process of
developing the plan to ensure that priority goals match the national agendas on AMR and HCAI.
A workshop with SC members will be organised to consolidate the recommendations included in the plan, and obtain
commitment of MS on adopting the plan.
Task 4.2: Integrating preventive strategies within national policies
Leader: MoH-FR ; Contributors: NMI, AEMPS / Start date: M12 End date: M36
Task description:
After identification of gaps and proposed priority goals resulting from surveys and/or pilot studies performed within
WP5, 6, 7, 8, the strengths and weaknesses of NAP will be assessed. The WP will elaborate concrete recommendations
targeting those gaps and adapted to various contexts and problems (e.g., countries with high antibiotic consumption,
countries with high levels of resistance, …). It will propose a set of measures to be implemented, based on available
recommendations and best practices identified, and include indicators for each group of actors to measure progress.
Strong interaction with WP5 will be maintained, especially with regard to action within the OneHealth network and the
supervising bodies network as supporting bodies following-up the adoption of actions proposed.
The actions, recommendations and tools selected for integration within the NAP and programs, as well as means for
dissemination will be described in a report available within the last 6 months of the JA. Policy briefs will be used for
dissemination to competent authorities. The integration task will require support and engagement of stakeholders and
support from implementation science experts for communication of recommendations to public health levels.
Indicators suggested for this task include the number of policy briefs endorsed by national competent authorities
Task 4.3: Fostering sustainability
Leader: MoH-FR ; Contributors : NMI, AEMPS / Start date: M30 End date: M36
Task description: besides integration into MS’ NAP of specific actions promoted within the JA WPs, some other
outcomes or actions will need tailored actions to be undertaken to ensure their sustainability. The strategy used for
this, involving national competent authorities and stakeholders as well as EU bodies, will be described in task 4.1
(DEL4.2). Sustainability of JA recommendations does not solely rely on international organisations or policy makers.
Each stakeholder is part of the solution to tackle AMR. In this regard, the input received from the Stakeholder forum
will be taken into consideration and specific recommendation for each target group will be included. For instance,
representatives of patient associations will be able to take the recommendation of JA to their constituency.
Depending on the actions selected in 4.1.1, recommendations or practice guidelines will be elaborated. These will entail
soliciting either institutions (eg, ECDC, WHO) or professional societies (eg, ESCMID). The guidelines will propose
indicators allowing follow-up of progresses made toward reaching the objectives set up in the recommendations.
The country-to-country assessment method and tool tested within WP5 could be proposed for endorsement by WHO
Europe and promoted among other MS not participating into WP5 for further joint assessment. Besides, the findings
from these and recommendation discussed with the supervisory network should be integrated in the national supervision
plans and procedures.
Likewise, the material produced and validated within WP6.1 and WP6.2 during pilot studies of implementing preventive
strategies for designated HCAI, notably the improvement model and approach taken will need to be expanded to
other settings and networks within EU MS and outside; this uptake could be promoted through two channels: the
supervising bodies network convened within WP5 (Del 5.5) for EU MS and/or the professional bodies within the
stakeholder forum; in addition, cooperation with WHO Europe will be needed to expand the approach to non-EU
member states. Likewise, the model for implementation of the antimicrobial stewardship program and short-lagged
Page 25 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
resistance surveillance designed within WP7 and pilot-tested will need, if successful, to be expanded to other settings
and networks.
In addition, reference documents produced during the JA, such as the review of guidelines for prudent use of antibiotics
(WP 7.1), best practices for promoting awareness and communication on AMR (WP8.1), or recommendation to ensure
that MS use best procedures to improve their input into the EU research agenda (WP9.1) will need to be endorsed by
external bodies and maintained /updated for example on the ECDC website. Indicators suggested for this action include
recommendations endorsed by ECDC and made available on its website, as well as the number of MS countries adopting
the implementation models and tools promoted by the JA.
Components of the JA included in the sustainability plan and specific processes used for their implementation will be
described in the final report.
Participation per Partner
Partner number and short name WP4 effort
2 - MoH-FR 14.40
29 - AEMPS 2.00
Total 16.40
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Integration plan
D4.1 and sustainability 2 - MoH-FR Report Public 30
Strategy
Report on
D4.2 2 - MoH-FR Report Public 30
integration plan
Updated report on
D4.3 2 - MoH-FR Report Public 36
integration plan
Report on
D4.4 2 - MoH-FR Report Public 36
sustainability plan
Description of deliverables
D4.1 : Integration plan and sustainability Strategy [30]
Report on the implementation plan for integration of key actions into national policies and strategy for sustainability
of JA outputs
D4.2 : Report on integration plan [30]
Specific measures for prevention and control of AMR and HCAI to be integrated in national action plans
D4.3 : Updated report on integration plan [36]
Specific measures for prevention and control of AMR and HCAI to be integrated in national action plans
D4.4 : Report on sustainability plan [36]
Specific measures for prevention and control of AMR and HCAI to be sustained beyond the JA
Page 26 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Survey of MS
MS23 2 - MoH-FR 12 Survey of MS priorities
priorities
Workshop with SC
members on priority goals
Workshop with SC
MS24 15 - ISS 24 and integration of JA
members
key actions into national
AMR-HCAI plans
Page 27 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP5 Lead beneficiary 10 21 - VWS
Work package title Implementation of One Health national strategies and National Action Plans for AMR
Start month 1 End month 36
Objectives
The main objective of this WP is to support MSs (and other participant countries) on the implementation of some of the
provisions laid down in the Council Conclusions on the next steps under a One Health approach to combat antimicrobial
resistance (2016/C 269/05) unanimously adopted by the Council of the European Union in June 2016.
The specific objectives of this WP are to:
1) Support MSs in the development and implementation of national strategies and national action plans based on the
One Health approach and in line with the WHO Global Action Plan (GAP) on AMR and the Council Conclusions on
the next steps under a One Health approach to combat antimicrobial resistance especially by:
a) the development of a self-assessment tool to monitor country progress and identify gaps and shortcomings on the
implementation of national strategies and national action plans;
b) the setting up of a country-to-country peer review system to evaluate each other’s national action plans and reflect
about policy options;
c) the establishment of a network of supervisory bodies to discuss different approaches on the way supervision,
inspection and enforcement in the Member States is organized and on how the level of compliance with legislation,
national (professional) guidelines, standards and recommendations relevant to AMR can be improved in the Member
States.
2) Report regularly and discuss within the One Health Network described in the Council Conclusions on the next steps
under a One Health approach to combat antimicrobial resistance on the outcome of the activities of WP5.
Description of work and role of partners
WP5 - Implementation of One Health national strategies and National Action Plans for AMR [Months: 1-36]
VWS, INSERM, MoH-FR, FPS HFCSE, NCIPD , NIPH, RKI, ESDY-NSPH, UNIFG, LSMULKK, HI, NMI,
UMPIH, NIJZ, AEMPS, FoHM, SBA, NFA, SVA, ANSES
WP Methodology
The methodology used in this WP is in line with WHO approach to move from exclusive self-evaluation to approaches
that combine self-evaluation, peer review and voluntary external evaluations involving a combination of domestic and
independent experts and the WHO framework for the monitoring and evaluation of the implementation of the Global
Action Plan on AMR, based on the tripartite self-assessment and the performance of the Joint External Evaluation.
All activities described in this WP are based on the implementation of the One Health approach. The representatives
of the WP5 participating countries are responsible for the engagement of the relevant sectors, including the formation
of team of policy makers and experts from both the human and veterinary domain and the other relevant areas (e.g.
agriculture, environment) within the country.
Workshops, electronic and physical meetings, tele/videoconferences, (self)-assessments, reports, literature/review,
presentations at the One Health Network, etc.
Task descriptions
Task 5.1: Mapping and self-assessment of National Action Plans and strategies
Leader: VWS (NL) Contributors: all WP5 participating countries / Start date: M1 End date: M12
Task description:
In order to support MSs in the development of national strategies and NAP on AMR, the WP5 participating countries
will:
• Map existing NAP and national strategies in the participating countries and in the rest of the EU, including, where
relevant, the elements of the GAP on AMR and the Council Conclusions (One Health approach, overview of measurable
goals, enforcement by competent authorities or national supervisory bodies, etc.).
• The mapping will be developed by the participant countries (at least one representative of each WP5 participating
country) and will be based on publicly available information (e.g. internet site of ECDC, European Commission,
Member State) and on direct information collected by the competent authorities in the MSs.
• Countries not participating in WP5 will be asked (thought the collaborative partners or partners involved in other WP
of this Joint Action) to voluntarily provide the same information about existing NAP and national strategies in their
countries in order to be able to also map the situation in these Member States.
Page 28 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• This mapping will provide an overview of the situation in the Member States and a view of the areas of concern and
will be used for the development of the self-assessment tool.
• Develop a tool for the self-assessment of national strategies and NAP, including the One Health approach. The tool
will be developed on the basis of the WHO (tripartite) tool “Global Monitoring of Country Progress on AMR: country
self-assessment questionnaire” (or similar tool developed/revised in the future by WHO), by extending it to the situation
in the EU, adding the specific requirements of the Council Conclusions on the next steps under a One Health approach
to combat antimicrobial resistance and the other requirements laid down in relevant EU legislation, recommendations,
guidelines, etc. The self assessment tool will allow for the analysis of the strengths and weaknesses in the Member States.
• The tool will be developed by the WP5 participating countries (at least one representative of each country), with the
assistance of collaborating stakeholders: EU agencies (ECDC, EMA, EFSA) and Directorate on Health and Food Audits
and Analysis of the European Commission, WHO-EURO, WHO-HQ and OIE.
• For the development of the tool, several electronic working groups or tele/video conferences and also a physical
meeting (workshop) will be organized. The tool will be presented to the participating countries. During the meeting
participating countries will receive the instructions for the capture of data in the tool.
• In preparation of the country-to-country assessment (Task 2 – see below), each of the participating countries will
perform the self-assessment using the tool described in this task. Each participating country will analyze the results
of its own self-assessment, in order to identify gaps in the NAP, evaluate the national strategy, etc. and will discuss at
the national (or where relevant regional) level how to address gaps and improve the national situation. This analysis
will preferably be SWOT-based in order to allow for the analysis of the strengths and weaknesses, identification of the
opportunities and threats to face.
• Each participating country will provide the results of the findings of the self-assessment and the outcome of the own
analysis to the WP5 leader.
• All participating countries will present, discuss and analyse together the report of the outcome of the self-assessments
during several electronic working groups and/or video/teleconferences and also a physical meeting (workshop).
• The results of the self-assessments and the discussions during the workshop will be presented and discussed within
the One Health Network.
NB: all WP5 participating countries will perform both Task 1 and Task 2. The performance of Task 1, the self-assessment,
is a preparatory work for Task 2 (country-to-country assessment). At least one of the contributors from each participating
country will be involved in the mapping task. The representatives of the WP5 participating countries will organize
a team of policy makers and experts from both the human and veterinary domain and the other relevant areas (e.g.
agriculture, environment) within the country to carry-out the self-assessments. These representatives are also responsible
for involvement of the relevant (competent) authorities in their own Member State in the discussion of the outcome
of the self-assessment.
Task 5.2: Country-to-country assessments
Leader: VWS (NL) Contributors: all WP5 participating countries / Start date: M4 End date: M36
Task description:
A country-to-country peer review/assessment system will be set up, as described in the Council Conclusions on the next
steps under a One Health approach to combat antimicrobial resistance. The country-to-country assessment will allow
representatives of one or several WP5 participating countries to evaluate each other’s national action plans and One
Health strategies, reflect about policy options and provide recommendations to support countries on the development
and implementation of the NAP and the measures taken.
The following actions will be performed:
• Development of the methodology and the tools to be used for the country-to country assessments. This activity will be
performed by a (multidisciplinary) group of representatives of the WP5 participating countries, in close collaboration
with the collaborating stakeholders: e.g. ECDC, the Directorate on Health and Food Audits and Analysis of the European
Commission and where relevant international institutions (e.g. WHO-EURO).
• The tool for the country-to-country assessments will be developed and based on the self-assessment tool from Task 1
and taking into consideration the experience of the performance of the self-assessments.
• Performance of 3 pilot “country-to-country” assessments in countries that have already performed a self-assessment
on NAP and have provided the summary of the findings and discussed them in the workshop.
• The 3 pilot countries will be chosen by the participating countries and will reflect, as much as possible, different
situations in Europe. For this selection, the geographical distribution, division of responsibilities within the Member
State (national vs regional), level of development and implementation of the NAP, etc. will be considered. All 3 selected
countries must have already performed the self-assessment as described in Task 5.1.
• The country-to-country pilot assessments will be performed by a (multidisciplinary) team of one or more
representatives of the WP5 participating countries. The team will consist of policy makers and experts and may include
representatives from the relevant collaborating stakeholders: ECDC, EMA, EFSA, Directorate on Health and Food
Page 29 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Audits and Analysis of the European Commission, WHO-Euro or other international organizations. The team will visit
a country, for example for 5 days (to be determined), in order to evaluate its national action plan, reflect about policy
options and provide recommendations to support and improve measures taken. The team will make use of the already
performed country self-assessment (see task 5.1) and where possible other existing assessment or audit activities (e.g.
ECDC, Directorate on Health and Food Audits and Analysis or WHO) in order to avoid overlap or get additional
information. At the end of the visit, the team will hold a wrap-up meeting with the relevant national competent authorities
to present the preliminary outcome of the assessment.
• The countries assessed will further discuss internally at country level and also in the context of the One Health Network,
the outcome of the country-to-country assessments and to follow up on identified shortcomings and gaps and address
them and sustain this action.
• The representatives in WP5 of the country assessed are responsible for the involvement of the relevant (competent)
authorities in their own Member State in the performance and the discussion of the outcome of the country-to-country
assessment. The representatives of WP5 participating countries will organise a team of policy makers and experts from
both the human and veterinary domain within the country to participate in the country assessment.
• The results of the 3 pilots will be discussed and the methodology and tool used for the country-to-country assessment
will be revised based on the experience of the 3 pilot country-to-country assessments. For this purpose, several electronic
working groups and/or video/teleconferences and a physical meeting (workshop) will be organized.
• The results of the 3 pilot country-to-country assessments will be presented and discussed at the One Health Network.
• Perform “country-to-country” assessments for the other countries in the WP that have already performed a self-
assessment on NAP and provide a summary on the findings, based on the revised tool and methodology and report and
discuss the results within the One Health Network.
NB: all WP5 participating countries will perform and participate in the country-to-country assessments. At least one
of the contributors of each Member State will be involved in the development and revision of the country-to-country
assessment. The representatives of the WP5 participating countries will organize a team of policy makers and experts
from both the human and veterinary domain and the other relevant areas (e.g. agriculture, environment) within the
country to participate in the country-assessment. They are also responsible for involvement of the relevant (competent)
authorities in their own Member State in the performance and the discussion of the outcome of the country- assessment.
Additional country-to-country assessments can be performed in additional countries not actively participating in WP5
provided that these countries have performed Task 5.1, the country-to-country assessment is supported, organized and
self-funded by a collaborative partner in this Member State and based on the agenda and resources, including availability
of the representatives of WP5.
Task 5.3 : Strengthening supervision
Leader: VWS (NL) Contributors all WP5 participating countries / Start date: M2 End date: M36
Task description:
Control activities (supervision, inspection) and enforcement by the competent authority or a (delegated) supervisory
body (including professional associations), provides information about the level of implementation of national policies,
the level of compliance with legislation and the adherence to guidelines and recommendations. Furthermore, it is a
tool to assess the execution of the NAP, to identify areas where action or improvement is needed, to assess the reasons
why compliance is not met and may help parties to comply or better abide by existing rules (legislation, guidelines,
recommendations).
For example, to achieve policy goals such as improvement of prudent use of antibiotics, strict adherence to the guidelines
for antibiotic use is necessary and inspections and strict enforcement may discourage activities such as over the counter
sales of antimicrobials.
However, these activities are organized in different ways in the different countries depending on the healthcare system,
national legislation and distribution of competences and responsibilities within the country. Additionally, competent
authorities and supervisory bodies may be responsible for the control of many different topics related to healthcare, and
AMR is either not always on the agendas of all supervisory bodies in all European countries, or not considered a priority.
To facilitate collaboration between supervisory bodies in the Member States, to facilitate control activities and
enforcement of national policies related to AMR and on the implementation of the NAPs, Task 3 will include the
following actions:
• Set up a voluntary network of national supervisory bodies in Europe and discuss methods of integrated supervision,
best practices, exchange of experiences, etc. For this purpose, all participating countries in WP5 will identify the
relevant supervisory bodies in their own country. A first meeting (workshop) will take place to establish the network, to
learn about the different situations in the EU and to discuss further work. Representatives of the relevant collaborating
stakeholders will be invited.
• The network will identify common white spots and shortcomings in the implementation of national strategies and
discuss possible solutions and recommendations to improve the situation and the work of supervisory bodies. The
Page 30 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
network will discuss the outcome of this work on a workshop and will present the results of this work to the One Health
Network.
NB: all in WP5 participating countries will participate in the task of identification of the supervisory bodies in own
country. At least one of the contributors of each member state will be involved in this task. All participating countries
will be requested to participate in the network.
Participation per Partner
Partner number and short name WP5 effort
1 - INSERM 9.00
2 - MoH-FR 4.00
4 - FPS HFCSE 4.00
5 - NCIPD 6.70
7 - NIPH 4.30
10 - RKI 5.40
12 - ESDY-NSPH 8.20
14 - UNIFG 6.00
17 - LSMULKK 6.50
19 - HI 12.00
21 - VWS 29.00
25 - NMI 7.00
27 - UMPIH 5.50
28 - NIJZ 10.00
29 - AEMPS 3.00
37 - FoHM 3.00
39 - SBA 0.80
40 - NFA 1.50
41 - SVA 0.70
44 - ANSES 6.00
Total 132.60
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Tool for country
D5.1 21 - VWS Report Public 6
self-assessments
Summary Country-
D5.2 to-country 21 - VWS Report Public 36
assessments
Overview
D5.3 21 - VWS Report Public 36
enforcement and
Page 31 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
recommendations
to be presented
to the One Health
Network
Assessment of the
cost-benefit for the
D5.4 implementation of 11 - HCDCP Report Public 36
an infection control
program
Description of deliverables
D5.1 : Tool for country self-assessments [6]
Availability of the tool for the country (self) assessment based on the WHO-tool and adapted to the EU situation
(Council Conclusions) : summary of the questionnaire.
D5.2 : Summary Country-to-country assessments [36]
Performance of the country-to-country assessments
D5.3 : Overview enforcement and recommendations to be presented to the One Health Network [36]
Report about white spots, shortcomings in the implementation of national strategies and discuss possible solutions
and recommendations and preparation to present to the One Health Network.
D5.4 : Assessment of the cost-benefit for the implementation of an infection control program [36]
Report
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Presentation, discussion
and analysis of the
MS25 Workshop 21 - VWS 10
outcome of the self-
assessments (workshop)
Workshop on the outcome
of the 3 pilot country-to-
MS26 Workshop WP5 2 21 - VWS 18 country assessment and
revision of the tool and
methods.
Invitational workshop for
the establishment of the
MS27 Invitational workshop 21 - VWS 18
network of supervisory
bodies
Page 32 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP6 Lead beneficiary 10 37 - FoHM
Work package title Policies for prevention of Health-Care-Associated Infections and their implementation
Start month 1 End month 36
Objectives
In line with the EU action plan COM (2011) 748 - WP6 objectives are to ensure that guidance on infection prevention and
control is developed, surveillance of HCAI is strengthened and that proper education and training of health-care workers
is organised - this work will support the establishment of efficient and feasible infection control programs through the
effective implementation of agreed key components for guidelines and/or other tools at national, regional and local level
to prevent infections and thereby limit the use of antibiotics and spread of resistant bacteria in health-care settings.
Two complementary objectives will be developed in this WP:
I. Promoting a top-down approach for preventing HCAI through the implementation of agreed infection control
programs and institutional behavior change.
II. Promoting a bottom-up approach from clinical practice to policy level by implementing evidence-based guidelines
and existing policies using a structured implementation model and working in country teams.
Patients and other relevant stakeholders must be involved in the improvement work concerning infection prevention
and control measures. Participating MSs should involve relevant stakeholders in this work including patients, health-
care professionals, infection prevention and control professionals, patient safety professionals, clinic management,
hospital management, regional health-care management, national health authorities, existing European associations and
networks within the field of infection prevention and control (IFIC, ESCMID, EUCIC, UMEMS, ESGNI, ISC and
EUNETIPS).
The two objectives of WP6 will have strong interaction between each other in order to secure tight links to reach overall
objective of WP6 - prevention of HCAI and also avoiding overlap in content.
Description of work and role of partners
WP6 - Policies for prevention of Health-Care-Associated Infections and their implementation [Months: 1-36]
FoHM, INSERM, GÖG, FPS HFCSE, NIPH, TA, HCDCP, ESDY-NSPH, 7HC, UNIFG, ISS, PSKUS, LSMULKK,
VULSK, HI, NVSC, VWS, DGS, NIJZ, AEMPS, GENCAT, IdISBa, FFIS, ISCIII, SoS, UAS
WP Methodology
Objective 6.I: top-down approach: Policies for preventing health-care associated infections through the implementation
of agreed infection control programs and institutional behavior change
The specific goals are to:
1. Determine the necessary institutional structures and resources for the implementation of infection control programs
and promote adequate hospital organization, management and structure for the prevention of HCAI.
2. Incorporate Infection control programs into clinical practice for the improvement of health professionals’ compliance
with infection control routine using the institutional behaviour change as a tool to accomplish it.
3. Develop the tools for increasing awareness and improving the training of health professionals to infection control
and prevention.
Given the differences in the AMR context in European countries, the aim of the objective 6.1 is to fill the gap between
policy and practice of infection control in healthcare facilities based on evidence based practices and the national
experience of participating partners for elaborating a concrete, implementable and reasonable Infection Control Plan
for the prevention of HCAIs. The WP will contribute to improve the infection control capacity within health-care
through institutional awareness using identified key components and specific interventions which will be adapted to the
real needs, resources and priorities of the national health systems.The project will use the JA web-based platform for
developing common protocols and sharing documents.
Objective 6.I will be divided into three main tasks which are a sequence of activities aimed at the development of a
Universal Infection Control Framework (UICFW) for health professionals according to which roles, responsibilities
and accountability will promote teamwork strengthening towards improved health professionals compliance and,
consequently, patient safety. Ideally, the same partner-countries will be involved in all three tasks.
This methodology will follow four phases: plan, action, evaluation and improvement. The plan will be based on
evidence-based practices and surveys, and action on the implementation of the infection control framework. Surveys will
address all European Union member-states targeting to increase our knowledge regarding the current situation and the
barriers that limit health system to restrict HCAIs. The implementation of the Universal Infection Control Framework
(UICF) will be performed in the selected hospitals of the participants aiming to estimate the gap between policy and
Page 33 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
practice. Each country should take advantage of the results of the surveys and the UICF implementation for improving
its capability to develop HCAIs prevention policies at local and national level. For that reason the active contribution
of national representatives is crucial for the collection of reliable data, the dissemination of the results, the feedback of
stakeholders and the sustainability of this venture.
Task 6.1.1. Determine the necessary institutional structures and resources for the implementation of infection control
programs and promote adequate hospital organization, management and structure for the prevention of HCAIs,
according to the EU Action Plan.
Leader: HCDCP; Contributors : GOG; NIPH; 7HRC; NCE; UNIFG; ISS; DGS; CCS; AEMPS; GENCAT; Illas
Baleares; DGPIFAC/SMS/FFIS; ISCII; FOHM / Start date: M1 End date: M36
Task description: the aim of this task is the determination of the necessary institutional structure and resources for
the implementation of efficient and feasible infection control programs in healthcare according to the standards and
requirements of the EU Action Plan for AMR.
This objective will be achieved through the following activities:
6.1.1.1- Survey for the key components of an infection control program based on the ECDC guidance (survey A in
the table above) and the requirements of the updated EU Action Plan for AMR regarding the hospital sector. The
questionnaire will be disseminated to all EU countries and will address public health organizations, relevant national
scientific committees, hospital Infection Control Committees and hospital managers. The participating healthcare
facilities to the survey will be determined from the partners depending on the health care structure in the country, with a
strong focus on acute care and long-term settings. Regarding the EU member states that are not participating in the task
the questionnaire will be disseminated with the contribution of the respective national public health organizations. The
aim of this extensive survey is to have the clearest picture of the reality associated with the capability of each country
to implement ICP policies. Finally, a workshop will be organized at the end of the survey by each participating country
at local or/and national level for feedback on the survey’s results, for raising the awareness of the contributors and the
determination of the real needs and priorities of each country. (M1 – M7)
6.1.1.2 - Review of the guidelines for the implementation of ICPs and their applicability to clinical reality based on the
result of the survey and the requirements of AMR action plans of WHO and EU. (M8 – M13)
6.1.1.3. Assessment of cost-benefit for the development and implementation of an infection control program. It is
of crucial importance to persuade the hospital managers and the politicians that the prevention of HAIs is saving
lives and resources. It will be a supportive element to the organization behaviour change bundle. Intensive efforts
for controlling AMR and HCAIs are costly and the cost-effectiveness of these efforts at the hospital or national
level has not been defined. The initial plan of the assessment will be based on the existing literature and the revised
guidelines. Its final formulation will be resulted from the implementation of the Universal Infection Control Framework
in participating countries. Once the core components of an infection control program have been determined, assessment
of their simultaneous impact on epidemiological, clinical and economic levels will follow on the basis of respective
indicators that will have been chosen. The aim is to assess the implementation of an infection control program within
the specific financial circumstances of each country so that the data produced can be totally compehensible and usable
by professionals, who are mainly hospital administrators. This venture is ambitious and demands the development of
broad collaborations among the participating countries, even at the level of health finances (M10- M36)
Task 6.1.2: Incorporation of infection control programs to clinical practice for the improvement of health professionals’
compliance with infection control routine using the institutional behaviour change as a tool to accomplish it.
Leader: HCDCP; Contributors : GOG; NIPH; 7HRC; NCE; UNIFG; ISS; DGS; CCS; AEMPS; GENCAT; Illas
Baleares; DGPIFAC/SMS/FFIS; ISCII; FOHM / Start date: M1 End date: M36
Task description: the aim of this task is to fill the gap between policy and practice of infection control in healthcare
facilities in European countries and evaluate the impact of the institutional behavior change on improving the HCWs
compliance with infection control and prevention measures.
This aim will be achieved through the following activities:
6.1.2.1. Survey of the infection control policies at hospital level (Survey B, Table above). The aim of this survey is
to examine and analyse barriers (attitudes, level of training, lack of awareness, etc) to an effective implementation of
an infection control program in clinical reality, which are mainly linked to the institutional policy and organizational
behavior. The survey will be based on common axes for all the participants, accounting for the peculiarity of each
country’s health system in which it will be performed for ensuring the sustainability of the project. A questionnaire will
be disseminated to the participating EU countries and will be conducted through interviews of hospital administrations,
Infection Control Committees, clinical department leaders, doctors and nurses at European level. The results of the
survey will be evaluated at national and European level. . (M1 – M8)
6.1.2.2. A framework with specific roles, priorities and necessary interventions for implementing an infection control
program (Universal Infection Control Framework –UICF)in healthcare facilities will be based on the results of the
Page 34 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
two first ongoing tasks and feedback from governments, public health organizations, scientific committees and health
professionals. (M8-M36)
6.1.2.3. Pilot testing of the Universal Infection Control Framework (UICF) in European hospitals. The aim of this testing
is to estimate its impact on routine clinical practice and the behavioural change of clinicians on infection control. A
limited number of healthcare facilities (at least two healthcare facilities) will be selected from partners to participate for a
year in the pilot framework implementation study. The implementation of the plan will be based on intervention without
additional costs and it will be modified in accordance to the operation, structure and resources of the hospitals. Hospitals
will adapt the UIC framework to their needs and priorities adopting and performing the appropriate interventions. The
final proposed UICF will be finalized with the incorporation of the pilot study results and it will be introduced at national
and EU level.
The UICF impact will be assessed by the repetition of the initial survey using the following indicators:
1. The number of the key components of the proposed plan which were performed by hospitals (structure and process
indicators
2. The cost-benefit assessment of the programme’s implementation
3. The response (positive/negative) of stakeholders regarding the implementation of the infection control framework
to the repetition of the survey
4. Additional outcome and process indicators (AMR and AB consumption rates, HCAIs incidence, hand hygiene
compliance) will be used despite the fact that the time frame of this pilot testing is very limited to produce significant
results. (M14 – M32)
Task 6.1.3: Development of tools for increasing awareness and improving the training of health professionals in infection
control and prevention.
Leader: HCDCP; Contributors : GOG; NIPH; 7HRC; NCE; UNIFG; ISS; DGS; CCS; AEMPS; GENCAT; Illas
Baleares; DGPIFAC/SMS/FFIS; ISCIII; FOHM / Start date: M7 End date: M36
Task description: the objective of this task is to develop tools based on the results of the previous surveys on supporting
the framework of hospital administrations and ICs regarding the implementation of an ICP and improving HCWs
compliance with infectious control measures.
The objective of this task will be achieved through the following activities: development of tools will be mainly
web-based and will aim at increasing professionals’ awareness and strengthen infection control training schedules for
prevention of HCAI and of the spread of multidrug resistant bacteria in hospital environment. The development of these
tools will be based on previous surveys and they will be improved through the pilot testing.
OBJECTIVE 6.2: BOTTOM-UP APPROACH: PROMOTING A BOTTOM-UP APPROACH FROM CLINICAL
PRACTICE TO POLICY LEVEL BY IMPLEMENTING EVIDENCE BASED GUIDELINES AND EXISTING
POLICIES USING AN ESTABLISHED IMPLEMENTATION MODEL AND WORKING IN COUNTRY TEAMS.
This objective will be focused on adaption and implementation of existing policies (national/regional/ local) and
evidence-based guidelines and on improving the infection control capacity within health-care. The improvement work
will be performed using the “The Breakthrough Series Model” as advocated by the Institute of Healthcare Improvement
(US). Thus another overarching objective is capacity building through education of the participants in this particular
improvement model and in adapting existing guidelines to country requirements.
The specific objectives of this part are to: (i) introduce an evidence-based implementation model which ensures co-
operation between key levels (national/regional/local) and stakeholders and (ii) promote that similar working routines
are implemented in EU and non-EU countries across Europe
Task descriptions
Task 6.2.1. Introduce an evidence-based implementation model
Leader: FOHM ; Contributors : FPS HFCSE; NIPH; TA; HCDCP; PSCUH; LSMULKK; VULSK; NVSC; HI; VWS;
NIJZ; SoS; UAS / Start date: M1 End date: M36
Task description:
We will implement existing policies and evidence-based guidelines (see list below) with the
aim to produce routines that can be implemented nationally. The Breakthrough Model from the
Institute for Health-Care Improvement will be used. This model has been used and documented in
numerous successful improvement projects within health-care (http://www.ihi.org/resources/pages/ihiwhitepapers/
thebreakthroughseriesihiscollaborativemodelforachievingbreakthroughimprovement.aspx). The model will initiate co-
operation between the levels represented (national/regional/hospital) depending on the health care structure in the
country, as they will participate as a ‘country team’ in the workshops and in line with the national activities planned
in between the workshops.
This objective will be achieved through the following activities:
Page 35 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
6.2.1.1. Selecting topics and participants, development of a framework and proposed changes. According to the model
“learning sessions”, called workshops in this task, are then alternated with “action periods”, called national activity
periods in this project. During the action periods the participants use iterative P-D-S-A (Plan-Do-Study-Act)-cycles
to test and finally implement small changes, which gradually leads to the goal of full implementation. In this work
process both discussion of current practices, development of implementation tools, barriers to change (e.g. difficulties
concerning behaviour change or administrative barriers), and adapting towards common policies and guidelines will
be included. The experience and expertise of participants from hospitals, regions and nations will be used when the
countries implement the changes nationwide as a continuation of the project.
The core components for infection prevention and control identified by WHO in 2009 and revised in 2016 will be used
for strengthening the capacity on both the national and local (health-care facilities) levels for the prevention of HCAI and
to prepare an efficient response to outbreaks of resistant bacteria. The WHO core components address key factors such as
the organisation of infection and prevention programmes at the hospital level, the development of technical guidelines,
training for health-care staff and specialised training of infection control professionals, surveillance of infections and
pathogens and several other key factors for a comprehensive infection prevention programme. The same key factors
and other complementary factors for the organization, management and structure for prevention of HCAI were recently
compiled in a review and expert consensus by Zingg and others published in 2015 and will be used in this WP. The paper
identified crucial elements for the organisation of effective infection-prevention programmes including ward occupancy
and staff workload, access to materials and equipment (i. e hand rub), the development of multimodal strategies and tools
and identification and engagement of strategy champions and creating a positive organisational culture. Assessment of
competencies and training of health-care staff and infection control professionals will use the ECDC core competencies
for infection control and hospital professionals in the European Union (2013) as a template.
6.2.1.2 Focus on specific topics. In addition to working with infection prevention and control policies general guidelines,
the countries will choose to work with one or several of the following specific topics: catheter-associated urinary tract
infection, hand hygiene, surgical site infections, and/or central line-associated blood stream infections. There are several
well established, international guidelines available for these, and they are suitable for a multi-modal or bundle approach.
Evidence-based guidelines are available for all these areas, and these will be provided to the participants as a basis for
development and adaption of local implementation tools. The aim is to compile the evidence to improve compliance
with routines. Based on the evidence the participants will agree on a model for improvement of compliance. After an
initial phase of testing the model in 1-2 wards using the Model for Improvement, the model will possibly be revised
and then implemented in several wards in the same hospital.
This task aims to engage key levels (national, regional, hospital) in participating MS in collaborative work to both start
implementation of general policies/guidelines and to start implementation in specific areas (e.g. hand hygiene, catheter
related UTI). For a sustained impact these teams are planned to continue the work towards nationwide implementation
after the Joint Action, a so called “full” participation. MS/partners involved in the Joint Action who lack capacity for
implementation at hospital level, may express interest in participating with one or two persons (who must be partners) at
those WP6 workshops that will be held in conjunction to other Joint Action meetings (as appropriate), to build capacity
on implementation in those countries and partner organisations, a so called “light-track” participation.
Criteria for taking part in this task
• The participating country needs to appoint one individual as country team coordinator and also appoint representatives
for relevant levels, e.g., national/regional/hospital levels
• The national level will select one or two hospitals that has designated professionals for infection control The hospital
management supports the project and is willing to actively support nation-wide implementation
Task 6.2.2: Promote that similar working routines are implemented in non-EU countries in Europe
Leader: FOHM ; Contributors : FPS HFCSE; NIPH; TA; HCDCP; PSCUH; LSMULKK; VULSK; NVSC; HI; VWS;
NIJZ; SoS; UAS / Start date: M1 End date: M36
Task description: the aim of the task is to engage European countries, other than MS, Norway, Iceland and Serbia by
involving existing and well established networks of professionals. The goal is to promote that the same guidelines and
methods are implemented throughout Europe. An implicit part of the chosen method is capacity-building, where the
participating organisations may be strengthened through education, by independently adapting published guidelines and
by practical improvement work.
The working model will be that participants in task 6.2.2 work closely and follow the model and participate in chosen
activities – with MS partners in task 6.2.1 to safeguard a wider spread and transfer of knowledge. Some of the countries in
task 6.2.2 can share their experiences with implementing the model and continue to carry out their own implementation
efforts.
One example of a network is the Baltic Antibiotic Resistance collaborative Network (BARN), which is a grass root
network for action against antibiotic resistance, with a focus on raising awareness and exchanging knowledge and
Page 36 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
experience among practitioners on effective interventions in health-care settings. The network has three focus areas:
Infection prevention and control; antibiotic stewardship and laboratory diagnosis and surveillance of resistant bacteria.
The network has active members in Belarus, Estonia, Georgia, Latvia, Lithuania, Moldova, Poland, Russia, Sweden and
Ukraine. It is a true multidisciplinary network: health-care personnel on all levels, microbiologists, infection control
specialists, pharmacists, governmental workers and more.
Other relevant networks should also be engaged in this task, depending on which partner organisations will participate
in Task 6.2.1. (both as full and light track participant).
Participation per Partner
Partner number and short name WP6 effort
1 - INSERM 12.00
3 - GÖG 6.00
4 - FPS HFCSE 8.30
7 - NIPH 24.50
9 - TA 5.00
11 - HCDCP 85.00
12 - ESDY-NSPH 2.00
13 - 7HC 11.50
14 - UNIFG 7.00
15 - ISS 7.00
16 - PSKUS 11.00
17 - LSMULKK 12.00
18 - VULSK 12.00
19 - HI 18.00
20 - NVSC 6.00
21 - VWS 7.00
26 - DGS 10.00
28 - NIJZ 11.00
29 - AEMPS 12.00
30 - GENCAT 12.00
31 - IdISBa 2.90
32 - FFIS 12.00
35 - ISCIII 4.00
37 - FoHM 41.20
38 - SoS 1.00
43 - UAS 1.00
Total 341.40
Page 37 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Revised
guidelines for the
implementation
D6.1 11 - HCDCP Report Public 13
of infection
control program in
healthcare settings
An Universal
Infection Control
framework
with specific
roles, priorities,
D6.2 resources and 11 - HCDCP Report Public 36
interventions for
the implementation
of an infection
control plan in
healthcare settings
Report on
experience from
country teams of
D6.3 introducing and 37 - FoHM Report Public 18
working with the
implementation
model
Updated report on
experience from
country teams of
D6.4 introducing and 37 - FoHM Report Public 36
working with the
implementation
model
Experience
from non-EU
country teams
D6.5 37 - FoHM Report Public 36
of introducing
implementation
model
Description of deliverables
D6.1 : Revised guidelines for the implementation of infection control program in healthcare settings [13]
Report
D6.2 : An Universal Infection Control framework with specific roles, priorities, resources and interventions for the
implementation of an infection control plan in healthcare settings [36]
Report
D6.3 : Report on experience from country teams of introducing and working with the implementation model [18]
Progress report
D6.4 : Updated report on experience from country teams of introducing and working with the implementation model
[36]
Page 38 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Progress report
D6.5 : Experience from non-EU country teams of introducing implementation model [36]
Report
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Results of survey A
MS28 Results of survey A 11 - HCDCP 8
(national-hospital policy)
Assessment of cost- Assessment of cost-
MS29 11 - HCDCP 12
benefit study benefit study
Results of survey B
(barriers for an effective
MS30 Results of survey B 11 - HCDCP 8
implementation of an
ICP)
Initial proposed of Initial proposed of
MS31 11 - HCDCP 14
UICFW UICFW
Evaluation of
Evaluation of the UICFW
MS32 the UICFW 11 - HCDCP 32
implementation
implementation
Initial presentation of Initial presentation of the
MS33 11 - HCDCP 12
the training tools training tools
Participating hospitals Participating hospitals
MS34 and topics selected 37 - FoHM 12 and topics selected per
per country country
Selected IPC-
Selected IPC-
guidelines and plan
guidelines and plan
for implementation
MS35 37 - FoHM 30 for implementation for
for participating
participating hospital(s) in
hospital(s) in line
line with national plans.
with national plans.
Implementation
Implementation work at
MS36 work at hospitals 37 - FoHM 36
hospitals established.
established.
Page 39 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP7 Lead beneficiary 10 23 - FHI
Work package title Appropriate use of antimicrobials in human and animals
Start month 1 End month 36
Objectives
The major objective of this WP is to collate and organise into a useable database the current guidelines for antibiotic
stewardship at all levels of the European health system and selected animal (food and companion) species, and to
establish workable tools for evaluating the implementation of antibiotic stewardship in all EU member states.
The specific objectives of this WP are to:
1. Identify and review existing guidelines, tools (including quality indicators) and importantly, implementation methods
in the human sector (by level-of-care, hospital, long-term care facility and community setting) and the animal sector
(diseased food and companion animals) and to summarize available information on the ECDC website
2. To use the results of objective 1 to guide a workshop with all the interested partners looking at barriers, opportunities
and successful strategies for implementation at the three levels of care and the animal sector in order to evaluate possible
options for the implementation of the work.
3. To report the level of implementation and level of acceptance of antibiotic stewardship strategies at different levels
of care, in food and companion animals in different countries, including both indicators for consumption of antibiotics
by humans and animals.
4. To design and run pilot projects looking at effective implementation (as defined by the previous two activities) of
antibiotic stewardship by introducing a simple surveillance system of antibiotic consumption and resistance, including
feedback mechanisms for a shorter time-lag than present alternatives. This would be done in parallel projects in settings
with differing resources in human and animals and focusing on different levels of care.
We envisage a high degree of synergy between WP7 and WP6 and suggest close cooperation between the two packages.
Description of work and role of partners
WP7 - Appropriate use of antimicrobials in human and animals [Months: 1-36]
FHI, GÖG, FPS HFCSE, NCIPD , CIPH, NIPH, SSI, TA, RKI, HCDCP, ESDY-NSPH, UNIFG, ISS, LSMULKK,
HI, NVSC, VWS, HdiR, NVI, NMI, DGS, UMPIH, AEMPS, GENCAT, IdISBa, FFIS, FMS, SAS, SERMAS,
FoHM, ANSES
Task 7.1: Identify and review existing guidelines, tools and importantly, implementation methods for antibiotic
stewardship by level-of-care (hospital, long-term care facility and community setting) and in food and companion
animals and to summarize available information on the ECDC website
Leader: FHI ; Contributors : HDir; AEMPS; DG de Planificación, Evaluación y Farmacia.- Consejería Salud Comunidad
Autónoma Illes Balears; NMI; UNIFG; VWS; SSI; UMPIH; RKI; GOG; ISS; ANSES; CIPH HZJZ; LSMULKK;
NVSC / Start date:M2 End date:M11
Collaborating with: ECDC dept. for antimicrobial resistance and Healthcare Associated Infections and OIE. ECDC
would be asked to host the information made available through this project on their website.
Task description:
• Review material from ECDC, EFSA and EMA and other actors such as OIE, FAO, WHO, GHSA, website, other
initiatives such as the ARNA project, the OECD report, the STRAMA network, and published literature
• Questionnaire to member states on current, past and proposed activities including receiving copies of tools and
guidelines with weight given to the level of implementation of antibiotic stewardship plans, reason for choice of tool/
guideline and implementation plan, “partners” in charge of work, success stories and the barriers that have hindered
implementation of this work. This will expand on work already conducted by the OECD
The aim will be to update and expand the information available on the ECDC website to include information on
existing guidelines, implementation methodology and work at different levels of the healthcare system. This will include
strategies aimed at different settings and the existence of national or local indicators (including structural, process and
outcome indicators of quality).
Task 7.2. Workshop involving all the registered partners to discuss models of implementation
Leader: FHI ; Contributors : Hdir; AEMPS; GOG; NMI; NIJZ; VWS; SSI; UMPIH; RKI; GOG; ISS; ANSES;
LSMULKK; NVSC / Start date: M11 End Date: M12, EFSA
Collaborating with: ECDC dept. for antimicrobial resistance and Healthcare Associated Infections: TBC
Task description:
Page 40 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Identify experts and organize expert group meetings (virtual and at least one face-to-face) to evaluate findings from
task 7.1, identifying key tools and implementation mechanisms (expert group around 10 people) in both the human
and animal sectors.
• Organize workshop to share experiences between countries and comment on expert group’s findings, with a focus
on barriers for implementation. – Interest from Austria to help organize meeting (workshop about 40-60 people at end
of year 1)
• Discuss suitability to different settings (cultural, epidemiological and financial)
Task 7.3 Qualitative evaluation of the level of implementation and acceptance of antibiotic stewardship at different
levels of healthcare and in animals, in different country settings. This will focus on identifying and establishing success
factors and barriers.
Leader: FHI; Contributors : HDir; SAS; FFIS; GENCAT; SERMAS; Illes Balears; NMI; FOHM; UNIFG; NPIH; SSI;
UMPIH; RKI; GOG; ISS; ANSES; LSMULKK; NVSC / Start date: M2 End date: M36
Task description:
• Follow-up questionnaire to active partners, which will be further disseminated in each member state or region. This will
include structured questions and oral interviews. The aim of this activity will be to collate information about attitudes
to stewardship methodologies and campaigns in order to determine both factors for success and barriers to acceptance.
• Evaluation and publication of recommendations on core components needed for implementation that can be used by
member states when planning their own programs based on the information from tasks 7.1, 7.2 and 7.4.
• We will deliver a report on which indicators of antibiotic use and resistance are available in each country in human
(for each level of care) and animals and, including for animal husbandry (as an indicator of the antibiotic burden in
the environment).
Task 7.4.1 Develop and test near real time surveillance of antimicrobials and multidrug resistant bacteria
Task description:
Current surveillance networks are informative and concise. However, there is a long delay in the data reported and some
countries do not have data. Therefore, there is a need for reinforcing current surveillance systems. Surveillance networks
need to be adapted to work in conjunction to provide a simple surveillance system of antibiotic use and resistance. This
subject is essential to guide the fight against the antimicrobial resistance (AMR) and to improve the results by means
of feedback and benchmarking. In addition, this system must work and data must be available in a shorter time-lag
than present alternatives.
Subtask 7.4.1. Surveillance in human medicines - consumption of antimicrobials and AMR
Leader: SAS ; Contributors: AEMPS; FFIS; GENCAT; SERMAS; Illes Balers; FMS; FHI; UMPIH; NMI; FPS HFCSE;
UNIFG; ESDY-NSPH; NIPH; SSI; RKI; GOG; ISS; NVSC; LSMULKK / Start date: M2 End date: M36
• Select basic indicators for surveillance system of antimicrobial consumption: : DDD/1000 stays (in hospital settings)
or inhabitants (in primary care settings) of:
-. Overall antimicrobial drugs consumption
-. Carbapenems, piperacillin-tazobactam, amoxicillin-clavulanate, aminoglycosides, quinolones, 3rd and 4th gen
cephalosporins, vancomycin and colistin (in hospitals)
-. Amoxicillin-clavulanate, 3rd gen cephalosporins, quinolones and macrolides (in primary care)
• Select basic indicators for surveillance system of antimicrobial resistance: Number of isolates in clinical samples per
patient/1000 stays (in hospital) or inhabitants (primary care) of of the following pathogens:
-. Carbapenemase-Producing Enterobacteriaceae, ESBL E. coli, ESBL K. pneumoniae, MDR A. baumannii, MDR P.
aeruginosa and methicillin-resistant S. aureus (MRSA), ), vancomycin resistant enterococci (E. faecalis and E. faecium)
in hospital settings.
-. Carbapenemase-Producing Enterobacteriaceae, ESBL E. coli, ESBL K. pneumoniae, methicillin-resistant S. aureus
(MRSA), in primary care area.
• Reinforce already existing local surveillance systems in order to have the available data as soon as possible.
• Select pilot sites that will represent the three levels of healthcare named above and to cover countries with different
resources available including regular meetings, follow-up and support.
• Frequency: quarterly. Data managers will have a two-month period after the end of each trimester to upload data onto
the website software.
• Collaborations with existing networks. Potential connections with EARS-net and ESAC: the project leader will have
periodical meetings with with ECDC networks EARS and ESAC to share the project status and outcomes, so that it
could be of interest for future collaborations.
• Quality of data: Indicators definitions and data management will be explained carefully in guidelines. A website with
data management software will be developed specifically. .Data will be entered by each participating hospital/primary
Page 41 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
care area/region/country in the form of numbers (two figures per each indicator). The accuracy of data will be under
each national coordinator’s responsibility.
Regional data could be cumulative (sum of hospitals data / primary care areas data) or directly entered specifically by
a designated responsible person.
Country data could be cumulative (sum of regional data) or directly entered specifically by a designated responsible
person.
Calculations will be carried out by the software to minimize human error. Prior to validate entered data, a technician
will supervise them quarterly in order to find out any possible outliers and take the measures to correct them. Besides,
the task leader will carry out random audits to any participating country.
Subtask 7.4.2. Surveillance of AMR in animals
Leader: ANSES and ISS ; Contributors: NVI, ESDY, SSI, AEMPS / Start date: M2 End date: M36
AMR surveillance in animals will be conducted to evaluate the correlation between AMR spread in humans and animals.
Thus, antimicrobial-resistant bacteria that will be surveyed will be mainly the same in a One Health strategy. Numerous
issues in the veterinary sector have already been covered by EU and/or MS initiatives sustained by scientific advice
from EFSA. It is particularly the case for AMR surveillance under EC directives in healthy food animals and antibiotic
consumption under ESVAC. On the contrary, the project will fill the gaps by focusing on the uncovered domain of AMR
surveillance in diseased animals in the EU. Thus, the objectives will be to:
• Assess the surveillance systems in place on AMR in animal pathogens in MS
• Identify the main gaps and appropriate strategies for AMR surveillance in diseased animals in Europe depending on
MS specificities towards their diversity in animal species and diseases
• Select appropriate AMR indicators in diseased animals in coherence with human ones, including carbapenemase-
producing Enterobacteriaceae, ESBL E. coli, ESBL K. pneumoniae, MDR P. aeruginosa, MDR A. baumannii,
methicillin-resistant S. aureus (MRSA), methicillin-resistant S. pseudintermedius (MRSP), colistin-resistant
Enterobacteriaceae, vancomycin resistant enterococci (E. faecalis and E. faecium). The choice of these indicators will
allow to correlate the animal data with the human data from subtask 7.4.1
• Identify laboratory and technical capacities in MS for potential establishment of a molecular-based AMR national
surveillance of relevant resistant pathogens, to be further compared with human counterparts
• Assess the opportunities to combine MS surveillance systems into a pilot EU network for the surveillance of AMR
in clinical animal isolates, covering prioritized animal species and relevant pathogens, based on existing networks in
place at national levels (RESAPATH, VetPath, …), and including common reporting and communication issues
• Draw guidelines for uploading, validation and management of the data, with particular emphasis on accuracy and types
of the data (per animal species, pathogen and disease) under each national coordinator’s responsibility.
• Provide global and specific recommendations to EU to build a European network covering AMR surveillance in
diseased animals, including interface with AMR surveillance in human medicine
Participation per Partner
Partner number and short name WP7 effort
3 - GÖG 5.30
4 - FPS HFCSE 2.50
5 - NCIPD 11.00
6 - CIPH 10.70
7 - NIPH 5.30
8 - SSI 12.00
9 - TA 5.00
10 - RKI 5.90
11 - HCDCP 12.00
12 - ESDY-NSPH 38.00
14 - UNIFG 6.00
Page 42 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Partner number and short name WP7 effort
15 - ISS 12.00
17 - LSMULKK 7.00
19 - HI 9.00
20 - NVSC 2.70
21 - VWS 2.00
22 - HdiR 3.80
23 - FHI 33.20
24 - NVI 6.00
25 - NMI 6.00
26 - DGS 5.00
27 - UMPIH 4.50
29 - AEMPS 18.00
30 - GENCAT 12.00
31 - IdISBa 7.30
32 - FFIS 4.80
33 - FMS 5.00
34 - SAS 17.10
36 - SERMAS 28.00
37 - FoHM 2.00
44 - ANSES 35.50
Total 334.60
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Website with Websites,
D7.1 evaluated tools and 23 - FHI patents filling, Public 12
information etc.
Report on
workshop of
D7.2 models for 23 - FHI Report Public 13
implementation of
stewarship tools
Indicators used
for monitoring
antibiotic use
D7.3 23 - FHI Report Public 36
and resistance
in humans and
animals
Page 43 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Surveillance of
antimicrobial use
D7.4 34 - SAS Report Public 36
and resistance in
human
Surveillance of
antimicrobial use
D7.5 44 - ANSES Report Public 36
and resistance in
animal
Description of deliverables
D7.1 : Website with evaluated tools and information [12]
Website hosted by ECDC organised by level of care
D7.2 : Report on workshop of models for implementation of stewarship tools [13]
Report on antibiotic stewardship implementation models
D7.3 : Indicators used for monitoring antibiotic use and resistance in humans and animals [36]
Report
D7.4 : Surveillance of antimicrobial use and resistance in human [36]
Results of pilot study from indicators selected to monitor antibiotic use and resistance in humans
D7.5 : Surveillance of antimicrobial use and resistance in animal [36]
Feasibility report for surveillance system in animals
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Progress check of Progress check of review
MS37 23 - FHI 4
review procedure procedure
Progress check in Progress check in terms
MS38 23 - FHI 12
terms of website of website
Progress check of Progress check of
MS39 implementation of 23 - FHI 24 implementation of
stewardship tools stewardship tools
Progress check Progress check
MS40 29 - AEMPS 15
surveillance system surveillance system
Page 44 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP8 Lead beneficiary 10 29 - AEMPS
Work package title Awareness raising and Communication
Start month 1 End month 36
Objectives
Despite the European Commission and the Member States having developed and implemented strategies and action
plans at national level to control the development of antimicrobial resistance, figures show that efforts should continue
to keep on fighting against the development and propagation of antimicrobial resistance.
The main objective of this WP is increasing Awareness and optimizing Communication strategies on antibiotic use
and AMR and prevention of Healthcare associated infections with the aim of promoting the responsible use of these
medicines and encouraging best practices among the general public and healthcare professionals and through dialogue
with young population and mass media.
The specific objectives of this WP are to:
1. Define best practices on Communication and Awareness: state-of-the-art as a guide for new or updated communication
strategies.
2. Reach different targets using different strategies: Develop a Communication and Awareness Plan that will address
these targets.
3. Use the website developed by WP2 as a key tool for promoting communication and interacting with social networks
and traditional media to guarantee reaching the general public, specific groups of society and professionals subgroups.
This website will work as a unifying platform that will collect all the contents created within the project, so it is a tool
to ensure both, correct dissemination on high quality information on JA deliverables and awareness raising on AMR
and HCAI issues. As for these contents, they will all be designed according to the different targets and properly updated
as the project moves forward.
4. Support coordination about World Week and the European Day of Appropriate Use of Antibiotics. Establish dialogue
with other initiatives and actors related to antibiotic use and antimicrobial resistance.
Description of work and role of partners
WP8 - Awareness raising and Communication [Months: 1-36]
AEMPS, INSERM, MoH-FR, CIPH, NIPH, SSI, TA, RKI, HCDCP, ESDY-NSPH, UNIFG, LSMULKK, HI, NVSC,
VWS, HdiR, DGS, NIJZ, GENCAT, IdISBa, FFIS, FMS, ISCIII, SERMAS
WP Methodology
The following tasks have been designed and planned in order to promote the responsible use of antibiotics by
highlighting the importance of appropriate prescribing and use as well as informing about the risks associated with
overuse and misuse of these medicines. Thus, this WP is intended to change minds and behaviors regarding antibiotics
use and the threat of increasing AMR and HCAI.
WP8 strategy will be designed and carried out by a team that will consist of health communication specialists with
relevant professional experience within this field. Communication between the Communication Officer in charge of
WP8 and each country’s contact person will be carried out via email on a monthly basis or more frequently if it is needed
or via TLC depending on the project’s dynamics. These active partners will maintain dialogue with its country´s contact
person for informing about relevant events, news, and other material related to awareness and communication.
Task descriptions
Task 8.1: Data Collection to define best practices in Awareness and Communication Plans
Leader: AEMPS; Contributors: TA and all WP8 participating partners / Start date: M1 End date: M12
8.1.1.
• Data collection on previous strategies, activities and materials targeting professionals in the fields of public health,
animal health and the environment (one health approach), the general public and other specific population groups such as
youth, medical students, caretakers or elderly. The objective is to collect and analyze all these materials to avoid efforts
duplication, share good practices and offer ideas to MSs for building further new awareness and communication plans.
• The analysis of the mentioned materials will help to implement new awareness and communication plans to reach
the following objectives:
o Increase awareness on the importance and consequences of the inappropriate use of antibiotics in human and animal
sector.
Page 45 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
o Optimize Compliance with treatment regimens of prescribed antibiotics.
o Avoid the use of antibiotics when they are not indicated.
o Avoid the storage and consumption of leftover antibiotics (self-medication).
o Strengthen the position of professionals in public and animal health, to make them feel less pressured to prescribe
and dispense antibiotics.
o Encourage Health professionals to undertake Continuing Professional Development activities (i.e e-learning,
webinars, live educational events)
• Selection of some efficient and innovative communication strategies and activities that have been performed in
previous years, regardless their relation to antibiotic use. Search for some relevant and successful cases to take advantage
of them.
• Analyze and evaluate previous awareness and communication materials and/or strategies.
• Prepare a report about Communication Good Practices as a guide or reference tool when designing new strategies.
8.1.2.
Analyze the use of the theme “antibiotic” in social networks and Internet. A pilot study will be conducted to analyze how
the theme “antibiotic” is approached by the society in the social networks. Different periods of time in each year will be
targeted to identify the key themes arising in relation to antibiotics (ie. April, October and January). A web-based tool
will be used to detect daily occurrences of the word 'antibiotic' and other related terms during the chosen time period
in Tweets. How the society dialogue about antibiotics as well as activity peaks (message frequency over three times
that of baseline) will be analyzed to identify key issues and events that need to be considered in future awareness and
communication campaigns. In that way, findings could determine the best period for launching campaigns in addition to
negative attitudes or perceptions that should be considered to better address overuse and misuse. For the data collection,
staff members will retrospectively analyze the selected periods.
8.1.3.
Identify some efficient and innovative educational strategies and activities performed in Europe focusing on prudent
use of antibiotic in both High School and Universities.
A content analysis of teaching materials will be conducted to explore and identify innovative strategies and activities
performed in the secondary high schools and universities. The project will organize strategies to share these activities
and motivate all MSs to implement them, for example, by promoting the use of the e-bug platform, and its adaptation,
or other similar initiatives.
Task 8.2: Design and Implementation of Awareness and Communication Plan
Leader: AEMPS; Contributors: VWS and all WP8 participating partners / Start date:M1 End date:M8
Task description: To design Awareness and Communication strategies targeting governments and stakeholders.
8.2.1. Prepare the Awareness and Communication Plan
• Definition of the objectives and identification of the relevant target audiences. Both WP8 and WP2 share target
audiences (general media and health-specialized journalists, general public -specially considering caretakers for elderly
and children-, healthcare professionals in both human and animal health, medical and veterinary students, human and
animal health industries, key decision makers) but differ in goals since WP8 is intended to change minds and behaviors
toward antibiotics by raising awareness of the dangers of AMR whereas WP2 is intended to disseminate outcomes and
deliverables produced by the JA that could lead to this change.
• Definition of basic key messages to be communicated to the general public, health professionals and specific target
audiences, along the same lines as ECDC’s messages through the activities included within WP8. Messages targeted
at general public:
- Antibiotic misuse and overuse creates antibiotic-resistant germs that could lead us to a scenario where antibiotics no
longer work.
- Antibiotics are effective only against bacterial infections. Taking them for wrong reasons, such as against colds or
flue, has no benefit for you.
- Antibiotics often give you side effects such as diarrhea. Always seek your doctor’s advice before taking them.
Messages targeted at health professionals (physicians and veterinarians, pharmacists, nurses, specialist nurses, …):
- Antibiotic resistance is an increasingly serious public health problem all over the world.
- While the number of infections due to antibiotic-resistant bacteria is growing, the pipeline of new antibiotics is
unpromising, thus presenting a bleak outlook on availability of effective antibiotic treatment in the future.
- Unnecessary antibiotic prescribing could boost the emergence and selection of antibiotic-resistant bacteria.
More specific messages targeted at more specific audiences according to each country will be designed as the project
moves forward, as well as the tools and the schedule to better spread them.
• Description of the issues to be tackled and identification of good practices and specific tools to be used or developed
in order to support effective actions.
Page 46 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
8.2.2. Implementation of some of the following proposed activities. Depending on budget, some pilot activities could
be carried out in some countries or could be removed, if necessary. First working meetings will clarify each participant
contribution so this schedule can be set up:
• Database design including European Science and Health Communication researchers. Organize 1 European webinar/
year during the 2nd and 3rd years (mass media, other communicators, etc). Trying to generate a starting point for a
network of communicators about increasing antibiotic use and antimicrobial resistance.
• Carry out 1 or 2conferences (similar to TED Conferences; maybe a pilot activity in some countries) in the second-third
years of the JA, one with scientific communicators, and another conference with High School and university students
as speakers. The conference with students will be organized with the aim of encouraging them to improve their public
speaking skills as well as spreading our key messages among youth. Each country will determine criteria and rules
for speakers’ selection. For instance, invitations to participate in this programme could be sent to the regional or local
authorities or to largest high schools in each region or the top-rated medical schools. A jury will select the best talk in
each region and those students will take part of a national competition. Each country winner will eventually compete
in a final contest that will take place in Brussels or in a Spanish city.
• High Level Awareness and Communication Meeting (included as activity developed in task 8.4): One High Level
European Meeting in the last year focusing on governments (relevant institutional organizations at the regional (e.g.
Health Authorities), national (MoH)) and stakeholder’s (Industry) awareness with the attendance of international
organizations (e.g. EIP, DG SANCO, OECD, WHO, JPI AMR, etc.). This High Level European Meeting could be
organized within the context of the ECDC’s European Antibiotic Awareness Day at the European Parliament or in a
Spanish city chosen to host it. As speakers we might invite scientific and healthcare professional communicators or
maybe some JA representatives (WPleaders). Organized as a workshop aimed to communicate the risks of misusing
antibiotics and the need for commitment to fight AMR coming from different stakeholders. Thus, topics included
will focus on highlighting the danger of not facing this problem from several perspectives (political, scientific and
economical) in order to change different behaviors. This meeting is intended to set up a conclusion document that
could work as a road map/call to action to be signed (supported) by different stakeholders (e.g. http://www.who.int/
globalchange/global-campaign/call-for-action/en/). In any case, specific details will be decided by participants involved
in WP8 at this work package’s kick-off meeting.
• Training webinars on AMR lead by physicians and veterinarians that will be targeted at general media and health-
specialized journalists. One purpose of these webinars is to provide clear and accurate scientific information about this
problem so journalists are able to correctly inform the audience about AMR consequences. Furthermore, physicians
and veterinarians will be asked to undertake Continuing Professional Development (CPD) activities on AMR. National
accreditation authorities will be asked to require their doctors to do that. All of these activities will be carried out in
close collaboration with different work packages involving interactions with physicians and veterinarians, so webinars
and CPD activities’ materials will be designed according to achievements that are being made.
Task 8.3: Tools for Awareness and Communication (probable interaction with WP2)
Leader: AEMPS; Contributors: UNIFG and all WP8 participating partners / Start date:M1 End date:36
Task description:
• Use of the web platform for promoting awareness and communication campaigns/materials or events carried out by
WP8. The exclusive use of English would undermine effective communication and devalue the funding efforts made
by all partners. Thus, our proposal would consider different versions in English, French and Spanish, as well as partial
translations (i.e. objectives, news or blogs) to each MS language.
• Creation and implementation of a (or some) relevant blog(s) and performing an active search for contents within the
website: news, podcast, reports, scientific papers, interviews, and general information about antimicrobial resistance.
As previously mentioned, each active country should have one contact person for communication activities. All Work
Packages leaders will notify any event, communications, news related to Awareness and Communication produced
during WP development.
• Social media promotion:
o Create profiles in Facebook, Twitter and Youtube, and make sure to update the content of these profiles on a regular
basis (daily and weekly updating). Contents will spread initiatives related to our goals that are being carried out all over
Europe and will also consider the organization of Twitter chats with healthcare professionals and contests that will boost
engagement (e.g. online quizzes or sharing experiences related to the use of antibiotics).
o Carry out 3 social media promotion actions per year in the 2nd and 3rd years to attract internet traffic to the website
(at European level) for example by JA-blog Promotion (promote communication and awareness materials) in the social
media. Paid media in Facebook or Twitter will create more exposure and will drive searchers to our website, to help
increase not just traffic but also conversations. Thus, tools such as advertising or collaboration with influencers will
impact the reach of our key messages.
Page 47 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
o Use of a social networks analysis tool to measure the impact of the promotion actions and to get a deeper knowledge
of the flow of information based on complex networks techniques and the topology of the network (Analytics, online
reputation, etc).
• Awards
o Award for the best European article or best video about antibiotic use. This award will be granted to the journalist whose
article/video presents the clearest, informative and scientifically-based piece of work. Articles/videos to be considered
will be chosen from the most read newspapers and top television news services.
o Award for a European competition with University students (High School students should be also considered if
it does not provoke legal difficulties in audio-visuals activities related to the use of underage images) presenting a
video work about antibiotic use and increasing AMR. The competition "Eurovision Antibiotic Contest" will grant the
most creative piece of work (a music video, a short film, a monologue, using their own language) explaining how
we should use antibiotics and how we actually use them. Just like in "Eurovision Song Contest" each country will
select a winner that will compete in a final contest. The winner will get a study-abroad grant. The organization of this
contest could work as an inter-university competition leaded by selected professors within each university (e.g. https://
www.consumerclassroom.eu/consumer-classroom-inter-school-competition-2016-2017). This competition will permit
future sustainability of this type of health competition and working closely with CHAFEA could also be the opportunity
to implement later a “Health classroom” within their “consumer classroom”.
• This social campaign will be designed in order to address general public and healthcare professionals in both human
and animal health, according to the One Health approach. Audiovisual materials will be created to be posted at social
networks profiles and leaflets/posters will be distributed among hospitals and medical centers and in professional
congress. Cited examples in the Luxembourg meeting were: use Term antibiotic in the box. Cooperation with the
industry. Or TV France example “antibiotic is not automatic anymore” or “proper prescribing”, Maybe use an ethical
message about a good prescription.
• Interview management with key national spokesperson in the top general and health-specialized media. Each partner
should contact the most relevant national media to offer an interview with the selected national spokesperson, who will
highlight the project's key messages during the interview. National spokesperson should be selected according to their
authority, expertise, communication skills and interview background.
Task 8.4: Support coordination about World Week and the European Day of Appropriate Use of Antibiotics. Establish
dialogue with other initiatives and actors.
Leader: AEMPS; Contributors: NIJZ and all WP8 participating partners / Start date:M1 End date:36
Task description:
• Following ECDC’s line of work, meetings with AMR JPI, IMI JU consortium working on antibiotics, WHO/Europe
and other initiatives will be held in order to share ideas and jointly collaborate in campaigns.
• Meetings with National Action Plan Coordinators to share best awareness practices.
• Coordination meetings on European Antibiotic Awareness Day. WP8 Communication team will be able to offer any
support and help in order to face any need and contribute to implementing any proposed activity.
• High Level Awareness and Communication Meeting (explained previously in subtask 8.2.2.3.)
Participation per Partner
Partner number and short name WP8 effort
1 - INSERM 7.50
2 - MoH-FR 1.00
6 - CIPH 0.50
7 - NIPH 0.50
8 - SSI 0.50
9 - TA 5.00
10 - RKI 0.10
11 - HCDCP 1.00
12 - ESDY-NSPH 1.00
Page 48 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Partner number and short name WP8 effort
14 - UNIFG 1.90
17 - LSMULKK 0.50
19 - HI 0.50
20 - NVSC 2.50
21 - VWS 2.00
22 - HdiR 0.10
26 - DGS 2.50
28 - NIJZ 3.50
29 - AEMPS 49.00
30 - GENCAT 4.00
31 - IdISBa 3.10
32 - FFIS 1.00
33 - FMS 0.50
35 - ISCIII 0.40
36 - SERMAS 3.00
Total 91.60
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
Awareness and
D8.1 Communication 29 - AEMPS Report Public 10
Plan
European Prize:
better journalism
D8.2 report or better 29 - AEMPS Report Public 27
video about
antibiotics
European
competition with
D8.3 29 - AEMPS Report Public 32
High Schools
students
Awareness and
Communication
D8.4 29 - AEMPS Report Public 34
High Level
Meeting
Description of deliverables
D8.1 : Awareness and Communication Plan [10]
Report
D8.2 : European Prize: better journalism report or better video about antibiotics [27]
Page 49 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Report: list of competitors, agenda of the event, report of the prices and winners, report of the applicants considered
and a short brief of their applications.
D8.3 : European competition with High Schools students [32]
Report: list of competitors, agenda of the event, report of the winners, report of the applicants considered and a short
brief of their applications.
D8.4 : Awareness and Communication High Level Meeting [34]
Report on road map for stakeholders with minutes and videos available
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Awareness and Awareness and
MS41 29 - AEMPS 7
Communication Plan Communication Plan
Database control
MS42 29 - AEMPS 7 Database control check
check
European Webinar European Webinar
and of Science and of Science and
MS43 and Health 29 - AEMPS 14 Health Communication
Communication researchers (Mass media):
researchers control point
Design of promotion
Design of promotion
activities related to
activities related to better
MS44 better journalism 29 - AEMPS 14
journalism report or better
report or better video
video about antibiotics
about antibiotics
European competition European competition
with High Schools with High Schools
MS45 29 - AEMPS 12
students: starting students: starting control
control point point
European competition European competition
with High Schools with High Schools
MS46 29 - AEMPS 24
students: intermediate students: intermediate
control point control point
Awareness and Awareness and
Communication Communication High
MS47 29 - AEMPS 16
High Level Meeting: Level Meeting: starting
starting control point control point
Awareness and Awareness and
Communication Communication
MS48 High Level Meeting: 29 - AEMPS 24 High Level Meeting:
intermediate 1 control intermediate 1 control
point point
Awareness and Awareness and
Communication Communication
MS49 High Level Meeting: 29 - AEMPS 30 High Level Meeting:
intermediate 2 control intermediate 2 control
point point
Page 50 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Work package number 9 WP9 Lead beneficiary 10 1 - INSERM
Work package title Prioritizing and implementing research and innovation for public health needs
Start month 1 End month 36
Objectives
The main objective of this WP is to contribute to a coordinated European response in regards to prioritizing and assisting
in the implementation of research and innovation expected to help achieve public health-related AMR and HCAI goals
and objectives. (This WP will not fund any research or innovation projects.) The three specific objectives of this WP
each corresponding to a dedicated task are to:
1. Work with Member States to ensure that national processes for research and innovation priority-setting are grounded
in a broad One Health approach and that both Member State research priorities and knowledge gaps are addressed in
the development of the update of the JPIAMR SRA (Strategic Research Agenda.
2. Explore and detail European strategies to implement mechanisms to increase innovation and other means to fight
against AMR and HCAI
3. Contribute to ensuring that evidence-informed public health policies and practices related to combatting AMR and
HCAI are implemented
Description of work and role of partners
WP9 - Prioritizing and implementing research and innovation for public health needs [Months: 1-36]
INSERM, 7HC, ISS, VWS, FHI, NVI, NIJZ, IdISBa, SERMAS, SRC
Task 9.1: Work with Member States to ensure that national processes for research and innovation priority-setting are
grounded in a broad One Health approach and that both Member State research priorities and knowledge gaps are
addressed in the development of the update of the JPIAMR SRA.
Leader: INSERM Main contributors: FHI, SRC ; Other contributors: 7HRC; ISS; VWS; NVI; NIJZ; Balearic Isles,
SERMAS / Start date: M1 End date: M36
Task description:
The aim of this task is to contribute to a strengthened process for European-wide and internationally acknowledged
agreement on research and innovation priorities to meet the public health goals related to AMR and HCAI in a broad
One Health approach.
The European Union Member States in 2016 through the Council Conclusions, particularly §22.8, expressed their will
to align strategic research agendas of existing EU R&D initiatives on new antibiotics, alternatives and diagnostic, and
set priorities based on societal needs in the field of public health, animal health and the environment, taking into account
gaps analysis in this domain.
Significant efforts led by JPIAMR in collaboration with the EU and IMI have already been established in regards to
AMR research and innovation priority-setting. Its Strategic Research Agenda (SRA) outlines key, neglected areas to
tackle, which guides JPIAMR and others to shape cohesive and coordinated AMR funding and research actions to
maximise on resources and reduce duplication of research. The SRA is scheduled to be updated in 2017. About half of
EU members, but also other countries, participate in JPIAMR.
This process can be expanded upon by working directly with Member States in preparation of their participation in
priority-setting activities with JPIAMR. Member States need to ensure that their national processes include: (1) a One
Health focus including not only the Ministry of Health but also Ministries of Agriculture, Fisheries, and Environment;
(2) ensure that the special needs of HCAI are also included; (3) ensure that an appropriate breadth of research fields is
considered including social sciences; and (4) consider where research syntheses are needed in order to inform policies.
Social sciences are an often forgotten aspect of research priorities but can have major impact on achieving stewardship
and infection control goals. Member States should also ensure that their own national research agendas are in line and
fill the identified gaps with the priorities set out by JPIAMR and other related initiatives like the international clinical
trial networks. Member States not participating in JPIAMR should be encouraged to share their priority research and
innovation topics with JPIAMR. Links to Horizon 2020 will also be evaluated.
Member State priority-setting for AMR and HCAI research and innovation in line with public health needs
• Gather national approaches to participation and input into the SRA update to assess best practices and gaps (INSERM,
FHI, SRC)
• Work with Member States to provide best practices and routines that can assist them with identifying national research
and innovation priorities to be communicated into the SRA process (INSERM, FHI, SRC)
Page 51 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Provide feedback to JPIAMR and potentially Horizon 2020 and others about perceived gaps and potential procedural
improvements to SRA update process (INSERM, FHI, SRC in conjunction with WP4 Implementation)
Task 9.2: Explore and detail European strategies to implement mechanisms to foster antimicrobial innovation and other
means to fight against AMR and HCAI
Leader: FHI Main contributor: INSERM; Other contributors: SRC; 7HRC; ISS; VWS; NVI; NIJZ; Balearic Isles,
SERMAS / Start date: M1 End date: M36
The aim of this task is to act upon recommendations for stimulating greater innovation (including medicines, vaccines,
diagnostics, and medical devices – for both human and animal health) to combat AMR and HCAI. Innovation has been
acknowledged to be dangerously lacking for the past decades. Yet this is not to say that this type of innovation has
been determined to be more impactful than other types of research and innovation. Significant funds have recently
been invested in projects, like the UK’s AMR Review and IMI’s DRIVE-AB, to explore new economic models and
strategies to stimulate innovation. It is timely now to react to the results of these initiatives and assist Member States
with implementation.
Since the cost of developing some products, like a new antibiotic, may be large, the financing for stimulating
innovation is also large, requiring coordination across countries. Other processes, like joint procurement mechanisms,
new regulatory classifications, and regulatory harmonization, can also be impactful and require collaboration.
UK’s AMR Review delivered its final report in May 2016 which included recommendations to stimulate both
antibacterial innovation for human and animal use as well as diagnostic innovation. DRIVE-AB will deliver its final
recommendations in September 2017.
Assist with EU-wide implementation of incentives to stimulate antimicrobial, diagnostic and other innovations for
fighting AMR and HCAI
• Hold a meeting where AMR Review, DRIVE-AB, and other potential actors present their recommendations to Member
States and non-Member States regarding the need for multi-country collaboration in order to stimulate the innovation of
antimicrobials (for both human and animal health) as well as diagnostics and other innovations, including an opportunity
for governments to ask questions and provide feedback (FHI, INSERM)
• Perform a gap analysis for any missing incentives with a special focus on how to align and/or differentiate what is
needed for AMR on the one side and HCAI on the other (FHI, INSERM)
• Hold follow-up meetings with about ten Member States and 3-5 non-Member States to gather direct feedback on the
recommendations and options for implementation; request written feedback from the remaining Member States (FHI,
INSERM)
• Develop an implementation strategy aligned with feedback from Member States (FHI, INSERM in conjunction with
WP4)
• Request that all Member States formally respond to the implementation strategy with firm commitments (FHI,
INSERM)
Task 9.3: Contribute to ensuring that evidence-informed public health policies and practices related to combatting AMR
and HCAI are implemented
Leader: FHI / INSERM ; Main contributor: SRC ; Other contributors: 7HRC; ISS; VWS; NVI; NIJZ; Balearic Isles,
SERMAS / Start date: M1 End date: M36
The aim of this task is to ensure that national procedures are in place to translate research findings (including
those from the social sciences) into public health policies and practices. Since the quality, certainty, and strength of
recommendations can vary for individual studies, it is important to first synthesize the existing evidence through a
systematic review where the evidence is graded and then summarize the findings in plain language for policymakers.
SURE Policy Briefs are a tested format that can be used to convey evidence to policymakers. This task will require
support of and engagement in fora for communication of research findings to public health implementation levels,
including the exchange of good practices as a procedure to reinforce implementation. A particular attention will be paid
to establish functional links with WP2, WP4 and WP8 in that regard.
Assist with evidence-informed policymaking.
• Evaluate existing tools for evidence-informed policymaking, like policy briefs, and modes of dissemination and
sharing, as well as implementation good practices (FHI)
• Recommend national dissemination and sharing strategies for policy briefs or other tools (FHI, SRC)
• Gather feedback on recommendations and update recommendations appropriately (INSERM)
• Request EU to agree to and publish the recommendations (INSERM)
Participation per Partner
Page 52 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Partner number and short name WP9 effort
1 - INSERM 31.00
13 - 7HC 1.50
15 - ISS 3.00
21 - VWS 4.00
23 - FHI 32.50
24 - NVI 1.00
28 - NIJZ 1.00
31 - IdISBa 2.40
36 - SERMAS 3.30
42 - SRC 4.60
Total 84.30
List of deliverables
Deliverable Dissemination level Due Date (in
Deliverable Title Lead beneficiary Type 15
Number 14 16
months) 17
National priority-
D9.1 setting best 1 - INSERM Report Public 34
practices
Implementation
D9.2 strategy for EU 23 - FHI Report Public 36
collaboration
Dissemination
D9.3 1 - INSERM Report Public 36
strategies
Description of deliverables
D9.1 : National priority-setting best practices [34]
Best practices and routines that can be implemented by Member States to improve the input that they send to SRA
regarding research and innovation priorities
D9.2 : Implementation strategy for EU collaboration [36]
A concrete strategy for implementing multi-country incentives to stimulate antimicrobial and diagnostic innovation
D9.3 : Dissemination strategies [36]
Policy briefs or other tools publicly available
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
Gathering of national
Gathering of national
approaches to providing
MS50 approaches to 1 - INSERM 18
input to SRA from at least
providing input to
five countries
Page 53 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Schedule of relevant Milestones
Due Date (in
Milestone number 18 Milestone title Lead beneficiary Means of verification
months)
SRA from at least
five countries
Inter-governmental
Inter-governmental
meeting to discuss
meeting to discuss
DRIVE-AB and
DRIVE-AB and AMR
MS51 AMR Review 23 - FHI 6
Review recommendations
recommendations
with regards to AMR and
with regards to AMR
HCAI
and HCAI
Recommendation Recommendation for
for dissemination of dissemination of policy
MS52 policy briefs or other 1 - INSERM 24 briefs or other tools sent
tools sent to Member to Member States for
States for review review
Page 54 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3.4. WT4 List of milestones
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Organisation of the kick-
off meeting completed
MS1 Kick-off meeting WP1 1 - INSERM 1
(meeting, agenda &
preparatory documents)
The Steering
The Steering committee and
committee and
MS2 WP1 1 - INSERM 2 Advisory Boards Forum are
Advisory Boards
set up
Forum are set up
Organisation of First
First annual annual meeting completed
MS3 WP1 1 - INSERM 10
meeting (meeting, agenda &
preparatory documents)
Organisation of second
Second annual annual meeting completed
MS4 WP1 1 - INSERM 22
meeting (meeting, agenda &
preparatory documents)
Communication
MS5 WP2 29 - AEMPS 6 Communication tool-kit
tool-kit
Dissemination
Dissemination Plan:
MS6 Plan: intermediate WP2 29 - AEMPS 7
intermediate control point
control point
Layman report:
intermediate control point
MS7 Layman report WP2 29 - AEMPS 30
about document design and
draft
Final Conference on
Final Conference
MS8 WP2 29 - AEMPS 30 dissemination: intermediary
on dissemination
control point
Agreement on ETs
MS9 WP3 15 - ISS 5 Agreement on ETs plan
plan
Availability of the
Availability of the web
web platform with
MS10 WP3 15 - ISS 7 platform with tools to
tools to support the
support the monitoring
monitoring
Periodic (every six months)
check of correspondence
MS11 Periodic check 1 WP3 15 - ISS 6
between planned activities
and timetable
Periodic (every six months)
check of correspondence
MS12 Periodic check 2 WP3 15 - ISS 12
between planned activities
and timetable
Periodic (every six months)
check of correspondence
MS13 Periodic check 3 WP3 15 - ISS 18
between planned activities
and timetable
Page 55 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Periodic (every six months)
check of correspondence
MS14 Periodic check 5 WP3 15 - ISS 30
between planned activities
and timetable
Periodic (every six months)
check of correspondence
MS15 Periodic check 6 WP3 15 - ISS 36
between planned activities
and timetable
Identification
Identification of interested
MS16 of interested WP3 15 - ISS 6
stakeholders
stakeholders
Report on quality of the
Quality meeting
MS17 WP3 15 - ISS 2 meetings within two months
report 1
after their conclusion
Report on quality of the
Quality meeting
MS18 WP3 15 - ISS 13 meetings within two months
report 2
after their conclusion
Report on quality of the
Quality meeting
MS19 WP3 15 - ISS 25 meetings within two months
report 3
after their conclusion
Report on quality of the
Quality meeting
MS20 WP3 15 - ISS 36 meetings within two months
report 4
after their conclusion
Interim evaluation
MS21 WP3 15 - ISS 19 Interim evaluation of JA
of JA
Final report on JA Final report on JA impact in
MS22 WP3 15 - ISS 36
impact in Europe Europe
Survey of MS
MS23 WP4 2 - MoH-FR 12 Survey of MS priorities
priorities
Workshop with SC
members on priority goals
Workshop with SC
MS24 WP4 15 - ISS 24 and integration of JA key
members
actions into national AMR-
HCAI plans
Presentation, discussion
and analysis of the outcome
MS25 Workshop WP5 21 - VWS 10
of the self-assessments
(workshop)
Workshop on the outcome
of the 3 pilot country-to-
MS26 Workshop WP5 2 WP5 21 - VWS 18 country assessment and
revision of the tool and
methods.
Invitational workshop for
Invitational the establishment of the
MS27 WP5 21 - VWS 18
workshop network of supervisory
bodies
Page 56 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Results of survey Results of survey A
MS28 WP6 11 - HCDCP 8
A (national-hospital policy)
Assessment of Assessment of cost-benefit
MS29 WP6 11 - HCDCP 12
cost-benefit study study
Results of survey B
Results of survey
MS30 WP6 11 - HCDCP 8 (barriers for an effective
B
implementation of an ICP)
Initial proposed of
MS31 WP6 11 - HCDCP 14 Initial proposed of UICFW
UICFW
Evaluation of
Evaluation of the UICFW
MS32 the UICFW WP6 11 - HCDCP 32
implementation
implementation
Initial presentation
Initial presentation of the
MS33 of the training WP6 11 - HCDCP 12
training tools
tools
Participating
hospitals and Participating hospitals and
MS34 WP6 37 - FoHM 12
topics selected per topics selected per country
country
Selected IPC-
guidelines and plan
Selected IPC-guidelines and
for implementation
plan for implementation for
MS35 for participating WP6 37 - FoHM 30
participating hospital(s) in
hospital(s) in
line with national plans.
line with national
plans.
Implementation
Implementation work at
MS36 work at hospitals WP6 37 - FoHM 36
hospitals established.
established.
Progress check of Progress check of review
MS37 WP7 23 - FHI 4
review procedure procedure
Progress check in Progress check in terms of
MS38 WP7 23 - FHI 12
terms of website website
Progress check of Progress check of
MS39 implementation of WP7 23 - FHI 24 implementation of
stewardship tools stewardship tools
Progress check
Progress check surveillance
MS40 surveillance WP7 29 - AEMPS 15
system
system
Awareness and
Awareness and
MS41 Communication WP8 29 - AEMPS 7
Communication Plan
Plan
Database control
MS42 WP8 29 - AEMPS 7 Database control check
check
European Webinar
European Webinar and
MS43 and of Science WP8 29 - AEMPS 14
of Science and Health
and Health
Page 57 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Communication Communication researchers
researchers (Mass media): control point
Design of
promotion
Design of promotion
activities related to
activities related to better
MS44 better journalism WP8 29 - AEMPS 14
journalism report or better
report or better
video about antibiotics
video about
antibiotics
European
competition with European competition with
MS45 High Schools WP8 29 - AEMPS 12 High Schools students:
students: starting starting control point
control point
European
competition
European competition with
with High
MS46 WP8 29 - AEMPS 24 High Schools students:
Schools students:
intermediate control point
intermediate
control point
Awareness and
Awareness and
Communication
Communication High Level
MS47 High Level WP8 29 - AEMPS 16
Meeting: starting control
Meeting: starting
point
control point
Awareness and
Communication Awareness and
High Level Communication High Level
MS48 WP8 29 - AEMPS 24
Meeting: Meeting: intermediate 1
intermediate 1 control point
control point
Awareness and
Communication Awareness and
High Level Communication High Level
MS49 WP8 29 - AEMPS 30
Meeting: Meeting: intermediate 2
intermediate 2 control point
control point
Gathering
of national Gathering of national
approaches to approaches to providing
MS50 WP9 1 - INSERM 18
providing input to input to SRA from at least
SRA from at least five countries
five countries
Inter-governmental
meeting to discuss Inter-governmental
DRIVE-AB and meeting to discuss DRIVE-
MS51 AMR Review WP9 23 - FHI 6 AB and AMR Review
recommendations recommendations with
with regards to regards to AMR and HCAI
AMR and HCAI
Page 58 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Milestone Lead Due Date (in
Milestone title WP number 9 Means of verification
number 18 beneficiary months) 17
Recommendation
for dissemination Recommendation for
of policy briefs or dissemination of policy
MS52 WP9 1 - INSERM 24
other tools sent to briefs or other tools sent to
Member States for Member States for review
review
Page 59 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3.5. WT5 Critical Implementation risks and mitigation actions
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
WP1, WP2, WP3, WP4,
Appropriate financial control: Reporting
1 Overspending WP5, WP6, WP7, WP8,
throughout project
WP9
Contractual agreement with subcontractor to cover
2 Subcontractor fails to deliver WP2, WP8
implication of non-delivery
WP1, WP2, WP3, WP4,
Partners’ commitment Efficient internal communication tools and close
3 WP5, WP6, WP7, WP8,
declines follow-up by WP leaders
WP9
WP1, WP2, WP3, WP4,
Project status meetings at WP level to identify
4 Staff turnover WP5, WP6, WP7, WP8,
issues on the horizon
WP9
Different level of Adopt English as official language. Content
understanding and sharing revision by MS representatives Evaluation
5 WP3
due to heterogeneity in native surveys about the understanding of released
languages documentation
Monitoring of the timeline of activities within WP
3. ETs will be reviewed by partners involved in
Differences in JA partners
the evaluation prior their use. Reminders will be
6 compliance/collaboration to WP3
sent to non-respondents. Communication with
evaluation activities
management bodies asking for direct actions on
partners.
Support by SC and Stakeholders Forum in
Lack of essential results/
reviewing documents - Communication with
7 information in the provided WP3
management bodies asking for direct actions on
documents
partners.
.Dissemination and review of the EP (at the
beginning of the JA) and the ETs (during the
Differences / non whole JA lifetime) will provide a common and
homogeneity among shared set of measures for indicators. .Revision
8 indicators adopted by WP3 of the EP/ETs will be carried out if necessary
different Work Packages and to avoid differences among indicators
for evaluation purposes used. .Consultation with SC and Stakeholders
Forum on the harmonization of indicators
proposed
.Promoting continuous communication among
Lack of coordination / WPs leaders. .Monitoring every six months of
9 synchrony amongst related WP3 the activities with respect to expected results
activities from different WPs and timelines .Sharing information and data on a
common web based platform
Leader will use its network to verify information
Lack of information on
10 WP5 from partners of the project and double check
national measures
information received
Leader will ensure that all partners are satisfied
No consensus on the priority
11 WP5 with priority goals proposed. Delphi process will
goals
help to reach consensus
Link/overlap with WP6 and We will ask WP6 leaders to develop or remark
12 WP5
WP7 (WP5 target group is on the HCAI aspects to be developed in the self-
Page 60 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
national policy level. WP6
assessment tool. Equally we will ask WP7 leaders
and WP7 target groups are
to do this for prudent use aspects.
professionals/local level).
Coordination with WP4 and EU agencies/
13 Link/overlap with WP4 WP5 institutions needed to ensure continuity of the
actions
Low engagement in the
self- and country-to-
country assessments: - Engagement of countries by informing/reporting
14 Not all MS participate -No WP5 to the One Health Network on the activities of
involvement of all relevant WP5
authorities -Disparity
between supervisory bodies
Until now, the One Health Network has met only
once and it's not clear which will be the frequency
No reporting to the One
15 WP5 of the meetings, etc. Contact with EC to ask for
Health Network
frequent, regular meetings of the One Health
Network.
Lack of appropriate
The hospitals will chose the core components they
monitoring of the
16 WP6 will perform regarding their priorities and needs,
implementation of the ICP in
so the hospital managers support is necessary.
the hospitals
The impact of the
The scope and the aim of the project must be
implementation of this
clarified from the begging and the partners should
17 WP depends on the active WP6
be encouraged continuously from the WP leader
participation of the partners
and the coordinator team
at local and national level.
Objectives and tasks for WP
6 might be too ambitious
Actions within this WP focus on supporting
18 and might run the risk of not WP6
implementation and setting realistic goals.
being manageable within the
time and resources allocated.
Good preparatory work and contacts in order to
Difficulties in having
19 WP6 explain the actions and also the added value of
hospitals joining actions.
these actions
Realistic time schedule and regularly monitor
20 Time constraints. WP6
progress.
Lack of funding in pilot .Restrict participants number .Encourage co-
21 WP7
states funding by MS
22 Lack of infrastructure WP7 Pilot only in countries that can deliver data
Lack of acceptance and
23 WP7 Early dialogue with ECDC as soon as WP agreed
cooperation from ECDC
Disagreement regarding
Define this early in the process to ensure that
24 scope of priorities between WP9
JPIAMR’s mandate is well understood
MS and JPIAMR
Lack of description Firmly engage all stakeholders to participate in
25 WP9
of the differences and this mapping
Page 61 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
communalities between the
needs for AMR and HCAI.
Engage countries from the start regarding
Lack of interest to align
26 WP9 the importance and cost savings potential of
public health priorities
alignment
Cost of stimulating greater Work with DRIVE-AB and AMR Review to
27 antibiotic innovation can be WP9 understand the counterfactual cost and different
significant methods of financing
Page 62 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3.6. WT6 Summary of project effort in person-months
Total Person/Months per
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9
Participant
1 - INSERM 46 4 3.50 0 9 12 0 7.50 31 113
· CHU Limoges 0 0 0 0 0 0 0 0 0 0
· UL 0 0 0 0 0 0 0 0 0 0
2 - MoH-FR 8.20 1.70 0.60 14.40 4 0 0 1 0 29.90
3 - GÖG 0 0.10 0 0 0 6 5.30 0 0 11.40
4 - FPS HFCSE 0 0.50 0 0 4 8.30 2.50 0 0 15.30
5 - NCIPD 0 0.70 0 0 6.70 0 11 0 0 18.40
6 - CIPH 0 0.20 0 0 0 0 10.70 0.50 0 11.40
7 - NIPH 0 0.50 0 0 4.30 24.50 5.30 0.50 0 35.10
8 - SSI 0 0.50 0 0 0 0 12 0.50 0 13
9 - TA 0 2 0 0 0 5 5 5 0 17
10 - RKI 0 0.10 0 0 5.40 0 5.90 0.10 0 11.50
11 - HCDCP 0 1 1 0 0 85 12 1 0 100
12 - ESDY-NSPH 0 1 0 0 8.20 2 38 1 0 50.20
13 - 7HC 0 0 0 0 0 11.50 0 0 1.50 13
· GH Heraklion 0 0 0 0 0 0 0 0 0 0
14 - UNIFG 0 0.40 2.50 0 6 7 6 1.90 0 23.80
15 - ISS 0 1 6 0 0 7 12 0 3 29
16 - PSKUS 0 1 0 0 0 11 0 0 0 12
17 - LSMULKK 0 1 0 0 6.50 12 7 0.50 0 27
18 - VULSK 0 1 0 0 0 12 0 0 0 13
19 - HI 0 0.50 0 0 12 18 9 0.50 0 40
20 - NVSC 0 0.10 0 0 0 6 2.70 2.50 0 11.30
Page 63 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Total Person/Months per
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9
Participant
21 - VWS 0 2 1 0 29 7 2 2 4 47
22 - HdiR 0 0.10 0 0 0 0 3.80 0.10 0 4
23 - FHI 0 1.50 0.40 0 0 0 33.20 0 32.50 67.60
24 - NVI 0 0 0 0 0 0 6 0 1 7
25 - NMI 0 0 0 0 7 0 6 0 0 13
26 - DGS 0 1 0 0 0 10 5 2.50 0 18.50
27 - UMPIH 0 2.50 0 0 5.50 0 4.50 0 0 12.50
28 - NIJZ 0 1.50 0 0 10 11 0 3.50 1 27
29 - AEMPS 0 39 1 2 3 12 18 49 0 124
30 - GENCAT 0 0 0 0 0 12 12 4 0 28
31 - IdISBa 0 0 0 0 0 2.90 7.30 3.10 2.40 15.70
32 - FFIS 0 1 5 0 0 12 4.80 1 0 23.80
· DGPIFAC 0 0 0 0 0 0 0 0 0 0
· SMS 0 0 0 0 0 0 0 0 0 0
33 - FMS 0 0.50 0 0 0 0 5 0.50 0 6
34 - SAS 0 1 0 0 0 0 17.10 0 0 18.10
· FISEVI 0 0 0 0 0 0 0 0 0 0
35 - ISCIII 0 0.80 0 0 0 4 0 0.40 0 5.20
36 - SERMAS 0 0 0 0 0 0 28 3 3.30 34.30
· FBRIPC 0 0 0 0 0 0 0 0 0 0
37 - FoHM 0 1 1 0 3 41.20 2 0 0 48.20
38 - SoS 0 0 0 0 0 1 0 0 0 1
39 - SBA 0 0 0 0 0.80 0 0 0 0 0.80
40 - NFA 0 0 0 0 1.50 0 0 0 0 1.50
41 - SVA 0 0 0 0 0.70 0 0 0 0 0.70
42 - SRC 0 0.40 0 0 0 0 0 0 4.60 5
Page 64 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Total Person/Months per
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9
Participant
43 - UAS 0 0 0 0 0 1 0 0 0 1
44 - ANSES 0 1 0 0 6 0 35.50 0 0 42.50
Total Person/Months 54.20 70.60 22 16.40 132.60 341.40 334.60 91.60 84.30 1147.70
Page 65 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.3.7. WT7 Tentative schedule of project reviews
Review Tentative Planned venue
Comments, if any
number 19 timing of review
RV1 20 in Chafea or over the phone If deemed necessary by PO
RV2 36 in Chafea or over the phone If deemed necessary by PO
Page 66 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1.4. Ethics Requirements
No ethics requirements indicated
Page 67 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1. Project number
The project number has been assigned by the Commission as the unique identifier for your project. It cannot be
changed. The project number should appear on each page of the grant agreement preparation documents (part A
and part B) to prevent errors during its handling.
2. Project acronym
Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym should
appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its
handling.
3. Project title
Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are
possible if agreed during the preparation of the grant agreement.
4. Starting date
Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement,
the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into
force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a
written justification.
5. Duration
Insert the duration of the project in full months.
6. Call (part) identifier
The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated
in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the
Commission in the letter inviting to prepare the grant agreement.
7. Abstract
8. Project Entry Month
The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start
dates being relative to this start date.
9. Work Package number
Work package number: WP1, WP2, WP3, ..., WPn
10. Lead beneficiary
This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this
work package
11. Person-months per work package
The total number of person-months allocated to each work package.
12. Start month
Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other
start dates being relative to this start date.
13. End month
Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.
14. Deliverable number
Deliverable numbers: D1 - Dn
15. Type
Please indicate the type of the deliverable using one of the following codes:
R Document, report
DEM Demonstrator, pilot, prototype
DEC Websites, patent fillings, videos, etc.
OTHER
ETHICS Ethics requirement
ORDP Open Research Data Pilot
16. Dissemination level
Page 68 of 69
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Please indicate the dissemination level using one of the following codes:
PU Public
CO Confidential, only for members of the consortium (including the Commission Services)
EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC)
EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC)
EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)
17. Delivery date for Deliverable
Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates
being relative to this start date.
18. Milestone number
Milestone number:MS1, MS2, ..., MSn
19. Review number
Review number: RV1, RV2, ..., RVn
20. Installation Number
Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be
used independently from the rest.
21. Installation country
Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is
an international organization, an ERIC or a similar legal entity.
22. Type of access
VA if virtual access,
TA-uc if trans-national access with access costs declared on the basis of unit cost,
TA-ac if trans-national access with access costs declared as actual costs, and
TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of
unit cost.
23. Access costs
Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access
fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the
basis of unit cost will result from the unit cost by the quantity of access to be provided.
Page 69 of 69
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1. TITLE OF PROPOSAL: EUROPEAN JOINT ACTION ON ANTIMICROBIAL RESISTANCE AND HEALTHCARE-
ASSOCIATED INFECTIONS (EU-JAMRAI)
Comments from the ESR Answer Reference in
the proposal
“The One Health approach should have a much stronger focus on The revised version focuses on more Section 2
specific activities and indicators oriented towards impact, than is concrete actions and identifies
suggested in the current proposal as this would increase the added specific indicators.
value to public health.”
Revision and refinement of ‘Methods
and means” Section 5
The outcome indicators for SO 1, 5, 6, 7 are in fact output indicators. The specific objectives outcomes Section 2
have been revised
“Cost-effectiveness of preventing infections and resistance should be A paragraph describing this task has Section 7
addressed more clearly in the proposal.” been added in WP6 (6.1.1.3) WP6
“Evidence base is missing in an in-depth problem analysis. Although Section 1 “Problem analysis including Section 1
the problem of AMR is well known, it would be appropriate to include evidence base” has been revised.
key references. Burden of AMR has been well described by O'Neil;
https://amr-review.org/”
“Actions with respect to capacity building and training (workshops) The revised version has included Section 6
are not addressed.” capacity building as one of the
expected outcomes
“There is massive overlap between activities of WP2 and WP8.” WP2 and WP8 have been revised Section 7
accordingly to distinguish precisely
dissemination from communication
activities.
“All partners should be included in WP2-3 for dissemination and Almost all partners will dedicate at Section 7
evaluation activities to ensure contributions to the dissemination and least 0.1 PM to the WP2 and all Work
evaluation activities (for instance 0,1 person-month per partner).” Package leaders will dedicate at least
1 PM to this WP
WP3: “The external evaluation strategy will be developed and refined WP3 has been revised accordingly. Section 7,
in a later stage (task 3.1) and some indicators are provided only as an WP3
example – by the time of the submission the evaluation strategy needs
to be finished and refined. Evaluation strategy is organised within the
partnership to keep track of the achievements, to support the
coordinator and other WP activities, and ensure that the project
reaches the objectives. An interim and final evaluation report are
suggested. Task 3.4. quality assessment is unclear and should be
explained more carefully. “
“It would be strongly suggested to include (sub-contract) an
evaluation expert to advise on the impact assessment as the suggested
method is not appropriate and to prepare the evaluation strategy. »
WP4: “evidence based tools will be made available but the interaction WP4 has been revised accordingly. Section 7,
with HCPs seems to be missing, although the proposal outlines that WP4
MS representatives will be consulted regularly during the process of
developing the plan). WP4 misses the target specified in the
description "Integration into national policies and sustainability" - the
activities included are only support measures: sustainability strategy,
guidelines, recommendations, proposal for endorsement. There are no
actual integration activities. The JA should focus specifically in
adjusting policies and focusing more on implementation science. To
ensure sustainability a bottom-up approach is essential as well as a
SWOT analysis; in that regard, a good collaboration with WP5 will
be necessary. Mapping of NAP through self-assessment is included in
1 of 137
EU-JAMRAI Confidential
09/08/2017
both SO 3 and 6; why is this separated and how is this included in Associated with document Ref. Ares(2017)4194538 - 28/08/2017
WPs?
WP5: “All countries need to be involved in the mapping of the NAP WP5 has been revised accordingly Section 7,
development progress, self-assessment and country-to-country WP5
review. This WP should be open to additional countries joining.
Consider to add the initiation of NAP implementation in several
countries and to document the improvement in NAP progress during
the course of JA. In Europe, 15 countries have already developed an
NAP. These countries are most likely engaged in the implementation
process, what kind of support is envisioned for those countries? It is
unclear whether a situational analysis will be part of the self-
assessment. JA needs to be aware that WHO has developed a tool for
self-assessment which is most likely going to be adapted. WHO is
planning a follow-up on NAP to monitor the progress (globally) - this
should be discussed and reviewed to avoid overlap. ECDC and WHO
Euro have developed a template for country missions AMR/HCAI
assessment. JA should liaise to ensure that no overlap will exist in
tools and activities (complimentary). WP5, Part C on strengthening
the supervisory functionality is very good and innovative as it will
encourage countries to discuss, review and improve their regularity
systems. Here, the animal and food sectors should be included as well.
This is not clear from the description of activities.”
WP7: “The proposal should include a stronger component addressing WP7 has been revised accordingly Section 7,
animal health, veterinary sector and AB use in the environment, food reflecting the animal sector WP7
sector, […]”
An additional partner has been
WP 7: includes the development of real-time-surveillance of AMR. It involved in the project: ANSES to
should be explained more carefully how this will be developed and address the animal and food sector
implemented with respect to quality of data, selection of pathogens
Participation of veterinarian partners
and timeliness in reporting and how this must be seen in connection
has been strengthened and thus
to the existing European AMR Resistance Surveillance network
increased the total budget.
(EARSNET).
Task 7.4.1.has been refined and an
WP 7: monitoring AB use: it would be a missed opportunity to not
include animal health. With respect to actions, there is no specific Additional task 7.4.2. about animal
project which includes animal health. Also, explain carefully how this surveillance has been added
connects with the activities of the European Surveillance of
Antimicrobial Consumption network (ESAC).
WP8 “is underestimated in the current proposal and should be The person-months for the Section ,
upgraded as a core activity of the JA. Consider to include a health communication specialist of the WP8 WP8
communication specialist.” leader (AEMPS) has been upgraded,
increasing the AEMPS budget, as
suggested (reshuffling of a decrease
of another partner).
WP9: Some of the activities seem to overlap with WP4, could be WP9 has been revised accordingly. Section 7,
integrated (strategies to implement). A rationale should be given for WP9
this WP as an important activity to contribute to the research agenda
including social sciences.
“Additional collaborative stakeholders should be invited to cover the OIE, EFSA, FAO as well as other Appendix 1
multisector approach. » healthcare professionals have been
contacted.
“[…] hygienist specialists and coordinators as well as hygiene teams Healthcare professionals have been Appendix 1
at hospital level should be targeted. » contacted to join stakeholder Forum.
In WP6, hygiene team at hospital will Section 7,
be involved. WP6
All partners should give justification of detailed person months per This has been done Section 10
activity.
This has been done
All partners should be included in WP2-3 for dissemination and
evaluation activities to ensure contributions to the dissemination and
evaluation activities (for instance 0,1 person-month per partner).
This has been added
An overview table with amounts per WP per partner is missing.
2 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
History of changes
Date Section and page Changes
29/05/2017 Section 2, page 5 Revision of the specific objectives outcomes
Section 5, pages 9 - 11 Revision and refinement of methods and means
Section 6, page 11 Addition of capacity building as one of the expected outcomes
Section 7, pages 12 - 46 Changes in WP2, WP3, WP4, WP5, WP6, WP7, WP8 and WP9
Section 8, pages 47 – 51 Revision of deliverables and milestones accordingly with changes in
Work Packages
Section 9, page 66 Presentation of the additional partner, n°47: ANSES
Section 10, pages 69 - 126 Revision and detailed information about each partner budget
Appendix 1, page 127
Detailed list of international organisation willing to contribute to the
Joint Action
16/06/2017 Whole text Change of the name partner n°32
Section 2, page 4 Minor changes in the main objective description
Section 5, page 10 Revision of the number of partners and countries (withdrawal of
Hungarian partners)
Section 7, pages 25, 35 - Changes in WP5 and WP7
37
Section 10, pages 70-71 Table of direct costs per partner per WP updated
page 72 Revision about INSERM budget (taking in charge Hungarian partners
budget)
page 74 Precision about other direct costs for partner n°2 (in charge of the
Kick-off Meeting organisation)
page 107 AEMPS will have an affiliated entity
page 113 SAS will have an affiliated entity
page 115 SERMAS will have an affiliated entity
Appendix 1, page 129 Updated list of stakeholders
12/07/2017 Title Add “Healthcare” to the title
List of applicants Change of the name of the partner 18 : VILNIUS UNIVERSITY
HOSPITAL SANTAROS KLINIKOS
Change of the partner 33: Fundación para la Formación e
Investigacion Sanitarias de la Región de Murcia instead of Dirección
General de Planificación, Investigación, Farmacia y Atención al
Ciudadano. Servicio Murciano de Salud
P28-CCS become collaborating partner and change of partner
numbering
Section 5, page 13 Updated number of partners
Section 7, page 16 Description of WP1 Task1.3 : one interim report and not two
Section 9, page 60 P18-VULSK: additional information about project manager
page 63 P28-CCS become collaborating partner
Removal of the description of capacity staff of partner CCS
3 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Section 10, page 70 Updated table of summary of staff effort
page 72 Updated table of all direct costs per WP per partners
page 74 P01-INSERM: revised budget and explanations
page 91 P15-ISS: details about subcontracting and other goods and services
items
page 105 P26-DGS: details about travel expenses items
page 108 P29-AEMPS : details about the budget of subcontracting items
page 112 P32-FFIS: reshuffling of budget between beneficiary and affiliated
entities
page 118 P37-FOHM: details about other goods and services items
page 125 P44-ANSES : details about travel expenses items
page 126 Additional table about subcontracting costs
Section 14, page 130 Adding CCS as a collaborating partner
Appendix 1, page 134 Updated list of stakeholders
24/07/2017 Section 7, page 44 Additional details in WP8, task 8.3
Section 8, page 17 Adding tangibility of deliverables of WP2, WP5 and WP8.
07/08/2017 Section 7.2 Update of Inserm effort in the WP5 and WP6 description
Section 10.2 Update of Inserm summary staff effort in the table
Section 10.3 Details on WP5 and WP6 costs in Inserm’s budget.
09/08/2017 Appendix 1, page 137 Updated list of stakeholders
LIST OF APPLICANTS
Applicant No* Applicant organisation name Country
FR-1 Institut National de la santé et la recherche médicale France
FR-2 Ministry of Social Affairs and health France
AT-3 Austrian Public Health Institute Austria
BE-4 Federal Public Service Health, Food Chain Safety and Environment Belgium
BG-5 National Center of Infectious and Parasitic Diseases Bulgaria
HR-6 Croatian Institute of Public Health Croatia
CZ-7 The National Institute of Public Health Czech Republic
DK-8 Statens Serum Institut Denmark
EE-9 Terviseamet (Health board) Estonia
DE-10 Robert Koch-Institute Germany
GR-11 HELLENIC CENTER FOR DISEASE CONTROL & PREVENTION (HCDCP) Greece
GR-12 ETHNIKI SCHOLI DIMOSIAS YGEIAS Greece
GR-13 7th HEALTH REGION CRETE Greece
IT-14 UNIVERSITY OF FOGGIA Italy
IT-15 ISTITUTO SUPERIORE DI SANITA' Italy
LV-16 Pauls Stradins Clinical University Hospital Latvia
THE HOSPITAL OF LITHUANIAN UNIVERSITY OF HEALTH SCIENCES KAUNO Lithuania
LT-17 KLINIKOS
LT-18 VILNIUS UNIVERSITY HOSPITAL SANTAROS KLINIKOS Lithuania
LT-19 INSTITUTE OF HYGIENE Lithuania
LT-20 NATIONAL PUBLIC HEALTH CENTRE Lithuania
NL-21 Dutch Ministry of Health, Welfare and Sport Netherlands
NO-22 Norwegian Directorate of Health Norway
NO-23 Norwegian Institute of Public Health Norway
NO-24 The Norwegian Veterinary Institute Norway
PL-25 The National Medicines Institute Poland
PT-26 Directorate-General of Health Portugal
UNIVERSITY OF MEDICINE AND PHARMACY "IULIU HATIEGANU"CLUJ- Romania
RO-27 NAPOCA
SI-28 National Institute of Public Health Slovenia
SP-29 AGENCIA ESPAÑOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS Spain
4 of 137
EU-JAMRAI Confidential
09/08/2017
Dirección General de Ordenación Profesional y Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Regulación Sanitaria. Spain
SP-30 Departamento de Salud de la Generalitat de Cataluña
SP-31 FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA ILLES BALEARS Spain
Fundación para la Formación e Investigacion Sanitarias de la Región de Spain
SP-32 Murcia.
Fundación Miguel Servet - Navarrabiomed. Dirección General de Salud. Spain
SP-33 Departamento de Salud del Gobierno de Navarra.
Entity: Servicio Andaluz de Salud - Department: Hospital Universitario Spain
Virgen del Rocío - Linked third party: Fundación Pública Andaluza para la
SP-34 Gestión de la Investigación en Salud de Sevilla
SP-35 Instituto de Salud Carlos III Spain
Subdirección General de Farmacia y Productos Sanitarios.- Dirección Spain
General de Coordinación de la Asistencia Sanitaria del Servicio Madrileño
SP-36 de Salud
SE-37 Folkhälsomyndigheten - Public Health Agency of Sweden Sweden
SE-38 Socialstyrelsen - The National Board of Health and Welfare Sweden
SE-39 Jordbruksverket - The Swedish Board of Agriculture Sweden
SE-40 Livsmedelsverket - The Swedish National Food Agency Sweden
Statens Veterinärmedicinska Anstalt - The Swedish National Veterinary Sweden
SE-41 Institute
SE-42 Vetenskapsrådet - Swedish Research Council Sweden
SE-43 Uppsala – UAS Sweden
FR-44 ANSES France
TABLE OF CONTENTS
1. PROBLEM ANALYSIS INCLUDING EVIDENCE BASE ...................................................................................................... 6
2. AIMS AND OBJECTIVES OF THE PROJECT .................................................................................................................... 7
2.1. General objective of the project ............................................................................................................................... 7
2.2. Specific objective(s) of the project ............................................................................................................................ 7
3. TARGET GROUPS .......................................................................................................................................................... 9
4. POLICY RELEVANCE .................................................................................................................................................... 10
4.1. Contribution to meeting the objectives and priorities defined in the annual work programme ........................... 10
4.2. Added value at EU level in the field of public health .............................................................................................. 11
4.3. Pertinence of geographical coverage ...................................................................................................................... 11
4.4. Consideration of the social, cultural and political context ...................................................................................... 12
5. METHODS AND MEANS ............................................................................................................................................. 12
6. EXPECTED OUTCOMES ............................................................................................................................................... 15
7. WORK PACKAGES....................................................................................................................................................... 15
7.1. Overview on work packages .................................................................................................................................... 15
7.2. Work package descriptions ..................................................................................................................................... 16
7.3. Timetable or Gantt Chart ........................................................................................................................................ 49
8. MILESTONES AND DELIVERABLES ............................................................................................................................. 50
9. PROJECT MANAGEMENT STRUCTURE ....................................................................................................................... 54
9.1. Management structure of the Joint Action ............................................................................................................. 54
9.2. Quality of the partnership ....................................................................................................................................... 55
9.3. Capacity of the staff ................................................................................................................................................ 55
9.4. External and internal risk analysis and contingency planning ................................................................................. 68
9.5. Financial management ............................................................................................................................................ 70
10. BUDGET .................................................................................................................................................................... 71
5 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
10.1. Content description and justification .................................................................................................................... 71
10.2. Summary of staff effort ......................................................................................................................................... 71
10.3. Detailed budget ..................................................................................................................................................... 75
11. PREVIOUS AND CURRENT GRANTS RELEVANT TO THE PROGRAMME (LIMITED TO THE LAST 3 YEARS) ........... 131
12. CURRENT APPLICATIONS RELEVANT TO THE PROGRAMME ................................................................................ 131
13. EXCEPTIONAL UTILITY ............................................................................................................................................ 131
14. COLLABORATING STAKEHOLDERS ......................................................................................................................... 131
15. APPENDIX 1 – DETAILED MANAGEMENT STRUCTURE ......................................................................................... 133
15.1.1. Governing bodies of the project consortium and their functions .................................................................... 133
15.1.2. Day-to-day management of the Joint Action ................................................................................................... 134
15.1.3. Advisory body: the Stakeholders Forum .......................................................................................................... 135
2. PROBLEM ANALYSIS INCLUDING EVIDENCE BASE
Today, microbial resistance to antibiotics (antimicrobial resistance, AMR) is a serious public health threat that is
gaining swift ground. The increase of multi-resistant bacteria associated to the lack of new antibiotics represents a
threat to global health. Some patients are faced with no therapeutic solutions as some bacteria resist to all
antibiotics. Moreover, “old” antibiotics and to sometimes more “recent” ones are gradually removed from the
market because they are not economically sustainable, albeit being still effective. The issue of antimicrobial
resistance is a major challenge that decision-makers are well aware of and has gained a high priority among public
health challenges.
AMR is not confined to a geographical region or a Member State. In 2008, the ECDC estimated that 25.000 deaths
and 2.5 million extra hospital days were caused annually by infections caused by multi-resistant bacteria across
Europe, and associated with yearly societal costs of about €1.5 billion.1 According to data provided by OECD, it is
estimated that about 700 000 deaths may be caused globally each year by AMR. Despite action taken by, amongst
others the World Health Organisation (WHO), the number of victims (mortality, morbidity) is steadily rising, and
the outlook is increasingly bleak; according to the “Review of antimicrobial resistance” coordinated by J. O’Neill,
antimicrobial resistance could become the #1 killer globally by 2050, if nothing is done.2 With the pressing needs
for infection prevention and prudent use of antibiotics, new therapies to be found, the efficacy of existing
antibiotics to be preserved and the spread of resistance in the environment to be contained, many countries and
international organizations have launched ambitious plans in the past few years.
The various national, European and international initiatives that have emerged over the last decade reflect the
shared commitment to actively tackle this issue. It is essential that all actors in the field of AMR join forces so as to
avoid duplication of efforts and ensure greater coherence in the global movement against AMR. In this sense, WHO
in collaboration with FAO and OIE has elaborated a global action plan (GAP)3 , after having reviewed the global
burden of AMR.4 The GAP sets 5 major goals and emphasizes the “OneHealth” approach, encompassing human,
animal health and the environment. Countries have committed themselves to draft and implement national
strategies aligned with the GAP by mid-2017. Moreover, the European Union has recently adopted ambitious
Council conclusions on the next steps to tackle AMR, which includes setting up a OneHealth network across member
states.5 The European Commission and its agencies, as well as other International organizations or agencies (i.e.
OECD, WHO Europe, ECDC, OIE, FAO) are best placed to support countries to implement national strategies for
raising awareness on AMR and develop policies for controlling AMR in the human and veterinarian health sectors.
Academia and industry are best placed to develop new drugs and alternatives approaches to therapy. National and
international agencies are best placed to strengthen surveillance and develop indicators to monitor antibiotic use
1
ECDC/EMEA Technical report, 2009. The bacterial challenge: time to react.
http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf
2
AMR Review: Tackling drug-resistant infections globally: Final report and recommendations. http://amr-
review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
3
World Health Organization 2015. Global action plan on antimicrobial resistance. http://www.who.int/antimicrobial-resistance/global-action-plan/en
4
WHO. AMR: Global report on surveillance, 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/
5
Council of the European Union. June 17, 2016. Council Conclusions on the next steps under a One Health approach to combat antimicrobial resistance.
http://www.consilium.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-antimicrobial-resistance/
6 of 137
EU-JAMRAI Confidential
09/08/2017
and resistance in the animal and human health sectors. HealthcareAssociated
providerswith
aredocument Ref. Ares(2017)4194538 - 28/08/2017
best placed to ensure AMR policies
and infection control and prevention strategies are efficiently integrated in routine human and animal care. In this
regard, controlling resistance and preserving the efficacy of antibiotics is the responsibility of everyone and can
only result from joint efforts towards sustainable development of antimicrobials.
Although AMR and HCAI (Health-Care Associated Infections) are often considered separately, the relationships
between AMR and HCAI are well established, and both are dealt with by the same bodies in many organizations.
Infection prevention and control strategies (IPC stewardship) should go hand in hand with i) prudent use of
antibiotics (antibiotic stewardship), ii) appropriate tools for monitoring and surveillance and iii) accurate diagnostic
tests to decide on the right therapy (diagnostic stewardship).
As also mentioned in the recently adopted council conclusions on AMR, strengthening national and international
health security initiatives against this public health challenge mandates a common European approach taking into
account local features and existing initiatives. Although there are important differences in the epidemiology of AMR
and organization of infection control activities across European countries, the principles underlying strategies to
control AMR and prevent HCAI6 are shared. However, these national specificities and various organizations and
approaches to infection prevention and control and antibiotic stewardship must be taken into account by involving
the many relevant stakeholders within the prioritization process of the JA actions.
This JA provides the opportunity to strengthen and coordinate efforts directed to both AMR and HCAI issues,
following a One Health approach. Ensuring consistency of actions of key players at the various levels is essential to
secure concrete outcomes.
3. AIMS AND OBJECTIVES OF THE PROJECT
3.1. General objective of the project
In line with the EU Action plan and the Council Conclusions on AMR (adopted on 17 June 2016) and the tripartite
GAP, the Joint Action on AMR and HCAI will build on existing works and initiatives by Member States as well as
international organizations (OECD, ECDC, WHO Europe, OIE and FAO). It will propose concrete steps enabling
European countries to strengthen the implementation of efficient and evidence-based measures to tackle AMR and
HCAI, for the benefit of Member States and overall public health in Europe.
Therefore, the overarching objective of the AMR-HCAI Joint Action is to support EU Member States develop and
implement effective one health policies to combat AMR and reduce healthcare-associated infections.
The Joint Action will therefore contribute to:
• Identifying and testing evidence-based measures to address AMR and HCAI in different contexts and, based
on the outcome of these tests, support capacity-building and provide recommendations to policy-makers
(WP6, WP7, WP4);
• Bringing together different networks of policy makers, experts and organizations on AMR and HCAI working
in different European and International initiatives and projects relevant for policy decision (WP1, WP2,
WP4, WP5, WP8);
• Promoting (i) the One Health approach through a closer collaboration, understanding and trust between
the animal health and human health sector, accounting for environmental issues, and (ii) the “One Health
in all policies” concept (health policies should have an intersectoral dimension) in addition to the “Health
in all policies” concept (all policies should have a health dimension) (WP5, WP7);
• Increase awareness and understanding of AMR across European member states (WP2, WP8)
• Producing concrete recommendations for a European contribution to international initiatives such as WHO,
GHSA, G7…(WP2, WP4, WP9)
3.2. Specific objective(s) of the project
Specific Objective N°1 Facilitate implementation of National Strategies for prevention of HCAI
6
Zingg W, Holmes A, Dettenkofer M, et al. Hospital organisation, management, and structure for prevention of health-care-associated infection : a systematic
review and expert consensus. Lancet Infect Dis 2015; 15:212-24.
7 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
at the national and regional/local levels, including optimising the
implementation at national level of work done by the ECDC
Process Indicator(s) Target
Development/implementation of an Availability of an instrument for assessing the national/regional ICFW
infection control framework (ICFW)
Output Indicator(s) Target
Implementation of ICFW Pilot testing of the UICFW in selected hospitals, using awareness and
training tools
Outcome/Impact Indicator(s) Target
Adoption of the ICFW at national or 80% of the partners involved in the WP6
local level
Adoption of working routines through 80% of the partners involved in the WP6
the evidence-based implementation
model
Specific N°2 Develop efficient tools and guidelines to facilitate implementation of
Objective best practices for antimicrobial stewardship and surveillance of
resistance in both human and animals
Process Indicator(s) Target
Analysis of existing guidelines Review of guidelines and recommendations performed in human and
Antibiotic use in primary care and in animal health
animals tools available
Model for implementation of antibiotic use
Output Indicator(s) Target
Summary available Best practices identified and summarized; policy briefs elaborated
Implementation of antibiotic use in Pilot testing of antibiotic use in primary care and in animal health and
primary care surveillance implementation model in human and animal sectors
Outcome/Impact Indicator(s) Target
Integration Integration of best practices into NAP of 80% EU MS; Guidelines for
Antimicrobial use antimicrobial use; Quarterly feedback on resistance trends in human
and animal sectors.
Specific N°3 Improve implementation of National Action Plans for AMR and HCAI
Objective
Process Indicator(s) Target
Mapping of NAP Gaps and barriers for implementation are identified
Output Indicator(s) Target
Integration of best practices Recommendations for implementation of AMR and HCAI best practices
and improvement of the available programs
Outcome/Impact Indicator(s) Target
Improvement of NAP for AMR and All EU MS have an operational NAP for AMR and HCAI by the end of
HCAI the JA
Specific N°4 Ensure discussion among policy makers on the development and
Objective implementation of the National Action Plans and strategies, measures
taken within member states and actions for improvement
Process Indicator(s) Target
Involvement of policy makers in the Planned workshops with the steering committee to review and discuss
improvement process of NAP gaps and barriers to implementation of NAP on AMR and HCAI, and
improvement strategies
Output Indicator(s) Target
Plan for implementing measures Integration and sustainability plan available
Outcome/Impact Indicator(s) Target
Improvement of NAP Uptake of key recommendations for integration into NAP by policy
makers of 80% EU MS
Specific N°5 Ensure consistency between national, European and International
Objective research programmes identify gaps in knowledge and contributing to
8 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ensure linkage between research on AMR/HCAI and Public Health
Policies
Process Indicator(s) Target
National priority-setting best practices Best practices and routines that can be implemented by EU MS to
improve the input that they send to SRA of the JPI AMR regarding
research and innovation priorities
Output Indicator(s) Target
Implementation strategy for EU A concrete strategy for implementing multi-country incentives to
collaboration stimulate antimicrobial and diagnostic innovation
Outcome/Impact Indicator(s) Target
Translate research findings (including SURE policy briefs or other tools made publicly available
those from the social sciences) into
public health policies and practices
Specific N°6 Ensure that all Member States have an objective-driven national
Objective strategy consistent with their national context and with the One Health
approach
Process Indicator(s) Target
Mapping of AMR national action plans All MS have an operational NAP involving the human and animal health
(NAP) to identify gaps sector; self-assessment performed
Output Indicator(s) Target
Country-to-country assessment based Pilot testing done; organisation and gap analyses is performed
on a standardised evaluation tool
Outcome/Impact Indicator(s) Target
Develop and involve the one health Analysis of NAP and recommendation from the OHN on
network (OHN) in monitoring MS implementation and follow-up of the NAP. Achievement of >80%
policies selected indicators fulfilled in the assessment tool
Specific N°7 Strengthening awareness on AMR and HCAI of all stakeholders
Objective
Process Indicator(s) Target
Mapping of existing strategies Review of effective targeted strategies for raising awareness and
improve communication on AMR available
Output Indicator(s) Target
Effective communication and Identify effective tools for awareness raising, adapted to relevant
dissemination tools target audiences
Outcome/Impact Indicator(s) Target
Integration Incorporation of recommendations into NAP through mobilizing
stakeholders
Specific N°8 Ensure efficient dissemination of activities and outcomes from the JA
Objective and contribute to sustaining its results
Process Indicator(s) Target
Develop an efficient communication JA website operational
tool for internal and external
communication
Output Indicator(s) Target
Communication on JA actions and Effective and timely dissemination of outputs (tools, guidelines,
outputs recommendations)
Outcome/Impact Indicator(s) Target
Improve knowledge and raise activities Use of tools and uptake by stakeholders ; endorsement by ECDC of key
related to prevention of AMR and HCAI recommendations
4. TARGET GROUPS
The JA aims at providing recommendations to a large variety of groups and key actors that are all affected in one
way or another by the challenges of antimicrobial resistance and HCAI. To be efficient, an AMR policy has to be
9 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
applicable to several groups from patients to policy makers at regional/local, national and international levels.
There is need for a consistent holistic approach through appropriate definition of the challenges to be addressed
at various levels. The rationale is that each actor in the field of AMR and HCAI should focus on its main added value
so as to avoid duplication of efforts and ensure greater coherence in the global movement against AMR.
The JA will notably target the following groups:
• Governments (Ministries of Health, Agriculture, Environment, Research…)
• Public Health and regulatory Agencies
• Local authorities
• Patients
• Healthcare providers (incl. healthcare professionals, hospital managers, etc)
• Industries
• Researchers and scientists
• International Organisations (OCDE, WHO, WHO Europe, European Union, OIE, FAO, ECDC)
The JA will contribute to shape tailored recommendations to each group taking into consideration each one’s
specificity and linkage between them, bearing in mind the need for concrete, pragmatic and realistic
recommendations. It will ensure that consistency of recommendation is safeguarded and integrated into a
comprehensive strategy thereby contributing to strengthen the EU action plan implementation.
5. POLICY RELEVANCE
The JA aims to contribute to adapt public health policies to the current challenges in AMR and HCAI based on
existing knowledge and initiatives. It aims to contribute to implementing European objectives as set out in the
Council conclusions and the European Action plan on AMR and foster cooperation among partners to achieve
concrete progress in line with WHO GAP. The JA management structure includes a Steering Committee, gathering
representatives of MS competent authorities to be involved in the JA program and adopt the conclusions of the JA,
adapting these to their specific context, thus contributing to the sustainability of the JA outcomes in their respective
countries.
5.1. Contribution to meeting the objectives and priorities defined in the annual work programme
According to its founding treaties, the EU has to ensure that human health is protected as part of all its policies,
and to work with the Member States to improve public health, prevent human illness and eliminate sources of
danger to physical and mental health.
The third programme of the Union's action in the field of health (2014-2020)7 seeks to promote health, prevent
diseases and foster supportive environments for healthy lifestyles taking into account the 'health in all policies'
principle; protect Union citizens from serious cross-border health threats; contribute to innovative, efficient and
sustainable health systems and, facilitate access to better and safer healthcare for Union citizens.
The 2017 annual work programme states that the “objective of this action co-financed with Member State
authorities is to increase the level and effectiveness of activities at EU, national and local levels to improve EU health
security by addressing the increasing threats to health from antimicrobial resistance (AMR) and the linked but
separate issue of healthcare-associated infections (HCAI).”
In this regard, the AMR-HCAI Joint Action aims to:
a. Support the development of national strategies and action plans on AMR;
b. Support strategy development at national, local, and health-care setting level (hospital, long term care,
community) in the field of HCAI, including optimising the implementation at national level of work done
by the ECDC;
c. Develop and enhance the implementation of evidence-based tools and capacity-building, and through
training, organisational change and/or other methods to enable sustainable improvements in practice
by health care staff and teams in hospitals, as well as in long term care and community settings;
7
REGULATION (EU) No 282/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 11 March 2014. http://eur-lex.europa.eu/legal-
content/EN/TXT/PDF/?uri=CELEX:32014R0282&from=EN
10 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
d. Strengthen the ‘One Health’ approach and coordination with relevant sectors – including for AMR with
animal health, food safety, agriculture, environmental and research and the Joint Programming
Initiative (JPI) on AMR;
e. Contribute to the implementation of relevant research findings and identify priorities for research;
f. Promote awareness and commitment by governments and stakeholders.
Activities planned in this proposal have been shaped to address all the objectives set out in the annual work
programme, as outlined in section 2.2.
5.2. Added value at EU level in the field of public health
The Joint Action will enhance cooperation between Member States, the European Commission and its agencies and
other international organisations and will enable each target group to contribute to address the issue of AMR and
HCAI. Through appropriate involvement of each group within the different work packages, the JA will strengthen
the existing public health policies both at the national or European level and contribute to achieve the objectives
of the WHO Global Action plan on AMR, the Council conclusions on AMR and the EU plan on AMR.
The involvement of a large variety of actors (competent authorities, patients, industry, researchers, healthcare and
infection control professionals …) to elaborate concrete recommendations and implementable measures will foster
synergies and imply cooperation among these. While each group is part of the solution to tackle AMR and HCAI,
the Joint Action will demonstrate the added value of each group and provide tailored measures to implement
national and EU action plans. Additionally, each group will disseminate the output of the Joint Action to its own
network both during and after the Joint Action.
AMR and HCAI have no border and cannot be fully addressed at national level if not embedded into a larger and
more comprehensive European action. In this sense, the Joint Action will capitalize on national best practices and
current European projects while acknowledging countries specificities (i.e antibiotic consumption or resistance
epidemiology may differ from one country to another, thereby justifying specific/tailored measures).
The JA will contribute to strengthen a European “One Health” strategy and propose actions for implementation
through National Plans, in line with the recommendations of the Council Conclusion on AMR adopted by the EU
Council on 17th June 2016. In this regard, it is expected that the work of the Joint action performed within WP5 with
regard to the One Health approach will serve as basis for the Commission to strengthen the role and impact of the
“One Health network” that will further continue the work done during the Joint Action.
The gap analysis of national action plans of European member states will contribute to orient decision-makers to
address the challenges identified, discuss progress and implementation of National Action plans, using insights from
the country-to-country assessments and best practices promoted through the JA.
5.3. Pertinence of geographical coverage
The high number of participants of the Joint Action as well as their variety (Competent Authorities, Public Health
institutes, Research institutes, Universities) will enable the Joint Action to cover the 28 EU countries. Additionally,
thanks to the involvement of the EU agencies, WHO Europe and other international organisations (OECD, OIE and
FAO), the geographical coverage and impact of the Joint Action will go beyond the borders of the EU. Being also
involved in several international fora (such as G7, G20, UN, GHSA or WHO), the coordinator France will ensure
consistency between JAMRAI’s outputs and discussions in these institutions or initiatives.
In line with the objectives of the JA pertaining to the linkage to existing national, European and international policies
and initiatives, it is expected that the JA output will extend and impact outside the EU’s remit stricto sensu. AMR is
a global challenge that needs a global action as outlined in the WHO GAP. The Joint Action will therefore be
embedded into this international context and strives to be at the European level, an example of initiative focusing
on achieving concrete results.
The burden of AMR varies across EU countries and even more so in neighbouring countries outside EU. Since AMR
is a cross border health threat, measures taken within one Member State influence other Member States. Therefore
AMR needs a coordinated response. Also, there are common issues and the recommended measures of the JA to
a specific group of countries will also be applicable to non-EU countries. Specific work done within WP6 will include
implementation of best practices and improvement in the prevention of HCAI within a European network outside
of EU MSs. Building on this experience, the implementation model tested in WP6 will be proposed to other
organisations or countries within WP4.
11 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
5.4. Consideration of the social, cultural and political context
The efficiency of any action addressing AMR and HCAI relies on involving different groups (see point 3) and on
understanding the context of each of these. The rationale underpinning the international action on AMR has to be
“Think global, act local”. This means that for each group, one has to identify the driving forces and consider its
social, cultural, economic and political environment.
For instance, as regards the public and patients, actions addressing AMR and HCAI targeted to this group within
WP8 will focus on increasing public awareness and providing appropriate information through campaigns targeting
the general public, general practitioners and healthcare professionals, insurances… It has to tailor the
recommendation to the categories of public and patients through different channels and take into consideration
their level of health literacy. Therefore, successful action towards patients will combine several complementary
measures and altogether constitute an efficient action. Through cooperation with and involvement of professional
organisations of the animal and human health sector and of patient groups within the JA stakeholders forum, the
JA will identify the appropriate means to reach the different categories of public, patients and healthcare
professionals.
6. METHODS AND MEANS
The aim of this JA is to join forces to define European common policies to fight AMR and to control HCAI in line with
ongoing EU and international policies. The JA will look over the best programmes in each country to get the best
for this JA and see how cooperation at EU level can improve national AMR-related policies. In line with Council
conclusion on AMR adopted on 17 June 2016, the JA will contribute to propose concrete steps to tackle AMR and
HCAI, so the political intentions must lead to practical actions shared by MS involved in the JA. To efficiently
implement concrete actions, the national specific political contexts of AMR and HCAI status (antibiotic prescription
behaviour, AMR epidemiology, hygiene measures, variety of health-care systems, population size …) will be taken
into account in all WPs. The JA will ensure that the key component of the Knoster modal (vision, skills, incentives,
ressources and action plan) are used to foster change and ensure implementation at local level of JA
recommendation.
By involving key stakeholders (see point 3 target groups), the JA will capitalise on existing expertise derived from
these various groups to elaborate and disseminate the JA outputs. Moreover, when appropriate, the stakeholders
will be directly involved in the WPs. Besides stakeholders, HCW (general practitioners, hygienists, nurses,…),
veterinarians and patient groups will be also highly involved. Only a coordinated action including all the partners
at local and national levels and with a OneHealth approach will be decisive to successfully reduce AMR and prevent
HCAI and have an impact on the overall public health in Europe.
Three main general objectives will be addressed, with concrete specific objectives involving the different JA
partners in the WPs.
General objective 1: Identifying and testing evidence-based measures to address AMR and HCAI in different
contexts and, based on the outcome of these tests, provide recommendations to policy-makers.
Specific objective 1: Facilitate implementation of National Strategies for prevention of HCAI at the national
and regional/ local levels, including optimising the implementation at national level of work done by the ECDC
(WP6)
In line with the EU action plan, the JA will support the establishment of efficient and feasible national infection
control programmes through the effective implementation of agreed key components for guidelines and/or other
tools at national, regional and local level to prevent infections and thereby limit the use of antibiotics and spread
of resistant bacteria in health-care settings. This work will be based on available evidence-based guidelines and
validated implementation strategies. Patient organizations and other relevant stakeholders (health-care
professionals, infection prevention and control professionals, patient safety professionals, clinic management,
hospital management, regional health-care management, and national health authorities) will be involved in the
improvement work concerning infection prevention and control measures. This co-operation at different levels
(national/regional/local) will depend on the health care structure in the country, and will be in line with the national
activities planned during the JA. The methods used will include health-care and infection control professional
education and training using the ECDC core competencies for infection control and hospital hygiene professionals
12 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
in the European Union (2013)8 as a template and outcomes from the systematic review and evidence-based
guidance on organization of hospital infection control programmes (SIGHT) study group.
Specific objective 2: Develop efficient tools and guidelines to facilitate implementation of best practices for
antimicrobial stewardship and surveillance of resistance in human and in animals (WP7)
The objective is to collate and organise into a useable database current guidelines for antibiotic stewardship and to
develop efficient tools for the implementation of guidelines for the proper use of antibiotics in all EU member states
in primary care in human and in animals. The JA will identify and review existing guidelines, tools and
implementation methods by level-of-care (hospital, long-term care facility and community setting) for human and
in food and companion animals. The different available guidelines or reports from ECDC, WHO, OECD, EFSA, EMA,
OIE, FAO … will be analysed to guide a workshop looking at barriers, incentives and effective measures of
implementation. Pilot projects will be performed, looking at effective implementation of guidelines in MS with
differing resources and focusing on different levels of care for human health, and outcome measures (indicators)
in both the human and animal sectors. Lastly, simple surveillance systems of antibiotic use and resistance in the
different levels of healthcare and in animals will be tested, based on existing surveillance systems. Following the
One Health strategy, antimicrobial-resistant bacteria surveyed will be essentially the same, in order to assess the
relationships between AMR spread in humans and animals.
General objective 2: Bringing together different networks of policy makers, experts and organizations on AMR
and HCAI working in different European and International initiatives and projects relevant for policy decision.
Specific objective 3: Identify the challenges faced by countries for implementation of National Action Plans
for AMR and HCAI (WP 4, 5, 6 and 7)
Fighting AMR and HCAI will need a holistic approach taking into account the One Health approach to provide
concrete coordinated actions. In all the core WPs (5, 6 and 7), the JA will take into account the specificities of each
country (AMR epidemiology, health-care systems, population size, institutional behaviour). Work planned in the
respective WPs will first identify potential barriers and gaps to the support and implementation of national action
plans for controlling AMR and HCAI after the respective WP analyses of existing guidelines and recommendations,
accounting for those from ECDC and the EC, ESCMID, or other institutions (eg, CDC, WHO Europe, OIE) or expert
panel recommendations when necessary. Pilot studies will be conducted in WP5, 6, and 7, allowing to identify gaps
and barriers to implementation of best practices, and then to provide tailored recommendations and guidelines to
inform WP4. Within the latter, policy makers and relevant stakeholders will be involved to structure networks for
a sustainable plan to fight AMR and HCAI (WP4).
Specific objective 4: Ensure discussion among policy makers on the development and implementation of
the National Action Plans and strategies, measures taken within member states and actions for improvement (WP2,
3 and 4)
By involving policy makers and competent authorities, the JA will contribute to implement the EU action plan on
AMR in the middle term and to ensure convergence of programs and actions of MS for prevention and control of
AMR and HCAI. Since this JA involves 44 partners from 21 countries, these goals imply the contribution of all
participants to the JA, and other bodies and institutions at the national and EU level, beyond the participating
institutions. Specifically, the ECDC, WHO Europe and the European Commission will be approached to contribute
to and support the sustainability of actions. The Steering Committee and the Stakeholder forum will be involved in
the evaluation tasks for comments, suggestions and recommendations on final core WPs deliverables. Given the
wide range of stakeholders involved in the JA, including National and Regional Governments, Patients’ Associations
and Scientific Societies (to be selected at the beginning of the project), their contribution in one or more phases of
the evaluation process (e.g. surveys on specific topics to specific target population) will be guaranteed.
Specific objective 5: Ensure consistency between national, European and International research
programmes, identify gaps in knowledge and contributing to ensure linkage between Research on AMR / HCAI and
Public Health policies (WP9)
The JA will contribute to a coordinated European response in regards to prioritizing and assisting in the
implementation of research and innovation expected to help achieve public health-related AMR and HCAI goals
and objectives. Significant efforts led by JPIAMR in collaboration with the EU and IMI have already been established
8
http://ecdc.europa.eu/en/publications/Publications/infection-control-core-competencies.pdf
13 of 137
EU-JAMRAI Confidential
09/08/2017
in regards to AMR research and innovation priority-setting. ItsAssociated
Strategicwith document Ref. Ares(2017)4194538 - 28/08/2017
Research Agenda (SRA) outlines key,
neglected areas to tackle, which guides JPIAMR and others to shape cohesive and coordinated AMR funding and
research actions to maximise on resources and reduce duplication of research. As the SRA is scheduled to be
updated in 2017, it can be expanded upon via the JA by working directly with MS in preparation of their participation
in priority-setting activities with JPIAMR. MS involved in the JA need to ensure that their national processes include:
(1) a One Health focus; (2) the special needs of HCAI; (3) an appropriate breadth of research fields including social
sciences; and (4) research policy briefs to inform policymakers. MS should also ensure that their own national
research agendas are in line with the priorities set out by JPIAMR and other related initiatives like the international
clinical trial networks.
General objective 3: Promoting (i) the One Health approach through a closer collaboration, understanding and
trust between the animal health and human health sector, accounting for environmental issues, and (ii) the “One
Health in all policies” concept (health policies should have an intersectoral dimension) in addition to the “Health
in all policies” concept (all policies should have a health dimension).
Specific objective 6: Ensure that all Member States have a “One Health” objective-driven national strategy
(WP 4 and 5).
The JA will support Member States (and other participant countries) on the implementation of some of the
provisions laid down in the Council Conclusions on the next steps under a One Health approach to combat
antimicrobial resistance (2016/C 269/05) unanimously adopted by the Council of the European Union in June 2016.
The JA aims also to support Member States in the development and implementation of national strategies and
national action plans on AMR in line with the tripartite (WHO, FAO, OIE) Global Action Plan (GAP) on AMR and to
reinforce the collaboration between Member States, European Commission and other European and international
organisations on the implementation of these strategies. To reach this objective, the JA will develop a self-
assessment tool to monitor country progress and identify gaps and shortcomings on the implementation of national
strategies and national action plans. The JA will set up a country-to-country peer review system to evaluate each
other’s national action plans and reflect about policy options. Furthermore, to ensure the sustainability of results
and actions initiated during the JA beyond the 3-year JA duration, the JA work will report regularly and discuss
within the One Health Network described in the Council Conclusions.
General objective 4: Producing concrete recommendations and promote awareness and commitment by
governments and stakeholders for a European contribution to international initiatives such as WHO, GHSA, G7…
Specific objective 7: Strengthening awareness on AMR and HCAI (WP8)
The JA will aim at promoting the responsible use of antibiotics and encouraging best practices among the general
public and healthcare professionals and through higher dialogue with young population and mass media. The
objective is to change minds and behaviors toward antibiotics by raising awareness of the dangers of AMR. The JA
will define basic key messages to be communicated to the general public, health professionals and specific target
audiences using different tools (JA website, social and traditional media, specific groups of society and professionals
subgroups). The JA will also have to foster the European Week initiatives by coordinating activities jointly with ECDC
and MS. Furthermore, two types of conferences (similar to TED Conferences; maybe a pilot activity in some
countries) will be carried out in the second-third years of the JA, one with scientific communicators, and another
conference with High School and university students as speakers. One European Meeting in the last year focusing
on increasing awareness among governments and stakeholders will be organized.
Specific objective 8: Ensure efficient dissemination of activities and outcomes from the JA and contribute
to sustaining its results (WP2, 3 and 4)
Dissemination of actions and results as well as exchanges and dialogue within WPs and between the JA partners
will be supported by a dedicated website (WP2). The JA will provide an integration plan for implementation of the
JA results into national policies as well as a sustainability plan to prolong the JA efforts and actions beyond its
duration. These plans will build on work done within the other WPs and the gap analyses performed within WP5, 6
and 7, and results of pilot studies conducted within these; the sustainability plan will also account for the
evaluations performed within WP3. The plan will result from strong interaction with the Steering Committee and
the stakeholder forum, including a dedicated workshop. Adoption of best practices for implementation of
preventive measures for HCAI and AMR identified within WP6 and WP7 will be sought, accounting for the specific
needs and context of the various MSs, and extension to existing networks and non-EU countries.
14 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
7. EXPECTED OUTCOMES
The overall expected outcome of this JA is the effective and sustainable implementation in MS of the Council
recommendations in the field of AMR and HCAI and, in particular, provide concrete recommendations to policy
makers to have a European strategy to tackle the threat of AMR and HCAI, taking a One Health approach.
This JA aims to:
• Support Member States in the development and implementation of national strategies and action plans
on AMR and HCAI and ensure a common approach at European level on the implementation of the
Global Action Plan.
• Produce guidance documents and tools allowing MS to improve the fight against AMR and the
management of HCAI at national, local, and health-care setting level (hospital, long term care,
community)
• Enhance the implementation of evidence-based tools and capacity-building, through training,
organisational change and/or other methods to enable sustainable improvements in practice by health
care professionals
• Strengthen the ‘One Health’ approach and coordination with relevant sectors – including for AMR with
animal health, food safety, agriculture, environmental and research and the Joint Programming
Initiative (JPI) on AMR
• Promote awareness and commitment by governments and stakeholders.
• Foster a coordinated European response in regards to prioritizing and assisting in the implementation
of research and innovation to help achieve public health-related AMR and HCAI goals and objectives
8. WORK PACKAGES
8.1. Overview on work packages
WP Title Description
number
1 Coordination of the project Actions undertaken to manage the project and to make sure that it is
implemented as planned
2 Dissemination of the Actions undertaken to ensure that the results and deliverables of the
project project will be made available to the target groups
3 Evaluation of the project Actions undertaken to verify if the project is being implemented as
planned and reaches its objectives
4 Integration in National Actions undertaken for integration of evidence-based policy initiatives
Policies and sustainability and key recommendations issued from the JA into MSs policies, to
support and improve national plans development, and to ensure the
sustainability of the JA activities at national or on the local or regional
level, based on the Knoster model.
5 Implementation of One Actions to support Member States (and other participant countries) on
Health national strategies the implementation of some of the provisions laid down in the Council
and National Action Plans Conclusions on the next steps under a One Health approach to combat
for AMR antimicrobial resistance (2016/C 269/05)9.
6 Policies for prevention of Actions to support the establishment of efficient and feasible infection
Health Care Associated control programs through the effective implementation of agreed key
Infections and their components for guidelines and/or other tools at national, regional and
implementation local level to prevent infections and thereby limit the use of antibiotics
and spread of resistant bacteria in health-care settings.
7 Appropriate use of Actions to collate and organise into a useable database current guidelines
antimicrobials in human for antibiotic stewardship at all levels of the European health system and
and animals to develop efficient tools and checklists for the implementation of
guidelines for the proper use of antibiotics in all EU member states.
9
OJ C269, 23.7.2016, p. 26 (http://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=uriserv:OJ.C_.2016.269.01.0026.01.ENG&toc=OJ:C:2016:269:TOC
15 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
8 Awareness raising and Actions to promote the responsible use of antibiotics and encourage best
communication practices among the general public and healthcare professionals and
through higher dialogue with young population and mass media.
9 Prioritizing and Actions to contribute to a coordinated European response in regards to
implementing research and prioritizing and assisting in the implementation of research and
innovation for public innovation expected to help achieve public health-related AMR and HCAI
health needs goals and objectives.
8.2. Work package descriptions
Work package Start date or starting event M1
WP1
number End date M36
Work package title Coordination
Leading participant INSERM
Participant nr. INSERM MOH-FR Total
Participant short FR-1 FR-2
name
Person-months 46 8.2 54.2
Objectives
The main objective of this WP is to set up an effective management framework and ensure the smooth
management and coordination of the project towards the planned objectives through effective internal
communication.
The specific objectives of this WP are three-fold:
1. At the strategic level, to ensure that the project reaches its objectives;
2. At the managerial level, to put in place the procedures and tools needed to ensure that the project
progresses in conformity with the work plan and produces timely and quality results as well as overseeing
conformity of all activities to EC rules and the Consortium agreement;
3. At the administrative level, to organise project meetings, prepare project reports, manage the project
budget and payments.
Description of work, role of the participants and interactions
Task 1.1 : Strategic steering
Leader: INSERM / Contributors: Governance bodies / Start date: M1 End date: M36
Task description: this task involves setting up and managing the relevant steering and management bodies
described fully in section 9:
• General Assembly: deciding board made up of one representative per associated partner
• Executive Board: operational body made up of WP leaders
• Steering Committee: composed of one representative (competent authority) from each Member State.
The members will be nominated at the start of the project.
• Stakeholders Forum: composed of external experts from international organizations such as WHO, ECDC,
OECD, EFSA, OIE, FAO and other representatives from industries, healthcare professionals’ organizations
and of patients (see section 9 for details). The members will be nominated at the start of the project.
This governance structure will ensure the relevance of the JA AMR HCAI activities in line with the work plan and
national and European strategies.
Task 1.2: Contractual and financial management
Leader: INSERM / Contributors: WP Leaders / Start date: M1 End date: M36
Task description: this task will be coordinated by the Joint Action Secretariat (JAS) that will be responsible for the
day-to-day management. It is composed of the project coordinator (Marie-Cécile Ploy, INSERM) assisted by
resources including a project manager based at INSERM. The JAS will be in charge of:
• Preparation of the Consortium Agreement to be signed by all beneficiaries at the start of the project
• Appraisal and monitoring of the project costs in order to oversee and check the overall costs incurred per
work package and per participant
• Management and distribution of EC payments
• Assistance to individual project partners on specific administrative and financial issues
The PMT will meet monthly and will hold every 4 months teleconferences with the Executive Board to share
16 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
updates on progress of the WPs.
Task 1.3 : Periodic reporting
Leader: INSERM / Contributors: Executive Board (technical), All partners (financial reporting) / Start date: M1 End
date: M36
Task description: this task will:
• Monitor the progress of the project in terms of deliverables, milestones, etc., using dedicated project
management tools;
• Identify and monitor risks and propose appropriate mitigation measures to the General Assembly and the
Steering Committee;
• Prepare periodic and final reporting to ensure timely and efficient submission to the EC
Task 1.4 : Communication: internal and with CHAFEA / DG SANTE
Leader : INSERM; Participants: MoH-FR / Start date: M1 End date: M36
Task description: the following activities will be carried out:
• To use the project website to be set up in WP2. It will act as a platform to share internal project documents;
• Regular web/audio conferences to support WP collaboration and interactions;
• Every 4 months, activity reports updating all project collaborators on the project activities;
The project coordinator will act as the official representative towards the CHAFEA and DG SANTE. The project
coordinator will provide the interim and final reports, assisted by the JAS (composed of a project manager at Inserm
and an assistant manager at MoH-FR).
Work package Start date or starting event M1
WP2
number End date M36
Work package title Dissemination
Leading participant AEMPS (SP)
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short
INSERM Moh GOG FCS NCIPD CIPH HZJZ NIPH SSI
name
Person-months per
4 1,7 0,1 0,5 0,7 0,2 0,5 0,5
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months per
2 0,1 1 1 0 0,4 1 1
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months per
1 1 0,5 0,1 2 0,1 1,5 0
participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
name
Person-months per
0 1 2,5 1,5 39 0 0 1
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
0,5 1 0,8 0 1 0 0 0
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
TOTAL
Participant short SVA SRC UAS ANSES
17 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
name
Person-months per
0 0,4 0 1 70,6
participant
Objectives
The main objective of this WP is to ensure correct dissemination on high quality information on JA deliverables
and progress among targeted groups through organised dissemination activities, which in turn will allow for
sustainability beyond the project end. The specific objectives of this WP are to:
• Develop an internal communication strategy to ensure back and forth communication amongst WPs to
build on the work coming from all the different WPs within the JA.
• Develop external communication strategies to disseminate information on JA both to general public and
stakeholders as well as ensuring the promotion of the project outcomes and results amongst the targeted
public and stakeholders.
• To widely and effectively coordinate and disseminate research outcomes and results through various
channels, including online dissemination channels (website; twitter; Facebook; newsletter) so that we
can actively engage all partners and stakeholders throughout the course of the project to ensure
applicable and appropriate results to the targeted public and partners.
Description of work, role of the participants and interactions
WP Methodology
In order to meet the main objectives, WP2 will pay special attention to both its internal and external
communication and will line up a qualified team for its development. A wide variety of dissemination methods
and tools to inform, engage and promote the outcomes of the JA will be put in place.
To start with, all WPs will designate a contact person to collaborate with WP2 for all matters related to
dissemination activities (events, articles, reports…). Communication between the WP2 leader and each WP
contact person (informing WP leaders and also the coordinator) will be carried out via email on regular basis, and
also via TLC, depending on the project’s needs.
WP2 facilitates coherent and sustainable external communication of the JA and ensures that its objectives,
activities, results, and deliverables are known. In order to do so, AEMPS will develop a dissemination plan that is
planned to cover relevant stakeholders and identify the appropriate timing of release of interim and final results
through appropriate and effective dissemination activities such as conferences, congresses or publications so that
widespread dissemination is achieved. This plan will be a living document and will be monitored and adapted to
reflect progress and changes.
The main dissemination tools (website, leaflet, layman report...) and materials will be produced in English. There
will be the option to send the same material translated into different languages (translated by the country itself),
however, that would depend on the tool or activity (relevance) and the resources of the country to carry out this
translation and work. Each participant will ensure language is appropriate for the audiences addressed. This WP
will ensure the quality of the website and tools as well as engage with other WP leaders and partners so as to
ensure the appropriate level of dissemination for each of the WP outputs, services, tools, events, etc.
Task 2.1: Design of a dissemination plan
Leader: AEMPS / Start date: M1 End date: M10
The main principles in order to elaborate the dissemination plan will be: Defining key messages, establishing target
audiences and selecting the appropriate tools and activities so that we can achieve the following aims of this task:
• To ensure that the results and deliverables are known to all partners and available to all key audiences
and target groups
• To bring knowledge, experience and best practice together in order to achieve the objectives, activities,
results and deliverables are known to all identified stakeholders and wider audience on EU and national /
regional levels.
• Assist different WPs in their communicational needs. Thus, active and collaborating partners will be able
to ask for support for any sort of dissemination event or activity related to their own aims, as well as any
advice to develop any of their initiatives. This assistance will strengthen the dissemination and make it
more effective.
• Creation of an official website with the aim of gathering and collecting a group of useful reference tools
18 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
that could be progressively updated.
Task 2.2: Communication tool-kit (visual identity)
All the dissemination related material, such as project logo, templates for internal and public documents, leaflet
format, etc., will be defined at the very beginning of the project in order to establish the project image as soon as
possible. The corporate identity and communication tools will be developed for the project in line with what will
be developed by JA to ensure consistency.
Leader: AEMPS / Start date: M1 End date: M12
Task description: a tool-kit will be developed, including
• Logo and claim: they should incorporate the project mission into one single graphic along with a catchy
slogan/claim able to engage with the target audience. Logo will indicate co-foundation as do other
materials.
• Web banner design as an extra tool, complementary one, for all the others (logo etc. ).-
• Develop Templates: Word, Power point
• Leaflets and Factsheet: Editing, publication and distribution of promotional leaflet for broad public with
focus on the promotion of JA objectives and planned activities that constitutes Leaflet will contain also
logo - JA visual identity and distribution will be realized according stakeholder analysis within the first
period of the dissemination plan. This tool will be targeted at all stakeholders through online
dissemination channel website, e – mail. Two “official” leaflets will be produced during the JA. One first
hand-out disseminated at an early stage of the JA to inform people about the project, and which would
include a general description of the project goals, aimed at informing the target groups about the project
existence and the planned activities. The second leaflet to be issued in the later stages of the JA when the
results are more visible and tangible. Special leaflet can also be created for promotional purposed for a
special Conference where our Joint Action can be represented and promoted.
• Distribution List
• Newsletter sent to different countries and different stakeholders, produced 3-monthly (M 1,4, 7,10,13,16,
19, 22, 25, 28, 31, 34). The exact timing could be adapted according to JA events and meetings, milestones,
political occasions or presidency activity. Dissemination channel used: website, e – mail, social media.
Newsletter will be free to view and download on our website.
• Social media communications strategy will be an essential component of the overall communications
strategy of the JA (Dissemination through twitter and facebook of all events/results related to JA)
• Website is the main tool where all the outcomes will be collected. (see task 2.4)
Task 2.3: Identification of the relevant target audiences and their expectations from the JA
Leader: AEMPS; Start date:M1 End date:M36
Task description: to design a plan that allows for dissemination strategies, it will be necessary to build a consistent
strategy based on a stakeholder analysis that has carefully planned to cover different target groups to allow
maximizing the impact of the efforts. The first step will be the identification of the relevant target audiences by a
stakeholder analysis looking at the different users of the JA relevant information and their needs in regards with
this output at EU level and within MSs. This analysis will include 4 target groups i.e. citizens (that includes patients
and the mass media), healthcare professionals (HCP, managers, veterinarians), industries (agribusiness, livestock
farming), and authorities (governments, regulators, public health and food safety agencies). This work will be
conducted with the support of the stakeholder forum. Regular updates will be conducted since new target
audiences might arise regularly
In order to analyze the target audience/stakeholders involvement on AMR and HCAI, it would be possible to use
social networks analysis tool.
Regular updates will be conducted since new target audiences might arise regularly
Task 2.4: Web site Design: Internal and external use
Leader: AEMPS ; Contributors: UMPIH / Start date:M1 End date:36
Task description: A website as central hub for internal communication as well as main platform to communicate
outputs and disseminate the information to the targeted audiences. This task is one of the most important
dissemination tools for the second JA period (2nd and 3rd year) and will aim to :
• Design a sharing platform (see task 2.4) as for internal communication.
• Design and Implementation of a web platform (use of English for all dissemination activities) as for
19 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
external dissemination. We believe the JA would benefit from easy to use software that will enable
correct classification, efficient search and interactive collaboration.
• Used of the web banner designed (see task 2.1) on the webs of beneficiaries and collaborative partners.
This banner will boost the JA visibility and will lead other websites' visitors to get to JA website
The first part of this task will involve the development of an interactive file-sharing platform where all partners
can interact and share relevant information. This platform will have private access for the partners and the
capacity of store the information.
The informative content of the external website with open access to all public, will consist partly of the information
of the project (each WP will have a section etc.) and also a section to publish project news, events and all relevant
information.
This website activity will be regularly monitored through feedback via public tools (Google analytics) and internal
methods (internal communications working groups, surveys, etc)
The benefit of developing this website in a way that best suits the needs of the project will ensure the key role of
WP2 as the coordinating body of the dissemination activities for the project and make sure that results and
relevant information produced over the lifetime of the project will not be lost and can continue to be a crucial
part of JA products and services well into the future. It will include conferences and materials produced for each
WP and websites of interest that can be shared as a tool for people to access relevant information about the JA
and the topic.
Task 2.5: Implement the Dissemination Plan
Leader: AEMPS ; Contributors: UMPIH/ Start date:M1 End date:36
Task description:
The main principles in order to ensure the implementation of the dissemination plan will be:
• Implementation of contents related to the JA: reports, interviews to key spokesperson within the JA and
general information about AMR and HCAI. Video interviews will allow us to edit the clips or promos that
will energize the website. For example, animated infographics videos will also contribute to get some
more attention into the project.
• Encourage the participation of all partners in international seminars and conferences to promote the
project. WP leaders/co-leaders will be responsible for writing at least one (informative) editorial related
to the JA specific results and send it to the WP2 leader/co-leader. This editorial will be then disseminated
by each partner through their networks/ social media channels and to any known relevant organization
and/or person of interest they may consider. On the other hand, all these editorials will be gathered on
the main website of the JA and the summaries of those articles could be gathered on a wordpress/blog to
help disseminate and engage more public.
• To develop one promotional online campaign (competition or game, at European level) in the 2nd and 3rd
years to attract general public to the website (campaign non-related to promote communication
materials). For example in a previous JA, that WP2 prepared a Facebook competition and games to attract
public, offering certain limited number of T-Shirts designed and signed by one celebrity and with a
message related to antibiotic use. Also, another example would be a photography contest related to the
overuse of medicines or something similar to get people thinking about the topic in their day-to-day life.
This might be used at European level.
• To plan press releases and Newsletters.informing about newsworthy outcomes and activities.
• Layman report: At the end of the project, beneficiaries should produce a Layman’s report, a
comprehensive information brochure targeted at a non-specialist audience. It serves to inform decision
makers and non-technical parties of the project objectives and results with a full overview of the project
outcomes.
• To organise a final Dissemination Conference (3º year). A final Conference will be organized at the end of
the project to disseminate the project results. This Conference will target at researchers, clinicians and
general practitioners, professional associations, mass media, patient organizations, etc., and also involve
some representatives of the JA active partners.
• To be able to verify if the strategy was well chosen and well implemented through an evaluation
20 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
component (in collaboration with WP3) into all dissemination activities to monitor the quality and to verify
whether they have achieved their aim.
Work package Start date or starting event M1
WP3
number End date M36
Work package title Evaluation of the project
Leading participant ISS (IT)
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short FPS
INSERM Moh GOG NCIPD CIPH HZJZ NIPH SSI
name HFCSE
Person-months per
3,5 0,6 0 0 0 0 0 0
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months per
0 0 1 0 0 2,5 6 0
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months per
0 0 0 0 1 0 0,4 0
participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short DGPIFA
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa
name C
Person-months per
0 0 0 0 1 0 0 5
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
0 0 0 0 1 0 0 0
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months per
0 0 0 0 22
participant
Objectives
The main objectives of this WP are:
(i) to assess the achievement of the project objectives;
(ii) to assess whether the outcomes meet the needs of the target groups.
The specific objectives of WP3 are:
1. Develop, share and disseminate an Evaluation Plan (EP);
2. Develop Evaluation Tools (ETs) for data collection according to the EP;
3. Perform interim and final evaluation;
4. Develop quality assessment and report it as a specific paragraph/chapter in JA deliverables and
documentation;
5. Report and share the evaluation results to participants and relevant stakeholders;
6. Evaluate the impact of JA in Europe (MS and regional governments).
21 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Description of work, role of the participants and interactions
WP Methodology
The evaluation process will include two major issues:
i) Progress and results evaluation (Internal evaluation);
ii) Quality evaluation (External evaluation).
The details of the evaluation process will be included in the Evaluation Plan (EP).
Relevant stakeholders will be engaged in the different phases of the evaluation process:
• one or more delegates for every WP and ECDC (due to its experience in infection prevention and control)
for Internal evaluation (progress and results evaluation);
• Institutions at national (e.g. representatives of Ministry of Health, Agriculture, Environment, Research)
and regional/local level, Policy-makers, Industries, Patients Association, Healthcare professionals
Association, Scientific Societies (ECDC, EPHA), International Organizations (WHO Europe, OECD, FAO) for
External evaluation (quality evaluation).
In order to reach the main objective (i) (progress and results evaluation), for every single JA objective and
milestone process, output and outcome will be explored through specific indicators, defined and shared with WPs’
leaders and relevant stakeholders.
These indicators will help evaluating the project progress, outcomes, impact and expected and unexpected
development.
Tools
i. Surveys through on-line questionnaires designed to be completed through self-assessment at
country level by project participants and internal stakeholders;
ii. Recording data out of routine documentation of WPs and pre-release deliverables (data from
internal WP surveys, training materials, developed guidelines, operations manual,
recommendations, results of pilot projects, questionnaire exploring: the carrying out and
accomplishments of general and technical meetings, characteristics of participants, outcomes
emerged and appreciation degree);
iii. Meetings (on-line or face to face) to agree the Evaluation Plan, agree and share Evaluation
Tools and share reports (interim and final) results with participant representatives of all JA
WPs.
In order to reach the main objective (ii) (quality evaluation), the evaluation plan will be based on comments,
suggestions and/or recommendation made by the Steering Committee and the Stakeholders Forum, which will
give their contribution to assess:
• accuracy of Evaluation Plan in all its phases and efficacy and usefulness of Evaluation tools;
• relevance of JA AMR and HAI issues perceived at different level (institutional, academic and
operational level);
• reproducibility, truthfulness and completeness of data provided by WPs’ leaders and
partners (e.g. through surveys’ questionnaires) through National and Regional health
institutions web-sites consultation, requests for integrations/clarifications, dispatch of
additional documentation, etc.;
• comprehensiveness and accessibility of contents of deliverables and documentation released
(e.g. clarity and realistic nature of conclusion and proposal);
• representativeness and relevance of stakeholders engaged and experts involved and of their
performance;
• satisfaction degree about JA strategies, actions, tools and outcomes by policy makers, HCWs,
Patients Associations and other stakeholders.
Tools
22 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
i. Surveys through on-line questionnaires designed to be completed through self-assessment at
country level;
ii. Consultations involving different participants and stakeholders (WP leaders and partners,
external stakeholders...) experts in HAI prevention and AMR;
iii. Meetings (on-line or face to face) to share reports (interim and final) with external
stakeholders.
iv. EU MS National and Regional health institutions web-sites consultation for the availability of
official data.
Progress and results evaluation and Quality evaluation will be included in interim and final reports, which will be
shared with both internal and external stakeholders.
The team of evaluators will be composed by several professionals from Institutions/University with expertise in
“projects evaluation” and previously engaged in similar experiences, both from Institution participating in the JA
or subcontracted.
Task descriptions
Task 3.1: Definition of the evaluation plan (EP)
Leader: ISS ; Contributors: FFIS / Start date: M1 End date: M4
Task description: EP, specifying evaluation activities, will be developed by the WP3 leader based on the set of
defined indicators and reviewed by collaborating with representatives of all relevant JA WPs. The evaluation
activities will include data recording out of routine documentation of WPs and pre-release deliverables, surveys
(conducted through web-based questionnaires) and consultations involving different participants and
stakeholders, and monitoring with a calendar of JA milestones. For each of these activities the evaluation plan will
identify specific responsibilities, time for completion and mode of data collection for evaluation.
Revision of the EP will be carried out during the project, if necessary.
Specific and well-defined actions:
i. assessment of the achievement of every single WP tasks and outputs;
ii. the respect of the defined timeline and deadlines for WPs activities and outputs;
iii. assessment of the correct development of general and technical meetings;
iv. monitoring (support, early reaction, securing data) of the calendar of JA milestones;
v. engagement of every single WPs leader and associated partner who contribute to the
development of WP3 by providing evaluation information on their own activities, attended events
(meetings, conferences, etc.) and deliverables.
Task 3.2: Development of evaluation tools.
Leader: ISS (subcontracting) ; Contributors: FFIS / Start date: M1 End date: M36
Task description: Based on the definition of the EP, ETs will be developed to collect all information that is not
easily accessible by data recording out of routine documentation of WPs and pre-release deliverables and require
instead surveys and consultations involving different participants and stakeholders. This task will include the
definition and implementation of web based tools to facilitate data collection and surveys conduction. Prior to
use, ETs will be reviewed by all relevant stakeholders included the participants of the Stakeholders forum, this will
maximise evaluation response rate and avoid issues during data collection activities, thus minimising risks for the
task. All ETs will be tested and piloted before their use and they will be revised during the project, if necessary.
Task 3.3: Conduct interim and final evaluation.
Leader: FFIS; Contributors: UNIFG, ISS / Start date: M5 End date: M36
Task description: based on the EP, interim and final evaluation activities will be carried out to monitor the
implementation process for WPs activities and assessment of achievement of JA specific objectives. Evaluation
activities (as described in the EP, see task 3.1) will provide information on WPs progress and timely attainment of
the milestones, deliverables together with assessment of pilot projects. In case of issues in carrying out the
evaluation activities, direct consultations will be performed with relevant partners and/or stakeholders (e.g.
reminders to partners not responding surveys, communication with WP leaders and partners in case of delays
with deliverables/activities, etc.).
23 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Task 3.4: Quality Assessment.
Leader: FFIS; Contributors: UNIFG, ISS / Start date: M1 End date: M36
Task description: WP3 leader, in collaboration with the leaders of others WP, will support the quality assessment
of JA documentation and deliverables and report it as a specific paragraph/chapter in JA deliverables and
documentation.
Deliverables and documentation will be assessed for quality aspects (e.g. comprehensibility, completeness, etc.)
by the WP3 leader, who will coordinate the evaluation involving relevant internal and external stakeholders.
Task 3.5: Report of evaluation results to relevant stakeholders
Leader: ISS (subcontracting) ; Contributors: UNIFG / Start date: M18 End date: M36
Task description: based on results from evaluation activities, the WP3 leader will produce an interim and a final
report including all collected information and indicators. Reports will be shared with internal and external
stakeholders, including the Steering Committee and the Stakeholders forum. This will ensure that quality of JA
output is always a top priority to the management bodies.
The final evaluation report will be focused on the positive and negative aspects of the impact of the action and
the reached aims (as a result of task 3.3); it will also evaluate usability and comprehensibility of JA results and
deliverables in the target population (as a result of task 3.4).
Task 3.6 : Evaluation of the JA impact in Europe
Leader: ISS (subcontracting) ; Contributors: UNIFG / Start date: M18 End date: M36
Task description: A final evaluation of the JA impact in Europe will be performed (M36). The first positive results
(if any) will be assessed, as well as possible barriers/room for improvements.
The impact will be evaluated at different levels:
• increase in number of professionals with skills on HAI prevention and AMR;
• availability of guidelines;
• increase in training initiatives for professionals.
According to the actions effectively adopted and the goals achieved by the Joint Action, also the following items
will be assessed:
• decrease in HAI prevalence rate in MS participating to JA;
• decrease in prescriptions/consumption of antibiotics (overall and of one or more classes);
• lower rate of AMR in human and veterinary areas for one or more target microorganism;
To reach the objectives two main actions will be adopted:
• Questionnaires to national, regional and local authorities as well as to professionals and citizens associations
on the main topics of the project; opinions will be collected about the first results of the JA;
• EU MS national and subnational web-site consultation for the availability of official data.
Work package Start date or starting event M3
number WP4
End date M36
Work package title Integration into national policies and sustainability
Leading participant MoH-FR
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short
INSERM Moh GOG FCS NCIPD CIPH HZJZ NIPH SSI
name
Person-months per
0 14,4 0 0 0 0 0 0
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months per
0 0 0 0 0 0 0 0
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
24 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
name
Person-months per
0 0 0 0 0 0 0 0
participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
name
Person-months per
0 0 0 0 2 0 0 0
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
0 0 0 0 0 0 0 0
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months per
0 0 0 0 16,4
participant
Objectives
This overarching task of WP4 is to foster the integration into national policies of the recommendations issued by
the consortium and/or ECDC and encourage healthcare workers and policy makers to expand and maintain their
implementation in their respective countries when and where needed.
Since this JA involves 44 partners from 21 countries, one goal of WP4 is to secure the contribution of all
participants to the JA (i.e associate and collaborative partners), and other bodies and institutions at the national
and EU level, beyond the participating institutions. Specifically, the ECDC, FAO, OIE, WHO Europe and the
European Commission will be involved to contribute to and support the sustainability of actions proposed within
WP4.
Since the scope of studies performed within the JA will be rather limited within its time-frame, the task of planning
the scaling-up of the results obtained when needed and obtaining adhesion to best practices from other
institutions, partners, and MS relies on this WP. Support from the ECDC to address a specific problem through
adapting guidelines or recommendation will be sought.
Several actions will need to be carried forward beyond the 3-year JA duration to ensure sustainability of results
and actions initiated during the JA. The first task of WP4 will be to design an integration and sustainability strategy
and plan based on the expected outputs from the JA. The strategy will account for potential differences in
identified priorities based on public health organisation, geographical area and epidemiology, and also define
potential indicators for follow-up of actions undertaken. As action on AMR and HCAI implies multilevel, multi-
actor and multi-sectoral approach, the WP will provide for tailored recommendation to JA partners and groups
targeted, associated with clear and measurable goals.
The specific objectives of this WP will include:
1. Developing an integration and sustainability plan
2. Ensuring integration of preventive strategies for AMR and HCAI into national policies
3. Fostering sustainability of core actions engaged by the JA WPs and uptake at the national level.
Description of work, role of the participants and interactions
WP Methodology
In general, the approach taken in WP4 will follow the Knoster model for promoting cultural, behavioural and
organisational change to further reduce the burden of AMR. This will be done through workshops and consultation
of stakeholders, policy makers and competent authorities represented in the Steering Committee, and partners.
Given the specific role of this WP in terms of extension/dissemination of actions and implementation of
sustainability strategies within Europe, it is clearly of importance that a maximum possible of MS, and whenever
25 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
possible associated states and non-EU members contribute or be associated with the steps taken within this WP.
Task descriptions
Task 4.1: Integration plan and sustainability strategy
Leader: MoH-FR ; Contributors : AEMPS / Start date: M3 ; End date: M30
Task description: the integration plan and sustainability strategy will propose, within the remit of the priorities
identified by the WP and validated by Member States, an implementation plan on AMR and HCAI, based on the
Knoster model, compliant with EU Action plan as well as WHO Global action plan. It will identify for each actor,
from patient groups to international organisations, achievable and realistic actions that are “game-changer”.
Based on the gap analysis performed within WP5, and a SWOT analysis of national strategies, the integration plan
will propose specific roadmap for national competent authorities to adapt their national strategy to identified
priority areas for intervention. Being focused on achieving reasonable and concrete objectives, the JA will share
the best practice and deliverables it has produce with key players.
The WP will ensure that all core WPs (5,6,7,8,9) take into account the sustainability of their action within their
work and reports. Close cooperation during the JA lifespan will ensure that from the beginning, sustainability and
integration into national policies are carefully considered. WP4 leaders will therefore closely follow-up and
contribute to the work done by other WPs through participation at meetings, iterative process of deliverables,
observation and guidance on other WP’s outputs.
4.1.1: Identify outputs from the JA which will should be widely disseminated and integrated into national
strategies for control of AMR and HCAI.
This preliminary step aims to analyse the expected outputs from the JA in terms of guidelines, recommendations
or implementation tools which are planned to be available by the end of the 3-year duration of the JA, and would
need to be promoted at the regional/ national/ EU level. This analysis will be based on the compilation of
objectives and deliverables from the JA WPs, and timing of availability of these outputs. After having analysed the
MS priorities with regard to prevention and control of AMR and HCAI through a survey of Stakeholders and
competent authorities as well as integrating information from gap analyses performed within WP5, 6 and 7, these
outputs will be put in perspective with MS priorities and existing reference documents (e.g., from ECDC, WHO,…)
and analysed for their added value and potential for integration into national policies and action plans. This will
form the basis for a draft version of the integration & sustainability plan. This draft version will be made available
of the JA website (with WP2) for all JA partners and advisory bodies to comment and provide input on the draft
plan.
4.1.2. Produce a sustainability plan
From the analysis performed in 4.1.1., priority areas for improvement will be discussed with the stakeholders’
forum and incorporated into a development program for prevention of AMR and HCAI, which will form the final
version of the integration plan and sustainability strategy, produced by M30. This task will be coordinated by
MoH-FR with the contribution of all partners. Representatives of Member States will be consulted regularly during
the process of developing the plan to ensure that priority goals match the national agendas on AMR and HCAI.
A workshop with SC members will be organised to consolidate the recommendations included in the plan, and
obtain commitment of MS on adopting the plan.
Task 4.2: Integrating preventive strategies within national policies
Leader: MoH-FR ; Contributors: AEMPS / Start date: M12 End date: M36
Task description:
After identification of gaps and proposed priority goals resulting from surveys and/or pilot studies performed
within WP5, 6, 7, 8, the strengths and weaknesses of NAP will be assessed. The WP will elaborate concrete
recommendations targeting those gaps and adapted to various contexts and problems (e.g., countries with high
antibiotic consumption, countries with high levels of resistance, …). It will propose a set of measures to be
implemented, based on available recommendations and best practices identified, and include indicators for each
group of actors to measure progress. Strong interaction with WP5 will be maintained, especially with regard to
action within the OneHealth network and the supervising bodies network as supporting bodies following-up the
adoption of actions proposed.
The actions, recommendations and tools selected for integration within the NAP and programs, as well as means
for dissemination will be described in a report available within the last 6 months of the JA. Policy briefs will be
used for dissemination to competent authorities. The integration task will require support and engagement of
26 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
stakeholders and support from implementation science experts for communication of recommendations to public
health levels.
Indicators suggested for this task include the number of policy briefs endorsed by national competent authorities
Task 4.3: Fostering sustainability
Leader: MoH-FR ; Contributors : AEMPS / Start date: M30 End date: M36
Task description: besides integration into MS’ NAP of specific actions promoted within the JA WPs, some other
outcomes or actions will need tailored actions to be undertaken to ensure their sustainability. The strategy used
for this, involving national competent authorities and stakeholders as well as EU bodies, will be described in task
4.1 (DEL4.2). Sustainability of JA recommendations does not solely rely on international organisations or policy
makers. Each stakeholder is part of the solution to tackle AMR. In this regard, the input received from the
Stakeholder forum will be taken into consideration and specific recommendation for each target group will be
included. For instance, representatives of patient associations will be able to take the recommendation of JA to
their constituency.
Depending on the actions selected in 4.1.1, recommendations or practice guidelines will be elaborated. These will
entail soliciting either institutions (eg, ECDC, WHO) or professional societies (eg, ESCMID). The guidelines will
propose indicators allowing follow-up of progresses made toward reaching the objectives set up in the
recommendations.
The country-to-country assessment method and tool tested within WP5 could be proposed for endorsement by
WHO Europe and promoted among other MS not participating into WP5 for further joint assessment. Besides, the
findings from these and recommendation discussed with the supervisory network should be integrated in the
national supervision plans and procedures.
Likewise, the material produced and validated within WP6.1 and WP6.2 during pilot studies of implementing
preventive strategies for designated HCAI, notably the improvement model and approach taken will need to be
expanded to other settings and networks within EU MS and outside; this uptake could be promoted through two
channels: the supervising bodies network convened within WP5 (Del 5.5) for EU MS and/or the professional bodies
within the stakeholder forum; in addition, cooperation with WHO Europe will be needed to expand the approach
to non-EU member states. Likewise, the model for implementation of the antimicrobial stewardship program and
short-lagged resistance surveillance designed within WP7 and pilot-tested will need, if successful, to be expanded
to other settings and networks.
In addition, reference documents produced during the JA, such as the review of guidelines for prudent use of
antibiotics (WP 7.1), best practices for promoting awareness and communication on AMR (WP8.1), or
recommendation to ensure that MS use best procedures to improve their input into the EU research agenda
(WP9.1) will need to be endorsed by external bodies and maintained /updated for example on the ECDC website.
Indicators suggested for this action include recommendations endorsed by ECDC and made available on its
website, as well as the number of MS countries adopting the implementation models and tools promoted by the
JA.
Components of the JA included in the sustainability plan and specific processes used for their implementation will
be described in the final report.
Work package Start date or starting event M01
number WP5
End date M36
Work package title Implementation of One Health national strategies and National Action Plans for AMR
Leading participant VWS (NL)
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short FPS
INSERM Moh GOG NCIPD CIPH HZJZ NIPH SSI
name HFCSE
Person-months per
9 4 0 4 6,7 0 4,3 0
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short TA RKI HCDCP ESDY 7HC UNIFG ISS PSKUS
27 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
name NSPH
Person-months per
0 5,4 0 8,2 0 6 0 0
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months per
6,5 0 12 0 29 0 0 0
participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
name
Person-months per
7 0 5,5 10 3 0 0 0
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
0 0 0 0 3 0 0,8 1,5
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months per
0,7 0 0 6 131,6
participant
Objectives
The main objective of this WP is to support MSs (and other participant countries) on the implementation
of some of the provisions laid down in the Council Conclusions on the next steps under a One Health
approach to combat antimicrobial resistance (2016/C 269/05)10 unanimously adopted by the Council of
the European Union in June 2016. The Council Conclusions on AMR call upon a new EU Action Plan
against AMR. This activity may also be included as an activity of the implementation of the new EU
Action plan.
The specific objectives of this WP are to:
1) Support MSs in the development and implementation of national strategies and national action plans based
on the One Health approach and in line with the WHO Global Action Plan (GAP) on AMR11 and the Council
Conclusions on the next steps under a One Health approach to combat antimicrobial resistance especially by:
a) the development of a self-assessment tool to monitor country progress and identify gaps and
shortcomings on the implementation of national strategies and national action plans;
b) the setting up of a country-to-country peer review system to evaluate each other’s national action plans
and reflect about policy options;
c) the establishment of a network of supervisory bodies to discuss different approaches on the way
supervision, inspection and enforcement in the Member States is organized and on how the level of
compliance with legislation, national (professional) guidelines, standards and recommendations relevant
to AMR can be improved in the Member States.
2) Report regularly and discuss within the One Health Network described in the Council Conclusions on the next
steps under a One Health approach to combat antimicrobial resistance on the outcome of the activities of
WP5.
Description of work, role of the participants and interactions
10
OJ C269, 23.7.2016, p. 26 (http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C_.2016.269.01.0026.01.ENG&toc=OJ:C:2016:269:TOC
11
http://www.who.int/antimicrobial-resistance/global-action-plan/en
28 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
WP Methodology
The methodology used in this WP is in line with WHO approach to move from exclusive self-evaluation to
approaches that combine self-evaluation, peer review and voluntary external evaluations involving a combination
of domestic and independent experts and the WHO framework for the monitoring and evaluation of the
implementation of the Global Action Plan on AMR, based on the tripartite self-assessment and the performance
of the Joint External Evaluation.
All activities described in this WP are based on the implementation of the One Health approach. The
representatives of the WP5 participating countries are responsible for the engagement of the relevant sectors,
including the formation of team of policy makers and experts from both the human and veterinary domain and
the other relevant areas (e.g. agriculture, environment) within the country.
Workshops, electronic and physical meetings, tele/videoconferences, (self)-assessments, reports,
literature/review, presentations at the One Health Network, etc.
Task descriptions
Task 5.1: Mapping and self-assessment of National Action Plans and strategies
Leader: VWS (NL) Contributors: all WP5 participating countries / Start date: M1 End date: M12
Task description:
In order to support MSs in the development of national strategies and NAP on AMR, the WP5 participating
countries will:
• Map existing NAP and national strategies in the participating countries and in the rest of the EU, including,
where relevant, the elements of the GAP on AMR and the Council Conclusions (One Health approach,
overview of measurable goals, enforcement by competent authorities or national supervisory bodies, etc.).
• The mapping will be developed by the participant countries (at least one representative of each WP5
participating country) and will be based on publicly available information (e.g. internet site of ECDC, European
Commission, Member State) and on direct information collected by the competent authorities in the MSs.
• Countries not participating in WP5 will be asked (thought the collaborative partners or partners involved in
other WP of this Joint Action) to voluntarily provide the same information about existing NAP and national
strategies in their countries in order to be able to also map the situation in these Member States.
• This mapping will provide an overview of the situation in the Member States and a view of the areas of
concern and will be used for the development of the self-assessment tool.
• Develop a tool for the self-assessment of national strategies and NAP, including the One Health approach.
The tool will be developed on the basis of the WHO (tripartite) tool “Global Monitoring of Country Progress
on AMR: country self-assessment questionnaire” (or similar tool developed/revised in the future by WHO), by
extending it to the situation in the EU, adding the specific requirements of the Council Conclusions on the next
steps under a One Health approach to combat antimicrobial resistance and the other requirements laid down
in relevant EU legislation, recommendations, guidelines, etc. The self assessment tool will allow for the
analysis of the strengths and weaknesses in the Member States.
• The tool will be developed by the WP5 participating countries (at least one representative of each country),
with the assistance of collaborating stakeholders: EU agencies (ECDC, EMA, EFSA) and Directorate on Health
and Food Audits and Analysis of the European Commission, WHO-EURO, WHO-HQ and OIE.
• For the development of the tool, several electronic working groups or tele/video conferences and also a
physical meeting (workshop) will be organized. The tool will be presented to the participating countries.
During the meeting participating countries will receive the instructions for the capture of data in the tool.
• In preparation of the country-to-country assessment (Task 2 – see below), each of the participating countries
will perform the self-assessment using the tool described in this task. Each participating country will analyze
the results of its own self-assessment, in order to identify gaps in the NAP, evaluate the national strategy, etc.
and will discuss at the national (or where relevant regional) level how to address gaps and improve the
national situation. This analysis will preferably be SWOT-based in order to allow for the analysis of the
strengths and weaknesses, identification of the opportunities and threats to face.
• Each participating country will provide the results of the findings of the self-assessment and the outcome of
the own analysis to the WP5 leader.
• All participating countries will present, discuss and analyse together the report of the outcome of the self-
assessments during several electronic working groups and/or video/teleconferences and also a physical
meeting (workshop).
• The results of the self-assessments and the discussions during the workshop will be presented and discussed
within the One Health Network.
29 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
NB: all WP5 participating countries will perform both Task 1 and Task 2. The performance of Task 1, the self-
assessment, is a preparatory work for Task 2 (country-to-country assessment). At least one of the contributors
from each participating country will be involved in the mapping task. The representatives of the WP5 participating
countries will organize a team of policy makers and experts from both the human and veterinary domain and the
other relevant areas (e.g. agriculture, environment) within the country to carry-out the self-assessments. These
representatives are also responsible for involvement of the relevant (competent) authorities in their own Member
State in the discussion of the outcome of the self-assessment.
Task 5.2: Country-to-country assessments
Leader: VWS (NL) Contributors: all WP5 participating countries / Start date: M4 End date: M36
Task description:
A country-to-country peer review/assessment system will be set up, as described in the Council Conclusions on
the next steps under a One Health approach to combat antimicrobial resistance. The country-to-country
assessment will allow representatives of one or several WP5 participating countries to evaluate each other’s
national action plans and One Health strategies, reflect about policy options and provide recommendations to
support countries on the development and implementation of the NAP and the measures taken.
The following actions will be performed:
• Development of the methodology and the tools to be used for the country-to country assessments. This
activity will be performed by a (multidisciplinary) group of representatives of the WP5 participating countries,
in close collaboration with the collaborating stakeholders: e.g. ECDC, the Directorate on Health and Food
Audits and Analysis of the European Commission and where relevant international institutions (e.g. WHO-
EURO).
• The tool for the country-to-country assessments will be developed and based on the self-assessment tool
from Task 1 and taking into consideration the experience of the performance of the self-assessments.
• Performance of 3 pilot “country-to-country” assessments in countries that have already performed a self-
assessment on NAP and have provided the summary of the findings and discussed them in the workshop.
• The 3 pilot countries will be chosen by the participating countries and will reflect, as much as possible,
different situations in Europe. For this selection, the geographical distribution, division of responsibilities
within the Member State (national vs regional), level of development and implementation of the NAP, etc.
will be considered. All 3 selected countries must have already performed the self-assessment as described in
Task 5.1.
• The country-to-country pilot assessments will be performed by a (multidisciplinary) team of one or more
representatives of the WP5 participating countries. The team will consist of policy makers and experts and
may include representatives from the relevant collaborating stakeholders: ECDC, EMA, EFSA, Directorate on
Health and Food Audits and Analysis of the European Commission, WHO-Euro or other international
organizations. The team will visit a country, for example for 5 days (to be determined), in order to evaluate
its national action plan, reflect about policy options and provide recommendations to support and improve
measures taken. The team will make use of the already performed country self-assessment (see task 5.1) and
where possible other existing assessment or audit activities (e.g. ECDC, Directorate on Health and Food Audits
and Analysis or WHO) in order to avoid overlap or get additional information. At the end of the visit, the team
will hold a wrap-up meeting with the relevant national competent authorities to present the preliminary
outcome of the assessment.
• The countries assessed will further discuss internally at country level and also in the context of the One Health
Network, the outcome of the country-to-country assessments and to follow up on identified shortcomings
and gaps and address them and sustain this action.
• The representatives in WP5 of the country assessed are responsible for the involvement of the relevant
(competent) authorities in their own Member State in the performance and the discussion of the outcome of
the country-to-country assessment. The representatives of WP5 participating countries will organise a team
of policy makers and experts from both the human and veterinary domain within the country to participate
in the country assessment.
• The results of the 3 pilots will be discussed and the methodology and tool used for the country-to-country
assessment will be revised based on the experience of the 3 pilot country-to-country assessments. For this
purpose, several electronic working groups and/or video/teleconferences and a physical meeting (workshop)
will be organized.
30 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• The results of the 3 pilot country-to-country assessments will be presented and discussed at the One Health
Network.
• Perform “country-to-country” assessments for the other countries in the WP that have already performed a
self-assessment on NAP and provide a summary on the findings, based on the revised tool and methodology
and report and discuss the results within the One Health Network.
NB: all WP5 participating countries will perform and participate in the country-to-country assessments. At least
one of the contributors of each Member State will be involved in the development and revision of the country-to-
country assessment. The representatives of the WP5 participating countries will organize a team of policy makers
and experts from both the human and veterinary domain and the other relevant areas (e.g. agriculture,
environment) within the country to participate in the country-assessment. They are also responsible for
involvement of the relevant (competent) authorities in their own Member State in the performance and the
discussion of the outcome of the country- assessment.
Additional country-to-country assessments can be performed in additional countries not actively participating in
WP5 provided that these countries have performed Task 5.1, the country-to-country assessment is supported,
organized and self-funded by a collaborative partner in this Member State and based on the agenda and resources,
including availability of the representatives of WP5.
Task 5.3 : Strengthening supervision
Leader: VWS (NL) Contributors all WP5 participating countries / Start date: M2 End date: M36
Task description:
Control activities (supervision, inspection) and enforcement by the competent authority or a (delegated)
supervisory body (including professional associations), provides information about the level of implementation
of national policies, the level of compliance with legislation and the adherence to guidelines and
recommendations. Furthermore, it is a tool to assess the execution of the NAP, to identify areas where action or
improvement is needed, to assess the reasons why compliance is not met and may help parties to comply or
better abide by existing rules (legislation, guidelines, recommendations).
For example, to achieve policy goals such as improvement of prudent use of antibiotics, strict adherence to the
guidelines for antibiotic use is necessary and inspections and strict enforcement may discourage activities such
as over the counter sales of antimicrobials.
However, these activities are organized in different ways in the different countries depending on the healthcare
system, national legislation and distribution of competences and responsibilities within the country. Additionally,
competent authorities and supervisory bodies may be responsible for the control of many different topics related
to healthcare, and AMR is either not always on the agendas of all supervisory bodies in all European countries, or
not considered a priority.
To facilitate collaboration between supervisory bodies in the Member States, to facilitate control activities and
enforcement of national policies related to AMR and on the implementation of the NAPs, Task 3 will include the
following actions:
• Set up a voluntary network of national supervisory bodies in Europe and discuss methods of integrated
supervision, best practices, exchange of experiences, etc. For this purpose, all participating countries in WP5
will identify the relevant supervisory bodies in their own country. A first meeting (workshop) will take place
to establish the network, to learn about the different situations in the EU and to discuss further work.
Representatives of the relevant collaborating stakeholders will be invited.
• The network will identify common white spots and shortcomings in the implementation of national strategies
and discuss possible solutions and recommendations to improve the situation and the work of supervisory
bodies. The network will discuss the outcome of this work on a workshop and will present the results of this
work to the One Health Network.
NB: all in WP5 participating countries will participate in the task of identification of the supervisory bodies in own
country. At least one of the contributors of each member state will be involved in this task. All participating
countries will be requested to participate in the network.
Work package Start date or starting event M01
number WP6
End date M36
Work package title Policies for prevention of Health-Care-Associated Infections and their implementation
31 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Leading HCDCP (GR) & FOHM (SE)
participants
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short FPS
INSERM Moh GOG NCIPD CIPH HZJZ NIPH SSI
name HFCSE
Person-months per
12 0 6 8,3 0 0 24,5 0
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months per
5 0 85 2 11,5 7 7 11
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months per
12 12 18 6 7 0 0 0
participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
name
Person-months per
0 10 0 11 12 12 3,5 12
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
0 0 4 0 41,2 1 0 0
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months per
0 0 1 0 329.4
participant
Objectives
In line with the EU action plan COM (2011) 748 - WP6 objectives are to ensure that guidance on infection
prevention and control is developed, surveillance of HCAI is strengthened and that proper education and training
of health-care workers is organised - this work will support the establishment of efficient and feasible infection
control programs through the effective implementation of agreed key components for guidelines and/or other
tools at national, regional and local level to prevent infections and thereby limit the use of antibiotics and spread
of resistant bacteria in health-care settings.
Two complementary objectives will be developed in this WP:
I. Promoting a top-down approach for preventing HCAI through the implementation of agreed
infection control programs and institutional behavior change.
II. Promoting a bottom-up approach from clinical practice to policy level by implementing evidence-
based guidelines and existing policies using a structured implementation model and working in
country teams.
Patients and other relevant stakeholders must be involved in the improvement work concerning infection
prevention and control measures. Participating MSs should involve relevant stakeholders in this work including
patients, health-care professionals, infection prevention and control professionals, patient safety professionals,
clinic management, hospital management, regional health-care management, national health authorities,
32 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
existing European associations and networks within the field of infection prevention and control (IFIC, ESCMID,
EUCIC, UMEMS, ESGNI, ISC and EUNETIPS).
The two objectives of WP6 will have strong interaction between each other in order to secure tight links to reach
overall objective of WP6 - prevention of HCAI and also avoiding overlap in content.
Description of work, role of the participants and interactions
WP Methodology
Objective 6.I: top-down approach: Policies for preventing health-care associated infections through the
implementation of agreed infection control programs and institutional behavior change
The specific goals are to:
1. Determine the necessary institutional structures and resources for the implementation of infection control
programs and promote adequate hospital organization, management and structure for the prevention of
HCAI.
2. Incorporate Infection control programs into clinical practice for the improvement of health professionals’
compliance with infection control routine using the institutional behaviour change as a tool to accomplish it.
3. Develop the tools for increasing awareness and improving the training of health professionals to infection
control and prevention.
Given the differences in the AMR context in European countries, the aim of the objective 6.1 is to fill the gap
between policy and practice of infection control in healthcare facilities based on evidence based practices and
the national experience of participating partners for elaborating a concrete, implementable and reasonable
Infection Control Plan for the prevention of HCAIs. The WP will contribute to improve the infection control
capacity within health-care through institutional awareness using identified key components and specific
interventions which will be adapted to the real needs, resources and priorities of the national health systems.The
project will use the JA web-based platform for developing common protocols and sharing documents.
Objective 6.I will be divided into three main tasks which are a sequence of activities aimed at the development
of a Universal Infection Control Framework (UICF) for health professionals according to which roles,
responsibilities and accountability will promote teamwork strengthening towards improved health professionals
compliance and, consequently, patient safety. Ideally, the same partner-countries will be involved in all three
tasks.
This methodology will follow four phases: plan, action, evaluation and improvement. The plan will be based on
evidence-based practices and surveys, and action on the implementation of the infection control framework.
Surveys will address all European Union member-states targeting to increase our knowledge regarding the
current situation and the barriers that limit health system to restrict HCAIs. The implementation of the Universal
Infection Control Framework (UICF) will be performed in the selected hospitals of the participants aiming to
estimate the gap between policy and practice. Each country should take advantage of the results of the surveys
and the UICFW implementation for improving its capability to develop HCAIs prevention policies at local and
national level. For that reason the active contribution of national representatives is crucial for the collection of
reliable data, the dissemination of the results, the feedback of stakeholders and the sustainability of this venture.
Task 6.1.1. Determine the necessary institutional structures and resources for the implementation of infection
control programs and promote adequate hospital organization, management and structure for the prevention
of HCAIs, according to the EU Action Plan.
Leader: HCDCP; Contributors : GOG; NIPH; 7HRC; UNIFG; ISS; DGS; AEMPS; GENCAT; IdISBa; DGPIFAC/SMS/FFIS;
ISCII; FOHM; Inserm / Start date: M1 End date: M36
Task description: the aim of this task is the determination of the necessary institutional structure and resources
for the implementation of efficient and feasible infection control programs in healthcare according to the
standards and requirements of the EU Action Plan for AMR.
This objective will be achieved through the following activities:
6.1.1.1- Survey for the key components of an infection control program based on the ECDC guidance (survey A
in the table above) and the requirements of the updated EU Action Plan for AMR regarding the hospital sector.
The questionnaire will be disseminated to all EU countries and will address public health organizations, relevant
national scientific committees, hospital Infection Control Committees and hospital managers. The participating
healthcare facilities to the survey will be determined from the partners depending on the health care structure
in the country, with a strong focus on acute care and long-term settings. Regarding the EU member states that
are not participating in the task the questionnaire will be disseminated with the contribution of the respective
33 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
national public health organizations. The aim of this extensive survey is to have the clearest picture of the reality
associated with the capability of each country to implement ICP policies. Finally, a workshop will be organized
at the end of the survey by each participating country at local or/and national level for feedback on the survey’s
results, for raising the awareness of the contributors and the determination of the real needs and priorities of
each country. (M1 – M7)
6.1.1.2 - Review of the guidelines for the implementation of ICPs and their applicability to clinical reality based
on the result of the survey and the requirements of AMR action plans of WHO and EU. (M8 – M13)
6.1.1.3. Assessment of cost-benefit for the development and implementation of an infection control program. It
is of crucial importance to persuade the hospital managers and the politicians that the prevention of HAIs is
saving lives and resources. It will be a supportive element to the organization behaviour change bundle. Intensive
efforts for controlling AMR and HCAIs are costly and the cost-effectiveness of these efforts at the hospital or
national level has not been defined. The initial plan of the assessment will be based on the existing literature
and the revised guidelines. Its final formulation will be resulted from the implementation of the Universal
Infection Control Framework in participating countries. Once the core components of an infection control
program have been determined, assessment of their simultaneous impact on epidemiological, clinical and
economic levels will follow on the basis of respective indicators that will have been chosen. The aim is to assess
the implementation of an infection control program within the specific financial circumstances of each country
so that the data produced can be totally compehensible and usable by professionals, who are mainly hospital
administrators. This venture is ambitious and demands the development of broad collaborations among the
participating countries, even at the level of health finances (M10- M36)
Task 6.1.2: Incorporation of infection control programs to clinical practice for the improvement of health
professionals’ compliance with infection control routine using the institutional behaviour change as a tool to
accomplish it.
Leader: HCDCP; Contributors : GOG; NIPH; 7HRC; UNIFG; ISS; DGS; AEMPS; GENCAT; IdISBa; DGPIFAC/SMS/FFIS;
ISCII; FOHM; Inserm / Start date: M1 End date: M36
Task description: the aim of this task is to fill the gap between policy and practice of infection control in
healthcare facilities in European countries and evaluate the impact of the institutional behavior change on
improving the HCWs compliance with infection control and prevention measures.
This aim will be achieved through the following activities:
6.1.2.1. Survey of the infection control policies at hospital level (Survey B, Table above). The aim of this survey is
to examine and analyse barriers (attitudes, level of training, lack of awareness, etc) to an effective
implementation of an infection control program in clinical reality, which are mainly linked to the institutional
policy and organizational behavior. The survey will be based on common axes for all the participants, accounting
for the peculiarity of each country’s health system in which it will be performed for ensuring the sustainability
of the project. A questionnaire will be disseminated to the participating EU countries and will be conducted
through interviews of hospital administrations, Infection Control Committees, clinical department leaders,
doctors and nurses at European level. The results of the survey will be evaluated at national and European level.
. (M1 – M8)
6.1.2.2. A framework with specific roles, priorities and necessary interventions for implementing an infection
control program (Universal Infection Control Framework –UICF)in healthcare facilities will be based on the results
of the two first ongoing tasks and feedback from governments, public health organizations, scientific committees
and health professionals. (M8-M36)
6.1.2.3. Pilot testing of the Universal Infection Control Framework (UICF) in European hospitals. The aim of this
testing is to estimate its impact on routine clinical practice and the behavioural change of clinicians on infection
control. A limited number of healthcare facilities (at least two healthcare facilities) will be selected from partners
to participate for a year in the pilot framework implementation study. The implementation of the plan will be
based on intervention without additional costs and it will be modified in accordance to the operation, structure
and resources of the hospitals. Hospitals will adapt the UIC framework to their needs and priorities adopting
and performing the appropriate interventions. The final proposed UICF will be finalized with the incorporation
of the pilot study results and it will be introduced at national and EU level.
The UICF impact will be assessed by the repetition of the initial survey using the following indicators:
1. The number of the key components of the proposed plan which were performed by hospitals (structure and
process indicators
2. The cost-benefit assessment of the programme’s implementation
34 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
3. The response (positive/negative) of stakeholders regarding the implementation of the infection control
framework to the repetition of the survey
4. Additional outcome and process indicators (AMR and AB consumption rates, HCAIs incidence, hand hygiene
compliance) will be used despite the fact that the time frame of this pilot testing is very limited to produce
significant results. (M14 – M32)
Task 6.1.3: Development of tools for increasing awareness and improving the training of health professionals
in infection control and prevention.
Leader: HCDCP; Contributors : GOG; NIPH; 7HRC; UNIFG; ISS; DGS; AEMPS; GENCAT; IdISBa; DGPIFAC/SMS/FFIS;
ISCIII; FOHM; Inserm / Start date: M7 End date: M36
Task description: the objective of this task is to develop tools based on the results of the previous surveys on
supporting the framework of hospital administrations and ICs regarding the implementation of an ICP and
improving HCWs compliance with infectious control measures.
The objective of this task will be achieved through the following activities: development of tools will be mainly
web-based and will aim at increasing professionals’ awareness and strengthen infection control training
schedules for prevention of HCAI and of the spread of multidrug resistant bacteria in hospital environment. The
development of these tools will be based on previous surveys and they will be improved through the pilot testing.
Objective 6.2: Bottom-up approach: Promoting a bottom-up approach from clinical practice to policy level by
implementing evidence based guidelines and existing policies using an established implementation model
and working in country teams.
This objective will be focused on adaption and implementation of existing policies (national/regional/ local) and
evidence-based guidelines and on improving the infection control capacity within health-care. The improvement
work will be performed using the “The Breakthrough Series Model” as advocated by the Institute of Healthcare
Improvement (US). Thus another overarching objective is capacity building through education of the participants
in this particular improvement model and in adapting existing guidelines to country requirements.
The specific objectives of this part are to: (i) introduce an evidence-based implementation model which
ensures co-operation between key levels (national/regional/local) and stakeholders and (ii) promote that
similar working routines are implemented in EU and non-EU countries across Europe
Description of work, role of the participants and interactions
Task descriptions
Task 6.2.1. Introduce an evidence-based implementation model12
Leader: FOHM ; Contributors : FPS HFCSE; NIPH; TA; HCDCP; PSKUS; LSMULKK; VULSK; NVSC; HI; VWS; NIJZ;
SoS; UAS / Start date: M1 End date: M36
Task description:
We will implement existing policies and evidence-based guidelines (see list below) with the aim to produce
routines that can be implemented nationally. The Breakthrough Model from the Institute for Health-Care
Improvement will be used. This model has been used and documented in numerous successful improvement
projects within health-care
(http://www.ihi.org/resources/pages/ihiwhitepapers/thebreakthroughseriesihiscollaborativemodelforachievin
gbreakthroughimprovement.aspx). The model will initiate co-operation between the levels represented
(national/regional/hospital) depending on the health care structure in the country, as they will participate as a
‘country team’ in the workshops and in line with the national activities planned in between the workshops.
This objective will be achieved through the following activities:
6.2.1.1. Selecting topics and participants, development of a framework and proposed changes. According to the
model “learning sessions”, called workshops in this task, are then alternated with “action periods”, called
national activity periods in this project. During the action periods the participants use iterative P-D-S-A (Plan-Do-
Study-Act)-cycles to test and finally implement small changes, which gradually leads to the goal of full
implementation. In this work process both discussion of current practices, development of implementation
tools, barriers to change (e.g. difficulties concerning behaviour change or administrative barriers), and adapting
35 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
towards common policies and guidelines will be included. The experience and expertise of participants from
hospitals, regions and nations will be used when the countries implement the changes nationwide as a
continuation of the project.
The core components for infection prevention and control identified by WHO in 2009 and revised in 2016 will
be used for strengthening the capacity on both the national and local (health-care facilities) levels for the
prevention of HCAI and to prepare an efficient response to outbreaks of resistant bacteria. The WHO core
components address key factors such as the organisation of infection and prevention programmes at the hospital
level, the development of technical guidelines, training for health-care staff and specialised training of infection
control professionals, surveillance of infections and pathogens and several other key factors for a comprehensive
infection prevention programme. The same key factors and other complementary factors for the organization,
management and structure for prevention of HCAI were recently compiled in a review and expert consensus by
Zingg and others published in 2015 and will be used in this WP. The paper identified crucial elements for the
organisation of effective infection-prevention programmes including ward occupancy and staff workload, access
to materials and equipment (i. e hand rub), the development of multimodal strategies and tools and
identification and engagement of strategy champions and creating a positive organisational culture. Assessment
of competencies and training of health-care staff and infection control professionals will use the ECDC core
competencies for infection control and hospital professionals in the European Union (2013) as a template.
6.2.1.2 Focus on specific topics. In addition to working with infection prevention and control policies general
guidelines, the countries will choose to work with one or several of the following specific topics: catheter-
associated urinary tract infection, hand hygiene, surgical site infections, and/or central line-associated blood
stream infections. There are several well established, international guidelines available for these, and they are
suitable for a multi-modal or bundle approach. Evidence-based guidelines are available for all these areas, and
these will be provided to the participants as a basis for development and adaption of local implementation tools.
The aim is to compile the evidence to improve compliance with routines. Based on the evidence the participants
will agree on a model for improvement of compliance. After an initial phase of testing the model in 1-2 wards
using the Model for Improvement, the model will possibly be revised and then implemented in several wards in
the same hospital.
This task aims to engage key levels (national, regional, hospital) in participating MS in collaborative work to both
start implementation of general policies/guidelines and to start implementation in specific areas (e.g. hand
hygiene, catheter related UTI). For a sustained impact these teams are planned to continue the work towards
nationwide implementation after the Joint Action, a so called “full” participation. MS/partners involved in the
Joint Action who lack capacity for implementation at hospital level, may express interest in participating with
one or two persons (who must be partners) at those WP6 workshops that will be held in conjunction to other
Joint Action meetings (as appropriate), to build capacity on implementation in those countries and partner
organisations, a so called “light-track” participation.
Criteria for taking part in this task
• The participating country needs to appoint one individual as country team coordinator and also appoint
representatives for relevant levels, e.g., national/regional/hospital levels
• The national level will select one or two hospitals that has designated professionals for infection control
The hospital management supports the project and is willing to actively support nation-wide
implementation
Task 6.2.2: Promote that similar working routines are implemented in non-EU countries in Europe
Leader: FOHM ; Contributors : FPS HFCSE; NIPH; TA; HCDCP; PSKUS; LSMULKK; VULSK; NVSC; HI; VWS; NIJZ;
SoS; UAS / Start date: M1 End date: M36
Task description: the aim of the task is to engage European countries, other than MS, Norway and Iceland by
involving existing and well established networks of professionals. The goal is to promote that the same guidelines
and methods are implemented throughout Europe. An implicit part of the chosen method is capacity-building,
where the participating organisations may be strengthened through education, by independently adapting
published guidelines and by practical improvement work.
The working model will be that participants in task 6.2.2 work closely and follow the model and participate in
chosen activities – with MS partners in task 6.2.1 to safeguard a wider spread and transfer of knowledge. Some
of the countries in task 6.2.2 can share their experiences with implementing the model and continue to carry
36 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
out their own implementation efforts.
One example of a network is the Baltic Antibiotic Resistance collaborative Network (BARN), which is a grass root
network for action against antibiotic resistance, with a focus on raising awareness and exchanging knowledge
and experience among practitioners on effective interventions in health-care settings. The network has three
focus areas: Infection prevention and control; antibiotic stewardship and laboratory diagnosis and surveillance
of resistant bacteria.
The network has active members in Belarus, Estonia, Georgia, Latvia, Lithuania, Moldova, Poland, Russia,
Sweden and Ukraine. It is a true multidisciplinary network: health-care personnel on all levels, microbiologists,
infection control specialists, pharmacists, governmental workers and more.
Other relevant networks should also be engaged in this task, depending on which partner organisations will
participate in Task 6.2.1. (both as full and light track participant).
Work package Start date or starting event M1
number WP7
End date M36
Work package title Appropriate use of antimicrobials in human and animals
Leading FHI & AEMPS
participant
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short FPS CIPH
INSERM Moh GOG NCIPD NIPH SSI
name HFCSE HZJZ
Person-months per
0 0 5,3 2,5 11 10,7 5,3 12
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months per
5 5,9 12 38 0 6 11 0
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months per
7 0 9 2,7 2 3,8 33,2 6
participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
name
Person-months per
6 5 4,5 0 18 12 8,4 4,8
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
5 17,1 0 28 2 0 0 0
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months per
0 0 0 33 326.20
participant
Objectives
37 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The major objective of this WP is to collate and organise into a useable database the current guidelines for
antibiotic stewardship at all levels of the European health system and selected animal (food and companion)
species, and to establish workable tools for evaluating the implementation of antibiotic stewardship in all EU
member states.
The specific objectives of this WP are to:
1. Identify and review existing guidelines, tools (including quality indicators) and importantly, implementation
methods in the human sector (by level-of-care, hospital, long-term care facility and community setting) and the
animal sector (diseased food and companion animals) and to summarize available information on the ECDC
website
2. To use the results of objective 1 to guide a workshop with all the interested partners looking at barriers,
opportunities and successful strategies for implementation at the three levels of care and the animal sector in
order to evaluate possible options for the implementation of the work.
3. To report the level of implementation and level of acceptance of antibiotic stewardship strategies at different
levels of care, in food and companion animals in different countries, including both indicators for consumption
of antibiotics by humans and animals.
4. To design and run pilot projects looking at effective implementation (as defined by the previous two activities)
of antibiotic stewardship by introducing a simple surveillance system of antibiotic consumption and resistance,
including feedback mechanisms for a shorter time-lag than present alternatives. This would be done in parallel
projects in settings with differing resources in human and animals and focusing on different levels of care.
We envisage a high degree of synergy between WP7 and WP6 and suggest close cooperation between the two
packages.
Description of work, role of the participants and interactions
Task 7.1: Identify and review existing guidelines, tools and importantly, implementation methods for
antibiotic stewardship by level-of-care (hospital, long-term care facility and community setting) and in food
and companion animals and to summarize available information on the ECDC website
Leader: FHI ; Contributors : HDir; AEMPS; DG de Planificación, Evaluación y Farmacia.- Consejería Salud
Comunidad Autónoma Illes Balears; NMI; UNIFG; VWS; SSI; UMPIH; RKI; GOG; ISS; ANSES; CIPH HZJZ; LSMULKK;
NVSC / Start date:M2 End date:M11
Collaborating with: ECDC dept. for antimicrobial resistance and Healthcare Associated Infections and OIE. ECDC
would be asked to host the information made available through this project on their website.
Task description:
• Review material from ECDC, EFSA and EMA and other actors such as OIE, FAO, WHO, GHSA, website, other
initiatives such as the ARNA project, the OECD report, the STRAMA network, and published literature
• Questionnaire to member states on current, past and proposed activities including receiving copies of tools
and guidelines with weight given to the level of implementation of antibiotic stewardship plans, reason for
choice of tool/guideline and implementation plan, “partners” in charge of work, success stories and the
barriers that have hindered implementation of this work. This will expand on work already conducted by the
OECD
The aim will be to update and expand the information available on the ECDC website to include information on
existing guidelines, implementation methodology and work at different levels of the healthcare system. This will
include strategies aimed at different settings and the existence of national or local indicators (including
structural, process and outcome indicators of quality).
Task 7.2. Workshop involving all the registered partners to discuss models of implementation
Leader: FHI ; Contributors : Hdir; AEMPS; GOG; NMI; NIJZ; VWS; SSI; UMPIH; RKI; GOG; ISS; ANSES; LSMULKK;
NVSC / Start date: M11 End Date: M12, EFSA
Collaborating with: ECDC dept. for antimicrobial resistance and Healthcare Associated Infections and OIE: TBC
Task description:
38 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Identify experts and organize expert group meetings (virtual and at least one face-to-face) to evaluate
findings from task 7.1, identifying key tools and implementation mechanisms (expert group around 10
people) in both the human and animal sectors.
• Organize workshop to share experiences between countries and comment on expert group’s findings, with
a focus on barriers for implementation. – Interest from Austria to help organize meeting (workshop about
40-60 people at end of year 1)
• Discuss suitability to different settings (cultural, epidemiological and financial)
Task 7.3 Qualitative evaluation of the level of implementation and acceptance of antibiotic stewardship at
different levels of healthcare and in animals, in different country settings. This will focus on identifying and
establishing success factors and barriers.
Leader: FHI; Contributors : HDir; SAS; FFIS; GENCAT; SERMAS; Illes Balears; NMI; FOHM; UNIFG; NPIH; SSI;
UMPIH; RKI; GOG; ISS; ANSES; LSMULKK; NVSC / Start date: M2 End date: M36
Task description:
• Follow-up questionnaire to active partners, which will be further disseminated in each member state or
region. This will include structured questions and oral interviews. The aim of this activity will be to collate
information about attitudes to stewardship methodologies and campaigns in order to determine both
factors for success and barriers to acceptance.
• Evaluation and publication of recommendations on core components needed for implementation that can
be used by member states when planning their own programs based on the information from tasks 7.1, 7.2
and 7.4.
• We will deliver a report on which indicators of antibiotic use and resistance are available in each country in
human (for each level of care) and animals (including for animal husbandry).
Task 7.4.1 Develop and test near real time surveillance of antimicrobials and multidrug resistant bacteria
Task description:
Current surveillance networks are informative and concise. However, there is a long delay in the data reported
and some countries do not have data. Therefore, there is a need for reinforcing current surveillance systems.
Surveillance networks need to be adapted to work in conjunction to provide a simple surveillance system of
antibiotic use and resistance. This subject is essential to guide the fight against the antimicrobial resistance
(AMR) and to improve the results by means of feedback and benchmarking. In addition, this system must work
and data must be available in a shorter time-lag than present alternatives.
Subtask 7.4.1. Surveillance in human medicines - consumption of antimicrobials and AMR
Leader: SAS ; Contributors: AEMPS; FFIS; GENCAT; SERMAS; Illes Balers; FMS; FHI; UMPIH; NMI; FPS HFCSE;
UNIFG; ESDY-NSPH; NIPH; SSI; RKI; GOG; ISS; NVSC; LSMULKK / Start date: M2 End date: M36
• Select basic indicators for surveillance system of antimicrobial consumption: : DDD/1000 stays (in
hospital settings) or inhabitants (in primary care settings) of:
-. Overall antimicrobial drugs consumption
-. Carbapenems, piperacillin-tazobactam, amoxicillin-clavulanate, aminoglycosides, quinolones, 3rd
and 4th gen cephalosporins, vancomycin and colistin (in hospitals)
-. Amoxicillin-clavulanate, 3rd gen cephalosporins, quinolones and macrolides (in primary care)
• Select basic indicators for surveillance system of antimicrobial resistance: Number of isolates in clinical
samples per patient/1000 stays (in hospital) or inhabitants (primary care) of of the following pathogens:
-. Carbapenemase-Producing Enterobacteriaceae, ESBL E. coli, ESBL K. pneumoniae, MDR A.
baumannii, MDR P. aeruginosa and methicillin-resistant S. aureus (MRSA), ), vancomycin resistant
enterococci (E. faecalis and E. faecium) in hospital settings.
-. Carbapenemase-Producing Enterobacteriaceae, ESBL E. coli, ESBL K. pneumoniae, methicillin-
resistant S. aureus (MRSA), in primary care area.
• Reinforce already existing local surveillance systems in order to have the available data as soon as
possible.
• Select pilot sites that will represent the three levels of healthcare named above and to cover countries
with different resources available including regular meetings, follow-up and support.
• Frequency: quarterly. Data managers will have a two-month period after the end of each trimester to
upload data onto the website software.
39 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Collaborations with existing networks. Potential connections with EARS-net and ESAC: the project
leader will have periodical meetings with with ECDC networks EARS and ESAC to share the project
status and outcomes, so that it could be of interest for future collaborations.
• Quality of data: Indicators definitions and data management will be explained carefully in guidelines. A
website with data management software will be developed specifically. .Data will be entered by each
participating hospital/primary care area/region/country in the form of numbers (two figures per each
indicator). The accuracy of data will be under each national coordinator’s responsibility.
Regional data could be cumulative (sum of hospitals data / primary care areas data) or directly entered
specifically by a designated responsible person.
Country data could be cumulative (sum of regional data) or directly entered specifically by a designated
responsible person.
Calculations will be carried out by the software to minimize human error. Prior to validate entered data,
a technician will supervise them quarterly in order to find out any possible outliers and take the measures
to correct them. Besides, the task leader will carry out random audits to any participating country.
Subtask 7.4.2. Surveillance of AMR in animals
Leader: ANSES and ISS ; Contributors: NVI, ESDY, SSI, AEMPS / Start date: M2 End date: M36
AMR surveillance in animals will be conducted to evaluate the correlation between AMR spread in humans and
animals. Thus, antimicrobial-resistant bacteria that will be surveyed will be mainly the same in a One Health
strategy. Numerous issues in the veterinary sector have already been covered by EU and/or MS initiatives
sustained by scientific advice from EFSA. It is particularly the case for AMR surveillance under EC directives in
healthy food animals and antibiotic consumption under ESVAC. On the contrary, the project will fill the gaps by
focusing on the uncovered domain of AMR surveillance in diseased animals in the EU. Thus, the objectives will
be to:
• Assess the surveillance systems in place on AMR in animal pathogens in MS
• Identify the main gaps and appropriate strategies for AMR surveillance in diseased animals in Europe
depending on MS specificities towards their diversity in animal species and diseases
• Select appropriate AMR indicators in diseased animals in coherence with human ones, including
carbapenemase-producing Enterobacteriaceae, ESBL E. coli, ESBL K. pneumoniae, MDR P. aeruginosa,
MDR A. baumannii, methicillin-resistant S. aureus (MRSA), methicillin-resistant S. pseudintermedius
(MRSP), colistin-resistant Enterobacteriaceae, vancomycin resistant enterococci (E. faecalis and E.
faecium). The choice of these indicators will allow to correlate the animal data with the human data
from subtask 7.4.1
• Identify laboratory and technical capacities in MS for potential establishment of a molecular-based AMR
national surveillance of relevant resistant pathogens, to be further compared with human counterparts
• Assess the opportunities to combine MS surveillance systems into a pilot EU network for the surveillance
of AMR in clinical animal isolates, covering prioritized animal species and relevant pathogens, based on
existing networks in place at national levels (RESAPATH, VetPath, …), and including common reporting
and communication issues
• Draw guidelines for uploading, validation and management of the data, with particular emphasis on
accuracy and types of the data (per animal species, pathogen and disease) under each national
coordinator’s responsibility.
• Provide global and specific recommendations to EU to build a European network covering AMR
surveillance in diseased animals, including interface with AMR surveillance in human medicine
Work package Start date or starting event M1
WP8
number End date M36
Work package title Awareness raising and Communication
Leading participant AEMPS
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short
INSERM Moh GOG FCS NCIPD CIPH HZJZ NIPH SSI
name
Person-months per 7,5 1 0 0 0 0,5 0,5 0,5
40 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months per
5 0,5 1 1 0 1,9 0 0
participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months per
0,5 0 0,5 2,5 2 0,1 0 0
participant
Participant nr. PL-25 PT-26 RO-27 SI-38 SP-29 SP-30 SP-31 SP-32
Participant short
NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
name
Person-months per
0 2,5 0 3,5 49 4 03,1 1
participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months per
0,5 0 0,4 3 0 0 0 0
participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months per
0 0 0 0 91.6
participant
Objectives
Despite the European Commission and the Member States having developed and implemented strategies and
action plans at national level to control the development of antimicrobial resistance, figures show that efforts
should continue to keep on fighting against the development and propagation of antimicrobial resistance.
The main objective of this WP is increasing Awareness and optimizing Communication strategies on antibiotic
use and AMR and prevention of Healthcare associated infections with the aim of promoting the responsible use
of these medicines and encouraging best practices among the general public and healthcare professionals and
through dialogue with young population and mass media.
The specific objectives of this WP are to:
1. Define best practices on Communication and Awareness: state-of-the-art as a guide for new or updated
communication strategies.
2. Reach different targets using different strategies: Develop a Communication and Awareness Plan that
will address these targets.
3. Use the website developed by WP2 as a key tool for promoting communication and interacting with
social networks and traditional media to guarantee reaching the general public, specific groups of
society and professionals subgroups. This website will work as a unifying platform that will collect all
the contents created within the project, so it is a tool to ensure both, correct dissemination on high
quality information on JA deliverables and awareness raising on AMR and HCAI issues. As for these
contents, they will all be designed according to the different targets and properly updated as the project
moves forward.
4. Support coordination about World Week and the European Day of Appropriate Use of Antibiotics.
Establish dialogue with other initiatives and actors related to antibiotic use and antimicrobial resistance.
Description of work, role of the participants and interactions
WP Methodology
The following tasks have been designed and planned in order to promote the responsible use of antibiotics by
highlighting the importance of appropriate prescribing and use as well as informing about the risks associated
41 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
with overuse and misuse of these medicines. Thus, this WP is intended to change minds and behaviors regarding
antibiotics use and the threat of increasing AMR and HCAI.
WP8 strategy will be designed and carried out by a team that will consist of health communication specialists
with relevant professional experience within this field. Communication between the Communication Officer in
charge of WP8 and each country’s contact person will be carried out via email on a monthly basis or more
frequently if it is needed or via TLC depending on the project’s dynamics. These active partners will maintain
dialogue with its country´s contact person for informing about relevant events, news, and other material related
to awareness and communication.
Task descriptions
Task 8.1: Data Collection to define best practices in Awareness and Communication Plans
Leader: AEMPS; Contributors: TA and all WP8 participating partners / Start date: M1 End date: M12
8.1.1.
• Data collection on previous strategies, activities and materials targeting professionals in the fields of public
health, animal health and the environment (one health approach), the general public and other specific
population groups such as youth, medical students, caretakers or elderly. The objective is to collect and
analyze all these materials to avoid efforts duplication, share good practices and offer ideas to MSs for
building further new awareness and communication plans.
• The analysis of the mentioned materials will help to implement new awareness and communication plans
to reach the following objectives:
o Increase awareness on the importance and consequences of the inappropriate use of antibiotics in
human and animal sector.
o Optimize Compliance with treatment regimens of prescribed antibiotics.
o Avoid the use of antibiotics when they are not indicated.
o Avoid the storage and consumption of leftover antibiotics (self-medication).
o Strengthen the position of professionals in public and animal health, to make them feel less
pressured to prescribe and dispense antibiotics.
o Encourage Health professionals to undertake Continuing Professional Development activities (i.e e-
learning, webinars, live educational events)
• Selection of some efficient and innovative communication strategies and activities that have been
performed in previous years, regardless their relation to antibiotic use. Search for some relevant and
successful cases to take advantage of them.
• Analyze and evaluate previous awareness and communication materials and/or strategies.
• Prepare a report about Communication Good Practices as a guide or reference tool when designing new
strategies.
8.1.2.
Analyze the use of the theme “antibiotic” in social networks and Internet. A pilot study will be conducted to
analyze how the theme “antibiotic” is approached by the society in the social networks. Different periods of time
in each year will be targeted to identify the key themes arising in relation to antibiotics (ie. April, October and
January). A web-based tool will be used to detect daily occurrences of the word 'antibiotic' and other related
terms during the chosen time period in Tweets. How the society dialogue about antibiotics as well as activity
peaks (message frequency over three times that of baseline) will be analyzed to identify key issues and events
that need to be considered in future awareness and communication campaigns. In that way, findings could
determine the best period for launching campaigns in addition to negative attitudes or perceptions that should
be considered to better address overuse and misuse. For the data collection, staff members will retrospectively
analyze the selected periods.
8.1.3.
Identify some efficient and innovative educational strategies and activities performed in Europe focusing on
prudent use of antibiotic in both High School and Universities.
A content analysis of teaching materials will be conducted to explore and identify innovative strategies and
activities performed in the secondary high schools and universities. The project will organize strategies to share
these activities and motivate all MSs to implement them, for example, by promoting the use of the e-bug
platform, and its adaptation, or other similar initiatives.
42 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Task 8.2: Design and Implementation of Awareness and Communication Plan
Leader: AEMPS; Contributors: VWS and all WP8 participating partners / Start date:M1 End date:M8
Task description: To design Awareness and Communication strategies targeting governments and stakeholders.
8.2.1. Prepare the Awareness and Communication Plan
• Definition of the objectives and identification of the relevant target audiences. Both WP8 and WP2 share
target audiences (general media and health-specialized journalists, general public -specially considering
caretakers for elderly and children-, healthcare professionals in both human and animal health, medical and
veterinary students, human and animal health industries, key decision makers) but differ in goals since WP8
is intended to change minds and behaviors toward antibiotics by raising awareness of the dangers of AMR
whereas WP2 is intended to disseminate outcomes and deliverables produced by the JA that could lead to
this change.
• Definition of basic key messages to be communicated to the general public, health professionals and specific
target audiences, along the same lines as ECDC’s messages through the activities included within WP8.
Messages targeted at general public:
- Antibiotic misuse and overuse creates antibiotic-resistant germs that could lead us to a scenario where
antibiotics no longer work.
- Antibiotics are effective only against bacterial infections. Taking them for wrong reasons, such as against
colds or flue, has no benefit for you.
- Antibiotics often give you side effects such as diarrhea. Always seek your doctor’s advice before taking
them.
Messages targeted at health professionals (physicians and veterinarians, pharmacists, nurses, specialist
nurses, …):
- Antibiotic resistance is an increasingly serious public health problem all over the world.
- While the number of infections due to antibiotic-resistant bacteria is growing, the pipeline of new
antibiotics is unpromising, thus presenting a bleak outlook on availability of effective antibiotic treatment in
the future.
- Unnecessary antibiotic prescribing could boost the emergence and selection of antibiotic-resistant
bacteria.
More specific messages targeted at more specific audiences according to each country will be designed as
the project moves forward, as well as the tools and the schedule to better spread them.
• Description of the issues to be tackled and identification of good practices and specific tools to be used or
developed in order to support effective actions.
8.2.2. Implementation of some of the following proposed activities. Depending on budget, some pilot activities
could be carried out in some countries or could be removed, if necessary. First working meetings will clarify
each participant contribution so this schedule can be set up:
• Database design including European Science and Health Communication researchers. Organize 1 European
webinar/year during the 2nd and 3rd years (mass media, other communicators, etc). Trying to generate a
starting point for a network of communicators about increasing antibiotic use and antimicrobial resistance.
• Carry out 1 or 2conferences (similar to TED Conferences; maybe a pilot activity in some countries) in the
second-third years of the JA, one with scientific communicators, and another conference with High School
and university students as speakers. The conference with students will be organized with the aim of
encouraging them to improve their public speaking skills as well as spreading our key messages among
youth. Each country will determine criteria and rules for speakers’ selection. For instance, invitations to
participate in this programme could be sent to the regional or local authorities or to largest high schools in
each region or the top-rated medical schools. A jury will select the best talk in each region and those students
will take part of a national competition. Each country winner will eventually compete in a final contest that
will take place in Brussels or in a Spanish city.
• High Level Awareness and Communication Meeting (included as activity developed in task 8.4): One High
Level European Meeting in the last year focusing on governments (relevant institutional organizations at the
regional (e.g. Health Authorities), national (MoH)) and stakeholder’s (Industry) awareness with the
attendance of international organizations (e.g. EIP, DG SANCO, OECD, WHO, JPI AMR, etc.). This High Level
European Meeting could be organized within the context of the ECDC’s European Antibiotic Awareness Day
43 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
at the European Parliament or in a Spanish city chosen to host it. As speakers we might invite scientific and
healthcare professional communicators or maybe some JA representatives (WPleaders). Organized as a
workshop aimed to communicate the risks of misusing antibiotics and the need for commitment to fight
AMR coming from different stakeholders. Thus, topics included will focus on highlighting the danger of not
facing this problem from several perspectives (political, scientific and economical) in order to change
different behaviors. This meeting is intended to set up a conclusion document that could work as a road
map/call to action to be signed (supported) by different stakeholders (e.g.
http://www.who.int/globalchange/global-campaign/call-for-action/en/). In any case, specific details will be
decided by participants involved in WP8 at this work package’s kick-off meeting.
• Training webinars on AMR lead by physicians and veterinarians that will be targeted at general media and
health-specialized journalists. One purpose of these webinars is to provide clear and accurate scientific
information about this problem so journalists are able to correctly inform the audience about AMR
consequences. Furthermore, physicians and veterinarians will be asked to undertake Continuing
Professional Development (CPD) activities on AMR. National accreditation authorities will be asked to
require their doctors to do that. All of these activities will be carried out in close collaboration with different
work packages involving interactions with physicians and veterinarians, so webinars and CPD activities’
materials will be designed according to achievements that are being made.
Task 8.3: Tools for Awareness and Communication (probable interaction with WP2)
Leader: AEMPS; Contributors: UNIFG and all WP8 participating partners / Start date:M1 End date:36
Task description:
• Use of the web platform for promoting awareness and communication campaigns/materials or events
carried out by WP8. The exclusive use of English would undermine effective communication and devalue the
funding efforts made by all partners. Thus, our proposal would consider different versions in English, French
and Spanish, as well as partial translations (i.e. objectives, news or blogs) to each MS language.
• Creation and implementation of a (or some) relevant blog(s) and performing an active search for contents
within the website: news, podcast, reports, scientific papers, interviews, and general information about
antimicrobial resistance. As previously mentioned, each active country should have one contact person for
communication activities. All Work Packages leaders will notify any event, communications, news related to
Awareness and Communication produced during WP development.
• Social media promotion:
o Create profiles in Facebook, Twitter and Youtube, and make sure to update the content of these profiles
on a regular basis (daily and weekly updating). Contents will spread initiatives related to our goals that
are being carried out all over Europe and will also consider the organization of Twitter chats with
healthcare professionals and contests that will boost engagement (e.g. online quizzes or sharing
experiences related to the use of antibiotics).
o Carry out 3 social media promotion actions per year in the 2nd and 3rd years to attract internet traffic to
the website (at European level) for example by JA-blog Promotion (promote communication and
awareness materials) in the social media. Paid media in Facebook or Twitter will create more exposure
and will drive searchers to our website, to help increase not just traffic but also conversations. Thus,
tools such as advertising or collaboration with influencers will impact the reach of our key messages.
o Use of a social networks analysis tool to measure the impact of the promotion actions and to get a
deeper knowledge of the flow of information based on complex networks techniques and the topology
of the network (Analytics, online reputation, etc).
• Awards
o Award for the best European article or best video about antibiotic use. This award will be granted to the
journalist whose article/video presents the clearest, informative and scientifically-based piece of work.
Articles/videos to be considered will be chosen from the most read newspapers and top television news
services.
o Award for a European competition with University students (High School students should be also
considered if it does not provoke legal difficulties in audio-visuals activities related to the use of
underage images) presenting a video work about antibiotic use and increasing AMR. The competition
"Eurovision Antibiotic Contest" will grant the most creative piece of work (a music video, a short film, a
monologue, using their own language) explaining how we should use antibiotics and how we actually
use them. Just like in "Eurovision Song Contest" each country will select a winner that will compete in a
44 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
final contest. The winner will get a study-abroad grant. The organization of this contest could work as
an inter-university competition leaded by selected professors within each university (e.g.
https://www.consumerclassroom.eu/consumer-classroom-inter-school-competition-2016-2017). This
competition will permit future sustainability of this type of health competition and working closely with
CHAFEA could also be the opportunity to implement later a “Health classroom” within their “consumer
classroom”.
• This social campaign will be designed in order to address general public and healthcare professionals in both
human and animal health, according to the One Health approach. Audiovisual materials will be created to
be posted at social networks profiles and leaflets/posters will be distributed among hospitals and medical
centers and in professional congress. Cited examples in the Luxembourg meeting were: use Term antibiotic
in the box. Cooperation with the industry. Or TV France example “antibiotic is not automatic anymore” or
“proper prescribing”, Maybe use an ethical message about a good prescription.
• Interview management with key national spokesperson in the top general and health-specialized media.
Each partner should contact the most relevant national media to offer an interview with the selected
national spokesperson, who will highlight the project's key messages during the interview. National
spokesperson should be selected according to their authority, expertise, communication skills and interview
background.
Task 8.4: Support coordination about World Week and the European Day of Appropriate Use of Antibiotics.
Establish dialogue with other initiatives and actors.
Leader: AEMPS; Contributors: NIJZ and all WP8 participating partners / Start date:M1 End date:36
Task description:
• Following ECDC’s line of work, meetings with AMR JPI, IMI JU consortium working on antibiotics,
WHO/Europe and other initiatives will be held in order to share ideas and jointly collaborate in campaigns.
• Meetings with National Action Plan Coordinators to share best awareness practices.
• Coordination meetings on European Antibiotic Awareness Day. WP8 Communication team will be able to
offer any support and help in order to face any need and contribute to implementing any proposed activity.
• High Level Awareness and Communication Meeting (explained previously in subtask 8.2.2.3.)
Work package Start date or starting event M1
WP9
number End date M36
Work package Prioritizing and implementing research and innovation for public health needs
title
Leading FHI & INSERM
participants
Participant nr. FR-1 FR-2 AT-3 BE-4 BG-5 HR-6 CZ-7 DK-8
Participant short
INSERM Moh GOG FPS HFCSE NCIPD CIPH HZJZ NIPH SSI
name
Person-months
31 0 0 0 0 0 0 0
per participant
Participant nr. EE-9 DE-10 GR-11 GR-12 GR-13 IT-14 IT-15 LV-16
Participant short ESDY
TA RKI HCDCP 7HC UNIFG ISS PSKUS
name NSPH
Person-months
0 0 0 0 1,5 0 3 0
per participant
Participant nr. LT-17 LT-18 LT-19 LT-20 NL-21 NO-22 NO-23 NO-24
Participant short
LSMULKK VULSK HI NVSC VWS HdiR FHI NVI
name
Person-months
0 0 0 0 4 0 32,5 1
per participant
Participant nr. PL-25 PT-26 RO-27 SI-28 SP-29 SP-30 SP-31 SP-32
Participant short NMI DGS UMPIH NIJZ AEMPS GENCAT IdISBa FFIS
45 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
name
Person-months
0 0 0 1 0 0 0,6 5
per participant
Participant nr. SP-33 SP-34 SP-35 SP-36 SE-37 SE-38 SE-39 SE-40
Participant short
FMS SAS ISCIII SERMAS FOHM SoS SBA NFA
name
Person-months
0 0 0 3,3 0 0 0 0
per participant
Participant nr. SE-41 SE-42 SE-43 FR-44
Participant short TOTAL
SVA SRC UAS ANSES
name
Person-months
0 4,6 0 0 82,5
per participant
Objectives
The main objective of this WP is to contribute to a coordinated European response in regards to prioritizing and
assisting in the implementation of research and innovation expected to help achieve public health-related AMR
and HCAI goals and objectives. (This WP will not fund any research or innovation projects.) The three specific
objectives of this WP each corresponding to a dedicated task are to:
1. Work with Member States to ensure that national processes for research and innovation priority-setting are
grounded in a broad One Health approach and that both Member State research priorities and knowledge
gaps are addressed in the development of the update of the JPIAMR SRA (Strategic Research Agenda.
2. Explore and detail European strategies to implement mechanisms to increase innovation and other means
to fight against AMR and HCAI
3. Contribute to ensuring that evidence-informed public health policies and practices related to combatting
AMR and HCAI are implemented
Description of work, role of the participants and interactions
Task 9.1: Work with Member States to ensure that national processes for research and innovation priority-
setting are grounded in a broad One Health approach and that both Member State research priorities and
knowledge gaps are addressed in the development of the update of the JPIAMR SRA.
Leader: INSERM Main contributors: FHI, SRC ; Other contributors: 7HRC; ISS; VWS; NVI; NIJZ; IdISBa, SERMAS
/ Start date: M1 End date: M36
Task description:
The aim of this task is to contribute to a strengthened process for European-wide and internationally
acknowledged agreement on research and innovation priorities to meet the public health goals related to AMR
and HCAI in a broad One Health approach.
The European Union Member States in 2016 through the Council Conclusions, particularly §22.8, expressed their
will to align strategic research agendas of existing EU R&D initiatives on new antibiotics, alternatives and
diagnostic, and set priorities based on societal needs in the field of public health, animal health and the
environment, taking into account gaps analysis in this domain.
Significant efforts led by JPIAMR in collaboration with the EU and IMI have already been established in regards
to AMR research and innovation priority-setting. Its Strategic Research Agenda (SRA) outlines key, neglected
areas to tackle, which guides JPIAMR and others to shape cohesive and coordinated AMR funding and research
actions to maximise on resources and reduce duplication of research. The SRA is scheduled to be updated in
2017. About half of EU members, but also other countries, participate in JPIAMR.
This process can be expanded upon through the EU-JAMRAI by working directly with Member States in
preparation of their participation in priority-setting activities with JPIAMR. Member States need to ensure that
their national processes include: (1) a One Health focus including not only the Ministry of Health but also
Ministries of Agriculture, Fisheries, and Environment; (2) ensure that the special needs of HCAI are also included;
(3) ensure that an appropriate breadth of research fields is considered including social sciences; and (4) consider
where research syntheses are needed in order to inform policies. Social sciences are an often forgotten aspect
of research priorities but can have major impact on achieving stewardship and infection control goals. Member
States should also ensure that their own national research agendas are in line and fill the identified gaps with
the priorities set out by JPIAMR and other related initiatives like the international clinical trial networks. Member
States not participating in JPIAMR should be encouraged to share their priority research and innovation topics
46 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
with JPIAMR. Links to Horizon 2020 will also be evaluated.
Member State priority-setting for AMR and HCAI research and innovation in line with public health needs
• Gather national approaches to participation and input into the SRA update to assess best practices and gaps
(INSERM, FHI, SRC)
• Work with Member States to provide best practices and routines that can assist them with identifying
national research and innovation priorities to be communicated into the SRA process (INSERM, FHI, SRC)
• Provide feedback to JPIAMR and potentially Horizon 2020 and others about perceived gaps and potential
procedural improvements to SRA update process (INSERM, FHI, SRC in conjunction with WP4
Implementation)
Task 9.2: Explore and detail European strategies to implement mechanisms to foster antimicrobial innovation
and other means to fight against AMR and HCAI
Leader: FHI Main contributor: INSERM; Other contributors: SRC; 7HRC; ISS; VWS; NVI; NIJZ; IdISBa, SERMAS /
Start date: M1 End date: M36
The aim of this task is to act upon recommendations for stimulating greater innovation (including medicines,
vaccines, diagnostics, and medical devices – for both human and animal health) to combat AMR and HCAI.
Innovation has been acknowledged to be dangerously lacking for the past decades. Yet this is not to say that this
type of innovation has been determined to be more impactful than other types of research and innovation.
Significant funds have recently been invested in projects, like the UK’s AMR Review and IMI’s DRIVE-AB, to
explore new economic models and strategies to stimulate innovation. It is timely now to react to the results of
these initiatives and assist Member States with implementation.
Since the cost of developing some products, like a new antibiotic, may be large, the financing for stimulating
innovation is also large, requiring coordination across countries. Other processes, like joint procurement
mechanisms, new regulatory classifications, and regulatory harmonization, can also be impactful and require
collaboration. UK’s AMR Review delivered its final report in May 2016 which included recommendations to
stimulate both antibacterial innovation for human and animal use as well as diagnostic innovation. DRIVE-AB
will deliver its final recommendations in September 2017.
Assist with EU-wide implementation of incentives to stimulate antimicrobial, diagnostic and other innovations
for fighting AMR and HCAI
• Hold a meeting where AMR Review, DRIVE-AB, and other potential actors present their recommendations
to Member States and non-Member States regarding the need for multi-country collaboration in order to
stimulate the innovation of antimicrobials (for both human and animal health) as well as diagnostics and
other innovations, including an opportunity for governments to ask questions and provide feedback (FHI,
INSERM)
• Perform a gap analysis for any missing incentives with a special focus on how to align and/or differentiate
what is needed for AMR on the one side and HCAI on the other (FHI, INSERM)
• Hold follow-up meetings with about ten Member States and 3-5 non-Member States to gather direct
feedback on the recommendations and options for implementation; request written feedback from the
remaining Member States (FHI, INSERM)
• Develop an implementation strategy aligned with feedback from Member States (FHI, INSERM in conjunction
with WP4)
• Request that all Member States formally respond to the implementation strategy with firm commitments
(FHI, INSERM)
Task 9.3: Contribute to ensuring that evidence-informed public health policies and practices related to
combatting AMR and HCAI are implemented
Leader: FHI / INSERM ; Main contributor: SRC ; Other contributors: 7HRC; ISS; VWS; NVI; NIJZ; IdISBa, SERMAS
/ Start date: M1 End date: M36
The aim of this task is to ensure that national procedures are in place to translate research findings (including
those from the social sciences) into public health policies and practices. Since the quality, certainty, and strength
of recommendations can vary for individual studies, it is important to first synthesize the existing evidence
through a systematic review where the evidence is graded and then summarize the findings in plain language
for policymakers. SURE Policy Briefs are a tested format that can be used to convey evidence to policymakers.
This task will require support of and engagement in fora for communication of research findings to public health
implementation levels, including the exchange of good practices as a procedure to reinforce implementation. A
47 of 137
EU-JAMRAI Confidential
09/08/2017
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
particular attention will be paid to establish functional links with WP2, WP4 and WP8 in that regard.
Assist with evidence-informed policymaking.
• Evaluate existing tools for evidence-informed policymaking, like policy briefs, and modes of dissemination
and sharing, as well as implementation good practices (FHI)
• Recommend national dissemination and sharing strategies for policy briefs or other tools (FHI, SRC)
• Gather feedback on recommendations and update recommendations appropriately (INSERM)
• Request EU to agree to and publish the recommendations (INSERM)
48 of 137
EU-JAMRAI Confidential
09/08/2017
8.3. Timetable or Gantt Chart
Year 1 Year 2 Year 3
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 M34 M35 M36
WP1 T1.1. Stra tegi c Ste eri ng
T1.2. Contra ctua l a nd fi na nci a l ma na gement
T1.3. Peri odi c reporti ng
T1.4. Communi ca ti on: i nte rna l a nd wi th CHAFEA / DG SANTE
Del i vera bl es
Meeti ngs KoM GA GA GA
WP2 T2.1. Des i gn of a di s s emi na ti on pl a n
T2.2. Communi ca ti on tool -ki t (Vi s ua l i denti ty)
T2.2. I denti fi a cti on of the rel eva nt ta rge a udi ences
T2.3. Webs i te des i gn: i nterna l a nd externa l us e
T2.4. I mpl eme nt a di s s emi na ti on pl a n
Del i vra bl es
Meeti ngs
WP3 T3.1. Defi ni ti on of the eva l ua ti on pl a n (EP)
T3.2. Deve l opment of eva l uti on tool s
T3.3. Conduct i nte ri m a nd fi na l eva l ua ti on a cti vi ti es
T3.4. Qua l i ty a s s e s s ment
T3.5. Report of eva l uti on res ul ts to re l eva nt s ta ke hol ders
T3.6. Eva l ua ti on of the JA i mpa ct i n Europe
Del i vera bl es
Meeti ngs
WP4 T4.1. I nte gra ti on pl a n a nd s us ta i na bi l i ty s tra tegy
T4.2. I nte gra ti ng preventi ve s tra te gi e s wi thi n na ti ona l pol i ci es
T4.3. Fos teri ng s us ta i na bi l i ty
Del i vebl e s
Meeti ngs
WP5 T5.1. Ma ppi ng a nd s e l f-a s s es s me nt of Na ti ona l Acti on Pl a ns a nd s tra tegi es
T5.2. Country-to-country a s s es s me nts
T5.3. Strenghe ni ng s upervi s i on
Del i vera bl es
Meeti n,gs WS WS One Health WS WS WS + One Health One Health + WS
WP6 T6.1.1. De termi ne the neces s a ry i ns ti tuti ona l s tructures a nd res ources for the i mpl e menta ti on
of ICFP a nd promote a dequa t hos pi ta l orga ni s a ti on, ma na ge me nt a nd s tructure for the
preve nti on of HCAI, a ccordi ng to the EU Acti on Pl a n
T6.1.2. Incorpora ti on of ICP to cl i ni ca l pra cti ce for the i mproveme nt of he a l th profes s i ona l s '
compl i a nce wi th i nfe cti on control routi ne us i ng the i ns ti tuti ona l be ha vi our cha nge a s a tool to
T6.1.3. De vel opme nt of tool s for i ncre a s i ng a wa rene s s a nd i mprovi ng the tra i ni ng of he a l th
profe s s i ona l s i n i nfe cti on control a nd preve nti on
T6.2.1. Introduce a n e vi de nce -ba s ed i mpl ementa ti on model
T6.2.2. Promote tha t s i mi l a r worki ng routi ne a re i mpl eme nte d i n non-EU countri es i n Europe
Del i vera bl es
Meeti ngs
WP7 T7.1. I denti fy a nd revi ew exi s ti ngs , gui de l i ne s , tool s a nd i mporta ntl y, i mpl e menta ti on methods
for a nti bi oti c s tewa rds hi p by l eve l -of-ca re a nd i n food a nd compa ni on a ni ma l s a nd to
s umma ri s e a va i l a bl e i nforma ti on on the ECDC webs i te
T7.2. Works hop i nvol vi ng a l l the regi s tere d pa rtners to di s cus s mode l s of i mpl e menta ti on
T7.3. Qua l i ta ti ve e va l ua ti on of the l e vel of i mpl e menta ti on a nd a cce pta nce of a nti bi oti c
s tewa rds hi p a t di fferent l eve l s of he a l thca re a nd i n a ni ma l s , i n di fferent country s e tti ngs .
T7.4.1. Survei l l a nce i n huma n me di ci nes - cons umpti on of a nti mi crobi a l s a nd AMR
T7.4.2. Survei l l a nce of AMR i n a ni ma l s
Del i vera bl es
Meeti ngs
WP8 T8.1. Da ta col l ecti on to defi ne be s t pra ti ces i n Awa re nes s a nd Communi ca ti on pl a ns
T8.2. Des i gn a nd i mpl ementa ti on of Awa rene s s a nd Communi ca ti on pl a n
T8.3. Tool s for Awa renes s a nd communi ca ti on
T8.4. Support coordi na ti on a bout Worl d Wee k a nd the Europea n Da y of Appropri a te Us e of
Anti bi oti cs . Es ta bl i s h di a l ogue wi th othe r i ni ti a ti ves a nd a ctors
Del i vera bl es
Meeti ngs TED TED High
T9.1. Work wi th Member Sta te s to ens ure tha t na ti ona l proce s s e s for res ea rch a nd i nnova ti on
pri ori ty-s etti ng a re grounded i n a broa d One Hea l th a pproa ch a nd tha t both Me mbe r Sta te
WP9 re s ea rch pri ori ti e s a nd knowl edge ga ps a re a ddres s ed i n the de vel opment of the upda te of the
JPIAMR SRA.
T9.2. Expl ore a nd deta i l Europea n s tra tegi es to i mpl e me nt mecha ni s ms to i ncre a s e
a nti mi crobi a l i nnova ti on a nd other mea ns to fi ght a ga i ns t AMR a nd HCAI
T9.3. Contri bute to ens uri ng tha t evi dence-i nformed publ i c hea l th pol i ci es a nd pra cti ces rel a ted
to comba tti ng AMR a nd HCAI a re i mpl emente d
Del i vera bl es
Meeti ngs
49 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
9. MILESTONES AND DELIVERABLES
Del N° Deliverable name WP N° Leader Content specification Dissemi Delive
acronym nation ry mo.
leval
D1.1 Interim reports 1 Inserm This report describes the CO M18
activities carried out, milestones
and results achieved in the first
half of the project. Deliverables
can be attached as annexes.
D1.2 Final report 1 Inserm This report describes the project CO M36
implementation and the results
achieved. The deliverables are
annexed.
D2.1 Dissemination Plan 2 AEMPS Report PU M10
D2.2 Layman report 2 AEMPS Report PU M33
D2.3 Final Conference on 2 AEMPS Conference event agenda and PU M36
dissemination minutes.
D3.1 Evaluation plan 3 ISS Release of the evaluation plan CO M4
D3.2 Validation of the evaluation 3 ISS / FFIS Report on the evaluation tools. CO M12
tools All processes reported on a
yearly basis.
D3.3 Progress monitoring and 3 ISS / FFIS Reports on actions and initiatives CO M12;
quality assessment of JA to support teams responsible for 24; 36
documentation and the release of deliverables and
deliverables documents. Interim and final
evaluation reports based on the
EP
D3.4 Report on stakeholders 3 ISS Report on the evaluation of the CO 36
evaluation and on JA impact actions and documents released
in Europe by the different WPs by relevant
stakeholders. Report on the
impact of actions and
documents on MS at national
and subnational level
D 4.1 Integration plan and 4 MoH-FR Report on the implementation PU M30
sustainability Strategy plan for integration of key
actions into national policies and
strategy for sustainability of JA
outputs
D 4.2 Report on integration plan 4 MoH-FR Specific measures for prevention PU M30-
and control of AMR and HCAI to 36
be integrated in national action
plans
D 4.3 Report on sustainability plan 4 MoH-FR Specific measures for prevention PU M36
and control of AMR and HCAI to
be sustained beyond the JA
D 5.1 Tool for country self- 5 VWS Availability of the tool for the PU M06
assessments country (self) assessment based
on the WHO-tool and adapted to
the EU situation (Council
Conclusions): summary of the
questionnaire.
D 5.2 Summary Country-to- 5 VWS Performance of the country-to- PU M36
country assessments country assessments
D 5.3 Overview enforcement and 5 VWS Report about white spots, PU M36
recommendations to be shortcomings in the
implementation of national
50 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
presented to the One Health strategies and discuss possible
Network solutions and recommendations
and preparation to present to
the One Health Network.
D6.1.1 Revised guidelines for the 6 HCDCP Report PU M13
implementation of infection
control program in
healthcare settings
D6.1.2 Assessment of the cost- 6 HCDCP Report PU M36
benefit for the
implementation of an
infection control program
D6.1.3 An Universal Infection 6 HCDCP Report PU M36
Control framework with
specific roles, priorities,
resources and interventions
for the implementation of
an infection control plan in
healthcare settings
D6.2.1 Report on experience from 6 FOHM Progress report PU M18;
country teams of M36
introducing and working
with the implementation
model
D6.2.2. Experience from non-EU 6 FOHM Report PU M36
country teams of
introducing implementation
model
D7.1 Website with evaluated 7 FHI Website hosted by ECDC PU M12
tools and information organised by level of care
D7.2 Report on workshop of 7 FHI/AEMP Report on antibiotic stewardship PU M13
models for implementation S implementation models
of stewarship tools (M12)
D7.3 Indicators used for 7 FHI/AEMP Report PU M36
monitoring antibiotic use S
and resistance in humans
and animals
D7.4 Surveillance of antimicrobial 7 SAS Results of pilot study from PU M36
use and resistance in human indicators selected to monitor
antibiotic use and resistance in
humans
D7.5 Surveillance of antimicrobial 7 ANSES Feasibility report for surveillance PU M36
use and resistance in animal system in animals
D 8.1 Awareness and 8 AEMPS Report PU M10
Communication Plan
D 8.2 European Prize: better 8 AEMPS Report: list of competitors, PU M27
journalism report or better agenda of the event, report of
video about antibiotics the prices and winners, report of
the applicants considered and a
short brief of their applications.
D 8.3 European competition with 8 AEMPS Report: list of competitors, PU M32
High Schools students agenda of the event, report of
the winners, report of the
applicants considered and a
short brief of their applications.
D 8.4 Awareness and 1-2-8 AEMPS Report on road map for PU M34
Communication High Level stakeholders with minutes and
Meeting videos available
51 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
D 9.1 National priority-setting 9 INSERM Best practices and routines that PU M34
best practices can be implemented by Member
States to improve the input that
they send to SRA regarding
research and innovation
priorities
D 9.2 Implementation strategy for 9 FHI A concrete strategy for PU M36
EU collaboration implementing multi-country
incentives to stimulate
antimicrobial and diagnostic
innovation
D 9.3 Dissemination strategies 9 INSERM / Policy briefs or other tools PU M36
WP4 FHI publicly available
Short name
Milestone Estimated
Milestone name lead
number date1
participant
MS1.1 Kick-off meeting INSERM M2
MS1.2 The Steering committee and Advisory Boards Forum are set up INSERM M2
Organisation of meetings completed (meeting, agenda & preparatory
MS1.3 INSERM M10, M22
documents)
MS2.1 Communication tool-kit AEMPS M6
MS2.2 Dissemination Plan: intermediate control point AEMPS M7
Layman report: intermediate control point about document design and
MS2.3 AEMPS M30
draft
MS2.4 Final Conference on dissemination: intermediary control point AEMPS M30
MS3.1 Agreement on ETs plan ISS M5
MS3.2 Availability of the web platform with tools to support the monitoring ISS M7
M 6, 12,
Periodic (every six months) check of correspondence between planned
MS3.3 ISS 18, 24, 30,
activities and timetable
36.
MS3.4 Identification of interested stakeholders ISS M6
M2; 13; 25;
MS3.5 Report on quality of the meetings within two months after their conclusion ISS
36
MS3.6 Interim evaluation of JA ISS M19
52 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
MS3.7 Final report on JA impact in Europe ISS M 36
MS4.1 Survey of MS priorities MoH-FR M12
Workshop with SC members on priority goals and integration of JA key
MS4.2 MoH-FR M24
actions into national AMR-HCAI plans
Presentation, discussion and analysis of the outcome of the self-
MS5.1 VWS M10
assessments (workshop)
Workshop on the outcome of the 3 pilot country-to-country assessment
MS5.2 VWS M18
and revision of the tool and methods.
Invitational workshop for the establishment of the network of supervisory
MS5.3 VWS M18
bodies
MS6.1.1.a Results of survey A (national-hospital policy) HCDCP M8
MS6.1.1.b Assessment of cost-benefit study HCDCP M12
MS6.1.2.a Results of survey B (barriers for an effective implementation of an ICP) HCDCP M8
MS6.1.2.b Initial proposed of UICFW HCDCP M14
MS6.1.2.c Evaluation of the UICFW implementation HCDCP M32
MS6.1.3 Initial presentation of the training tools HCDCP M12
MS6.2.1.a Participating hospitals and topics selected per country. FOHM M12
Selected IPC-guidelines and plan for implementation for participating
MS6.2.1.b FOHM M30
hospital(s) in line with national plans.
MS6.2.1.c Implementation work at hospitals established. FOHM M36
MS7.1 Progress check of review procedure FHI M4
MS7.2 Progress check in terms of website FHI M12
MS7.3 Progress check of implementation of stewardship tools FHI /AEMPS M24
MS7.4 Progress check surveillance system AEMPS M15
53 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
MS8.1 Awareness and Communication Plan AEMPS M7
Database // European Webinar and of Science and Health Communication
MS8.2 AEMPS M7/14
researchers (Mass media): control point
Design of promotion activities related to better journalism report or better
MS8.3 AEMPS M14
video about antibiotics
European competition with High Schools students: starting // intermediate
MS8.4 AEMPS M12//M24
control point
Awareness and Communication High Level Meeting: starting // M16//M24
MS8.5 AEMPS
intermediate 1 // intermediate 2 control points //30
Gathering of national approaches to providing input to SRA from at least
MS 9.1 INSERM M18
five countries
Inter-governmental meeting to discuss DRIVE-AB and AMR Review
MS 9.2 FHI M6
recommendations with regards to AMR and HCAI
Recommendation for dissemination of policy briefs or other tools sent to
MS 9.3 INSERM M24
Member States for review
10. PROJECT MANAGEMENT STRUCTURE
10.1. Management structure of the Joint Action (A detailed presentation of the management structure in appendix 1)
The management structure of JA AMR HCAI has been defined to:
• Plan, organize and monitor the effort to achieve the JA AMR HCAI’s objectives within constraints of time
schedule and budget.
• Define clearly the decision making procedures and bodies.
• Run performance control procedures leading to the expected quality of achievements and deliverables
described in the work plan.
• Continually inform the partners on the project status and progress.
• Drive the project implementation in accordance with administrative, financial and legal issues defined by the
European regulations and national peculiarities.
• Guarantee that the rights and obligations of the partners are kept compliant with the Grant Agreement signed
with the Commission and the Consortium Agreement.
A consortium agreement will be signed between the partners to specify the project governance, the internal
organization of the consortium, the management of the project and any other critical aspects such as liability and
confidentiality.
The organisational structure of the consortium will be as follow:
• The Coordinator Marie-Cécile Ploy (INSERM) will monitor the compliance by the partners with their obligations
under the Grant Agreement.
• Work package Leaders will be in charge of managing their Work Package resources and planning. They will
form together the Executive Board (ExB) that provides assistance to the Coordinator for the monitoring of the
action.
• The Joint Action Secretariat (JAS) will assist with the administrative and financial management of the action.
• The General Assembly (GA) will be responsible for the execution of the JA and will take major decisions with
regards to its implementation.
• The Steering Committee (SC) will provide strategic guidance to the GA and the ExB and ensure adequacy
between the JA activities and National Strategies.
54 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
To ensure engagement with relevant stakeholders, a Stakeholders Forum will be set up that will receive periodic
update from the ExB on the Joint Action developments, as well as provide recommendations to the GA.
10.2. Quality of the partnership
All the participants of the JA AMR HCAI have been nominated by the respective MS for their involvement in the
field of AMR and/or HCAI and their capacity to run the activities foreseen in this joint action. The partners are not
only from Ministries but also research institutes (such as INSERM), Clinical centres, Public Health agencies,
Universities or else. This JA will cover all the national specificities of AMR and HCAI as it gathers all EU countries as
beneficiaries or collaborating partners. Moreover, most of the participants have already successfully collaborated
in former or ongoing projects around AMR and HCAI proving the excellence of the Consortium: MoH-FR and INSERM
are involved in the national taskforce on AMR, INSERM is part of JPI AMR and IMI committees, In addition, several
partners are involved in ongoing projects and actions related to the JA major themes. For example, Norway is co-
coordinating the IMI funded DRIVE-AB project to define new approaches for research and development of
antimicrobials; Sweden is currently leading the JPI-AMR board. Finally, some partners (French MoH, Austrian MoH,
…) already cooperate within the Health Security Committee (HSC), one priority of which is antimicrobial resistance.
10.3. Capacity of the staff
1. Coordinator : France - INSERM
The coordination institution is the French National Institute of Health and Medical Research (INSERM), founded in
1964, is a public scientific and technological institute which operates under the joint authority of the French
Ministry of Health and French Ministry of Research
Research at Inserm covers all fields of health research, from basic research to applied research. It is central to the
French health care and public health systems. Today, Inserm coordinates more than 300 research structures
(research units, centres of clinical investigation (CIC)) throughout France and its overseas departments. Amongst
the 13,000 researchers, engineers, technicians and administrative staff working in Inserm laboratories, 5,000 are
permanent employees, more than 2,700 have contractual positions and almost 4,500 have positions in universities,
teaching hospitals or other research organizations. As for results, Inserm is the leading health research institution
in Europe in terms of publications, patent filings and participation in European research programs. Inserm is ranked
2nd amongst health research institutes in the world in publications (roughly 10,000) following the American NIH
(National Institutes of Health). In addition, Inserm and Inserm Transfert are world leaders in innovation in the fields
of life science and human health with good practice and results in terms of technology transfer. In the European
55 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Patents Office’s 2014 listings, Inserm ranks sixth overall among French patent submitters (all sectors). At national
level, INSERM plays a key leadership role in the structuration as it pertains to ensuring greater alignment and
cohesion between health research organizations and funding bodies, to ensure greater uptake and impact of
France’s investments in the health field.
In line with the evolution of antimicrobial resistance in the world, Inserm Institute has encouraged its fundamental
and translational research teams to accelerate research innovation to implement prevention, diagnostic, research
and innovation in the aim to fight AMR and HCAI. Beside, Inserm has organized meetings to favour the combination
of synergistic scientific competences that are an essential factor to stimulate new strategies and perspectives to
fight drug resistance in all its forms. Finally, Inserm has significantly contributed to the elaboration of the French
national plan entitled “Propositions pour une politique de recherche et d’innovation dédiée à la lutte contre la
résistance bactérienne aux antibiotiques ». This plan tackles the burden of antimicrobial resistance by identification
of gaps and an effective proposal of major research and societal challenges in a “One Health” approach, with the
following needs and priorities: improve the understanding of the mechanisms of resistance and transmission,
accelerate the drug discovery, develop efficient diagnostics tools, reinforce information and education for a better
use of antibiotics in human and animals and create a comprehensive network of surveillance system. Globally, the
french national plan and the great expertise of Inserm to head interdisciplinarity program in the field of the health
at national and European level are a roadbed to intend the JA AMR-HCAI actions.
The coordinator: Professor Marie-Cécile Ploy, PharmD, PhD, will coordinate the JA on AMR and HCAI scientific
program. She is a medical microbiologist and head of the clinical microbiology department and infection control
team in the Limoges teaching hospital in France. She also heads an Inserm research team on antimicrobial
resistance. Her main research focuses on genetic elements involved in antimicrobial resistance dissemination and
on biomarkers for early diagnostic of infections and AMR in Intensive Care. She works at the borders of AMR with
a One Health approach. Indeed, she is involved in European/H2020 programs on antimicrobial resistance both in
the environment (PILLS and no PILLS programs, Marie Curie) and in clinics through academic or industrial research
programs, including IMI COMBACTE. In 2015, she was nominated by Inserm to co-lead the research and innovation
group for the French taskforce on AMR. She was the vice-deputy of the Inserm Scientific Committee microbiology-
immunology (2013-2016). She is member of the Inserm institute “Immunology, inflammation, infectiology and
microbiology”, of the French committee for antibiogram and vice-deputy of the antimicrobials section of the French
Society for Microbiology. She is also the coordinator of the French network on the surveillance of resistance and
serotypes of Streptococcus pneumoniae (Observatoires Régionaux du Pneumocoque). She is expert for different
national and international research programs (French expert for the 1st JPI AMR call on therapeutic innovations and
member of the advisory board to elaborate the JPI AMR transmission call). She is the author of 111 peer-reviewed
manuscripts in international journals.
Key staff involved in parallel to the coordinator
Professor Antoine Andremont - M.D., Ph. D. is amongst the leading international experts in the field focused on
the consequences of antimicrobial therapies on the evolution of bacterial resistance and on the occurrence of
nosocomial infections. He is the author of over 140 international publications and has filed 5 patents dealing with
mechanisms of resistance. He is also part of the WHO Advisory Group on Integrated Surveillance of Antimicrobial
Resistance (AGISAR) and the EU Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) as an expert and
a scientific advisor. Evelyne Jouvin Marche- Ph. D, director of research at Inserm, has developed a translational
research focused on the role of the immune cells of the liver in patients infected with hepatitis virus and provided
the root of two patents currently licensed to two companies. She is author of over 135 international publications
and is a partner in European H2020-NMBP project. She is member of “Pôle Chimie, Biologie, Santé “ at University
Grenoble Alpes and director of fundation Finovi which supports research in respiratory diseases and nosocomial
infections. At national level, she is deputy director of the thematic multi-organization institutes “Immunology,
inflammation, infectiology and microbiology” which covers in particular, the emergence of new
epidemics/pandemics and the evolution of antimicrobial resistance. Professor Jean-François Delfraissy - MD, PhD,
is currently Director of the Institute of Immunology, Inflammation, Infectious Diseases and Microbiology (I3M) at
Inserm/Aviesan. This institute brings together research teams working on immunology, inflammation, infectiology
and microbiology. Its challenges are both cognitive and medical. The purpose is to develop multidisciplinary
research combining the clinical approach, microbiology, genomics, molecular and human epidemiology,
56 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
entomology, mathematics and sociology across a broad range of diseases affecting both animals and humans that
can interact in complex ways with ecosystems and social and medical practices. Pr Delfraissy is deeply involved in
research in a range of programmes and therapeutic trials. Olivier Barraud- PharmD, PhD is clinical microbiologists
working with the coordinator and involved in IMI programmes on AMR and HCAI. He develops a translational
research on multidrug resistant bacteria and more specifically on their early diagnostic in critical care patients.
Elodie Pfender – Pharm D, is project manager at the Limoges hospital, France. She is involved in the financial
coordination of European IMI projects. She will guide the project manager who will be hired in WP1.
2 France - MoH
Participant’s institution: The Ministry of Health (MoH) is responsible for ensuring that the population’s health is
assured and protected. Within the MoH, the Directorate General for Health is responsible for the elaboration of
Public Health policies. It elaborates national plans and monitors their implementation together with other
competent bodies (i.e the National public health agencies, Regional health agencies), including the national plans
on antibiotics (since 2001) and for prevention of healthcare associated infections.
Key staff: Prof. Christian Brun-Buisson is a medical doctor trained in Intensive Care. He has been appointed in
February 2016 by Minister Touraine as Ministerial delegate on AMR to coordinate the action of key actors in the
field of AMR. He has a long-standing experience in HCAI and antimicrobial resistance and has been involved in
various European (FP6-FP7) and international projects. Dr Jean-Michel Azanowsky is medical doctor specialist in
Public Health. He is responsible for the national action plan on antibiotics, its steering committee, and monitors
its implementation since the first plan. He has excellent knowledge of the national AMR policy, its strengths and
weaknesses. M. Jean-Baptiste Rouffet is Policy Advisor on European Affairs. Based on his solid experience of Joint
Actions, he initiated the idea of France coordinating the Joint Action to share its experience and benefit from
European cooperation. He is the French representative to the Health Programme Committee and contributed to a
concept paper on AMR detailing the French views in this regard.
3 Austria – GÖG
Participant’s institution: The Austrian Public Health Institute Gesundheit Österreich GmbH has one shareholder:
the Austrian Federal Government, represented by the Federal Minister of Health and Women’s Affairs. One of the
core assets of GÖG is, due to its nature as a think-tank for health care topics, its strong network with both academic
research institutions and public bodies. This is reflected by the fact that GÖG managed and has been managing
several EU projects, some of them with participation from all Member States. We are involved in AMR- and HCAI-
related activities for more than 15 years. GÖG is also involved in WHO or OECD activities.
Key staff: Eva-Maria Kernstock is head of the Austrian Federal Institute for Quality in Health Care (BIQG), a business
unit of GÖG since 2006. She has extensive experience in the field of quality in healthcare, risk-management and
management of patient safety programmes including prevention and control of healthcare-associated infections.
Anton Hlava, who works as epidemiologist at GÖG since 2000, has been working on the issue of prevention and
control of healthcare-associated infections (HCAI) for many years. He has been involved in writing national and
regional health reports, in data management and project management and in projects concerning healthcare
associated infections and antimicrobial resistances in the healthcare sector. Vera Buhmann is a professionally
trained nurse and has studied Health Care Management. She has experience in field of project management of EU
projects and has been working in projects to HCAI and antimicrobial resistances in the healthcare sector.
4 Belgium - FPS HFCSE
Participant’s institution: The Belgian Federal Public Service Health, Food Chain Safety and Environment (FPS Health)
is responsible for policy preparation and execution with a view to guarantee the public health, the safety of the
food chain and a safe environment. Its healthcare department, including its service for patient safety and quality of
care which is also responsible for work on antimicrobial resistance, falls under the responsibility of the Belgian
federal minister for Health and Social Affairs Dr. Maggie De Block.
Key staff: Dr. Greet Haelterman (Federal Public Service Health, Food Chain Safety and Environment) is a medical
doctor and head of the service for quality and patient safety in the Federal Public Service Health, Food Chain Safety
and Environment. She is responsible for the Joint Action on AMR in Belgium. Dr. Ann Versporten is working for the
Belgian Commission for the Coordination of Antibiotic Policy, a Commission which is hosted by the Federal Public
Service Health, Food Chain Safety and Environment and in the past years she was in charge of the data management
for several European projects on antimicrobial consumption. Gilles Van Onacker (Federal Public Service Health,
57 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Food Chain Safety and Environment) studied history and EU-studies and is working as public health official on
patient safety, quality management in healthcare and antimicrobial resistance. Lieven De Raedt (Federal Public
Service Health, Food Chain Safety and Environment) studied political sciences and public management and has 10
years of experience in health policy with a focus on international health policy.
5 Bulgaria – NCIPD
Participant’s institution: NCIPD is a national institution with the status of scientific organization under the Ministry
of Health, which aims to develop the scientific foundations of the fight against infectious diseases and methods for
its implementation. It is where all the specialized Reference Laboratories for diagnosis and management of viral,
bacterial, fungal and parasitic infections are situated. The experts form NCIPD are nominated as focal points on
various infections from the European Centre for Disease Control.
Key staff: Dr. Todor Kantardjiev, MD, DSc, Microbiologist/ Immunologist, President of NCIPD, National Consultant
in Microbiology, exuberant experience with BSL3 pathogens, clinical microbiology and mycology, antibiotics and
therapy of immunocompromised patients. Coordinator of the external quality assessment and surveillance of the
national microbiological lab network. Ivan Ivanov, PhD, Molecular biologist (15 years’ experience), Head of the
Nat. Reference lab for AMR. Development and optimization of molecular techniques, DNA sequencing and
bioinformatics in the field of AMR and HAI. Martyn Nedyalkov, MD, PhD, experience with pediatrics, allergology,
microbiology, antibiotics and therapy.
6 Croatia - HZJZ/CIPH
Participant’s institution: CROATIAN INSTITUTE OF PUBLIC HEALTH (CIPH) is Public health institute on national level
with 120 years of tradition in public health. Its main missions are to maintain and promote health of Croatia’s
population, and promote Public Health Actions on national level. Also, CIPH has obligation to coordinate public
health activities in network of County Institutes of Public Health in all country. Microbiology department in CIPH
has specfic role in public health and performs microbiological activities at professional, scientific and educational
level.Microbiology department is in constant cooperation with the World Health Organization (WHO), and also has
19 national reference centers for cooperation with the European Centre for Disease Control and Prevention (ECDC).
Mycrobiology is organized into five departments: Department for tuberculose diagnostics, Department of
Parasitology and Mycology, Department of Virology, Department of Bacteriology and Department of Molecular
Diagnostics with the unit for intervent diagnostic of highly infectious agents.
Key staff: A microbiologist, medical doctor, with PhD thesis/field of quinolone resistance, 15 years of professional
experience in microbiology, especially in bacteriology and in the antimicrobial resistance (AMR) , abroad experience
, fluent knowledge in English. Two engineers of laboratory diagnostics, with 15 years of professional experience
in microbiology, especially in the AMR, and hospital infections, having also a high command of English, high IT
knowledge in managing of applied microbiology in primary health care units (PHCU). Financial officer – with 4 years
of experience in financial administration and preparation of financial reports, internal and external, experience in
Co-ordination and project management tasks. Administrative officer – experience in administrative work on
projects as support to project management staff, tasks implementation and coordination.
7 Czech Republic – NIPH
Participant’s institution: NRC-HAI and NRL for ATB are core structures within CEM of the Czech NIPH (CCB for ECDC).
NRC HAI is responsible for coordination of HAI surveillance, education and training of IC professionals,
implementing hospital IC/ABS programmes and creating IC guidance at the nat. level. NRL for ATB concentrates on
epidemiologic surveillance of AMR in national, and international projects, is responsible for a national coordination
of EARS-Net and participate in Czech National Antibiotic Programme.
Key staff: Professional at clinical microbiology, antimicrobial stewardship, hospital epidemiology, infection
prevention and control, experienced in EU projects (ABS International, IPSE), NFP for HAI (ECDC), recent activities
focused on implementing hospital programmes on prevention and control of infections, local – national – European
surveillance of HAI, training on IC/hospital hygiene professionals (European core competencies). Professional at
hospital epidemiology, hospital hygiene, experienced in EU projects IPSE, TRICE-IS. Professional in medical
microbiology with experience in surveillance of antibiotic resistance, in methods of detection of antibiotic
resistance, and molecular epidemiology of antibiotic resistant bacteria. An applicant is in charge of Czech working
Group on Monitoring Resistance, and is a national coordinator of EARS-Net (ECDC), is a member of EARS-Net
Disease Network Coordination Committee, and Czech NFP for AMR (ECDC).
58 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
8 Denmark – SSI
Participant’s institution: Statens Serum Institut (SSI) is internationally recognised as the Danish National Public
Health Institute for Infectious Diseases. SSI is responsible for research-based health surveillance and analysis, as
well as the prevention and control of infectious diseases, biological threats and congenital disorders.
Key staff: Brian Kristensen, MD, PhD: Head of National Center for Infection Control, Denmark: a microbiologist
with 20 years of professional experience within antibiotic use and infectious disease epidemiology. Ute Wolf
Sönksen, MD: Project-manager of the Danish One-Health project, DanMap: microbiologist with 10 years of
professional experience within antibiotic use and infectious disease epidemiology. Sissel Skovgaard, MD, PhD:
Project-manager of the national Danish collaboration on surveillance of antibiotic-resistance (e-Res): microbiologist
with 5 years of professional experience within antibiotic use and infectious disease epidemiology. Mikkel Lyndrup;
Int. M.Sc. in Economics and Business Administration, part of SSI´s Executive Office, which supports researchers with
external funding issues and Grant Management. His role will be to support the allocated staff in Administrative
matters.
9 Estonia – TA
Participant’s institution: Terviseamet (Health Board) is a governmental institution and the competent authority for
surveillance, prevention, and control of communicable diseases, risk analysis in epidemiology.
Key staff: An infectionist with a university degree in medicine (residency -infection diseases) and 10 years
experience in infection control (hospital level) incl. participation in international projects (HCAI, AMR, AB
stewardship). 5 years experience at national level (HCAI in ICU, SSI, PPS). Excellent command of English. Project
manager, university degree in chemistry, more than 15 years of experience of managerial work, national
coordination of international projects (several Transition Facility projects, ENHIS-2, SINPHONIE, QUANDHIP,
EMERGE). Excellent command of English.
10 Germany – RKI
Participant’s institution: The Robert Koch-Institute (RKI) is the German federal institution for disease control and
prevention, and provides national and European reference diagnostics, surveillance and management plans for
communicable diseases. RKI runs national surveillance systems for antibiotic use and resistance, and hosts the
Commission for Anti-Infective Drugs, Resistance and Therapy (ART), the Centre for the Prevention and Control of
Antibiotic Resistance, and it is broadly linked to European and international health institutions.
Key staff: an epidemiologist with a university degree in medicine and more than 3 years of professional experience
in infectious disease epidemiology
11 Greece - HCDCP
Participant’s institution: HAIs and Antimicrobial Resistance Office of HCDCP is responsible for the implementation
of the national strategy for the fight against AMR in healthcare settings as also for the AB use in ambulatory sector
(surveillance at national level, professionals training programs, research, guidelines, and national focal point in
ECDC for HAIs and AB consumption). Additionally, HAIs/AMR Office has a key role in the formulation of the Greek
national action plan for AMR according to EU and WHO requirements.
Key staff: The staff will participate in the performance of WP6 and WP7 includes professionals with the followings
specialties: The scientific manager of the project is the head of HAIs and AMR Office-HCDCP, an Infectious disease
specialist (MD,PhD) with specific experience in AMR issues at national and European level, responsible for the
monitoring of the national surveillance, guidance and training of health professionals . The leading team includes
also infectious diseases and infection control specialists, infection control nurses with significant experience in
Infection Control Committees, intensivists specialized in infection control in ICUs. Additionally, there is an
epidemiologist with at least 5 year professional experience in public health and also a biostatistician. The technical
stuff includes a data manager and administrative support from professionals dedicated EU programs.
12 Greece - ESDY- NSPH
Participant’s institution: ESDY/NSPH has long experience in AR epidemiology including electronic surveillance (see
www.mednet.gr/whonet), detecting newly-emerged resistant genes, and (molecular) typing. Also there is
increasing experience in communication and collaboration with the veterinary institutions in Greece in setting up
common databases and assessing the spread of (AR) bacteria among the two departments (human and veterinary).
59 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Key staff: Our team include a medical microbiologist (MD PhD) with long (20 years) experience in AR epidemiology
including setting up electronic surveillance systems international collaboration (WHO, EU), identifying new AR
genes, and molecular typing. Also in setting up collaboration with veterinary institutions to follow AR in Greece. A
Biologist (PhD) who plays a leading role in studying the molecular mechanisms of AR and the dissemination of
resistant genes and bacteria in Greece for the last 15 years. A veterinarian (DVM, PhD) who has a leading role in
Greece in implementing the One Health approach in relation to zoonotic diseases. All staff have experience in
running FP7 project and a high command of English
13 Greece – 7th HR CRETE
Participant’s institution: The 7th Health Region Crete is the tactician vector control and management of the
National Health System at the Region of Crete. The 7th HR will work in close cooperation with the Medical School of
the University of Crete. The staff participating in the joint action on its behalf is highly qualified and experienced in
administrative, scientific, technical and research terms, presenting active work in the international bibliography.
Key staff: The project management will be carried out by a project manager with a relevant university degree and
experience in managing projects at national or EU level, having also a high command of English. The team will also
include highly qualified infection control specialists with at least 3 years of hospital experience, a medical statistics
specialist with academic experience, a molecular microbiologist with academic experience and an infectious
diseases specialist with additional expertise on infection control and more than 20 years of European experience,
active bibliography and participation in projects.
14 Italy – UNIFG
Participant’s institution: The Unit of Hygiene of the University of Foggia is taking part in drafting the Italian Plan on
AMR, drawing the section on “awareness raising and communication”. Close connected to the Italian Ministry of
Health and the Istituto Superiore di Sanità, the Unifg team has participated in several national and European
initiatives on HCAI and AMR surveillance, control, and prevention (e.g., ESAC-3 NH project 2008, HALT project 2009-
2010, ECDC PPS-ICA 2016-2017).
Key staff: The head of the Unit is a medical doctor specialized in Public Health, epidemiologist, full professor of
Hygiene, with approximately 20 years of professional experience in infectious disease and chronic disease
epidemiology, leading a team of 12 persons, chief of a Public Health Department, managing most of the
epidemiological activities at Apulia regional Health Authorities, with >15 years of experience in coordinating
research projects in public health field, having a high command of English. The other key staff member is a medical
doctor, specialized in Public Health, PhD in Oncology, epidemiologist, assistant professor of Hygiene, with 10
years of professional experience in infectious disease and chronic disease epidemiology, working in the same Public
Health Department and serving as epidemiologist at the regional Public Health Authorities, with >5 years of
experience in managing research projects, having high command of English.
15 Italy – ISS
Participant’s institution: ISS is the leading technical and scientific body of the Italian National Health Service. Its
activities include research, surveillance, training in public health, advice and consultation, with a special multi-
disciplinary approach and integration between the human and the veterinary field. ISS is engaged in several national
and international projects including EU-funded projects and has a long standing experience in AMR, coordinating
the national surveillance and research projects on this issue.
Key staff: Annalisa Pantosti a specialist in Infectious Diseases, and is in charge of the national program for the
surveillance of antibiotic resistance and AMR Focal Point at ECDC. She leads a research group with expertise in
antibiotic-resistance surveillance and molecular epidemiology. Dr. Alessandra Carattoli, PhD, Molecular
Microbiologist, leads projects on innovative typing methods and genomics for detection and control of AMR
bacteria. She served as Italian Member Board at the JPI-AMR. Dr. Patrizio Pezzotti, statistician and epidemiologist,
has more than 25 years of experience in statistical analysis, infectious diseases epidemiology, surveillance and
public health. Dr. Luca Busani is a veterinarian epidemiologist for the evaluation of public health priorities in regards
to risk assessment and surveillance for zoonoses
16 Latvia - PSKUS
Participant’s institution: PSKUS is a leading terciary teaching hospital and leading biomedical research institution
in Latvia. European antimicrobial resistance surveillance system (EARSS-Net) and European Surveillance of
Antibiotic-Consumption (ESAC-Net) have been coordinated by the researchers from the PSKUS from the very start.
60 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Hospital have also participated in European Comission supported intervention projects that all were focusing on
the spread of multidrug resistant microorganisms in hospital setting.
Key staff: The research team in Latvia includes medical practitioners with a particular focus on infectious diseases
and an extensive involvement in setting up local, national and international infection control policies. Uga Dumpis
has been working in the field of antimicrobial resistance for more than 15 years with a particular interest in the
spread of multidrug resistant microorganisms in the hospitals and antibiotic stewardship. He has lead Latvian
Nosocomial infection study group, was the lead investigator in the Latvian study site for three multicentre
intervention projects. Epidemiologist Elina Dimiņa has completed her PhD in 2014 on point prevalence studies in
Latvian Hospitals. Medical doctor Alise Grāmatniece has been working on A. baumannii spread and containment
in neonatal intensive care unit. She will enter her PhD work during the project. Infection control nurse Jelena
Urbena has been coordinating infection control activities in the PSKUS.
17 Lithuania - LSMULKK
Participant’s institution: The Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos is the
largest healthcare institution in Lithuania, it has 37 departments devoted to all medical and surgical specialties, 8
intensive care units, 2 300 hospital beds. We could contribute in WP6: implementation of the infection control
policies at hospital level, expanding tasks to non-EU countries, improving the training of health professionals and
WP7: to take part in developing and testing near real time surveillance of antimicrobials and multidrug
resistant bacteria.
Key staff: Astra Vitkauskiene – MD, PhD, Professor, clinical microbiologist, the head of Laboratory Medicine
Department, over 20 years of experience in consulting and forming politics of antimicrobial usage in tertiary health
care hospital, the research field – multidrug resistant bacteria (Pseudomonas aeruginosa, Acinetobacter and ect.)
Asta Dambrauskiene – MD, physician of Laboratory Medicine, PhD student, the head of Infection Control Service,
10 years of experience in clinical microbiology, the head of hospital infection control group in hospital. Lukas
Cemnalanskis – MD, the resident of Laboratory Medicine, takes part in researches with multidrug resistant bacteria,
risk factors and their impact on infection diseases.
18 Lithuania - VULSK
Participant’s institution: VULSK is the biggest hospital in Lithuania with 1200 beds, 4 ICUs. Has experience in MDR
infections. Hospital has capacity to work in several tasks of WP6: implementation of the infection control policies
at hospital level, expanding tasks to non-EU countries, improving the training of health professionals,
microbiological and molecular testing as part of epidemiologic surveillance organized by partner NVSC.
Key staff: Edita Kazenaite – MD, PhD, clinical pharmacologist, representative of the hospital administration, 15
years professional experience in regulating antimicrobials usage in the hospital. Silvija Kiveryte – MD, PhD, head
of laboratory of microbiology, 15 years professional experience in clinical microbiology, molecular diagnostics of
infectious agents, 10 years of pedagogical work with students and hospital staff. Ruta Ambrazaitiene – MD, senior
physician of laboratory medicine, 20 years professional experience in diagnostic microbiology and MDR, HAI
surveillance group in hospital. Asta Macioniene – MD, physician of laboratory medicine, 9 years professional
experience in diagnostic microbiology, participation in AMR surveillance networks (EARS-Net, BARN). Kristina
Marcinkeviciene - MD, physician of laboratory medicine, 8 years professional experience in diagnostic
microbiology, participation in AMR surveillance networks (EARS-Net, BARN). Project manager - 5 years experience
in managing different projects in hospital, will be a key staff member in WP2
19 Lithuania - HI
Participant’s institution: Institute of Hygiene (HI) is responsible for planning, coordination and implementation of
different activities related to antimicrobial resistance (AMR) and healthcare associated infections (HCAI) on national
level: (i) coordinates national surveillance of antimicrobial consumption and HCAI and provides data to European
Centre for Disease Prevention and Control networks ESAC-Net and HAI-Net; (ii) was responsible for elaboration and
coordination of previous national HCAI and AMR programs and currently is involved in preparation of national AMR
strategy; (iii) coordinates the activities of regional AMR management groups; (iv) organizes annual European
Antibiotic Awareness events.
Key staff: An epidemiologist with PHD (in healthcare-associated infections) and more than 20 years professional
experience in AMR management and healthcare-associated infections surveillance, experience in project
management, participation in international and national projects, postgraduate training, national contact person
61 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
for AMR (ECDC). A public health bachelor (in healthcare-associated infections) and more than 5 years professional
experience in antimicrobial consumption surveillance, national coordinator of regional antimicrobial resistance
management groups, participation in international projects, national contact person for ESAC-Net (ECDC).
20 Lithuania - NVSC
Participant’s institution: Lithuanian National Public Health Centre (NVSC), is institution that has 10 regional
departments and is responsible for coordination of activities of antimicrobial resistance (AMR) management groups
in every Lithuania’s district. NPHC is responsible institution for identifying and dealing with antimicrobial resistance
and antimicrobial agents’ consumption problems in every district, submitting proposals to interested institutions
about AMR monitoring and control.
Key staff: Designated Manager is administration staff with a Master university degree in public health and a half of
year of experience in managing Joint Action at national level, having a high command of English. Other designated
staff: a) 2 chief district epidemiologists, doctors of hygiene and epidemiology with a university degree in medicine
and at least 20 years of professional experience in infectious disease epidemiology (at least 1 year in managing
antimicrobial resistance (AMR) groups activities); b) doctor of hygiene and epidemiology with a university degree
and at least 10 years of experience in public health inspections of health care institutions; c) public health specialist
with a university degree, at least 3 years of professional experience in infectious disease epidemiology (at least 3
year in managing antimicrobial resistance (AMR) groups activities) and at least 5 years of experience in coordinating
Joint Action at national level. All designated staff have also a high command of English.
21 Netherlands – VWS
Participant’s institution: The Dutch Ministry of Health, Welfare and Sport is the national authority responsible for
the coordination of the One Health AMR policy in the Netherlands, in close cooperation with the Dutch Ministry of
Economic Affairs. International collaboration has been a priority in the Dutch approach. The Ministry of Health is
involved in several international and bilateral initiatives related to AMR. The Health Care Inspectorate (IGZ) and
the Dutch Institute for Public Health and Environment (RIVM) are part of Ministry of Health, Welfare and Sport.
Key staff: The multidisciplinary team of the Dutch Min. of Health includes professionals from the departments of:
International affairs (IZ): a coordinator/senior advisor AMR with degree on veterinary medicine, agricultural
engineering and food technology and post-doc degree in veterinary public health, with 20 years’ experience on
the field of public health and food safety in 3 Member States and 4 years’ experience at the EC as policy officer
AMR/coordinator of the EU Action Plan against AMR (2011-15); Public Health (PG): 2 senior policy officers AMR
with degree on public health and bioprocess technology, with international experience and responsible for the
Dutch One Health National Action Plan on AMR (2015-20). Health Inspectorate (IGZ): a manager, trained as
immunologist, responsible in NL of the supervision of infection prevention and control and AMR in all health care
settings and member of the Dutch National Healthcare Council. NL National Institute for Public Health (RIVM): a
biologist and clinical epidemiologist with specialisation in infectious diseases, policy advisor for AMR and
coordinator of international AMR activities. Medicines and Medical Technology (GMT): a policy officer responsible
for Innovation with a degree on biomedical Sciences. Communication (DCo): a project leader Communication,
responsible for the communication strategy and multimedia communication campaigns in the Netherlands.
22 Norway – Hdir
Participant’s institution: Executive agency and professional, regulatory and implementing authority under the
Ministry of Health and Care services. Responsible for developing, revising and implementing clinical guidelines for
use of antimicrobials in human health. Responsible for coordinating implementation of national action plan against
antimicrobial resistance in Norwegian health care services.
Key staff: Senior adviser, MD from the University of Oslo (1982); Specialist in General Practice from 1990. Since
2012 responsible for infectious diseases at the department of Community Health Services and for the Norwegian
guidelines for antibiotic use in General Practice at the Norwegian Directorate of Health. Senior adviser with MSc in
pharmacy and MSc in Molecular biology of infectious diseases and 4 years of professional experience in
implementing policies and interventions in health care services, including clinical guidelines and action plans against
antimicrobial resistance.
23 Norway – FHI
Participant’s institution: The Norwegian Institute of Public Health (NIPH) is a subordinate institution to the
Norwegian Ministry of Health and Care Services. NIPH acts as a national competence institution for governmental
62 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
authorities, the health service, the judiciary, prosecuting authorities, politicians, the media and the general public.
The institute’s responsibilities include infectious disease control and research.
Key staff: An MD PhD with experience working with AMR both in terms of control and interventions. An MD
researching for her doctorate the impact of responsible use on antibacterial innovation and access. A policy expert
with a university degree in business and doctorate focused on innovation models, experience working across
healthcare sectors including national health services, industry, and more. A pharmacist with experience in
multinational financing and coordination, currently researching policies to link antibacterial innovation to
stewardship and access.
24 Norway – NVI
Participant’s institution: NVI is a biomedical research institute with research, preparedness, diagnostics,
surveillance, scientific advisory and risk assessment as the most important areas of operation. The institute is
Norway’s leading centre of expertise on antimicrobial resistance and usage within the veterinary sector, is
designated as National Reference Laboratory for antimicrobial resistance and coordinates the Norwegian
monitoring program for antimicrobial resistance in the veterinary sector (NORM-VET).
Key staff: The staff at the Norwegian Veterinary Institute (NVI) that will be involved in the action consist of scientists
with various complementary backgrounds within veterinary antimicrobial usage and resistance, microbiology,
bacteriology, molecular microbiology, epidemiology, bioinformatics, food safety, surveillance, method
development, veterinary medicine and veterinary public health. These staff members have been active in
development and implementation of the Norwegian strategy and action plan against AMR in the veterinary sector.
Additionally, many of these staff members are part of the NVI AMR research group currently involved in several
AMR research and development projects.
25 Poland - NMI
Participant’s institution: National Medicines Institute located in Warsaw, Poland is involved in control, legislative
and research activities. Department of Epidemiology and Clinical Microbiology who will be responsible for Joint
Action on AMR and HCAI has long time experience in leading the National Program for Antibiotic Protection based
on One Health concept and EU recommendations, and cooperate with ECDC in coordination of EARS-Net, ESAC-Net
and part of HAI-Net in Poland.
Key staff: Clinical microbiologist with the professor title in medicine and more than 10 years’ experience in leading
the National Program for Antibiotic Protection and the main author and editor of the based on EBM national
antibiotic treatment guidelines. Clinical microbiologists with the university degree in medicine or biological science
and more than 5 years’ experience in clinical microbiology, epidemiology and antimicrobial resistance surveillance
or healthcare associated infections surveillance. Public health professionals with the university degree and more
than 5 years professional experience and involvement in the tasks of the National Program for Antibiotic Protection,
including antibiotic consumption surveillance and public campaigns on prudent use of antibiotics.
26 Portugal – DGS
Participant’s institution: The Directorate-General of Health (DGS) is a public body of the Portuguese Ministry of
Health that positions itself as a reference for all those who think and operate in the healthcare field. Among its
main areas of activity are to issue clinical and organizational guidelines and to guide and develop programs related
to public health issues. PPCIRA is the DGS program for IPC & AMR, responsible for defining and implementing
strategies and monitoring results in both fields of HAI and antibiotic use.
Key staff: Paulo André Fernandes – Physician, Intensivist, MasterD in HAI, director of national program for IPC
&AMR; field work in ES, IPC & AMR. Carlos André Palos - Physician, Intensivist, member of IPC&AMR national
program coordination, Postgraduate in HAI, university lecturer , field work in ES, IPC & AMR Pedro Pacheco –
Physician, General Practicioner, member of IPC&AMR national program coordination, field work in ES, IPC,AMR.
Ana Paula Cruz – RN Specialist, MasterD in HAI, member of IPC&AMR national program coordination, field work
in ES, IPC&AMR. Margarida Valente - RN Pediatric Specialist, Postgraduate in HAI, member of IPC&AMR national
program coordination, field work in ES, IPC&AMR. Isabel Neves - Physician, Infecciologist, member of IPC&AMR
national program coordination, field work in ES, IPC, AMR.
27 Romania – UMPIH
Participant’s institution: The UMPIH is an educational health research unit operating with clinical settings, being
one of the leading research institutions in Romania that also integrates educational programs. Our activities develop
63 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
mainly in clinical units and include, among others, clinical and experimental studies at a national and international
level and active contribution to public health programs. The institution lead a JA project, conducting the Evaluation
WP (CANCUN project).
Key staff: CR, MD, PhD from UMPIH has extensive experience in conducting clinical research projects in Romania.
He won and lead 4 national projects regarding screening programs for malignancy and was also member in 6 others.
MD, MD, PhD is the head of the department which provides clinical and experimental support for developing
research projects. He has extensive experience in coordinating and managing public health research and capacity
building projects. He coordinated 4 national and international projects with a strong focus on clinical aspects. IC,
MD, PhD conducted several clinical studies and his focus is on developing international health networks and
capacity building in Eastern Europe. MA, MD, PhD has experience in financial and technical reporting for research
and will conduct financial management and prepare financial reports.
28 Slovenia – NIJZ
Participant’s institution: NIJZ is the central Slovenian institution for public health in the areas of communicable and
non-communicable diseases, health promotion, health protection, health system research, national coordination
of preventive programmes in primary health care and health statistics. NIJZ is organised as a central unit and nine
regional units and employs over 400 staff members. NIJZ has participated in many international projects and
successfully coordinated EPAAC JA, PARENT JA and CANCON JA.
Key staff: Marija Magajne (F) is medical doctor with specialization in epidemiology and master in management.
She coordinated PARENT JA and has been actively involved in other JAs and projects. Jana Kolman (F) is a specialist
in clinical microbiology with university degree in medicine, with professional experiences in AMR and HAI for more
than 10 years – coordination of EARSS/EARS-Net in Slovenia from 2000 and active involvement in HAI prevention,
control and epidemiology. Maja Šubelj (F) is a medical epidemiologist with a PhD in Biomedical Sciences and 6
years of professional experiences in Infectious Disease Epidemiology, with diploma in European Program for
Intervention Epidemiology Training (EPIET) governed by the ECDC. Mojca Serdt (F) is a microbiologist with
university degree and 5 years experiences in HCAI epidemiology, being partly involved in one JA (CanCon).
29 Spain – AEMPS
Participant’s institution: Spanish Agency of Medicines and Medical Devices (AEMPS) mission is to give guarantees
to the general public on quality, safety, efficacy and accurate information on medicines and medical devices from
research to end use, to protect and promote health. AEMPS is leading and coordinating the National Action Plan on
Antimicrobial Resistance (PRAN) together with the collaboration of six Ministries, all the Spanish autonomous
communities, universities, and professional societies, associations and organizations.
Key staff: A Professional Expert with high knowledge about the JA matter. A WPs Manager with a relevant
university degree, some knowledge in Public Health and antibiotic resistance, experience on managing projects
including high English level. A Communication Officer with university degree and experience in developing
international Conferences, social networks management, and interactions with international organizations and also
experience in coordinating communication strategies and content generation. A Communication Officer with
university degree and experience in European projects dissemination, meetings organization, online and traditional
campaigns. A Webmaster with relevant experience in managing websites. A Managing Assistance with experience
in information management with international organizations, budget coordinating and controlling, and supporting
other managerial, administrative and financial services.
30 Spain – GENCAT
Participant’s institution: Departament de Salut (DS) – Generalitat de Catalunya has exclusive competences in the
field of health in its region. Through a network of healthcare professionals (in all health system areas), DS has
implement the “Best Practices” in Patient Safety.
We have wide experience in the coordination and implementation of different projects of prevention of HCAI-
associated AMR, also in the appropriate use of antimicrobials in health care.
In addition, DS has been working for more than 10 years in the surveillance of organisms with specific AMR
problems and develops a standardized monitoring of hospital antimicrobial consumption.
Key staff: The group is integrated of different discipline members: Medical Doctor, specialist in Preventive
Medicine and Public Health, with experience in Healthcare Research and assessment of health services. Medical
Doctor, specialist in Infectious Diseases, with experience in Clinical Research in Infectious Diseases and
64 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Antimicrobial Therapy Antibiotic Stewardship. Medical Doctor, specialist in Preventive Medicine and Public Health
and epidemiology, with experience in the field of patient safety. Medical Doctor, specialist in General Practitioner
Medical, with experience in methodology in Expert Quality in Healthcare Quality and Policy. Pharmacists, with
knowledge in appropriate use of antimicrobial, antimicrobial resistances, etc.
31 Spain – IdISBa
Participant’s institution: Conselleria de Salud (Regional Ministry of Health) from the Government of the Balearic
Islands has exclusive competences in the field of health in its region. It takes responsibility for the correct
implementation and achievement of the JA activities and it delegates the financial management to the Health
Research Foundation of the Balearic Islands Ramon Llull (FISIB).
Key staff: The current General Manager of “Planning, Evaluation and Pharmacy” with a degree in law, master
degree in legal practice and nine years of professional experience in health management, having also a good
command of English and French. An Official of Service of Health Planning of the Consejería de Salud. A pediatrician
with a university degree in medicine. Master in economics of health and health management.
32 Spain –FFIS
Participant’s institution: The Foundation for Health Research and Training in the Region of Murcia (FFIS) is a public
nonprofit organization constituted by the Autonomous Community Region of Murcia. The General Direction of
Planning, Research, Pharmacy and Care for Citizens (DGPIFAC) depend of the Regional Ministry of health is
responsible for regional health planning of health services and management and development of pharmaceutical
care in the law on Pharmacy of the Region of Murcia, planning and coordination of strategies for the development
of a comprehensive drug policy. ServicioMurciano de Salud (SMS), depending directly on Ministry, is a public entity
responsible for the provision of health care to citizens, in the different levels of care, Primary Health Care,
Specialized Healthcare.
Key staff: PhD in Medicine. Primary Physician and Preventive Medicine and Public Health. Currently Director
General of Planning, Research, Pharmacy and Citizen of the Ministry of Health of the Region of Murcia (Spain)/
Bachelor of Pharmacy. Specialist in Clinical Analysis, Graduated in Tropical, Parasitic Diseases. Certificate of Business
Management in Health organizations. current Deputy Director General of Pharmacy and Research/PhD
Pharmacology PharmD, Health Inspector, Drug Information and Evaluation Centre, Pharmaceutical Management
and Care Services/ Master Degree in Public Health, Project Manager in 4 European projects, Research in Health/
BSc in Pharmacy, Senior technical research in strategic programs of Rational Use of Medicines for 8 years and
Coordinator of the Program of Responsible Use of Antibiotics in Early Childhood at the Ministry of Health of the
Region of Murcia/ Two Pediatrician advisers of the Program of Responsible Use of Antibiotics in Early Childhood in
Primary Care and hospitals. Researchers in the area of biomedical data quality and construction standards.
Experience in Hospital Management for 15 years, Master in Management of Health Services, Master in Health Law
and Bioethics, an expert in High Direction/ Nursing BA in Anthropology. PhD in Health Sciences. Researcher on
health Experience in early development and implementation of health programs and clinical guidelines and
collaborator in Use of Antibiotics in Early Childhood.
33 Spain – FMS
Participant’s institution: NavarraBiomed-Fundación Pública Miguel Servet, carries out research in health sciences
in the framework of the objectives and priorities of the Health Department and the Health Plan of the region
Navarre in Spain. Its objectives include promoting research through the creation and maintenance of human teams
and stable lines of research, guaranteeing them basic equipment and adequate infrastructure. It also manages the
banks of biological material of Navarre.
Key staff: The team consists of the following members: One specialist in clinical microbiology, with an university
degree in medicine with over 15 years’ experience in clinical microbiology, and specifically in the areas of
antimicrobial resistance, tuberculosis, STD and primary care microbiology. One specialist in clinical microbiology
with an university degree in medicine with specific training in infectious diseases for 5 years, with a doctorate in
microbiology with professional experience of over 20 years in clinical microbiology and infectious diseases,
specifically in the areas of bacteremia, infection control, antimicrobial resistance, molecular microbiology. Both are
involved in national and European research projects on flu, pneumococcus, tuberculosis, fungal infections, and
prosthetic joint infections.
34 Spain – SAS
65 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Participant’s institution: Servicio Andaluz de Salud or Andalusian Health Service (SAS) is an autonomous public
body attached to the Ministry of Health from the Government of Andalusia. Its mission is to provide public health
care to the citizens, seeking for quality and efficient use of resources. SAS has a network of integrated care services
and is organized to ensure the accessibility of the population, including 1,491 primary care centers, 29 hospitals
and 84.706 employees. Departments involved in the proposal include Infectious Diseases from Hospital
Universitario Virgen del Rocio (HUVR). Besides, research at HUVR is managed by FISEVI foundation. FISEVI is a
Foundation created in order to handle the administrative/financial tasks of the beneficiary. FISEVI is a legal entity
which is in charge of the financial administration of the beneficiary.
Key staff: José Miguel Cisneros Herreros is Chief of the Infectious Diseases Department in Hospital Universitario
Virgen del Rocio in Sevilla. He was the project coordinator of MagicBullet "Optimisation of treatment with off-
patent antimicrobial agents of ventilator-associated pneumonia" (FP7-HEALTH-2011 - 278232) and is currently
involved in COMBACTE-Care IMI project, as National coordinator for clinical studies (trial REJUVENATE). Jose Miguel
Cisneros has conceived and implemented at regional level the institutional programm of the Andalusian Health
Service approved in February 2013 called PIRASOA to better antibiotics use strategy.
35 Spain – ISCIII
Participant’s institution: The Instituto de Salud Carlos III (ISCIII) is the national body offering technical and scientific
support to the National Health System and public health. ISCIII hosts the national reference centres for public
health, including inter alia microbiology and epidemiology. ISCIII also runs the national health research programme
and is member of the Joint Programming Initiative on Antimicrobial Resistance. ISCIII coordinates the Joint Action
CHRODIS and will coordinate the new JA on chronic diseases.
Key staff: Carlos Segovia is family physician and master of public health. He coordinates Joint Action CHRODIS. He
is Chair of the Joint Programming Initiative on Antimicrobial Resistance, and has ten years of experience in European
public health and research programmes, including three Joint Actions. María José González de Suso, MD, is Spanish
National Focal Point for EU Health Programme, PhD on Medicine and Master on Research and Innovation on Health
Sciences. She has been research team leader in different RTD departments in hospitals and pharmaceutical
industries. José Campos is head of the reference antibiotic lab and Resistance programme of the National Centre
for Microbiology. He is MD, clinical microbiologist, Spanish coordinator for EARSS and ESAC programmes of ECDC,
and for TATFAR. Carmen Varela is epidemiologist working in the area of epidemiologic surveillance. She has been
working for several years at the Public Health Capacity and Communication unit of ECDC.
36 Spain – SERMAS
Participant’s institution: Our institution, Assistant Direction of Pharmaceutical Management, is a public
organization, part of the Health System of the region of Madrid, dedicated to the pharmaceutical management.
Among its functions it is to promote the application of criteria for the rational use of medicines in primary care and
hospitals and works in coordination with other organizational structures of the health system. It is the coordinator
of the antibiotic´s policy.
Key staff: Pharmacist with several years of experience as Assistant Director of pharmaceutical management. She is
the president of the commission of Central antimicrobial policy. The Director of the Foundation for Research and
Biomedical Innovation Primary Care. Two Hospital pharmacists who work in the Assistant Direction of
Pharmaceutical Management with experience in the coordination work teams. One of them also worked for 5 years
in primary care and was coordinator of a guideline of antimicrobial use.
37 Sweden – FOHM
Participant’s institution: In April 2016 the Unit for Antibiotics and Infection Control at the Public Health Agency of
Sweden (PHAS) was designated as a WHO Collaborating Centre for Antimicrobial Resistance Containment that aims
to develop the strategic direction of global AMR containment with focus on implementing surveillance. The unit
has collaborations with India, China and the Baltic Sea region, and multilateral collaborations with European and
international organisations, such as ECDC, WHO and ReAct. PHAS has a national responsibility for public health
issues and works to ensure good public health. The agency also works to ensure that the population is protected
against communicable diseases and other health threats.
Key staff: A project leader with a university degree in medicine or similar and 5 years of professional experience
in infection control. Experience in international project management. A senior MD specialised in clinical
microbiology with 15 years of professional experience with focus on AMR. 5 years´ experience of leading
66 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
international multicentre improvement projects within the field of infection prevention and control. A pharmacist
with a PhD in the area of antimicrobial resistance and 5 years professional experience of policy work within
infection control and antibiotic stewardship.
38 Sweden – SoS
Participant’s institution: The National Board of Health and Welfare is a Swedish governmental institution
responsible to produce and develop statistics, regulations and knowledge for the Government and those working
within health and medical care and social service. Knowledge is produce in a number of areas such as patient safety
which includes basic hygiene in the Swedish health service to prevent hospital acquired infections and thereby
lower antibiotic consumption.
Key staff: From the National Board of Health and Welfare one senior employee with a PhD- degree in Clinical
Bacteriology is going to participate in the Joint action project. The participant has professional experience in
research related to AMR and infectious diseases both on a national and international level. Previous experience
working on a three year EU finance project between Europe and India can be noteworthy. The participant has
experience from pharmaceutical industry and 6 years’ experience in public service.
39 Sweden – SBA
Participant’s institution: The Swedish Board of Agriculture (SBA) is the Government's expert authority in matters
of agri-food policy, and is responsible for the agricultural and horticultural sectors. SBA is a legislative authority and
the risk manager regarding animal health including spread of AMR. SBA report sales statistics regarding veterinary
drugs and manages the reporting framework regarding use of veterinary drugs. The SBA together with the Public
Health Agency have since 2012 a government mandate to coordinate the work on containment of antimicrobial
resistance.
Key staff: At the Swedish Board of Agriculture, the Department of Animal Welfare and Health there are about 100
persons employed and a majority of the staff have a university degree. There are for instance lawyers, economists,
agronomists, biologists and about 30 veterinarians. Of these mainly 6-8 persons are involved in the work on AMR,
all of those with university degree in veterinary medicine and with more than 5 years of professional experience of
animal contagious disease control (including AMR) and epidemiology. Most involved are one person with 15 years
professional experience related to veterinary drugs and AMR issues, one person with 8 years professional
experience on AMR issues and one person with 30 years’ experience from microbiology, veterinary public health
and contagious disease control. At the SBA there are also competence in contingency planning and comprehensive
investigations.
40 Sweden – NFA
Participant’s institution: The National Food Agency (NFA) is a Swedish national authority with the responsibility for
safe and healthy food and drinking water. From a safe food perspective this includes chemical and biological hazards
such as pharmaceutical residuals and antimicrobial resistance, which has been a prioritized area since the last five
years.
Key staff: NFA has an internal working group on AMR including two microbiologists, three risk assessors, three risk
managers and a risk communicator. The team members have a long experience working in the area of AMR and
have participated in and coordinated national and international AMR projects. The main expert to be involved in JA
AMR, WP5, is an associate professor in infection biology working as a risk assessor. He has been WP-leader in three
EU projects and committee member in the action group of One Health Sweden.
41 Sweden – SVA
Participant’s institution: The National Veterinary Institute (SVA) is a Swedish national authority whose most
important role is to align the activities towards contagious and other serious infectious diseases of animals including
diseases that can be transferred to humans, i.e., zoonoses. This includes antimicrobial resistance and SVA monitor
the situation in bacteria from animals and food conducts research into this field. Thus, at SVA there is both expertize
and laboratory capacity in the field of antimicrobial resistance.
Key staff: At SVA there are 7 senior employees with PhD-degrees working in the field of antimicrobial resistance
(AMR) in the veterinary sector. Of these 6 have a university degree in veterinary medicine and 1 in microbiology.
All 7 have more than 5 years professional experience of research in AMR on a national and international level. The
employees also have large national as well as international networks within the field of AMR and are experienced
in communicating issues related to AMR in scientific as well as to non-scientific contexts. The employees are also
67 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
experienced in policymaking, risk assessment and other tasks related to AMR at an expert governmental authority
such as SVA. Two of the employees have more than 15 years’ experience of working in this field and 1 employee
more than 20 years’ experience.
42 Sweden – SRC
Participant’s institution: The Swedish Research Council (SRC) is the leading government agency for funding and
developing Swedish basic research of the highest academic quality within all areas of knowledge. The SRC is working
to stimulate Swedish participation in international research cooperation and is the host of the Joint Programming
Initiative on Antimicrobial Resistance (JPIAMR) Secretariat. SRC is also the coordinator of the ERA-Net Cofund JPI-
EC-AMR and the CSA EXEDRA within JPIAMR.
Key staff: Dr. Jan-Ingvar Jönsson, Secretary-General for medicine and health at the SRC and vice-Chair of the
JPIAMR. PhD in tumor immunology 1990. Professor of medical cell biology, Linköping Univeristy 2008. Member of
HIROs (Head of International Research Organizations). Laura Marin, Project Manager of the JPIAMR. Previously
responsible for Science Policy and Member Relations at the European Science Foundation. Dr. Patriq Fagerstedt,
Senior Research Officer, JPIAMR Secretariat. MSc microbiology and biochemistry, PhD neuroscience 2000.
Research experience from both academia and AstraZeneca. Dr Maria Starborg, Senior Research Officer, JPIAMR
Secretariat, national expert in H2020 societal challenge Health, Demographic Change and well-being, PhD in
molecular genetics 1995. Research experience from academia.
43 Sweden – UAS
Participant’s institution: Uppsala University Hospital (UUH) is a highly specialized public hospital responsible for a
region of 3 million citizens. UUH has 5 intensive care units (burn´s, neonatal, medical/surgery, thoracic and
neurosurgical) and 8 operating theatres. UUH has approximately 50 wards and 1000 beds. The hospital collaborate
closely with Uppsala University.
Key staff: A medical doctor, specialized in clinical microbiology and infection prevention and control with a PhD
in medical sciences, with 10 years professional experience in infectious disease epidemiology and infection
prevention and control having also a high command of the English language. 5 years´ experience of leading
international multicenter improvement projects within the field of infection prevention and control.
44 France - ANSES
Participant’s institution: Anses is a key partner of the One Health National Strategic Plan for AMR set up in France
with specific duties on AMR in the non-human sector. Anses is the scientific body holding the national surveillance
network for AMR in animals in France (Resapath) and is responsible for all issues dealing with antibiotic marketing
authorizations, surveillance of antibiotic use, antibiotic stewardship and guidelines in veterinary medicine.
Key staff: Anses will include the contribution of 3 senior scientists (2 microbiologists and 1 epidemiologist) and four
technical staff. All scientists are PhD with 10 years of professional experience in AMR and antibiotic use in animals,
in relation with AMR and antibiotic use in humans. Two also are veterinary doctors. One of them, who will be the
coordinator of the tasks, has over 10 years of experience in supervising, coordinating and managing activities on
AMR, and particularly as National Supervisor on AMR issues at Anses within the One Health National Strategic Plan
on AMR, including daily contacts with relevant stakeholders, professional bodies and national/EU authorities. The
latter also has over 5 years of experience in coordinating workpackages in several EU or international scientific
projects on AMR. The four technical staff have daily experience with managing the surveillance network of AMR
and collecting antibiotic use in animals in France.
10.4. External and internal risk analysis and contingency planning
The JA Secretariat in collaboration with the ExB will put in place a risk management plan from the project
start. This will include open communication about risk management process during the Kick off meeting, so that it
becomes part of the JA’s culture and that partners feel comfortable with notifying the WP leader or the Coordinator
when a risk occurs.
During the course of the action, project partners and in particular WP leaders will be supported by the SC
and the Stakeholder Forum in identifying risks, quantifying risks and developing appropriate responses to risk. The
JAS will be responsible for the maintenance of a Risk Register containing a comprehensive listing of all risks
68 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
identified during the course of the project and the manner in which they are being addressed. This register will be
reviewed periodically during ExB meetings, as part of the project risk management process.
The table below describes the critical risks already identified in relation to the action implementation and
the associated measures that will be taken to mitigate them:
WP / Identified Risk Likeli- Impact Contingency planning
Task hood
All WPs Overspending low medium Appropriate financial control: Reporting throughout
project
WP2; Subcontractor fails to deliver medium medium Contractual agreement with subcontractor to cover
WP8 implication of non-delivery
All WPs Partners’ commitment medium low Efficient internal communication tools and close
declines follow-up by WP leaders
All WPs Staff turnover medium low Project status meetings at WP level to identify
issues on the horizon
WP3 Different level of high medium .Adopt English as official language.
(tasks understanding and sharing .Content revision by MS representatives
3.3 & due to heterogeneity in .Evaluation surveys about the understanding of
3.4 native languages released documentation
WP3 Differences in JA partners medium high .Monitoring of the timeline of activities within WP 3.
(task compliance/collaboration to ETs will be reviewed by partners involved in the
3.3) evaluation activities evaluation prior their use.
.Reminders will be sent to non-respondents.
Communication with management bodies asking for
direct actions on partners.
WP3 Lack of essential low high Support by SC and Stakeholders Forum in reviewing
(task results/information in the documents -
3.4) provided documents Communication with management bodies asking for
direct actions on partners.
WP3 Differences / non medium medium .Dissemination and review of the EP (at the
(tasks homogeneity among beginning of the JA) and the ETs (during the whole
3.1 & indicators adopted by JA lifetime) will provide a common and shared set of
3.2 different Work Packages and measures for indicators.
for evaluation purposes .Revision of the EP/ETs will be carried out if
necessary to avoid differences among indicators
used.
.Consultation with SC and Stakeholders Forum on
the harmonization of indicators proposed
WP3 Lack of coordination / high high .Promoting continuous communication among WPs
(tasks synchrony amongst related leaders.
3.3 & activities from different WPs .Monitoring every six months of the activities with
3.5) respect to expected results and timelines
.Sharing information and data on a common web
based platform
WP5 Lack of information on medium high Leader will use its network to verify information
national measures from partners of the project and double check
information received
WP5 No consensus on the priority medium medium Leader will ensure that all partners are satisfied
goals with priority goals proposed. Delphi process will
help to reach consensus
WP5 Link/overlap with WP6 and medium low We will ask WP6 leaders to develop or remark on
WP7 (WP5 target group is the HCAI aspects to be developed in the self-
national policy level. WP6 assessment tool. Equally we will ask WP7 leaders to
and WP7 target groups are do this for prudent use aspects.
professionals/local level).
WP5 Link/overlap with WP4 low high Coordination with WP4 and EU agencies/institutions
needed to ensure continuity of the actions
69 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
WP5 Low engagement in the self- medium high Engagement of countries by informing/reporting to
and country-to-country the One Health Network on the activities of WP5
assessments:
-Not all MS participate
-No involvement of all
relevant authorities
-Disparity between
supervisory bodies
WP5 No reporting to the One low medium Until now, the One Health Network has met only
Health Network once and it's not clear which will be the frequency of
the meetings, etc. Contact with EC to ask for
frequent, regular meetings of the One Health
Network.
Lack of appropriate The hospitals will chose the core components they
WP61.2 monitoring of the low medium will perform regarding their priorities and needs, so
implementation of the ICP in the hospital managers support is necessary.
the hospitals
The impact of the The scope and the aim of the project must be
implementation of this WP clarified from the begging and the partners should
WP61.1 depends on the active low medium
be encouraged continuously from the WP leader
participation of the partners and the coordinator team
at local and national level.
WP6.2 Objectives and tasks for WP 6 medium high Actions within this WP focus on supporting
might be too ambitious and implementation and setting realistic goals.
might run the risk of not
being manageable within the
time and resources allocated.
WP6.2 Difficulties in having hospitals low medium Good preparatory work and contacts in order to
joining actions. explain the actions and also the added value of
these actions
WP6 Time constraints. medium high Realistic time schedule and regularly monitor
progress.
WP7 Lack of funding in pilot states medium medium .Restrict participants number
Task7.2 .Encourage co-funding by MS
Task7.3 Lack of infrastructure high high Pilot only in countries that can deliver data
WP7 Lack of acceptance and low high Early dialogue with ECDC as soon as WP agreed
cooperation from ECDC
WP9 Disagreement regarding medium low Define this early in the process to ensure that
Task 9.1 scope of priorities between JPIAMR’s mandate is well understood
MS and JPIAMR
WP9 Lack of description of the medium high Firmly engage all stakeholders to participate in this
Task 9.1 differences and mapping
communalities between the
needs for AMR and HCAI.
WP9 Lack of interest to align public medium medium Engage countries from the start regarding the
Task 9.1 health priorities importance and cost savings potential of alignment
WP9 Cost of stimulating greater high high Work with DRIVE-AB and AMR Review to
Task antibiotic innovation can be understand the counterfactual cost and different
9.2 significant methods of financing
10.5. Financial management
The EC financial contribution has been carefully distributed amongst the beneficiaries, based on:
• the effort necessary to perform the JA tasks
• travel and subsistence to JA meetings (GA, WP meetings or workshops)
• logistic costs for the organisation of meetings (catering)
• other costs necessary for perform the WP tasks (printing costs, communication costs)
70 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
The Coordinator INSERM has extensive experience in the financial management of research collaborative projects
and public health actions (Joint Action Orphanet, Joint Action Alcove…). It will be supported in these tasks by the
JA Secretariat.
The JAS will also provide continuous direct support to all beneficiaries. It will check all data reported by beneficiaries
before submission to the EC. In particular, the JA Secretariat will verify:
• the quality and accuracy of financial reports submitted (in relation to the work performed)
• the on time uploading of reports to the Participants portal
• the use of funding according to existing guidelines
• that costs actually incurred are consistent with those initially budgeted
• that sufficient justification is provided in case of significant deviation
• that the banking information from the beneficiaries is kept up to date
The JA Secretariat will instruct the beneficiaries on proper time recording practices and prepare comprehensive
reporting templates that will be sent to all beneficiaries well before the EC reporting deadline, to allow timely
submission of reports. After validation of periodic reports by the EC, distribution of co-funding to beneficiaries will
be made by the Coordinator’s financial officer without unjustified delay.
Permanent supervision on financial balance of the action will allow the JA Secretariat to alert promptly the ExB as
to whether or not resources are being used effectively and efficiently and to give suggestions and recommendations
for proper reactions, such as reallocation between partners or WPs.
11. BUDGET
11.1. Content description and justification
The EC financial contribution has been carefully distributed amongst the beneficiaries, based on:
• the effort necessary to perform the JA tasks
• travel and subsistence to JA meetings (GA, WP meetings or workshops)
• logistic costs for the organisation of meetings (catering)
• other costs necessary for perform the WP tasks such as printing costs or communication costs
Budget was first discussed individually with WP leaders through conference calls and mail discussions. Templates
were then sent to all beneficiaries with:
• The indicative Person-Month per partner per WP and the associated tasks
• Number of meetings/workshops expected to take place during the project (when possible, we have tried
to combine WP workshops with annual General Assembly meetings to minimize travel costs). Beneficiaries
took these indications into account to calculate their travel and subsistence costs, according to their
involvement in each of the WPs.
• Personnel costs represent the highest cost item. Most of the effort (75%), and thus most of the JA costs,
concentrates on the following core work packages: WP5: Implementation of One Health national strategies
and National Action Plans for AMR; WP6: Policies for prevention of Health-Care-Associated Infections and
their implementation; WP7: Appropriate use of antimicrobials in health care.
The costs for the organization of 4 consortium meetings was dispatched between partners FR-1 INSERM, FR2- MOH-
FR, IT-17 ISS and SP32- AEMPS.
11.2. Summary of staff effort
TOTAL
Participant Participant PERSON/M
number Short name
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 ONTH per
Participant
01 INSERM 46,0 4,0 3,5 0,0 9,0 12,0 0,0 7,5 31,0 113,0
02 Moh 8,2 1,7 0,6 14,4 4,0 0,0 0,0 1,0 0,0 29,9
03 GOG 0,0 0,1 0,0 0,0 0,0 6,0 5,3 0,0 0,0 11,4
71 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
04 FPS HFCSE 0,0 0,5 0,0 0,0 4,0 8,3 2,5 0,0 0,0 15,3
05 NCIPD 0,0 0,7 0,0 0,0 6,7 0,0 11,0 0,0 0,0 18,4
06 CIPH HZJZ 0,0 0,2 0,0 0,0 0,0 0,0 10,7 0,5 0,0 11,4
07 NIPH 0,0 0,5 0,0 0,0 4,3 24,5 5,3 0,5 0,0 35,0
08 SSI 0,0 0,5 0,0 0,0 0,0 0,0 12,0 0,5 0,0 13,0
09 TA 0,0 2,0 0,0 0,0 0,0 5,0 5,0 5,0 0,0 17,0
10 RKI 0,0 0,1 0,0 0,0 5,4 0,0 5,9 0,1 0,0 11,5
11 HCDCP 0,0 1,0 1,0 0,0 0,0 85,0 12,0 1,0 0,0 100,0
12 ESDY NSPH 0,0 1,0 0,0 0,0 8,2 2,0 38,0 1,0 0,0 50,2
13 SEVEN HC 0,0 0,0 0,0 0,0 0,0 11,5 0,0 0,0 1,5 13,0
14 UNIFG 0,0 0,4 2,5 0,0 6,0 7,0 6,0 1,9 0,0 23,8
15 ISS 0,0 1,0 6,0 0,0 0,0 7,0 12,0 0,0 3,0 29,0
16 PSCUH 0,0 1,0 0,0 0,0 0,0 11,0 0,0 0,0 0,0 12,0
17 LSMULKK 0,0 1,0 0,0 0,0 6,5 12,0 7,0 0,5 0,0 27,0
18 VULSK 0,0 1,0 0,0 0,0 0,0 12,0 0,0 0,0 0,0 13,0
19 HI 0,0 0,5 0,0 0,0 12,0 18,0 9,0 0,5 0,0 40,0
20 NVSC 0,0 0,1 0,0 0,0 0,0 6,0 2,7 2,5 0,0 11,4
21 VWS 0,0 2,0 1,0 0,0 29,0 7,0 2,0 2,0 4,0 47,0
22 HdiR 0,0 0,1 0,0 0,0 0,0 0,0 3,8 0,1 0,0 4,0
23 FHI 0,0 1,5 0,4 0,0 0,0 0,0 33,2 0,0 32,5 67,6
24 NVI 0,0 0,0 0,0 0,0 0,0 0,0 6,0 0,0 1,0 7,0
25 NMI 0,0 0,0 0,0 0,0 7,0 0,0 6,0 0,0 0,0 13,0
26 DGS 0,0 1,0 0,0 0,0 0,0 10,0 5,0 2,5 0,0 18,5
27 UMPIH 0,0 2,5 0,0 0,0 5,5 0,0 4,5 0,0 0,0 12,5
28 NIJZ 0,0 1,5 0,0 0,0 10,0 11,0 0,0 3,5 1,0 27,0
29 AEMPS 0,0 39,0 1,0 2,0 3,0 12,0 18,0 49,0 0,0 124,0
30 GENCAT 0,0 0,0 0,0 0,0 0,0 12,0 12,0 4,0 0,0 28,0
31 IDIBAs 0,0 0,0 0,0 0,0 0,0 2,9 7,3 3,1 2,4 15,8
32 FFIS 0,0 1,0 5,0 0,0 0,0 12,0 4,8 1,0 0,0 23,8
33 FMS 0,0 0,5 0,0 0,0 0,0 0,0 5,0 0,5 0,0 6,0
34 SAS 0,0 1,0 0,0 0,0 0,0 0,0 17,1 0,0 0,0 18,1
35 ISCIII 0,0 0,8 0,0 0,0 0,0 4,0 0,0 0,4 0,0 5,2
36 SERMAS 0,0 0,0 0,0 0,0 0,0 0,0 28,0 3,0 3,3 34,3
37 FOHM 0,0 1,0 1,0 0,0 3,0 41,2 2,0 0,0 0,0 48,2
38 SoS 0,0 0,0 0,0 0,0 0,0 1,0 0,0 0,0 0,0 1,0
39 SBA 0,0 0,0 0,0 0,0 0,8 0,0 0,0 0,0 0,0 0,8
40 NFA 0,0 0,0 0,0 0,0 1,5 0,0 0,0 0,0 0,0 1,5
41 SVA 0,0 0,0 0,0 0,0 0,7 0,0 0,0 0,0 0,0 0,7
42 SRC 0,0 0,4 0,0 0,0 0,0 0,0 0,0 0,0 4,6 5,0
43 UAS 0,0 0,0 0,0 0,0 0,0 1,0 0,0 0,0 0,0 1,0
44 ANSES 0,0 1,0 0,0 0,0 6,0 0,0 35,5 0,0 0,0 42,5
TOTAL 54,2 70,6 22,0 16,4 132,6 341,5 334,6 91,6 84,3 1147,8
72 of 137
EU-JAMRAI Confidential
09/08/2017
Below the breakdown of all direct costs per WP:
TOTAL
Participant Participant DIRECT
number Short name
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 COSTS per
Participant
01 INSERM 341 954,00 26 366,00 19 077,00 0,00 38 560,00 41 470,00 0,00 50 170,00 207 733,00 725 329,00
02 Moh 58 060,00 10 600,00 4 800,00 88 044,00 26 000,00 0,00 0,00 8 000,00 0,00 195 504,00
03 GOG 14 740,00 593,00 0,00 0,00 0,00 63 957,00 43 926,00 0,00 0,00 123 216,00
FPS
04 0,00 2 242,00 0,00 0,00 33 453,00 52 211,00 23 840,00 0,00 0,00 111 745,00
HFCSE
05 NCIPD 7 520,00 620,00 0,00 0,00 18 810,00 0,00 9 550,00 0,00 0,00 36 500,00
06 CIPH HZJZ 7 520,00 700,00 0,00 0,00 0,00 0,00 43 220,00 650,00 0,00 52 090,00
07 NIPH 7 520,00 1 204,00 0,00 0,00 21 388,00 73 189,00 10 153,00 1 204,00 0,00 114 657,00
08 SSI 7 520,00 2 000,00 0,00 0,00 0,00 0,00 70 000,00 2 000,00 0,00 81 520,00
09 TA 7 520,00 3 640,00 0,00 0,00 0,00 14 860,00 9 100,00 12 235,00 0,00 47 355,00
10 RKI 7 520,00 750,00 0,00 0,00 50 660,00 0,00 44 250,00 750,00 0,00 103 930,00
11 HCDCP 0,00 2 200,00 2 200,00 0,00 0,00 276 216,00 27 000,00 2 200,00 0,00 309 816,00
ESDY
12 7 520,00 2 503,00 0,00 0,00 33 303,00 12 129,00 79 498,00 2 503,00 0,00 137 455,00
NSPH
13 SEVEN HC 7 520,00 0,00 0,00 0,00 0,00 37 677,00 0,00 0,00 7 741,00 52 938,00
14 UNIFG 7 520,00 1 709,00 11 387,00 0,00 39 190,00 36 183,00 25 220,00 10 984,00 0,00 132 193,00
15 ISS 15 940,00 8 123,00 145 304,00 0,00 0,00 102 698,00 88 435,00 0,00 24 558,00 385 058,00
16 PSCUH 7 520,00 1 938,00 0,00 0,00 0,00 25 372,00 0,00 0,00 0,00 34 830,00
17 LSMULKK 7 520,00 1 800,00 0,00 0,00 11 700,00 19 400,00 5 550,00 900,00 0,00 46 870,00
18 VULSK 7 520,00 2 900,00 0,00 0,00 0,00 43 520,00 0,00 0,00 0,00 53 940,00
19 HI 3 760,00 1 138,00 0,00 0,00 42 458,00 50 156,00 22 592,00 1 255,00 0,00 121 359,00
20 NVSC 7 520,00 279,00 0,00 0,00 0,00 19 495,00 5 158,00 3 230,00 0,00 35 682,00
21 VWS 7 520,00 18 500,00 9 250,00 0,00 303 500,00 96 000,00 55 000,00 17 160,00 31 440,00 538 370,00
22 HdiR 7 520,00 911,00 0,00 0,00 0,00 0,00 39 134,00 1 050,00 0,00 48 615,00
23 FHI 7 520,00 10 843,00 3 543,00 0,00 0,00 0,00 277 561,00 0,00 219 880,00 519 347,00
24 NVI 3 760,00 0,00 0,00 0,00 0,00 0,00 42 000,00 0,00 7 720,00 53 480,00
25 NMI 7 520,00 0,00 0,00 0,00 26 534,00 0,00 9 239,00 0,00 0,00 43 293,00
73 of 137
EU-JAMRAI Confidential
09/08/2017
26 DGS 7 520,00 4 600,00 0,00 0,00 0,00 50 320,00 17 600,00 12 760,00 0,00 92 800,00
27 UMPIH 7 520,00 2 500,00 0,00 0,00 20 020,00 0,00 6 200,00 0,00 0,00 36 240,00
28 NIJZ 7 520,00 3 900,00 0,00 0,00 46 140,00 66 760,00 0,00 11 660,00 6 140,00 142 120,00
29 AEMPS 7 520,00 223 400,00 3 125,00 6 250,00 22 415,00 40 300,00 63 750,00 226 550,00 0,00 593 310,00
30 GENCAT 7 520,00 0,00 0,00 0,00 0,00 29 760,00 24 000,00 11 440,00 0,00 72 720,00
31 IdISBa 7 520,00 0,00 0,00 0,00 0,00 25 179,00 44 563,00 21 099,00 15 702,00 114 063,00
32 FFIS 7 520,00 0,00 18 844,00 0,00 0,00 64 919,00 19 919,00 5 418,00 0,00 116 618,00
33 FMS 7 520,00 2 340,00 0,00 0,00 0,00 0,00 23 364,00 2 333,00 0,00 35 557,00
34 SAS 5 640,00 4 500,00 0,00 0,00 0,00 0,00 87 350,00 0,00 0,00 97 490,00
35 ISCIII 7 520,00 3 200,00 0,00 0,00 0,00 27 280,00 0,00 1 600,00 0,00 39 600,00
36 SERMAS 7 520,00 0,00 0,00 0,00 0,00 0,00 48 000,00 9 000,00 9 923,00 74 443,00
37 FOHM 7 520,00 0,00 0,00 0,00 71 075,00 494 327,00 41 087,00 0,00 0,00 614 009,00
38 SoS 3 760,00 0,00 0,00 0,00 0,00 10 270,00 0,00 0,00 0,00 14 030,00
39 SBA 2 820,00 0,00 0,00 0,00 9 479,00 0,00 0,00 0,00 0,00 12 299,00
40 NFA 3 760,00 0,00 0,00 0,00 12 300,00 0,00 0,00 0,00 0,00 16 060,00
41 SVA 2 850,00 0,00 0,00 0,00 9 587,00 0,00 0,00 0,00 0,00 12 437,00
42 SRC 7 520,00 2 880,00 0,00 0,00 0,00 0,00 0,00 0,00 34 560,00 44 960,00
43 UAS 3 760,00 0,00 0,00 0,00 0,00 15 665,00 0,00 0,00 0,00 19 425,00
44 ANSES 3 760,00 3 724,00 0,00 0,00 32 512,00 0,00 214 773,00 0,00 0,00 254 769,00
TOTAL 682 644,00 352 603,00 217 530,00 94 294,00 869 083,00 1 789 312,00 1 521 032,00 416 149,00 565 397,00 6 508 041,00
74 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
11.3. Detailed budget
1. France – Inserm
Applicant Number FR-1
Short Name INSERM
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Deputy director ITMO I3M (Evelyne 4 32 484,00 €
Jouvin-Marche)
Scientific advisor (Antoine Andremont) 6 69 894,18 €
Post-doc (WP9) to be hired 18 72 000,00 €
Project manager (WP1) to be hired 36 144 000,00 €
JA project assistant (WP1) to be hired 13 39 000,00 €
Infection control senior expert (WP5) 9 18 000.00 €
to be appointed*
Senior consultant (WP6) to be 10 19 830.00 €
appointed*
Assistant (WP6) to be appointed* 2 2 800.00 €
Total Costs (€) of (A) 398 008.18 €
Justification
One person to be recruited to ensure the thre main objectives of the WP9, an engineer
speaking fluently english will be usefull to assist the leaders of this WP in the matter regarding
the interface with the governments and institutions of all participating countries. On the
French side, three permanent scientists are associated to develop the JA action: Marie Cécile
Ploy to coordinate the JA, Antoine Andremont to drive the WP9 and Evelyne Jouvin Marche
to help to identify public health needs and priority in AMR and HCAI research and innovation
and to communicate on research finding and good practices in France. In addition, Christelle
Hubert, assistant director will contribute to a secretariat work. Contribution to all the 3 tasks
of WP5* with special interest in the developing of the tool for the self-assessment of the
national strategies and action plans. Senior consultant (epidemiologist) working at national
level, responsible for executing and/or coordinating all professional tasks listed in WP6*
Track-1 (WP6a, Tasks 6.1.1., 6.1.2., 6.1.3.). One assistant in WP6* will be responsible for
organisational and logistical matters as well as accounting tasks related to local project
administration of W6 Track-1 (WP6a, Tasks 6.1.1., 6.1.2., 6.1.3.).
(C) Other direct costs
(C.1) Travel Costs (€) Justification
8 460,00 € Travel to 3 GA meetings for 3 participants + KoM
60 480,00 € .Collaborating partners travel to attend 4 Steering
Committee meetings (16 people = 1
representative max per collaborating partner)
.5 Stakeholders Forum members x 4 GA
9 360,00 € WP9 travels for task 9.2 = 13 visits for Antoine
Andremont
20 560.00 € Travel of the WP5* infection control senior expert
for WP5 country to country assessment (8000€),
general and one day meetings participation
(12560€)
11 840.00 € Travel of the WP6* epidemiologist for WP1
meetings (7520€) and WP6a meetings (2 one-day
interim meetings in conjunction with the G.A.s
with 1 national + 2 WP6a pilot hospital
representatives) (4320€)
75 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
17 520,00 € Additional budget** to cover miscellaneous travel
expenses:
- Coordinator travels and attendance at
European events related to AMR & HCAI to
disseminate and communicate about the Joint
Action: expected up to 5 events per year (920 € x
5 x 3 = 13 800 €)
- Travels expenses for the project manager
to attend the KoM and the 3 General Assembly
(920€ x 4 = 3 720 €). Indeed the project manager
is located in Limoges near the coordinator and will
have to attend the KoM in Paris as well as the
General Assembly meetings.
(C.3) Other goods and Costs (€) Justification
services
3 000,00 € Webex platform
10 300,00 € Organisation of a General Assembly Meeting in
Paris (catering, lunch, diner; travels + per diem for
2 experts) = 69 participants + 2 experts
7 000.00 € WP6a accommodation, printings*...
Total Costs (€) of (C) 148 520.00 €
(D) Indirect Costs (Max. 7% 38 256.97 €
on A, B and C)
Total estimated eligible 584 785.15 €
costs
Total requested EC 350 871.09 €
contribution (60% max)
*Due to the situation of both former Hungarian entities (former OCMO & NCE), partners of the JA, and unable to proceed with
administrative steps of the Grant Agreement preparation. These partners and INSERM agree to withdraw OCMO and NCE, to
transfer and keep their budget at the coordinator’s one until their situation will be cleared. Once it will be the case, they will be
reintroduced to the consortium in the course of the project. In case both Hungarian partners cannot join the project during its
course, INSERM will contact WP leaders of WP5 and WP6 as well as participants of these two Work Packages to assess which
entity-ies could carry out the work NCE and OCMO were supposed to perform. Any transfer will be made after detailed
justification and validation of the General Assembly.
**Due to the withdrawal of the Serbian partner, CCS, this amount (33 280 €) will be dedicated to cover additional travel
expenses that were at first forgotten (17 520 €) and the coordinator (Prof. Marie-Cécile Ploy) involvement in the project that
has been refined (+1.03 PM).
76 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Applicant Number FR-1 Affiliated entity
Short Name University of Limoges
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Prof MD & director of laboratory 10,03 102 808,16 €
(Marie-Cécile Ploy)
PharmD (Olivier Barraud) 2,5 6 375,00 €
Total Costs (€) of (A) 109 183,16 €
Justification
Marie Cécile Ploy to coordinate the JA
(D) Indirect Costs (Max. 7% 7 642,82 €
on A, B and C)
Total estimated eligible 116 825,98 €
costs
Total requested EC 70 095,59 €
contribution (60% max)
Applicant Number FR-1 Affiliated entity
Short Name CHU Limoges
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Prof MD & director of laboratory 10,03 51 242,87 €
(Marie-Cécile Ploy)
PharmD (Elodie Pfender) 2,5 10 750,00 €
PharmD (Olivier Barraud) 2,5 7 625,00 €
Total Costs (€) of (A) 69 617,87 €
Justification
Marie Cécile Ploy to coordinate the JA
(D) Indirect Costs (Max. 7% 4 873,25 €
on A, B and C)
Total estimated eligible 74 491,12 €
costs
Total requested EC 44 694,67 €
contribution (60% max)
77 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
2. France – MoH
Applicant Number FR-2
Short Name MoH
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Christian Brun-Buisson - Medical 5,4 43 200,00 €
doctor trained in Intensive Care
Jean-Michel Azanowsky - Medical 2 16 000,00 €
doctor specialist in Public Health
Jean-Baptiste Rouffet - Policy Advisor 1,9 15 200,00 €
on European Affairs
Project assistant (to be hired) 20,4 102 800,00 €
Total Costs (€) of (A) 177 200,00 €
Justification
One person will be recruited to ensure support of the French experts in the Joint Action. the
foreseen person will have a policy and scientific background with experience in project
management to enable appropriate understanding of the issues at stake. He/she will provide
support to the work undertaken and act as liaison officer for partners involved in this WP4
throughout the whole Joint Action. This person will also provide support to the French
coordination Team as necessary, and build on the experience of the national roadmap and its
ongoing development to ensure sustainability and consistency between national actions and
the work done in JAMRAI.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
6 960,00 € 3 x General meetings for 2 persons (airplanes tickets +
per diem) -attendance at General Assembly + WP4
annual meeting in the framework of General
Assembly meetings
(C.3) Other goods and Costs (€) Justification
services
1 044,00 € TLC (for instance Go To Meeting = 29€ per month)
10 300,00 € Organisation of a General Assembly Meeting (Kick-off
Meeting especially) in Paris (catering, lunch, diner;
travels + per diem for 2 experts) = 69 participants + 2
experts
Total Costs (€) of (C) 18 304,00 €
(D) Indirect Costs (Max. 7% 13 685,28 €
on A, B and C)
Total estimated eligible 209 189,28 €
costs
Total requested EC 125 513,57 €
contribution (60% max)
78 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
3. Austria - GÖG
Applicant Number AT-3
Short Name GOG
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Eva Kernstock (Senior Researcher 2,40 31 003,51 €
Nursing and Risk-Managment Expert)
Anton Hlava (Senior Researcher, 5,40 51 294,39 €
Epidemiologist and Statistic Expert)
Vera Buhmann (junior researcher for 3,64 21 578,32 €
HCAI and AMR)
Total Costs (€) of (A) 103 876,22 €
Justification
The team of the Austrian Public Health Institute (Gesundheit Österreich GmbH) will participate
in WP 7 "Appropriate use of antimicrobials in health care" and in WP 6 „Policies for prevention
of Health-Care-Associated Infections and their implementation“ with the following employees:
E. Kernstock has extensive experience in the field of quality in healthcare. She will be involved
as a supervisor in the work of both WPs. The epidemiologist and senior advisor A. Hlava has
been working on the issue of prevention and control of healthcare-associated infections (HCAI)
for many years. V. Buhmann, a junior advisor, has experience in field of EU project management
and has been working in projects dealing with HCAI and antimicrobial resistances in the
healthcare sector. They will all participate in the completion of the tasks selected in the WPs.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
4 600,00 € 4 add. WP6 meetings in var. EU countries 1 pax 2 day
9 200,00 € KoM + 3 GA for 2 people 2 days
(C.3) Other goods and Costs (€) Justification
services
5 540,00 € Hosting and Catering WS in 2018 incl. 2 speaker
travels (30 participants max + 2 speakers according to
our guidelines)
Total Costs (€) of (C) 19 340,00 €
(D) Indirect Costs (Max. 7% 8 625,13 €
on A, B and C)
Total estimated eligible 131 841,35 €
costs
Total requested EC 79 104,81 €
contribution (60% max)
GOG will have an affiliated entity: the Austrian Ministry of Health (MoH-AT)
79 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
4. Belgium - FPS HFCSE
Applicant Number BE-4
Short Name FPS Health, Food Chain Safety and Environment
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Statistician (Dr Versporten - WP6.2) 1,80 12 174,72 €
Attaché (Mr Van Onacker - WP6.2) 4,50 20 532,00 €
Attaché (Mr De Raedt - WP5) 4,50 20 174,25 €
Medical doctor (Dr Legiest - WP6.2 & 32 544,44 €
WP7) 4,50
Total Costs (€) of (A) 85 425,41 €
Justification
For Belgium, four people are associated to develop the JA. Lieven De Raedt will coordinate the
Belgian participation to the JA and drive WP5. Gilles Van Onacker will help coordinate the
Belgian contribution to the JA in general and WP6.2 in particular. Ann Versporten is a
statistician and an expert on AMR and HCAI and will contribute to WP6.2 by adapting and
implementing existing policies and guidelines and by reviewing if compliance has improved. Dr.
Barbara Legiest will coordinate Belgian WP7 efforts and will provide medical insight for the
specific topic chosen in WP6.2. She will also help with the implementation of the selected
guidelines for WP6.2.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
18 320,00 € Participation at final conference + WP5 + WP6b +
WP7 at proposed rates
8 000,00 € WP5 country to country assessment
Total Costs (€) of (C) 26 320,00 €
(D) Indirect Costs (Max. 7% 7 822,18 €
on A, B and C)
Total estimated eligible 119 567,59 €
costs
Total requested EC 71 740,55 €
contribution (60% max)
80 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
5. Bulgaria – NCIPD
Applicant Number BG-5
Short Name NCIPD
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Todor Kantardjiev Microbiologist 4 3 600,00 €
Ivan Ivanov Microbiologist 4 3 600,00 €
Martyn Nedyalkov Microbiologist 3,9 3 315,00 €
Elina Dobreva Microbiologist 4,5 3 825,00 €
Rumiana Hristova technician 2 1 600,00 €
Total Costs (€) of (A) 15 940,00 €
Justification
Todor Kantardjiev is a national consultant in microbiology in the MH. He will coordinate the
implementation of the national action plan on AMR and evaluate the outcomes of the JA. His
activities will contribute to the recognition of the JA priorities on governmental level.
Ivan Ivanov will harmonize the implementation of the objectives from the global AMR plan to
national level and participate in the cross-country assessment.
Martyn Nedyalkov will design and run pilot projects looking at effective implementation of
guidelines.
Elina Dobreva is National Focal point on HAI and will ensure the relations with health care
facilities for the implementation of the JA.
Rumiana Hristova will provide technical assistance on each task.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 2 persons partitipation in 4 GA meetings
5 040,00 € 1 person partitipation in 7 mid-terms for WP5
8 000,00 € WP5 country to country assessment
Total Costs (€) of (C) 20 560,00 €
(D) Indirect Costs (Max. 7% 2 555,00 €
on A, B and C)
Total estimated eligible 39 055,00 €
costs
Total requested EC 23 433,00 €
contribution (60% max)
81 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
6. Croatia - HZJZ/CIPH
Applicant Number HR-6
Short Name CIPH
(A) Direct personnel Persons (position) Total Person-Month Total Costs (€) of (A)
costs (including Public Blazenka Hunjak - 4 14 000,00 €
officials) Microbiologist MD
Anamarija Pejnovic - Engineer 2,75 3 575,00 €
of laboratory diagnostics
Vladimir Hunjak Stula - 0,95 1 615,00 €
Administrative officer
Tatjana Unukic – Engineer of 2,75 3 575,00 €
laboratory diagnostics
Martina Jelinic – Financial 0,95 1 805,00 €
officer
Total Costs (€) of (A) 24 570,00 €
Justification
CIPH has allocated staff to the project according to the needs to fulfill the individual
tasks of the work package and persons availability by using our best knowledge and
experience. Also we would like to hire a full time person to work on the project, Project manager
- non Public official person who will successfully plan, implement and monitor this project.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € Kick off meeting + 3 General Assembly for 2 people 2 days
10 000,00 € Representation - 4 workshops in 4 different cities in Croatia -
Venue and cattering coffee breaks and lunch
(C.3) Other goods and Costs (€) Justification
services
10 000,00 € Cost for WP7 materials for workshops (training materials etc)
Total Costs (€) of (C) 27 520,00 €
(D) Indirect Costs (Max. 3 646,30 €
7% on A, B and C)
Total estimated eligible 55 736,30 €
costs
Total requested EC 33 441,78 €
contribution (60% max)
82 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
7. Czech Republic – NIPH
Applicant Number CZ-7
Short Name NIPH
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Mackova Barbora - Project 2 4 815,00 €
manager
Zemlickova Helena – 7 13 556,00 €
Microbiologist
Jakubu Vladislav - Data manager 2 3 741,00 €
Jindrak Vlastimil - Microbiologist 13 28 704,00 €
Vanis Vaclav - Microbiologist 3 5 407,00 €
Hedlova Dana - Epidemiologist 4 7 222,00 €
Adamjak Tomas - Financial expert 4 9 852,00 €
Total Costs (€) of (A) 73 297,00 €
Justification
All experts are the NIPH staff, project manager is the head of Centre for Epidemiology and
microbiology and financial expert is deputy head of the economic department NIPH. All
professionals are heads or deputy heads of the National reference laboratory or centre
and have minimal ten years experience and expert knowledge in topics of projects. They
communicate, in their main topics, with national and international subjects (MoH, MoA,
ECDC, WHO, etc.). They have the experience in the science, research and teaching.
NIPH is a health care establishment for basic disciplines in public health. The main
activities of NIPH comprise science and research, reference and methodological advice,
surveillance of communicable diseases, preparation of legislation in the field of health
protection, including harmonization of Czech legislation with the norms of the European
Union. NIPH plays an active role in pre- and post graduate training and in continuing
medical education of physicians and other health care workers.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
23 360,00 € all meetings
8 000,00 € WP5 country to country assessment
(C.3) Other goods and services Costs (€) Justification
6 000,00 € organization on the national workshops
4 000,00 € materials for workshops for implementation on
national level, administration, translation, etc.
Total Costs (€) of (C) 41 360,00 €
(D) Indirect Costs (Max. 7% on 8 025,99 €
A, B and C)
Total estimated eligible costs 122 682,99 €
Total requested EC contribution 73 609,79 €
(60% max)
83 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
8. Denmark – SSI
Applicant Number DK-8
Short Name SSI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) B. Kristensen (Head, 3,5 14 000,00 €
microbiologist)
UW Sönksen (project manager) 4 16 000,00 €
S Skovgaard (project manager) 3,5 12 000,00 €
Technician 2 4 000,00 €
Total Costs (€) of (A) 46 000,00 €
Justification
B. Kristensen: Coordinating the Danish participation, UW Sönksen: coordinating the pilot
project. S Skovgaard projectmanaging of the pilot project. Technichian (NN): handling of
data
(B) Direct costs of sub- Costs (€) Tasks subcontracted
contracting 28 000,00 € In WP7, task 7.4.2 related to animal sector
Total Costs (€) of (B) 28 000,00 €
Justification for resorting to subcontracting
Danish National Veterinary Institute (DTU VET) will contribute to task 7.4.2, having the
skills and expertise to do so.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 1 KoM + 3 General Assembly for 2 people 2 days
(including mid-terms WP7 meetings)
Total Costs (€) of (C) 7 520,00 €
(D) Indirect Costs (Max. 7% on 5 706,40 €
A, B and C)
Total estimated eligible costs 87 226,40 €
Total requested EC contribution 52 335,84 €
(60% max)
84 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
9. Estonia – TA
Applicant Number EE-9
Short Name TA
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Pille Mârtin - 6 10 920,00 €
Infectionist, Senior
Researcher
Iiris Saluri - Information 5 10 075,00 €
specialist
Olga Sadikova – 6 10 920,00 €
Epidemiologist, Chief
specialist
Total Costs (€) of (A) 31 915,00 €
Justification
Dr Pille Märtin is an infection control doctor employed by Estonian Health Board. 10
years experience in infection control (hospital level) incl. participation in
international projects (HCAI, AMR, AB stewardship).5 years experience at national
level (HCAI in ICU, SSI, PPS); excellent command of English. Her experience is needed
for participating in WP6 (Containing AMR and preventing HCAI by implementing
evidence based guidelines) and WP7 (Appropriate use of antimicrobials in
healthcare).
Ms Iiris Saluri is a manager of public relations in Estonian Health Board for over 10
years. She has university degree in social sciences. Experience in carrying out
WHO/ECDC AMR awareness projects and in analyzing information sources; excellent
command of English. Her experience is needed to carry out activities in WP8
(Awareness raising and communication).
Dr Olga Sadikova is an epidemiologist in Estonian Health Board. She has university
degree in medicine. Over 10 years of excperience in carrying out infection
prevention and control activities; excellent command of English. Dr Sadikova will
assist the remaining team in their activities.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € WP1, 2 persons, 4 General Assembly meetings x 2 days
5 760,00 € WP6 a+b, 1 person, 8 meetings x 1 day
2 160,00 € WP8, 3 meetings, 2 persons
Total Costs (€) of (C) 15 440,00 €
(D) Indirect Costs (Max. 7% on 3 314,85 €
A, B and C)
Total estimated eligible costs 50 669,85 €
Total requested EC contribution 30 401,91 €
(60% max)
85 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
10. Germany – RKI
Applicant Number DE-10
Short Name RKI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Epidemiologist (WP7) 6 45 000,00 €
Epidemiologist (WP5) 5,5 41 250,00 €
Total Costs (€) of (A) 86 250,00 €
Justification
WP7: we need an experienced epidemiologist who ist able to perform:
a review of the literature of measurements to foster the prudent use of antibiotics in
the outpatient setting. Especially feedback systems in different health systems will be a
focus of the review. E.g. in the German setting one way to do so is the communication
channels of the Associations of Health Insurance Doctors. But this is done only in some
of the 17 Associations and in different forms.
For the country exchanges Germany will provide a structured questionnaire, which will
be discussed by the countries in the meeting.
WP5: we need an experienced epidemiologist who is experienced in auditing of
countries.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € annual GA Meetings (3x) + KoM
2 160,00 € WP5 3 midterms meetings (outside GA Meetings)
8 000,00 € WP5 country to country assessment
Total Costs (€) of (C) 17 680,00 €
(D) Indirect Costs (Max. 7% on A, 7 275,10 €
B and C)
Total estimated eligible costs 111 205,10 €
Total requested EC contribution 66 723,06 €
(60% max)
86 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
11. Greece - HCDCP
Applicant Number GR-11
Short Name HCDCP
(A) Direct personnel costs Persons (position) Total Person- Total Costs (€) of (A)
(including Public officials) Month
(To be hired) Project manager (1) 36 79 200,00 €
Scientific staff (HCDCP personnel) 39 95 796,21 €
Technical support (HCDCP personnel) 8 16 000,00 €
scientific staff for WP6 (HCDCP 12 28 800,00 €
personnel)
scientific staff for WP7 (HCDCP 5 12 000,00 €
personnel)
Total Costs (€) of (A) 231 796,21 €
Justification
HCDCP health professionals are specialists in the area of epidemiology, infection control
and infectious diseases with significant experience in Infection Control Commitees and
in public health. They will participate in all of the activities of the leading team of the
three tasks of the WP61. Additionally, they are going to contribute to the
implementation of the Universal Infection Control Preogram of the 2nd Task in Greek
hospitals and participate in W6.2.1 and in W7.4 tasks. The technical personel will be
occupied with the collection of surveillance data and the administrative support of the
project. A project manager- a fulltime job dedicated professional will be hired for
monitoring the implementation of the WP61.at national and European level.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 760,00 € participation in WP.6.1
5 760,00 € participation in WP.6.2
6 000,00 € leading team (2 professionals for their
participation in the 4 main meetings of 6.1
objective)
500,00 € Interviews of survey B
(C.2) Equipment Costs (€) Justification
20 000,00 € inetractive platform specific for training tools
regarding HAIs prevention (WP6)
20 000,00 € electronic form and surveillance data base
development (WP7)
(C.3) Other goods and services Costs (€) Justification
10 000,00 € Health economics study (WP6)
10 000,00 € Translation editing (WP6)
Total Costs (€) of (C) 78 020,00 €
(D) Indirect Costs (Max. 7% on A, 21 687,13 €
B and C)
Total estimated eligible costs 331 503,34 €
Total requested EC contribution 198 902,01 €
(60% max)
87 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
12. Greece - ESDY- NSPH
Applicant Number GR-12
Short Name ESDY-NSPH
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Medical Microbiologist (A. Vatopoulos) 7 22 291,20 €
Biologist PhD (P Giakkoupi) 12 30 033,26 €
Veterinarian PhD (Em. Papadogianakis) 7 16 604,00 €
Veterinarian PhD (M Kontarini) 6 14 706,40 €
Sientist (biology. Bioinformatics) 18 27 500,00 €
Total Costs (€) of (A) 111 134,86 €
Justification
OA. Vatopoulos has a long (20 years) experience in AR epidemiology including setting up
electronic surveillance systems international collaboration (WHO, EU), identifying new
AR genes, and molecular typing. He will coordinate the participation of NHPH in all WPs
(1 PM in WP5, 2WP in 6a, 4 pm in WP 7). P. Giakkoupi, who plays a leading role in
studying the molecular mechanisms of AR and the dissemination of resistant genes and
bacteria in Greece for the last 15 years, will participate in WP7 (PM 10) especially in the
task “Develop and test near real time surveillance of antimicrobials and multidrug
resistant bacteria” on “Select basic indicators for surveillance system of antimicrobial
resistance” and “Reinforce current surveillance systems in order to have the data
analyzed and available as soon as possible. He will also dedicated 1 PM in WP2 and 1 PM
in WP8.
Em Papadogiannakis and M Kontarini have experience in developing the one health
approach in Greece will particiapte in WP 5 (4 and 3,2 PM each). They will also
participate in WP7 bringing their expertise for the veterinarian side of this WP7. Each
will participate at 3 PM.
A. Vatopoulos, P Giakkoupi, Em Papadogainnakis and M Kontarini are already employes
of NSPH. The Biologist / Bioinforamics will work in WP7 (we will include a pilot study of
data plus strains collection for real time typing in order to asess the feacibitity of this
project.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 040,00 € WP5
5 760,00 € WP6a
7 520,00 € WP1 Kick-off meeting + 3 General
Assembly meetings
8 000,00 € WP5 country to country assessment
Total Costs (€) of (C) 26 320,00 €
(D) Indirect Costs (Max. 7% on A, 9 621,84 €
B and C)
Total estimated eligible costs 147 076,70 €
Total requested EC contribution 88 246,02 €
(60% max)
88 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
13. Greece – 7th HR CRETE
Applicant Number GR-13
Short Name 7HC
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Aimilia Magkanaraki (Administration 1 2 202,00 €
staff, Head of Health Policies Planning
and Development Department)
Total Costs (€) of (A) 2 202,00 €
Justification
Mrs Magkanaraki (MSc) will carry out the administration and organizational procedures
neccessary to fullfill the project.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € Travels for KoM + 3 GA meetings
5 760,00 € WP6.1 meetings
1 440,00 € WP9 meetings
Total Costs (€) of (C) 14 720,00 €
(D) Indirect Costs (Max. 7% on 1 184,54 €
A, B and C)
Total estimated eligible costs 18 106,54 €
Total requested EC contribution 10 863,92 €
(60% max)
Applicant Number GR-13 Affiliated entity
Short Name University General Hospital of Heraklion- PAGNI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Gikas Achilles (Prof Int. Medicine - 4 20 800,00 €
Infectius Diseases at University General
Hospital of Heraklion PAGNI)
Irini Astrinaki (Infection diseases 4 7 608,00 €
specialist, University General Hospital
of Heraklion PAGNI)
Argiri Messaritaki (Infection diseases 4 7 608,00 €
specialist, University General Hospital
of Heraklion PAGNI)
Total Costs (€) of (A) 36 016,00 €
Justification
Professor Achilles Gikas is an infectius diseases specialist with expertise on infection
control and more than 20 years of European experience, active bibliography and
participation in projects. Due to his expertise, he will lead the team on behalf of the 7th
Health Region of Crete for all WPs involved.Mrs Astrinaki and Mrs Messaritaki are highly
qualified infection control specialists with at least 5 years of hospital experience and will
assist in carrying out the tasks assigned in WP6 and WP9.
89 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(D) Indirect Costs (Max. 7% on 2 521,12 €
A, B and C)
Total estimated eligible costs 38 537,12 €
Total requested EC contribution 23 122,27 €
(60% max)
90 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
14. Italy – UNIFG
Applicant Number IT-14
Short Name UNIFG
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Full professor of Hygiene (Rosa 7 36 419,25 €
Prato, UNIFG)
Assistant Professor of Hygiene 6,8 29 054,65 €
(Domenico Martinelli, UNIFG)
Medical doctor (Contractor) 10 38 239,50 €
Total Costs (€) of (A) 103 713,41 €
Justification
The UNIFG Unit is involved in WPs 3, 5, 6a, 7, and 8. A full professor of Hygiene,
epidemiologist, with approximately 20 years of professional experience in infectious
disease and chronic disease epidemiology will coordinate the tasks selected in each WPs.
An Assistant Professor of Hygiene will manage the activities and their progress. A
Contractor Medical doctor will work full time on them.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 4 General Assembly (2-day meetings for 2 person)
5 040,00 € WP5 - 7 mid-terms meetings (one person for 1 day
meeting)
5 760,00 € WP6a - 4 mid-terms meetings (Two persons for 1-
day meeting)
8 000,00 € WP5 country to country assessment
2 160,00 € WP8 - 3 (2 Teds & 1 High Level)
Total Costs (€) of (C) 28 480,00 €
(D) Indirect Costs (Max. 7% on 9 253,54 €
A, B and C)
Total estimated eligible costs 141 446,94 €
Total requested EC contribution 84 868,17 €
(60% max)
91 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
15. Italy – ISS
Applicant Number IT-15
Short Name ISS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) A. Pantosti - Director of Research 4 43 951,40 €
A. Carattoli - Director of Research 3 24 369,48 €
P. Pezzotti - Senior Researcher 5 37 937,35 €
L. Busani - Senior Researcher 11 75 583,75 €
F. Prestinaci - Tecnologist 4 29 210,00 €
A. M. Marella - Technical 2 7 131,90 €
collaborator
Total Costs (€) of (A) 218 183,88 €
Justification
A. Pantosti, a microbiologist with a background in Infectious Diseases and a long-standing
experience in peer-review and in evaluation of EU research proposals will lead WP3 (2 PM)
and participate to WP6 (1 PM) and WP7 (1 PM). A. Carattoli, a world-renown Molecular
Microbiologist expert in AMR transmission at the molecular level will participate in WP2 (1
PM) and WP9 (2 PM) (task 9.1-9.2). P. Pezzotti, a statistician epidemiologist will participate in
WP6 (3 PM) and WP7 (2PM) (task 7.3). L. Busani, a veterinarian epidemiologist with
experience in project evaluation will participate in WP7 (11 PM) and WP9 (1PM). F. Prestinaci,
a famacist will participate in WP6 (3 PM) and WP7 (1PM). A. M. Marella, a technical
collaborator, will give secretarial assistance to WP3 (2 PM).
(B) Direct costs of sub- Costs (€) Tasks subcontracted
contracting 75 000,00 € WP3 task 3.2-3.5-3.6
Total Costs (€) of (B) 75 000,00 €
Justification for resorting to subcontracting
Some of the activities of WP3 will be subcontracted to a party with proven experience in the
field of evaluation and experience in the setting and use of appropriate evaluation tools.
Subcontracting will regard the activities related: 25,000 Euro for task 3.2 (Development of
evaluation tool): Definition and provision of web-based tools to collect data and run surveys.
Their testing and revision during the project; 25,000 Euro for task 3.5 (Report of results to
relevant stakeholders): Preparation of an interim and final reports containing all indicators
and data and the evaluation of the impact of the project actions. Presentation of the reports
to the internal and external stakeholder; 25,000 Euro for the evaluation of the impact in
Europe. Preparation and analysis of questionnaires to national, regional and local authorities
as well as to professionals and citizens associations and analysis of official data and other
information from EU MS national and subnational web-sites
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 640,00 € ISS - 2 person for 2 day per 3 GA meeting
1 440,00 € WP9 - 1 person for 1 day per 2 meetings
15 040,00 € WP6a/b - 8 mid-terms for 2 persons + WP6 WP7 2
persons to visit 4 recruited hospitals in Italy
1 440,00 € ISS _WP3 pre-final meeting 2 persons x 1 day (other
location than Rome)
(C.2) Equipment Costs (€) Justification
5 000,00 € pc, laptops, tablets and printers
92 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(C.3) Other goods and services Costs (€) Justification
11 314,00 € GA general meeting event preparation + WP3 1st mid-
term meeting prepartion (13 persons)
20 000,00 € teleconferences, web tools, software updating at the
central and laboratory level (to reinforce surveillance
system), courier mail, printed materials
32 000,00 € Reimbursement to the hospitals for the pilot studies of
WP6 (Universal Infection Control Framework):
contribution to the expenses of 4 hospitals for
laboratory investigations and a part-ime infection
control person in each hospital for 1 year.
Total Costs (€) of (C) 91 874,00 €
(D) Indirect Costs (Max. 7% on 26 954,05 €
A, B and C)
Total estimated eligible costs 412 011,93 €
Total requested EC 247 207,16 €
contribution (60% max)
Answer to CHAFEA questions about the salary amount: The monthly rate is correct and includes: salary, social
security contribution, and direct income taxes
93 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
16. Latvia - PSKUS
Applicant Number LV-16
Short Name PSKUS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Uga Dumpis - Project team leader 2,6 8 794,00 €
Elina Dimina, Alise Gramatniece - 3,4 4 216,00 €
Medical expert
Jelena Urbena - Infection control 3,4 3 000,00 €
nurse
Liga Grudule - Administrative 2,6 5 040,00 €
coordinator
Total Costs (€) of (A) 21 050,00 €
Justification
Project team leader - coordination of medical team and project activities, communication
with WP leader and project lead partner, representative of the project in national and
international level. Medical experts - technical implementation of JA activities in hospital
level, cooperation with other specialists, data collection and analysis, trainings for medical
staff. Infection control nurse - applying project guidelines for internal use, implementation
of infection control measures, reporting on project medical activities and progress.
Administrative coordinator - management of financial and administrative tasks,
communication with lead partner, reporting, organizational work for travels, project
meetings.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € General Assembly 4 meetings (2 persons, 2 days)
5 760,00 € WP6 midterm 4 meetings (2 persons, 1 day)
(C.3) Other goods and Costs (€) Justification
services
500,00 € Training materials (simulators, disposables, visual aids)
Total Costs (€) of (C) 13 780,00 €
(D) Indirect Costs (Max. 7% 2 438,10 €
on A, B and C)
Total estimated eligible 37 268,10 €
costs
Total requested EC 22 360,86 €
contribution (60% max)
94 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
17. Lithuania - LSMULKK
Applicant Number LT-17
Short Name LSMULKK
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Astra Dambrauskiene - 9 16 200,00 €
Information scientist
Asta Vitkauskiene – 9 16 200,00 €
Information scientist
Lukas Cemnalianskis – 9 3 510,00 €
Information scientist
Total Costs (€) of (A) 35 910,00 €
Justification
Astra Vitkauskiene – MD, PhD, Professor, clinical microbiologist, the head of Laboratory
Medicine Department, over 20 years of experience in consulting and forming politics of
antimicrobial usage in tertiary health care hospital. She will be staff member in the
implementation of WP2, WP5, WP6, WP7. Asta Dambrauskiene – MD, physician of
Laboratory Medicine, the head of Infection Control Service in tertiary health care hospita,
10 years of experience in clinical microbiology, the head of hospital infection control group
in hospital. She will be staff member in in the implementation of WP5, WP6, WP8. Lukas
Cemnalanskis – MD, the resident of Laboratory Medicine, works in hospital Microbiology
Laboratory, responsible for management of Microbiology Laboratory information system.
He will be staff member in in the implementation of WP6, WP7.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2 880,00 € WP6A meetings
4 320,00 € WP7 meetings
3 760,00 € WP1 Kick-off meeting and General Assembly
Total Costs (€) of (C) 10 960,00 €
(D) Indirect Costs (Max. 7% on 3 280,90 €
A, B and C)
Total estimated eligible costs 50 150,90 €
Total requested EC contribution 30 090,54 €
(60% max)
95 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
18. Lithuania - VULSK
Applicant Number LT-18
Short Name VULSK
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Edita Kazenaite – Clinical 3 9 900,00 €
pharmacologist
Silvija Kiveryte – Physician of 3 8 700,00 €
laboratory medicine
Ruta Ambrazaitiene – Physician of 2 5 800,00 €
laboratory medicine
Asta Macioniene – Physician of 2 5 800,00 €
laboratory medicine
Kristina Marcinkeviciene – Physician 2 5 800,00 €
of laboratory medicine
Igne Venceviciute – Physician of 1 2 900,00 €
laboratory medicine
Total Costs (€) of (A) 38 900,00 €
Justification
Clinical pharmacologist - 15 years experience in regulating antimicrobials usage in the
hospital, leading HAI surveillance group in hospital, will be a key staff member in the
implementation of WP6:2
Physician of laboratory medicine - long experience working with HCAI and AMR,
participation in AMR networks, will be a key staff member in the implementation of WP6:2.
Physician of laboratory medicine - long experience working with HCAI and AMR, member of
the HAI surveillance group in hospital, will be a key staff member in the implementation of
WP6:2.
Physician of laboratory medicine - experience working with AMR, participation in AMR
networks, will be a staff member in the implementation of WP6:2.
Physician of laboratory medicine - experience working with AMR, participation in AMR
networks, will be a staff member in the implementation of WP6:2.
Project manager - 5 years experience in managing different projects in hospital, will be a
key staff member in WP2.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 760,00 € 4 European travel in WP6:2, task 6:2:1, 2 persons
(hospital)
7 520,00 € 4 General assembly, WP1, meetings, 2 persons
(hospital)
1 760,00 € 4 WP6:2 meetings in conjuction to general
assembly, one day, 2 persons. (EUR 220 per diem x
8 days) (hospital)
Total Costs (€) of (C) 15 040,00 €
(D) Indirect Costs (Max. 7% on 3 775,80 €
A, B and C)
Total estimated eligible costs 57 715,80 €
Total requested EC 34 629,48 €
contribution (60% max)
96 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
19. Lithuania - HI
Applicant Number LT-19
Short Name HI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Akvile Kenstaviciene - WP5 3,5 7 965,00 €
Specialist
Rolanda Valinteliene - WP5 6,5 16 315,00 €
& 7 Leader
Agne Plentaite - WP6 6 13 654,00 €
Specialist
Virginija Kanpeckiene - 6 15 061,00 €
WP6Leader
Greta Gasiunaite - Project 18 45 184,00 €
coordinator
Total Costs (€) of (A) 98 179,00 €
Justification
Akvile Kenstaviciene has experience in organisation and implementation of national and
regional AMR programs, participation in preparation and implementation of national legal
acts, ECDC national technical focal point for AMR and AB consumption. Rolanda Valinteliene
has experience in organisation and implementation of national AMR and HCAI control
programs, initiation and implementation of national legal act, participation in European
projects and programs, ECDC national focal point for AMR and HCAI. Agne Plentaite has
experience in organisation and implementation of national HCAI surveillance programs,
initiation and implementation of national legal acts, ECDC national technical focal point for
HCAI. Virginija Kanpeckiene has experience in planning and organisation of national HCAI
surveillance and national public health programs. Greta Gasiunaite has experience in planning
and organisation of national and regional public health projects.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3 760,00 € *General Assembly: (500+220+220)x1x4 (WP7)
5 040,00 € 7 mid-terms: 500+220) x1 x4 (WP5)
2 880,00 € 4 mid-terms: (500+220) x1 x4 (WP6b)
8 000,00 € WP5 country to country assessment
(C.3) Other goods and Costs (€) Justification
services
3 500,00 € Estimated 1 national conference to represent JA project
results and 2 local meeting with stakeholders (conference
room rent, coffee break, equipment, travel costs).
Total Costs (€) of (C) 23 180,00 €
(D) Indirect Costs (Max. 7% 8 495,13 €
on A, B and C)
Total estimated eligible 129 854,13 €
costs
Total requested EC 77 912,48 €
contribution (60% max)
97 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
20. Lithuania - NVSC
Applicant Number LT-20
Short Name NVSC
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Robertas Petraitis (Manager) 1,8 5 016,86 €
Asta Razmiene (Researcher) 3 6 039,64 €
Ingrida Skridailiene (Researcher) 2 4 907,73 €
Giedre Aleksiene (Researcher) 1,7 2 949,73 €
Brigita Kairiene (Researcher) 1,22 2 029,27 €
Ginreta Valinciute (Researcher) 1,64 1 458 ?43 €
Total Costs (€) of (A) 22 401,65 €
Justification
Robertas Petraitis a Doctor of Hygiene and Epidemiology with a university degree in
medicine and has a half of year of experience in managing Joint Action Programme at
national level. The role in JA – managing JA at national level, communication with JA
management bodies, communication with national institutions, stakeholders.
Asta Razmiene is a Doctor of Hygiene and Epidemiology with a university degree in
medicine and has more than 20 years of professional experience in public health safety
control in Vilnius County, including inspections of healthcare institutions, also in
communicable and non-communicable diseases epidemiology and environmental health.
The role in JA – WP6.2 activities at regional level, focus on study and acting activities.
Ingrida Skridailiene is a Public Health Specialist with a university degree; has more than 10
years of professional experience in public health activities at national level, including
planning and implementation. The role in JA – WP6.2 activities at national level, focus on
planning and implementation measures.
Giedre Aleksiene is an Epidemiologist with a university degree; has more than 20 years of
professional experience in public health activities, including control of communicable
diseases and hospital acquired infections in Vilnius County and a half of year of experience
in public health activities at national level, planning and implementation. The role in JA –
WP8 activities at national level, focus on planning and implementation of measures.
Brigita Kairiene – is a Public Health Specialist with a university degree, has more than 13
years of professional experience in Public Health, 4 of them – in communicable diseases
epidemiology and 3 years experience in managing antimicrobial resistance (AMR) group
activities in Klaipeda County. The role in JA – coordinating WP7 activities in regional level,
providing comments and suggestions for implementation of measures at regional level.
Ginreta Valinciute is a Public Health Specialist with a university degree (related field of
study – Epidemiology field) and has more than 2 years of experience as Chief Specialist in
the Department of Communicable Diseases Control (responsibilities: investigate and
eradicate outbreaks, conduct analytical epidemiological studies). The role in JA –
implementation of WP8 activities at regional level, focus on promoting the responsible use
of antibiotics.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € KoM + 3 General Assembly (WP1) for 2 people 2 days
5 760,00 € 4 European travels for WP6
Total Costs (€) of (C) 13 280,00 €
(D) Indirect Costs (Max. 7% 2 497,72 €
on A, B and C)
98 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Total estimated eligible 38 179,37 €
costs
Total requested EC 22 907,62 €
contribution (60% max)
99 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
21. Netherlands – VWS
Applicant Number NL-21
Short Name VWS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) (Rosa Peran) WP nr. 5 coordination WVS- 12 111 000,00 €
IZ
(Jacqueline Pronk) WP nr. 5 coord. Adm. 3 13 800,00 €
VWS-IZ
(Maria Legrand / Jolanda vd Kamp) WP 3 22 500,00 €
nr. 5 policy officer WVS-PG
(Merel Langelaar) WP nr. 5 expert VWS- 7 64 750,00 €
IGZ
(Carline vd Dool) WP nr. 5 expert VWS- 7 52 500,00 €
RIVM
(Lili Guo) WP nr. 9 policy advisor 4 30 000,00 €
innovation VWS-GMT
(Arjan Elsenmulder) WP nr. 8 2 15 000,00 €
communication spec. VWS-DCO
(Merel Langelaar / Carline vd Dool) WP 2 18 500,00 €
nr. 6 experts VWS-RIVM/IGZ
(Merel Langelaar / Carline vd Dool) WP nr 5 37 500,00 €
6 professional VWS RIVM-IGZ
To be defined WP nr. 7 profesional VWS- 2 15 000,00 €
RIVM
Total Costs (€) of (A) 380 550,00 €
Justification
WP 5: Rosa Peran (or equivalent): coordination VWS-IZ including the general coordination
Joint Action in NL and coordination and management of WP5, incl. contact with other
institutions, and contribution to all task of WP5 and coordination within VWS/NL of all
activities of the Joint Action. Jacqueline Pronk (or equivalent): administration/logistics;
Maria Legrand/Jolanda vd Kamp (or equivalent): Policy offcier VWS-PG contribution to WP5,
specially Task 5.1 and 5.2. Merel Langelaar (or equivalent): Expert VWS-IGZ, contribution to
all task of WP5 and leader Task 5.3. Carline vd Dool (or equivalent): Expert VWS-RIVM:
contribution to task 5.1 and 5.2.; WP9: Lili Guo (or equivalent): policy advisor innovation
VWS-GMT: contribution to WP9; WP8: Arjan Elsenmulder (or equivalent): Communication
specialist VWS-DCO, contribution to WP8 (task 1 and 4) and affiliated for the otehr pther
tasks in this WP. WP6: Merel Langelaar and Carline vd Dool (or equivalent): experts on
infection prevention from VWS-RIVM and VWS-IGZ: (contribution 0,8+0,4) contribution to
both WP6 and coordination in the NL of hospitals and nursing homes. + names not known
at this moment: (contribution 3+1,7 person-month) professional of RIVM/IGZ on infection
prevention. WP 7: Carline vd Dool (or equivalent) contribution 0,42 person/month of
experts of VWS-RIVM to the activities of WP7 and coordination with hospital/nursing homes
+ Names not known at this moment (contribution 0,8 person month): professionals from
VWS-RIVM (microbiology, phfarmacology and epidemiology).
(B) Direct costs of sub- Costs (€) Tasks subcontracted
contracting 80 000,00 € WP 6 & 7: costs of participating hospitals and
nursing homes.
Total Costs (€) of (B) 80 000,00 €
Justification for resorting to subcontracting
Hospitals and nursing homes don't belong to the Dutch government. They are private
instituitions. That's the reason they are considered sub contractors. Based on the available
100 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
information as provided by the WP leaders at the time of stimating this budget, the cost of
the subcontracting has been estimated calculating the workload and translating it into
person month units. Other cost like travel cost or equipment are not included in this
estimation and will be coverd by VWS. WP6: 5,6 person month x 7500 euro = 37500 euro =
(incl: profesionals on infection prevention and manamgent) WP6B: 5,1 person month x 7500
euro = 37500 euro (incl. professionals on infection prevention). WP7: 3,84 person month x
7500 euro = 28800 euro (incl. micorbiologist/phamacologist/nurse). With the information
available at this moment it is not possible to sign start yet a formal dialogue contract with
hospitals/nursing homes, and therefore it is not possible to indicate the name of the
hospital/nursing homes and provide a more exhaustive estimation of the costs.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 040,00 € WP5. One person for a one day pWG meeting
(720). Seven p WG-meetings. In three years.
Wp 5 in case of meetings not hold in
Netherland (but for example in BXL or LUX).
15 000,00 € WP5, 3 experts invited for one pWG meeting
(720). 5 pWG meetings in 3 years.
1 440,00 € WP 9, two meetings
2 160,00 € WP 8 three meetings
8 000,00 € WP5: Country to country visits
7 520,00 € WP1: AG Assembly meetings (4x2 persons)
5 760,00 € report to the One health Workgroup in
Brussels (4)
(C.3) Other goods and Costs (€) Justification
services
30 800,00 € Organisation seven physical meetings.
Average 50 participants. 88 euro per person.
2 100,00 € Webex/Audio conference 14 times 150€
Total Costs (€) of (C) 77 820,00 €
(D) Indirect Costs (Max. 7% 37 685,90 €
on A, B and C)
Total estimated eligible 576 055,90 €
costs
Total requested EC 345 633,54 €
contribution (60% max)
101 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
22. Norway – Hdir
Applicant Number NO-22
Short Name HdiR
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Senior advisor 1, antiobiotic use 2,00 18 217,00 €
in GP
Senior advisor 2, AMR action plans 2,00 20 998,00 €
Total Costs (€) of (A) 39 215,00 €
Justification
Hdir will participate in WP 7 "Appropriate use of antimicrobials in health care" with the
following employees: Senior adviser 1 is working at the department of Community Health
Services and is responsible for infectious diseases and for the Norwegian guidelines for
antibiotic use in General Practice. Senior adviser 2 is working at the Department of
Medicinal Devices and Medicinal products and especially with implementing policies and
interventions in health care services, including clinical guidelines and action plans against
antimicrobial resistance. Tasks 7.1, 7.3 and workshop 7.2. Participation in 7.4 is currently
not clarified yet.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7520 € KoM + 3 GA meetings for 2 people 2 days
1 880,00 € Additional WP 7 meeting, 2 days, 2 people
Total Costs (€) of (C) 9 400,00 €
(D) Indirect Costs (Max. 7% on 3 403,05 €
A, B and C)
Total estimated eligible costs 52 018,05 €
Total requested EC contribution 31 210,83 €
(60% max)
102 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
23. Norway – FHI
Applicant Number NO-23
Short Name FHI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Senior Advisor - Christine Årdal 16,37 120 006,60 €
(WP9)
Advisor - Live Storehagen (WP9) 16,33 91 980,05 €
Senior physician - Oliver Kacelnik 14,52 150 786,92 €
(WP7)
Physcian PhD candidate - Cecilia 18,00 101 706,52 €
Kållberg (WP7)
Senior Researcher - Hege Salvesen 2,41 25 027,18 €
Blix (WP7)
Total Costs (€) of (A) 489 507,27 €
Justification
As per the partner description, the Norwegian Institute of Public Health is leading two
work packages - WP7 and WP9. These labor costs represent the leaders' time
contributions as well as support staff.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
9 360,00 € Thirteen European travels for one person of WP9
(9.1=3; 9.2=6)
12 960,00 € Six travels per participant in WP7 to cover face to
face meetings for the implementation of the pilot
projects.
7 520,00 € General Assembly - 2 persons for 2 days for 4
meetings
Total Costs (€) of (C) 29 840,00 €
(D) Indirect Costs (Max. 7% on 36 354,31 €
A, B and C)
Total estimated eligible costs 555 701,58 €
Total requested EC contribution 333 420,95 €
(60% max)
103 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
24. Norway – NVI
Applicant Number NO-24
Short Name NVI
(A) Direct personnel costs Persons (position) Total Person- Total Costs (€) of (A)
(including Public officials) Month
WP9, NVI staff members with 7,00 49 000,00 €
complementary expertise as
described in partner description
form (senior scientists)
Total Costs (€) of (A) 49 000,00 €
Justification
Research staff at the Norwegian Veterinary Institute (NVI) that will be involved in the action
have complementary backgrounds as described in partner description form. These staff
members have been active in development and implementation of the Norwegian strategy
and action plan against AMR in the veterinary sector and are involved in several AMR
research and development projects. The total costs may seem high, but simply reflects the
high costs in Norway.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
720,00 € Mandatory meeting WP9, one person
3 760,00 € Three mandatory GA meeting, 1 persons + KOM
Total Costs (€) of (C) 4 480,00 €
(D) Indirect Costs (Max. 7% on 3 743,60 €
A, B and C)
Total estimated eligible costs 57 223,60 €
Total requested EC contribution 34 334,16 €
(60% max)
104 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
25. Poland - NMI
Applicant Number PL-25
Short Name NMI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Waleria Hryniewicz - Prof. in 4 9 638,55 €
medicine expert in AMR and
HAI
Dorota Zabicka - PhD 5 7 831,33 €
specialist in clinical
microbiology and AMR
Anna Olczak-Pienkowska – 4 5 263,16 €
Public health professional,
specialist in antibiotic
consumption
Total Costs (€) of (A) 22 733,04 €
Justification
The experts from our team will participate in the following WPsWP5 involvement of the Prof
in medicine with more than 10 years experience in leading the National Program for Antibiotic
Protection and an experts with the experience in the participation in the program in Poland;
WP7 participation of public health professional, specialist in antibiotic consumption.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 4 General Assembly meetings for 2 persons (1
national/regional)
5 040,00 € WP5 7 meetings one day for 1 person
8 000,00 € WP5 country to country assessment
Total Costs (€) of (C) 20 560,00 €
(D) Indirect Costs (Max. 7% 3 030,51 €
on A, B and C)
Total estimated eligible 46 323,55 €
costs
Total requested EC 27 794,13 €
contribution (60% max)
105 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
26. Portugal – DGS
Applicant Number PT-26
Short Name DGS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Paulo André Fernandes - Physician, 2 9 200,00 €
Intensivist, IPC&AMR practicioner
Carlos André Palos - Physician, 2 9 200,00 €
Intensivist, IPC&AMR practicioner
Pedro Pacheco - Physician, General 2 9 200,00 €
Practicioner
Ana Paula Cruz - Reg. Nurse 3 8 400,00 €
Specialist, IPC practicioner
Margarida Valente - Reg. Nurse 4,5 12 600,00 €
Specialist, IPC practicioner
Isabel Neves - Physician, 5 23 000,00 €
Infecciologist,IPC&AMR practicioner
Total Costs (€) of (A) 71 600,00 €
Justification
Paulo André Fernandes – Physician, Intensivist, MasterD in HAI, director of national program
for IPC &AMR; field work in ES, IPC & AMR. Carlos André Palos -Physician, Intensivist, member
of IPC&AMR national program coordination, Postgraduate in HAI, university lecturer , field
work in ES, IPC & AMR Pedro Pacheco– Physician,General Practicioner,member of IPC&AMR
national program coordination, field work in ES, IPC,AMR. Ana Paula Cruz – RN Specialist,
MasterD in HAI, member of IPC&AMR national program coordination, field work in ES,
IPC&AMR. Margarida Valente - RN Pediatric Specialist, Postgraduate in HAI, member of
IPC&AMR national program coordination, field work in ES, IPC&AMR. Isabel Neves - Physician,
Infecciologist, member of IPC&AMR national program coordination, field work in ES,
IPC,AMR.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
11 520,00 € WP6 A & B meetings (5720€ for each objectives,
meetings in Europe for 2 people)
2 160,00 € WP8 three meetings
7 520,00 € WP1 : Kick-off meeting + 3 General Assembly
meetings for 2 people 2 days
Total Costs (€) of (C) 21 200,00 €
(D) Indirect Costs (Max. 7% on 6 496,00 €
A, B and C)
Total estimated eligible costs 99 296,00 €
Total requested EC 59 577,60 €
contribution (60% max)
106 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
27. Romania – UMPIH
Applicant Number RO-27
Short Name UMPIH
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Mihu Dan - Professor 3,5 7 000,00 €
Ciortea Razvan - Lecturer 4 4 400,00 €
Malutan Andrei - Assistant 2,5 2 500,00 €
professor
Iuhas Cristian - Assistant 2,5 2 500,00 €
professor
Total Costs (€) of (A) 16 400,00 €
Justification
Professor - extensive experience in coordinating and managing public health research and
capacity building projects; also member in Academic Organizations that may facilitate
dissemination of the research results. Lecturer - extensive experience in conducting
clinical research; can have an essential contribution in initiating and managing a pilot
study, having access in clinical settings. Assistant professor - focuses on developing
international health networks. Assistant professor - has experience in financial
management and provides technical support for project implementation. Staff members
will contribute to activities included in WP2, WP5, WP7.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
11 840,00 € 4 General Assembly (2 days meetings)- WP1 and WP5
meetings
8 000,00 € WP5 country to country assessment
Total Costs (€) of (C) 19 840,00 €
(D) Indirect Costs (Max. 7% on 2 536,80 €
A, B and C)
Total estimated eligible costs 38 776,80 €
Total requested EC contribution 23 266,08 €
(60% max)
107 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
28. Slovenia – NIJZ
Applicant Number SI-28
Short Name NIJZ
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Jana Kolman (senior researcher) 13 61 100,00 €
Maja Subelj (junior epidemiologist) 6 18 000,00 €
Mojca Serdt (junior epidemiologist) 3 6 300,00 €
Mitja Vrdelja (communication 2 5 600,00 €
researcher)
Katja Turk (communication 2 4 800,00 €
researcher)
Petra Džinić (administration and 1 2 000,00 €
financial officer)
Total Costs (€) of (A) 97 800,00 €
Justification
Jana Kolman, Mojca Serdt and Maja Subelj are experts in the field of AMR and HCAI. They will be
involved in WP5 to contribute to the tasks (Task 5.1, Task 5.3); in WP6 to contribute to Task 6.2.1
and Task 6.2.2 and with 1 PM in WP9. Mitja Vrdelja and Katja Turk, experts in communication,
and Maja Subelj, will be involved in WP8 to contribute to the Tasks 8.4. Maja Subelj and Katja
Turk will be actively involved in the activities of dissemination of the JA results (WP2).
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 4 GA meetings (2 persons)
5 040,00 € WP5 meetings (1 person, 7 one day meetings)
2 160,00 € WP8 meetings (3 one day meetings, one person)
8 640,00 € European travel in WP6:2, task 6:2:1, 3 persons (1
national/regional and 2 hospital)
2 640,00 € WP6:2 meetings in conjuction to general assembly, one
day, 3 persons. (EUR 220 per diem x 8 days) (1
national/regional and 2 hospital)
2 880,00 € European travel in WP6:2, light track, 1 person
8 000,00 € WP5 country to country assessment
1 440,00 € WP9 meetings (2 one day meetings, one person)
(C.3) Other goods and Costs (€) Justification
services
6 000,00 € national meetings (room hiring, catering…) to build
capacities in all hospitals (not only in those being
involved in the pilot)
Total Costs (€) of (C) 44 320,00 €
(D) Indirect Costs (Max. 7% 9 948,40 €
on A, B and C)
Total estimated eligible 152 068,40 €
costs
Total requested EC 91 241,04 €
contribution (60% max)
108 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
29. Spain – AEMPS
Applicant Number SP-29
Short Name AEMPS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) WP4,5,6,7, AEMPS Manager 36 112 500,00 €
WP2 Communication Officer 30 93 750,00 €
WP8 Communication Officer 18 56 250,00 €
Communication Strategy 22 68 750,00 €
AEMPS Coordinator WP7 6 24 000,00 €
WP2&WP8 AEMPS Coordinator 12 42 000,00 €
Total Costs (€) of (A) 397 250,00 €
Justification
WP2 is a dissemination WP and it will have to manage the website, create the visual identity,
support the dissemination needs of the rest of the WP, manage news, newsletters, etc. We think
it would be needed a Communication Officer and a Webmaster and also a coordination (with the
WP8) of a AEMPS staff. We think that WP8 is still more complex due to generate content, attract
the public attention and the health and mass media interest. It is necessary to carry out different
types of activities and promotions. It is need a Strategy Manager (partial time) and a
Communication Officer (almost full time). AEMPS also participates as leader in WP7 and as
associate partners in other WPs and our activity hast to be managed for a staff similar to Project
manager. This would be coordinated for a AEMPS staff (6 months) and almost sure we will need
to manage much information beetween partners and it would be very useful a manager
assistance .
(B) Direct costs of sub- Costs (€) Tasks subcontracted
contracting 32 000,00 € Website Design and Implementation
22 000,00 € conference type TED x1
25 000,00 € SOCIAL CAMPAIGN 1 UNIT
Total Costs (€) of (B) 79 000,00 €
Justification for resorting to subcontracting
Develop a website as central hub for internal communication as well as main platform to
communicate outputs and disseminate the information to the targeted audiences: Design a
document sharing or repository platform as for internal communication, and design and
implementation of a web platform as for external dissemination. The benefit of developing this
website in a way that best suits the needs of the project will ensure the key role of WP2 as the
coordinating body of the dissemination activities for the project and make sure that results and
relevant information produced over the lifetime of the project will not be lost and can continue
to be a crucial part of JA products and services well into the future
In the WP8 we propose to carry out one conference, with scientific communicators or with High
School students or university students as speakers. It will focus on scientific spreading targeted
at the general public, journalists and healthcare/veterinary professionals or their representative
organizations. This event will cover the most recent data on AMR in order to inform all of these
groups in a clear, accurate way so that, eventually, we raise awareness on the topic. The
conference could be divided in several presentations by different experts participating in JAMRAI
and to be selected from, for example, ECDC, WHO experts). The event will be held in a location
to be confirmed. All the details related to this conference’s contents and organization will be
studied and decided by the JAMRI WP8 team.
In the WP8, a Social campaign will be designed in order to address general public and healthcare
professionals in both human and animal health, according to the One Health approach. The social
campaign will be mainly structured online, on the basis of a video that will be promoted through
109 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
social media profiles. The video will be made as a creative and visually attractive piece of work
that grabs general attention on the AMR problem. The project budget will consider organizing
different online complementary materials/activities to the video (e.g. gifs, collaboration with
influencers) in order to improve chances of it going viral and for the better spreading of our
messages. All of the actions involved in this social campaign should be planned in detail and
finally agreed upon between all the members of the JAMRI WP8 team in collaboration with the
rest of participant or collaborating entities, (JA coordinator, ECDC, WHO-Europe) for this proposal
to work as a starting point.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
15 360,00 € WP1, 5,6a,6b, 8 AEMPS travel costs
3 000,00 € Awards report and video 4 flights and DSA
13 000,00 € High level and Dissemination Conference 20 flights and
DSA
8 000,00 € WP5 country to country assessment
(C.3) Other goods and Costs (€) Justification
services
12 000,00 € Visual identity: logo, layman report, leaflets
25 300,00 € Catering high level and dissemination Conference
300 px + Organisation of a General Assembly meeting
3 300,00 € catering WP8 6 F2F
15px
6 000,00 € Prizes report and video
4 prizes
2 500,00 € 1 promotional online
campaign as
competition or game
7 000,00 € High level and Dissemination Conference streaming and
short interviews
21 600,00 € 3 promotional online campaigns to atract traffic to the
website
Total Costs (€) of (C) 117 060,00 €
(D) Indirect Costs (Max. 7% 41 531,70 €
on A, B and C)
Total estimated eligible 634 841,70 €
costs
Total requested EC 380 905,02 €
contribution (60% max)
110 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
30. Spain – GENCAT
Applicant Number SP-30
Short Name GENCAT
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials)
Gloria Oliva - Public health 8 20 000,00 €
specialist
Marta Massanes - Pharmacy 8 20 000,00 €
technician
Laura Navarro - Infectious 12 18 000,00 €
disease physician
Total Costs (€) of (A) 58 000,00 €
Justification
Down below we detail the breakdown between the Work Package for Public Health specialist
(PHS), the Pharmacy technician (PT) and the two Infectious disease physicians (IDP):
PHS: 3 months WP6 + 3 months WP7 + 2 months WP8: 8 months * 2.500 € = 20.000 €
PT: 3 months WP6 + 3 months WP7 + 2 months WP8: 8 months * 2.500 € = 20.000 €
IDP: 6 months WP6 + 6 months WP7: 12 months * 1.500 € = 18.000 €
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 760,00 € Two persons for 1-day meeting corresponding to WP6a
1 440,00 € Corresponding to WP8
7 520,00 € General Assembly meetings + KoM
Total Costs (€) of (C) 14 720,00 €
(D) Indirect Costs (Max. 7% on A, 5 090,40 €
B and C)
Total estimated eligible costs 77 810,40 €
Total requested EC contribution 46 686,24 €
(60% max)
111 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
31. Spain – IdISBa
Applicant Number SP-31
Short Name IdISBa
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Benito Prosper - General 1,44 7 971,21 €
Manager of Planning, Evaluation
and Pharmacy
Eusebi Castano - Head Service of 2,88 16 180,56 €
Health Planning
Antonio Oliver - Clinical 4,68 28 803,45
Microbiologist
Leonor Perianez - Clinical 4,32 32 693,50 €
Pharmacist
Elena Ferragut - Project Manager 2,52 8 654,29 €
Total Costs (€) of (A) 94 303,01 €
Justification
A General Manager from the Regional Ministry of Health to critical review the documents
generated in WP6, 7, 8 and 9. A Head Service of Health Planning from the Regional Ministry of
Health to critical review the documents generated in WP6, 7, 8 and 9.
A Clinical Microbiologist from the Health Service of the Balearics (Hospital Universitario Son
Espases) to actively contribute to Task 1, 3 and 4 of WP7 and critical review of documents
generated in WP6, 8 and 9. A Clinical Pharmacist from the Health Service of the Balearics
(Hospital Universitario Son Espases) to actively contribute to Task 1, 3 and 4 of WP7 and critical
review of documents generated in WP6, 8 and 9. A Project Manager from FISIB to manage the
budgetary, legal and administrative aspects of the JA.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € WP1: 4 General assembly meetings, 2 persons, 2 days (1
regional and 2 hospital)
8 640,00 € WP6: 4 Mid-term meetings, 3 persons, 1 day (1 regional
and 2 hospital)
2 160,00 € WP8: 3 Mid-term meetings, 1 persons, 1 days
1 440,00 € WP9: 2 Mid-term meetings, 1 persons, 1 day
Total Costs (€) of (C) 19 760,00 €
(D) Indirect Costs (Max. 7% 7 984,41 €
on A, B and C)
Total estimated eligible 122 047,42 €
costs
Total requested EC 73 228,45 €
contribution (60% max)
112 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
32. Spain – FFIS
Applicant Number SP-32 Fundacion para la Formacion e Investigacion Sanitarias de la region
de Murcia
Short Name FFIS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Maria del Pilar Lopez Acuna -
Project Manager Coordinator
(FFIS) 7,50 23 857,50 €
Gema Martin Ayala -
Pharmacist/Project research
technician(2)(FFIS) 2,20 5 555,00 €
Hana Hukelova - Project
management Technician (FFIS) 3,00 6 627,00 €
Total Costs (€) of (A) 36 039 ,50 €
Justification
Project Manager Coordinator (FFIS) Coordinate all the activities related to the tasks of the
work packages, actively participate in the evaluation process. Pharmacist/Project research
technician (2)(FFIS) Participation in the development of prescribing recommendations for
responsible use of antibiotics in infectious diseases, and development of community
interventions to promote the responsible use of antibiotics. Project management
Technician (FFIS) Participation in evaluation, administrative support and communication
skills.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 4 General assambly 2-days meetings (2 persons)
(WP1)
11 520,00 € 4 mid-terms 1-day meetings (2 persons) (WP6a) + 4
mid-terms 1-day meetings (2 persons) (WP6b)
1 734,00 € 1 meeting 1-day (1 person) and cost for preparing a
pre-final meeting for 13 persons (WP3)
1 440,00 € 1 Ted and 1 high level 1-day meetings (1 person)
(WP8)
Total Costs (€) of (C) 22 214,00 €
(D) Indirect Costs (Max. 7% 4 077,75 €
on A, B and C)
Total estimated eligible 62 331,25 €
costs
Total requested EC 37 398,75 €
contribution (60% max)
Applicant Number SP-32 FFIS – Affiliated entity
Short Name DGPIFAC
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Casimiro Jimenez Guillen -
Pharmacist/Project Research
Manager (DGPIFAC) 0,50 2 720,00 €
Total Costs (€) of (A) 2 720,00 €
113 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Justification
Pharmacist/Project Research Manager (DGPIFAC) Support the design of strategies for
action related to AMR HCAIs in the region in Primary Care and Hospitals.
(D) Indirect Costs (Max. 7% 190,40 €
on A, B and C)
Total estimated eligible 2 910 ?40 €
costs
Total requested EC 1 746,24 €
contribution (60% max)
Applicant Number SP-32 FFIS - Affiliated entity
Short Name SMS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Ricardo Garcia de Leon Gonzalez
- Pediatrician/Project
Research(1) (SMS) 1,70 12 211,10
Santiago Alfayate Miguelez -
Medical Clinician Expert(1) (SMS) 2,50 13 750,00
Olga Monteagudo - Public Health
/ Project Research (SMS) 1,50 5 859,00
Manuel Alcaraz Quinonero -
Medical Clinician Expert (SMS) 2,20 12 927,20
Jose Arnau Sanchez - Nurse/
Project Research Technician
(SMS) 2,70 10 897,20
Total Costs (€) of (A) 55 644,50 €
Justification
Pediatrician/Project Research(1) (SMS )Support relief actions for the appropriate use of
antimicrobials, implementation and prioritization of evidence for the use in specific
contexts, analysis of implementation and change of attitude in the responsible use of
antibiotics, selection of AMR indicators and support communication actions and
awareness on the issue. Medical Clinic Expert(1) (SMS) Participation in evaluation and
support in the top-down and the bottom-up approach for HCAI for institutional behavior
change and clinical change. He works in our Region in the AMR and control infections al
Hospital Level. Medical Clinician Expert (2) (SMS) Support actions for the appropriate use
of antimicrobials, implementation and prioritization of evidence for the use in specific
contexts, analysis of implementation and change of attitude in the responsible use of
antibiotics, selection of AMR indicators and support communication actions and
awareness on the issue in Primary Care and has a wide clinical and manager experience
and good promoter of the change both, in hospital environment and in Primary Care.
Principal’s promoters of the AMR in the region. Public Health / Project Research (SMS)
Evaluation process, policies for prevention HCAI and their implementation, activities to
implement appropriate use of AM in Health care developing communication strategy’s at
professional level. Nurse/ Project Research Technician (SMS)Actions to implement clinical
guidelines and the analysis of social-health context, training of professionals and
qualitative research to explore the social knowledge about AMR
(D) Indirect Costs (Max. 7% 3 895,12 €
on A, B and C)
Total estimated eligible 59 539,62 €
costs
Total requested EC 35 723,77 €
contribution (60% max)
114 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
33. Spain – FMS
Applicant Number SP-33
Short Name FMS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials)
Carmen Ezpeleta - Principal 3 14 037,00 €
investigator-Clinician
Albetro Gil - Specialist 3 14 000,00 €
Microbiology
Total Costs (€) of (A) 28 037,00 €
Justification
One specialist in clinical microbiology, with a university degree in medicine with over 15
years experience in clinical microbiology, and specifically in the areas of antimicrobial
resistance, tuberculosis, STD and primary care microbiology. One specialist in clinical
microbiology with an university degree in medicine with specific training in infectious
diseases for 5 years, with a doctorate in microbiology with professional experience of over
20 years in clinical microbiology and infectious diseases, specifically in the areas of
bacteremia, infection control, antimicrobial resistance, molecular microbiology.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 €1 KoM & 3 General assembly for 2 days 1 people
Total Costs (€) of (C) 7 520,00 €
(D) Indirect Costs (Max. 7% on A, 2 488,99 €
B and C)
Total estimated eligible costs 38 045,99 €
Total requested EC contribution 22 827,59 €
(60% max)
115 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
34. Spain – SAS
Applicant Number SP-34
Short Name SAS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Jose Miguel Cisneros (PI Task 4 15 750,00 €
coord medical staff)4
Jose Antonio Lepe - 3 11 250,00 €
Microbiologist
Maria Victoria Gil Navarro - 3 13 500,00 €
Farmaceutic
Raquel Valencia - Infectious 3,1 13 950,00 €
Disease Clinician
Total Costs (€) of (A) 54 450,00 €
Justification
Jose Miguel Cisneros - PI task coord medical staff
Expertise: Infectious Diseases
Role: Coordination of activities and risks assessment.
José Antonio Lepe (Expertise: microbiology) + María Victoria Gil Navarro (Expertise:
Pharmacy) + Raquel Valencia (Preventive Medicine)
Role: They will take the lead of the definition and updating of indicators for surveillance
system (Resistance and consumption of antimicrobials) in working groups.
(D) Indirect Costs (Max. 7% 3 811,50 €
on A, B and C)
Total estimated eligible 58 261,50 €
costs
Total requested EC 34 956,90 €
contribution (60% max)
Applicant Number SP-34 Affiliated entity
Short Name FISEVI
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Research assistant: to be 6 17 400,00 €
selected by Public offer - actual
staff involved: German Penalva
Total Costs (€) of (A) 17 400,00 €
Justification
Research assistant: to be selected by Public offer - actual staff involved: Germán Peñalva.
Expertise: Data management
Role: Database design and implementation; data management follow-up; quality of data
issues.
(B) Direct costs of sub- Costs (€) Tasks subcontracted
contracting 10 000,00 € Database
10 000,00 € Training database management
Total Costs (€) of (B) 20 000,00 €
Justification for resorting to subcontracting
116 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 640,00 € KoM + General Assembly
Total Costs (€) of (C) 5 640,00 €
(D) Indirect Costs (Max. 7% 3 012,80 €
on A, B and C)
Total estimated eligible 46 052,80 €
costs
Total requested EC 27 631,68 €
contribution (60% max)
117 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
35. Spain – ISCIII
Applicant Number SP-35
Short Name ISCIII
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Carlos Segovia – Public 0,8 3 200,00 €
official
Maria Jose Gonzalez – 0,8 3 200,00 €
Public official
Pilar Gallego – Public 1,8 7 200,00 €
official
José Campos – Public 1,8 7 200,00 €
official
Total Costs (€) of (A) 20 800,00 €
Justification
Carlos Segovia is head of unit for Heatlth Research Institutes based on teaching hospitals
across the country. María José González is national focal point for the health programme.
Pilar Gallego is head of the area of chronic diseases at the National Centre for Epidemiology
- ISCIII. José Campos is head of the unit for AMR at the National Centre for Microbiolody -
ISCIII.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
8 640,00 € 4 European travel in WP6:2, task 6:2:1, 3 persons (1
national/regional and 2 hospital)
7 520,00 € 4 General assembly, WP1, meetings, 2 persons (1
national/regional and 2 hospital)
2 640,00 € 4 WP6:2 meetings in conjuction to general assembly, one day,
3 persons. (EUR 220 per diem x 8 days) (1 national/regional
and 2 hospital)
Total Costs (€) of (C) 18 800,00 €
(D) Indirect Costs (Max. 7% on 2 772,00 €
A, B and C)
Total estimated eligible costs 42 372,00 €
Total requested EC 25 423,20 €
contribution (60% max)
118 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
36. Spain – SERMAS
SERMAS budget will be totally managed by its affiliated entity, see below
Applicant Number SP-36 – Affiliated Entity
Short Name FBRIPC
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) José Manuel Izquierdo Palomares, Ainhoa 10,31 30 922,50 €
Aranguren Oyarzabal and Tomas Gomez
Gascon - Internal coordination WP7,8,9
To be hired – Computer programmer 12 18 000,00 €
To be hired – pharmacists 12 18 000,00 €
Total Costs (€) of (A) 66 922,50 €
Justification
The internal coordination team will consist of pharmacists, microbiologists, epidemiologists
and infectious diseases clinical physicians. Other professionals from primary care and
hospital settings will also participate mainly in the pilots under the tasks of WP 7.3, 7.4.1 ,
awareness and communication plan of tasks WP 8.2 and 8.3 and contribution of the
implementation of evidence-informed public health policies and practices related to
combatting AMR and HCAI of task WP 9.3.
There will be necessary to hire a computer programmer and pharmacist to work in the
Subtask 7.4.1 Antimicrobial surveillance in humans. The pharmacist will contribute to: -
Select basic indicators for surveillance system of antimicrobials consumption. - Select basic
indicators for surveillance system of antimicrobial resistance. - Map out the information of
the different sites - Coordinate the actions to develop the pilots: meetings, information of
the different data bases, design and implementation of the website, validate the software
and the analysis of the results. The computer programmer will create the software that
will be developed specifically to carry out the pilot, combining different sources of
information, and the website that collect the whole information.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € 4 General Assembly for 2 people
Total Costs (€) of (C) 7 520,00 €
(D) Indirect Costs (Max. 7% on 5 210,98 €
A, B and C)
Total estimated eligible costs 79 653,48 €
Total requested EC contribution 47 792,09 €
(60% max)
119 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
37. Sweden – FOHM
Applicant Number SE-37
Short Name FOHM
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) PHAS AMR Expert, MD, WP 6 – 7,2 103 579,00 €
Olof Aspevall
PHAS Analyst, AMR competence, 36 310 737,00 €
project leader for WP6, to hire
PHAS Pharmacist WP5&7 – 5 88 333,33 €
Malin Grape
Total Costs (€) of (A) 502 649,33 €
Justification
WP6:2: A project leader with a university degree in medicine or similar and professional
experience in infection control. Experience in international project management. Recruitment
ongoing as of January 2017. Olov Aspevall, a senior MD specialised in clinical microbiology with
15 years of professional experience with focus on AMR. 5 years´ experience of leading
international multicentre improvement projects within the field of infection prevention and
control. WP5 and WP7: Malin Grape, a pharmacist with a PhD in the area of antimicrobial
resistance and 5 years professional experience of policy work within infection control and
antibiotic stewardship.
(B) Direct costs of sub- Costs (€) Tasks subcontracted
contracting 20 000,00 € Conference facilites, 4 European meetings, approx 50
participants at 150 EUR.
Total Costs (€) of (B) 20 000,00 €
Justification for resorting to subcontracting
Venues with proper equipment are essential for productive meetings.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5 760,00 € 4 European travel in WP6:2, task 6:2:1 & 2, 2 persons
(national/regional)
7 520,00 € 4 General assembly, WP1, meetings, 2 persons
(national/regional)
4 320,00 € 6 mid-terms WP 5, 1 person, national/regional
8 000,00 € WP5 country to country assessment
5 760,00 € 4 mid-terms WP6a, 2 persons national/regional
(C.3) Other goods and Costs (€) Justification
services
60 000,00 € Development of training material (Checklists, leaflets,
summaries of information on different subjects
(implementation model, specific HCAI), etc. with different
target groups. The estimated costs are; communicator,
translation (multiple), print work and distribution.
Total Costs (€) of (C) 91 360,00 €
(D) Indirect Costs (Max. 7% 42 980,65 €
on A, B and C)
Total estimated eligible 656 989,992 €
costs
Total requested EC 394 193,99 €
contribution (60% max)
120 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
38. Sweden – SoS
Applicant Number SE-38
Short Name SoS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Axana Haggar (participant in WP6) 1 6 509,59 €
Total Costs (€) of (A) 6 509,99 €
Justification
I am representing the National Board of Health and Welfare, Sweden. My participation will
be in WP6 and WP1 and I will contribute with my experience on AMR, infectious diseases
and hospital acquired infections with a major focus on patient safety.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2 880,00 € 4 European travel in WP6:2, task 6:2:1, 1 persons (1
national/regional)
3 760,00 € 4 General assembly, WP1, meetings, 3 persons (1
national/regional)
880,00 € 4 WP6:2 meetings in conjuction to general assembly,
one day, 1 persons. (EUR 220 per diem x 12 days) (1
national/regional)
Total Costs (€) of (C) 7 520,00 €
(D) Indirect Costs (Max. 7% 982,07 €
on A, B and C)
Total estimated eligible 15 011,67 €
costs
Total requested EC 9 007,00 €
contribution (60% max)
121 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
39. Sweden – SBA
Applicant Number SE-39
Short Name SBA
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Senior Veterinary Advisor 0,8 6 658,60 €
Total Costs (€) of (A) 6 658,60 €
Justification
Participation WP 5
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2 820,00 € Annual General Assembly, 1 person 3 occasions
2 820,00 € 3 Workshops 2 days (?) Task 1 and 2, 1 person
Total Costs (€) of (C) 5 640,00 €
(D) Indirect Costs (Max. 7% on 860,90 €
A, B and C)
Total estimated eligible costs 13 159,50 €
Total requested EC contribution 7 895,70 €
(60% max)
122 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
40. Sweden – NFA
Applicant Number SE-40
Short Name NFA
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Jakob Ottoson - Associate 1,5 12 300,00 €
professor
Total Costs (€) of (A) 12 300,00 €
Justification
Microbiologist and risk assessor that will take active part in the development and
evaluation of a self-assessment tool to monitor country progress and identify gaps in the
implementation of national strategies and action plans (WP5, tasks 1 and 2).
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3760,00 € KoM + 3 General assembly meeting
Total Costs (€) of (C) 3 760,00 €
(D) Indirect Costs (Max. 7% on 1 124,20 €
A, B and C)
Total estimated eligible costs 17 184,20 €
Total requested EC contribution 10 310,52 €
(60% max)
123 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
41. Sweden – SVA
Applicant Number SE-41
Short Name SVA
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Bjorn Bengtsson - 0,7 7 466,67 €
Associate professor
Total Costs (€) of (A) 7 466,67 €
Justification
A person with insight and knowledge in issues related to antimicrobial resistance (AMR) in
the veterinary field and in national strategies and action plans to mitigate emergence and
spread of AMR in animals and food.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
2 850,00 € Participation in 3 yearly GA-meetings
2 120,00 € Participation in 3 yearly workshops
Total Costs (€) of (C) 4 970,00 €
(D) Indirect Costs (Max. 7% on 870,57 €
A, B and C)
Total estimated eligible costs 13 307,23 €
Total requested EC 7 984,34 €
contribution (60% max)
124 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
42. Sweden – SRC
Applicant Number SP-42
Short Name SRC
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Scientific officer (Maria Starborg) 2,5 18 000,00 €
Scientific officer (Patriq Fagerstedt) 2,5 18 000,00 €
Total Costs (€) of (A) 36 000,00 €
Justification
The Swedish Research Council will mainly take part in task 1 and 3 in WP9. Maria Starborg is an
experienced scientific officer that work in the secretariat of JPIAMR focusing on JPIAMR calls,
research infrastructure as well as databases. Maria is also the Swedish expert at the Health
committee in SC1. Patriq Fagersdtedt is an experienced scientific officer at the JPIAMR secretariat
as well as the SRC representative at JPND. Patriq´s main task is to coordinate scientific activities as
call topics, scientific workshops, bibliometrics etc.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7 520,00 € General assembly meetings 2 persons
1 440,00 € WP9 2 meetings, 1 person
Total Costs (€) of (C) 8 960,00 €
(D) Indirect Costs (Max. 7% 3 147,20 €
on A, B and C)
Total estimated eligible 48 107,20 €
costs
Total requested EC 28 864,32 €
contribution (60% max)
125 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
43. Sweden – UAS
Applicant Number SE-43
Short Name UAS
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials)
Birgitta Lytsy - MD Infection 1 11 904,76 €
Control specialist
Total Costs (€) of (A) 11 904,76 €
Justification
A medical doctor, specialised in clinical microbiology and infection prevention and control with
a PhD in medical sciences, with 10 years professional experience in infectious disease
epidemiology and infection prevention and control having also a high command of the English
language. 5 years´ experience of leading international multicenter improvement projects within
the field of infection prevention and control.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3 760,00 €4 European travel in WP6:2, task 6:2:1, 2 persons
3 760,00 €4 General assembly, WP1, meetings, 2 persons
Total Costs (€) of (C) 7 520,00 €
(D) Indirect Costs (Max. 7% 1 359,73 €
on A, B and C)
Total estimated eligible costs 20 784,49 €
Total requested EC 12 470,70 €
contribution (60% max)
126 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
44. France – ANSES
Applicant Number FR - 44
Short Name ANSES
(A) Direct personnel costs Persons (position) Total Person-Month Total Costs (€) of (A)
(including Public officials) Deputy Director Anses - Lyon 7 59 488,00 €
Lab - Head of AMR unit
Deputy Head Microbiology 1 5 360,00 €
Unit
Deputy Head Epidemiology 1 7 081,00 €
Unit
microbiology Technical support 3 11 173,00 €
(3)
Epidemiologist 1 4 619,00 €
Post Doctorate - scientific staff 30 138 015,00 €
Total Costs (€) of (A) 225 736,00 €
Justification
Anses will include the contribution of 3 senior scientists (2 microbiologists and 1
epidemiologist) and four technical staff. All scientists are PhD with 10 years of
professional experience in AMR and antibiotic use in animals, in relation with AMR and
antibiotic use in humans. Two also are veterinary doctors. One of them, who will be
the coordinator of the tasks, has over 10 years of experience in supervising,
coordinating and managing activities on AMR, and particularly as National Supervisor
on AMR issues at Anses within the One Health National Strategic Plan on AMR,
including daily contacts with relevant stakeholders, professional bodies and
national/EU authorities. The latter also has over 5 years of experience in coordinating
workpackages in several EU or international scientific projects on AMR. The four
technical staff have daily experience with managing the surveillance network of AMR
and collecting antibiotic use in animals in France.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
1 880,00 € General Project meeting - 2 pers - 2 days
1 880,00 € Mid term meeting for WP5
1 880,00 € Mid term meeting for WP7
23 393.07 € Travels for visiting up to 25 countries
About 40 institutions take part in the project, in 25 countries.
In order to assess and understand what is already done (or
existant) in these countries as for AMR surveillance, Anses has
decided to go for short visits (average of 2 days) in most of
the countries involved. The junior scientist (Post doctorant to
be recruited) will either go on his own, or be accompanied by
the task coordinator (senior scientist).
We consider each visit to cost 500+ 2*220 = 940 €. The
estimated cost has therefore been calculated at 940*25 = 23
500, automatic calculations on the project excel sheet
reconsidering it to 23 393,07 €.
This amount will allow Anses to either go to all 25 countries
(1 person, 2 days) or most of them (2 people, 1 or 2 days).
Total Costs (€) of (C) 29 033,07 €
127 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(D) Indirect Costs (Max. 7% 17 833.83 €
on A, B and C)
Total estimated eligible 272 602.90 €
costs
Total requested EC 163 561.74 €
contribution (60% max)
128 of 137
EU-JAMRAI Confidential
09/08/2017
Below table of subcontracting per partners
Partner Short Amount WP & task Justification
number name subcontracting related
8 SSI 28 000,00 € WP7 Danish National Veterinary Institute (DTU VET) will contribute to task 7.4.2, having the skills and expertise
to do so.
tasks 7.4.2
15 ISS 75 000,00 € WP3 Some of the activities of WP3 will be subcontracted to a party with proven experience in the field of
evaluation and experience in the setting and use of appropriate evaluation tools (University of Udine).
tasks 3.2, Subcontracting will regard the activities related: 25,000 Euro for task 3.2 (Development of evaluation tool):
3.5, 3.6 Definition and provision of web-based tools to collect data and run surveys. Their testing and revision during
the project; 25,000 Euro for task 3.5 (Report of results to relevant stakeholders): Preparation of an interim
and final reports containing all indicators and data and the evaluation of the impact of the project actions.
Presentation of the reports to the internal and external stakeholder; 25,000 Euro for the evaluation of the
impact in Europe. Preparation and analysis of questionnaires to national, regional and local authorities as
well as to professionals and citizens associations and analysis of official data and other information from EU
MS national and subnational web-sites
21 VWS 80 000,00 € WP6 Hospitals and nursing homes don't belong to the Dutch government. They are private instituitions. That's
the reason they are considered sub-contractors. Based on the available information as provided by the WP
WP7 leaders at the time of stimating this budget, the cost of the subcontracting has been estimated calculating
the workload and translating it into person month units. Other cost like travel cost or equipment are not
included in this estimation and will be coverd by VWS. WP6: 5,6 person month x 7500 euro = 37500 euro =
(incl: profesionals on infection prevention and manamgent) WP6B: 5,1 person month x 7500 euro = 37500
euro (incl. professionals on infection prevention). WP7: 3,84 person month x 7500 euro = 28800 euro (incl.
micorbiologist/phamacologist/nurse). With the information available at this moment it is not possible to
sign start yet a formal dialogue contract with hospitals/nursing homes, and therefore it is not possible to
indicate the name of the hospital/nursing homes and provide a more exhaustive estimation of the costs.
30 AEMPS 32 000,00 € WP2 Develop a website as central hub for internal communication as well as main platform to communicate
outputs and disseminate the information to the targeted audiences: Design a document sharing or
repository platform as for internal communication, and design and implementation of a web platform as for
external dissemination. The benefit of developing this website in a way that best suits the needs of the
project will ensure the key role of WP2 as the coordinating body of the dissemination activities for the
project and make sure that results and relevant information produced over the lifetime of the project will
not be lost and can continue to be a crucial part of JA products and services well into the future.
22 000,00 € WP8 In the WP8 we propose to carry out one conference, with scientific communicators or with High School
students or university students as speakers. It will focus on scientific spreading targeted at the general
public, journalists and healthcare/veterinary professionals or their representative organizations. This event
will cover the most recent data on AMR in order to inform all of these groups in a clear, accurate way so
129 of 137
EU-JAMRAI Confidential
09/08/2017
that, eventually, we raise awareness on the topic. The conference could be divided in several presentations
by different experts participating in JAMRAI and to be selected from, for example, ECDC, WHO experts). The
event will be held in a location to be confirmed. All the details related to this conference’s contents and
organization will be studied and decided by the JAMRI WP8 team.
25 000,00 € WP8 In the WP8, a Social campaign will be designed in order to address general public and healthcare
professionals in both human and animal health, according to the One Health approach. The social campaign
will be mainly structured online, on the basis of a video that will be promoted through social media profiles.
The video will be made as a creative and visually attractive piece of work that grabs general attention on the
AMR problem. The project budget will consider organizing different online complementary
materials/activities to the video (e.g. gifs, collaboration with influencers) in order to improve chances of it
going viral and for the better spreading of our messages. All of the actions involved in this social campaign
should be planned in detail and finally agreed upon between all the members of the JAMRI WP8 team in
collaboration with the rest of participant or collaborating entities, (JA coordinator, ECDC, WHO-Europe) for
this proposal to work as a starting point.
35 SAS 20 000,00 € WP7 Database and training database management
37 FOHM 20 000,00 € WP6 Conference facilites, 4 European meetings, approximately 50 participants’ at 150 EUR. Venues with proper
equipment are essential for productive meetings.
130 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
12. PREVIOUS AND CURRENT GRANTS RELEVANT TO THE PROGRAMME (LIMITED TO THE LAST 3 YEARS)
• EU project EFFORT :
EFFORT against antimicrobial resistance (Ecology from Farm to Fork Of microbial drug Resistance and
Transmission)
http://www.effort-against-amr.eu/
• EU network GRACE: the European Network of Excellence to combat resistance to antibiotics in the
community.
http://www.grace-lrti.org/portal/en-GB/homepage
• EU project COMBACTE : Combatting Bacterial Resistance in Europe – improving clinical trials for antibiotics
http://www.combacte.com/
• Joint Programming Initiative on Anti Microbial Resistance (JPI AMR) :
European strategic research agenda on Antimicrobial Resistance
http://www.jpiamr.eu/wp-
content/uploads/2014/05/SRA1_JPIAMR.pdf?bcsi_scan_628cd39dca2568d2=0&bcsi_scan_filename=SRA
1_JPIAMR.pdf
• IMI project Drive AB
Driving reinvestment in research and development and responsible antibiotic use:
Collaborative public-private research project focused on developing detailed economic policies to stimulate
antibiotic innovation that meets global health needs.
http://drive-ab.eu/
• IMI project ENABLE (European Gram Negative AntiBacterial Engine)
Public private partnership to advance the development of potential antibiotics against Gram-negative
bacteria, such as Escherichia coli.
http://nd4bb-enable.eu/
• IMI project ND4BB (New Drugs for Bad Bugs)
Public private partnership to bring new antimicrobials closer to patients, to share information and to boost
research on improving the uptake and decreasing the efflux of antibiotics into Gram-negative bacteria
http://www.nd4bb.eu/
• IMI Initiative
Call for proposals on Antimicrobial resistance
http://www.imi.europa.eu/
13. CURRENT APPLICATIONS RELEVANT TO THE PROGRAMME
No current applications relevant to the programme.
14. EXCEPTIONAL UTILITY
Non-application for the Joint Action AMR- HCAI
15. COLLABORATING STAKEHOLDERS
Below the list of up to 20 most important collaborating stakeholders and/or external experts participating in your
project. This list excluding the “de facto” collaborating stakeholders that will join the Stakeholders Forum such as
ECDC, WHO, FAO, OECD etc.
Institution Contact person City & Country
131 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(First name and last name)
University Hospital for Infectious Arjana Tambic Andrasevic Zagreb, Croatia
Diseases
Ministry of Health Dr Niki Pafitou (
[email protected]) Cyprus
National Institute for Health and Jari Jalava (
[email protected]) Helsinki, Finland
Welfare
Agence nationale de sécurité sanitaire Salma Elreedy (
[email protected]) Paris, France
de l’alimentation, de l’environnement
et du travail
Santé Publique France Bruno Coignard Paris, France
(
[email protected])
Anne Berger-Carbonne (anne.berger-
[email protected])
Ministry of Health Irini Kyriaki (
[email protected]) Athenes, Greece
Semmelweis University Balázs Hankó MD. Hungary
(
[email protected]
univ.hu)
University of Debrecen István Várkonyi MD. Hungary
(
[email protected])
Department of Health (Patient Safety Rosarie Lynch Dublin, Ireland
Unit) (
[email protected])
Eithne Barron
(
[email protected])
NATIONAL PUBLIC HEALTH Greta Vizuje (
[email protected]) Lithuania
SURVEILLANCE LABORATORY
Pathology Department – Mater Dei Dr. Christopher Barbara Malta
Hospital (
[email protected])
Public Institution Coordination, Nicolae Furtuna (
[email protected]) Moldova
Implementation and Monitoring Unit
of the Health System Projects.
Norwegian Medicines Agency Seline Gustavsen Norway
(
[email protected])
Ministry of Health of Republic of Ljiljana Jovanovic, MD Serbia
Serbia (
[email protected])
Clinical Center of Serbia, Clinic for Goran STEVANOVIC - Serbia
Infectious and Tropical Diseases
[email protected]
Ministry of Health of the Slovak Zuzana Matloňová Slovakia
republic (
[email protected])
National Reference Centre for Danica Staneková Bratislava, Slovakia
HIV/AIDS prevention, Slovak Medical (
[email protected])
University
Public Health Authority of the Slovak Dagmar Némethová Slovakia
republic (
[email protected])
132 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Fundación para el Fomento de la Hector Perpinan (
[email protected]) Valencia, Spain
Investigación Biomédica y Sanitaria de
la Comunidad Valenciana.- Consellería
Sanitat Universal i Salut Pública
The Swedish Association of Local Eva Estling, (
[email protected]) Stockholm, Sweden
Authorities and Regions (SALAR)
Agneta Andersson
(
[email protected])
University Carlos III of Madrid, Carlos Elias Peres (
[email protected]) Madrid, Spain
Department of Journalism and
Daniel Catalan Matamoros
Communication
(
[email protected])
Public Health England George Leahy London, United Kingdom
(
[email protected])
16. APPENDIX 1 – DETAILED MANAGEMENT STRUCTURE
16.1.1. Governing bodies of the project consortium and their functions
a. The General Assembly is the decision-making body of the JA. It is chaired by the Coordinator and is composed
of one representative from each partner. The GA monitors the work progress of the Joint Action and provides
awareness on related projects, actions or changes within the EU Health Program. The Coordinator chairs the
GA and ensures liaison with the ExB.
The tasks of the GA are as follows:
• Take decisions as to the implementation of the JA and its deliverables, as proposed by the ExB;
• Decide on the overall development of the project based on input from the Coordinator and the ExB;
• Monitor and review the progress of the project;
• Validate re-allocation of budget whenever changes need to be done;
• Take the necessary actions and corrective measures in case of default of a partner.
The GA will meet once a year from the start of the project execution. Intermediate meetings will be held by web-
conference if needed (allowing sharing and modification of documents online while talking over the phone). The
GA meetings will be convened and prepared by the Coordinator with the support of the Joint Action Secretariat.
The JAS will prepare in writing the agenda of the meetings and send it to each GA member at least 2 weeks before
meetings, with all relevant background information and supporting documents to any decision proposed to be
taken. Quorum and majority requirements will be laid down in the Consortium Agreement. In the event of a tie,
the decision by the Coordinator will prevail. These decisions may be taken via email, tele- or videoconferences or
face to face meetings. Minutes of GA will be sent by the Joint Action Secretariat to all members.
Delegates of the EC DG SANTE and CHAFEA may participate in GA meetings but will have no voting right.
b. The Steering Committee (SC) will be made up of representatives of competent authorities (Ministry of
Health) of each Member State willing to be part of the Joint Action. The SC will thus gather 31 representatives
representing the 28 Member States of the European Union, and 3associated countries to this project: Norway
Moldova and Serbia . The chair will be elected during the Kick-off Meeting at the very beginning of the project. SC
members will provide strategic directions to the GA on behalf of their respective government and contribute to the
successful implementation of the Joint Action results. SC meetings will be held 4 times within the project duration
– at the official Kick-off Meeting and once per year, in parallel to GA meetings. If necessary, additional meetings
could be held. The Coordinator and JA Secretariat will be invited to attend all SC meetings.
The SC will provide support, guidance and oversight of the JA progress. In particular, the tasks of the SC include:
• Provide input to the development of the JA, including the evaluation strategy;
133 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Review documents prepared by the JA and provide prompt feedback to the GA
• Identify the priorities in the JA where the most energy should be directed;
• Identify potential risks and propose recommended courses of action;
• Monitor the quality of the JA as it develops;
• Provide advice about changes to the JA work plan as it develops;
• Define and help to achieve the JA outcomes at the national level;
• Promptly inform the GA of any potential obstacles regarding national commitment
• Contribute to the sustainability of the JA activities at the national, local or regional level
c. The Executive Board (ExB) is the main executive body of the Joint Action. It is made up of the Work Package
leaders, the JA secretariat and is chaired by the Coordinator. The ExB will put forward and then ensure the proper
implementation and execution of the strategic orientations of the JA and of any decision committing the
participating organisations. The ExB will prepare all the management decisions needed to keep the JA focused on
its objectives. These decisions will then be put to the vote of the GA. The ExB will meet at least every 4 months.
Every second meeting will be held via conference call. The ExB specific tasks will thus be to:
• Monitor and review the project’s progress;
• Prioritize the projects objectives and outcomes;
• Prepare draft decisions to be considered by the GA;
• Formulate risk management strategies and ensure that risks are regularly reassessed;
• Propose re-allocation of budget whenever changes need to be done;
• Help the Coordinator resolve potential conflicts and disputes.
16.1.2. Day-to-day management of the Joint Action
JA Coordinator
The Coordinator will act as the direct link and intermediary between the Agency and the consortium. It will request
and review any documents or information required by the Agency and verify their completeness and correctness
before passing them on to the Agency. In these tasks, the Coordinator will be assisted by JA Secretariat and the ExB.
Responsibilities of the Coordinator:
To the European Commission:
• Responsible for the management and the achievement of the objectives of the project;
• Intermediary in all communications (interim/final progress reports);
• Receives and distributes all payments (from the EC to Partners);
• Ensures timely delivery of the project deliverables.
To the Partners:
• Informs of the requirements from the EC;
• Informs of any events that may delay WP implementation;
• Facilitates communication between WPs (using restricted access area on the project website);
• Gives budgetary and financial information necessary for WP implementation;
• Provides overview of project status;
• Act as a mediator in case of conflicts or disagreement between partners
Work Package leaders
All JA activities will be coordinated at the Work Package (WP) level, under the responsibility of one or two WP
leader(s). WP leaders will coordinate the work within the individual WPs, ensuring that the work plan is executed
as anticipated, in close collaboration with the participating WP partners. Additionally, the WP leaders will be
responsible for the timely implementation of the GA decisions within their WP. They will also report WP progress
to the Coordinator and to the ExB. WP leaders’ specific tasks include:
• Coordinate and supervise their respective WP;
• Follow-up the WP deliverables and milestones and ensure their timely achievement;
• Ensure that each participant fulfils its commitment to the WP;
134 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
• Present progress reports on the state of advancement of the WP;
• Make proposals on the allocation of WP tasks, financial need and allocation among the contractors;
• Draft and validate WP deliverables to be submitted to the EC;
• Identify potential risk(s) within the WP and propose contingency plans;
• Organise WP meetings with the WP teams whenever necessary;
• Inform the coordinator and the GA of any work plan modification, adjustment or other difficulty arising in
connection with the WP.
The JA secretariat
A JA secretariat will be constituted to assist the ExB and the GA in the administrative and financial management of
the JA. It will be composed of a project manager at Inserm and an administrative assistant at MoH-FR.
The JA secretariat will be responsible for the following activities:
• Preparation and signature of the Consortium Agreement and any other legal document pertaining to the
JA;
• Preparation of GA and ExB meetings’ agenda and minutes;
• Compilation and review of periodic and final reports to the commission;
• Day to day administrative and financial management ;
• Management of a secured extranet platform for the exchange of information between the partners;
• Organization of webconferences and physical meetings;
• Ensure transparency in communication between all JA partners;
• Coordinate activities of the Stakeholder Forum.
16.1.3. Advisory body: the Stakeholders Forum
In order to have a permanent structure for involvement of stakeholders during the JA, a Stakeholders Forum will
be constituted as part of the management structure. The Stakeholders Forum will be composed of representatives
of the major stakeholders having a legitimate interest in the Joint Action, such as:
• International organisations in charge of policies and guidelines (WHO, OECD, ECDC, FAO, OIE, EFSA, …)
• Industries
• Healthcare professionals (may be representatives of scientific societies as European Society for Clinical
Microbiology and Infectious Diseases)
• Representatives of European programs such as JPI AMR and IMI programs (COMBACTE, DRIVE-AB, …)
• Patient associations
• Other possible interested partners (EPHA,…)
The primary role of the Stakeholders Forum will be one of strategic advice to the ExB as well as maintaining the
flow of information with relevant organisations or societies. The Forum will reflect on and contribute to overall
conceptual development during the Joint Action based on their respective expertise, with a particular emphasis on
sustainability beyond the project period.
Members of the Stakeholders Forum will be invited to all GA physical meetings, and consulted by the Coordinator
and WP leaders when needed for the JA implementation. The ultimate goal in equipping the project with this
independent body is to guarantee that the consortium decisions will be strategically connected to the global
challenges and developments in the field and that the JA outputs are commensurate with ground realities.
The existence of a Stakeholders Forum does not preclude the consultation of other stakeholders whose insight will
be needed during the course of the JA.
The below table presents all the organizations willing to collaborate and/or contribute to the EU-JAMRAI project:
135 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
Organisation name Short Type of stakeholders Contact name Contribution
name to WP #
European Centre for ECDC International organisations Dominique Monnet WP6, WP7
Disease Prevention and
Control
World Health WHO International organisations Danilo Lo Fo Wong WP5
Organization
Organisation for Economic OECD International organisations Michele Cecchini To be
Co-operation and defined
Development
World Organization for OIE International organisations In contact WP5
Animal Health
Food and Agriculture FAO International organisations In contact WP5
Organization of the United
Nations
European Food Safety EFSA International organisations In contact WP5
Agency
European Public Health EPHA Healthcare professionals Sascha Marschang To be
Alliance defined
Pharmaceutical Group in PGEU Healthcare professionals Jamie Wilkinson To be
the European Union defined
Health First Europe HFE Healthcare professionals Melina Raso To be
defined
Pfizer Pfizer Pharmaceutical company Eva Grut-Aandahl & WP9
Bruce Altevogt
International Federation IMFSA Healthcare professionals In contact To be
of Medical Students defined
Associations
European Wound EWMA Healthcare professionals Niels Fibaek Bertel To be
Management Association defined
European Federation of EFPIA Industries In contact To be
Pharmaceutical Industries defined
and Associations
International Federation IFPMA Industries In contact To be
of Pharmaceutical defined
Manufacturers
Standing Committee of CPME Healthcare professionals Carole Rouaud To be
European Doctors defined
Council of European CED Healthcare professionals Lea Pfefferle To be
Dentists defined
Responsibilities of the JA Partners
JA partners are responsible for the implementation of their respective WP tasks, as described in the Grant
Agreement. They shall take all necessary steps to perform and fulfil promptly, actively and on time all of their agreed
upon obligations. They shall endeavor to be represented at all GA meetings and will be responsible for:
• Ensuring the participation of appropriate members in the SC;
• Being familiar with national procedures regarding agreement on the key aspects of the project
implementation;
• Promptly informing the consortium of any potential obstacles regarding national commitment through
regular contact with SC members.
Responsibilities of the JA partners:
136 of 137
EU-JAMRAI Confidential
09/08/2017 Associated with document Ref. Ares(2017)4194538 - 28/08/2017
To the WP leaders:
• Timely provision of information necessary for WP implementation and adherence to the work plan.
To the Coordinator:
• Timely provision of all data for reports, financial statements and other documents;
• Immediately inform of any event delaying the implementation of the project;
• Provide updated contact information for all representatives involved in the project.
Administrative and Legal Provisions
JA Meetings
Meetings of the different project groups (e.g. ExB, GA, SC and WP teams) will take place as planned in the
Consortium agreement. The exact schedule will be posted and updated as necessary in the members-only section
of the JA AMR HCAI website.
GA Quorum and voting rules
Quorum and voting rules will be provided for in the Consortium Agreement. Decisions shall only be executed once
the relevant part of the minutes is accepted.
Decision without meeting
Any GA decision may also be taken without a meeting by circulating to all partners a written document then signed
electronically by the defined majority of partners or by answering by emails.
Minutes
Minutes of the ExB, GA, SC and WP meetings shall be made available to all partners. Corrections shall be returned
by email within a period specified by the WP leader (for WP meetings) or the JA Secretariat (for GA, SC and ExB
meetings), and shall become official upon publication on the extranet (project members only area) of JA AMR HCAI
website.
Internal communication strategy
Internal communication within the JA will be key to keep the project on track, keep the partners motivated and
involved and bring the JA to a successful conclusion. The Joint Action Secretariat will set up an effective
communication strategy to ensure that all partners:
• Have the same level of information (what is done, why and when, responsibilities, deadlines, etc.);
• Identify with the main aims of the JA and feel like they are part of the JA;
• Know their responsibilities and tasks and those of other JA partners.
Tools provided by the Joint Action Secretariat to improve workflows include:
• Support to the organisation of face-to-face or online meetings
• Animation of a secured online collaborative platform for file sharing and online storage of files (WP2
deliverable), with restricted access
• Uploading written minutes with “action items” for all JA meetings on the secured platform
• Uploading of JA reports on the secured platform
• Maintenance of a complete and up-to-date JA address book
• Video-conferencing system available on request
• Information/events posted on the JA public website
Information contained on the JA secured platform will be continually updated by the Joint Action Secretariat, to
ensure that the action runs at critical mass and that there is no information missing which could have an impact on
the programme.
137 of 137
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 1 of 5) Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
1. INSERM 398008.18 0.00 148520.00 38256.97 584785.15 350871.09 0.00 0.00 0.00
- CHU Limoges 69617.87 0.00 0.00 4873.25 74491.12 44694.67 0.00 0.00 0.00
- UL 109183.16 0.00 0.00 7642.82 116825.98 70095.59 0.00 0.00 0.00
Total beneficiary 576809.21 0.00 148520.00 50773.04 776102.25 465661.35 0.00 0.00 0.00
2. MoH-FR 177200.00 0.00 18304.00 13685.28 209189.28 125513.57 0.00 0.00 0.00
3. GÖG 103876.22 0.00 19340.00 8625.14 131841.36 79104.82 0.00 0.00 0.00
4. FPS HFCSE 85425.41 0.00 26320.00 7822.18 119567.59 71740.55 0.00 0.00 0.00
5. NCIPD 15940.00 0.00 20560.00 2555.00 39055.00 23433.00 0.00 0.00 0.00
6. CIPH 24570.00 0.00 27520.00 3646.30 55736.30 33441.78 0.00 0.00 0.00
7. NIPH 73297.00 0.00 41360.00 8025.99 122682.99 73609.79 0.00 0.00 0.00
8. SSI 46000.00 28000.00 7520.00 5706.40 87226.40 52335.84 0.00 0.00 0.00
9. TA 31915.00 0.00 15440.00 3314.85 50669.85 30401.91 0.00 0.00 0.00
10. RKI 86250.00 0.00 17680.00 7275.10 111205.10 66723.06 0.00 0.00 0.00
11. HCDCP 231796.21 0.00 78020.00 21687.13 331503.34 198902.00 0.00 0.00 0.00
12. ESDY-NSPH 111134.86 0.00 26320.00 9621.84 147076.70 88246.02 0.00 0.00 0.00
1
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 2 of 5) Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
13. 7HC 2202.00 0.00 14720.00 1184.54 18106.54 10863.92 0.00 0.00 0.00
- GH Heraklion 36016.00 0.00 0.00 2521.12 38537.12 23122.27 0.00 0.00 0.00
Total beneficiary 38218.00 0.00 14720.00 3705.66 56643.66 33986.19 0.00 0.00 0.00
14. UNIFG 103713.41 0.00 28480.00 9253.54 141446.95 84868.17 0.00 0.00 0.00
15. ISS 218183.88 75000.00 91874.00 26954.05 412011.93 247207.16 0.00 0.00 0.00
16. PSKUS 21050.00 0.00 13780.00 2438.10 37268.10 22360.86 0.00 0.00 0.00
17. LSMULKK 35910.00 0.00 10960.00 3280.90 50150.90 30090.54 0.00 0.00 0.00
18. VULSK 38900.00 0.00 15040.00 3775.80 57715.80 34629.48 0.00 0.00 0.00
19. HI 98179.00 0.00 23180.00 8495.13 129854.13 77912.48 0.00 0.00 0.00
20. NVSC 22401.65 0.00 13280.00 2497.72 38179.37 22907.62 0.00 0.00 0.00
21. VWS 380550.00 80000.00 77820.00 37685.90 576055.90 345633.54 0.00 0.00 0.00
22. HdiR 39215.00 0.00 9400.00 3403.05 52018.05 31210.83 0.00 0.00 0.00
23. FHI 489507.27 0.00 29840.00 36354.31 555701.58 333420.95 0.00 0.00 0.00
24. NVI 49000.00 0.00 4480.00 3743.60 57223.60 34334.16 0.00 0.00 0.00
25. NMI 22733.04 0.00 20560.00 3030.51 46323.55 27794.13 0.00 0.00 0.00
2
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 3 of 5) Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
26. DGS 71600.00 0.00 21200.00 6496.00 99296.00 59577.60 0.00 0.00 0.00
27. UMPIH 16400.00 0.00 19840.00 2536.80 38776.80 23266.08 0.00 0.00 0.00
28. NIJZ 97800.00 0.00 44320.00 9948.40 152068.40 91241.04 0.00 0.00 0.00
29. AEMPS 397250.00 79000.00 117060.00 41531.70 634841.70 380905.02 0.00 0.00 0.00
30. GENCAT 58000.00 0.00 14720.00 5090.40 77810.40 46686.24 0.00 0.00 0.00
31. IdISBa 94303.01 0.00 19760.00 7984.41 122047.42 73228.45 0.00 0.00 0.00
32. FFIS 36039.50 0.00 22214.00 4077.75 62331.25 37398.75 0.00 0.00 0.00
- DGPIFAC 2720.00 0.00 0.00 190.40 2910.40 1746.24 0.00 0.00 0.00
- SMS 55644.50 0.00 0.00 3895.12 59539.62 35723.77 0.00 0.00 0.00
Total beneficiary 94404.00 0.00 22214.00 8163.27 124781.27 74868.76 0.00 0.00 0.00
33. FMS 28037.00 0.00 7520.00 2488.99 38045.99 22827.59 0.00 0.00 0.00
34. SAS 54450.00 0.00 0.00 3811.50 58261.50 34956.90 0.00 0.00 0.00
- FISEVI 17400.00 20000.00 5640.00 3012.80 46052.80 27631.68 0.00 0.00 0.00
Total beneficiary 71850.00 20000.00 5640.00 6824.30 104314.30 62588.58 0.00 0.00 0.00
35. ISCIII 20800.00 0.00 18800.00 2772.00 42372.00 25423.20 0.00 0.00 0.00
3
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 4 of 5) Associated with document Ref. Ares(2017)4194538 - 28/08/2017
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate % contribution3 grant amount4 total receipts
the action parties to the
beneficiary
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form5 Actual Actual Actual Flat-rate
7%6
d = 0.07×(a
a b c e = a+b+c+d f g= e×f h k l m=k+l
+b+c)
36. SERMAS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
- FBRIPC 66922.50 0.00 7520.00 5210.98 79653.48 47792.09 0.00 0.00 0.00
Total beneficiary 66922.50 0.00 7520.00 5210.98 79653.48 47792.09 0.00 0.00 0.00
37. FoHM 502649.33 0.00 111360.00 42980.65 656989.98 394193.99 0.00 0.00 0.00
38. SoS 6509.59 0.00 7520.00 982.07 15011.66 9007.00 0.00 0.00 0.00
39. SBA 6658.60 0.00 5640.00 860.90 13159.50 7895.70 0.00 0.00 0.00
40. NFA 12300.00 0.00 3760.00 1124.20 17184.20 10310.52 0.00 0.00 0.00
41. SVA 7466.67 0.00 4970.00 870.57 13307.24 7984.34 0.00 0.00 0.00
42. SRC 36000.00 0.00 8960.00 3147.20 48107.20 28864.32 0.00 0.00 0.00
43. UAS 11904.76 0.00 7520.00 1359.73 20784.49 12470.69 0.00 0.00 0.00
44. ANSES 225736.00 0.00 29033.07 17833.83 272602.90 163561.74 0.00 0.00 0.00
7
Total consortium 4948366.62 282000.00 1277675.07 455562.92 6963604.61 60 4178162.75 4178162.75 0.00 0.00 0.00
4
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
ESTIMATED BUDGET FOR THE ACTION (page 5 of 5) Associated with document Ref. Ares(2017)4194538 - 28/08/2017
(1) See Article 6 for the eligibility conditions
(2) The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme). A beneficiary that receives an operating grant during the action's duration
cannot claim any indirect costs for the year(s)/reporting period(s) covered by the operating grant
(3) This is the theoretical amount of the EU contribution that the system calculates automatically (by multiplying all the budgeted costs by the reimbursement rate). This theoretical amount is capped by the 'maximum grant
amount' (that the Agency decided to grant for the action) (see Article 5.1)
(4) The 'maximum grant amount' is the maximum grant amount decided by the Agency. It normally corresponds to the requested grant, but may be lower
(5) See Article 5 for the cost forms
(6) flat rate : 7% of eligible direct costs
(7) The reimbursement rate is applied at consortium level only (i.e. to the total costs). The reimbursement rate is normally 60% (or 80% in cases of exceptional utility)
5
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERE DES AFFAIRES SOCIALES ET DE LA SANTE (MoH-FR), N/A, established in
AVENUE DUQUESNE 14, PARIS CEDEX 75350, France, N/A ('the beneficiary'), represented for
the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘2’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998887377_75_210--]
Jérôme BARON with ECAS id nbarojer signed in the
Participant Portal on 06/09/2017 at 14:00:46 (transaction id
SigId-76474-
a8le3khahtiQWqhzgOCkinqDBgjv7uvtxWrzYzTcpzfpJvMV
SFQK0fVlcQZ8zsBiqU4Rzef9EPjmqAAVBFnfNEnW-
Jj71zxYb8yrN6HT4pVHCoC-
6wV8beLLM9g5828rfzbsvzWkvS7fzkSqDpWQWVzIxMuv).
Timestamp by third party at
Wed Sep 06 15:00:58 CEST 2017
1
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
GESUNDHEIT ÖSTERREICH GMBH (GÖG) GMBH, FN281909Y, established in
STUBENRING 6, WIEN 1010, Austria, ATU62777178 ('the beneficiary'), represented for the purpose
of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘3’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-928836208_75_210--]
Vera BUHMANN with ECAS id nbuhmave signed in the
Participant Portal on 21/09/2017 at 16:44:06 (transaction id
SigId-204711-
zjJnrcETULdWKj8hd7I6wwtCTL1FD44SvWrktdZDvEn4EG
kHPZzjiRt5g5QXKk79UzViqfvHumET2RbJ9rtXlEW-
Jj71zxYb8yrN6HT4pVHCoC-
0UMRkYfvppHCOXozaQ0vITzuW39JoBnzxRnvIPzb8eYM
). Timestamp by third party at
Thu Sep 21 17:44:16 CEST 2017
2
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SERVICE PUBLIC FEDERAL SANTE PUBLIQUE, SECURITE DE LA CHAINE
ALIMENTAIRE ET ENVIRONNEMENT (FPS HFCSE), N/A, established in SQUARE VICTOR
HORTA 40 BUR 1D 1G, BRUSSELS 1060, Belgium, N/A ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘4’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998853815_75_210--]
Els EEMAN with ECAS id neemanel signed in the
Participant Portal on 31/08/2017 at 10:44:03 (transaction
id SigId-34412-
Y8ysTPhRxs0KPvBMAfRYpQYusLJb57NzoDsnZYjL3Vvk
6ctNalHxl1n6oWKRGJIMCozKnmgHaUrAPtwdi5bzRRW-
Jj71zxYb8yrN6HT4pVHCoC-
3
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES (NCIPD ), 000662721,
established in blvd. Yanko Sakazov 26, SOFIA 1504, Bulgaria ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘5’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999493724_75_210--]
4
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), 080407487, established in
ROCKEFELLEROVA 7, ZAGREB 10000, Croatia, HR75297532041 ('the beneficiary'), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘6’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998128255_75_210--]
5
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATNI ZDRAVOTNI USTAV (NIPH), 75010330, established in Srobarova 48, PRAHA 10 10042,
Czech Republic ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘7’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999478689_75_210--]
Jitka SOSNOVCOVA with ECAS id nsosnoji signed in the
Participant Portal on 29/08/2017 at 10:34:03 (transaction
id SigId-13543-
4T7V32SIzUpZqYcPO5ZgtILNZARpmGKBOHi39HAxFNy
4R5k8zT5fLQFXNgs9tgnVEYTwXbwQj6xAeagSiUX38j-
Jj71zxYb8yrN6HT4pVHCoC-
6
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATENS SERUM INSTITUT (SSI), 46837428, established in ARTILLERIVEJ 5, KOBENHAVN
S 2300, Denmark, DK46837428 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘8’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999937402_75_210--]
Kare MOLBAK with ECAS id nmolbaka signed in the
Participant Portal on 29/08/2017 at 14:48:45 (transaction
id SigId-17588-
Awkh0fRtyeCyKwNajPdQ2HbUaj4LfXgozizJUc2C7zyaA7
WCKe46rk0LX6gQP0QXPESqzTGHQzQUuDF8uYrn761-
Jj71zxYb8yrN6HT4pVHCoC-
7
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
TERVISEAMET (TA), 70008799, established in PALDISKI MNT 81, TALLINN 10617, Estonia,
EE101339803 ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘9’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-933659727_75_210--]
Merike JÜRILO with ECAS id njuemeri signed in the
Participant Portal on 25/09/2017 at 15:00:30 (transaction id
SigId-10107-
e9TrwvZ8WmPHAmovLAE8btc1Nwhyq5vXp1o81gfvrTKsZ
Knm7RXzxtzRO8YaGxqivKEvd4B7lfHcXkox9mZuwO-
PHslUMVSXYC5hxZtLv2jzQ-
xXTdzplNgl7bjBYUUrWYkxRDdDyyfrEnAPMJxG1wxrn).
Timestamp by third party at
Mon Sep 25 16:00:42 CEST 2017
8
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ROBERT KOCH-INSTITUT (RKI), n/a, established in Nordufer 20, Berlin 13353, Germany ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘10’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999515549_75_210--]
Katharina SCHMITT with ECAS id nschmawg signed in
the Participant Portal on 31/08/2017 at 09:16:16
(transaction id SigId-32608-
gLLT5gzvOe4R1Q4tGqZRiM8imGprBvxpieNAxRY4XNW
CJl6KMfdV90aUUEzcDS6sLxQzjxAMnpykp4IXgFMN9O0
-Jj71zxYb8yrN6HT4pVHCoC-
9
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
KENTRO ELENCHOU & PROLIPSIS NOSIMATON (HCDCP) GR8, 2071, established in
AGRAFON STREET 3-5, MAROUSI 15123, Greece, EL090193594 ('the beneficiary'), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘11’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-986568959_75_210--]
Theofilos ROSENBERG with ECAS id nrosethe signed in
the Participant Portal on 05/09/2017 at 12:17:31
(transaction id SigId-62797-
E2FzcFB2V6xUnDC05dQ0FkWvdAcPqdV2vmdD5yIzx0Bv
lvb3RqbN4lJSqLEhGwkX4Dan8p8WV2GVu1b0PL1ISQ-
Jj71zxYb8yrN6HT4pVHCoC-
aMW22FiTfg2LftVWoHtzzuCSd8NtAov06CGNI1hVNcUG).
Timestamp by third party at
Tue Sep 05 13:17:43 CEST 2017
10
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ETHNIKI SCHOLI DIMOSIAS YGEIAS (ESDY-NSPH), 2194, established in 196
ALEXANDRAS AVENUE, ATHINA 11521, Greece, EL099017070 ('the beneficiary'), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘12’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-986102486_75_210--]
ALKIVIADIS VATOPOULOS with ECAS id nvatopal signed
in the Participant Portal on 11/09/2017 at 12:41:04
(transaction id SigId-106572-
jULLblAMsgwwBztJbpjoDYlBFR5wvfQc3Q1envvW360zR
QRzIfQoAPmFq2eToFxy1lWWXFqG16vvm7ezWL711NO-
Jj71zxYb8yrN6HT4pVHCoC-
wzsdTzKYKzgl6Ldm6oKIWfqGfUkdzhukeVW9zcEmVErF0
). Timestamp by third party at
Mon Sep 11 13:41:14 CEST 2017
11
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
DIOIKHSH YGEIONOMIKHS PERIFEREIAS KRHTHS (7HC), ., established in 3RD KM
NATIONAL ROAD HERAKLION MOIRES, HERAKLION 71500, Greece, EL999161778 ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘13’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-944960033_75_210--]
Eleni MAVROMMATI with ECAS id nmvroele signed in
the Participant Portal on 28/08/2017 at 20:56:14
(transaction id SigId-10371-
MzrI779OblrMAxcsRVkH8teHhcRyX2zhyfbFMcOPpX7Da
OaY2Ky8ULOBVmLEO8wxziHKSZzu5v06VKGZxzjszfzq-
Jj71zxYb8yrN6HT4pVHCoC-
12
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
UNIVERSITA DEGLI STUDI DI FOGGIA (UNIFG), CF94045260711, established in VIA
GRAMSCI 89/91, FOGGIA 71122, Italy, IT03016180717 ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘14’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999888514_75_210--]
Maurizio RICCI with ECAS id nrimauri signed in the
Participant Portal on 29/08/2017 at 07:55:00 (transaction
id SigId-11208-
RP6e1smP9UT5vSZOO3dcZOZ9D44FK9bfqSI2jze3maZ
viXCeDFosZLT8fPrCAUhCYa9PcXxZ5RdDF7yELGehgG
-Jj71zxYb8yrN6HT4pVHCoC-
13
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ISTITUTO SUPERIORE DI SANITA (ISS), 80211730587, established in Viale Regina Elena 299,
ROMA 00161, Italy ('the beneficiary'), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary (‘15’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999978821_75_210--]
Gualtiero RICCIARDI with ECAS id ngaracen signed in
the Participant Portal on 31/08/2017 at 11:17:17
(transaction id SigId-35204-
skjbB9zwBPtBHK1jGCzXm8HDjFNpw0CwXaWVBQ1Oyk
UzH0b00OG9pH7COjFQ76J8jdtlVGx54Fugspy5jMiE7Vm
-Jj71zxYb8yrN6HT4pVHCoC-
14
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
PAULA STRADINA KLINISKA UNIVERSITATES SLIMNICA (PSKUS) SIA, 40003457109,
established in PILSONU IELA 13, RIGA 1002, Latvia, LV40003457109 ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘16’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-953605449_75_210--]
Ilze KREICBERGA with ECAS id nkreiilz signed in the
Participant Portal on 13/09/2017 at 07:34:45 (transaction id
SigId-124891-
MLEiqmsFuA4VJKrt3UD6JXuvOrYVhcdzuBYyCJ6zPgOs1
7D9F55nRvathzIqwzzOxuUw3CPsjjQmHcHKwmTqTrr-
Jj71zxYb8yrN6HT4pVHCoC-
zNequkn9mrJXCbkcOSVCYzzwoayhRobnNUhOct9ZC3yK
). Timestamp by third party at
Wed Sep 13 08:34:55 CEST 2017
15
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETO LIGONINE KAUNO KLINIKOS
(LSMULKK) LT3, 135163499, established in EIVENIU 2, KAUNAS 50009, Lithuania,
LT351634917 ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘17’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-923616832_75_210--]
Lina JARUSEVICIENE with ECAS id njarulin signed in the
Participant Portal on 08/09/2017 at 09:56:20 (transaction id
SigId-93471-
zNwg3luT7epKTIE9GuIztEC4F5ZoLxR5PzoWUif0zvv4bQl
2g2ujerjmHbrHUBQuNi2rjzJE1NosdZGIVekzqwdm-
Jj71zxYb8yrN6HT4pVHCoC-
aUjbMVsUn8ISzfVbG0VBFFyzjSJcRpB5YzseRWziJFjV).
Timestamp by third party at
Fri Sep 08 10:56:32 CEST 2017
16
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS
(VULSK) LT3, 124364561, established in SANTARISKIU G 2, VILNIUS 08661, Lithuania,
LT243645610 ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘18’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-991636530_75_210--]
Elena JUREVIČIENĖ with ECAS id njurevel signed in the
Participant Portal on 29/08/2017 at 08:43:25 (transaction
id SigId-11679-
lFF8pW4JJSh2EKOqYZtCHzHYuR096quzdvDzHAnJzxE
LG0uZjzg6bJWAQnIXAP2szeRf3abDdzdXxc4sMUxJI0P
G-Jj71zxYb8yrN6HT4pVHCoC-
17
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HIGIENOS INSTITUTAS (HI), 111958286, established in DIDZIOJI STREET 22, VILNIUS
LT-01128, Lithuania ('the beneficiary'), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary (‘19’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-941996780_75_210--]
Ausra GRIGOSAITIENE with ECAS id ngrigaus signed in
the Participant Portal on 29/08/2017 at 09:42:25
(transaction id SigId-12582-
OLIZGgAZc9A6m3aL6gf5mMDQXsYAOc27BFXaFHkiyK
FPjlK60Z6tbagkEzNua3IcbDB1ULpOAyQKDeZAU907Ce-
Jj71zxYb8yrN6HT4pVHCoC-
18
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NACIONALINIS VISUOMENES SVEIKATOS CENTRAS PRIE SVEIKATOS APSAUGOS
MINISTERIJOS (NVSC), 291349070, established in KALVARIJU 153, VILNIUS LT-08221,
Lithuania ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘20’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-918030796_75_210--]
INGRIDA SKRIDAILIENE with ECAS id nskridin signed in
the Participant Portal on 30/08/2017 at 09:53:56
(transaction id SigId-23107-
jvVN1odVSBYEnG2MAYUEEh0gb4FNbWlsKQKYIG6apy
BryeFzTugzh5w6q3mhHEBJye5i1tiuPsuNlbbRwyxkfN-
Jj71zxYb8yrN6HT4pVHCoC-
19
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT (VWS), N/A, established
in PARNASSUSPLEIN 5, DEN HAAG 2500 EJ, Netherlands ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘21’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998886601_75_210--]
20
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HELSEDIREKTORATE (HdiR), 983544622, established in UNIVERSITETSGATA 2, OSLO
0164, Norway ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘22’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-974772304_75_210--]
Marit ENDRESEN with ECAS id nenmarit signed in the
Participant Portal on 01/09/2017 at 09:08:50 (transaction
id SigId-42262-
QPKdfthYuWCYPtBd08fou1Qv9hkQ2rYeUyJPsf1VoIOA9
oEPxVCVzNomaK66by5FtycHPmuMYPURaKXrHCAeL0-
Jj71zxYb8yrN6HT4pVHCoC-
21
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FOLKEHELSEINSTITUTTET (FHI), 983744516, established in LOVISENBERGGATA 8,
OSLO 0456, Norway, NO983744516MVA ('the beneficiary'), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘23’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999478883_75_210--]
Geir BUKHOLM with ECAS id nbukhoge signed in the
Participant Portal on 29/08/2017 at 11:55:45 (transaction
id SigId-14819-
gvuizV7Oo5cIJ9C2MssSwFuD3dfpasd1IN8H19yzIKEUHI
M0XHJxNFo6pzWhovvXQwE86kdEN2fZP2kwHNH29aG-
Jj71zxYb8yrN6HT4pVHCoC-
22
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
VETERINAERINSTITUTTET - NORWEGIAN VETERINARY INSTITUTE (NVI),
970955623, established in ULLEVALSVEIEN 68, OSLO 0454, Norway ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘24’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999511378_75_210--]
Gaute LENVIK with ECAS id nlenvgau signed in the
Participant Portal on 01/09/2017 at 10:14:48 (transaction
id SigId-43125-
RL6vm7qKulVXNezoG4XW6uKmzzTlJBKFhY4Uj0RlBaP
zhjNhMsYbIOTQZ9Tm2SZQcxXXvCsbJZxbKCBysuKrgN
u-Jj71zxYb8yrN6HT4pVHCoC-
23
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NARODOWY INSTYTUT LEKOW (NMI), 015244176, established in ULICA CHELMSKA
30/34, WARSZAWA 00 725, Poland, PL5213212384 ('the beneficiary'), represented for the purpose
of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘25’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998545452_75_210--]
Edyta WOLCZYNSKA with ECAS id nwolczed signed in
the Participant Portal on 04/09/2017 at 13:05:50
(transaction id SigId-53042-
WCMXlI8ZSzdFBg4kLU6ZUVVZO06wJU5yb7qX4iRQDnL
3zxM3bDYEFKVDvwt80jM1UDuNmvJjgYJSzj643NbQalm-
Jj71zxYb8yrN6HT4pVHCoC-
Uu0rlYbgWsuNJl39JX0eJiITEzlr6DgiRgSeMzvnsQzy).
Timestamp by third party at
Mon Sep 04 14:06:01 CEST 2017
24
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (DGS), Decreto-Lei n.º 212/2006,
de 27 de Outubro , established in Av. João Crisóstomo, 9, LISBOA 1049-062 , Portugal ('the
beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘26’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-986364095_75_210--]
Francisco GEORGE with ECAS id ngeorgfo signed in the
Participant Portal on 05/09/2017 at 12:52:51 (transaction id
SigId-63295-
KkG8DEKJmzyOhJRMrQT1LNeJwgUfJ2fznSbwD7aTE4S
ckMra5KG2PlQE2y1I7MHY58wDJl9fUmNgzXo8UM6UQ2
0-Jj71zxYb8yrN6HT4pVHCoC-
zrwrYGiPIIgmnQXeakSR7aLjJnguwZt9jsQoa1UuoGU).
Timestamp by third party at
Tue Sep 05 13:53:01 CEST 2017
25
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA
(UMPIH), 263327, established in Emil Isac Street 13, Cluj-Napoca 400023, Romania, RO4288047
('the beneficiary'), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘27’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999842439_75_210--]
ALEXANDRU IRIMIE with ECAS id nirialex signed in the
Participant Portal on 29/08/2017 at 08:20:05 (transaction
id SigId-11433-
7HZ4wzsJh0NCDqzXmyEu9Y84RAopfBsTZfZCNGmfQvl
bpPoLuAkP2Vp17LQheY8r6iSviO5QbY06fTFAJzcXfs0-
Jj71zxYb8yrN6HT4pVHCoC-
26
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) SI2, 6462642000, established in
TRUBARJEVA CESTA 2, LJUBLJANA 1000, Slovenia, SI44724535 ('the beneficiary'), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘28’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-948891346_75_210--]
Ivan ERŽEN with ECAS id nerzivan signed in the
Participant Portal on 29/08/2017 at 06:12:40 (transaction
id SigId-10823-
MVZv4zkRE1GzrpjrbjkMuEvMg7NgO4bJg8vGyLVvAzLx
G3ZwzTrzMHw6ZwDcmsQ3pNK8oaedSFySR3kp0nm5Tl
v-Jj71zxYb8yrN6HT4pVHCoC-
27
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS (AEMPS),
established in c/ Campezo Edificio 8 1, MADRID 28022, Spain, ESQ2827023I ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘29’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999563952_75_210--]
Belén CRESPO with ECAS id ncresbel signed in the
Participant Portal on 21/09/2017 at 08:02:19 (transaction id
SigId-195412-
FzzkAkQzG0fN4yl4LzzvLaNxmnWtWMyr1fN4IT03TtjVHpz
bE6P9sJA40Yf8Rty3Fo03PzgagzZPuNfhKTMlYtGa-
Jj71zxYb8yrN6HT4pVHCoC-
JfUdjUq1ZfdOcMyeEIbsElc0KAiKHJ5gxzzrRDTXi1qG).
Timestamp by third party at
Thu Sep 21 09:02:38 CEST 2017
28
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
DEPARTAMENT DE SALUT - GENERALITAT DE CATALUNYA (GENCAT), established
in Trav. de les Corts (Pavelló Ave Maria) 131-159, BARCELONA 08028, Spain ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘30’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999826919_75_210--]
29
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
CONSELLERIA DE SALUD (IdISBa) ES8, established in PLAZA DE ESPANA 9, PALMA DE
MALLORCA 07002, Spain, ESS0711001H ('the beneficiary'), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘31’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-917008901_75_210--]
Patricia GOMEZ with ECAS id ngomeaaz signed in the
Participant Portal on 29/08/2017 at 08:03:15 (transaction
id SigId-11275-
M2tB0SzduqdlkIQ2IixzvxcGhSthelk0k5PIKu27lnNfx7zza
mjBiXTAWWoQJR66znIN1edeVhSpzRbqzdkEfaAS-
Jj71zxYb8yrN6HT4pVHCoC-
30
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION
DE MURCIA (FFIS) ES3, 92, established in CALLE LUIS FONTES PAGAN 9 EDIF EMI
HOSPITAL REINA SOFIA, MURCIA 30003, Spain, ESG73338857 ('the beneficiary'), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘32’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-962632463_75_210--]
Jesus Angel SANCHEZ with ECAS id nsajeusa signed in
the Participant Portal on 29/08/2017 at 14:20:03
(transaction id SigId-16926-
kftB0W0wQ5vDzQTQ0R558HisxnDNCWhq18zty52R5qZ
v9eDNkMFzqYaqx3zVD8AT72STHjVkugztckce3QFipdC-
Jj71zxYb8yrN6HT4pVHCoC-
31
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FUNDACION PUBLICA MIGUEL SERVET (FMS) ES3, 406, established in CALLE
IRUNLARREA 3 CENTRO INVESTIGACION BIOMEDICA RECINTO COMPLEJO
HOSPITALARIO DE NAVARRA, PAMPLONA 31008, Spain, ESG31187420 ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘33’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-966802493_75_210--]
Iñigo LASA UZCUDUN with ECAS id nlasauin signed in
the Participant Portal on 29/08/2017 at 07:43:27
(transaction id SigId-11139-
bJ9Xh4cgxoSzabngJHRS6wRzmlWNgZbcTuEBvUU3xf1
1lKuUrM1L9ufC3ccloSHHqu1RVpO1xGmfJvfVlG2w1l-
Jj71zxYb8yrN6HT4pVHCoC-
32
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SERVICIO ANDALUZ DE SALUD (SAS), not applicable, established in AVENIDA DE LA
CONSTITUCION 18, SEVILLA 41071, Spain, ESQ9150013B ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘34’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998853621_75_210--]
Francisca ANTÓN MOLINA with ECAS id narajema signed
in the Participant Portal on 22/09/2017 at 13:34:53
(transaction id SigId-212783-
7QfGSNah5Fqq5VWlnwjCp6etJAaYNUIebqwEgDdeWrsv
WJI4QtwPR07SL1S1mMxXsVwpbXwVsIzga2zzT2BKBzi-
Jj71zxYb8yrN6HT4pVHCoC-
VddoTgPir2if4Y4mzIs4u2lwpmWRxizaPB4EgKbNM7F0).
Timestamp by third party at
Fri Sep 22 14:35:04 CEST 2017
33
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, ESQ2827015E ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘35’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999507886_75_210--]
JESUS F.CRESPO with ECAS id narenjoa signed in the
Participant Portal on 14/09/2017 at 09:26:23 (transaction id
SigId-137560-
Xhsv8RvMlRMw0VykcUSG2pxuU2rhmkcMpgoGPDYiL6B
kDsUcTN2wwukb1zhGTgOxDswzaBazGjB8TRRBAxwM6
kW-Jj71zxYb8yrN6HT4pVHCoC-
ZQk17QGqWmOJjaFVcmeMwV1SQQKLFnwpuY1ZkRlG
MSW). Timestamp by third party at
Thu Sep 14 10:26:45 CEST 2017
34
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SERVICIO MADRILENO DE SALUD (SERMAS), 142005, established in PLAZA CARLOS
TRIAS BERTRAN 7, MADRID 28020, Spain, ESQ2801221I ('the beneficiary'), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘36’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999481987_75_210--]
Maria José CALVO with ECAS id nclvmiaj signed in the
Participant Portal on 25/09/2017 at 08:34:26 (transaction id
SigId-1982-
dVUeO9PHFFzbRZsiYlzUdQdaOggr6UCrPxO2mSY6zGo
LORCChdiMjeazSx82pfOxE1xEgjJGrjBFzzfwnXMQCRLG-
PHslUMVSXYC5hxZtLv2jzQ-
ebO8qFJyfQXybmwq919RL32fm3NQZptQkizHYJR3RJj).
Timestamp by third party at
Mon Sep 25 09:34:37 CEST 2017
35
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FOLKHALSOMYNDIGHETEN (FoHM), 2021006545, established in NOBELS VAG 18, SOLNA
171 82, Sweden, SE202100654501 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘37’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-949789954_75_210--]
Anders TEGNELL with ECAS id ntegande signed in the
Participant Portal on 29/08/2017 at 15:21:45 (transaction
id SigId-18261-
8sa5zZKyUYLCrlUdAUTzK3a2kPhojFt6P2SOE3aduxff4fg
I7n0qCSAk7VD0qGdouvYLUWpJocSjU2L2ZCMhyO-
Jj71zxYb8yrN6HT4pVHCoC-
36
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SOCIALSTYRELSEN (SoS), 2021000555, established in RALAMBSVAGEN 3, STOCKHOLM
106 30, Sweden, SE202100055501 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘38’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998248147_75_210--]
Axana HAGGAR with ECAS id nhaggaax signed in the
Participant Portal on 29/08/2017 at 09:40:14 (transaction
id SigId-12538-
0AeJ2CziGNNDDviM9TKiwknIbN0M7PRirAwIP6QqBQtH
840Vl4oElETAtFHLliXJui5XS1Fo8RYnoS8iLMuk70-
Jj71zxYb8yrN6HT4pVHCoC-
37
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATENS JORDBRUKSVERK (SBA), 2021004151, established in JONKOPING, JONKOPING
551 82, Sweden, SE202100415101 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘39’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-917953487_75_210--]
Ingrid EILERTZ with ECAS id neilerin signed in the
Participant Portal on 22/09/2017 at 11:03:30 (transaction id
SigId-210388-
mMpJbyfZjnAV8ayJAOnx7mc3H5HaoqDcpzpBNrnVjDKyh
ZZJy1NakWSzKgzU2WrHhzNOqRxv6wfIZwZdNlVkzlzW-
Jj71zxYb8yrN6HT4pVHCoC-
YeJ3IoSU0GjL0DLSG4WEVzRlZETzGLRLQbsrZGGXcBv
m). Timestamp by third party at
Fri Sep 22 12:03:40 CEST 2017
38
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
LIVSMEDELS VERKET (NFA), 202100-1850 , established in Hamnesplanaden 5, UPPSALA 751
26, Sweden ('the beneficiary'), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary (‘40’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-997318402_75_210--]
Annika RIMLAND with ECAS id nrimlaan signed in the
Participant Portal on 04/09/2017 at 08:24:31 (transaction
id SigId-49108-
czWydzf6pAOEmVZs41od7AFZZBh8N2uq8i3wPduJjDod
vKiYnYzcp78yD2Hd5QeOJs8VmUFXejSe4vasazq6Dji-
Jj71zxYb8yrN6HT4pVHCoC-
39
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
STATENS VETERINAERMEDICINSKA ANSTALT (SVA), 2021001868, established in Ulls
Vaeg 2B, UPPSALA 75189, Sweden ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘41’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999755818_75_210--]
Jens MATTSSON with ECAS id nmattsje signed in the
Participant Portal on 29/08/2017 at 06:39:24 (transaction
id SigId-10881-
zyEommeFxUjNFHcTco9YoWfae1zdairwa3azQRad7ojFg
Zaq5Tjx52TmCRdTq0hDAyXvp5hu5GMHgH1d1zzYSqn-
Jj71zxYb8yrN6HT4pVHCoC-
40
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL (SRC), 2021005208, established
in VASTRA JARNVAGSGATAN 3, STOCKHOLM 111 64, Sweden ('the beneficiary'), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘42’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-999586165_75_210--]
Ann FUST with ECAS id nfustaac signed in the Participant
Portal on 20/09/2017 at 11:05:44 (transaction id SigId-
186598-
BaPTar9N7aZTX3RZf3FWLzV1Y7GN0VOfcDBzqpSg4iejT
VHFkmdiksOeBGHeNf9SdsTarf5EsjWj9fpKPB1Zvs-
Jj71zxYb8yrN6HT4pVHCoC-
wVpzWkABDVgOHWzRxbzeLGGOOnzR9TW4K4vnqtziY
mceG). Timestamp by third party at
Wed Sep 20 12:06:00 CEST 2017
41
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
UPPSALA LANS LANDSTING (UAS), 2321000024, established in PO BOX 602, UPPSALA
751 25, Sweden, SE232100002401 ('the beneficiary'), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘43’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-998923946_75_210--]
Staffan ISLING with ECAS id nislinst signed in the
Participant Portal on 01/09/2017 at 08:41:36 (transaction
id SigId-41950-
9zvfwHYn0IDC3LCUzLcjfnzk9Y5RMFvL78KwWB0fqWTN
ANjXRzhkPVovcnrDuVzZhszj2YXRXtoNI1vrZ6mzM6ti-
Jj71zxYb8yrN6HT4pVHCoC-
42
Grant Agreement number: 761296 — EU-JAMRAI — HP-JA-2016
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L
ENVIRONNEMENT ET DU TRAVAIL (ANSES), 130012024, established in 14 RUE PIERRE
ET MARIE CURIE, MAISONS ALFORT 94700, France, FR54130012024 ('the beneficiary'),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary (‘44’)
in Grant Agreement No 761296 (‘the Agreement’)
between INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE and the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under the
powers delegated by the European Commission ('the Commission'),
for the action entitled ‘European Joint Action on antimicrobial resistance and associated infections
(EU-JAMRAI )’.
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement the grant
in accordance with the Agreement, with all the obligations and conditions it sets out .
SIGNATURE
For the beneficiary
[--TGSMark#signature-983552356_75_210--]
Caroline GARDETTE with ECAS id nmortuma signed in
the Participant Portal on 08/09/2017 at 09:31:25
(transaction id SigId-92928-
qBm5NeoO91PSjpUW6w0KsrFG01rzczUSQHUpAxF38wh
SUIWlCyBU6XqsJzZoOpL8Xmzv9Mf0uB58m80NFBhzWk
2-Jj71zxYb8yrN6HT4pVHCoC-
w0NCuo6w6qBuYvSBLmd4cgw803OsXtST3wIr1zoFUM7)
. Timestamp by third party at
Fri Sep 08 10:31:37 CEST 2017
43
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
i print format A4
MODEL ANNEX 4 CHAFEA MGA — MULTI
landscape
FINANCIAL STATEMENT FOR [BENEFICIARY [name]/AFFILIATED ENTITY [name]] FOR REPORTING PERIOD [reporting period]
1 Receipts
Eligible costs (per budget category) EU contribution
Financial
A. Direct personnel B. Direct costs of C. Other direct D. Indirect Income generated contributions given Requested EU
2 Total costs Total receipts 3
costs subcontracting costs costs by the action by third parties to contribution
the beneficiaries
A.1 Employees C.1 Travel
A.2 Natural persons
C.2 Equipment
under direct contract
and seconded persons
C.3 Other goods and
services
5
4 Actual Actual Actual Flat-rate
Cost form
7%
d= e=
a b c f g h=f+g i
0,07 * (a + b + c) a+b+c+d
[short name
beneficiary/affiliated
entity]
The beneficiary/affiliated entity hereby confirms that:
The information provided is complete, reliable and true.
The costs declared are eligible (see Article 6).
The costs can be substantiated by adequate records and supporting documentation that will be produced upon request or in the context of checks, reviews, audits and investigations (see Articles 12, 13
and 17).
For the last reporting period: that all the receipts have been declared (see Article 5.3.3).
i Please declare all eligible costs, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Only amounts that were declared in your individual financial statements can be
taken into account lateron, in order to replace other costs that are found to be ineligible.
1
See Article 6 for the eligibility conditions
2
The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme); see Article 6.2.D. If you have received an operating
grant during this reporting period, you cannot claim any indirect costs
3
You may request up to 100% of the total cost declared. The reimbursement rate mentioned in Article 5.2 applies only at consortium level (and will only be checked by the Agency at the payment of
the balance)
4
See Article 5 for the cost forms
5
Flat rate : 7% of eligible direct costs
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
i print format A4
ANNEX 4 CHAFEA MGA — MULTI: Details
landscape
A. Direct personnel costs
A.1 Employees
Name/Function No of hours worked for the project Hourly rate Total costs
(a) (b) (c) = (a) * (b)
Total for A.1 Employees
A.2 Natural persons under direct contract and seconded persons
Name/Function No of hours worked for the project Hourly rate Total costs
(a) (b) (c) = (a) * (b)
Total for A.2 Natural persons under direct contract and
seconded persons
Total for A. Direct personnel costs
B. Direct costs of subcontracting
Invoice Number Subcontractor and Description of task Price
Total for B. Direct costs of subcontracting
C. Other direct costs
C.1 Travel
Description (Name of person travelling, meeting as referenced in the technical report, place of the meeting) Travel cost No of days Daily rate Total costs
(a) (b) (c) (d) = (a) + ((b) * (c))
Total for C.1 Travel
C.2 Equipment
Number of month of
Depreciation method (36 % of use for the purpose
Invoice Number Description of the equipment Purchase price Date of purchase depreciation allocated to Total costs
or 60 month) of the project
the project
(a) (b) (c) (d) (e) (f) = ((d)/(c) * (e)) * (a)
Total for C.2 Equipment
C.3 Other goods and services
Invoice Number Description of service or good Purchase price
Total for C.3 Other goods and services
Total for C. Other direct costs
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
ANNEX 5
MODEL OF THE CERTIFICATE ON THE FINANCIAL STATEMENTS
For options [in italics in square brackets]: choose the applicable option. Options not chosen should
be deleted.
For fields in [grey in square brackets]: enter the appropriate data
TABLE OF CONTENTS
1. TERMS OF REFERENCE FOR INDEPENDENT CERTIFICATE ON FINANCIAL STATEMENTS
AND REPORT ON FINDINGS ON COSTS DECLARED UNDER A GRANT AGREEMENT
FINANCED UNDER THE HEALTH AND CONSUMER PROGRAMMES 2014-2020
2.MODEL OF CERTIFICATE ON FINANCIAL STATEMENTS TO BE PROVIDED BY
INDEPENDENT AUDITOR
3. TEMPLATE OF THE REPORT ON FINDINGS ON COSTS DECLARED UNDER A GRANT
AGREEMENT FINANCED UNDER HEALTH AND CONSUMER PROGRAMMES 2014-2020
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Terms of Reference for an Independent Certificate on Financial Statements and Report
on Findings on costs declared under a Grant Agreement financed under the Health and
Consumer Programmes 2014-2020
This document sets out the ‘Terms of Reference (ToR)’ under which
[insert name of the beneficiary] (‘the Beneficiary’)]
agrees to engage
[insert legal name of the auditor] (‘the Auditor’)
to issue an Independent Certificate on the Financial Statements’ (‘CFS’) referred to in Articles
15.3 and 15.4 of the Agreement based on the compulsory reporting template stipulated by the
Agency, and
to produce an independent Report of findings (‘the Report’) concerning the Financial
Statement(s)1 drawn up by the [Beneficiary] [Affiliated Entity] for the [Health] / [Consumer]
Programme 2014-2020 grant agreement [insert number of the grant agreement, title of the
action, acronym and duration from/to] (‘the Agreement’),
The Agreement has been concluded under the [Health] / [Consumer] Programme 2014-2020
between the Beneficiary and Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) (‘the Agency’), under the powers delegated by the European Commission (‘the
Commission’).
The Agency is mentioned as a signatory of the Agreement with the Beneficiary only. The
Agency is not a party to this engagement.
1.1 Subject of the engagement
The coordinator must submit to the Agency the final report within 60 days following the end
of the each reporting period which should include, amongst other documents, a CFS for each
beneficiary (and linked affiliated entity), for which the total contribution in the form of
reimbursement of actual costs as referred to in Article 5.2 of the Agreement is at least EUR
750.000, and which requests a reimbursement in that form of EUR 325 000 or more, as
reimbursement of actual costs calculated on the basis of its usual cost accounting practices.
The CFS must cover the reporting period of the beneficiary (or linked Affiliated Entity)
concerned by the payment.
The Beneficiary must submit to the coordinator the CFS for itself and for its linked Affiliated
Entity, if the CFS must be included in the interim and final reports according to Articles 15.3
and 15.4 of the Agreement.
The CFS is composed of the following documents:
1
By which costs under the Agreement are declared (see template ‘Model Financial Statements’ in
Annex 4 to the Grant Agreement).
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
- The Terms of Reference (‘the ToR’) to be signed by the [Beneficiary] [Affiliated
Entity] and the Auditor;
- the Auditor’s Certificate on Financial Statements and Independent Report of Findings
(‘the Report’) to be issued on the Auditor’s letterhead, dated, stamped and signed by
the Auditor (or the competent public officer) which includes the agreed-upon checks
(laid down in the Annex I to the Report) to be performed by the Auditor, and the
standard findings (‘the Findings’) to be confirmed by the Auditor.
If the CFS must be included in the interim and final report according to Articles 15.3 and 15.4
of the Agreement, the request for interim payment or payment of the balance to the
Agreement cannot be made without the CFS. However, the payment for reimbursement of
costs covered by the CFS does not preclude the Agency, the European Anti-Fraud Office and
the European Court of Auditors from carrying out checks, reviews, audits and investigations
in accordance with Article 17 of the Agreement.
1.2 Responsibilities
The [Beneficiary] [Linked Affiliated Entity]:
must draw up the Financial Statement(s) for the action financed by the Agreement in
compliance with the obligations under the Agreement. The Financial Statement(s)
must be drawn up according to the [Beneficiary’s] [Linked Affiliated Entity’s]
accounting and book-keeping system and the underlying accounts and records;
must send the Financial Statement(s) to the Auditor;
is responsible and liable for the accuracy of the Financial Statement(s);
is responsible for the completeness and accuracy of the information provided to enable
the Auditor to carry out the checks.;
accepts that the Auditor cannot carry out the checks unless he/she is given full access
to the [Beneficiary’s] [Linked Affiliated Entity’s] staff and accounting as well as any
other relevant records and documentation.
The Auditor:
[Option 1 by default: is qualified to carry out statutory audits of accounting
documents in accordance with Directive 2006/43/EC of the European Parliament and
of the Council of 17 May 2006 on statutory audits of annual accounts and consolidated
accounts, amending Council Directives 78/660/EEC and 83/349/EEC and repealing
Council Directive 84/253/EEC or similar national regulations].
[Option 2 if the Beneficiary or Linked Affiliated Officer has an independent Public
Officer: is a competent and independent Public Officer for which the relevant national
authorities have established the legal capacity to audit the Beneficiary].
The Auditor:
must be independent from the Beneficiary [and the Linked Affiliated Entity], in
particular, it must not have been involved in preparing the [Beneficiary’s] [Linked
Affiliated Entity’s] Financial Statement(s);
must plan work so that the checks may be carried out and the Findings may be
assessed;
must adhere to the checks laid down in Annex I to the Report and the compulsory
report format;
must carry out the engagement in accordance with this ToR;
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
must document matters which are important to support the Report;
must base its Report on the evidence gathered;
must submit the Report to the [Beneficiary] [Linked Affiliated Entity].
The Agency sets out the list of checks to be carried out by the Auditor which is defined in
detail in the Annex I to the Report. The Auditor has to examine the Financial Statements and
verify the supporting documentation in order to provide a reasonable assurance on their
correctness.
1.3 Applicable Standards
The Auditor must comply with these Terms of Reference and with2:
- the International Standard on Related Services (‘ISRS’) 4400 Engagements to
perform Agreed-upon Procedures regarding Financial Information as issued by
the International Auditing and Assurance Standards Board (IAASB);
- the Code of Ethics for Professional Accountants issued by the International Ethics
Standards Board for Accountants (IESBA). Although ISRS 4400 states that
independence is not a requirement for engagements to carry out agreed-upon
checks, the Agency requires that the Auditor also complies with the Code’s
independence requirements.
The Auditor’s Report must state that there is no conflict of interests in establishing this Report
between the Auditor and the Beneficiary [and the Linked Affiliated Entity], and must specify -
if the service is invoiced - the total fee paid to the Auditor for providing the Report.
1.4 Reporting
The Report must be written in the language of the Agreement.
Under Article 17 of the Agreement, the Agency, the European Anti-Fraud Office and the
Court of Auditors have the right to audit any work that is carried out under the action and for
which costs are declared from the European Union budget. This includes work related to this
engagement. The Auditor must provide access to all working papers (e.g. recalculation of
hourly rates, verification of the time declared for the action) related to this assignment if the
Agency, the European Anti-Fraud Office or the European Court of Auditors requests them.
1.5 Timing
The CFS must be provided together with the request for the interim and balance payment, if
required according to Articles 15.3 and 15.4 of the Agreement.
1.6 Other terms
2
Supreme Audit Institutions applying INTOSAI-standards may carry out the Procedures according
to the corresponding International Standards of Supreme Audit Institutions and code of ethics
issued by INTOSAI instead of the International Standard on Related Services (‘ISRS’) 4400 and
the Code of Ethics for Professional Accountants issued by the IAASB and the IESBA.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
[The [Beneficiary] [Linked Affiliated Entity] and the Auditor can use this section to agree
other specific terms, such as the Auditor’s fees, liability, applicable law, etc. Those specific
terms must not contradict the terms specified above.]
[legal name of the Auditor [legal name of the [Beneficiary][Linked Affiliated
Entity]]
[name & function of authorised representative] [name & function of authorised
representative]
[dd Month yyyy] [dd Month yyyy]
Signature of the Auditor Signature of the [Beneficiary][Linked Affiliated
Entity]
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Independent certificate on the financial statements declared under grant agreements
signed under the Health and Consumer Programmes 2014-2020
(To be submitted by each beneficiary if the maximum grant amount in the form of reimbursement of ‘actual
costs’ is at least EUR 750 000 and if it requests a reimbursement of actual costs of at least EUR 325 000 (see
Articles 15.3 and 15.4)
To be drawn up and signed by an approved auditor or, in case of public bodies, by a competent and independent
public officer (and printed on their letterhead).)
To
[ name of contact person(s)], [Position]
[ [Beneficiary’s] [Linked Affiliated Entity’s] name ]
[ Address]
[ dd Month yyyy]
Dear [Name of contact person(s)],
As agreed under the terms of reference dated [dd Month yyyy]
with [OPTION 1: [insert name of the beneficiary] (‘the Beneficiary’)] [OPTION 2: [insert
name of the linked Affiliated Entity (‘the Linked Affiliated Entity), Affiliated Entity linked to
the Beneficiary [insert name of the beneficiary] (‘the Beneficiary’)],
we
[name of the auditor ] (‘the Auditor’),
established at
[full address/city/state/province/country],
represented by
[name and function of an authorised representative],
have carried out an audit relating to the provisions of the Terms of Reference, the costs
declared in the Financial Statement(s)3 of the [Beneficiary] [Linked Affiliated Entity], the
documents provided in their support , to which this Certificate is attached, and which is to be
presented to Agency together with the request for payment under the grant agreement [insert
grant agreement reference: number, title of the action and acronym] (‘the Agreement’), for the
following period (s) covered by Agreement [insert period(s) covered by the Financial
Statements].
The audit and subsequent checks were carried out solely to assist Agency in evaluating
whether the[Beneficiary][Linked Affiliated Entity’s] costs in the accompanying Financial
Statement(s) were declared in accordance with the Agreement. The Agency will draw its own
conclusions from the Report and any additional information it may require.
The above mentioned Financial Statement(s) of the [Beneficiary] [Linked Affiliated Entity],
their supporting documentation and accounting records were examined in accordance with
3
By which the Beneficiary declares costs under the Agreement (see template ‘Financial Statement’
in Annex 4 to the Agreement).
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
the upon-agreed checks , as detailed in Annex I to the Report, in order to provide Agency with
the following reasonable assurance:
the amount of the total eligible costs ([insert amount in number] ([insert amount in
words4])) declared in the attached Financial Statement(s) of the [Beneficiary] [Linked
Affiliated Entity] is complying with the following cumulative conditions, as defined in the
Article 6.1 of the Agreement:
they are actual and recorded in the [Beneficiary’s] [Linked Affiliated
Entity’s]accounts at the date of the establishment of this audit certificate;
they have been incurred during the periods covered by the Financial Statement(s)
concerned by this audit certificate;
[they also include the eligible costs incurred in drawing up the final reports
referred to in Article 15 of the Agreement, which may be incurred up to two
calendar months after the end of the action;]
they are determined in accordance with the beneficiary’s accounting standards
applicable in the country where the [Beneficiary] [Linked Affiliated Entity]is
established, and with the beneficiary’s usual cost accounting practices;
they comply with the national law on taxes, labour and social security applicable in
the country where the [Beneficiary] [Linked Affiliated Entity]is established;
they are exclusive of any non-eligible costs identified below which are established
in Article 6.4 of the above mentioned agreement with the Agency:
return on capital;
debt and debt service charges;
provisions for future losses or debts;
interest owed;
doubtful debts;
currency exchange losses;
bank costs charged by the beneficiary’s bank for transfers from the
Agency;
deductible VAT;
costs incurred during suspension of the implementation of the action;
excessive or reckless expenditure;
contributions in kind provided by third-parties;
costs declared under another EU or Euratom grant, in particular,
indirect costs if beneficiary is already receiving an operating grant
financed by EU or Euratom in the same period.
[they are claimed according to the EUR conversion rate as defined in the Article
15.5 of the Agreement;
as declared in the Financial Statement(s) of the [Beneficiary] [Linked Affiliated Entity]
and only for the request of payment of the balance, the total amount of receipts for the
total period covered by this(those) Financial Statement(s) is equal to ([insert amount in
number] ([insert amount in words5]) ;
4
In EUR.
5
In EUR.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
accounting procedures used in the recording of eligible costs and receipts respect the
accounting rules of the State in which the beneficiary is established and permit the direct
reconciliation between the costs and receipts incurred for the implementation of the
project covered by the Agreement and the overall statement of accounts relating to the
beneficiary’s overall business activity6;
based on our audit, we can conclude that the financial management of the grant was
carried out in an acceptable manner and in compliance with the requirements of [grant
agreement reference: title, acronym, number]
our company [organisation – for competent public officers] is qualified to deliver this
audit certificate in full compliance with the Articles 15.3 and 15.4 of the agreement;
[Relevant information establishing this qualification is included with this audit
certificate;]7
The list of Findings, Exceptions and Further remarks, if any, is presented in the Report
annexed to this Certificate.
The Certificate on Financial Statement(s) and Report was prepared solely for the confidential
use of the [Beneficiary] [Linked Affiliated Entity] and the Agency, and only to be submitted
to the Agency in connection with the requirements set out in Articles 15.3 and 15.4 of the
Agreement. The Certificate and Report may not be used by the [Beneficiary] [Linked
Affiliated Entity] or by the Agency for any other purpose, nor may it be distributed to any
other parties. The Agency may only disclose these documents to authorised parties, in
particular to the European Anti-Fraud Office (OLAF) and the European Court of Auditors.
Both Certificate and Report relate only to the Financial Statement(s) submitted to the Agency
by the [Beneficiary] [Linked Affiliated Entity] for the Agreement. Therefore, they do not
extend to any other of the [Beneficiary’s] [Linked Affiliated Entity’s] Financial Statement(s).
There was no conflict of interest8 between the Auditor and the Beneficiary [and Linked
Affiliated Entity] in establishing these documents. As declared in the Financial Statement(s)
the total fee paid to the Auditor for providing the Report was EUR ______ (including
EUR______ of deductible VAT).
.
[legal name of the Auditor]
[name and function of an authorised representative]
6
Article 6.1.
7
If the auditor is not known internationally or for a competent public officer whose competence to provide an audit
certificate has not been attested to by its national authorities.
8
A conflict of interest arises when the Auditor's objectivity to establish the certificate is compromised in fact or in
appearance when the Auditor for instance:
- was involved in the preparation of the Financial Statements;
- stands to benefit directly should the certificate be accepted;
- has a close relationship with any person representing the beneficiary;
- is a director, trustee or partner of the beneficiary; or
- is in any other situation that compromises his or her independence or ability to establish the certificate impartially.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
[dd Month yyyy]
Signature of the Auditor
Report of Findings on costs declared under grant agreement signed under Health and
Consumer Programmes 2014-2020
Not applicable Findings
We examined the Financial Statement(s) stated above and considered the following Findings
not applicable:
Explanation (to be removed from the Report):
If a Finding was not applicable, it must be marked as ‘N.A.’ (‘Not applicable’) in the corresponding row on the
right-hand column of the table and means that the Finding did not have to be corroborated by the Auditor and
the related check(s) did not have to be carried out.
The reasons of the non-application of a certain Finding must be obvious i.e.
i) if no cost was declared under a certain category then the related Finding(s) and check(s) are not
applicable;
ii) if the condition set to apply certain check(s) are not met the related Finding(s) and those check(s)
are not applicable. For instance, for ‘beneficiaries with accounts established in a currency other
than euro’ the check and Finding related to ‘beneficiaries with accounts established in euro’ are not
applicable. Similarly, if no additional remuneration is paid, the related Finding(s) and check(s) for
additional remuneration are not applicable.
List here all Findings considered not applicable for the present engagement and explain
the reasons of the non-applicability.
….
Exceptions
The [Beneficiary] [Linked Affiliated Entity] provided the Auditor all the documentation and
accounting information needed by the Auditor to carry out the requested checks and evaluate
the Findings.
Explanation (to be removed from the Report):
- If the Auditor was not able to successfully complete a procedure requested,. The reason such as the
inability to reconcile key information or the unavailability of data that prevents the Auditor from
carrying out the audit must be indicated below.
- If the Auditor cannot corroborate a standard finding after having carried out the corresponding audit,
it must state, the reasons why the Finding was not fulfilled and its possible impact must be explained
here below.
List here any exceptions and add any information on the cause and possible
consequences of each exception, if known. If the exception is quantifiable, include the
corresponding amount.
….
Example (to be removed from the Report):
1. The Beneficiary was unable to substantiate the Finding number 1 on … because ….
2. Finding number 30 was not fulfilled because the methodology used by the Beneficiary to
calculate daily costs was different from the one accepted by the Agency. The differences were as
follows: …
3. After carrying out the agreed checks to confirm the Finding number 31, the Auditor found a
difference of _____________ EUR. The difference can be explained by …
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Further Remarks
In addition to reporting on the results of the specific procedures carried out, the Auditor
would like to make the following general remarks:
Example (to be removed from the Report):
1. Regarding Finding number 8 the conditions for additional remuneration were considered as
fulfilled because …
2. In order to be able to confirm the Finding number 15 we carried out the following additional
procedures: ….
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
ANNEX I to the Report on Findings: Agreed-upon checks to be performed and standard findings to be confirmed by the Auditor
The Agency reserves the right to i) provide the auditor with additional guidance regarding the checks to be followed or the facts to be ascertained
and the way in which to present them (this may include sample coverage and findings) or to ii) change the checks, by notifying the Beneficiary in
writing. The list of checks to be carried out by the auditor in order to confirm the standard findings is laid down in the table below.
If this certificate relates to a Linked Affiliated Entity, any reference here below to ‘the Beneficiary’ is to be considered as a reference to ‘the Linked Affiliated Entity’.
The ‘result’ column has three different options: ‘C’, ‘E’ and ‘N.A.’:
‘C’ stands for ‘confirmed’ and means that the auditor can confirm the ‘standard finding’ and, therefore, there is no exception to be
reported.
‘E’ stands for ‘exception’ and means that the Auditor carried out the checks but cannot confirm the ‘standard finding’, or that the Auditor
was not able to carry out a specific check (e.g. because it was impossible to reconcile key information or data were unavailable),
‘N.A.’ stands for ‘not applicable’ and means that the Finding did not have to be examined by the Auditor and the related check(s) did not
have to be carried out. The reasons of the non-application of a certain Finding must be obvious i.e. i) if no cost was declared under a
certain category then the related Finding(s) and check(s) are not applicable; ii) if the condition set to apply certain checks(s) are not met
then the related Finding(s) and checks(s) are not applicable. For instance, if no additional remuneration is paid, the related Finding(s) and
check(s) for additional remuneration are not applicable.
Result
Ref Checks Standard finding (C / E
/N.A)
ACTUAL PERSONNEL COSTS CALCULATED BY THE BENEFICIARY IN ACCORDANCE WITH ITS USUAL COST
A
ACCOUNTING PRACTICE
The Auditor draws the full list of persons (including employees and natural persons
working under a direct contract ) whose costs were declared in the Financial
Statement(s) in order to carry out the checks indicated in the consecutive points of this
section A.
(The Auditor sampled ______ people out of the total of ______ people.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
A.1 PERSONNEL COSTS 1) The employees were i)
For the persons declared by the beneficiary or Linked Affiliated Entity in the Financial directly hired by the
Statement, and working under an employment contract or equivalent act (general Beneficiary in accordance
procedures for individual actual personnel costs) with its national legislation,
ii) under the Beneficiary’s
To confirm standard findings 1-5 listed in the next column, the Auditor reviewed
sole technical supervision and
following information/documents provided by the Beneficiary:
responsibility and iii)
o a list of the persons declared by Beneficiary or Linked Affiliated Entity indicating remunerated in accordance
the period(s) during which they worked for the action, their position with the Beneficiary’s usual
(classification or category) and type of contract; practices.
o the payslips of the employees;
o reconciliation of the personnel costs declared in the Financial Statement(s) with 2) Personnel costs were recorded
the accounting system (project accounting and general ledger) and payroll system; in the Beneficiary's
o information concerning the employment status and employment conditions of the accounts/payroll system.
declared personnel, in particular their employment contracts or equivalent;
3) Costs were adequately
o the Beneficiary’s usual policy regarding payroll matters (e.g. salary policy,
supported and reconciled with
overtime policy, variable pay);
the accounts and payroll
o applicable national law on taxes, labour and social security and
records.
o any other document that supports the personnel costs declared.
4) Personnel costs did not
contain any ineligible
elements.
5) There were no discrepancies
between the personnel costs
charged to the action and the
costs recalculated by the
Auditor.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
Further procedures if ‘additional remuneration’ is paid 6) The Beneficiary paying
To confirm standard factual findings 6-8 listed in the next column, the Auditor: “additional remuneration”
was a non-profit legal entity.
o reviewed relevant documents provided by the Beneficiary (legal form,
legal/statutory obligations, the Beneficiary’s usual policy on additional
7) The amount of additional
remuneration, criteria used for its calculation…);
remuneration paid
o recalculated the amount of additional remuneration eligible for the action based corresponded to the
on the supporting documents received (full-time or part-time work, exclusive or Beneficiary’s usual
non-exclusive dedication to the action, etc.). remuneration practices and
was consistently paid
whenever the same kind of
IF ANY PART OF THE REMUNERATION PAID TO THE EMPLOYEE IS NOT MANDATORY ACCORDING work or expertise was
TO THE NATIONAL LAW OR THE EMPLOYMENT CONTRACT ("ADDITIONAL REMUNERATION") AND required.
IS ELIGIBLE UNDER THE PROVISIONS OF ARTICLE 6.2.A., THIS CAN BE CHARGED AS ELIGIBLE
COST TO THE ACTION. 8) The criteria used to calculate
the additional remuneration
were objective and generally
applied by the Beneficiary
regardless of the source of
funding used.
For natural persons included in the sample and working with the Beneficiary under a 9) The natural persons reported
direct contract other than an employment contract, such as consultants (no to the Beneficiary (worked under
the Beneficiary’s instructions).
subcontractors).
To confirm standard factual findings 9-13 listed in the next column the Auditor reviewed 10) They worked on the
following information/documents provided by the Beneficiary: Beneficiary’s premises (unless
otherwise agreed with the
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
o the contracts, especially the cost, contract duration, work description, place of Beneficiary).
work, ownership of the results and reporting obligations to the Beneficiary;
o the employment conditions of staff in the same category to compare costs and;
o any other document that supports the costs declared and its registration (e.g. 11) The results of work carried
invoices, accounting records, etc.). out belong to the Beneficiary.
12) Their costs were not
significantly different from those
for staff who performed similar
tasks under an employment
contract with the Beneficiary.
13) The costs were supported by
audit evidence and registered in
the accounts.
A.2 PRODUCTIVE HOURS 14) The Beneficiary applied
method [choose one option and
To confirm standard factual findings 14-19 listed in the next column, the Auditor delete the others]
reviewed relevant documents, especially national legislation, labour agreements and
[A: 1720 hours]
contracts and time records of the persons included in the sample, to verify that:
[B: the ‘total number of
o the annual productive hours applied were calculated in accordance with one of the
hours worked’]
methods described below,
[C: ‘annual productive
o the full-time equivalent (FTEs) ratios for employees not working full-time were
hours’ used correspond to
correctly calculated.
usual accounting practices]
If the Beneficiary applied method B, the auditor verified that the correctness in which the 15) Productive hours were
total number of hours worked was calculated and that the contracts specified the annual calculated annually.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
workable hours. 16) For employees not working
full-time the full-time equivalent
If the Beneficiary applied method C, the auditor verified that the ‘annual productive (FTE) ratio was correctly
hours’ applied when calculating the hourly rate were equivalent to at least 90 % of the applied.
‘standard annual workable hours’. The Auditor can only do this if the calculation of the
standard annual workable hours can be supported by records, such as national legislation, If the Beneficiary applied
labour agreements, and contracts. method B.
17) The calculation of the
BENEFICIARY'S PRODUCTIVE HOURS' FOR PERSONS WORKING FULL TIME SHALL BE ONE OF THE number of ‘annual workable
FOLLOWING METHODS: hours’, overtime and absences
A. 1720 ANNUAL PRODUCTIVE HOURS (PRO-RATA FOR PERSONS NOT WORKING FULL-TIME) was verifiable based on the
documents provided by the
B. THE TOTAL NUMBER OF HOURS WORKED BY THE PERSON FOR THE BENEFICIARY IN THE YEAR Beneficiary.
(THIS METHOD IS ALSO REFERRED TO AS ‘TOTAL NUMBER OF HOURS WORKED’ IN THE NEXT
COLUMN). THE CALCULATION OF THE TOTAL NUMBER OF HOURS WORKED WAS DONE AS If the Beneficiary applied
FOLLOWS: ANNUAL WORKABLE HOURS OF THE PERSON ACCORDING TO THE EMPLOYMENT method C.
CONTRACT, APPLICABLE LABOUR AGREEMENT OR NATIONAL LAW PLUS OVERTIME WORKED 18) The calculation of the
MINUS ABSENCES (SUCH AS SICK LEAVE OR SPECIAL LEAVE). number of ‘standard annual
C. THE STANDARD NUMBER OF ANNUAL HOURS GENERALLY APPLIED BY THE BENEFICIARY FOR workable hours’ was verifiable
ITS PERSONNEL IN ACCORDANCE WITH ITS USUAL COST ACCOUNTING PRACTICES (THIS based on the documents
METHOD IS ALSO REFERRED TO AS ‘TOTAL ANNUAL PRODUCTIVE HOURS’ IN THE NEXT provided by the Beneficiary.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
COLUMN). THIS NUMBER MUST BE AT LEAST 90% OF THE STANDARD ANNUAL WORKABLE
19) The ‘annual productive
HOURS.
hours’ used for calculating the
hourly rate were consistent with
‘ANNUAL WORKABLE HOURS’ MEANS THE PERIOD DURING WHICH THE PERSONNEL MUST BE the usual cost accounting
WORKING, AT THE EMPLOYER’S DISPOSAL AND CARRYING OUT HIS/HER ACTIVITY OR DUTIES
practices of the Beneficiary and
UNDER THE EMPLOYMENT CONTRACT, APPLICABLE COLLECTIVE LABOUR AGREEMENT OR
were equivalent to at least 90 %
NATIONAL WORKING TIME LEGISLATION.
of the ‘annual workable hours’.
A.3 TIME RECORDING SYSTEM 20) All persons recorded their
To verify that the time recording system ensures the fulfilment of all minimum time dedicated to the action on a
requirements and that the hours declared for the action were correct, accurate and daily/ weekly/ monthly basis
properly authorised and supported by documentation, the Auditor made the following using a paper/computer-based
checks for the persons included in the sample that declare time as worked for the action system. (delete the answers that
on the basis of time records: are not applicable)
o description of the time recording system provided by the Beneficiary (registration,
21) Their time-records were
authorisation, processing in the HR-system);
authorised at least monthly by
o its actual implementation; the project manager or other
o time records were signed at least monthly by the employees (on paper or superior.
electronically) and authorised by the project manager or another manager;
22) Hours declared were worked
o the hours declared were worked within the project period; within the project period and
o there were no hours declared as worked for the action if HR-records showed were consistent with the
absence due to holidays or sickness (further cross-checks with travels are carried presences/absences recorded in
out in B.1 below) ; HR-records.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
o the hours charged to the action matched those in the time recording system.
23) There were no discrepancies
between the number of hours
ONLY THE HOURS WORKED ON THE ACTION CAN BE CHARGED. ALL WORKING TIME TO BE
charged to the action and the
CHARGED SHOULD BE RECORDED THROUGHOUT THE DURATION OF THE PROJECT, ADEQUATELY
number of hours recorded.
SUPPORTED BY EVIDENCE OF THEIR REALITY AND RELIABILITY (SEE SPECIFIC PROVISIONS
BELOW FOR PERSONS WORKING EXCLUSIVELY FOR THE ACTION WITHOUT TIME RECORDS).
If the persons are working exclusively for the action and without time records
For the persons selected that worked exclusively for the action without time records, the 24) The exclusive dedication is
Auditor verified evidence available demonstrating that they were in reality exclusively supported by a declaration
dedicated to the action and that the Beneficiary signed a declaration confirming that they signed by the Beneficiary’s and
have worked exclusively for the action. by any other evidence gathered.
B COSTS OF SUBCONTRACTING
B.1 The Auditor obtained the detail/breakdown of subcontracting costs and sampled 25) The use of claimed
______ cost items selected randomly (full coverage is required if there are fewer than subcontracting costs was
10 items, otherwise the sample should have a minimum of 10 item, or 10% of the total, foreseen in Annex 1 to the
whichever number is highest). Agreement and costs were
To confirm standard factual findings 25-29 listed in the next column, the Auditor declared in the Financial
Statements under the
reviewed the following for the items included in the sample:
subcontracting category.
o the use of subcontractors was foreseen in Annex 1of grant agreement;
26) There were documents of
o subcontracting costs were declared in the subcontracting category of the Financial requests to different providers,
Statement; different offers and assessment
of the offers before selection of
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
o supporting documents on the selection and award procedure were followed; the provider in line with internal
procedures and procurement
o the Beneficiary ensured best value for money (key elements to appreciate the
rules. Subcontracts were
respect of this principle are the award of the subcontract to the bid offering best
awarded in accordance with the
price-quality ratio, under conditions of transparency and equal treatment. In case
principle of best value for
an existing framework contract was used the Beneficiary ensured it was
money.
established on the basis of the principle of best value for money under conditions
of transparency and equal treatment). (When different offers were
not collected the Auditor
In particular,
explains the reasons
i. if the Beneficiary acted as a contracting authority within the meaning of Directive provided by the Beneficiary
2004/18/EC or of Directive 2004/17/EC, the Auditor verified that the applicable under the caption
national law on public procurement was followed and that the subcontracting “Exceptions” of the Report.
complied with the Terms and Conditions of the Agreement. The Agency will analyse this
ii. if the Beneficiary did not fall under the above-mentioned category the Auditor information to evaluate
verified that the Beneficiary followed their usual procurement rules and respected whether these costs might be
the Terms and Conditions of the Agreement.. accepted as eligible)
For the items included in the sample the Auditor also verified that: 27) The subcontracts were not
awarded to other Beneficiaries
o the subcontracts were not awarded to other Beneficiaries in the consortium; of the consortium.
o there were signed agreements between the Beneficiary and the subcontractor;
28) All subcontracts were
o there was evidence that the services were provided by subcontractor; supported by signed agreements
between the Beneficiary and the
subcontractor.
29) There was evidence that the
services were provided by the
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
subcontractors.
C OTHER ACTUAL DIRECT COSTS
C.1 COSTS OF TRAVEL AND RELATED SUBSISTENCE ALLOWANCES 30) Costs were incurred,
The Auditor sampled ______ cost items selected randomly (full coverage is required approved and reimbursed in line
if there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, with the Beneficiary's usual
policy for travels.
or 10% of the total, whichever number is the highest).
The Auditor inspected the sample and verified that: 31) There was a link between the
o travel and subsistence costs were consistent with the Beneficiary's usual policy for trip and the action.
travel. In this context, the Beneficiary provided evidence of its normal policy for
32) The supporting documents
travel costs (e.g. use of first class tickets, reimbursement by the Beneficiary on the
were consistent with each other
basis of actual costs, a lump sum or per diem) to enable the Auditor to compare
regarding subject of the trip,
the travel costs charged with this policy;
dates, duration and reconciled
o travel costs are correctly identified and allocated to the action (e.g. trips are with time records and
directly linked to the action) by reviewing relevant supporting documents such as accounting.
minutes of meetings, workshops or conferences, their registration in the correct
project account, their consistency with time records or with the dates/duration of 33) No ineligible costs or
the workshop/conference; excessive or reckless
expenditure was declared.
o no ineligible costs or excessive or reckless expenditure was declared.
C.2 DEPRECIATION COSTS FOR EQUIPMENT, INFRASTRUCTURE OR OTHER 34) Procurement rules,
ASSETS principles and guides were
The Auditor sampled ______ cost items selected randomly (full coverage is required followed.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
if there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, 35) There was a link between the
or 10% of the total, whichever number is the highest). grant agreement and the asset
charged to the action.
For “equipment, infrastructure or other assets” selected in the sample the Auditor verified
that: 36) The asset charged to the
o the assets were acquired in conformity with the Beneficiary's internal guidelines action was traceable to the
and procedures; accounting records and the
underlying documents.
o they were correctly allocated to the action (with supporting documents such as
delivery note invoice or any other proof demonstrating the link to the action) 37) The depreciation method
used to charge the asset to the
o they were entered in the accounting system; action was in line with the
o the extent to which the assets were used for the action (as a percentage) was applicable rules of the
supported by reliable documentation (e.g. usage overview table); Beneficiary's country and the
Beneficiary's usual accounting
The Auditor recalculated the depreciation costs and verified that they were in line with policy.
the applicable rules in the Beneficiary’s country and with the Beneficiary’s usual 38) The amount charged
accounting policy (e.g. depreciation calculated on the acquisition value). corresponded to the actual usage
The Auditor verified that no ineligible costs such as deductible VAT, exchange rate for the action.
losses, excessive or reckless expenditure were declared (see Article 6.4 GA). 39) No ineligible costs or
excessive or reckless
expenditure were declared.
C.3 COSTS OF OTHER GOODS AND SERVICES 43) Contracts for works or
The Auditor sampled ______ cost items selected randomly (full coverage is required services did not cover tasks
if there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, described in Annex 1to the
Grant Agreement.
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
or 10% of the total, whichever number is highest). 44) Costs were allocated to the
For the purchase of goods, works or services included in the sample the Auditor verified correct action and the goods
were not placed in the inventory
that:
of durable equipment.
o the contracts did not cover tasks described in Annex 1;
45) The costs were charged in
o they were correctly identified, allocated to the proper action, entered in the line with the Beneficiary’s
accounting system (traceable to underlying documents such as purchase orders, accounting policy and were
invoices and accounting); adequately supported.
o the goods were not placed in the inventory of durable equipment; 46) No ineligible costs or
o the costs charged to the action were accounted in line with the Beneficiary’s usual excessive or reckless
accounting practices; expenditure were declared. For
internal invoices/charges only
o no ineligible costs or excessive or reckless expenditure were declared (see Article the cost element was charged,
6.4 GA). without any mark-ups.
In addition, the Auditor verified that these goods and services were acquired in
conformity with the Beneficiary's internal guidelines and procedures, in particular: 47) Procurement rules,
principles and guides were
o if Beneficiary acted as a contracting authority within the meaning of Directive followed. There were documents
2004/18/EC or of Directive 2004/17/EC, the Auditor verified that the applicable of requests to different
national law on public procurement was followed and that the procurement providers, different offers and
contract complied with the Terms and Conditions of the Agreement. assessment of the offers before
o if the Beneficiary did not fall into the category above, the Auditor verified that the selection of the provider in line
Beneficiary followed their usual procurement rules and respected the Terms and with internal procedures and
Conditions of the Agreement. procurement rules. The
purchases were made in
For the items included in the sample the Auditor also verified that:
accordance with the principle of
o the Beneficiary ensured best value for money (key elements to appreciate the best value for money.
respect of this principle are the award of the contract to the bid offering best
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
price-quality ratio, under conditions of transparency and equal treatment. In case (When different offers were
an existing framework contract was used the Auditor also verified that the not collected the Auditor
Beneficiary ensured it was established on the basis of the principle of best value explains the reasons
for money under conditions of transparency and equal treatment); provided by the Beneficiary
under the caption
SUCH GOODS AND SERVICES INCLUDE, FOR INSTANCE, CONSUMABLES AND SUPPLIES,
“Exceptions” of the Report.
DISSEMINATION (INCLUDING OPEN ACCESS), PROTECTION OF RESULTS, SPECIFIC EVALUATION
The Agency will analyse this
OF THE ACTION IF IT IS REQUIRED BY THE AGREEMENT, CERTIFICATES ON THE FINANCIAL
information to evaluate
STATEMENTS IF THEY ARE REQUIRED BY THE AGREEMENT AND CERTIFICATES ON THE
whether these costs might be
METHODOLOGY, TRANSLATIONS, REPRODUCTION.
accepted as eligible)
D USE OF EXCHANGE RATES
D.1 a) For Beneficiaries with accounts established in a currency other than euros
The Auditor sampled ______ cost items selected randomly and verified that the
exchange rates used for converting other currencies into euros were in accordance
with the following rules established in the Agreement ( full coverage is required if
there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, 48) The exchange rates used to
or 10% of the total, whichever number is highest): convert other currencies into
Euros were in accordance with
COSTS INCURRED IN ANOTHER CURRENCY SHALL BE CONVERTED INTO EURO AT THE AVERAGE the rules established of the Grant
OF THE DAILY EXCHANGE RATES PUBLISHED IN THE C SERIES OF OFFICIAL JOURNAL OF THE Agreement and there was no
EUROPEAN UNION (https://www.ecb.int/stats/exchange/eurofxref/html/index.en.html ), difference in the final figures.
DETERMINED OVER THE CORRESPONDING REPORTING PERIOD.
IF NO DAILY EURO EXCHANGE RATE IS PUBLISHED IN THE OFFICIAL JOURNAL OF THE
EUROPEAN UNION FOR THE CURRENCY IN QUESTION, CONVERSION SHALL BE MADE AT THE
AVERAGE OF THE MONTHLY ACCOUNTING RATES ESTABLISHED BY THE COMMISSION AND
Grant Agreement number: [insert number] [insert acronym] [insert call identifier]
Associated with document Ref. Ares(2017)4194538 - 28/08/2017
CHAFEA Model Grant Agreements: CHAFEA MGA — Multi: 09.01.2015
Result
Ref Checks Standard finding (C / E
/N.A)
PUBLISHED ON ITS WEBSITE
(http://ec.europa.eu/budget/contracts_grants/info_contracts/inforeuro/inforeuro_en.cfm
), DETERMINED OVER THE CORRESPONDING REPORTING PERIOD.
b) For Beneficiaries with accounts established in euros
The Auditor sampled ______ cost items selected randomly and verified that the
exchange rates used for converting other currencies into euros were in accordance
with the following rules established in the Agreement ( full coverage is required if 49) The Beneficiary applied
there are fewer than 10 items, otherwise the sample should have a minimum of 10 item, its usual accounting
or 10% of the total, whichever number is highest): practices.
COSTS INCURRED IN ANOTHER CURRENCY SHALL BE CONVERTED INTO EURO BY APPLYING THE
BENEFICIARY’S USUAL ACCOUNTING PRACTICES.
[legal name of the audit firm]
[name and function of an authorised representative]
[dd Month yyyy]
<Signature of the Auditor
Digitally sealed by the European Commission
Date: 2017.08.28 08:40:27 CEST
This document is digitally sealed. The digital sealing mechanism uniquely binds the
document to the modules of the Participant Portal of the European Commission, to the
transaction for which it was generated and ensures its integrity and authenticity.
Any attempt to modify the content will lead to a breach of the electronic seal, which can
be verified at any time by clicking on the digital seal validation symbol.
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111
Virve-Hella Haavam
Rahandusministeerium
[email protected] Meie 02.04.2019 nr 1.8-1/996-1
Terviseameti taotlus sildfinantseerimise
avamiseks
Lugupeetud Virve-Hella Haavam
Palun avada Terviseameti välisabiprojektidele 9T70-MODEX, 9T70-JAMRAI ja 9T70-JATC
2019. aastaks sildfinantseerimised vastavalt lisale 1.
Lugupidamisega
(allkirjastatud digitaalselt)
Ester Timmas
toetuste juht
Lisa: 1. Sildfinantseerimise taotlus
2. Lisa 1 Toetuse avamise _taotlus_2019_TA
3. Grant Agreement-761296-EU-JAMRAI_ID 218821
4. ID 229337, Grant Agreement-761297-JATC
Ülle Näksi 6269710
[email protected]
Suur-Ameerika 1 / 10122 Tallinn / 626 9301 /
[email protected] / www.sm.ee / registrikood 70001952